PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wiese, MF				Wiese, MF			British hospitals and different versions of the Glasgow coma scale: telephone survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Kings Coll Hosp London, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Wiese, MF (corresponding author), Kings Coll Hosp London, Denmark Hill, London SE5 9RS, England.	wiese@doctors.org.uk						*AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP S; Diringer MN, 1997, ARCH NEUROL-CHICAGO, V54, P606, DOI 10.1001/archneur.1997.00550170078017; Lenfant F, 1997, ANN FR ANESTH, V16, P239, DOI 10.1016/S0750-7658(97)86408-8; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81	5	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 4	2003	327	7418					782	783		10.1136/bmj.327.7418.782	http://dx.doi.org/10.1136/bmj.327.7418.782			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525875	Bronze, Green Published			2022-12-28	WOS:000185805100019
J	Clubb, R; Mason, G				Clubb, R; Mason, G			Captivity effects on wide-ranging carnivores	NATURE			English	Editorial Material							DEPRIVATION; PHYLOGENY; ECOLOGY; SIZE		Univ Oxford, Dept Zool, Anim Behav Res Grp, Oxford OX1 3PS, England	University of Oxford	Clubb, R (corresponding author), Univ Oxford, Dept Zool, Anim Behav Res Grp, S Parks Rd, Oxford OX1 3PS, England.							Bahr NI, 1998, PHYSIOL BEHAV, V64, P429, DOI 10.1016/S0031-9384(98)00057-2; Bininda-Emonds ORP, 1999, BIOL REV, V74, P143, DOI 10.1017/S0006323199005307; CLUBB RE, 2001, THESIS U OXFORD; DAWKINS MS, 1988, APPL ANIM BEHAV SCI, V20, P209, DOI 10.1016/0168-1591(88)90047-0; GITTLEMAN JL, 1986, J MAMMAL, V67, P23, DOI 10.2307/1380998; GITTLEMAN JL, 1982, BEHAV ECOL SOCIOBIOL, V10, P57, DOI 10.1007/BF00296396; Lewis M.H., 1996, STEREOTYPED MOVEMENT, P37; Mason GJ, 2001, NATURE, V410, P35, DOI 10.1038/35065157; Meier J.E., 1986, P842; Mellen J.D., 1998, 2 NATURE ENV ENRICHM, P329; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; Robbins TW, 1996, J PSYCHOPHARMACOL, V10, P39, DOI 10.1177/026988119601000107; Woodroffe R, 1998, SCIENCE, V280, P2126, DOI 10.1126/science.280.5372.2126	13	239	247	9	330	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					473	474		10.1038/425473a	http://dx.doi.org/10.1038/425473a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523435	Green Published			2022-12-28	WOS:000185648100033
J	Hjalgrim, H; Askling, J; Rostgaard, K; Hamilton-Dutoit, S; Frisch, M; Zhang, J; Madsen, M; Rosdahl, N; Konradsen, HB; Storm, HH; Melbye, M				Hjalgrim, H; Askling, J; Rostgaard, K; Hamilton-Dutoit, S; Frisch, M; Zhang, J; Madsen, M; Rosdahl, N; Konradsen, HB; Storm, HH; Melbye, M			Characteristics of Hodgkin's lymphoma after infectious mononucleosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; DISEASE; YOUNG; CANCERS; RISK	BACKGROUND: Infectious mononucleosis-related Epstein-Barr virus (EBV) infection has been associated with an increased risk of Hodgkin's lymphoma in young adults. Whether the association is causal remains unclear. METHODS: We compared the incidence rates of Hodgkin's lymphoma in two population-based Danish cohorts of patients who were tested for infectious mononucleosis: 17,045 with serologic evidence of having had acute EBV infection, and 24,614 with no such evidence. We combined the cohort of patients who had serologically verified infectious mononucleosis with a cohort of 21,510 Swedish patients with infectious mononucleosis (combined total, 38,555). Biopsy specimens of Hodgkin's lymphomas occurring during follow-up in this combined cohort were tested serologically for the presence of EBV. Using this information, we modeled the relative risk of EBV-negative and EBV-positive Hodgkin's lymphoma in different periods after the diagnosis of infectious mononucleosis and estimated the median incubation time for mononucleosis-related EBV-positive Hodgkin's lymphoma. RESULTS: Only serologically confirmed infectious mononucleosis was associated with a persistently increased risk of Hodgkin's lymphoma. Sixteen of 29 tumors (55 percent), obtained from patients with infectious mononucleosis, had evidence of EBV. There was no evidence of an increased risk of EBV-negative Hodgkin's lymphoma after infectious mononucleosis. In contrast, the risk of EBV-positive Hodgkin's lymphoma was significantly increased (relative risk, 4.0; 95 percent confidence interval, 3.4 to 4.5). The estimated median incubation time from mononucleosis to EBV-positive Hodgkin's lymphoma was 4.1 years (95 percent confidence interval, 1.8 to 8.3). CONCLUSIONS: A causal association between infectious mononucleosis-related EBV infection and the EBV-positive subgroup of Hodgkin's lymphomas is likely in young adults.	Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark; Statens Serum Inst, Dept Resp Infect Meningitis & STDs, DK-2300 Copenhagen, Denmark; Statens Serum Inst, Dept Microbiol, DK-2300 Copenhagen S, Denmark; Statens Serum Inst, Dept Diagnost, DK-2300 Copenhagen S, Denmark; Danish Inst Publ Hlth, Copenhagen, Denmark; Med Off Hlth, Copenhagen, Denmark; Danish Canc Soc, Dept Canc Prevent & Documentat, Copenhagen, Denmark; Karolinska Hosp & Inst, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden; Aarhus Univ Hosp, Inst Pathol, DK-8000 Aarhus, Denmark	Aarhus University; Statens Serum Institut; Statens Serum Institut; Statens Serum Institut; Statens Serum Institut; Danish Cancer Society; Karolinska Institutet; Karolinska University Hospital; Aarhus University	Hjalgrim, H (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, 5 Artillerivej, DK-2300 Copenhagen S, Denmark.		Frisch, Morten/E-9206-2016; Hjalgrim, Henrik/AAG-4973-2021; Dutoit, Stephen Hamilton/E-1815-2013; Madsen, Mette/B-4341-2008	Frisch, Morten/0000-0002-3864-8860; melbye, mads/0000-0001-8264-6785; Rostgaard, Klaus/0000-0001-6220-9414; Storm, Hans/0000-0001-7223-8198; Hamilton-Dutoit, Stephen/0000-0003-2158-3885	NCI NIH HHS [1 R01 CA 69269-01A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander FE, 2001, CANCER EPIDEM BIOMAR, V10, P705; Ambinder RF, 2000, AM J PATHOL, V156, P1, DOI 10.1016/S0002-9440(10)64697-4; [Anonymous], 1997, IARC MON EV CARC RIS, V70; Breslow N.E., 1987, IARC SCI PUBL, V82, P48; Enblad G, 1999, ACTA ONCOL, V38, P425, DOI 10.1080/028418699431942; Glaser SL, 1997, INT J CANCER, V70, P375, DOI 10.1002/(SICI)1097-0215(19970207)70:4&lt;375::AID-IJC1&gt;3.0.CO;2-T; GUTENSOHN N, 1977, INT J CANCER, V19, P595, DOI 10.1002/ijc.2910190502; GUTENSOHN N, 1981, NEW ENGL J MED, V304, P135, DOI 10.1056/NEJM198101153040302; Haahr S, 1995, Mult Scler, V1, P73; HAMILTONDUTOIT SJ, 1994, HISTOPATHOLOGY, V25, P101, DOI 10.1111/j.1365-2559.1994.tb01565.x; Hjalgrim H, 2000, J NATL CANCER I, V92, P1522, DOI 10.1093/jnci/92.18.1522; Hjalgrim H, 2002, J NATL CANCER I, V94, P678, DOI 10.1093/jnci/94.9.678; KRISTENSEN M., 1938, ADA PATH ET MICROBIOL SCAND SUPPL, V37, P339; Mueller N., 1997, EBV REP, V4, P1; Mueller NE, 1996, CANC EPIDEMIOLOGY PR, P893; ROSDAHL N, 1974, BMJ-BRIT MED J, V2, P253, DOI 10.1136/bmj.2.5913.253; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Sleckman BG, 1998, CANCER EPIDEM BIOMAR, V7, P1117; VESTLEV PM, 1992, INT J CANCER, V50, P670, DOI 10.1002/ijc.2910500432; Zhou XG, 2001, CANCER-AM CANCER SOC, V92, P1621, DOI 10.1002/1097-0142(20010915)92:6<1621::AID-CNCR1488>3.0.CO;2-P	20	255	274	1	16	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1324	1332		10.1056/NEJMoa023141	http://dx.doi.org/10.1056/NEJMoa023141			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523140				2022-12-28	WOS:000185644000006
J	Kefalov, V; Fu, YB; Marsh-Armstrong, N; Yau, KW				Kefalov, V; Fu, YB; Marsh-Armstrong, N; Yau, KW			Role of visual pigment properties in rod and cone phototransduction	NATURE			English	Article							RETINAL CONES; DARK NOISE; ABSORPTION-SPECTRA; XENOPUS-LAEVIS; PHOTORECEPTORS; SENSITIVITY; RHODOPSIN; GREEN; TRANSDUCIN; COMPONENTS	Retinal rods and cones share a phototransduction pathway involving cyclic GMP(1). Cones are typically 100 times less photosensitive than rods and their response kinetics are several times faster(2),but the underlying mechanisms remain largely unknown. Almost all proteins involved in phototransduction have distinct rod and cone variants. Differences in properties between rod and cone pigments have been described, such as a 10-fold shorter lifetime of the meta-II state (active conformation) of cone pigment(3-6) and its higher rate of spontaneous isomerization(7,8), but their contributions to the functional differences between rods and cones remain speculative. We have addressed this question by expressing human or salamander red cone pigment in Xenopus rods, and human rod pigment in Xenopus cones. Here we show that rod and cone pigments when present in the same cell produce light responses with identical amplification and kinetics, thereby ruling out any difference in their signalling properties. However, red cone pigment isomerizes spontaneously 10,000 times more frequently than rod pigment. This high spontaneous activity adapts the native cones even in darkness, making them less sensitive and kinetically faster than rods. Nevertheless, additional factors are probably involved in these differences.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute	Yau, KW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.			Kefalov, Vladimir/0000-0002-1659-008X	NEI NIH HHS [R01 EY014596, R37 EY006837, R01 EY006837-16A1, R37 EY006837-14, R37 EY006837-13, R37 EY006837-15S1, R01 EY014596-01, R01 EY014596-02, R01 EY006837, R37 EY006837-15] Funding Source: Medline; NIDCD NIH HHS [R01 DC006904, R01 DC006904-03] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006837, R01EY014596, R37EY006837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006904] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BARLOW HB, 1958, VISUAL PROBLEMS COLO, V2, P617; BAYLOR DA, 1987, INVEST OPHTH VIS SCI, V28, P34; BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529; BOWMAKER JK, 1980, J PHYSIOL-LONDON, V298, P501, DOI 10.1113/jphysiol.1980.sp013097; Govardovskii VI, 2000, VISUAL NEUROSCI, V17, P509, DOI 10.1017/S0952523800174036; HAROSI FI, 1975, J GEN PHYSIOL, V66, P357, DOI 10.1085/jgp.66.3.357; HAROSI FI, 1994, VISION RES, V34, P1359, DOI 10.1016/0042-6989(94)90134-1; IMAI H, 1995, BIOCHEMISTRY-US, V34, P10525, DOI 10.1021/bi00033a026; Imai H, 1997, BIOCHEMISTRY-US, V36, P12773, DOI 10.1021/bi970809x; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Lyubarsky AL, 2000, J NEUROSCI, V20, P2209; Ma JX, 2001, NEURON, V32, P451, DOI 10.1016/S0896-6273(01)00482-2; Makino CL, 1999, BIOPHYS J, V77, P1024, DOI 10.1016/S0006-3495(99)76953-5; MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0; Miller James L., 1994, Current Opinion in Neurobiology, V4, P488, DOI 10.1016/0959-4388(94)90048-5; MILLER JL, 1993, VISUAL NEUROSCI, V10, P653, DOI 10.1017/S0952523800005356; Moritz OL, 2001, J BIOL CHEM, V276, P28242, DOI 10.1074/jbc.M101476200; NAKATANI K, 1989, J PHYSIOL-LONDON, V409, P525, DOI 10.1113/jphysiol.1989.sp017511; OKADA T, 1994, BIOCHEMISTRY-US, V33, P4940, DOI 10.1021/bi00182a024; Palacios AG, 1998, VISUAL NEUROSCI, V15, P319, DOI 10.1017/S0952523898152136; Rieke F, 1996, BIOPHYS J, V71, P2553, DOI 10.1016/S0006-3495(96)79448-1; Rieke F, 2000, NEURON, V26, P181, DOI 10.1016/S0896-6273(00)81148-4; Sampath AP, 2002, BIOPHYS J, V83, P184, DOI 10.1016/S0006-3495(02)75160-6; Starace DM, 1997, J BIOL CHEM, V272, P1095, DOI 10.1074/jbc.272.2.1095; Tachibanaki S, 2001, P NATL ACAD SCI USA, V98, P14044, DOI 10.1073/pnas.241396898; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WHITMORE AV, 1989, J COMP PHYSIOL A, V166, P103; WITKOVSKY P, 1981, VISION RES, V21, P867, DOI 10.1016/0042-6989(81)90187-5; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9	30	97	100	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					526	531		10.1038/nature01992	http://dx.doi.org/10.1038/nature01992			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523449	Green Accepted			2022-12-28	WOS:000185648100048
J	Switzer, JA; Kothari, HM; Poizot, P; Nakanishi, S; Bohannan, EW				Switzer, JA; Kothari, HM; Poizot, P; Nakanishi, S; Bohannan, EW			Enantiospecific electrodeposition of a chiral catalyst	NATURE			English	Article							EPITAXIAL ELECTRODEPOSITION; AMINO-ACIDS; ADSORPTION; OXIDE; CALCITE; GROWTH; DESORPTION; SURFACES; CU(643); FILMS	Many biomolecules are chiral-they can exist in one of two enantiomeric forms that only differ in that their structures are mirror images of each other. Because only one enantiomer tends to be physiologically active while the other is inactive or even toxic, drug compounds are increasingly produced in an enantiomerically pure form(1) using solution-phase homogeneous catalysts and enzymes. Chiral surfaces offer the possibility of developing heterogeneous enantioselective catalysts that can more readily be separated from the products and reused. In addition, such surfaces might serve as electrochemical sensors for chiral molecules. To date, chiral surfaces have been obtained by adsorbing chiral molecules(2-6) or slicing single crystals so that they exhibit high-index faces(7-13), and some of these surfaces act as enantioselective heterogeneous catalysts(5,6,10). Here we show that chiral surfaces can also be produced through electrodeposition, a relatively simple solution-based process that resembles bio-mineralization(14-17) in that organic molecules adsorbed on surfaces have profound effects on the morphology of the inorganic deposits(18-20). When electrodepositing a copper oxide film on an achiral gold surface in the presence of tartrate ion in the deposition solution, the chirality of the ion determines the chirality of the deposited film, which in turn determines the film's enantiospecificity during subsequent electrochemical oxidation reactions.	Univ Missouri, Dept Chem, Rolla, MO 65409 USA; Univ Missouri, Grad Ctr Mat Res, Rolla, MO 65409 USA	University of Missouri System; Missouri University of Science & Technology; University of Missouri System; Missouri University of Science & Technology	Switzer, JA (corresponding author), Univ Missouri, Dept Chem, Rolla, MO 65409 USA.	jswitzer@umr.edu	POIZOT, Philippe/E-5722-2017	POIZOT, Philippe/0000-0003-1865-4902; Nakanishi, Shuji/0000-0002-3313-2689				Addadi L, 2001, NATURE, V411, P753, DOI 10.1038/35081227; Ahmadi A, 1999, LANGMUIR, V15, P2420, DOI 10.1021/la9810915; [Anonymous], 1998, ELEC SOC S; Attard GA, 2001, J PHYS CHEM B, V105, P3158, DOI 10.1021/jp0041508; Attard GA, 1999, J PHYS CHEM B, V103, P1381, DOI 10.1021/jp983553t; Bohannan EW, 1999, CHEM MATER, V11, P2289, DOI 10.1021/cm990304o; CATANA A, 1992, PHYS REV B, V46, P15477, DOI 10.1103/PhysRevB.46.15477; CODY AM, 1991, J CRYST GROWTH, V113, P508, DOI 10.1016/0022-0248(91)90086-K; Hazen RM, 2001, P NATL ACAD SCI USA, V98, P5487, DOI 10.1073/pnas.101085998; Horvath JD, 2002, J AM CHEM SOC, V124, P2384, DOI 10.1021/ja012182i; Horvath JD, 2001, J AM CHEM SOC, V123, P7953, DOI 10.1021/ja015890c; Humblot V, 2002, J AM CHEM SOC, V124, P503, DOI 10.1021/ja012021e; IZUMI Y, 1983, ADV CATAL, V32, P215, DOI 10.1016/S0360-0564(08)60441-1; Josell D, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.016102; Kuhnle A, 2002, NATURE, V415, P891, DOI 10.1038/415891a; LeBlond C, 1999, J AM CHEM SOC, V121, P4920, DOI 10.1021/ja990653j; Lorenzo MO, 2000, NATURE, V404, P376, DOI 10.1038/35006031; McFadden CF, 1996, LANGMUIR, V12, P2483, DOI 10.1021/la950348l; Missavage R. J., 1972, Journal of Coordination Chemistry, V2, P145, DOI 10.1080/00958977208072964; Orme CA, 2001, NATURE, V411, P775, DOI 10.1038/35081034; Poizot P, 2003, ELECTROCHEM SOLID ST, V6, pC21, DOI 10.1149/1.1535753; Sholl DS, 2001, J PHYS CHEM B, V105, P4771, DOI 10.1021/jp004524x; Sorenson TA, 2002, J AM CHEM SOC, V124, P7604, DOI 10.1021/ja0201101; Stinson SC, 2001, CHEM ENG NEWS, V79, P79, DOI 10.1021/cen-v079n040.p079; Switzer JA, 1999, SCIENCE, V284, P293, DOI 10.1126/science.284.5412.293; Switzer JA, 2002, J PHYS CHEM B, V106, P12369, DOI 10.1021/jp0266188; Switzer JA, 2002, J PHYS CHEM B, V106, P4027, DOI 10.1021/jp014638o; Teng HH, 1998, SCIENCE, V282, P724, DOI 10.1126/science.282.5389.724; VAZHEV VV, 1980, SOV ELECTROCHEM+, V16, P1445; XIE YQ, 1991, ANAL CHEM, V63, P1714, DOI 10.1021/ac00017a012	30	297	303	11	218	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2003	425	6957					490	493		10.1038/nature01990	http://dx.doi.org/10.1038/nature01990			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523441				2022-12-28	WOS:000185648100039
J	Moumjid, N; Callu, MF				Moumjid, N; Callu, MF			Commentary: informed consent and risk communication in France	BRITISH MEDICAL JOURNAL			English	Editorial Material									Ctr Leon Berard, CNRS, Mixed Res Univ 5823, Res Grp Hlth Econ & Networks Canc Care, F-69008 Lyon, France; Jean Moulin Fac Law, Inst Format & Res Hlth Care & Social Serv, CNRS, Mixed Res Unit 5823, F-69007 Lyon, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); Universite Jean Moulin Lyon 3	Moumjid, N (corresponding author), Ctr Leon Berard, CNRS, Mixed Res Univ 5823, Res Grp Hlth Econ & Networks Canc Care, 28 Rue Laennec, F-69008 Lyon, France.							MEMETEAU G, 1999, INFORMATION PATIENT, P6; PORTES L, 1964, RECHERCHE UNE ETHIQU, P168; World Medical Association, DECL HELS	3	7	7	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	2003	327	7417					734	735		10.1136/bmj.327.7417.734	http://dx.doi.org/10.1136/bmj.327.7417.734			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728FZ	14512485	Green Published			2022-12-28	WOS:000185708300025
J	Hoberman, A; Greenberg, DP; Paradise, JL; Rockette, HE; Lave, JR; Kearney, DH; Colborn, DK; Kurs-Lasky, M; Haralam, MA; Byers, CJ; Zoffel, LM; Fabian, IA; Bernard, BS; Kerr, JD				Hoberman, A; Greenberg, DP; Paradise, JL; Rockette, HE; Lave, JR; Kearney, DH; Colborn, DK; Kurs-Lasky, M; Haralam, MA; Byers, CJ; Zoffel, LM; Fabian, IA; Bernard, BS; Kerr, JD			Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY VIRUSES; INFECTION; EFFICACY	Context Acute otitis media (AOM) frequently complicates influenza infection. Previous studies have found influenza vaccine effective in reducing the occurrence of AOM in children mainly older than 2 years. Objective To evaluate the effectiveness of inactivated influenza vaccine in preventing AOM in children aged 6 to 24 months. Design, Setting, and Patients Randomized, double-blind, placebo-controlled trial of 786 children aged 6 to 24 months enrolled at Children's Hospital of Pittsburgh before the 1999-2000 (411 children) and 2000-2001 (375 children) respiratory seasons (defined as December 1 through March 31 of the respective following year). Children received influenza vaccine or placebo in a 2:1 ratio. The first cohort was observed for 1 year and the second cohort until the end of the ensuing respiratory season. Intervention Two doses (0.25 mL each) of inactivated trivalent subvirion influenza vaccine or placebo were administered intramuscularly approximately 4 weeks apart. Main Outcome Measures Proportion of children who developed AOM, monthly occurrence rate of AOM, estimated proportion of time with middle ear effusion, and utilization of selected health care and related resources. Results Of the 66 children in the vaccine group from whom serum samples were collected, seroconversion against strains in the vaccine formulations developed in 88.6% to 96.8%, depending on the specific strain. The efficacy of the vaccine against culture-confirmed influenza was 66% (95% confidence interval (CI], 34%-82%) in 1999-2000 and -7% (95% Cl, -247% to 67%) in 2000-2001; however, influenza attack rates differed between these 2 periods (in the placebo group, 15.9% and 3.3%, respectively). Compared with placebo, influenza vaccine did not reduce the proportion of children who had at least 1 episode of AOM during the respiratory season (in the first cohort: vaccine, 49.2% vs placebo, 52.2%; P=.56]; in the second cohort: vaccine, 55.8% vs placebo, 48.3%; P=17). The vaccine also did not reduce the monthly rate of AOM; the estimated proportion of time with middle ear effusion; or the utilization of selected health care and related resources. There were also no differences between the vaccine and placebo groups regarding any of these outcomes during peak influenza periods. The vaccines administered to both cohorts of children were well tolerated. Conclusion Administration of inactivated trivalent influenza vaccine to children aged 6 to 24 months did not reduce their burden of AOM or their utilization of selected health care and related resources.	Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Hlth Serv Adm, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hoberman, A (corresponding author), Childrens Hosp Pittsburgh, 3705 5th Ave, Pittsburgh, PA 15213 USA.	hoberman@chp.edu						Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; Bridges Carolyn B, 2002, MMWR Recomm Rep, V51, P1; CHONMAITREE T, 1990, J INFECT DIS, V162, P546, DOI 10.1093/infdis/162.2.546; CHONMAITREE T, 1992, J PEDIATR-US, V120, P856, DOI 10.1016/S0022-3476(05)81950-X; CLEMENTS DA, 1995, ARCH PEDIAT ADOL MED, V149, P1113, DOI 10.1001/archpedi.1995.02170230067009; Couch RB, 1995, DIAGNOSTIC PROCEDURE, P431; Dowell SF, 1999, PEDIATR INFECT DIS J, V18, P1, DOI 10.1097/00006454-199901000-00002; Ewell M, 1996, STAT MED, V15, P2379, DOI 10.1002/(SICI)1097-0258(19961115)15:21<2379::AID-SIM457>3.3.CO;2-C; Heikkinen T, 1999, NEW ENGL J MED, V340, P260, DOI 10.1056/NEJM199901283400402; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; Hurwitz ES, 2000, J INFECT DIS, V182, P1218, DOI 10.1086/315820; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Marchisio P, 2002, CLIN INFECT DIS, V35, P168, DOI 10.1086/341028; McIntosh K, 2000, NEW ENGL J MED, V342, P275, DOI 10.1056/NEJM200001273420409; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; *WHO COLL CTR INFL, 1981, HEM INH TEST INFL VI, P1	17	197	210	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	2003	290	12					1608	1616		10.1001/jama.290.12.1608	http://dx.doi.org/10.1001/jama.290.12.1608			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	723ZK	14506120	Bronze			2022-12-28	WOS:000185461300026
J	Brown, DR				Brown, DR			Conformational exposure: a new handle on prions	LANCET			English	Editorial Material							PROTEIN; ANTIBODIES; DISEASE		Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of Bath	Brown, DR (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.		Brown, David/A-4083-2008					*CAN FOOD INSP AG, 2003, BSE DIS INV ALB; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; SCHREUDER BEC, 1996, NATURE, V381, P583; Sigurdsson EM, 2002, AM J PATHOL, V161, P13, DOI 10.1016/S0002-9440(10)64151-X; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457	11	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					929	930		10.1016/S0140-6736(03)14395-4	http://dx.doi.org/10.1016/S0140-6736(03)14395-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511922				2022-12-28	WOS:000185489600003
J	Buchan, JC; Alberts, SC; Silk, JB; Altmann, J				Buchan, JC; Alberts, SC; Silk, JB; Altmann, J			True paternal care in a multi-male primate society	NATURE			English	Article							BARBARY MACAQUES; MACACA-SYLVANUS; FEMALE BABOONS; BODY ODOR; BEHAVIOR; CHIMPANZEES; PREFERENCES; SAMPLES; HUMANS; CHOICE	Although male parental care is rare among mammals 1, adult males of many cercopithecine primate species provide care for infants and juveniles. This care is often in the form of grooming, carrying, support in agonistic interactions, and protection against infanticide(2,3). For these behaviours to be interpreted as true parental care, males must selectively direct care towards their own offspring and this care must result in fitness benefits(4). With the exception of males defending probable offspring from infanticide(5), male primates living in multi-male, multi-female social groups have not been shown to selectively direct care towards their own offspring(6,7). We determined paternity for 75 juveniles in a population of wild savannah baboons (Papio cynocephalus) and collected data on interventions in agonistic disputes by adult males on behalf of juveniles as a form of male care. Here we show that adult males differentiate their offspring from unrelated juveniles and selectively support their offspring in agonistic disputes. As support in agonistic disputes is likely to contribute to rank acquisition and protect juveniles from injury and stress(2,3,5), this can be considered true parental care.	Duke Univ, Dept Biol, Durham, NC 27708 USA; Natl Museums Kenya, Inst Primate Res, Nairobi, Kenya; Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90095 USA; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Brookfield Zoo, Dept Conservat Biol, Brookfield, IL 60513 USA	Duke University; University of California System; University of California Los Angeles; Princeton University	Alberts, SC (corresponding author), Duke Univ, Dept Biol, Box 90338, Durham, NC 27708 USA.			Buchan, John/0000-0003-1005-7011				Alberts SC, 1999, P ROY SOC B-BIOL SCI, V266, P1501, DOI 10.1098/rspb.1999.0807; ALBERTS SC, 1995, BEHAV ECOL SOCIOBIOL, V36, P397, DOI 10.1007/BF00177335; Altmann J, 1996, P NATL ACAD SCI USA, V93, P5797, DOI 10.1073/pnas.93.12.5797; Borries C, 1999, BEHAV ECOL SOCIOBIOL, V46, P350, DOI 10.1007/s002650050629; HALPIN ZT, 1991, KIN RECOGNITION, P220; Hauber ME, 2001, TRENDS NEUROSCI, V24, P609, DOI 10.1016/S0166-2236(00)01916-0; Hausfater G., 1975, DOMINANCE REPROD BAB; Jacob S, 2002, NAT GENET, V30, P175, DOI 10.1038/ng830; Marshall TC, 1998, MOL ECOL, V7, P639, DOI 10.1046/j.1365-294x.1998.00374.x; Menard N, 2001, CR ACAD SCI III-VIE, V324, P601, DOI 10.1016/S0764-4469(01)01339-7; Morin PA, 2001, MOL ECOL, V10, P1835, DOI 10.1046/j.0962-1083.2001.01308.x; Ober C, 1997, AM J HUM GENET, V61, P497, DOI 10.1086/515511; Palombit RA, 1997, ANIM BEHAV, V54, P599, DOI 10.1006/anbe.1996.0457; Parr LA, 1999, NATURE, V399, P647, DOI 10.1038/21345; Paul A, 1996, ANIM BEHAV, V51, P155, DOI 10.1006/anbe.1996.0013; SHAIKH A A, 1982, Primates, V23, P444, DOI 10.1007/BF02381326; Sherman Paul W., 1997, P69; Silk JB, 2002, INT J PRIMATOL, V23, P849, DOI 10.1023/A:1015581016205; SILK JB, IN PRESS ANIM BEHAV; Singh D, 2001, P ROY SOC B-BIOL SCI, V268, P797, DOI 10.1098/rspb.2001.1589; Smith K, 2003, P ROY SOC B-BIOL SCI, V270, P503, DOI 10.1098/rspb.2002.2277; Smith KL, 2000, AM J PRIMATOL, V51, P219; Smuts B., 1992, FATHER CHILD RELATIO, P1, DOI DOI 10.1002/AJHB.1310060321; Soltis J, 2000, BEHAV ECOL SOCIOBIOL, V48, P195, DOI 10.1007/s002650000224; Taberlet P, 1996, NUCLEIC ACIDS RES, V24, P3189, DOI 10.1093/nar/24.16.3189; TRIVERS RL, 1972, SEXUAL SELECTION DES; van Schaik Carel, 1996, Evolutionary Anthropology, V5, P152, DOI 10.1002/(SICI)1520-6505(1996)5:5<152::AID-EVAN3>3.3.CO;2-9; Wedekind C, 1997, P ROY SOC B-BIOL SCI, V264, P1471, DOI 10.1098/rspb.1997.0204; WEDEKIND C, 1995, P ROY SOC B-BIOL SCI, V260, P245, DOI 10.1098/rspb.1995.0087; Widdig A, 2001, P NATL ACAD SCI USA, V98, P13769, DOI 10.1073/pnas.241210198; WOODROFFE R, 1994, TRENDS ECOL EVOL, V9, P294, DOI 10.1016/0169-5347(94)90033-7	31	246	255	3	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2003	425	6954					179	181		10.1038/nature01866	http://dx.doi.org/10.1038/nature01866			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968180				2022-12-28	WOS:000185236000042
J	Barnaby, B; Drummond, C; McCloud, A; Burns, T; Orrm, N				Barnaby, B; Drummond, C; McCloud, A; Burns, T; Orrm, N			Substance misuse in psychiatric inpatients: comparison of a screening questionnaire survey with case notes	BRITISH MEDICAL JOURNAL			English	Article							HISTORY; AUDIT		Univ London St Georges Hosp, Sch Med, Dept Addict Behav & Psychol Med, London SW17 0RE, England; SW London & St Georges Mental Hlth NHS Trust, London SW17 7DJ, England	St Georges University London	Drummond, C (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Addict Behav & Psychol Med, London SW17 0RE, England.		Drummond, Colin/O-9141-2019	Drummond, Colin/0000-0001-9379-5452				FARRELL MP, 1988, BRIT MED J, V296, P395, DOI 10.1136/bmj.296.6619.395; National Association of Psychiatric Intensive Care & Low Secure Units, 2018, CAPACITY DEV RESOURC; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SINGLETON N, 2001, PSYCHIAT MORBIDITY A; TAYLOR SJ, 1995, IRISH J PSYCHOL MED, V12, P37, DOI 10.1017/S0790966700002044	5	47	48	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					783	784		10.1136/bmj.327.7418.783	http://dx.doi.org/10.1136/bmj.327.7418.783			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525876	Green Published, Bronze			2022-12-28	WOS:000185805100020
J	Marsicano, G; Goodenough, S; Monory, K; Hermann, H; Eder, M; Cannich, A; Azad, SC; Cascio, MG; Gutierrez, SO; van der Stelt, M; Lopez-Rodriguez, ML; Casanova, E; Schutz, G; Zieglgansberger, W; Di Marzo, V; Behl, C; Lutz, B				Marsicano, G; Goodenough, S; Monory, K; Hermann, H; Eder, M; Cannich, A; Azad, SC; Cascio, MG; Gutierrez, SO; van der Stelt, M; Lopez-Rodriguez, ML; Casanova, E; Schutz, G; Zieglgansberger, W; Di Marzo, V; Behl, C; Lutz, B			CB1 cannabinoid receptors and on-demand defense against excitotoxicity	SCIENCE			English	Article							N-ACYLETHANOLAMINE PHOSPHOLIPIDS; ACUTE NEURONAL INJURY; ANANDAMIDE; BRAIN; RAT; ENDOCANNABINOIDS; GLUTAMATE; MICE; NEUROPROTECTION; NEUROTOXICITY	Abnormally high spiking activity can damage neurons. Signaling systems to protect neurons from the consequences of abnormal discharge activity have been postulated. We generated conditional mutant mice that lack expression of the cannabinoid receptor type 1 in principal forebrain neurons but not in adjacent inhibitory interneurons. In mutant mice, the excitotoxin kainic acid (KA) induced excessive seizures in vivo. The threshold to KA-induced neuronal excitation in vitro was severely reduced in hippocampal pyramidal neurons of mutants. KA administration rapidly raised hippocampal levels of anandamide and induced protective mechanisms in wild-type principal hippocampal neurons. These protective mechanisms could not be triggered in mutant mice. The endogenous cannabinoid system thus provides on-demand protection against acute excitotoxicity in central nervous system neurons.	Max Planck Inst Psychiat, Clin Neuropharmacol Grp, D-80804 Munich, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany; Univ Munich, Klinikum Grosshadern, Clin Anaesthesiol, D-81377 Munich, Germany; CNR, Inst Biomol Chem, Endocannabinoid Res Grp, I-80078 Naples, Italy; Univ Complutense, Dept Organ Chem, E-28040 Madrid, Spain; German Canc Res Ctr, Div Mol Biol Cell 1, D-69120 Heidelberg, Germany	Max Planck Society; Johannes Gutenberg University of Mainz; University of Munich; Consiglio Nazionale delle Ricerche (CNR); Complutense University of Madrid; Helmholtz Association; German Cancer Research Center (DKFZ)	Lutz, B (corresponding author), Max Planck Inst Psychiat, Clin Neuropharmacol Grp, Kraepelinstr 2-10, D-80804 Munich, Germany.	lutz@mpipsykl.mpg.de	Ortega-Gutierrez, Silvia/ABC-7653-2021; Di Marzo, Vincenzo/AAD-7742-2019; Lopez-Rodriguez, Maria L/S-6342-2016; Lutz, Beat/AFK-6229-2022; Casanova, Emilio/Y-6553-2019; Lutz, Beat/AAG-4538-2022; Marsicano, Giovanni/I-9603-2016; Ortega-Gutierrez, Silvia/I-1935-2017	Di Marzo, Vincenzo/0000-0002-1490-3070; Lopez-Rodriguez, Maria L/0000-0001-8607-1085; Casanova, Emilio/0000-0001-7992-5361; Ortega-Gutierrez, Silvia/0000-0002-0257-6754; Behl, Christian/0000-0001-8453-2378; Eder, Matthias/0000-0002-2579-2628; Marsicano, Giovanni/0000-0003-3804-1951				Baker D, 2001, FASEB J, V15, P300, DOI 10.1096/fj.00-0399fje; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; Cadas H, 1996, J NEUROSCI, V16, P3934; Casanova E, 2001, GENESIS, V31, P37, DOI 10.1002/gene.1078; Chan GCK, 1998, J NEUROSCI, V18, P5322, DOI 10.1523/JNEUROSCI.18-14-05322.1998; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Clement AB, 2003, J NEUROSCI, V23, P3916; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Croxford JL, 2003, CNS DRUGS, V17, P179, DOI 10.2165/00023210-200317030-00004; de Lago E, 2002, EUR J PHARMACOL, V449, P99, DOI 10.1016/S0014-2999(02)01996-9; Derkinderen P, 2003, J NEUROSCI, V23, P2371; Di Marzo V, 2002, PROSTAG LEUKOTR ESS, V66, P377, DOI 10.1054/plef.2001.0349; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Ferrer I, 2002, ACTA NEUROPATHOL, V103, P391, DOI 10.1007/s00401-001-0481-9; Gratacos E, 2001, J NEUROCHEM, V78, P1287, DOI 10.1046/j.1471-4159.2001.00538.x; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HH, 2002, J NEUROCHEM, V82, P154, DOI 10.1046/j.1471-4159.2002.00961.x; Hansen HH, 2001, J NEUROCHEM, V76, P39, DOI 10.1046/j.1471-4159.2001.00006.x; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Katona I, 1999, J NEUROSCI, V19, P4544; Marsicano G, 1999, EUR J NEUROSCI, V11, P4213, DOI 10.1046/j.1460-9568.1999.00847.x; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; MARSICANO G, UNPUB; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; McNamara JO, 1999, NATURE, V399, pA15, DOI 10.1038/399a015; MECHOULAM R, 2002, SCI STKE, pRE1; Moesgaard B, 2003, LIPIDS, V38, P387, DOI 10.1007/s11745-003-1073-1; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Selley DE, 2001, J NEUROCHEM, V77, P1048, DOI 10.1046/j.1471-4159.2001.00308.x; Tandon P, 1999, NEUROSCIENCE, V91, P293, DOI 10.1016/S0306-4522(98)00609-5; van der Stelt M, 2002, MOL NEUROBIOL, V26, P317, DOI 10.1385/MN:26:2-3:317; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Veldhuis WB, 2003, J NEUROSCI, V23, P4127; Wallace MJ, 2002, EUR J PHARMACOL, V452, P295, DOI 10.1016/S0014-2999(02)02331-2; Zhang JH, 2002, NAT GENET, V30, P416, DOI 10.1038/ng859	40	921	959	3	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					84	88		10.1126/science.1088208	http://dx.doi.org/10.1126/science.1088208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526074				2022-12-28	WOS:000185678500039
J	Lee, HH; Norris, A; Weiss, JB; Frasch, M				Lee, HH; Norris, A; Weiss, JB; Frasch, M			Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers	NATURE			English	Article							ANAPLASTIC LYMPHOMA KINASE; CELL FATES; DROSOPHILA MESODERM; BOX-GENE; FUSION; IDENTIFICATION; SEGMENTATION; EMBRYOGENESIS; SPECIFICATION; INDUCTION	The secreted protein Jelly belly (Jeb) is required for an essential signalling event in Drosophila muscle development. In the absence of functional Jeb, visceral muscle precursors are normally specified but fail to migrate and differentiate(1). The structure and distribution of Jeb protein implies that Jeb functions as a signal to organize the development of visceral muscles(1). Here we show that the Jeb receptor is the Drosophila homologue of anaplastic lymphoma kinase (Alk), a receptor tyrosine kinase of the insulin receptor superfamily. Human ALK was originally identified as a proto-oncogene, but its normal function in mammals is not known(2). In Drosophila, localized Jeb activates Alk and the downstream Ras/mitogen-activated protein kinase cascade to specify a select group of visceral muscle precursors as muscle-patterning pioneers. Jeb/Alk signalling induces the myoblast fusion gene dumbfounded (duf; also known as kirre) as well as org-1, a Drosophila homologue of mammalian TBX1, in these cells.	Oregon Hlth Sci Univ, Portland, OR 97201 USA; Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA	Oregon Health & Science University; Icahn School of Medicine at Mount Sinai	Weiss, JB (corresponding author), Oregon Hlth Sci Univ, 3181 SW Sam Jackson Pk Rd NRC3, Portland, OR 97201 USA.		Frasch, Manfred/H-7002-2013	Frasch, Manfred/0000-0003-1373-9798; LEE, HSIU-HSIANG/0000-0001-7707-8461				AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Azpiazu N, 1996, GENE DEV, V10, P3183, DOI 10.1101/gad.10.24.3183; Baldini A, 2002, HUM MOL GENET, V11, P2363, DOI 10.1093/hmg/11.20.2363; BATE M, 1990, DEVELOPMENT, V110, P791; Baylies MK, 2001, CURR OPIN GENET DEV, V11, P431, DOI 10.1016/S0959-437X(00)00214-8; BODMER R, 1993, DEVELOPMENT, V118, P719; Carmena A, 1998, GENE DEV, V12, P3910, DOI 10.1101/gad.12.24.3910; Cripps RM, 2002, DEV BIOL, V246, P14, DOI 10.1006/dbio.2002.0666; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Dworak HA, 2002, BIOESSAYS, V24, P591, DOI 10.1002/bies.10115; Flanagan JG, 2000, METHOD ENZYMOL, V327, P198, DOI 10.1016/S0076-6879(00)27277-7; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gabay L, 1997, DEVELOPMENT, V124, P3535; Gobron S, 1999, NEUROSCIENCE, V88, P655, DOI 10.1016/S0306-4522(98)00252-8; Ishihara T, 2002, CELL, V109, P639, DOI 10.1016/S0092-8674(02)00748-1; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Klapper R, 2002, MECH DEVELOP, V110, P85, DOI 10.1016/S0925-4773(01)00567-6; Lee HH, 2000, DEVELOPMENT, V127, P5497; Li L, 2000, J EXP MED, V191, P1077, DOI 10.1084/jem.191.6.1077; Loren CE, 2001, GENES CELLS, V6, P531, DOI 10.1046/j.1365-2443.2001.00440.x; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Porsch M, 1998, GENE, V212, P237, DOI 10.1016/S0378-1119(98)00180-2; Riechmann V, 1997, DEVELOPMENT, V124, P2915; San Martin B, 2001, DEVELOPMENT, V128, P3331; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Sym M, 1999, CELL, V98, P25, DOI 10.1016/S0092-8674(00)80603-0; Weiss JB, 2001, CELL, V107, P387, DOI 10.1016/S0092-8674(01)00540-2; Zaffran S, 2001, GENE DEV, V15, P2900	30	133	135	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					507	512		10.1038/nature01916	http://dx.doi.org/10.1038/nature01916			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523446				2022-12-28	WOS:000185648100044
J	Pantsari, MW; Coleman, TA				Pantsari, MW; Coleman, TA			Kala-azar	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Dwight D Eisenhower Army Med Ctr, Ft Gordon, GA 30905 USA	United States Department of Defense; United States Army	Pantsari, MW (corresponding author), Dwight D Eisenhower Army Med Ctr, Ft Gordon, GA 30905 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					E13	E13		10.1056/ENEJMicm010681	http://dx.doi.org/10.1056/ENEJMicm010681			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523156				2022-12-28	WOS:000185644000010
J	Huf, G; Coutinho, ESF; Adams, CE; Borges, RVS; Ferreira, MAV; Silva, FJF; Pereira, AJCR; Abreu, AM; Lugao, SM; Santos, MPCP; Gewandsznajder, M; Mercadante, VRP; Lange, W; Dias, CL; Brasil, MA; Huf, G; Coutinho, ESF; Adams, CE; Fagundes, HM; Lopez, JRRA; Lima, M; Campos, MB; Rozenfeld, S; Braz, RM; Struchiner, CJ; Camacho, LB; Mari, JD				Huf, G; Coutinho, ESF; Adams, CE; Borges, RVS; Ferreira, MAV; Silva, FJF; Pereira, AJCR; Abreu, AM; Lugao, SM; Santos, MPCP; Gewandsznajder, M; Mercadante, VRP; Lange, W; Dias, CL; Brasil, MA; Huf, G; Coutinho, ESF; Adams, CE; Fagundes, HM; Lopez, JRRA; Lima, M; Campos, MB; Rozenfeld, S; Braz, RM; Struchiner, CJ; Camacho, LB; Mari, JD		TREC Collaborative Grp	Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LORAZEPAM; BEHAVIOR	Objective To compare two widely used drug treatments for people with aggression or agitation due to mental illness. Design Pragmatic, randomised clinical trial. Setting Three psychiatric emergency rooms in Rio de Janeiro, Brazil. Subjects 301 aggressive or agitated people. Interventions Open treatment with intramuscular midazolam or intramuscular haloperidol plus promethazine. Main outcome measures Patients tranquil or sedated at 20 minutes. Secondary outcomes: patients tranquil or asleep by 40, 60, and 120 minutes; restrained or given extra drugs within 2 hours; severe adverse events; another episode of agitation or aggression; needing extra visits from doctor during first 24 hours; overall antipsychotic load in first 24 hours; and not discharged by two weeks. Results 151 patients were randomised to midazolam, and 150 to haloperidol-promethazine mix. Follow up for the primary outcome was available for 298 (99%): 134/151 (89%) of patients given midazolam were tranquil or asleep after 20 minutes compared with 101/150 (67%) of those given haloperidol plus promethazine (relative risk 1.32 (95% confidence interval 1.16 to 1.49)). By 40 minutes, midazolam still had a statistically and clinically significant 13% relative advantage (1.13 (1.01 to 1.26)). After 1 hour, about 90% of both groups were tranquil or asleep. One important adverse event occurred in each group: a patient given midazolam had transient respiratory depression, and one given haloperidol-promethazine had a grande mal seizure. Conclusions Both treatments were effective. Midazolam was more rapidly sedating than haloperidol-promethazine, reducing the time people are exposed to aggression. Adverse effects and resources to deal with them should be considered in the choice of the treatment.	Univ Fed Rio de Janeiro, Edificio Hosp Univ, BR-21941590 Rio De Janeiro, Brazil; Fundacao Osvaldo Cruz, Rio De Janeiro, Brazil; Univ Leeds, Leeds, W Yorkshire, England; Inst Municipal Philippe Pinel, Rio De Janeiro, Brazil; Hosp Municipal Jurandyr Manfredini, Rio De Janeiro, Brazil; Inst Municipal Assistencia Saude Nise Silveira, Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; University of Leeds	Huf, G (corresponding author), Univ Fed Rio de Janeiro, Edificio Hosp Univ, Av Brigadeiro Trompowsky S-N,5 Andar,Ilha Fundao, BR-21941590 Rio De Janeiro, Brazil.	gisele@ensp.fiocruz.br	Struchiner, Claudio Jose/HGB-9492-2022; Struchiner, Claudio J/M-9360-2013; R. G. Mercadante, Vitor/ABC-2721-2021; de Jesus Mari, Jair/A-7309-2008; huf, gisele/F-1121-2013; Coutinho, Evandro S/E-2408-2011	Struchiner, Claudio J/0000-0003-2114-847X; R. G. Mercadante, Vitor/0000-0002-1229-2325; de Jesus Mari, Jair/0000-0002-5403-0112; huf, gisele/0000-0002-3560-343X; 				Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Battaglia J, 1997, AM J EMERG MED, V15, P335, DOI 10.1016/S0735-6757(97)90119-4; Binder RL, 1999, PSYCHIATR SERV, V50, P1553, DOI 10.1176/ps.50.12.1553; Coutinho E, 2000, SCHIZOPHR RES, V46, P111, DOI 10.1016/S0920-9964(99)00226-1; Cunnane J., 1994, PSYCHIAT B, V18, P138; Dorevitch A, 1999, AM J PSYCHIAT, V156, P142, DOI 10.1176/ajp.156.1.142; DULEY L, 1995, LANCET, V345, P1455; *EXP CONS GUID GRO, 1999, J CLIN PSYCHIAT S11, V60, P3; Fenton M, 2001, COCHRANE DB SYST REV; Huf G, 2002, BMC PSYCHIATRY, V2, DOI 10.1186/1471-244X-2-11; Huf G, 2002, BMC PSYCHIATRY, V2, DOI 10.1186/1471-244X-2-4; Jablensky A, 1992, Psychol Med Monogr Suppl, V20, P1; Joy CB, 2001, COCHRANE DB SYST REV; Kaplan HI., 1994, KAPLAN SADOCKS SYNOP; McAllister-Williams RH, 2002, BRIT J PSYCHIAT, V180, P485, DOI 10.1192/bjp.180.6.485; Moritz F, 1999, PRESSE MED, V28, P1630; NESTOROS JN, 1982, PROG NEURO-PSYCHOPH, V6, P513, DOI 10.1016/S0278-5846(82)80141-3; PILOWSKY LS, 1992, BRIT J PSYCHIAT, V160, P831, DOI 10.1192/bjp.160.6.831; SALZMAN C, 1991, J CLIN PSYCHIAT, V52, P177; *WHO, WHO MOD LIST ESS DRU; Wing JK, 1998, OP41 ROYAL COLL PSYC; World Medical Association, 2002, WORLD MED ASS DECL H	22	103	107	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 27	2003	327	7417					708	711						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728FZ	14512476				2022-12-28	WOS:000185708300015
J	Laughlin, SB; Sejnowski, TJ				Laughlin, SB; Sejnowski, TJ			Communication in neuronal networks	SCIENCE			English	Review							ENERGY-METABOLISM; OPTIMIZATION; ORIENTATION; PATTERNS; MATTER	Brains perform with remarkable efficiency, are capable of prodigious computation, and are marvels of communication. We are beginning to understand some of the geometric, biophysical, and energy constraints that have governed the evolution of cortical networks. To operate efficiently within these constraints, nature has optimized the structure and function of cortical networks with design principles similar to those used in electronic networks. The brain also exploits the adaptability of biological systems to reconfigure in response to changing needs.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; Salk Institute; University of Cambridge; University of California System; University of California San Diego	Sejnowski, TJ (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.	terry@salk.edu	Sejnowski, Terrence/AAV-5558-2021; Bullmore, Ed/C-1706-2012; Patanaik, Amiya/G-4336-2010	Bullmore, Ed/0000-0002-8955-8283; 	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Aiello LC, 2001, EVOLUTIONARY ANATOMY OF THE PRIMATE CEREBRAL CORTEX, P57; Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Baddeley R, 1997, P ROY SOC B-BIOL SCI, V264, P1775, DOI 10.1098/rspb.1997.0246; Balasubramanian V, 2002, NETWORK-COMP NEURAL, V13, P531, DOI 10.1088/0954-898X/13/4/306; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; Braitenberg V, 1998, CORTEX STAT GEOMETRY; CHERNIAK C, 1994, J NEUROSCI, V14, P2418; Chklovskii DB, 2000, VISION RES, V40, P1765, DOI 10.1016/S0042-6989(00)00023-7; Chklovskii DB, 2002, NEURON, V34, P341, DOI 10.1016/S0896-6273(02)00679-7; Chklovskii DB, 2000, J NEUROPHYSIOL, V83, P2113, DOI 10.1152/jn.2000.83.4.2113; Davis JA, 1998, IEEE T ELECTRON DEV, V45, P580, DOI 10.1109/16.661219; Destexhe A., 2001, THALAMOCORTICAL ASSE, DOI [10.7554/elife.47314, DOI 10.7554/eLife.47314]; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; FAISAL A, UNPUB; FIELD DJ, 1994, NEURAL COMPUT, V6, P559, DOI 10.1162/neco.1994.6.4.559; Franks KM, 2002, BIOESSAYS, V24, P1130, DOI 10.1002/bies.10193; Fries P, 2001, SCIENCE, V291, P1560, DOI 10.1126/science.1055465; HOFMAN MA, 1983, Q REV BIOL, V58, P495, DOI 10.1086/413544; Klyachko VA, 2003, P NATL ACAD SCI USA, V100, P7937, DOI 10.1073/pnas.0932745100; Koch Christof, 1999, P1; Koulakov AA, 2001, NEURON, V29, P519, DOI 10.1016/S0896-6273(01)00223-9; Lennie P, 2003, CURR BIOL, V13, P493, DOI 10.1016/S0960-9822(03)00135-0; Levy WB, 1996, NEURAL COMPUT, V8, P531, DOI 10.1162/neco.1996.8.3.531; Levy WB, 2002, J NEUROSCI, V22, P4746, DOI 10.1523/JNEUROSCI.22-11-04746.2002; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MITCHISON G, 1991, P ROY SOC B-BIOL SCI, V245, P151, DOI 10.1098/rspb.1991.0102; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; Pesaran B, 2002, NAT NEUROSCI, V5, P805, DOI 10.1038/nn890; Ramon y Cajal S, 1995, HISTOLOGY NERVOUS SY; Salinas E, 2001, NAT REV NEUROSCI, V2, P539, DOI 10.1038/35086012; Sarpeshkar R, 1998, NEURAL COMPUT, V10, P1601, DOI 10.1162/089976698300017052; Schreiber S, 2002, NEURAL COMPUT, V14, P1323, DOI 10.1162/089976602753712963; Sejnowski TJ, 1999, NEURON, V24, P773, DOI 10.1016/S0896-6273(00)81025-9; Simoncelli EP, 2001, ANNU REV NEUROSCI, V24, P1193, DOI 10.1146/annurev.neuro.24.1.1193; van Rossum MCW, 2003, J NEUROPHYSIOL, V89, P2406, DOI 10.1152/jn.01106.2002; VanEssen DC, 1997, NATURE, V385, P313, DOI 10.1038/385313a0; von der Malsburg C, 1999, NEURON, V24, P95, DOI 10.1016/S0896-6273(00)80825-9; von der Twer T, 2001, NETWORK-COMP NEURAL, V12, P395, DOI 10.1088/0954-898X/12/3/309; Von Neumann J., 2012, COMPUTER BRAIN; Warnock JD, 2002, IBM J RES DEV, V46, P27, DOI 10.1147/rd.461.0027; Watts D. J., 1998, NATURE, V363, P202; Weibel E.R., 2000, SYMMORPHOSIS FORM FU; White JA, 2000, TRENDS NEUROSCI, V23, P131, DOI 10.1016/S0166-2236(99)01521-0; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197	45	605	619	0	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1870	1874		10.1126/science.1089662	http://dx.doi.org/10.1126/science.1089662			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512617	Green Accepted			2022-12-28	WOS:000185536700039
J	Yan, H; Park, SH; Finkelstein, G; Reif, JH; LaBean, TH				Yan, H; Park, SH; Finkelstein, G; Reif, JH; LaBean, TH			DNA-templated self-assembly of protein arrays and highly conductive nanowires	SCIENCE			English	Article							CONSTRUCTION; COMPUTATION; MACHINE	A DNA nanostructure consisting of four four-arm junctions oriented with a square aspect ratio was designed and constructed. Programmable self-assembly of 4x4 tiles resulted in two distinct lattice morphologies: uniform-width nanoribbons and two-dimensional nanogrids, which both display periodic square cavities. Periodic protein arrays were achieved by templated self-assembly of streptavidin onto the DNA nanogrids containing biotinylated oligonucleotides. On the basis of a two-step metallization procedure, the 4x4 nanoribbons acted as an excellent scaffold for the production of highly conductive, uniform-width, silver nanowires.	Duke Univ, Dept Comp Sci, Durham, NC 27708 USA; Duke Univ, Dept Phys, Durham, NC 27708 USA	Duke University; Duke University	Yan, H (corresponding author), Duke Univ, Dept Comp Sci, Durham, NC 27708 USA.	hy1@cs.duke.edu; thl@cs.duke.edu	Reif, John H/C-2684-2008; LaBean, Thomas H/G-2859-2011	LaBean, Thomas H/0000-0002-6739-2059				ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Benenson Y, 2001, NATURE, V414, P430, DOI 10.1038/35106533; Braich RS, 2002, SCIENCE, V296, P499, DOI 10.1126/science.1069528; Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; FENG L, IN PRESS ANGEW CHEM; Ford WE, 2001, ADV MATER, V13, P1793, DOI 10.1002/1521-4095(200112)13:23<1793::AID-ADMA1793>3.0.CO;2-V; Keren K, 2002, SCIENCE, V297, P72, DOI 10.1126/science.1071247; LaBean T. H., 2003, COMPUTATIONAL BIOL G, P35; LaBean TH, 2000, J AM CHEM SOC, V122, P1848, DOI 10.1021/ja993393e; Li JWJ, 2002, NANO LETT, V2, P315, DOI [10.1021/nl015713+, 10.1021/n1015713+]; Liu QH, 2000, NATURE, V403, P175, DOI 10.1038/35003155; Mao CD, 1999, NATURE, V397, P144, DOI 10.1038/16437; Mao CD, 1999, J AM CHEM SOC, V121, P5437, DOI 10.1021/ja9900398; Mao CD, 2000, NATURE, V407, P493, DOI 10.1038/35035038; Mirkin CA, 2000, INORG CHEM, V39, P2258, DOI 10.1021/ic991123r; Monson CF, 2003, NANO LETT, V3, P359, DOI 10.1021/nl034016+; Niemeyer CM, 1998, ANGEW CHEM INT EDIT, V37, P2265, DOI 10.1002/(SICI)1521-3773(19980904)37:16<2265::AID-ANIE2265>3.0.CO;2-F; Patolsky F, 2002, ANGEW CHEM INT EDIT, V41, P2323, DOI 10.1002/1521-3773(20020703)41:13<2323::AID-ANIE2323>3.0.CO;2-H; Richter J, 2000, ADV MATER, V12, P507, DOI 10.1002/(SICI)1521-4095(200004)12:7<507::AID-ADMA507>3.0.CO;2-G; Seeman NC, 1999, TRENDS BIOTECHNOL, V17, P437, DOI 10.1016/S0167-7799(99)01360-8; Seeman NC, 2003, NATURE, V421, P427, DOI 10.1038/nature01406; Sha RJ, 2000, CHEM BIOL, V7, P743, DOI 10.1016/S1074-5521(00)00024-7; Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998; Winfree E, 2000, J BIOMOL STRUCT DYN, P263; Xiao SJ, 2002, J NANOPART RES, V4, P313, DOI 10.1023/A:1021145208328; Yan H, 2002, NATURE, V415, P62, DOI 10.1038/415062a; Yan H, 2003, P NATL ACAD SCI USA, V100, P8103, DOI 10.1073/pnas.1032954100; Yurke B, 2000, NATURE, V406, P605, DOI 10.1038/35020524	29	1458	1543	11	644	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1882	1884		10.1126/science.1089389	http://dx.doi.org/10.1126/science.1089389			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512621				2022-12-28	WOS:000185536700043
J	Neumann, FJ; Kastrati, A; Pogatsa-Murray, G; Mehilli, J; Bollwein, H; Bestehorn, HP; Schmitt, C; Seyfarth, M; Dirschinger, J; Schomig, A				Neumann, FJ; Kastrati, A; Pogatsa-Murray, G; Mehilli, J; Bollwein, H; Bestehorn, HP; Schmitt, C; Seyfarth, M; Dirschinger, J; Schomig, A			Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLYCOPROTEIN IIB/IIIA INHIBITORS; WAVE MYOCARDIAL-INFARCTION; RECEPTOR INHIBITION; HEPARIN-THERAPY; ANGIOPLASTY; ANGINA; ABCIXIMAB; MANAGEMENT; TIROFIBAN; EVENTS	Context In unstable coronary syndromes, catheter intervention is frequently preceded by antithrombotic treatment to reduce periprocedural risk; however, evidence from clinical trials to support antithrombotic pretreatment is sparse. Objective To test the hypothesis that prolonged antithrombotic pretreatment improves the outcome of catheter intervention in patients with acute unstable coronary syndromes compared with early intervention. Design, Setting, and Patients Randomized controlled trial conducted from February 27, 2000, to April 8, 2002, and including patients admitted to 2 German tertiary care centers with symptoms of unstable angina plus either ST-segment depression or elevation of cardiac troponin T levels. Interventions Patients were randomly allocated to antithrombotic pretreatment for 3 to 5 days or to early intervention after pretreatment for less than 6 hours. In both groups, antithrombotic pretreatment consisted of intravenous unfractionated heparin (60-U/kg bolus followed by infusion adjusted to maintain partial thromboplastin time of 60 to 85 seconds), aspirin (500-mg intravenous bolus followed by 100-mg twice-daily oral dose), oral clopidogrel (600-mg loading dose followed by 75-mg twice-daily dose), and intravenous tirofiban (10-mug/kg bolus followed by continuous infusion of 0.10 mug/kg per min). Main Outcome Measure Composite 30-day incidence of large nonfatal myocardial infarction or death from any cause. Results Of the 410 patients enrolled, 207 were allocated to receive prolonged antithrombotic pretreatment and 203 to receive early intervention. Elevated levels of cardiac troponin T were present in 274 patients (67%), while 268 (65%) had ST-segment depression. The antithrombotic pretreatment and the early intervention groups were well matched with respect to major baseline characteristics and definitive treatment (catheter revascularization: 133 [64.3%] vs 143 [70.4%], respectively; coronary artery bypass graft surgery: 16 [7.7%] vs 16 [7.9%]). The primary end point was reached in 11.6% (3 deaths, 21 infarctions) of the group receiving prolonged antithrombotic pretreatment and in 5.9% (no deaths, 12 infarctions) of the group receiving early intervention (relative risk, 1.96 [95% confidence interval, 1.01-3.82]; P=.04). This outcome was attributable to events occurring before catheterization; after catheterization, both groups incurred 11 events each (P=.92). Conclusion In patients with unstable coronary syndromes, deferral of intervention for prolonged antithrombotic pretreatment does not improve the outcome compared with immediate intervention accompanied by intense antiplatelet treatment.	Herz Zentrum Bad Krozingen, D-79189 Bad Krozingen, Germany; Tech Univ Munich, Med Klin, D-8000 Munich, Germany; Tech Univ Munich, Deutsch Herzzentrum, D-8000 Munich, Germany	Technical University of Munich; German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich	Neumann, FJ (corresponding author), Herz Zentrum Bad Krozingen, Sudring 15, D-79189 Bad Krozingen, Germany.	Franz-Josef.Neumann@herzzentrum.de	, Kastrati/Y-2389-2019; Mehilli, Julinda/F-2629-2016					Berger VW, 2002, CONTROL CLIN TRIALS, V23, P502, DOI 10.1016/S0197-2456(02)00233-7; Bjessmo S, 2001, AM HEART J, V141, P9, DOI 10.1067/mhj.2001.111955; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boersma E, 1999, CIRCULATION, V100, P2045, DOI 10.1161/01.CIR.100.20.2045; Boersma E, 2002, LANCET, V359, P189, DOI 10.1016/S0140-6736(02)07442-1; BRAUNWALD E, 2002, ACC AHA 2002 GUIDELI; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Capture Investigators, 1997, Lancet (North American Edition), V349, P1429; Coller BS, 1997, THROMB HAEMOSTASIS, V78, P730; DEFEYTER P, 1999, TXB INTERVENTIONAL C, P244; DEFEYTER PJ, 1991, CIRCULATION, V83, P927, DOI 10.1161/01.CIR.83.3.927; Fox KAA, 2002, LANCET, V360, P743, DOI 10.1016/S0140-6736(02)09894-X; Hanrath P, 1997, CIRCULATION, V96, P1445; KASTRATI A, 2002, LAT BREAK TRIAL SESS; LASKEY MAL, 1990, AM J CARDIOL, V65, P1425, DOI 10.1016/0002-9149(90)91348-A; LASKEY MAL, 1990, AM J CARDIOL, V65, P179, DOI 10.1016/0002-9149(90)90081-B; Muller I, 2001, HEART, V85, P92, DOI 10.1136/heart.85.1.92; Neumann FJ, 2001, J AM COLL CARDIOL, V37, P1323, DOI 10.1016/S0735-1097(01)01165-2; Pache J, 2002, CATHETER CARDIO INTE, V55, P436, DOI 10.1002/ccd.10092; Schuhlen H, 1998, CIRCULATION, V98, P104, DOI 10.1161/01.CIR.98.2.104; Simoons ML, 2001, LANCET, V357, P1915; Smith SC, 2001, CIRCULATION, V103, P3019, DOI 10.1161/01.CIR.103.24.3019; Stone GW, 2002, CIRCULATION, V105, P2347, DOI 10.1161/01.CIR.0000017635.82128.8C; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 2001, NEW ENGL J MED, V344, P1888, DOI 10.1056/NEJM200106213442502; van den Brand M, 1999, EUR HEART J, V20, P1572, DOI 10.1053/euhj.1999.1662; Wallentin L, 1999, LANCET, V354, P708; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; Zhao XQ, 1999, CIRCULATION, V100, P1609, DOI 10.1161/01.CIR.100.15.1609	29	332	354	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	2003	290	12					1593	1599		10.1001/jama.290.12.1593	http://dx.doi.org/10.1001/jama.290.12.1593			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	723ZK	14506118	Bronze			2022-12-28	WOS:000185461300024
J	von Schwedler, UK; Stuchell, M; Muller, B; Ward, DM; Chung, HY; Morita, E; Wang, HE; Davis, T; He, GP; Cimbora, DM; Scott, A; Krausslich, HG; Kaplan, J; Morham, SG; Sundquist, WI				von Schwedler, UK; Stuchell, M; Muller, B; Ward, DM; Chung, HY; Morita, E; Wang, HE; Davis, T; He, GP; Cimbora, DM; Scott, A; Krausslich, HG; Kaplan, J; Morham, SG; Sundquist, WI			The protein network of HIV budding	CELL			English	Article							LATE-DOMAIN; MULTIVESICULAR-BODY; PLASMA-MEMBRANE; VIRUS; TSG101; HRS; GAG; P6; TRAFFICKING; UBIQUITIN	HIV release requires TSG101, a cellular factor that sorts proteins into vesicles that bud into multivesicular bodies (MVB). To test whether other proteins involved in MVB biogenesis (the class E proteins) also participate in HIV release, we identified 22 candidate human class E proteins. These proteins were connected into a coherent network by 43 different protein-protein interactions, with AIP1 playing a key role in linking complexes that act early (TSG101/ESCRT-I) and late (CHMP4/ESCRT-III) in the pathway. AIP1 also binds the HIV-1 p6(Gag) and EIAV p9(Gag) proteins, indicating that it can function directly in virus budding. Human class E proteins were found in HIV-1 particles, and dominant-negative mutants of late-acting human class E proteins arrested HIV-1 budding through plasmal and endosomal membranes. These studies define a protein network required for human MVB biogenesis and indicate that the entire network participates in the release of HIV and probably many other viruses.	Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA; Univ Klinikum Heidelburg, Abt Virol, D-69120 Heidelberg, Germany; Myriad Pharmaceut Inc, Salt Lake City, UT 84108 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Ruprecht Karls University Heidelberg; Myriad Genetics, Inc	Sundquist, WI (corresponding author), Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA.	wes@biochem.utah.edu	Morita, Eiji/D-2453-2015	Morita, Eiji/0000-0002-3781-6121; Muller, Barbara/0000-0001-5726-5585				Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Basyuk E, 2003, DEV CELL, V5, P161, DOI 10.1016/S1534-5807(03)00188-6; Biscone MJ, 2002, CURR OPIN PHARMACOL, V2, P529, DOI 10.1016/S1471-4892(02)00200-X; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Cook RF, 1998, J VIROL, V72, P1383, DOI 10.1128/JVI.72.2.1383-1393.1998; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002; Denzer K, 2000, J CELL SCI, V113, P3365; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; Freed EO, 2002, J VIROL, V76, P4679, DOI 10.1128/JVI.76.10.4679-4687.2002; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Gross I, 1997, EUR J BIOCHEM, V249, P592, DOI 10.1111/j.1432-1033.1997.t01-1-00592.x; Hermida-Matsumoto L, 2000, J VIROL, V74, P8670, DOI 10.1128/JVI.74.18.8670-8679.2000; Howard TL, 2001, J CELL SCI, V114, P2395; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Kamura T, 2001, J BIOL CHEM, V276, P16528, DOI 10.1074/jbc.M010142200; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Licata JM, 2003, J VIROL, V77, P1812, DOI 10.1128/JVI.77.3.1812-1819.2003; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; Muller B, 2002, J VIROL, V76, P1015, DOI 10.1128/JVI.76.3.1015-1024.2002; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Ott DE, 2000, VIROLOGY, V266, P42, DOI 10.1006/viro.1999.0075; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; POMILLOS O, 2002, NAT STRUCT BIOL, V9, P812; POMILLOS O, 2003, J CELL BIOL, V162, P425; POMILLOS O, 2002, EMBO J, V21, P2397; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Puffer BA, 1998, J VIROL, V72, P10218, DOI 10.1128/JVI.72.12.10218-10221.1998; Puffer BA, 1997, J VIROL, V71, P6541, DOI 10.1128/JVI.71.9.6541-6546.1997; Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x; Scheuring S, 2001, J MOL BIOL, V312, P469, DOI 10.1006/jmbi.2001.4917; SHERER NM, 2003, IN PRESS TRAFFIC; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Vincent O, 2003, MOL CELL BIOL, V23, P1647, DOI 10.1128/MCB.23.5.1647-1655.2003; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; Welker R, 2000, J VIROL, V74, P1168, DOI 10.1128/JVI.74.3.1168-1177.2000	52	656	691	0	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					701	713		10.1016/S0092-8674(03)00714-1	http://dx.doi.org/10.1016/S0092-8674(03)00714-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505570	Bronze			2022-12-28	WOS:000185464000008
J	Allen, MR				Allen, MR			Possible or probable?	NATURE			English	Editorial Material									Univ Oxford, Dept Phys, Oxford OX11 0QXJ, England	University of Oxford	Allen, MR (corresponding author), Univ Oxford, Dept Phys, Oxford OX11 0QXJ, England.		Allen, Myles R/A-5172-2012					ALLEN MR, P 2002 EOMWF PRED SE, P275; Houghton J. T., 2001, CLIMATE CHANGE 2001; Schneider SH, 2002, CLIMATIC CHANGE, V52, P441, DOI 10.1023/A:1014221225434	3	22	22	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					242	242		10.1038/425242a	http://dx.doi.org/10.1038/425242a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679894				2022-12-28	WOS:000185370900023
J	Golden, MR; Marra, CM; Holmes, KK				Golden, MR; Marra, CM; Holmes, KK			Update on syphilis - Resurgence of an old problem	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SEXUALLY-TRANSMITTED-DISEASES; PENICILLIN-G; CLINICAL MANIFESTATIONS; TREPONEMA-PALLIDUM; HIV; PREVALENCE; TRANSMISSION; AZITHROMYCIN; BENZATHINE; DIAGNOSIS		Univ Washington, Ctr AIDS & STD, Div Infect Dis, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Publ Hlth Seattle & King Cty, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Golden, MR (corresponding author), Harborview Med Ctr, Box 359777,325 9th Ave, Seattle, WA 98104 USA.	golden@u.washington.edu	, Holmes/K-6215-2019; Golden, Matthew/AAE-4314-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001846] Funding Source: NIH RePORTER; NIAID NIH HHS [K23 AI01846-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bellis MA, 2002, J EPIDEMIOL COMMUN H, V56, P235, DOI 10.1136/jech.56.3.235; Blankenship KM, 2000, AIDS, V14, pS11, DOI 10.1097/00002030-200006001-00003; Blocker ME, 2000, SEX TRANSM DIS, V27, P53, DOI 10.1097/00007435-200001000-00011; BROWN S T, 1976, Journal of the American Venereal Disease Association, V3, P136; *CDCP, 2002, SEX TRANSM DIS SURV; Centers for Disease Control and Prevention (CDC), 2016, DEV WAT MAN PROGR RE; Ciesielski Carol A., 2003, Curr Infect Dis Rep, V5, P145, DOI 10.1007/s11908-003-0051-5; CLARK EG, 1964, MED CLIN N AM, V48, P613; Collis TK, 2001, CLIN INFECT DIS, V32, P611, DOI 10.1086/318722; DiCarlo RP, 1997, CLIN INFECT DIS, V25, P292, DOI 10.1086/514548; ELLIOTT W C, 1976, Journal of the American Venereal Disease Association, V3, P128; Erbelding EJ, 1997, J INFECT DIS, V176, P1397, DOI 10.1086/517330; FERNANDO WL, 1968, BRIT J VENER DIS, V44, P134; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Garnett GP, 1997, SEX TRANSM DIS, V24, P185, DOI 10.1097/00007435-199704000-00002; HART G, 1986, ANN INTERN MED, V104, P368, DOI 10.7326/0003-4819-104-3-368; HICKS CB, 1987, ANN INTERN MED, V107, P492, DOI 10.7326/0003-4819-107-4-492; Hook EW, 1999, ANN INTERN MED, V131, P434, DOI 10.7326/0003-4819-131-6-199909210-00007; Hook EW, 2002, SEX TRANSM DIS, V29, P486, DOI 10.1097/00007435-200208000-00010; HUTCHINSON CM, 1994, ANN INTERN MED, V121, P94, DOI 10.7326/0003-4819-121-2-199407150-00003; Johnson WD, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001230.pub2; Katz MH, 2002, AM J PUBLIC HEALTH, V92, P388, DOI 10.2105/AJPH.92.3.388; LARSEN SA, 1990, MANUAL TESTS SYPHILI, P2; Laumann EO, 1999, SEX TRANSM DIS, V26, P250, DOI 10.1097/00007435-199905000-00003; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MARRA CM, 1995, ARCH NEUROL-CHICAGO, V52, P68, DOI 10.1001/archneur.1995.00540250072015; Marra CM, 2000, CLIN INFECT DIS, V30, P540, DOI 10.1086/313725; MERRITT H, 1940, NEUROSYPHILIS; Morgan CA, 2002, INFECT IMMUN, V70, P6811, DOI 10.1128/IAI.70.12.6811-6816.2002; PARRAN T, 1937, SHADOW LAND; Rekart ML, 2003, LANCET, V361, P313, DOI 10.1016/S0140-6736(03)12335-5; Riedner G, 2000, SEX TRANSM INFECT, V76, P363, DOI 10.1136/sti.76.5.363; Rolfs RT, 1997, NEW ENGL J MED, V337, P307, DOI 10.1056/NEJM199707313370504; ROMANOWSKI B, 1991, ANN INTERN MED, V114, P1005, DOI 10.7326/0003-4819-114-12-1005; Rompalo AM, 2001, SEX TRANSM DIS, V28, P158, DOI 10.1097/00007435-200103000-00007; ROSAHN P, 1947, J VENER DIS S21, V649, P1; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; Stokes JH, 1945, MODERN CLIN SYPHILOL; WOLF FC, 1980, SEX TRANSM DIS, V7, P49, DOI 10.1097/00007435-198004000-00003; 2002, MMWR MORB MORTAL WKL, V51, P853	40	253	266	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1510	1514		10.1001/jama.290.11.1510	http://dx.doi.org/10.1001/jama.290.11.1510			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RE	13129993				2022-12-28	WOS:000185329000035
J	Gray, N; Boyle, P				Gray, N; Boyle, P			The future of the nicotine-addiction market	LANCET			English	Editorial Material							HEALTH		European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Gray, N (corresponding author), European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy.		Boyle, Peter/A-4380-2014	Boyle, Peter/0000-0001-6251-0610				Gray N, 2000, TOB CONTROL, V9, P351, DOI 10.1136/tc.9.3.351; Henningfield JE, 2001, TOB CONTROL, V10, P253, DOI 10.1136/tc.10.3.253; Ramstrom L., 2000, NICOTINE PUBLIC HLTH, P159; Sumner W, 2003, TOB CONTROL, V12, P124, DOI 10.1136/tc.12.2.124; 1991, LANCET, V337, P1191; DATABASE ED RESOURCE	6	20	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					845	846		10.1016/S0140-6736(03)14348-6	http://dx.doi.org/10.1016/S0140-6736(03)14348-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678968				2022-12-28	WOS:000185329400005
J	Han, SC; Tang, RH; Anderson, LK; Woerner, TE; Pei, ZM				Han, SC; Tang, RH; Anderson, LK; Woerner, TE; Pei, ZM			A cell surface receptor mediates extracellular Ca2+ sensing in guard cells	NATURE			English	Article							CALCIUM; ARABIDOPSIS; PLANT; OSCILLATIONS; REGULATOR; PROTEINS; CHANNEL; BINDING	Extracellular Ca2+ (Ca-o(2+)) is required for various physiological and developmental processes in animals and plants(1-3). In response to varied Ca-o(2+) levels, plants maintain relatively constant internal Ca2+ content, suggesting a precise regulatory mechanism for Ca2+ homeostasis(4). However, little is known about how plants monitor Ca-o(2+) status and whether Ca-o(2+)-sensing receptors exist. The effects of Ca-o(2+) on guard cells in promoting stomatal closure by inducing increases in the concentration of cytosolic Ca2+ ([Ca2+](i))(5-8) provide a clue to Ca-o(2+) sensing. Here we have used a functional screening assay in mammalian cells 9 to isolate an Arabidopsis complementary DNA clone encoding a Ca2+-sensing receptor, CAS. CAS is localized to the plasma membrane, exhibits low-affinity/high-capacity Ca2+ binding, and mediates Ca-o(2+)-induced [Ca2+](i) increases. CAS is expressed predominantly in the shoot, including guard cells. Repression of CAS disrupts Ca-o(2+) signalling in guard cells, and impairs bolting (swift upward growth at the transition to seed production) in response to Ca2+ deficiency, so we conclude that CAS may be a primary transducer of Ca-o(2+) in plants.	Duke Univ, Dept Biol, Dev Cell & Mol Biol Grp, Durham, NC 27708 USA; Duke Univ, Dept Chem, Durham, NC 27708 USA	Duke University; Duke University	Pei, ZM (corresponding author), Duke Univ, Dept Biol, Dev Cell & Mol Biol Grp, Durham, NC 27708 USA.	zpei@duke.edu		Han, Shengcheng/0000-0002-4039-7589; Tang, Ruhang/0000-0003-4918-3525; Pei, Zhen-Ming/0000-0003-1473-696X				Allen GJ, 2001, NATURE, V411, P1053, DOI 10.1038/35082575; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; CLARKSON DT, 1984, PLANT CELL ENVIRON, V7, P449, DOI 10.1111/j.1365-3040.1984.tb01435.x; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; Li X, 1999, CELL, V98, P329, DOI 10.1016/S0092-8674(00)81962-5; LONERAGAN JF, 1969, AUST J AGR RES, V20, P465, DOI 10.1071/AR9690465; Luan S, 2002, PLANT CELL, V14, pS389, DOI 10.1105/tpc.001115; MACROBBIE EAC, 1992, PHILOS T R SOC B, V338, P5, DOI 10.1098/rstb.1992.0124; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MCAINSH MR, 1995, PLANT CELL, V7, P1207, DOI 10.1105/tpc.7.8.1207; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Pei ZM, 1998, P NATL ACAD SCI USA, V95, P6548, DOI 10.1073/pnas.95.11.6548; Roelfsema MRG, 2002, NEW PHYTOL, V153, P425, DOI 10.1046/j.1469-8137.2002.00344.x; Sanders D, 2002, PLANT CELL, V14, pS401, DOI 10.1105/tpc.002899; Sattelmacher B, 2001, NEW PHYTOL, V149, P167, DOI 10.1046/j.1469-8137.2001.00034.x; Schroeder JI, 2001, NATURE, V410, P327, DOI 10.1038/35066500; SCHWARTZ A, 1985, PLANT PHYSIOL, V79, P1003, DOI 10.1104/pp.79.4.1003; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Staxen I, 1999, P NATL ACAD SCI USA, V96, P1779, DOI 10.1073/pnas.96.4.1779; Wakabayashi H, 2002, BIOCHEMISTRY-US, V41, P8485, DOI 10.1021/bi025589o	26	163	179	5	63	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					196	200		10.1038/nature01932	http://dx.doi.org/10.1038/nature01932			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968184				2022-12-28	WOS:000185236000047
J	Wallraff, A; Lukashenko, A; Lisenfeld, J; Kemp, A; Fistul, MV; Koval, Y; Ustinov, AV				Wallraff, A; Lukashenko, A; Lisenfeld, J; Kemp, A; Fistul, MV; Koval, Y; Ustinov, AV			Quantum dynamics of a single vortex	NATURE			English	Article							JOSEPHSON TUNNEL-JUNCTIONS; FLUXON DYNAMICS; MAGNETIC-FIELD; SUPERCONDUCTORS; STATES; SUPERPOSITION; TEMPERATURE; VORTICES; MOTION; QUBIT	Vortices occur naturally in a wide range of gases and fluids, from macroscopic to microscopic scales. In Bose-Einstein condensates of dilute atomic gases(1), superfluid helium(2) and superconductors, the existence of vortices is a consequence of the quantum nature of the system. Quantized vortices of supercurrent(3) are generated by magnetic flux penetrating the material, and play a key role in determining the material properties(4) and the performance of superconductor-based devices(5,6). At high temperatures the dynamics of such vortices are essentially classical, while at low temperatures previous experiments have suggested collective quantum dynamics(7,8). However, the question of whether vortex tunnelling occurs at low temperatures has been addressed only for large collections of vortices. Here we study the quantum dynamics of an individual vortex in a superconducting Josephson junction. By measuring the statistics of the vortex escape from a controllable pinning potential, we demonstrate the existence of quantized levels of the vortex energy within the trapping potential well and quantum tunnelling of the vortex through the pinning barrier.	Univ Erlangen Nurnberg, Inst Phys 3, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Wallraff, A (corresponding author), Yale Univ, Dept Appl Phys, New Haven, CT 06520 USA.		Lisenfeld, Juergen/O-7449-2014; Ustinov, Alexey/J-4663-2015; Wallraff, Andreas J/C-2130-2009; Fistul, Mikhail/AAD-2185-2022	Lisenfeld, Juergen/0000-0001-8605-4373; Ustinov, Alexey/0000-0002-1202-1787; Wallraff, Andreas J/0000-0002-3476-4485; 				Abo-Shaeer JR, 2001, SCIENCE, V292, P476, DOI 10.1126/science.1060182; Bennett CH, 2000, NATURE, V404, P247, DOI 10.1038/35005001; Blaauwgeers R, 2000, NATURE, V404, P471, DOI 10.1038/35006583; BLATTER G, 1994, REV MOD PHYS, V66, P1125, DOI 10.1103/RevModPhys.66.1125; Bugoslavsky Y, 2001, NATURE, V410, P563, DOI 10.1038/35069029; Chiorescu I, 2003, SCIENCE, V299, P1869, DOI 10.1126/science.1081045; CLARKE J, 1988, SCIENCE, V239, P992, DOI 10.1126/science.239.4843.992; DEVORET MH, 1992, QUANTUM TUNNELING CO; Fazio R, 2001, PHYS REP, V355, P235, DOI 10.1016/S0370-1573(01)00022-9; Friedman JR, 2000, NATURE, V406, P43, DOI 10.1038/35017505; FULTON TA, 1974, PHYS REV B, V9, P4760, DOI 10.1103/PhysRevB.9.4760; GRONBECHJENSEN N, 1991, PHYS LETT A, V154, P14, DOI 10.1016/0375-9601(91)90420-D; Hoekstra AFT, 1998, PHYS REV LETT, V80, P4293, DOI 10.1103/PhysRevLett.80.4293; Huebener R. P, 2001, MAGNETIC FLUX STRUCT, V2nd; Kato T, 1996, J PHYS SOC JPN, V65, P2963, DOI 10.1143/JPSJ.65.2963; Kemp A, 2002, PHYS STATUS SOLIDI B, V233, P472, DOI 10.1002/1521-3951(200210)233:3<472::AID-PSSB472>3.0.CO;2-J; Koval Y, 1999, IEEE T APPL SUPERCON, V9, P3957, DOI 10.1109/77.783894; Lee CS, 1999, NATURE, V400, P337, DOI 10.1038/22578; Martucciello N, 1998, PHYS REV B, V57, P5444, DOI 10.1103/PhysRevB.57.5444; MCLAUGHLIN DW, 1978, PHYS REV A, V18, P1652, DOI 10.1103/PhysRevA.18.1652; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; Nicodemi M, 2001, PHYS REV LETT, V86, P4378, DOI 10.1103/PhysRevLett.86.4378; Pashkin YA, 2003, NATURE, V421, P823, DOI 10.1038/nature01365; Savel'ev S, 2002, NAT MATER, V1, P179, DOI 10.1038/nmat746; Shnirman A, 1997, PHYS REV B, V56, P14677, DOI 10.1103/PhysRevB.56.14677; TIGHE TS, 1991, PHYS REV B, V44, P10286, DOI 10.1103/PhysRevB.44.10286; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; Ustinov AV, 1998, PHYSICA D, V123, P315, DOI 10.1016/S0167-2789(98)00131-6; Ustinov AV, 1997, J LOW TEMP PHYS, V106, P193, DOI 10.1007/BF02399614; van der Wal CH, 2000, SCIENCE, V290, P773, DOI 10.1126/science.290.5492.773; VANDERZANT HSJ, 1991, PHYS REV LETT, V66, P531; Wallraff A, 2003, REV SCI INSTRUM, V74, P3740, DOI 10.1063/1.1588752; Wallraff A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.037003; Wallraff A, 2000, J LOW TEMP PHYS, V118, P543, DOI 10.1023/A:1004674908169	34	144	147	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2003	425	6954					155	158		10.1038/nature01826	http://dx.doi.org/10.1038/nature01826			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968173				2022-12-28	WOS:000185236000035
J	Villunger, A; Michalak, EM; Coultas, L; Mullauer, F; Bock, G; Ausserlechner, MJ; Adams, JM; Strasser, A				Villunger, A; Michalak, EM; Coultas, L; Mullauer, F; Bock, G; Ausserlechner, MJ; Adams, JM; Strasser, A			p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa	SCIENCE			English	Article							COLORECTAL-CANCER CELLS; BCL-2 FAMILY; DNA-DAMAGE; P53; DEATH; GENE; THYMOCYTES; EXPRESSION; INDUCTION; SURVIVAL	Apoptosis provoked by DNA damage requires the p53 tumor suppressor, but which of the many p53-regulated genes are required has remained unknown. Two genes induced by this transcription factor, noxa and puma (bbc3), stand out, because they encode BH3-only proteins, proapoptotic members of the Bcl-2 family required to initiate apoptosis. In mice with either noxa or puma disrupted, we observed decreased DNA damage-induced apoptosis in fibroblasts, although only loss of Puma protected lymphocytes from cell death. Puma deficiency also protected cells against diverse p53-independent cytotoxic insults, including cytokine deprivation and exposure to glucocorticoids, the kinase inhibitor staurosporine, or phorbol ester. Hence, Puma and Noxa are critical mediators of the apoptotic responses induced by p53 and other agents.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Innsbruck, Inst Pathophysiol, A-6020 Innsbruck, Austria	Walter & Eliza Hall Institute; University of Innsbruck	Villunger, A (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	andreas.villunger@uibk.ac.at; strasser@wehi.edu.au	Strasser, Andreas/C-7581-2013; Adams, Jerry M/E-1199-2013	Strasser, Andreas/0000-0002-5020-4891; Adams, Jerry/0000-0002-4360-8628; Michalak, Ewa/0000-0002-5772-2122; Ausserlechner, Michael/0000-0002-1015-2302				Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SENTMAN CL, 1991, CELL, V67, P79; SHIBUE T, 2003, GENE DEV, V2, P2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; VILLUNGER A, UNPUB; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	24	1030	1065	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1036	1038		10.1126/science.1090072	http://dx.doi.org/10.1126/science.1090072			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14500851				2022-12-28	WOS:000186396300045
J	Rietveld, RP; van Weert, HCPM; ter Riet, G; Bindels, PJE				Rietveld, RP; van Weert, HCPM; ter Riet, G; Bindels, PJE			Diagnostic impact of signs and symptoms in acute infectious conjunctivitis: systematic literature search	BRITISH MEDICAL JOURNAL			English	Article									Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, Div Clin Methods & Publ Hlth, NL-1105 AZ Amsterdam, Netherlands; Univ Spital Zurich, Horten Zentrum, CH-8091 Zurich, Switzerland	University of Amsterdam; Academic Medical Center Amsterdam; University of Zurich; University Zurich Hospital	Rietveld, RP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, Div Clin Methods & Publ Hlth, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.		Riet, Gerben ter/A-6943-2011	Riet, Gerben ter/0000-0002-2231-7637				KANSKI JJ, 1999, CLIN OPHTHALMOLOGY S; KARCHMER JH, 1997, CORNEA; Riva C, 1992, Minerva Pediatr, V44, P595; Sheikh A, 2001, BRIT J GEN PRACT, V51, P473; TASMAN W, 2001, DUANES CLIN OPTHALMO	5	37	39	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					789	789		10.1136/bmj.327.7418.789	http://dx.doi.org/10.1136/bmj.327.7418.789			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525879	Green Published, Bronze			2022-12-28	WOS:000185805100023
J	Calverley, PMA; Walker, P				Calverley, PMA; Walker, P			Chronic obstructive pulmonary disease	LANCET			English	Review							QUALITY-OF-LIFE; AIR-FLOW OBSTRUCTION; RANDOMIZED CONTROLLED-TRIAL; VOLUME-REDUCTION SURGERY; ACUTE EXACERBATIONS; HEALTH-STATUS; LUNG-FUNCTION; NONINVASIVE VENTILATION; INHALED CORTICOSTEROIDS; GLOBAL BURDEN	Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability worldwide. Recognition that the burden of this disorder will continue to increase over the next 20 years despite medical intervention has stimulated new research into the underlying mechanisms, leading to a rational basis for evaluation of existing therapies, and has suggested novel treatment approaches. Tobacco exposure remains the main but not exclusive cause of COPD. Whether the lung is injured by changes in the balance of proteases and antiproteases, tissue damage by oxidative stress, or a combination of the two is still not known. The genetic basis of susceptibility to COPD is now being studied as is the role of computed tomography in the identification of structural damage in individuals with less symptomatic disease. Clinical diagnosis still relies heavily on an appropriate history confirmed by abnormal spirometry. Smoking cessation is possible in a substantial proportion of individuals with symptoms but is most effective if withdrawal is supported by pharmacological treatment. Treatment with long-acting inhaled bronchodilators and, in more severe disease, inhaled corticosteroids reduces symptoms and exacerbation frequency and improves health status. Rehabilitation can be even more effective, at least for a year after the treatment. Recent guidelines have made practical suggestions about how to optimise these treatments and when to consider addition of oxygen, surgery, and non-invasive ventilation. Regular review of this guidance is important if future management advances are to be implemented effectively.	Univ Liverpool, Dept Med, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Calverley, PMA (corresponding author), Aintree Univ Hosp NHS Fdn Trust, Ctr Clin Sci, Longmoor Lane, Liverpool L9 7AL, Merseyside, England.	pmacal@liv.ac.uk						Agusti AGN, 2001, NOVART FDN SYMP, V234, P242; Altose MD, 2000, NEW ENGL J MED, V343, P1902; American Thoracic Society, 1999, AM J RESP CRIT CARE, V159, P1666; [Anonymous], 1980, Ann Intern Med, V93, P391; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1999, AM J RESP CRIT CARE, V159, pS1; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Anyanwu AC, 2002, HEART, V87, P449, DOI 10.1136/heart.87.5.449; Barnes PJ, 2000, AM J RESP CRIT CARE, V161, P342; Baudouin S, 2002, THORAX, V57, P192; Berry MJ, 1999, AM J RESP CRIT CARE, V160, P1248, DOI 10.1164/ajrccm.160.4.9901014; Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley PMA, 2000, AM J RESP CRIT CARE, V161, P341; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; CHAPMAN KR, 1992, CAN MED ASSOC J, V147, P420; COLEBATCH HJ, 1973, J APPL PHYSIOL, V34, P143, DOI 10.1152/jappl.1973.34.2.143; Compton CH, 2001, LANCET, V358, P265, DOI 10.1016/S0140-6736(01)05481-2; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; Corradi M, 2001, AM J RESP CRIT CARE, V163, P854, DOI 10.1164/ajrccm.163.4.2001108; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; Cotton MM, 2000, THORAX, V55, P902, DOI 10.1136/thorax.55.11.902; Criner GJ, 1999, AM J RESP CRIT CARE, V160, P2018, DOI 10.1164/ajrccm.160.6.9902117; DAHL R, AM J RESP CRIT CARE, V5, P778; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; Davies L, 2000, BRIT MED J, V321, P1265, DOI 10.1136/bmj.321.7271.1265; Davies L, 1999, LANCET, V354, P456, DOI 10.1016/S0140-6736(98)11326-0; Diaz O, 2000, EUR RESPIR J, V16, P269, DOI 10.1034/j.1399-3003.2000.16b14.x; Dirksen A, 1999, AM J RESP CRIT CARE, V160, P1468, DOI 10.1164/ajrccm.160.5.9901055; Domingo-Salvany A, 2002, AM J RESP CRIT CARE, V166, P680, DOI 10.1164/rccm.2112043; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; Donohue JF, 2002, CHEST, V122, P47, DOI 10.1378/chest.122.1.47; Dowson LJ, 2001, AM J RESP CRIT CARE, V163, P936, DOI 10.1164/ajrccm.163.4.2007048; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; Fishman A, 2003, NEW ENGL J MED, V348, P2059; Fishman A, 2001, NEW ENGL J MED, V345, P1075; FLENLEY DC, 1981, LANCET, V1, P681; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; Geddes D, 2000, NEW ENGL J MED, V343, P239, DOI 10.1056/NEJM200007273430402; GOLDSTEIN RS, 1994, LANCET, V344, P1394, DOI 10.1016/S0140-6736(94)90568-1; Gorecka D, 1997, THORAX, V52, P674, DOI 10.1136/thx.52.8.674; Gravil JH, 1998, LANCET, V351, P1853, DOI 10.1016/S0140-6736(97)11048-0; Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7; Hajiro T, 1998, AM J RESP CRIT CARE, V157, P785, DOI 10.1164/ajrccm.157.3.9703055; Hansen EF, 1999, AM J RESP CRIT CARE, V159, P1267, DOI 10.1164/ajrccm.159.4.9807121; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hosenpud JD, 1998, LANCET, V351, P24, DOI 10.1016/S0140-6736(97)06405-2; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Jones PW, 1997, AM J RESP CRIT CARE, V155, P1283, DOI 10.1164/ajrccm.155.4.9105068; Kasahara Y, 2001, AM J RESP CRIT CARE, V163, P737, DOI 10.1164/ajrccm.163.3.2002117; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Ketelaars CAJ, 1996, THORAX, V51, P39, DOI 10.1136/thx.51.1.39; Lancaster T, 2000, BRIT MED J, V321, P355, DOI 10.1136/bmj.321.7257.355; Lomas DA, 2002, J CLIN INVEST, V110, P1585, DOI 10.1172/JCI200216782; *LUNG ATHM INF AG, 20014 ST GEORG HOSP; Mahler DA, 1999, CHEST, V115, P957, DOI 10.1378/chest.115.4.957; Mahler DA, 2002, AM J RESP CRIT CARE, V166, P1084, DOI 10.1164/rccm.2112055; Maltais F, 2002, AM J RESP CRIT CARE, V165, P698, DOI 10.1164/ajrccm.165.5.2109093; McCloskey SC, 2001, AM J RESP CRIT CARE, V164, P1419, DOI 10.1164/ajrccm.164.8.2105002; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; Milic-Emili J, 2000, CHEST, V117, p219S, DOI 10.1378/chest.117.5_suppl_1.219S-a; MONSO E, 1995, AM J RESP CRIT CARE, V152, P1316, DOI 10.1164/ajrccm.152.4.7551388; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175, DOI 10.1164/ajrccm.162.3.2001063; Morgan MDL, 2001, THORAX, V56, P827; MORGAN MDL, 2001, EUR RESP SOC C BERL; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; MURRAY CJL, 2001, 36 WHO; *NAT CTR HLTH STAT, 1974, VIT HLTH STAT 10; *NAT HEART LUNG BL, 2002, NHLBI MORB MORT CHAR; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Nishikawa M, 1999, AM J RESP CELL MOL, V20, P189, DOI 10.1165/ajrcmb.20.2.3305; Nishimura K, 2002, CHEST, V121, P1434, DOI 10.1378/chest.121.5.1434; O'Donnell DE, 1999, AM J RESP CRIT CARE, V160, P542, DOI 10.1164/ajrccm.160.2.9901038; O'Donnell DE, 2001, AM J RESP CRIT CARE, V163, P892, DOI 10.1164/ajrccm.163.4.2007026; O'Donnell DE, 2001, AM J RESP CRIT CARE, V164, P770, DOI 10.1164/ajrccm.164.5.2012122; Ojoo JC, 2002, THORAX, V57, P167, DOI 10.1136/thorax.57.2.167; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852, DOI 10.1164/ajrccm.155.3.9117016; Osman LM, 1997, THORAX, V52, P67; Pandey M R, 1985, Tokai J Exp Clin Med, V10, P471; PANDEY MR, 1984, THORAX, V39, P331, DOI 10.1136/thx.39.5.331; Patel IS, 2002, THORAX, V57, P759, DOI 10.1136/thorax.57.9.759; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pearson MG, 1997, THORAX, V52, pS1; PENMAN RWB, 1970, AM REV RESPIR DIS, V101, P536; PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701, DOI 10.1164/ajrccm.154.3.8810608; Pesci A, 1998, EUR RESPIR J, V12, P380, DOI 10.1183/09031936.98.12020380; PETO R, 1983, AM REV RESPIR DIS, V128, P491, DOI 10.1164/arrd.1983.128.3.491; Plant PK, 2000, THORAX, V55, P550, DOI 10.1136/thorax.55.7.550; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; Ram FSF, 2003, COCHRANE LIB; Rennard S, 2002, EUR RESPIR J, V20, P1; Rennard SI, 2001, AM J RESP CRIT CARE, V163, P1087, DOI 10.1164/ajrccm.163.5.9903053; Retamales I, 2001, AM J RESP CRIT CARE, V164, P469, DOI 10.1164/ajrccm.164.3.2007149; Roberts CM, 1996, THORAX, V51, P831, DOI 10.1136/thx.51.8.831; Rodriguez-Roisin R, 2000, CHEST, V117, p398S, DOI 10.1378/chest.117.5_suppl_2.398S; *ROYAL COLL PHYS, 1999, DOM OX THER SERV CLI; Saeta M, 1999, AM J RESP CRIT CARE, V160, P711, DOI 10.1164/ajrccm.160.2.9812020; Sala E, 1999, AM J RESP CRIT CARE, V159, P1726, DOI 10.1164/ajrccm.159.6.9804136; Sandford AJ, 2002, THORAX, V57, P736, DOI 10.1136/thorax.57.8.736; Schols AMWJ, 1998, AM J RESP CRIT CARE, V157, P1791, DOI 10.1164/ajrccm.157.6.9705017; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032; Sethi S, 2000, CHEST, V118, P1557, DOI 10.1378/chest.118.6.1557; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Silverman EK, 1998, AM J RESP CRIT CARE, V157, P1770, DOI 10.1164/ajrccm.157.6.9706014; Sin DD, 2001, AM J RESP CRIT CARE, V164, P580, DOI 10.1164/ajrccm.164.4.2009033; Skwarska E, 2000, THORAX, V55, P907, DOI 10.1136/thorax.55.11.907; Soler N, 1998, AM J RESP CRIT CARE, V157, P1498, DOI 10.1164/ajrccm.157.5.9711044; Soriano JB, 2000, THORAX, V55, P789, DOI 10.1136/thorax.55.9.789; SORIANO JB, 2002, EUR RESPIR J, V20, P799; Spencer S, 2001, AM J RESP CRIT CARE, V163, P122, DOI 10.1164/ajrccm.163.1.2005009; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; Tashkin DP, 2001, LANCET, V357, P1571, DOI 10.1016/S0140-6736(00)04724-3; Thompson WH, 1996, AM J RESP CRIT CARE, V154, P407, DOI 10.1164/ajrccm.154.2.8756814; THURLBECK WM, 1999, CHRONIC AIRFLOW OBST; Turato G, 2002, AM J RESP CRIT CARE, V166, P105, DOI 10.1164/rccm.2111084; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Vincken W, 2002, EUR RESPIR J, V19, P209, DOI 10.1183/09031936.02.00238702; WIJKSTRA PJ, 1994, EUR RESPIR J, V7, P269, DOI 10.1183/09031936.94.07020269; Young P, 1999, AUST NZ J MED, V29, P59, DOI 10.1111/j.1445-5994.1999.tb01589.x; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458	128	183	196	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2003	362	9389					1053	1061		10.1016/S0140-6736(03)14416-9	http://dx.doi.org/10.1016/S0140-6736(03)14416-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522537				2022-12-28	WOS:000185564600024
J	Edwards, A; Unigwe, S; Elwyn, G; Hood, K				Edwards, A; Unigwe, S; Elwyn, G; Hood, K			Effects of communicating individual risks in screening programmes: Cochrane systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; RANDOMIZED TRIAL; DECISION-MAKING; HEALTH-CARE; MAMMOGRAPHY; INTERVENTIONS; OUTCOMES; IMPACT; SCALE; INFORMATION	Objective To assess the effects of different types of individualised risk communication for patients who are deciding whether to participate in screening. Design Systematic review. Data sources Specialist register of the Cochrane consumers and communication review group, scientific databases, and a manual follow up of references. Selection of studies Studies were randomised controlled trials addressing decisions by patients whether or not to undergo screening and incorporating an intervention with an element of "individualised" risk communication-based on the individual's own risk factors for a condition (such as age or family history). Outcome measures The principal outcome was uptake of screening tests; further cognitive and affective measures were also assessed to gauge informed decision making. Results 13 studies were included, 10 of which addressed mammography programmes. Individualised risk communication was associated with an increased uptake of screening tests (odds ratio 1.5, 95% confidence interval 1.11 to 2.03). Few cognitive or affective outcomes were reported consistently, so it was not possible to conclude whether this increase in the uptake of tests was related to informed decision making by patients. Conclusions Individualised risk estimates may be effective for purposes of population health, but their effects on increasing uptake of screening programmes may not be interpretable as evidence of informed decision making by patients. Greater attention is required to ways of developing interventions for screening programmes that can achieve this.	Univ Coll Swansea, Swansea Clin Sch, Dept Primary Care, Swansea SA2 8PP, W Glam, Wales; Cardiff Univ, Coll Med, Llanedeyrn Hlth Ctr, Dept Gen Practice, Cardiff CF23 9PN, S Glam, Wales	Swansea University; Cardiff University	Edwards, A (corresponding author), Univ Coll Swansea, Swansea Clin Sch, Dept Primary Care, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	a.g.k.edwards@swan.ac.uk	Elwyn, G./L-4292-2015; Hood, Kerenza/C-2528-2008; Elwyn, Glyn/B-4798-2009	Hood, Kerenza/0000-0002-5268-8631; Elwyn, Glyn/0000-0002-0917-6286				Bastani R, 1999, PREV MED, V29, P355, DOI 10.1006/pmed.1999.0556; Bottorff JL, 1998, PATIENT EDUC COUNS, V33, P67, DOI 10.1016/S0738-3991(97)00047-5; Britton A, 1998, HLTH TECHNOLOGY ASSE, V2, P1; CHAMPION V, 1995, J BEHAV MED, V18, P169, DOI 10.1007/BF01857868; CHAMPION VL, 1994, MED CARE, V32, P118, DOI 10.1097/00005650-199402000-00003; Covello V.T., 1986, RISK ABSTRACTS, V3, P171; CURRY SJ, 1993, PREV MED, V22, P350, DOI 10.1006/pmed.1993.1029; Edwards A, 2000, J EVAL CLIN PRACT, V6, P177, DOI 10.1046/j.1365-2753.2000.00212.x; Edwards A, 2000, MED DECIS MAKING, V20, P290, DOI 10.1177/0272989X0002000305; Edwards A, 2001, J HEALTH COMMUN, V6, P61, DOI 10.1080/10810730150501413; Edwards A, 1999, MED DECIS MAKING, V19, P428, DOI 10.1177/0272989X9901900411; EDWARDS A, 2003, COCHRANE LIB; FISCHHOFF B, 1999, J NATL CANC I MONOGR, V25, P7, DOI DOI 10.1093/OXFORDJOURNALS.JNCIMONOGRAPHS.A024213; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; General Medical Council, 1999, SEEK PAT CONS ETH CO; GIGERENZER G, 2002, RECKONING RISK LEARN, P201; HolmesRovner M, 1996, MED DECIS MAKING, V16, P58, DOI 10.1177/0272989X9601600114; Hutchison B, 1998, BMJ-BRIT MED J, V316, P1208, DOI 10.1136/bmj.316.7139.1208; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JEPSON R, DETERMINANTS SCREENI; KEENEY RL, 1986, RISK ANAL, V6, P417, DOI 10.1111/j.1539-6924.1986.tb00954.x; Kreuter MW, 1996, HEALTH EDUC RES, V11, P97, DOI 10.1093/her/11.1.97; LEE C Y, 1991, Yonsei Medical Journal, V32, P131; Lerman C, 1997, JNCI-J NATL CANCER I, V89, P148, DOI 10.1093/jnci/89.2.148; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; LERMAN C, 1995, J NATL CANCER I, V87, P286, DOI 10.1093/jnci/87.4.286; LLEWELLYNTHOMAS HA, 1995, MED DECIS MAKING, V15, P101, DOI 10.1177/0272989X9501500201; Marteau T M, 2001, Health Expect, V4, P99, DOI 10.1046/j.1369-6513.2001.00140.x; Marteau TM, 2002, BRIT MED J, V325, P78, DOI 10.1136/bmj.325.7355.78; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Matthews E J, 1999, Health Libr Rev, V16, P112; Myers RE, 1999, CANCER-AM CANCER SOC, V86, P88, DOI 10.1002/(SICI)1097-0142(19990701)86:1<88::AID-CNCR14>3.0.CO;2-D; *NAT CTR REV DISS, 1996, 4 NAT CTR REV DISS; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105; Raffle A E, 2001, Health Expect, V4, P92, DOI 10.1046/j.1369-6513.2001.00138.x; Raffle AE, 2003, BRIT MED J, V326, P901, DOI 10.1136/bmj.326.7395.901; Rimer BK, 2001, PATIENT EDUC COUNS, V43, P269; Rogers WA, 2002, BRIT J GEN PRACT, V52, P663; Sarfati D, 1998, J MED SCREEN, V5, P137, DOI 10.1136/jms.5.3.137; Saywell RM, 1999, PREV MED, V29, P374, DOI 10.1006/pmed.1999.0568; Schwartz MD, 1999, AM J PUBLIC HEALTH, V89, P924, DOI 10.2105/AJPH.89.6.924; SKINNER CS, 1994, AM J PUBLIC HEALTH, V84, P43, DOI 10.2105/AJPH.84.1.43; Slaytor EK, 1998, BRIT MED J, V317, P263, DOI 10.1136/bmj.317.7153.263; StewartBrown S, 1997, BRIT MED J, V314, P533, DOI 10.1136/bmj.314.7080.533	45	76	76	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 27	2003	327	7417					703	707		10.1136/bmj.327.7417.703	http://dx.doi.org/10.1136/bmj.327.7417.703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	728FZ	14512475	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000185708300014
J	Webber, LJ; Stubbs, S; Stark, J; Trew, GH; Margara, R; Hardy, K; Franks, S				Webber, LJ; Stubbs, S; Stark, J; Trew, GH; Margara, R; Hardy, K; Franks, S			Formation and early development of follicles in the polycystic ovary	LANCET			English	Article							TERM-FOLLOW-UP; WOMEN; HORMONE; GROWTH; CELLS	Background Polycystic ovary syndrome is the most common cause of anovulatory infertility. It has long-term health implications and is an important risk factor for type 2 diabetes. However, little is known about the cause of polycystic ovaries. We have used detailed morphological analysis to assess the hypothesis that there is an intrinsic ovarian abnormality that affects the earliest stages of follicular development. Methods We took small cortical biopsies during routine laparoscopy from 24 women with normal ovaries and regular cycles and from 32 women with polycystic ovaries, 16 of whom had regular, ovulatory cycles and 16 of whom had oligomenorrhoea. We used computerised image analysis to assess the density and developmental stage of small preantral follicles in serial sections of fixed tissue. Findings Median density of small preantral follicles, including those at primordial and primary stages, was six-fold greater in biopsies from polycystic ovaries in anovulatory women than in normal ovaries (p=0.009). In both ovulatory and anovulatory women with polycystic ovaries, we noted a significant increase in the percentage of early growing (primary) follicles and a reciprocal decrease in the proportion of primordial follicles compared with normal ovaries. Interpretation Our findings indicate that there are fundamental differences between polycystic and normal ovaries in early follicular development, suggesting an intrinsic ovarian abnormality. The increased density of small preantral follicles in polycystic ovaries could result from increased population of the fetal ovary by germ cells, or from decreased rate of loss of oocytes during late gestation, childhood, and puberty.	Hammersmith Hosp, Imperial Coll London, Inst Reprod & Dev Biol, Wolfson & Weston Res Ctr Family Hlth, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Dept Math, London SW7 2AZ, England	Imperial College London; Imperial College London	Franks, S (corresponding author), Hammersmith Hosp, Imperial Coll London, Inst Reprod & Dev Biol, Wolfson & Weston Res Ctr Family Hlth, London W12 0NN, England.	s.franks@imperial.ac.uk	Norman, Robert J/A-1155-2007	Norman, Robert J/0000-0002-3118-3896; Webber, Lisa/0000-0003-3129-9212				Abbott DH, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740001; BAKER TG, 1963, PROC R SOC SER B-BIO, V158, P417, DOI 10.1098/rspb.1963.0055; BALEN AH, 1995, HUM REPROD, V10, P2107, DOI 10.1093/oxfordjournals.humrep.a136243; DAHLGREN E, 1992, FERTIL STERIL, V57, P505; DUNAIF A, 1987, J CLIN ENDOCR METAB, V65, P499, DOI 10.1210/jcem-65-3-499; Durlinger ALL, 2002, ENDOCRINOLOGY, V143, P1076, DOI 10.1210/en.143.3.1076; FARQUHAR CM, 1994, AUST NZ J OBSTET GYN, V34, P67, DOI 10.1111/j.1479-828X.1994.tb01041.x; Franks S, 1997, HUM REPROD, V12, P2641, DOI 10.1093/humrep/12.12.2641; FRANKS S, 1989, CLIN ENDOCRINOL, V31, P87, DOI 10.1111/j.1365-2265.1989.tb00457.x; GillingSmith C, 1997, CLIN ENDOCRINOL, V47, P93, DOI 10.1046/j.1365-2265.1997.2321049.x; GILLINGSMITH C, 1994, J CLIN ENDOCR METAB, V79, P1158, DOI 10.1210/jc.79.4.1158; GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325; Gougeon A, 1996, ENDOCR REV, V17, P121, DOI 10.1210/er.17.2.121; Hovatta O, 1997, HUM REPROD, V12, P1032; Hughesdon P E, 1982, Obstet Gynecol Surv, V37, P59, DOI 10.1097/00006254-198202000-00001; KURILO LF, 1981, HUM GENET, V57, P86; Lass A, 1997, HUM REPROD, V12, P1028; MELICA F, 1995, INT J FERTIL MENOP S, V40, P79; POLSON DW, 1988, LANCET, V1, P870; ROBINSON S, 1993, CLIN ENDOCRINOL, V39, P351, DOI 10.1111/j.1365-2265.1993.tb02376.x; Teixeira FL, 2002, J CLIN ENDOCR METAB, V87, P1337, DOI 10.1210/jc.87.3.1337; Vendola K, 1999, HUM REPROD, V14, P2328, DOI 10.1093/humrep/14.9.2328; Wild S, 2000, CLIN ENDOCRINOL, V52, P595, DOI 10.1046/j.1365-2265.2000.01000.x; Willis DS, 1998, J CLIN ENDOCR METAB, V83, P3984, DOI 10.1210/jc.83.11.3984; Wright CS, 1999, HUM REPROD, V14, P1555, DOI 10.1093/humrep/14.6.1555; Zawadzki JK, 1992, POLYCYSTIC OVARY SYN, P59	26	311	335	1	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2003	362	9389					1017	1021		10.1016/S0140-6736(03)14410-8	http://dx.doi.org/10.1016/S0140-6736(03)14410-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522531				2022-12-28	WOS:000185564600008
J	Abbott, MB; Wolfe, AP				Abbott, MB; Wolfe, AP			Intensive pre-Incan metallurgy recorded by lake sediments from the Bolivian Andes	SCIENCE			English	Article							PERU; POLLUTION	The history of pre-Columbian metallurgy in South America is incomplete because looting of metal artifacts has been pervasive. Here, we reconstruct a millennium of metallurgical activity in southern Bolivia using the stratigraphy of metals associated with smelting (Pb, Sb, Bi, Ag, Sn) from lake sediments deposited near the major silver deposit of Cerro Rico de Potosi. Pronounced metal enrichment events coincide with the terminal stages of Tiwanaku culture (1000 to 1200 A.D.) and Inca through early Colonial times (1400 to 1650 A.D.). The earliest of these events suggests that Cerro Rico ores were actively smelted at a large scale in the Late Intermediate Period, providing evidence for a major pre-Incan silver industry.	Univ Pittsburgh, Dept Geol & Planetary Sci, Pittsburgh, PA 15260 USA; Univ Alberta, Dept Earth & Atmospher Sci, Edmonton, AB T6G 2E3, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alberta	Abbott, MB (corresponding author), Univ Pittsburgh, Dept Geol & Planetary Sci, Pittsburgh, PA 15260 USA.		Wolfe, Alexander P/G-6867-2011					Abbott MB, 1997, QUATERNARY RES, V47, P169, DOI 10.1006/qres.1997.1881; Bakewell Peter J., 1984, MINERS RED MOUNTAIN; Bandelier A., 1910, ISLANDS TITICACA KOA; Bartos PJ, 2000, ECON GEOL BULL SOC, V95, P645, DOI 10.2113/95.3.645; BAUER BS, 2001, RITUAL PILGRIMAGE AN; BENSON EP, 1979, PRECOLUMBIAN METALLU; Branvall ML, 2001, J PALEOLIMNOL, V25, P421, DOI 10.1023/A:1011186100081; Bruhns K., 1994, ANCIENT S AM; Burger RL, 1998, SCIENCE, V282, P1108, DOI 10.1126/science.282.5391.1108; CRAIG AK, 1989, PRECIOUS METALS COIN, P159; Ek AS, 2001, J PALEOLIMNOL, V26, P89, DOI 10.1023/A:1011112020621; ERICKSEN GE, 1990, EPISODES, V13, P5; Gobeil C, 1999, ENVIRON SCI TECHNOL, V33, P2953, DOI 10.1021/es981322u; KOLATA AL, 1993, TIWANAKU PORTRAIT AN; LECHTMAN H, 2002, ARCHAEOLOGY PALEOECO, V2, P404; Muhly J., 1980, COMING AGE IRON, P267; Peele Robert Jr., 1893, SCH MINES Q, V15, P8; RENBERG I, 1994, NATURE, V368, P323, DOI 10.1038/368323a0; RIVERADUARTE I, 1994, GEOCHIM COSMOCHIM AC, V58, P3307, DOI 10.1016/0016-7037(94)90059-0; RUDOLPH WE, 1936, AM GEOGR SOC, V26, P529; SHIMADA I, 1982, SCIENCE, V216, P952, DOI 10.1126/science.216.4549.952; THOMPSON LG, 1985, SCIENCE, V229, P971, DOI 10.1126/science.229.4717.971; Vuille M, 1999, INT J CLIMATOL, V19, P1579, DOI 10.1002/(SICI)1097-0088(19991130)19:14<1579::AID-JOC441>3.0.CO;2-N; Williams PR, 2002, WORLD ARCHAEOL, V33, P361, DOI 10.1080/00438240120107422; Wilson WE, 1999, MINERAL REC, V30, P9; Wolfe BB, 2001, PALAEOGEOGR PALAEOCL, V176, P177, DOI 10.1016/S0031-0182(01)00337-6	26	80	82	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1893	1895		10.1126/science.1087806	http://dx.doi.org/10.1126/science.1087806			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512625	Green Submitted			2022-12-28	WOS:000185536700047
J	Caldeira, K; Wickett, ME				Caldeira, K; Wickett, ME			Anthropogenic carbon and ocean pH	NATURE			English	Editorial Material							DIOXIDE; CYCLE; CO2		Lawrence Livermore Natl Lab, Energy & Environm Directorate, Livermore, CA 94550 USA; Lawrence Livermore Natl Lab, Ctr Appl Sci Comp, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Caldeira, K (corresponding author), Lawrence Livermore Natl Lab, Energy & Environm Directorate, 7000 East Ave, Livermore, CA 94550 USA.	kenc@llnl.gov	Moe, Kaitlin/P-5316-2019; Caldeira, Ken/E-7914-2011	Caldeira, Ken/0000-0002-4591-643X				Beerling DJ, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001637; CALDEIRA K, 1993, PALEOCEANOGRAPHY, V8, P515, DOI 10.1029/93PA01163; Caldeira K, 2000, GEOPHYS RES LETT, V27, P225, DOI 10.1029/1999GL002364; Caldeira K, 2000, SCIENCE, V287, P620, DOI 10.1126/science.287.5453.620; Caldeira K., 1999, SCIENCE, V286, P2043, DOI DOI 10.1126/SCIENCE.286.5447.2043A; CROWLEY TJ, 2001, SCIENCE, V292, P780; Houghton JT, 2001, CONTRIBUTION WORKING; Kleypas JA, 1999, SCIENCE, V284, P118, DOI 10.1126/science.284.5411.118; MARLAND G, 2002, TRENDS COMPENDIUM DA; Pan J., 2001, CLIMATE CHANGE 2001; Riebesell U, 2000, NATURE, V407, P364, DOI 10.1038/35030078; SANYAL A, 1995, NATURE, V373, P234, DOI 10.1038/373234a0; Seibel BA, 2001, SCIENCE, V294, P319, DOI 10.1126/science.1065301	13	2376	2503	37	1012	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					365	365		10.1038/425365a	http://dx.doi.org/10.1038/425365a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508477	Green Published			2022-12-28	WOS:000185502300029
J	Holmes, KC; Angert, I; Kull, FJ; Jahn, W; Schroder, RR				Holmes, KC; Angert, I; Kull, FJ; Jahn, W; Schroder, RR			Electron cryo-microscopy shows how strong binding of myosin to actin releases nucleotide	NATURE			English	Article							RABBIT SKELETAL-MUSCLE; MOTOR DOMAIN; COMPLEX; CONTRACTION; VISUALIZATION; ACTOMYOSIN; MICROSCOPY; MOLSCRIPT; MECHANISM; KINESIN	Muscle contraction involves the cyclic interaction of the myosin cross-bridges with the actin filament, which is coupled to steps in the hydrolysis of ATP(1). While bound to actin each cross-bridge undergoes a conformational change, often referred to as the "power stroke"(2), which moves the actin filament past the myosin filaments; this is associated with the release of the products of ATP hydrolysis and a stronger binding of myosin to actin. The association of a new ATP molecule weakens the binding again, and the attached cross-bridge rapidly dissociates from actin. The nucleotide is then hydrolysed, the conformational change reverses, and the myosin cross-bridge reattaches to actin. X-ray crystallography has determined the structural basis of the power stroke, but it is still not clear why the binding of actin weakens that of the nucleotide and vice versa. Here we describe, by fitting atomic models of actin and the myosin cross-bridge into high-resolution electron cryo-microscopy three-dimensional reconstructions, the molecular basis of this linkage. The closing of the actin-binding cleft when actin binds is structurally coupled to the opening of the nucleotide-binding pocket.	Max Planck Inst Med Res, Dept Biophys, D-69120 Heidelberg, Germany	Max Planck Society	Holmes, KC (corresponding author), Max Planck Inst Med Res, Dept Biophys, Jahnstr 29, D-69120 Heidelberg, Germany.		Schröder, Rasmus R/S-6220-2016	Holmes, Kenneth/0000-0001-8894-9453				Angert I, 2000, ULTRAMICROSCOPY, V81, P203, DOI 10.1016/S0304-3991(99)00190-4; CONIBEAR PB, IN PRESS NATURE STRU; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Egelman EH, 2000, ULTRAMICROSCOPY, V85, P225, DOI 10.1016/S0304-3991(00)00062-0; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Geeves M. A., 1995, Biophysical Journal, V68, P194; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; JAHN W, 1995, J MICROSC-OXFORD, V179, P333, DOI 10.1111/j.1365-2818.1995.tb03649.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; LOBAU V, 1997, THESIS U STUTTGART; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Naber N, 2003, SCIENCE, V300, P798, DOI 10.1126/science.1082374; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REUBOLD T, IN PRESS NATURE STRU; Sasaki N, 1999, J BIOL CHEM, V274, P37840, DOI 10.1074/jbc.274.53.37840; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SCHROEDER RR, 2002, P 15 INT C EL MICR, V3, P443; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; Volkmann N, 2003, P NATL ACAD SCI USA, V100, P3227, DOI 10.1073/pnas.0536510100; Volkmann N, 2000, NAT STRUCT BIOL, V7, P1147; YAGLE AE, 1999, DISCRETE TOMOGRAPHY; Yengo CM, 2002, J BIOL CHEM, V277, P24114, DOI 10.1074/jbc.M111253200	31	300	303	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					423	427		10.1038/nature02005	http://dx.doi.org/10.1038/nature02005			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508495				2022-12-28	WOS:000185502300047
J	Lee, H; Zones, SI; Davis, ME				Lee, H; Zones, SI; Davis, ME			A combustion-free methodology for synthesizing zeolites and zeolite-like materials	NATURE			English	Article							MESOPOROUS MOLECULAR-SIEVES; HIGH-SILICA ZEOLITE; CONSTRAINT INDEX; CATALYSIS; ACID	Zeolites are mainly used for the adsorption and separation of ions and small molecules, and as heterogeneous catalysts. More recently, these materials are receiving attention in other applications, such as medical diagnosis and as components in electronic devices(1). Modern synthetic methodologies for preparing zeolites and zeolite-like materials typically involve the use of organic molecules that direct the assembly pathway and ultimately fill the pore space(2-6). Removal of these enclathrated species normally requires high temperature combustion that destroys this high cost component, and the associated energy release in combination with the formed water can be extremely detrimental to the inorganic structure(7). Here we report a synthetic methodology that avoids these difficulties by creating organic structure-directing agents (SDAs) that can be disassembled within the zeolite pore space to allow removal of their fragments for possible use again by reassembly. The methodology is shown for the synthesis of zeolite ZSM-5 using a SDA that contains a cyclic ketal group that is removed from the SDA while it is inside the zeolite without destruction of the inorganic framework. This approach should be applicable to the synthesis of a wide variety of inorganic and organometallic structures.	CALTECH, Pasadena, CA 91125 USA; Chevron Texaco Energy & Res Ctr, Richmond, CA 94802 USA	California Institute of Technology; Chevron	Davis, ME (corresponding author), CALTECH, Pasadena, CA 91125 USA.		Lee, Hyunjoo/G-8034-2012	Lee, Hyunjoo/0000-0002-4538-9086				CHEN CY, 1993, MICROPOROUS MATER, V2, P17, DOI 10.1016/0927-6513(93)80058-3; Corma A, 2002, NATURE, V418, P514, DOI 10.1038/nature00924; Corma A, 1997, CHEM REV, V97, P2373, DOI 10.1021/cr960406n; Davis ME, 2002, NATURE, V417, P813, DOI 10.1038/nature00785; Freyhardt CC, 1996, NATURE, V381, P295, DOI 10.1038/381295a0; FRILLETTE VJ, 1981, J CATAL, V67, P218, DOI 10.1016/0021-9517(81)90273-6; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Kuehl GH, 2000, MICROPOR MESOPOR MAT, V35-6, P521, DOI 10.1016/S1387-1811(99)00247-4; Piccione PM, 2002, J PHYS CHEM B, V106, P3629, DOI 10.1021/jp014427j; SRINIVASACHAR K, 1989, BIOCHEMISTRY-US, V28, P2501, DOI 10.1021/bi00432a023; TANEV PT, 1995, SCIENCE, V267, P865, DOI 10.1126/science.267.5199.865; Wagner P, 1997, CHEM COMMUN, P2179, DOI 10.1039/a704774f; Wagner P, 2000, J AM CHEM SOC, V122, P263, DOI 10.1021/ja990722u; Wang ZB, 2001, ADV MATER, V13, P746, DOI 10.1002/1521-4095(200105)13:10<746::AID-ADMA746>3.0.CO;2-J; Whitehurst D.D., 1992, US Patent, Patent No. [5143879 A, 5143879]; Wright PA, 2000, J CHEM SOC DALTON, P1243, DOI 10.1039/a909249h; Zones SI, 2000, MICROPOR MESOPOR MAT, V35-6, P31, DOI 10.1016/S1387-1811(99)00206-1	17	148	156	13	175	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					385	388		10.1038/nature01980	http://dx.doi.org/10.1038/nature01980			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508485				2022-12-28	WOS:000185502300037
J	Mello, MM; Brennan, TA				Mello, MM; Brennan, TA			Due process in investigations of research misconduct	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SCIENTIFIC MISCONDUCT		Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Brennan, TA (corresponding author), Brigham & Womens Hosp, 75 Francis St,PBB4, Boston, MA 02115 USA.	tabrennan@partners.org		Mello, Michelle/0000-0003-2877-4270				ANDERSON RM, 1988, J LAW TECHNOLOGY, V3, P121; BRADSHAW RA, 1996, COMMUNICATION   0513; Broad W., 1982, BETRAYERS TRUTH; Burk DL, 1995, GEO MASON INDEP L RE, V3, P305; CHPS Consulting, 2000, AN I POL RESP ALL SC; *COMM RES INT, 1995, INT MISC RES REP COM; *COMM SCI ENG PUBL, 1992, RESP SCI, V1; *DEP HLTH HUM SERV, 2002, REP DEP HLTH HUM SER; DRESSER R, 1993, JAMA-J AM MED ASSOC, V269, P895; Friedly J, 1996, SCIENCE, V273, P1481; Friedly J, 1996, SCIENCE, V273, P873, DOI 10.1126/science.273.5277.873; Goldner JA, 1998, AM J LAW MED, V24, P293; GREENBERG DS, 1995, LANCET, V345, P639, DOI 10.1016/S0140-6736(95)90530-8; Kalb PE, 2002, JAMA-J AM MED ASSOC, V287, P85, DOI 10.1001/jama.287.1.85; *OFF RES INT, 2003, HHS DEP APP BOARD IN; *OFF RES INT, 1995, ORI MOD POL PROC RES; Office of Science and Technology Policy, 2000, FED REGISTER, V65, P76260; Pascal CB, 2000, P SOC EXP BIOL MED, V224, P220, DOI 10.1046/j.1525-1373.2000.22425.x; Research Triangle Institute, 1996, SURV ACC EX IND RES; Stein SJ, 2000, INT J TECHNOL DES ED, V10, P105, DOI 10.1023/A:1008945013123; Steinbrook R, 2002, NEW ENGL J MED, V346, P1842, DOI 10.1056/NEJMp020046; Steinbrook R, 2002, NEW ENGL J MED, V346, P1425, DOI 10.1056/NEJM200205023461828; *TASK FORC FIN CON, 2001, PROT SUBJ PRES TRUST; US Public Health Service, 1989, Fed Regist, V54, P32446; Weiss RB, 2000, LANCET, V355, P999, DOI 10.1016/S0140-6736(00)90024-2; WOOD A, 2002, PRES COUNC BIOETH SE; 1993, FED REG, V58, P66009	27	17	18	2	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2003	349	13					1280	1286		10.1056/NEJMhpr035095	http://dx.doi.org/10.1056/NEJMhpr035095			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LJ	14507953				2022-12-28	WOS:000185488800012
J	Konishi, A; Shimizu, S; Hirota, J; Takao, T; Fan, YH; Matsuoka, Y; Zhang, LL; Yoneda, Y; Fujii, Y; Skouitchi, AI; Tsujimoto, Y				Konishi, A; Shimizu, S; Hirota, J; Takao, T; Fan, YH; Matsuoka, Y; Zhang, LL; Yoneda, Y; Fujii, Y; Skouitchi, AI; Tsujimoto, Y			Involvement of histone H1.2 in apoptosis induced by DNA double-strand breaks	CELL			English	Article							CYTOCHROME-C RELEASE; BCL-2 PROTEIN FAMILY; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; P53-DEPENDENT APOPTOSIS; IN-VIVO; P53-INDUCED APOPTOSIS; CONFORMATIONAL-CHANGE; BAX; P53	It is poorly understood how apoptotic signals arising from DNA damage are transmitted to mitochondria, which release apoptogenic factors into the cytoplasm that activate downstream destruction programs. Here, we identify histone H1.2 as a cytochrome c-releasing factor that appears in the cytoplasm after exposure to X-ray irradiation. While all nuclear histone H1 forms are released into the cytoplasm in a p53-dependent manner after irradiation, only H1.2, but not other H1 forms, induced cytochrome c release from isolated mitochondria in a Bak-dependent manner. Reducing H1.2 expression enhanced cellular resistance to apoptosis induced by X-ray irradiation or etoposide, but not that induced by other stimuli including TNF-alpha and UV irradiation. H1.2-deficient mice exhibited increased cellular resistance in thymocytes and the small intestine to X-ray-induced apoptosis. These results indicate that histone H1.2 plays an important role in transmitting apoptotic signals from the nucleus to the mitochondria following DNA double-strand breaks.	Osaka Univ, Sch Med, Dept Post Genom & Dis, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, JST, SORST, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, JST, CREST, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Suita, Osaka 5650871, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Osaka University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Osaka University; Osaka University; Nagoya City University; Nagoya City University; Yeshiva University; Albert Einstein College of Medicine	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Post Genom & Dis, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp	Konishi, Akimitsu/J-4024-2019	Konishi, Akimitsu/0000-0002-3291-0821	NCI NIH HHS [R01 CA079057] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079057] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Albig W, 1997, HUM GENET, V101, P284, DOI 10.1007/s004390050630; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Attardi LD, 2000, GENE DEV, V14, P704; Bleher R, 1999, CHROMOSOMA, V108, P308, DOI 10.1007/s004120050382; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chadee DN, 1997, J BIOL CHEM, V272, P8113, DOI 10.1074/jbc.272.13.8113; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Fan YH, 2001, MOL CELL BIOL, V21, P7933, DOI 10.1128/MCB.21.23.7933-7943.2001; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Franke K, 1998, BBA-GENE STRUCT EXPR, V1398, P232, DOI 10.1016/S0167-4781(98)00062-1; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kratzmeier M, 1999, BIOCHEM J, V337, P319, DOI 10.1042/0264-6021:3370319; LENNOX RW, 1983, J BIOL CHEM, V258, P262; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; MATSUOKA Y, 1994, J CELL SCI, V107, P693; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PEPE I, 1990, BIOCHIM BIOPHYS ACTA, V1041, P14, DOI 10.1016/0167-4838(90)90116-W; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Shimizu S, 1996, ONCOGENE, V12, P2251; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Tanaka M, 2001, DEVELOPMENT, V128, P655; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vignali M, 1998, NAT STRUCT BIOL, V5, P1025, DOI 10.1038/4133; Vila R, 2000, PROTEIN SCI, V9, P627; Wang XD, 2001, GENE DEV, V15, P2922; Wang ZF, 1997, J MOL BIOL, V271, P124, DOI 10.1006/jmbi.1997.1166; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Wolf BB, 2002, CURR BIOL, V12, pR177, DOI 10.1016/S0960-9822(02)00736-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	59	253	269	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					673	688		10.1016/S0092-8674(03)00719-0	http://dx.doi.org/10.1016/S0092-8674(03)00719-0			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505568	Bronze			2022-12-28	WOS:000185464000006
J	Linden, DJ				Linden, DJ			From molecules to memory in the cerebellum	SCIENCE			English	Editorial Material							LONG-TERM DEPRESSION; KINASE-C INHIBITOR; EXPRESSION; LTD		Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Linden, DJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	dlinden@jhmi.edu						AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; Bear MF, 2001, SYNAPSES, P455; Chung HJ, 2003, SCIENCE, V300, P1751, DOI 10.1126/science.1082915; De Zeeuw CI, 1998, NEURON, V20, P495, DOI 10.1016/S0896-6273(00)80990-3; Gao WC, 2003, J NEUROSCI, V23, P1859; Goossens J, 2001, J NEUROSCI, V21, P5813, DOI 10.1523/JNEUROSCI.21-15-05813.2001; Hansel C, 2000, NEURON, V26, P473, DOI 10.1016/S0896-6273(00)81179-4; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Kitazawa S, 2002, NATURE, V416, P270, DOI 10.1038/416270a; Koekkoek SKE, 2003, SCIENCE, V301, P1736, DOI 10.1126/science.1088383; Koekkoek SKE, 2002, J NEUROPHYSIOL, V88, P2124, DOI 10.1152/jn.2002.88.4.2124; Martin SJ, 2002, HIPPOCAMPUS, V12, P609, DOI 10.1002/hipo.10107; Medina JF, 2000, NAT NEUROSCI, V3, P1205, DOI 10.1038/81486; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519	15	58	64	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1682	+		10.1126/science.1090462	http://dx.doi.org/10.1126/science.1090462			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500971				2022-12-28	WOS:000185387700032
J	Xu, L; Wei, Y; Reboul, J; Vaglio, P; Shin, TH; Vidal, M; Elledge, SJ; Harper, JW				Xu, L; Wei, Y; Reboul, J; Vaglio, P; Shin, TH; Vidal, M; Elledge, SJ; Harper, JW			BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3	NATURE			English	Article							CAENORHABDITIS-ELEGANS; C-ELEGANS; CYCLIN-E; DEGRADATION; GENE; FAMILY; MEI-1	Programmed destruction of regulatory proteins through the ubiquitin-proteasome system is a widely used mechanism for controlling signalling pathways(1,2). Cullins(3) are proteins that function as scaffolds for modular ubiquitin ligases typified by the SCF (Skp1-Cul1-F-box) complex(4-6). The substrate selectivity of these E3 ligases is dictated by a specificity module that binds cullins. In the SCF complex, this module is composed of Skp1, which binds directly to Cul1, and a member of the F-box family of proteins(4-7). F-box proteins bind Skp1 through the F-box motif(7), and substrates by means of carboxy-terminal protein interaction domains(1,2,5). Similarly, Cul2 and Cul5 interact with BC-box-containing specificity factors through the Skp1-like protein elongin C-2. Cul3 is required for embryonic development in mammals and Caenorhabditis elegans(8-10) but its specificity module is unknown. Here we report the identification of a large family of BTB-domain proteins as substrate-specific adaptors for C. elegans CUL-3. Biochemical studies using the BTB protein MEL-26 and its genetic target MEI-1 (refs 12, 13) indicate that BTB proteins merge the functional properties of Skp1 and F-box proteins into a single polypeptide.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell & Mol Biol, Houston, TX 77030 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Genet, Boston, MA 02115 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Harper, JW (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.	wade_harper@hms.harvard.edu	Reboul, Jerome/P-9103-2016	Reboul, Jerome/0000-0002-5513-4546; Vaglio, Philippe/0000-0003-2900-5596; Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG011085] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; CLARKMAGUIRE S, 1994, GENETICS, V136, P533; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dow MR, 1998, GENETICS, V150, P119; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; PINTARD L, 2003, NATURE          0903, DOI DOI 10.1038/NATURE01959; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Srayko M, 2000, GENE DEV, V14, P1072; Uren AG, 1996, TRENDS BIOCHEM SCI, V21, P244, DOI 10.1016/S0968-0004(96)30022-4; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Winston JT, 1999, GENE DEV, V13, P2751, DOI 10.1101/gad.13.21.2751; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	23	378	396	1	35	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 18	2003	425	6955					316	321		10.1038/nature01985	http://dx.doi.org/10.1038/nature01985			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679922				2022-12-28	WOS:000185370900050
J	Goodwin, FK; Fireman, B; Simon, GE; Hunkeler, EM; Lee, J; Revicki, D				Goodwin, FK; Fireman, B; Simon, GE; Hunkeler, EM; Lee, J; Revicki, D			Suicide risk in bipolar disorder during treatment with lithium and divalproex	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECURRENT AFFECTIVE-ILLNESS; DOUBLE-BLIND; I DISORDER; MENTAL-DISORDERS; IMIPRAMINE; DEPRESSION; CARBONATE; UNIPOLAR; PROPHYLAXIS; TRIAL	Context Several studies have suggested that lithium treatment reduces risk of suicide in bipolar disorder, but no research has examined suicide risk during treatment with divalproex, the most commonly prescribed mood-stabilizing drug in the United States. Objective To compare risk of suicide attempt and suicide death during treatment with lithium with that during treatment with divalproex. Design and Setting Retrospective cohort study conducted at 2 large integrated health plans in California and Washington. Patients Population-based sample of 20638 health plan members aged 14 years or older who had at least 1 outpatient diagnosis of bipolar disorder and at least 1 filled prescription for lithium, divalproex, or carbamazepine between January,1, 1994, and December 31, 2001. Follow-up for each individual began with first qualifying prescription and ended with death, disenrollment from the health plan, or end of the study period. Main Outcome Measures Suicide attempt, recorded as a hospital discharge diagnosis or an emergency department diagnosis; suicide death, recorded on death certificate. Results In both health plans, unadjusted rates were greater during treatment with divalproex than during treatment with lithium for emergency department suicide attempt (31.3 vs 10.8 per 1000 person-years; P<.001), suicide attempt resulting in hospitalization (10.5 vs 4.2 per 1000 person-years; P<.001), and suicide death (1.7 vs 0.7 per 1000 person-years; P=.04). After adjustment for age, sex, health plan, year of diagnosis, comorbid medical and psychiatric conditions, and concomitant use of other psychotropic drugs, risk of suicide death was 2.7 times higher (95% confidence interval [CI], 1.1-6.3; P=.03) during treatment with divalproex than during treatment with lithium. Corresponding hazard ratios for nonfatal attempts were 1.7 (95% Cl, 1.2-2.3; P=.002) for attempts resulting in hospitalization and 1.8 (95% C1, 1.4-2.2; P<.001) for attempts diagnosed in the emergency department. Conclusion Among patients treated for bipolar disorder, risk of suicide attempt and suicide death is lower during treatment with lithium than during treatment with divalproex.	George Washington Univ, Med Ctr, Dept Psychiat, Washington, DC 20037 USA; MEDTAP Int, Ctr Hlth Outcomes Res, Bethesda, MD USA; Best Practice LLC, Bethesda, MD USA; Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	George Washington University; Kaiser Permanente; Group Health Cooperative	Goodwin, FK (corresponding author), George Washington Univ, Med Ctr, Dept Psychiat, 2150 Penn Ave NW, Washington, DC 20037 USA.							ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Baldessarini RJ, 2001, ANN NY ACAD SCI, V932, P24; Bauer M, 2000, AM J PSYCHIAT, V157, P1429, DOI 10.1176/appi.ajp.157.9.1429; Blanco C, 2002, AM J PSYCHIAT, V159, P1005, DOI 10.1176/appi.ajp.159.6.1005; Bostwick JM, 2000, AM J PSYCHIAT, V157, P1925, DOI 10.1176/appi.ajp.157.12.1925; Bowden CL, 2000, ARCH GEN PSYCHIAT, V57, P481, DOI 10.1001/archpsyc.57.5.481; Bowden CL, 2003, ARCH GEN PSYCHIAT, V60, P392, DOI 10.1001/archpsyc.60.4.392; Brodersen A, 2000, BRIT J PSYCHIAT, V176, P429, DOI 10.1192/bjp.176.5.429; CALABRESE JR, 2002, ANN M AM PSYCH ASS M; CAMPBELL M, 1984, PSYCHOSOMATICS, V25, P95, DOI 10.1016/S0033-3182(84)73079-9; CAMPBELL M, 1984, J AM ACAD CHILD ADOL, V25, P105; Fenn HH, 1996, AM J PSYCHIAT, V153, P711; FIEVE RR, 1976, AM J PSYCHIAT, V133, P925; Goodwin F, 1990, MANIC DEPRESSIVE ILL; GOODWIN FK, 1972, AM J PSYCHIAT, V129, P44, DOI 10.1176/ajp.129.1.44; GUZE SB, 1970, BRIT J PSYCHIAT, V117, P437, DOI 10.1192/bjp.117.539.437; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; KANE JM, 1982, ARCH GEN PSYCHIAT, V39, P1065; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Lim PZ, 2001, BIPOLAR DISORD, V3, P165, DOI 10.1034/j.1399-5618.2001.030401.x; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Malone RP, 2000, ARCH GEN PSYCHIAT, V57, P649, DOI 10.1001/archpsyc.57.7.649; Mann JJ, 2002, ANN INTERN MED, V136, P302, DOI 10.7326/0003-4819-136-4-200202190-00010; MORRISON SD, 1973, DIS NERV SYST, V34, P186; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Narrow WE, 2002, ARCH GEN PSYCHIAT, V59, P115, DOI 10.1001/archpsyc.59.2.115; Nemeroff CB, 2001, AM J PSYCHIAT, V158, P906, DOI 10.1176/appi.ajp.158.6.906; PRIEN RF, 1984, ARCH GEN PSYCHIAT, V41, P1096; PRIEN RF, 1973, ARCH GEN PSYCHIAT, V29, P420; PRIEN RF, 1973, ARCH GEN PSYCHIAT, V28, P337; PRIEN RF, 1974, AM J PSYCHIAT, V131, P198, DOI 10.1176/ajp.131.2.198; QUITKIN F M, 1981, Psychopharmacology Bulletin, V17, P142; *SAS I INC, 2002, SAS STAT CHANG ENH R; SAUNDERS KW, 1994, PHARMACOEPIDEMIOLOGY; SHARMA R, 1994, J AFFECT DISORDERS, V31, P91, DOI 10.1016/0165-0327(94)90112-0; SHEARD MH, 1976, AM J PSYCHIAT, V133, P1409; Simon GE, 1996, J CLIN EPIDEMIOL, V49, P1067, DOI 10.1016/0895-4356(96)00139-4; STALLONE F, 1973, AM J PSYCHIAT, V130, P1006, DOI 10.1176/ajp.130.9.1006; ThiesFlechtner K, 1996, PHARMACOPSYCHIATRY, V29, P103, DOI 10.1055/s-2007-979553; TREISER SL, 1981, SCIENCE, V213, P1529, DOI 10.1126/science.6269180; TUPIN JP, 1973, COMPR PSYCHIAT, V14, P311, DOI 10.1016/0010-440X(73)90022-9; Unutzer J, 2000, GEN HOSP PSYCHIAT, V22, P1, DOI 10.1016/S0163-8343(99)00057-2; WATANABE S, 1975, ARCH GEN PSYCHIAT, V32, P659; WORRALL EP, 1979, BRIT J PSYCHIAT, V135, P255, DOI 10.1192/bjp.135.3.255; Yerevanian BI, 2003, J AFFECT DISORDERS, V73, P223, DOI 10.1016/S0165-0327(02)00302-6	46	339	347	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1467	1473		10.1001/jama.290.11.1467	http://dx.doi.org/10.1001/jama.290.11.1467			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	721RE	13129986	Bronze			2022-12-28	WOS:000185329000028
J	Oquendo, MA; Mann, JJ				Oquendo, MA; Mann, JJ			Intervention research for suicidal behaviour	LANCET			English	Editorial Material							CLINICAL-TRIALS; REDUCTION; RISK; DISORDERS; BIPOLAR		New York State Psychiat Inst & Hosp, Dept Neurosci, New York, NY 10032 USA; Columbia Univ, New York, NY 10032 USA	New York State Psychiatry Institute; Columbia University	Oquendo, MA (corresponding author), New York State Psychiat Inst & Hosp, Dept Neurosci, New York, NY 10032 USA.	mao4@columbia.edu	Oquendo, Maria/AAC-6237-2019					Cornelius JR, 2001, ANN NY ACAD SCI, V932, P78; FILTEAU MJ, 1993, J PSYCHIATR NEUROSCI, V18, P114; Harkavy-Friedman JM, 2001, CLIN NEUROSCI RES, V1, P345, DOI 10.1016/S1566-2772(01)00036-6; Kaufman KR, 2002, SEIZURE-EUR J EPILEP, V11, P51, DOI 10.1053/seiz.2001.0585; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Khan A, 2000, ARCH GEN PSYCHIAT, V57, P311, DOI 10.1001/archpsyc.57.4.311; MONTGOMERY SA, 1995, EUR NEUROPSYCHOPHARM, V5, P5, DOI 10.1016/0924-977X(94)00131-T; *NAT I MENT HLTH, 2001, ETH ISS INCL SUIC IN; Post RM, 2003, J PSYCHIATR RES, V37, P61, DOI 10.1016/S0022-3956(02)00057-2; ROUILLON F, 1989, Encephale, V15, P527; Storosum JG, 2003, ARCH GEN PSYCHIAT, V60, P365, DOI 10.1001/archpsyc.60.4.365; ThiesFlechtner K, 1996, PHARMACOPSYCHIATRY, V29, P103, DOI 10.1055/s-2007-979553; *WHO, 2002, MENT HLTH PREV SUIC	14	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 13	2003	362	9387					844	845		10.1016/S0140-6736(03)14347-4	http://dx.doi.org/10.1016/S0140-6736(03)14347-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	721RH	13678967				2022-12-28	WOS:000185329400004
J	Sharp, D				Sharp, D			Faster, higher, stronger ... and deeper?	LANCET			English	Editorial Material							SCUBA-DIVERS		Lancet, London NW1 7BY, England		Sharp, D (corresponding author), Lancet, 32 Jamestown Rd, London NW1 7BY, England.							*BBC NEWS, TIT BOUGHT NAT; *INT ASS DEV APN, 2002, REG REC REC VERS 5 2; *INT ASS FREE DIV, IAFDS OFF REP A MEST; Nakayama H, 2003, EMERG MED J, V20, P332, DOI 10.1136/emj.20.4.332; Taylor DM, 2003, WILD ENVIRON MED, V14, P83, DOI 10.1580/1080-6032(2003)014[0083:ESDIAA]2.0.CO;2	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					846	846		10.1016/S0140-6736(03)14349-8	http://dx.doi.org/10.1016/S0140-6736(03)14349-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678969				2022-12-28	WOS:000185329400006
J	Papineni, P				Papineni, P			Children of bad memories	LANCET			English	Article									UCL, Int Hlth & Med Educ Ctr, London N19 5LW, England	University of London; University College London	Papineni, P (corresponding author), UCL, Int Hlth & Med Educ Ctr, London N19 5LW, England.	p.papineni@ucl.ac.uk		Papineni, Padmasayee/0000-0001-6923-1542				Carpenter RC, 2000, HUM RIGHTS QUART, V22, P428, DOI 10.1353/hrq.2000.0020; *HUM RIGHTS WATCH, 1996, SHATT LIV SEX VIOL R; Lewis M, 1998, SHAME INTERPERSONAL; SANDHER H, 2000, WOMEN VIOLENCE WAR W; Stiglmayer Alexandra, 1994, MASS RAPE WAR WOMEN	5	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					825	826		10.1016/S0140-6736(03)14277-8	http://dx.doi.org/10.1016/S0140-6736(03)14277-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	719DN	13678880				2022-12-28	WOS:000185188500025
J	Lee, CH; Chawla, A; Urbiztondo, N; Liao, D; Boisvert, WA; Evans, RM				Lee, CH; Chawla, A; Urbiztondo, N; Liao, D; Boisvert, WA; Evans, RM			Transcriptional repression of atherogenic inflammation: Modulation by PPAR delta	SCIENCE			English	Article							REDUCES ATHEROSCLEROSIS; GENE-EXPRESSION; DEFICIENT MICE; MACROPHAGES; GAMMA; BCL-6; COREPRESSOR; ABSENCE	The formation of an atherosclerotic lesion is mediated by lipid-laden macrophages (foam cells), which also establish chronic inflammation associated with lesion progression. The peroxisome proliferator-activated receptor (PPAR) gamma promotes lipid uptake and efflux in these atherogenic cells. In contrast, we found that the closely related receptor PPARdelta controls the inflammatory status of the macrophage. Deletion of PPARdelta from foam cells increased the availability of inflammatory suppressors, which in turn reduced atherosclerotic lesion area by more than 50%. We propose an unconventional ligand-dependent transcriptional pathway in which PPARdelta controls an inflammatory switch through its association and disassociation with transcriptional repressors. PPARdelta and its ligands may thus serve as therapeutic targets to attenuate inflammation and slow the progression of atherosclerosis.	Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA; Brigham & Womens Hosp, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Salk Institute; Harvard University; Brigham & Women's Hospital	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Evans, Ronald/AAF-4001-2019; Lee, Chih-Hao/E-9635-2018	Evans, Ronald/0000-0002-9986-5965; Lee, Chih-Hao/0000-0002-3898-6421	NHLBI NIH HHS [HL69474] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069474] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Chawla A, 2003, P NATL ACAD SCI USA, V100, P1268, DOI 10.1073/pnas.0337331100; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Dawson TC, 1999, ATHEROSCLEROSIS, V143, P205; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Huynh KD, 2000, GENE DEV, V14, P1810; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Lee C., UNPUB; Lee CH, 2002, TRENDS ENDOCRIN MET, V13, P331, DOI 10.1016/S1043-2760(02)00668-9; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Steinberg D, 2002, NAT MED, V8, P1211, DOI 10.1038/nm1102-1211; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200	22	482	519	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					453	457		10.1126/science.1087344	http://dx.doi.org/10.1126/science.1087344			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	12970571				2022-12-28	WOS:000185963200045
J	Roberts, SE; Goldacre, MJ				Roberts, SE; Goldacre, MJ			Time trends and demography of mortality after fractured neck of femur in an English population, 1968-98: database study	BRITISH MEDICAL JOURNAL			English	Article							PROXIMAL FEMORAL FRACTURE; HIP FRACTURE; STROKE INCIDENCE; MONICA PROJECT; CORONARY-EVENT; CASE-FATALITY; SURVIVAL; ENGLAND; RATES; ADMISSIONS	Objectives To investigate time trends in mortality after admission to hospital for fractured neck of femur from 1968 to 1998, and to report on the effects of demographic factors on mortality. Design Analysis of hospital inpatient statistics for fractured neck of femur, incorporating linkage to death certificates. Setting Four counties in southern England. Subjects 32 590 people aged 65 years or over admitted to hospital with fractured neck of femur between 1968 and 1998. Main outcome measures Case fatality nates at 30,90, and 365 days after admission, and standardised mortality ratios at monthly intervals up to one year after admission. Results Case fatality rates declined between the 1960s and the early 1980s, but there was no appreciable fall thereafter. They increased sharply with increasing age: for example, fatality rates at 30 days in 1984-98 increased from 4% in men aged 64-69 years to 3 1 % in those aged greater than or equal to90. They were higher in men than women, and in social classes IV and V than in classes I and R. In the first month after fracture, standardised mortality ratios in women were 16 times higher, and those in men 12 times higher, than mortality in the same age group in the general population Conclusions The high mortality rates, and the fact that they have not fallen over the past 20 years, reinforce the need for measures to prevent osteoporosis and falls and their consequences in elderly people. Whether post-fracture mortality has fallen to an irreducible minimum, or whether further decline is possible, is unclear.	Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Oxford	Roberts, SE (corresponding author), Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.							Balacco Giuseppe, 2000, Molecular Biology Today, V1, P23; Balasegaram S, 2001, J PUBLIC HEALTH MED, V23, P11, DOI 10.1093/pubmed/23.1.11; BERINGER TRO, 1991, ULSTER MED J, V60, P28; BOEREBOOM FTJ, 1992, NETH J MED, V41, P4; BOYCE WJ, 1985, LANCET, V1, P150; Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140-6736(98)09075-8; Evans JG, 1997, J EPIDEMIOL COMMUN H, V51, P424, DOI 10.1136/jech.51.4.424; EVANS JG, 1979, AGE AGEING, V8, P246, DOI 10.1093/ageing/8.4.246; FALCH JA, 1993, BONE, V14, P643, DOI 10.1016/8756-3282(93)90086-P; Fitzpatrick P, 2001, IRISH J MED SCI, V170, P49, DOI 10.1007/BF03167722; Goldacre MJ, 2002, BRIT MED J, V325, P868, DOI 10.1136/bmj.325.7369.868; HEDLUND R, 1987, CLIN ORTHOP RELAT R, P132; Kannus P, 1999, LANCET, V353, P802, DOI 10.1016/S0140-6736(98)04235-4; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; LAU EMC, 1993, MED J AUSTRALIA, V158, P604, DOI 10.5694/j.1326-5377.1993.tb137627.x; *ORG EC COOP DEV, 2003, DIS BAS COMP HLTH SY; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; SPECTOR TD, 1990, BRIT MED J, V300, P1173, DOI 10.1136/bmj.300.6733.1173; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; TODD CJ, 1995, BRIT MED J, V310, P904, DOI 10.1136/bmj.310.6984.904; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; Volmink JA, 1998, HEART, V80, P40, DOI 10.1136/hrt.80.1.40; Walker N, 1999, NEW ZEAL MED J, V112, P269; WEATHERALL M, 1994, NEW ZEAL MED J, V107, P308; Wolfe CDA, 2000, STROKE, V31, P2074, DOI 10.1161/01.STR.31.9.2074	25	222	232	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					771	774		10.1136/bmj.327.7418.771	http://dx.doi.org/10.1136/bmj.327.7418.771			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525871	Green Published, Bronze			2022-12-28	WOS:000185805100015
J	Rowell, P; Braude, P				Rowell, P; Braude, P			ABC of subfertility assisted conception. I - General principles	BRITISH MEDICAL JOURNAL			English	Article									Guys & St Thomas Assisted Concept Unit, London, England; Guys & St Thomas Sch Med, Dept Womens Hlth, London, England	University of London; King's College London	Rowell, P (corresponding author), Guys & St Thomas Assisted Concept Unit, London, England.								0	13	15	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					799	801		10.1136/bmj.327.7418.799	http://dx.doi.org/10.1136/bmj.327.7418.799			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525882	Green Published			2022-12-28	WOS:000185805100026
J	Skinner, J; Weinstein, JN; Sporer, SM; Wennberg, JE				Skinner, J; Weinstein, JN; Sporer, SM; Wennberg, JE			Racial, ethnic, and geographic disparities in rates of knee arthroplasty among Medicare patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; RESIDENTIAL SEGREGATION; REVASCULARIZATION PROCEDURES; DECISION-MAKING; UNITED-STATES; HEALTH-CARE; FOLLOW-UP; TOTAL HIP; OSTEOARTHRITIS; REPLACEMENT	BACKGROUND: There are large variations in the use of knee arthroplasty among Medicare enrollees according to race or ethnic group and sex. Are racial and ethnic disparities more pronounced in some regions than in others, and if so, why? METHODS: We used all Medicare fee-for-service claims data for 1998 through 2000 to determine the incidence of knee arthroplasty according to Hospital Referral Region, sex, and race or ethnic group. A total of 430,726 knee arthroplasties were performed during the three-year study period. RESULTS: At the national level, the annual rate of knee arthroplasty was higher for non-Hispanic white women (5.97 procedures per 1000) than for Hispanic women (5.37 per 1000) and black women (4.84 per 1000). The rate for non-Hispanic white men (4.82 procedures per 1000) was higher than that for Hispanic men (3.46 per 1000) and more than double that for black men (1.84 per 1000). The rates were significantly lower for black men than for non-Hispanic white men in nearly every region of the country (P<0.05). For the Hispanic population and for black women, racial or ethnic disparities at the national level were due in part to geographic differences rather than to differences in the rates for different racial and ethnic groups within geographic areas. Residential segregation and low income levels contributed to racial and ethnic disparities in arthroplasty rates. CONCLUSIONS: In the Medicare population, the rate of surgical treatment for osteoarthritis of the knee varies dramatically according to sex, race or ethnic group, and region. These variations underscore the importance of geography and sex in determining racial or ethnic barriers to health care.	Dartmouth Hitchcock Med Ctr, Dept Orthoped, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci & Community & Family Med, Lebanon, NH USA; Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA	Dartmouth College; Dartmouth College; Dartmouth College; National Bureau of Economic Research	Weinstein, JN (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Orthoped, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	james.weinstein@dartmouth.edu	Sporer, Scott/AAQ-6186-2020		NIAMS NIH HHS [U01-AR45444-01A1, 60-AR048094-01A1] Funding Source: Medline; NIA NIH HHS [KO1 AG00752, P01 AG019783-03, P01 AG19783, P01 AG019783] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR048094, U01AR045444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG000752, P01AG019783] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acevedo-Garcia D, 2000, SOC SCI MED, V51, P1143, DOI 10.1016/S0277-9536(00)00016-2; ALTONJI J, 2000, HDB LABOR EC C, V3; ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; Arday SL, 2000, HEALTH CARE FINANC R, V21, P107; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; BLINDER AS, 1973, J HUM RESOUR, V8, P436, DOI 10.2307/144855; Callaghan JJ, 2000, J BONE JOINT SURG AM, V82A, P487, DOI 10.2106/00004623-200004000-00004; CHANDRA A, 2003, 9513 NAT BUR EC RES; Cromley EK., 2002, GIS PUBLIC HLTH; Deaton A., 1997, The analysis of household surveys: a microeconometric approach to development policy.; *DEP COMM, 2002, CENS 2000 SUMM FIL 3; DIEHR P, 1992, MED CARE, V30, P484, DOI 10.1097/00005650-199206000-00003; Duncan OD, 1955, AM SOCIOL REV, V20, P210, DOI 10.2307/2088328; Escalante A, 2000, ARTHRITIS RHEUM-US, V43, P390, DOI 10.1002/1529-0131(200002)43:2<390::AID-ANR20>3.0.CO;2-R; Ferguson JA, 1998, ARCH INTERN MED, V158, P1450, DOI 10.1001/archinte.158.13.1450; FISHER L, 1993, BIOSTATISTICS METHOD, P769; FORMAN MD, 1983, J RHEUMATOL, V10, P282; GLAESER E, 2001, SURVEY SERIES RACIAL, P1; Gomes C, 2001, IDENTIFYING SOURCES; Hawker G, 1998, J BONE JOINT SURG AM, V80A, P163, DOI 10.2106/00004623-199802000-00003; Hawker GA, 2000, NEW ENGL J MED, V342, P1016, DOI 10.1056/NEJM200004063421405; Hawker GA, 2001, MED CARE, V39, P206, DOI 10.1097/00005650-200103000-00002; Hirsch R, 2001, ARTHRITIS RHEUM, V44, pS225; Ibrahim SA, 2001, ARTHRIT RHEUM-ARTHR, V45, P340, DOI 10.1002/1529-0131(200108)45:4<340::AID-ART346>3.0.CO;2-5; Ibrahim SA, 2002, MED CARE, V40, P44; KATZ JN, 1994, ARTHRITIS RHEUM, V37, P687, DOI 10.1002/art.1780370512; Katz JN, 2001, JAMA-J AM MED ASSOC, V286, P1506, DOI 10.1001/jama.286.12.1506; Lavernia CJ, 1997, CLIN ORTHOP RELAT R, P134; MASSEY DS, 1988, SOC FORCES, V67, P281, DOI 10.2307/2579183; MIYASAKA KC, 1997, CLIN ORTHOP RELAT R, V345, P29; Nelson AR, 2002, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; OAXACA RL, 1975, J HUM RESOUR, V10, P529, DOI 10.2307/144990; Petersen LA, 2002, MED CARE, V40, P86; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON MGE, 1992, J BONE JOINT SURG AM, V74A, P1530, DOI 10.2106/00004623-199274100-00012; Phelan EA, 2001, SPINE, V26, P206, DOI 10.1097/00007632-200101150-00016; Polednak AP, 1996, AM J PUBLIC HEALTH, V86, P723, DOI 10.2105/AJPH.86.5.723; Schneider EC, 2001, ANN INTERN MED, V135, P328, DOI 10.7326/0003-4819-135-5-200109040-00009; Schulman KA, 1999, NEW ENGL J MED, V340, P1130; Schwartz LM, 1999, NEW ENGL J MED, V341, P279, DOI 10.1056/NEJM199907223410411; Sedlis SP, 1997, J CLIN EPIDEMIOL, V50, P899, DOI 10.1016/S0895-4356(97)00089-9; WEINSTEIN J, 2000, DARTMOUTH ATLAS MUSC; Weinstein JN, 2000, SPINE, V25, P1; WENNBERG J, 1986, NEW ENGL J MED, V314, P310, DOI 10.1056/NEJM198601303140509; Wennberg JE, 1999, DARTMOUTH ATLAS HLTH; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wilson Marcus Garvey, 1994, Ethnicity and Disease, V4, P57	48	402	403	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1350	1359		10.1056/NEJMsa021569	http://dx.doi.org/10.1056/NEJMsa021569			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	727EM	14523144				2022-12-28	WOS:000185644000011
J	Tucker, T; Slack, C				Tucker, T; Slack, C			Not if but how? Caring for HIV-1 vaccine trial participants in South Africa	LANCET			English	Editorial Material									S African AIDS Vaccine Initiat, ZA-7505 Tygerberg, South Africa; Univ Natal, HIV AIDS Vaccines Eth Grp, ZA-3200 Pietermaritzburg, South Africa	University of Kwazulu Natal	Tucker, T (corresponding author), S African AIDS Vaccine Initiat, POB 19070, ZA-7505 Tygerberg, South Africa.							Benatar SR, 2000, BMJ-BRIT MED J, V321, P824, DOI 10.1136/bmj.321.7264.824	1	15	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					995	995		10.1016/S0140-6736(03)14374-7	http://dx.doi.org/10.1016/S0140-6736(03)14374-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14513854				2022-12-28	WOS:000185489600027
J	Alexander, RM				Alexander, RM			A rodent as big as a buffalo	SCIENCE			English	Editorial Material									Univ Leeds, Dept Pure & Appl Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Alexander, RM (corresponding author), Univ Leeds, Dept Pure & Appl Biol, Leeds LS2 9JT, W Yorkshire, England.	r.m.alexander@leeds.ac.uk						BIEWENER AA, 1989, SCIENCE, V245, P45, DOI 10.1126/science.2740914; Biknevicius A.R., 1993, American Museum Novitates, V3079, P1; FORTELIUS M, 1993, ZOOL J LINN SOC-LOND, V108, P85, DOI 10.1006/zjls.1993.1018; Gordon IJ, 1996, J ANIM ECOL, V65, P18, DOI 10.2307/5696; Sanchez-Villagra MR, 2003, SCIENCE, V301, P1708, DOI 10.1126/science.1089332	5	5	6	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1678	1679		10.1126/science.1090964	http://dx.doi.org/10.1126/science.1090964			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500968				2022-12-28	WOS:000185387700029
J	Chen, JG; Willard, FS; Huang, J; Liang, JS; Chasse, SA; Jones, AM; Siderovski, DP				Chen, JG; Willard, FS; Huang, J; Liang, JS; Chasse, SA; Jones, AM; Siderovski, DP			A seven-transmembrane RGS protein that modulates plant cell proliferation	SCIENCE			English	Article							HETEROTRIMERIC G-PROTEIN; ALPHA-SUBUNIT; ARABIDOPSIS; REGULATOR; EXPRESSION; GPA1	G protein coupled receptors (GPCRs) at the cell surface activate heterotrimeric G proteins by inducing the G protein alpha (Galpha) subunit to exchange guanosine diphosphate for guanosine triphosphate. Regulators of G protein signaling (RGS) proteins accelerate the deactivation of Galpha subunits to reduce GPCR signaling. Here we identified an RGS protein (AtRGS1) in Arabidopsis that has a predicted structure similar to a GPCR as well as an RGS box with GTPase accelerating activity. Expression of AtRGS1 complemented the pheromone supersensitivity phenotype of a yeast RGS mutant, sst2Delta. Loss of AtRGS1 increased the activity of the Arabidopsis Galpha subunit, resulting in increased cell elongation in hypocotyls in darkness and increased cell production in roots grown in light. These findings suggest that AtRGS1 is a critical modulator of plant cell proliferation.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, UNC Neurosci Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Yangzhou Univ, Coll Biosci & Biotechnol, Yangzhou 225009, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Yangzhou University	Jones, AM (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	alan_jones@unc.edu	Chen, Jin-Gui/AFV-6337-2022; Siderovski, David Peter/AAA-9603-2019; Chen, Jin-Gui/A-4773-2011	Chen, Jin-Gui/0000-0002-1752-4201; Siderovski, David Peter/0000-0002-0688-8210; Chen, Jin-Gui/0000-0002-1752-4201	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065989, P01GM065533, R01GM062338, R01GM055316, R29GM055316] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM065989-02, GM65533, GM055316, GM65989, R01 GM065989-01, R01 GM065989-03, GM62338, R01 GM065989-04, R01 GM065989] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Assmann SM, 2002, PLANT CELL, V14, pS355, DOI 10.1105/tpc.001792; de Alba E, 1999, J MOL BIOL, V291, P927, DOI 10.1006/jmbi.1999.2989; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HUANG H, 1994, INT J PLANT SCI, V155, P3, DOI 10.1086/297142; Jones AM, 2003, PLANT PHYSIOL, V131, P1623, DOI 10.1104/pp.102.017624; Jones AM, 2002, CURR OPIN PLANT BIOL, V5, P402, DOI 10.1016/S1369-5266(02)00288-1; Kim MC, 2002, NATURE, V416, P447, DOI 10.1038/416447a; Kimple RJ, 2003, COMB CHEM HIGH T SCR, V6, P399; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ullah H, 2003, PLANT CELL, V15, P393, DOI 10.1105/tpc.006148; Ullah H, 2001, SCIENCE, V292, P2066, DOI 10.1126/science.1059040	18	241	266	4	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1728	1731		10.1126/science.1087790	http://dx.doi.org/10.1126/science.1087790			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500984				2022-12-28	WOS:000185387700046
J	Pintard, L; Willis, JH; Willems, A; Johnson, JLF; Srayko, M; Kurz, T; Glaser, S; Mains, PE; Tyers, M; Bowerman, B; Peter, M				Pintard, L; Willis, JH; Willems, A; Johnson, JLF; Srayko, M; Kurz, T; Glaser, S; Mains, PE; Tyers, M; Bowerman, B; Peter, M			The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase	NATURE			English	Article							CAENORHABDITIS-ELEGANS; DEGRADATION; GENE; FAMILY; MEI-1; COMPLEX; TARGET; MEMBER	Many biological processes, such as development and cell cycle progression are tightly controlled by selective ubiquitin-dependent degradation of key substrates. In this pathway, the E3-ligase recognizes the substrate and targets it for degradation by the 26S proteasome. The SCF (Skp1-Cul1-F-box) and ECS (Elongin C-Cul2-SOCS box) complexes are two well-defined cullin-based E3-ligases(1-3). The cullin subunits serve a scaffolding function and interact through their C terminus with the RING-finger-containing protein Hrt1/Roc1/Rbx1, and through their N terminus with Skp1 or Elongin C, respectively. In Caenorhabditis elegans, the ubiquitin-ligase activity of the CUL-3 complex is required for degradation of the microtubule-severing protein MEI-1/katanin at the meiosis-to-mitosis transition(4). However, the molecular composition of this cullin-based E3-ligase is not known. Here we identified the BTB-containing protein MEL-26 as a component required for degradation of MEI-1 in vivo. Importantly, MEL-26 specifically interacts with CUL-3 and MEI-1 in vivo and in vitro, and displays properties of a substrate-specific adaptor. Our results suggest that BTB-containing proteins may generally function as substrate-specific adaptors in Cul3-based E3-ubiquitin ligases.	ETH Honggerberg, Inst Biochem, CH-8093 Zurich, Switzerland; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med Genet & Microbiol, Toronto, ON M5G 1X5, Canada; Univ Calgary, Genes & Dev Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Oregon; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Calgary; University of Calgary	Pintard, L (corresponding author), ETH Honggerberg, Inst Biochem, CH-8093 Zurich, Switzerland.	lionel.pintard@bc.biol.ethz.ch; matthias.peter@bc.biol.ethz.ch	PINTARD, Lionel/H-3756-2018; pintard, lionel/AAD-8356-2020; Kurz, Thimo/E-4116-2012; Srayko, Martin/A-3755-2014; Tyers, Michael/ABE-3194-2021; PINTARD, Lionel/AAP-7361-2020	PINTARD, Lionel/0000-0003-0286-4630; PINTARD, Lionel/0000-0003-0286-4630; Kurz, Thimo/0000-0003-0700-6993; Peter, Matthias/0000-0002-2160-6824; Srayko, Martin/0000-0003-0196-0364				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRENNER S, 1974, GENETICS, V77, P71; CLARKMAGUIRE S, 1994, GENETICS, V136, P533; CLARKMAGUIRE S, 1994, J CELL BIOL, V126, P199, DOI 10.1083/jcb.126.1.199; Dow MR, 1998, GENETICS, V150, P119; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; HARPER JW, 1993, CELL, V75, P805; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; MAINS PE, 1990, GENETICS, V126, P593; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Seibert V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-22; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Srayko M, 2000, GENE DEV, V14, P1072; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wolf DA, 1999, CURR BIOL, V9, P373, DOI 10.1016/S0960-9822(99)80165-1; XU L, 2003, NATURE          0903, DOI DOI 10.1038/NATURE01985; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	27	337	351	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2003	425	6955					311	316		10.1038/nature01959	http://dx.doi.org/10.1038/nature01959			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679921				2022-12-28	WOS:000185370900049
J	Quigg, A; Finkel, ZV; Irwin, AJ; Rosenthal, Y; Ho, TY; Reinfelder, JR; Schofield, O; Morel, FMM; Falkowski, PG				Quigg, A; Finkel, ZV; Irwin, AJ; Rosenthal, Y; Ho, TY; Reinfelder, JR; Schofield, O; Morel, FMM; Falkowski, PG			The evolutionary inheritance of elemental stoichiometry in marine phytoplankton	NATURE			English	Article							CADMIUM; ZINC	Phytoplankton is a nineteenth century ecological construct for a biologically diverse group of pelagic photoautotrophs that share common metabolic functions but not evolutionary histories(1). In contrast to terrestrial plants, a major schism occurred in the evolution of the eukaryotic phytoplankton that gave rise to two major plastid superfamilies(2-4). The green superfamily appropriated chlorophyll b, whereas the red superfamily uses chlorophyll c as an accessory photosynthetic pigment(5). Fossil evidence suggests that the green superfamily dominated Palaeozoic oceans. However, after the end-Permian extinction, members of the red superfamily rose to ecological prominence. The processes responsible for this shift are obscure. Here we present an analysis of major nutrients and trace elements in 15 species of marine phytoplankton from the two superfamilies. Our results indicate that there are systematic phylogenetic differences in the two plastid types where macronutrient (carbon:nitrogen:phosphorus) stoichiometries primarily reflect ancestral pre-symbiotic host cell phenotypes, but trace element composition reflects differences in the acquired plastids. The compositional differences between the two plastid superfamilies suggest that changes in ocean redox state strongly influenced the evolution and selection of eukaryotic phytoplankton since the Proterozoic era.	Rutgers State Univ, Inst Marine & Coastal Sci, Environm Biophys & Mol Ecol Program, New Brunswick, NJ 08901 USA; Rutgers State Univ, Dept Geol Sci, New Brunswick, NJ 08901 USA; Rutgers State Univ, Dept Environm Sci, New Brunswick, NJ 08901 USA; Rutgers State Univ, Coastal Ocean Observat Lab, New Brunswick, NJ 08901 USA; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Princeton University	Quigg, A (corresponding author), Rutgers State Univ, Inst Marine & Coastal Sci, Environm Biophys & Mol Ecol Program, New Brunswick, NJ 08901 USA.	aquigg@imcs.rutgers.edu; falko@imcs.rutgers.edu	Morel, Francois M M/A-8107-2008; Finkel, Zoe V/B-9626-2008; Quigg, Antonietta S/A-9345-2010; Irwin, Andrew/B-2245-2008; Reinfelder, John/C-7214-2016; Ho, Tung-Yuan/F-2323-2017; Schofield, Oscar/H-4169-2018	Finkel, Zoe V/0000-0003-4212-3917; Reinfelder, John/0000-0002-3737-604X; Irwin, Andrew/0000-0001-7784-2319; Schofield, Oscar/0000-0003-2359-4131				Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cullen JT, 2001, J ANAL ATOM SPECTROM, V16, P1307, DOI 10.1039/b104398f; Delwiche CF, 1999, AM NAT, V154, pS164, DOI 10.1086/303291; Des Marais DJ, 2000, SCIENCE, V289, P1703; Falkowski P.G., 2013, AQUATIC PHOTOSYNTHES; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; Falkowski PG, 2000, J PHYCOL, V36, P3, DOI 10.1046/j.1529-8817.2000.99161.x; FALKOWSKI PG, 1981, PLANT PHYSIOL, V68, P969, DOI 10.1104/pp.68.4.969; FALKOWSKI PG, IN PRESS COCCOLITHOP; Geider RJ, 2002, EUR J PHYCOL, V37, P1, DOI 10.1017/S0967026201003456; Grzebyk D, 2003, J PHYCOL, V39, P259, DOI 10.1046/j.1529-8817.2003.02082.x; HAECKEL E, 1990, PLANKTON STUDIEN VER; HO TY, UNPUB J PHYCOL; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; LEE JG, 1995, MAR ECOL PROG SER, V127, P305, DOI 10.3354/meps127305; Martin W, 2002, P NATL ACAD SCI USA, V99, P12246, DOI 10.1073/pnas.182432999; Palmer JD, 2003, J PHYCOL, V39, P4, DOI 10.1046/j.1529-8817.2003.02185.x; PRICE N M, 1988, Biological Oceanography, V6, P443; PRICE NM, 1990, NATURE, V344, P658, DOI 10.1038/344658a0; Raven JA, 1999, PHOTOSYNTH RES, V60, P111, DOI 10.1023/A:1006282714942; Redfield A. C., 1934, P176; Sterner R.W, 2002, ECOLOGICAL STOICHIOM, DOI DOI 10.1086/382444; Sverdrup H.U., 1942, OCEANS; Venables W., 2013, MODERN APPL STAT S, V53, P86; Whitfield M, 2001, ADV MAR BIOL, V41, P1, DOI 10.1016/S0065-2881(01)41002-9; Williams R.J.P., 1996, NATURAL SELECTION CH	27	379	395	9	208	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2003	425	6955					291	294		10.1038/nature01953	http://dx.doi.org/10.1038/nature01953			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679916				2022-12-28	WOS:000185370900044
J	Reichenberger, F; Brant, J				Reichenberger, F; Brant, J			Gigantic pulmonary arteries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Papworth Hosp, Cambridge CB3 8RE, England	Papworth Hospital	Reichenberger, F (corresponding author), Papworth Hosp, Cambridge CB3 8RE, England.		Reichenberger, Frank/AAJ-7232-2020	Reichenberger, Frank/0000-0003-1136-4769					0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1148	1148		10.1056/NEJMicm020488	http://dx.doi.org/10.1056/NEJMicm020488			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679529				2022-12-28	WOS:000185369700008
J	Bleharski, JR; Li, HY; Meinken, C; Graeber, TG; Ochoa, MT; Yamamura, M; Burdick, A; Sarno, EN; Wagner, M; Rollinghoff, M; Rea, TH; Colonna, M; Stenger, S; Bloom, BR; Eisenberg, D; Modlin, RL				Bleharski, JR; Li, HY; Meinken, C; Graeber, TG; Ochoa, MT; Yamamura, M; Burdick, A; Sarno, EN; Wagner, M; Rollinghoff, M; Rea, TH; Colonna, M; Stenger, S; Bloom, BR; Eisenberg, D; Modlin, RL			Use of genetic profiling in leprosy to discriminate clinical forms of the disease	SCIENCE			English	Article							INTRACELLULAR INFECTION; CELL RESPONSES; EXPRESSION; LESIONS; ACTIVATION; PATHOGENS; RECEPTORS; PATTERNS; SUBSETS; GAMMA	Leprosy presents as a clinical and immunological spectrum of disease. With the use of gene expression pro. ling, we observed that a distinction in gene expression correlates with and accurately classifies the clinical form of the disease. Genes belonging to the leukocyte immunoglobulin-like receptor (LIR) family were significantly up-regulated in lesions of lepromatous patients suffering from the disseminated form of the infection. In functional studies, LIR-7 suppressed innate host defense mechanisms by shifting monocyte production from interleukin-12 toward interleukin-10 and by blocking antimicrobial activity triggered by Toll-like receptors. Gene expression profiles may be useful in de. ning clinical forms of disease and providing insights into the regulation of immune responses to pathogens.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, UCLA Dept Energy Inst Genom & Proteom, Howard Hughes Med Inst, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Erlangen Nurnberg, Inst Klin Mikrobiol Immunol & Hyg, D-91054 Erlangen, Germany; Okayama Univ, Grad Sch Med & Dent, Okayama, Japan; Univ Miami, Dept Dermatol & Cutaneous Surg, Miami, FL 33101 USA; Inst Oswaldo Cruz, Leprosy Lab, BR-20001 Rio De Janeiro, Brazil; Klinikum Nurnberg, Med Klin 3, D-90340 Nurnberg, Germany; Univ So Calif, Sch Med, Dermatol Sect, Los Angeles, CA 90033 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Harvard Univ, Sch Publ Hlth, Off Dean, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Erlangen Nuremberg; Okayama University; University of Miami; Fundacao Oswaldo Cruz; Klinikum Nurnberg Nord; University of Southern California; Washington University (WUSTL); Harvard University; Harvard T.H. Chan School of Public Health	Modlin, RL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA.		Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X; Ochoa, Maria T/0000-0001-6550-5008; Graeber, Thomas/0000-0001-8574-9181; Nunes Sarno, Euzenir/0000-0003-0129-2159; Colonna, Marco/0000-0001-5222-4987	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI147868, R01AI022553, R01AI047868, R37AI047868, R22AI022553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040312] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 47868, AI 22553, AI 07118] Funding Source: Medline; NIAMS NIH HHS [AR 40312] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; BLEHARSKI JR, UNPUB; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; Borges L, 2000, CYTOKINE GROWTH F R, V11, P209, DOI 10.1016/S1359-6101(00)00007-1; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EISEN MB, TREEVIEW 1 60; Garcia VE, 2001, J IMMUNOL, V167, P5719, DOI 10.4049/jimmunol.167.10.5719; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Jullien D, 1997, J IMMUNOL, V158, P800; Krutzik SR, 2003, NAT MED, V9, P525, DOI 10.1038/nm864; MODLIN RL, 1983, J AM ACAD DERMATOL, V8, P182, DOI 10.1016/S0190-9622(83)70021-6; MODLIN RL, 1988, P NATL ACAD SCI USA, V85, P1213, DOI 10.1073/pnas.85.4.1213; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Nakajima H, 1999, J IMMUNOL, V162, P5; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; Sieling PA, 1999, J IMMUNOL, V162, P1851; SIELING PA, 1994, J IMMUNOL, V153, P3639; SIELING PA, 1995, J IMMUNOL, V154, P2775; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	23	125	130	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1527	1530		10.1126/science.1087785	http://dx.doi.org/10.1126/science.1087785			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970564				2022-12-28	WOS:000185255300048
J	Dobson, A				Dobson, A			Metalife!	SCIENCE			English	Editorial Material							PARASITE POPULATION INTERACTIONS; DYNAMICS; METAPOPULATION; COMPETITION; STABILITY; MODELS		Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA	Princeton University	Dobson, A (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	dobber@princeton.edu						ANDERSON R M, 1991; ANDERSON RM, 1978, J ANIM ECOL, V47, P219, DOI 10.2307/3933; ANDERSON RM, 1985, J HYG-CAMBRIDGE, V94, P365, DOI 10.1017/S002217240006160X; [Anonymous], 1999, OXFORD SERIES ECOLOG; Caswell H, 1993, PATCH DYNAMICS, P93; Diekmann O., 2000, MATH EPIDEMIOLOGY IN; DOBSON AP, 1985, PARASITOLOGY, V91, P317, DOI 10.1017/S0031182000057401; DOBSON AP, 1999, PARASITOLOGY S, V109, P97; Durrett R, 2000, J THEOR BIOL, V205, P201, DOI 10.1006/jtbi.2000.2061; GILPIN M, 1991, BIOL J LINN SOC, V42, P165, DOI 10.1111/j.1095-8312.1991.tb00558.x; Grenfell B, 1997, TRENDS ECOL EVOL, V12, P395, DOI 10.1016/S0169-5347(97)01174-9; GRENFELL BT, 1985, J HYG-CAMBRIDGE, V95, P419, DOI 10.1017/S0022172400062859; HANSKI I, 1997, METAPOPULATION BIOL; Harrison Susan, 1994, P111; Hastings A, 2003, SCIENCE, V301, P1525, DOI 10.1126/science.1087570; Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118; Keymer JE, 2000, AM NAT, V156, P478, DOI 10.1086/303407; LAMBERSON RH, 1992, CONSERV BIOL, V6, P505, DOI 10.1046/j.1523-1739.1992.06040505.x; LANDE R, 1987, AM NAT, V130, P624, DOI 10.1086/284734; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; MAY RM, 1978, J ANIM ECOL, V47, P249, DOI 10.2307/3934; McCullough D.R., 1996, METAPOPULATIONS WILD; Moilanen A, 1998, ECOLOGY, V79, P2503, DOI 10.1890/0012-9658(1998)079[2503:MDEOHQ]2.0.CO;2; Nee Sean, 1997, P123, DOI 10.1016/B978-012323445-2/50009-2; Olivieri Isabelle, 1997, P293, DOI 10.1016/B978-012323445-2/50017-1; Pacala SW, 1995, OIKOS, V74, P357, DOI 10.2307/3545980; PACALA SW, 1994, AM NAT, V143, P222, DOI 10.1086/285602; Pascual M, 2001, ECOLOGY, V82, P2357, DOI 10.1890/0012-9658(2001)082[2357:ODASST]2.0.CO;2; ROBERTS MG, 1995, MATH BIOSCI, V126, P191, DOI 10.1016/0025-5564(94)00036-Y; Ronce O, 1997, AM NAT, V150, P220, DOI 10.1086/286064; Schenzle D, 1984, IMA J Math Appl Med Biol, V1, P169	31	20	22	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1488	1490		10.1126/science.1090481	http://dx.doi.org/10.1126/science.1090481			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970552				2022-12-28	WOS:000185255300034
J	Rabiner, L				Rabiner, L			The power of speech	SCIENCE			English	Editorial Material									Rutgers State Univ, Ctr Adv Informat Proc, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Rabiner, L (corresponding author), Rutgers State Univ, Ctr Adv Informat Proc, Piscataway, NJ 08854 USA.							BEUTNAGEL M, 1999, J ACOUST SOC AM 2, V105, P1030; Cox RV, 2000, P IEEE, V88, P1314, DOI 10.1109/5.880086; Cox RV, 1998, P IEEE, V86, P755, DOI 10.1109/5.664272; GORIN A, 1995, J ACOUST SOC AM, V97, P3441, DOI 10.1121/1.412431; Gorin AL, 1997, SPEECH COMMUN, V23, P113, DOI 10.1016/S0167-6393(97)00040-X; HUNT A, 1996, P ICASSP, P373; Kleijn W.B., 1995, SPEECH CODING SYNTHE; MAKHOUL J, 1994, VOICE COMMUNICATION BETWEEN HUMANS AND MACHINES, P165; Rabiner L., 1993, FUNDAMENTALS SPEECH; ROSENBERG AE, 1997, P EUR 97, P1371	10	10	22	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1494	1495		10.1126/science.1088904	http://dx.doi.org/10.1126/science.1088904			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970555				2022-12-28	WOS:000185255300037
J	Peumans, P; Uchida, S; Forrest, SR				Peumans, P; Uchida, S; Forrest, SR			Efficient bulk heterojunction photovoltaic cells using small-molecular-weight organic thin films	NATURE			English	Article							PHTHALOCYANINE; TRANSPORT; PERYLENE; DEVICES	The power conversion efficiency of small-molecular-weight and polymer organic photovoltaic cells has increased steadily over the past decade. This progress is chiefly attributable to the introduction of the donor-acceptor heterojunction(1,2) that functions as a dissociation site for the strongly bound photogenerated excitons. Further progress was realized in polymer devices through use of blends of the donor and acceptor materials(3-5) : phase separation during spin-coating leads to a bulk heterojunction that removes the exciton diffusion bottleneck by creating an interpenetrating network of the donor and acceptor materials. The realization of bulk heterojunctions using mixtures of vacuum-deposited small-molecular-weight materials has, on the other hand, posed elusive: phase separation induced by elevating the substrate temperature inevitably leads to a significant roughening of the film surface and to short-circuited devices. Here, we demonstrate that the use of a metal cap to confine the organic materials during annealing prevents the formation of a rough surface morphology while allowing for the formation of an interpenetrating donor-acceptor network. This method results in a power conversion efficiency 50 per cent higher than the best values reported for comparable bilayer devices, suggesting that this strained annealing process could allow for the formation of low-cost and high-efficiency thin film organic solar cells based on vacuum-deposited small-molecular-weight organic materials.	Princeton Univ, Ctr Photon & Optoelect Mat, Dept Elect Engn, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA	Princeton University; Princeton University	Forrest, SR (corresponding author), Princeton Univ, Ctr Photon & Optoelect Mat, Dept Elect Engn, Princeton, NJ 08544 USA.	forrest@princeton.edu		Uchida, Soichi/0000-0001-8714-9809				Aernouts T, 2002, THIN SOLID FILMS, V403, P297, DOI 10.1016/S0040-6090(01)01584-X; Baldo MA, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.085201; Burrows PE, 1996, J APPL PHYS, V79, P7991, DOI 10.1063/1.362350; Dittmer JJ, 2000, SOL ENERG MAT SOL C, V61, P53, DOI 10.1016/S0927-0248(99)00096-3; Feng W, 2000, J APPL PHYS, V88, P7120, DOI 10.1063/1.1323514; Forrest SR, 1997, CHEM REV, V97, P1793, DOI 10.1021/cr941014o; Geens W, 2002, THIN SOLID FILMS, V403, P438, DOI 10.1016/S0040-6090(01)01585-1; Granstrom M, 1998, NATURE, V395, P257, DOI 10.1038/26183; HALLS JJM, 1995, NATURE, V376, P498, DOI 10.1038/376498a0; Halls JJM, 1997, SYNTHETIC MET, V85, P1307, DOI 10.1016/S0379-6779(97)80252-4; Hiramoto M, 2002, JPN J APPL PHYS 1, V41, P2763, DOI 10.1143/JJAP.41.2763; Israelachvili JN, 1992, INTERMOLECULAR SURFA, P176; Kim J, 2003, APPL PHYS LETT, V82, P4238, DOI 10.1063/1.1582359; Lee TW, 2000, APPL PHYS LETT, V77, P3334, DOI 10.1063/1.1328095; Niu YH, 2003, SYNTHETIC MET, V135, P477, DOI 10.1016/S0379-6779(02)00697-5; Padinger F, 2003, ADV FUNCT MATER, V13, P85, DOI 10.1002/adfm.200390011; Peumans P, 2003, J APPL PHYS, V93, P3693, DOI 10.1063/1.1534621; Peumans P, 2001, APPL PHYS LETT, V79, P126, DOI 10.1063/1.1384001; Peumans P, 2000, APPL PHYS LETT, V76, P2650, DOI 10.1063/1.126433; Peumans P, 2000, APPL PHYS LETT, V76, P3855, DOI 10.1063/1.126800; Prabakaran R, 2002, PHYS STATUS SOLIDI B, V229, P1175, DOI 10.1002/1521-3951(200202)229:3<1175::AID-PSSB1175>3.0.CO;2-K; Raabe D, 2002, ANNU REV MATER RES, V32, P53, DOI 10.1146/annurev.matsci.32.090601.152855; Shaheen SE, 2001, APPL PHYS LETT, V78, P841, DOI 10.1063/1.1345834; Shtein M, 2001, J APPL PHYS, V89, P1470, DOI 10.1063/1.1332419; TANG CW, 1986, APPL PHYS LETT, V48, P183, DOI 10.1063/1.96937; Tsuzuki T, 2000, SOL ENERG MAT SOL C, V61, P1, DOI 10.1016/S0927-0248(99)00091-4; YU G, 1995, SCIENCE, V270, P1789, DOI 10.1126/science.270.5243.1789; YU G, 1994, APPL PHYS LETT, V64, P1540, DOI 10.1063/1.111885	28	1152	1185	12	594	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					158	162		10.1038/nature01949	http://dx.doi.org/10.1038/nature01949			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968174				2022-12-28	WOS:000185236000036
J	Wong, CSM; Strange, RC; Lear, JT				Wong, CSM; Strange, RC; Lear, JT			Basal cell carcinoma	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NONMELANOMA SKIN-CANCER; RECURRENCE RATES; PHOTODYNAMIC THERAPY; MALIGNANT-TUMORS; UNITED-STATES; RISK-FACTORS; EXPOSURE; ASSOCIATION; HISTORY; ULTRAVIOLET	The authors of this review aim to provide a comprehensive overview of basal cell carcinoma, concentrating in particular on incidence, risk factors, molecular genetics, clinical features, and treatment	Univ Manchester, Hope Hosp, Dermatol Ctr, Salford M6 8HD, Lancs, England; Keele Univ, N Staffordshire Hosp, Sch Med, Stoke On Trent, Staffs, England	University of Manchester; Keele University; University Hospital of North Staffordshire NHS Trust	Lear, JT (corresponding author), Univ Manchester, Hope Hosp, Dermatol Ctr, Salford M6 8HD, Lancs, England.	lisa.redfern@ccmmc.nhs.uk	Saavalainen, Liisu/C-3190-2017; lear, john/I-5465-2015	Saavalainen, Liisu/0000-0001-8002-0789; lear, john/0000-0002-2969-9922				Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Bower CPR, 2000, J AM ACAD DERMATOL, V42, P988, DOI 10.1016/S0190-9622(00)90291-3; Boyd AS, 2002, J AM ACAD DERMATOL, V46, P706, DOI 10.1067/mjd.2002.120467; CHIMENTI S, 1995, DERMATOLOGY, V190, P214, DOI 10.1159/000246688; Corona R, 2001, ARCH DERMATOL, V137, P1162; Diepgen TL, 2002, BRIT J DERMATOL, V146, P1, DOI 10.1046/j.1365-2133.146.s61.2.x; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; Friedman GD, 2000, CANCER CAUSE CONTROL, V11, P891, DOI 10.1023/A:1026591016153; Frisch M, 1996, ANN INTERN MED, V125, P815, DOI 10.7326/0003-4819-125-10-199611150-00005; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Gallagher RP, 1996, CANCER EPIDEM BIOMAR, V5, P419; GALLAGHER RP, 1995, ARCH DERMATOL, V131, P157, DOI 10.1001/archderm.131.2.157; GOETTE DK, 1981, J AM ACAD DERMATOL, V4, P633, DOI 10.1016/S0190-9622(81)80196-X; GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204; HARTEVELT MM, 1990, TRANSPLANTATION, V49, P506, DOI 10.1097/00007890-199003000-00006; HODAK E, 1987, INT J DERMATOL, V26, P606, DOI 10.1111/j.1365-4362.1987.tb02319.x; Holme SA, 2000, BRIT J DERMATOL, V143, P1224, DOI 10.1046/j.1365-2133.2000.03892.x; Kahn HS, 1998, JAMA-J AM MED ASSOC, V280, P910, DOI 10.1001/jama.280.10.910; KUFLIK EG, 1991, J AM ACAD DERMATOL, V24, P1002, DOI 10.1016/0190-9622(91)70160-4; Lear JT, 1997, CARCINOGENESIS, V18, P1499, DOI 10.1093/carcin/18.8.1499; Lear JT, 1997, J ROY SOC MED, V90, P371, DOI 10.1177/014107689709000704; LINDELOF B, 1991, J AM ACAD DERMATOL, V25, P245, DOI 10.1016/0190-9622(91)70189-9; LO JS, 1991, J AM ACAD DERMATOL, V24, P715, DOI 10.1016/0190-9622(91)70108-E; Maloney ME, 1996, DERMATOL SURG, V22, P301, DOI 10.1111/j.1524-4725.1996.tb00322.x; Marcil I, 2000, ARCH DERMATOL, V136, P1524, DOI 10.1001/archderm.136.12.1524; MARKS R, 1993, INT J CANCER, V53, P585, DOI 10.1002/ijc.2910530410; Marks R, 2001, J AM ACAD DERMATOL, V44, P807, DOI 10.1067/mjd.2001.113689; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Miller SJ, 1995, CLIN DERMATOL, V13, P527, DOI 10.1016/0738-081X(95)00062-K; MOLLER R, 1975, ARCH DERMATOL, V111, P584, DOI 10.1001/archderm.111.5.584; Peng Q, 1997, CANCER-AM CANCER SOC, V79, P2282; Ramachandran S, 2001, CANCER, V92, P354, DOI 10.1002/1097-0142(20010715)92:2<354::AID-CNCR1330>3.0.CO;2-F; Ramachandran S, 2001, J PHOTOCH PHOTOBIO B, V63, P1, DOI 10.1016/S1011-1344(01)00194-4; Ramachandran S, 2000, CANCER, V89, P1012, DOI 10.1002/1097-0142(20000901)89:5<1012::AID-CNCR10>3.0.CO;2-O; Rosso S, 1996, BRIT J CANCER, V73, P1447, DOI 10.1038/bjc.1996.275; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P315, DOI 10.1111/j.1524-4725.1989.tb03166.x; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P424, DOI 10.1111/j.1524-4725.1989.tb03249.x; SILVERMAN MK, 1992, J DERMATOL SURG ONC, V18, P471, DOI 10.1111/j.1524-4725.1992.tb03307.x; SILVERMAN MK, 1992, J DERMATOL SURG ONC, V18, P549, DOI 10.1111/j.1524-4725.1992.tb03508.x; SILVERMAN MK, 1991, J DERMATOL SURG ONC, V17, P720, DOI 10.1111/j.1524-4725.1991.tb03425.x; STERN RS, 1988, J INVEST DERMATOL, V91, P120, DOI 10.1111/1523-1747.ep12464137; SVANBERG K, 1994, BRIT J DERMATOL, V130, P743, DOI 10.1111/j.1365-2133.1994.tb03412.x; Telfer NR, 1999, BRIT J DERMATOL, V141, P415; VITASA BC, 1990, CANCER, V65, P2811, DOI 10.1002/1097-0142(19900615)65:12<2811::AID-CNCR2820651234>3.0.CO;2-U; Yamada M, 1996, RADIAT RES, V146, P223, DOI 10.2307/3579594; Zanetti R, 1996, BRIT J CANCER, V73, P1440, DOI 10.1038/bjc.1996.274	46	308	324	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 4	2003	327	7418					794	798		10.1136/bmj.327.7418.794	http://dx.doi.org/10.1136/bmj.327.7418.794			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525881	Green Published			2022-12-28	WOS:000185805100025
J	Brent, L				Brent, L			The 50th anniversary of the discovery of immunologic tolerance	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Brent, L (corresponding author), 30 Hugo Rd, London, England.							BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BILLINGHAM RE, 1956, PHILOS T R SOC B, V239, P357, DOI 10.1098/rstb.1956.0006; BILLINGHAM RE, 1957, TRANSPLAN B, V4, P58; BILLINGHAM RE, 1952, HEREDITY, V6, P200, DOI 10.1038/hdy.1952.20; Brent Leslie, 1997, HIST TRANSPLANTATION; Burnet FM, 1949, PRODUCTION ANTIBODIE; Calne R, 1998, LANCET, V352, P408; CALNE RY, 1960, LANCET, V1, P417; Hasek M., 1953, CESCOSL BIOL, V2, P265; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; SCHWARTZ R, 1959, NATURE, V183, P1682, DOI 10.1038/1831682a0; SIMONSEN MORTEN, 1957, ACTA PATHOL ET MICROBLOL SCAND, V40, P480; Starzl TE, 2003, LANCET, V361, P1502, DOI 10.1016/S0140-6736(03)13175-3	14	18	22	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1381	1383		10.1056/NEJMon035589	http://dx.doi.org/10.1056/NEJMon035589			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523148				2022-12-28	WOS:000185644000015
J	Dillon, N				Dillon, N			Positions, please ...	NATURE			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Clin Sci Ctr,Gene Regulat & Chromatin Grp, London W12 0NN, England	Imperial College London	Dillon, N (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Clin Sci Ctr,Gene Regulat & Chromatin Grp, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.							Beurton P. J., 2000, CONCEPT GENE DEV EVO; Dillon N, 2000, BIOESSAYS, V22, P657, DOI 10.1002/1521-1878(200007)22:7<657::AID-BIES8>3.3.CO;2-U; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5	3	20	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					457	457		10.1038/425457a	http://dx.doi.org/10.1038/425457a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523423	Bronze			2022-12-28	WOS:000185648100023
J	Black, DM; Greenspan, SL; Ensrud, KE; Palermo, L; McGowan, JA; Lang, TF; Garnero, P; Bouxsein, ML; Bilezikian, JP; Rosen, CJ				Black, DM; Greenspan, SL; Ensrud, KE; Palermo, L; McGowan, JA; Lang, TF; Garnero, P; Bouxsein, ML; Bilezikian, JP; Rosen, CJ		PaTH Study Investigators	The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; VERTEBRAL FRACTURES; WOMEN; TRIAL; METAANALYSIS; RISEDRONATE; TURNOVER; STRENGTH; THERAPY; RISK	BACKGROUND: Parathyroid hormone increases bone strength primarily by stimulating bone formation, whereas antiresorptive drugs reduce bone resorption. We conducted a randomized, double-blind clinical study of parathyroid hormone and alendronate to test the hypothesis that the concurrent administration of the two agents would increase bone density more than the use of either one alone. METHODS: A total of 238 postmenopausal women (who were not using bisphosphonates) with low bone mineral density at the hip or spine (a T score of less than -2.5, or a T score of less than -2.0 with an additional risk factor for osteoporosis) were randomly assigned to daily treatment with parathyroid hormone (1-84) (100 microg; 119 women), alendronate (10 mg; 60 women), or both (59 women) and were followed for 12 months. Bone mineral density at the spine and hip was assessed by dual-energy x-ray absorptiometry and quantitative computed tomography. Markers of bone turnover were measured in fasting blood samples. RESULTS: The bone mineral density at the spine increased in all the treatment groups, and there was no significant difference in the increase between the parathyroid hormone group and the combination-therapy group. The volumetric density of the trabecular bone at the spine increased substantially in all groups, but the increase in the parathyroid hormone group was about twice that found in either of the other groups. Bone formation increased markedly in the parathyroid hormone group but not in the combination-therapy group. Bone resorption decreased in the combination-therapy group and the alendronate group. CONCLUSIONS: There was no evidence of synergy between parathyroid hormone and alendronate. Changes in the volumetric density of trabecular bone, the cortical volume at the hip, and levels of markers of bone turnover suggest that the concurrent use of alendronate may reduce the anabolic effects of parathyroid hormone. Longer-term studies of fractures are needed to determine whether and how antiresorptive drugs can be optimally used in conjunction with parathyroid hormone therapy.	Univ Calif San Francisco, Dept Epidemiol & Biostat, Coordinating Ctr, San Francisco, CA 94105 USA; Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94105 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; Vet Affairs Med Ctr, Dept Med, Minneapolis, MN 55417 USA; Vet Affairs Med Ctr, Dept Epidemiol, Minneapolis, MN USA; Univ Minnesota, Minneapolis, MN USA; NIAMSD, NIH, Bethesda, MD 20892 USA; Synarc, Lyon, France; Beth Israel Deaconess Med Ctr, Dept Orthoped Surg, Boston, MA 02215 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; St Joseph Hosp, Maine Ctr Osteoporosis Res, Bangor, ME USA; Jackson Lab, Bar Harbor, ME 04609 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Synarc; Harvard University; Beth Israel Deaconess Medical Center; Columbia University; Jackson Laboratory	Black, DM (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, Coordinating Ctr, 74 New Montgomery St,Suite 600, San Francisco, CA 94105 USA.		Lang, Thomas F/B-2685-2012	Lang, Thomas F/0000-0002-3720-8038; Ensrud, Kristine/0000-0002-9069-3036	NIAMS NIH HHS [N01-AR-9-2245] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157; Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001-2002; Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001-9002; Cranney A, 2002, ENDOCR REV, V23, P517, DOI 10.1210/er.2001-3002; Cummings SR, 2002, JAMA-J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; CUMMINGS SR, 2002, JAMA-J AM MED ASSOC, V288, P2825; Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846; Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725; Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069; Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914; Lang TF, 1997, BONE, V21, P101, DOI 10.1016/S8756-3282(97)00072-0; Lang TF, 1999, J COMPUT ASSIST TOMO, V23, P130, DOI 10.1097/00004728-199901000-00027; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; *MEDRA MAINT SUPP, MEDDRA MED DICT REG; Misof BM, 2003, J CLIN ENDOCR METAB, V88, P1150, DOI 10.1210/jc.2002-021988; National Osteoporosis Foundation, 1999, PHYS GUID PREV TREAT; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9; Rehman Q, 2003, OSTEOPOROSIS INT, V14, P77, DOI 10.1007/s00198-002-1312-0; Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129; Zanchetta JR, 2003, J BONE MINER RES, V18, P539, DOI 10.1359/jbmr.2003.18.3.539	25	856	908	0	36	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2003	349	13					1207	1215		10.1056/NEJMoa031975	http://dx.doi.org/10.1056/NEJMoa031975			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LJ	14500804				2022-12-28	WOS:000185488800003
J	Semmann, D; Krambeck, HJR; Milinski, M				Semmann, D; Krambeck, HJR; Milinski, M			Volunteering leads to rock-paper-scissors dynamics in a public goods game	NATURE			English	Article							SIZABLE GROUPS; EVOLUTION; COOPERATION; COMMONS; RECIPROCITY; PUNISHMENT; TRAGEDY; HUMANS	Collective efforts are a trademark of both insect and human societies(1). They are achieved through relatedness in the former(2) and unknown mechanisms in the latter. The problem of achieving cooperation among non-kin has been described as the 'tragedy of the commons', prophesying the inescapable collapse of many human enterprises(3,4). In public goods experiments, initial cooperation usually drops quickly to almost zero(5). It can be maintained by the opportunity to punish defectors(6) or the need to maintain good reputation(7). Both schemes require that defectors are identified. Theorists propose that a simple but effective mechanism operates under full anonymity. With optional participation in the public goods game, 'loners' (players who do not join the group), defectors and cooperators will coexist through rock-paper-scissors dynamics(8,9). Here we show experimentally that volunteering generates these dynamics in public goods games and that manipulating initial conditions can produce each predicted direction. If, by manipulating displayed decisions, it is pretended that defectors have the highest frequency, loners soon become most frequent, as do cooperators after loners and defectors after cooperators. On average, cooperation is perpetuated at a substantial level.	Max Planck Inst Limnol, Dept Evolutionary Ecol, D-24306 Plon, Germany	Max Planck Society	Milinski, M (corresponding author), Max Planck Inst Limnol, Dept Evolutionary Ecol, D-24306 Plon, Germany.							AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; BERKES F, 1989, NATURE, V340, P91, DOI 10.1038/340091a0; BOLTON GE, 2001, WHATS REPUTATION IND; BOYD R, 1992, ETHOL SOCIOBIOL, V13, P171, DOI 10.1016/0162-3095(92)90032-Y; BOYD R, 1988, J THEOR BIOL, V132, P337, DOI 10.1016/S0022-5193(88)80219-4; Colman AM, 2013, GAME THEORY ITS APPL; DAWES RM, 1980, ANNU REV PSYCHOL, V31, P169, DOI 10.1146/annurev.ps.31.020180.001125; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 2003, NATURE, V422, P137, DOI 10.1038/nature01474; Fehr E, 2000, AM ECON REV, V90, P980, DOI 10.1257/aer.90.4.980; Gintis H, 2000, J THEOR BIOL, V206, P169, DOI 10.1006/jtbi.2000.2111; Gintis H., 2000, GAME THEORY EVOLVING; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Hardin G, 1998, SCIENCE, V280, P682, DOI 10.1126/science.280.5364.682; Hauert C, 2002, J THEOR BIOL, V218, P187, DOI 10.1006/jtbi.2002.3067; Hauert C, 2002, SCIENCE, V296, P1129, DOI 10.1126/science.1070582; Ledyard JO, 1995, HDB EXPT EC, P111, DOI DOI 10.3987/CONTENTS-12-85-7; MAGURRAN AE, 1987, PROC R SOC SER B-BIO, V229, P439, DOI 10.1098/rspb.1987.0004; Michor F, 2002, NATURE, V419, P677, DOI 10.1038/419677a; Milinski M, 2002, NATURE, V415, P424, DOI 10.1038/415424a; Nowak MA, 1998, NATURE, V393, P573, DOI 10.1038/31225; Ostrom E., 1999, GOVERNING COMMONS; Ridley Matt, 1996, ORIGINS VIRTUE; SCHELLING TC, 1973, J CONFLICT RESOLUT, V17, P381, DOI 10.1177/002200277301700302; SEINEN I, 2001, T120010031 TINB I; SOBER E, 1999, OTHER EVOLUTION PSYC; Sugden R, 1986, EC RIGHTS COOPERATIO; Trivers R. L., 1985, SOCIAL EVOLUTION; Wedekind C, 2000, SCIENCE, V288, P850, DOI 10.1126/science.288.5467.850	30	259	264	3	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					390	393		10.1038/nature01986	http://dx.doi.org/10.1038/nature01986			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	724TG	14508487				2022-12-28	WOS:000185502300039
J	Chalder, T; Goodman, R; Wessely, S; Hotopf, M; Meltzer, H				Chalder, T; Goodman, R; Wessely, S; Hotopf, M; Meltzer, H			Epidemiology of chronic fatigue syndrome and self reported myalgic encephalomyelitis in 5-15 year olds: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Guys Kings & St Thomass Sch Med, Dept Psychol Med, London SE5 8AZ, England; Inst Psychiat, Dept Child & Adolescent Psychiat, London SE5 8AF, England; Off Natl Stat, London SW1V 2QQ, England	University of London; King's College London; University of London; King's College London	Chalder, T (corresponding author), Guys Kings & St Thomass Sch Med, Dept Psychol Med, London SE5 8AZ, England.		Chalder, Trudie/A-5717-2011; Hotopf, Matthew/E-4971-2010; Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929; Hotopf, Matthew/0000-0002-3980-4466; Chalder, Trudie/0000-0003-0775-1045; Goodman, Robert/0000-0001-5596-1667				Dobbins J.G., 1997, J CHRONIC FATIGUE SY, V3, P15, DOI DOI 10.1300/J092v03n02_03; Dowsett E. J., 1997, J CHRONIC FATIGUE SY, V3, P29, DOI DOI 10.1300/J092V03N02_; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Goldberg D.P, 1972, DETECTION PSYCHIAT I; Goodman R, 2000, J CHILD PSYCHOL PSYC, V41, P645, DOI 10.1017/S0021963099005909; Jordan K. M., 2000, J CHRONIC FATIGUE SY, V6, P3; Meltzer H., 2000, MENTAL HLTH CHILDREN; Richards J., 1998, PSYCHIAT B, V22, P203; SPEIGHT A, 2000, ARCH DIS CHILD, V82, pG215	9	95	96	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 20	2003	327	7416					654	655		10.1136/bmj.327.7416.654	http://dx.doi.org/10.1136/bmj.327.7416.654			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724AC	14500438	Bronze, Green Published			2022-12-28	WOS:000185463100022
J	Bent, J; Hutchings, LR; Richards, RW; Gough, T; Spares, R; Coates, PD; Grillo, I; Harlen, OG; Read, DJ; Graham, RS; Likhtman, AE; Groves, DJ; Nicholson, TM; McLeish, TCB				Bent, J; Hutchings, LR; Richards, RW; Gough, T; Spares, R; Coates, PD; Grillo, I; Harlen, OG; Read, DJ; Graham, RS; Likhtman, AE; Groves, DJ; Nicholson, TM; McLeish, TCB			Neutron-mapping polymer flow: Scattering, flow visualization, and molecular theory	SCIENCE			English	Article							NUMERICAL-SIMULATION; ENTANGLED POLYMERS; MICROSCOPIC THEORY; SPIN-ECHO; DYNAMICS; MELTS; NETWORKS; MOTION; MODEL	Flows of complex fluids need to be understood at both macroscopic and molecular scales, because it is the macroscopic response that controls the fluid behavior, but the molecular scale that ultimately gives rise to rheological and solid-state properties. Here the flow field of an entangled polymer melt through an extended contraction, typical of many polymer processes, is imaged optically and by small-angle neutron scattering. The dual-probe technique samples both the macroscopic stress field in the flow and the microscopic configuration of the polymer molecules at selected points. The results are compared with a recent "tube model" molecular theory of entangled melt flow that is able to calculate both the stress and the single-chain structure factor from first principles. The combined action of the three fundamental entangled processes of reptation, contour length fluctuation, and convective constraint release is essential to account quantitatively for the rich rheological behavior. The multiscale approach unearths a new feature: Orientation at the length scale of the entire chain decays considerably more slowly than at the smaller entanglement length.	Univ Leeds, Dept Phys & Astron, Leeds LS2 9JT, W Yorkshire, England; Univ Queensland, Div Chem Engn, St Lucia, Qld 4072, Australia; Univ Leeds, Dept Appl Math, Leeds LS2 9JT, W Yorkshire, England; Univ Durham, Dept Chem, Durham DH1 3HP, England; Univ Bradford, Dept Mech Engn, Bradford BD7 1DP, W Yorkshire, England; Inst Max Von Laue Paul Langevin, F-38042 Grenoble 9, France	University of Leeds; University of Queensland; University of Leeds; Durham University; University of Bradford; Institut Laue-Langevin (ILL)	McLeish, TCB (corresponding author), Univ Leeds, Dept Phys & Astron, Leeds LS2 9JT, W Yorkshire, England.	t.c.b.mcleish@leeds.ac.uk	Graham, Richard/N-8167-2019; Likhtman, Alexei/F-3974-2015; Read, Daniel J/F-8318-2014; Hutchings, Lian R/F-8754-2012; Gough, Tim D/B-1936-2010; Harlen, Oliver/P-5958-2014; Grillo, Isabelle/O-5756-2017; Graham, Richard S/C-9196-2011; Read, Daniel/O-6450-2019	Graham, Richard/0000-0002-5530-8120; Hutchings, Lian R/0000-0003-2841-3176; Gough, Tim D/0000-0002-6155-5697; Harlen, Oliver/0000-0002-4593-3547; Grillo, Isabelle/0000-0002-5774-6773; Graham, Richard S/0000-0002-5530-8120; Read, Daniel/0000-0003-1194-9273; Coates, Philip/0000-0001-5193-5621; McLeish, Tom/0000-0002-2025-0299				Bielawski CW, 2002, SCIENCE, V297, P2041, DOI 10.1126/science.1075401; Bird R.B., 1977, DYNAMICS POLYM LIQUI, V2; Bird RB, 1977, DYNAMICS POLYM LIQUI, V1; Bishko GB, 1999, J NON-NEWTON FLUID, V82, P255, DOI 10.1016/S0377-0257(98)00165-7; Doi M., 1988, THEORY POLYM DYNAMIC; Graham RS, 2003, J RHEOL, V47, P1171, DOI 10.1122/1.1595099; Higgins J. S., 1994, POLYM NEUTRON SCATTE; HIGGINS JS, 1985, J CHEM SOC FARAD T 2, V81, P757, DOI 10.1039/f29858100757; KLEIN J, 1983, NATURE, V304, P5926; Komlosh ME, 1998, J CHEM PHYS, V109, P10053, DOI 10.1063/1.477674; Lee K, 2001, J RHEOL, V45, P1261, DOI 10.1122/1.1389316; Likhtman AE, 2000, PHYS REV LETT, V85, P4550, DOI 10.1103/PhysRevLett.85.4550; Likhtman AE, 2002, MACROMOLECULES, V35, P6332, DOI 10.1021/ma0200219; LIKHTMAN AE, IN PRESS J NONNEWT F; Marrucci G, 1996, J NON-NEWTON FLUID, V62, P279, DOI 10.1016/0377-0257(95)01407-1; McLeish T, 2002, SCIENCE, V297, P2005, DOI 10.1126/science.1076810; McLeish TCB, 2002, ADV PHYS, V51, P1379, DOI 10.1080/00018730210153216; Mead DW, 1998, MACROMOLECULES, V31, P7895, DOI 10.1021/ma980127x; MULLER R, 1993, MACROMOLECULES, V26, P4356, DOI 10.1021/ma00068a044; QUACK G, 1980, IND ENG CHEM PROD RD, V19, P587, DOI 10.1021/i360076a020; Read DJ, 1997, MACROMOLECULES, V30, P6376, DOI 10.1021/ma970571k; RICHTER D, 1989, PHYS REV LETT, V62, P2140, DOI 10.1103/PhysRevLett.62.2140; Rubinstein M, 1997, MACROMOLECULES, V30, P8036, DOI 10.1021/ma970364k; SHULL KR, 1990, NATURE, V345, P790, DOI 10.1038/345790a0; Smith DE, 1999, SCIENCE, V283, P1724, DOI 10.1126/science.283.5408.1724; Smith DE, 1998, SCIENCE, V281, P1335, DOI 10.1126/science.281.5381.1335	26	144	147	2	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1691	1695		10.1126/science.1086952	http://dx.doi.org/10.1126/science.1086952			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500974				2022-12-28	WOS:000185387700035
J	Gillespie, DAF; Vousden, KH				Gillespie, DAF; Vousden, KH			The secret life of histones	CELL			English	Editorial Material							H2AX; P53		Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Beatson Institute; University of Glasgow	Gillespie, DAF (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Fan YH, 2001, MOL CELL BIOL, V21, P7933, DOI 10.1128/MCB.21.23.7933-7943.2001; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; ZHANG Y, 2003, IN PRESS MOL CELL BI	9	12	12	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 19	2003	114	6					655	656		10.1016/S0092-8674(03)00723-2	http://dx.doi.org/10.1016/S0092-8674(03)00723-2			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505563	Bronze			2022-12-28	WOS:000185464000001
J	Mair, W; Goymer, P; Pletcher, SD; Partridge, L				Mair, W; Goymer, P; Pletcher, SD; Partridge, L			Demography of dietary restriction and death in Drosophila	SCIENCE			English	Article							AGE-SPECIFIC MORTALITY; LIFE-SPAN; CALORIE RESTRICTION; OXIDATIVE STRESS; MELANOGASTER; LONGEVITY; MICE; RECEPTOR	Dietary restriction (DR) increases life-span in organisms from yeast to mammals, presumably by slowing the accumulation of aging-related damage. Here we show that in Drosophila, DR extends life-span entirely by reducing the short-term risk of death. Two days after the application of DR at any age for the first time, previously fully fed flies are no more likely to die than flies of the same age that have been subjected to long-term DR. DR of mammals may also reduce short-term risk of death, and hence DR instigated at any age could generate a full reversal of mortality.	UCL, Dept Biol, London WC1E 6BT, England; Univ London Imperial Coll Sci Technol & Med, Ctr Populat Biol, NERC, Ascot SL5 7PY, Berks, England	University of London; University College London; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Partridge, L (corresponding author), UCL, Dept Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.	l.partridge@ucl.ac.uk	Partridge, Linda/A-5501-2010; Partridge, Linda/E-7342-2015	Mair, William/0000-0002-0661-1342; Partridge, Linda/0000-0001-9615-0094; Goymer, Patrick/0000-0002-2789-9373	Biotechnology and Biological Sciences Research Council [SF19106] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Carey J. R., 2003, LONGEVITY BIOL DEMOG, DOI [10.1515/9780691224084, DOI 10.1515/9780691224084]; Carey JR, 1998, SCIENCE, V281, P996, DOI 10.1126/science.281.5379.996; Chapman T, 1996, P ROY SOC B-BIOL SCI, V263, P755, DOI 10.1098/rspb.1996.0113; Good TP, 2001, J INSECT PHYSIOL, V47, P1467, DOI 10.1016/S0022-1910(01)00138-X; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Kealy RD, 2002, J AM VET MED ASSOC, V220, P1315, DOI 10.2460/javma.2002.220.1315; Kenyon C, 1996, CELL, V84, P501, DOI 10.1016/S0092-8674(00)81024-7; Lee E, 2013, STAT METHODS SURVIVA; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; MIQUEL J, 1976, MECH AGEING DEV, V5, P347, DOI 10.1016/0047-6374(76)90034-8; Partridge L, 2002, NAT REV GENET, V3, P165, DOI 10.1038/nrg753; PARTRIDGE L, 1985, J INSECT PHYSIOL, V31, P393, DOI 10.1016/0022-1910(85)90084-8; Pearl R., 1928, RATE LIVING; Pletcher SD, 2000, J GERONTOL A-BIOL, V55, pB381, DOI 10.1093/gerona/55.8.B381; Pletcher SD, 2002, CURR BIOL, V12, P712, DOI 10.1016/S0960-9822(02)00808-4; Richardson A., 1992, POTENTIAL NUTR MODUL, P177; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854	21	374	389	3	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1731	1733		10.1126/science.1086016	http://dx.doi.org/10.1126/science.1086016			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500985				2022-12-28	WOS:000185387700047
J	Kofoed, EM; Hwa, V; Little, B; Woods, KA; Buckway, CK; Tsubaki, J; Pratt, KL; Bezrodnik, L; Jasper, H; Tepper, A; Heinrich, JJ; Rosenfeld, RG				Kofoed, EM; Hwa, V; Little, B; Woods, KA; Buckway, CK; Tsubaki, J; Pratt, KL; Bezrodnik, L; Jasper, H; Tepper, A; Heinrich, JJ; Rosenfeld, RG			Growth hormone insensitivity associated with a STAT5b mutation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LARON-SYNDROME; GH INSENSITIVITY; RECEPTOR; ACTIVATION; DOMAIN		Lucile Packard Fdn Childrens Hlth, Palo Alto, CA 94304 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA; Hosp Gen Niros Ricardo Gutierez Buenos Aires, Dept Endocrinol, Buenos Aires, DF, Argentina; Hosp Gen Niros Ricardo Gutierez Buenos Aires, Dept Pulmonol, Buenos Aires, DF, Argentina	Oregon Health & Science University	Rosenfeld, RG (corresponding author), Lucile Packard Fdn Childrens Hlth, 770 Welch Rd,Suite 350, Palo Alto, CA 94304 USA.	ron.rosenfeld@lpfch.org		Jasper, Hector/0000-0002-3451-8647	NATIONAL CANCER INSTITUTE [R01CA058110] Funding Source: NIH RePORTER; NCI NIH HHS [CA58110] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosio R, 2002, GENE, V285, P311, DOI 10.1016/S0378-1119(02)00421-3; Amit T, 2000, J CLIN ENDOCR METAB, V85, P927, DOI 10.1210/jc.85.3.927; Ayling RM, 1997, NAT GENET, V16, P13, DOI 10.1038/ng0597-13; Buckway CK, 2001, J CLIN ENDOCR METAB, V86, P5176, DOI 10.1210/jc.86.11.5176; Burren CP, 2001, HORM RES, V55, P125, DOI 10.1159/000049983; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; DUQUESNOY P, 1994, EMBO J, V13, P1386, DOI 10.1002/j.1460-2075.1994.tb06392.x; Freeth JS, 1998, ENDOCRINOLOGY, V139, P20, DOI 10.1210/en.139.1.20; Iida K, 1999, J CLIN ENDOCR METAB, V84, P1011, DOI 10.1210/jc.84.3.1011; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Krishnan K, 1998, J BIOL CHEM, V273, P19495, DOI 10.1074/jbc.273.31.19495; LARON Z, 1966, ISRAEL J MED SCI, V2, P152; LARON Z, 1993, ISRAEL J MED SCI, V29, P757; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; ROSENFELD RG, 1994, ENDOCR REV, V15, P369, DOI 10.1210/er.15.3.369; Salerno M, 2001, J CLIN ENDOCR METAB, V86, P3882, DOI 10.1210/jc.86.8.3882; Savage M, 1999, ACTA PAEDIATR, V88, P147, DOI 10.1111/j.1651-2227.1999.tb14371.x; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Silva CM, 2002, ENDOCRINOLOGY, V143, P2610, DOI 10.1210/en.143.7.2610; Sobrier ML, 1997, J CLIN ENDOCR METAB, V82, P435, DOI 10.1210/jc.82.2.435; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Welte T, 1999, SCIENCE, V283, P222, DOI 10.1126/science.283.5399.222; Wojcik R, 1998, J CLIN ENDOCR METAB, V83, P4481, DOI 10.1210/jc.83.12.4481; Woods KA, 1996, J CLIN ENDOCR METAB, V81, P1686, DOI 10.1210/jc.81.5.1686; Woods KA, 1997, J CLIN ENDOCR METAB, V82, P3529, DOI 10.1210/jc.82.11.3529	29	363	377	2	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1139	1147		10.1056/NEJMoa022926	http://dx.doi.org/10.1056/NEJMoa022926			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679528	Bronze			2022-12-28	WOS:000185369700007
J	Wallace, J				Wallace, J			Update in pulmonary diseases - Pulmonary hypertension: New treatments and outcomes	ANNALS OF INTERNAL MEDICINE			English	Review							LUNG-CANCER; PRIME-TIME; SURVIVAL; READY		Olive View UCLA Med Ctr, Sylmar, CA 91342 USA	University of California System; University of California Los Angeles	Wallace, J (corresponding author), Olive View UCLA Med Ctr, 14445 Olive View Dr, Sylmar, CA 91342 USA.							Channick RN, 2001, LANCET, V358, P1119, DOI 10.1016/S0140-6736(01)06250-X; Grannis FW, 2002, CHEST, V121, P1388, DOI 10.1378/chest.121.5.1388; Heffner JE, 2002, AM J RESP CRIT CARE, V165, P433, DOI 10.1164/ajrccm.165.4.2112073a; Jett JR, 2001, AM J RESP CRIT CARE, V163, P812, DOI 10.1164/ajrccm.163.4.16342a; McLaughlin VV, 2002, CIRCULATION, V106, P1477, DOI 10.1161/01.CIR.0000029100.82385.58; Patz EF, 2001, AM J RESP CRIT CARE, V163, P813, DOI 10.1164/ajrccm.163.4.16342b; Sitbon O, 2002, J AM COLL CARDIOL, V40, P780, DOI 10.1016/S0735-1097(02)02012-0	7	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					499	504		10.7326/0003-4819-139-6-200309160-00014	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00014			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679328				2022-12-28	WOS:000185324100007
J	Wald, NJ; Morris, JK				Wald, NJ; Morris, JK			Teleoanalysis: combining data from different types of study	BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL CONCENTRATION; ISCHEMIC-HEART-DISEASE; NEURAL-TUBE DEFECTS; PREVENTION		Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Wald, NJ (corresponding author), Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England.		Morris, Joan/AAT-9211-2020; Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021	Morris, Joan/0000-0002-7164-612X; 				Botto LD, 1999, NEW ENGL J MED, V341, P1509, DOI 10.1056/NEJM199911113412006; *BRIT MED ASS ROYA, 2002, BRIT NAT FORM, P440; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; Hooper L, 2001, BMJ-BRIT MED J, V322, P757, DOI 10.1136/bmj.322.7289.757; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; *MRC VIT STUD RES, 1991, LANCET, V338, P132; PETO R, 1985, CIRCULATION, V72, P451; Spiegelhalter DJ, 1996, BUGS BAYESIAN INFERE; WALD N, 1993, ANN NY ACAD SCI, V678, P112; Wald NJ, 2001, LANCET, V358, P2069, DOI 10.1016/S0140-6736(01)07104-5	11	37	39	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					616	618		10.1136/bmj.327.7415.616	http://dx.doi.org/10.1136/bmj.327.7415.616			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969936	Green Published			2022-12-28	WOS:000185358700032
J	Kotliar, G				Kotliar, G			Driving the electron over the edge	SCIENCE			English	Editorial Material							TRANSITION		Rutgers State Univ, Dept Phys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Kotliar, G (corresponding author), Rutgers State Univ, Dept Phys, Piscataway, NJ 08854 USA.	kotliar@physics.rutgers.edu						CASTELLANI C, 1979, PHYS REV LETT, V43, P1957, DOI 10.1103/PhysRevLett.43.1957; Georges A, 1996, REV MOD PHYS, V68, P13, DOI 10.1103/RevModPhys.68.13; KAGAWA F, IN PRESS CONDENS MAT; Kotliar G, 2000, PHYS REV LETT, V84, P5180, DOI 10.1103/PhysRevLett.84.5180; Lander GH, 2003, SCIENCE, V301, P1057, DOI 10.1126/science.1088510; Limelette P, 2003, SCIENCE, V302, P89, DOI 10.1126/science.1088386; Mott N.F, 1974, METAL INSULATOR TRAN; Osborne IS, 2000, SCIENCE, V288, P461, DOI 10.1126/science.288.5465.461	8	17	17	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					67	+		10.1126/science.1090580	http://dx.doi.org/10.1126/science.1090580			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526068				2022-12-28	WOS:000185678500032
J	Ahmed, S; Gunaratnam, NT				Ahmed, S; Gunaratnam, NT			Melanosis coli	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									St Joseph Mercy Hosp, Ann Arbor, MI 48109 USA	Saint Joseph Mercy Health System (SJMHS)	Ahmed, S (corresponding author), St Joseph Mercy Hosp, Ann Arbor, MI 48109 USA.								0	12	13	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1349	1349		10.1056/NEJMicm020208	http://dx.doi.org/10.1056/NEJMicm020208			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523143				2022-12-28	WOS:000185644000009
J	Anderson, GL; Judd, HL; Kaunitz, AM; Barad, DH; Beresford, SAA; Pettinger, M; Liu, J; McNeeley, SG; Lopez, AM				Anderson, GL; Judd, HL; Kaunitz, AM; Barad, DH; Beresford, SAA; Pettinger, M; Liu, J; McNeeley, SG; Lopez, AM		Women's Hlth Initiative Investigat	Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures - The Women's Health Initiative randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; EPITHELIAL OVARIAN-CANCER; ENDOMETRIAL CANCER; POSTMENOPAUSAL WOMEN; RISK; PREVENTION; PIPELLE	Context The effects of continuous combined hormone therapy on gynecologic cancers have not been investigated previously in a randomized trial setting. Objective To determine the possible associations of estrogen plus progestin on gynecologic cancers and related diagnostic procedures. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial of 16608 postmenopausal women, who had not had a hysterectomy at baseline and who had been recruited from 40 US clinical centers between September 1993 and October 1998 (average follow-up, 5.6 years). Intervention One tablet per day containing 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate (n=8506) or placebo (n=8102). Main Outcome Measure Incident invasive cancer of the ovary and endometrium. Results In 5.6 years of follow-up, there were 32 cases of invasive ovarian cancer, 58 cases of endometrial cancer, 1 case of nonendometrial uterine cancer, 13 cases of cervical cancer, and 7 cases of other gynecologic cancers. The hazard ratio (HR) for invasive ovarian cancer in women assigned to estrogen plus progestin compared with placebo Was 1.58 (95% confidence interval [CI], 0.77-3.24). The HR for endometrial cancer was 0.81 (95% Cl, 0.48-1.36). No appreciable differences were found in the distributions of tumor histology, stage, or grade for either cancer site. The incidence of other gynecologic cancers was low and did not differ by randomization assignment. More women taking estrogen plus progestin required endometrial biopsies (33% vs 6%; P<.001) Conclusions This randomized trial suggests that continuous combined estrogen plus progestin therapy may increase the risk of ovarian cancer while producing endometrial cancer rates similar to placebo. The increased burden of endometrial biopsies required to assess vaginal bleeding further limits the acceptability of this regimen. These data provide additional support for caution in the use of continuous combined hormones.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA; Univ Florida, Hlth Sci Ctr, Dept Obstet & Gynecol, Jacksonville, FL 32209 USA; Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10467 USA; Case Western Reserve Univ, Dept Reprod Biol, Cleveland, OH 44106 USA; Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA; Univ Arizona, Ctr Canc, Dept Internal Med, Tucson, AZ USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; State University System of Florida; University of Florida; Yeshiva University; Albert Einstein College of Medicine; Case Western Reserve University; Wayne State University; University of Arizona	Anderson, GL (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,MP-1002, Seattle, WA 98109 USA.		Kaunitz, Andrew/AAL-8448-2020; Barad, David/AAF-4332-2021	Anderson, Garnet/0000-0001-5087-7837; Lopez, Ana Maria/0000-0002-2759-5353				*AM COLL OBST GYN, HORM THER QUEST ANSW; Berg AO, 2002, ANN INTERN MED, V137, P834, DOI 10.7326/0003-4819-137-10-200211190-00013; BOOTH M, 1989, BRIT J CANCER, V60, P592, DOI 10.1038/bjc.1989.320; Cramer Daniel W., 1995, Annals of Epidemiology, V5, P310, DOI 10.1016/1047-2797(94)00098-E; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; FATHALLA MF, 1971, LANCET, V2, P163; Freedman L, 1996, CONTROL CLIN TRIALS, V17, P509, DOI 10.1016/S0197-2456(96)00016-5; GARDNER WU, 1961, J NATL CANCER I, V26, P829; Hill DA, 2000, AM J OBSTET GYNECOL, V183, P1456, DOI 10.1067/mob.2000.108081; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Judd HL, 1996, JAMA-J AM MED ASSOC, V275, P370, DOI 10.1001/jama.1996.03530290040035; KAUNITZ AM, 1988, J REPROD MED, V33, P427; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; *NAT CANC I, 1992, SEER PROGR COD MAN R; *NAT CANC I, 1973, SURV EP END RES SEER; Ness RB, 1999, JNCI-J NATL CANCER I, V91, P1459, DOI 10.1093/jnci/91.17.1459; Ness RB, 2000, AM J EPIDEMIOL, V152, P233, DOI 10.1093/aje/152.3.233; Percy C., 1990, INT CLASSIFICATION D; Pike MC, 1997, J NATL CANCER I, V89, P1110, DOI 10.1093/jnci/89.15.1110; PURDIE D, 1995, INT J CANCER, V62, P678, DOI 10.1002/ijc.2910620606; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Risch HA, 1996, GYNECOL ONCOL, V63, P254, DOI 10.1006/gyno.1996.0315; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Rodriguez GC, 1998, J SOC GYNECOL INVEST, V5, P271, DOI 10.1016/S1071-5576(98)00017-3; Smith-Bindman R, 1998, JAMA-J AM MED ASSOC, V280, P1510, DOI 10.1001/jama.280.17.1510; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; Stadel B V, 1975, Am J Obstet Gynecol, V123, P772; STOVALL TG, 1991, OBSTET GYNECOL, V77, P954; Weiderpass E, 1999, J NATL CANCER I, V91, P1131, DOI 10.1093/jnci/91.13.1131; WEISS NS, 1982, J NATL CANCER I, V68, P95; WHITTEMORE AS, 1993, CANCER-AM CANCER SOC, V71, P558; *WOM HLTH IN STUD, 1998, JAMA-J AM MED ASSOC, V19, P61; WOODRUFF JD, 1994, AM J OBSTET GYNECOL, V170, P1213	34	352	375	2	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1739	1748		10.1001/jama.290.13.1739	http://dx.doi.org/10.1001/jama.290.13.1739			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519708	Bronze			2022-12-28	WOS:000185606100023
J	Nanayakkara, PWB; Hartdorff, CM; Stehouwer, CDA; Vermeulen, RJ; de Visser, M				Nanayakkara, PWB; Hartdorff, CM; Stehouwer, CDA; Vermeulen, RJ; de Visser, M			A man with fever and a persistent handgrip	LANCET			English	Editorial Material							MYOTONIC-DYSTROPHY		Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, VU Univ Med Ctr, Dept Paediat Neurol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam	Nanayakkara, PWB (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands.		Stehouwer, Coen/AAB-3435-2021	Vermeulen, R. Jeroen/0000-0002-3503-3625				Bennun M, 2000, BRIT J ANAESTH, V85, P407, DOI 10.1093/bja/85.3.407; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; de Die-Smulders CEM, 1998, BRAIN, V121, P1557, DOI 10.1093/brain/121.8.1557; RONNBLOM A, 1996, SCAND J GASTROENTERO, V31, P645	4	0	0	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 27	2003	362	9389					1038	1038		10.1016/S0140-6736(03)14413-3	http://dx.doi.org/10.1016/S0140-6736(03)14413-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522534				2022-12-28	WOS:000185564600011
J	Steed, PM; Tansey, MG; Zalevsky, J; Zhukovsky, EA; Desjarlais, JR; Szymkowski, DE; Abbott, C; Carmichael, D; Chan, C; Cherry, L; Cheung, P; Chirino, AJ; Chung, HH; Doberstein, SK; Eivazi, A; Filikov, AV; Gao, SX; Hubert, RS; Hwang, M; Hyun, L; Kashi, S; Kim, A; Kim, E; Kung, J; Martinez, SP; Muchhal, US; Nguyen, DHT; O'Brien, C; O'Keefe, D; Singer, K; Vafa, O; Vielmetter, J; Yoder, SC; Dahiyat, BI				Steed, PM; Tansey, MG; Zalevsky, J; Zhukovsky, EA; Desjarlais, JR; Szymkowski, DE; Abbott, C; Carmichael, D; Chan, C; Cherry, L; Cheung, P; Chirino, AJ; Chung, HH; Doberstein, SK; Eivazi, A; Filikov, AV; Gao, SX; Hubert, RS; Hwang, M; Hyun, L; Kashi, S; Kim, A; Kim, E; Kung, J; Martinez, SP; Muchhal, US; Nguyen, DHT; O'Brien, C; O'Keefe, D; Singer, K; Vafa, O; Vielmetter, J; Yoder, SC; Dahiyat, BI			Inactivation of TNF signaling by rationally designed dominant-negative TNF variants	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; MUTATIONAL ANALYSIS; THERAPY; INVOLVEMENT; TOXICITY	Tumor necrosis factor (TNF) is a key regulator of inflammatory responses and has been implicated in many pathological conditions. We used structure-based design to engineer variant TNF proteins that rapidly form heterotrimers with native TNF to give complexes that neither bind to nor stimulate signaling through TNF receptors. Thus, TNF is inactivated by sequestration. Dominant-negative TNFs represent a possible approach to anti-inflammatory biotherapeutics, and experiments in animal models show that the strategy can attenuate TNF-mediated pathology. Similar rational design could be used to engineer inhibitors of additional TNF superfamily cytokines as well as other multimeric ligands.	Xencor, Monrovia, CA 91016 USA		Dahiyat, BI (corresponding author), Xencor, 111 W Lemon Ave, Monrovia, CA 91016 USA.	baz@xencor.com	Zhukovsky, Eugene/Q-3218-2019	Szymkowski, David/0000-0002-8934-7902				AGGARWAL BB, 2000, CYTOKINE REFERENCE; Ameloot P, 2001, J BIOL CHEM, V276, P27098, DOI 10.1074/jbc.M104486200; Bendele AM, 2000, ARTHRITIS RHEUM-US, V43, P2648, DOI 10.1002/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M; Beutler B, 2001, IMMUNITY, V15, P5, DOI 10.1016/S1074-7613(01)00176-5; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROUCKAERT P, 1992, LYMPHOKINE CYTOK RES, V11, P193; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Filikov AV, 2002, PROTEIN SCI, V11, P1452, DOI 10.1110/ps.3500102; Goldbach-Mansky R, 2003, ANNU REV MED, V54, P197, DOI 10.1146/annurev.med.54.101601.152342; Hayes RJ, 2002, P NATL ACAD SCI USA, V99, P15926, DOI 10.1073/pnas.212627499; HISHINUMA I, 1990, HEPATOLOGY, V12, P1187, DOI 10.1002/hep.1840120518; Horiuchi T, 1999, ENDOCR J, V46, P643, DOI 10.1507/endocrj.46.643; Li YP, 2001, BIOL PHARM BULL, V24, P666, DOI 10.1248/bpb.24.666; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luo P, 2002, PROTEIN SCI, V11, P1218, DOI 10.1110/ps.4580102; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Ruuls SR, 2001, IMMUNITY, V15, P533, DOI 10.1016/S1074-7613(01)00215-1; Sakaguchi S, 2000, INT J IMMUNOPHARMACO, V22, P935, DOI 10.1016/S0192-0561(00)00056-4; SREEKRISHNA K, 1989, BIOCHEMISTRY-US, V28, P4117, DOI 10.1021/bi00435a074; Steiner G, 1999, RHEUMATOLOGY, V38, P202, DOI 10.1093/rheumatology/38.3.202; Ulfgren AK, 2000, ARTHRITIS RHEUM, V43, P2391, DOI 10.1002/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F; Ware CF, 2000, J EXP MED, V192, pF35, DOI 10.1084/jem.192.11.F35; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	27	176	201	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1895	1898		10.1126/science.1081297	http://dx.doi.org/10.1126/science.1081297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512626				2022-12-28	WOS:000185536700048
J	Barr, RG; Rowe, BH; Camargo, CA				Barr, RG; Rowe, BH; Camargo, CA			Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RELEASE THEOPHYLLINE; AIRWAYS OBSTRUCTION; AMINOPHYLLINE; SALBUTAMOL; THERAPY; MANAGEMENT	Objective To evaluate the addition of methylxanthines to standard treatments in patients presenting with acute exacerbations of chronic obstructive pulmonary disease (COPD). Design Meta-analysis of randomised controlled trials. Data source The Cochrane air-ways review group's COPD register. Two reviewers independently selected articles for inclusion, assessed methodological quality, and extracted data. Selection of studies Four trials met the inclusion criteria, with 169 patients. Main outcome measures Mean change in spirometry, clinical end points, symptom scores, and adverse events. Results Mean change in forced expiratory volume at one second at two hours was similar in methylxanthine and placebo groups but transiently increased with methylxanthines at three days. Non-significant reductions in admissions to hospital and length of stay were offset by a non-significant increase in relapses at one week. Changes in symptom scores did not reach significance. Methylxanthines caused more nausea and vomiting than placebo (odds ratio 4.6,95% confidence interval 1.7 to 12.6), and non-significant increases in tremor, palpitations, and arrhythmias were also observed. Conclusions The available data do not support the use of methylxanthines for the treatment of exacerbations of chronic obstructive pulmonary disease. Potential benefits of methylxanthines for lung function and symptoms were generally not confirmed at standard levels of significance, whereas the potentially important adverse events of nausea and vomiting were significantly increased in patients receiving methylxanthines.	Columbia Presbyterian Med Ctr, Div Gen Med, New York, NY 10032 USA; Univ Alberta, Div Emergency Med, Edmonton, AB T6G 2B7, Canada; Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA	Columbia University; NewYork-Presbyterian Hospital; University of Alberta; Harvard University; Massachusetts General Hospital	Barr, RG (corresponding author), Columbia Presbyterian Med Ctr, Div Gen Med, New York, NY 10032 USA.	rgb9@columbia.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007427, R01HL063841] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-63841, HL-07427] Funding Source: Medline; BHP HRSA HHS [PE-11001] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BHP HRSA HHS		BONE RC, 1980, ARCH INTERN MED, V140, P1018, DOI 10.1001/archinte.140.8.1018; Brantingham P, 1970, Br J Clin Pract, V24, P165; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CHIAPPINI F, 1990, Clinica Terapeutica, V135, P121; CHIN R, 1983, CRIT CARE Q, V6, P1; DOLCETTI A, 1988, J INT MED RES, V16, P264, DOI 10.1177/030006058801600403; DONNER C, 1980, G ITAL MAL TORACE, V34, P307; DOROW P, 1978, ARZNEIMITTELFORSCH, V28-1, P853; FURUKAWA CT, 1988, ANN ALLERGY, V60, P472; HOLFORD N, 1993, CLIN PHARMACOKINET, V25, P495, DOI 10.2165/00003088-199325060-00007; HOLFORD N, 1993, CLIN PHARMACOKINET, V25, P506, DOI 10.2165/00003088-199325060-00008; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JENKINS PF, 1982, BRIT J DIS CHEST, V76, P57; JONSSON S, 1988, CHEST, V94, P723, DOI 10.1378/chest.94.4.723; LIGHT RW, 1983, RESP CARE, V28, P561; LLOBERES P, 1988, EUR RESPIR J, V1, P536; MORANDINI GC, 1989, CLIN TRIALS J, V26, P163; MUSIL J, 1998, PRAKT LEK, V78, P319; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pearson MG, 1997, THORAX, V52, pS1; Peleman RA, 1998, CLIN EXP ALLERGY, V28, P53; PERRET L, 1980, FINSKA LAKARESALLSKA, V124, P101; RAM FSF, 2000, AM J RESP CRIT CAR S, V161, pA489; Ram FSF., 2002, COCHRANE DB SYST REV, V2002, pCD003902, DOI DOI 10.1002/14651858.CD003902; REINECKE T, 1986, ANN EMERG MED, V15, P147, DOI 10.1016/S0196-0644(86)80009-9; RICE KL, 1987, ANN INTERN MED, V107, P305, DOI 10.7326/0003-4819-107-2-305; SAHAY JN, 1984, CURR MED RES OPIN, V9, P1, DOI 10.1185/03007998409109551; SAHAY JN, 1986, BRIT J CLIN PRACT, V40, P198; Schmidt E W, 1988, Prax Klin Pneumol, V42, P600; SEIDENFELD JJ, 1984, ANN EMERG MED, V13, P248, DOI 10.1016/S0196-0644(84)80472-2; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Snow V, 2001, ANN INTERN MED, V134, P595, DOI 10.7326/0003-4819-134-7-200104030-00015; TANSER AR, 1982, PRACTITIONER, V226, P569; TEDDERS JG, 1976, BRIT J CLIN PRACT, V30, P212; THOMAS P, 1992, CHEST, V101, P160, DOI 10.1378/chest.101.1.160; VOZEH S, 1982, AM REV RESPIR DIS, V125, P181; Weinberger M, 1996, NEW ENGL J MED, V334, P1380, DOI 10.1056/NEJM199605233342107; WRENN K, 1991, ANN INTERN MED, V115, P241, DOI 10.7326/0003-4819-115-4-241	38	70	75	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2003	327	7416					643	646A		10.1136/bmj.327.7416.643	http://dx.doi.org/10.1136/bmj.327.7416.643			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724AC	14500434	Bronze, Green Published			2022-12-28	WOS:000185463100014
J	Weiss, R; Dufour, S; Taksali, SE; Tamborlane, WV; Petersen, KF; Bonadonna, RC; Boselli, L; Barbetta, G; Allen, K; Rife, F; Savoye, M; Dziura, J; Sherwin, R; Shulman, GI; Caprio, S				Weiss, R; Dufour, S; Taksali, SE; Tamborlane, WV; Petersen, KF; Bonadonna, RC; Boselli, L; Barbetta, G; Allen, K; Rife, F; Savoye, M; Dziura, J; Sherwin, R; Shulman, GI; Caprio, S			Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; MUSCLE TRIGLYCERIDE CONTENT; PROTEIN-KINASE-C; SKELETAL-MUSCLE; SENSITIVITY; ADOLESCENTS; SPECTROSCOPY; ACTIVATION; OXIDATION; CHILDREN	Background Impaired glucose tolerance is common among obese adolescents, but the changes in insulin sensitivity and secretion that lead to this prediabetic state are unknown. We investigated whether altered partitioning of myocellular and abdominal fat relates to abnormalities in glucose homoeostasis in obese adolescents with prediabetes. Methods We studied 14 obese children with impaired glucose tolerance and 14 with normal glucose tolerance, of similar ages, sex distribution, and degree of obesity. Insulin sensitivity and secretion were assessed by the euglycaemic-hyperinsulinaemic clamp and the hyperglycaemic clamp. Intramyocellular lipid was assessed by proton nuclear magnetic resonance spectroscopy and abdominal fat distribution by magnetic resonance imaging. Findings Peripheral glucose disposal was significantly lower in individuals with impaired than in those with normal glucose tolerance (mean 35.4 [SE 4.0] vs 60.6 [7.2] mumoles per kg lean body mass per min; p=0.023) owing to a reduction in non-oxidative glucose disposal metabolism (storage). individuals with impaired glucose tolerance had higher intramyocellular lipid content (3.04 [0.43] vs 1.99 [0.19]%, p=0.03), lower abdominal subcutaneous fat (460 [471 vs 626 [39] cm(2), p=0.04), and slightly higher visceral fat than the controls (70 [111 vs 47 [6] cm(2), p=0.065), resulting in a higher ratio of visceral to subcutaneous fat (0.15 [0.02] vs 0.07 [0.01], p=0.002). Intramyocellular and visceral lipid contents were inversely related to the glucose disposal and non-oxidative glucose metabolism and positively related to the 2 h plasma glucose concentration. Interpretation In obese children and adolescents with prediabetes, intramyocellular and intra-abdominal lipid accumulation is closely linked to the development of severe peripheral insulin resistance.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Childrens Res Ctr, New Haven, CT 06520 USA; Yale Univ, Sch Med, Adult Gen Clin Res Ctr, New Haven, CT 06520 USA; Howard Hughes Med Inst, Dept Internal Med, New Haven, CT 06510 USA; Howard Hughes Med Inst, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Univ Verona, Div Endocrinol & Metab Dis, I-37100 Verona, Italy; Azienda Osped Verona, Verona, Italy	Yale University; Yale University; Yale University; Howard Hughes Medical Institute; Howard Hughes Medical Institute; University of Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Caprio, S (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St,POB 208064, New Haven, CT 06520 USA.	sonia.caprio@yale.edu	Weiss, Ram/AAC-3964-2020; Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668; Bonadonna, Riccardo/0000-0002-9809-1005	NCRR NIH HHS [M01 RR000125, M01 RR-00125, M01 RR-06022, M01 RR006022] Funding Source: Medline; NIA NIH HHS [R01 AG023686-01A1, R01 AG023686-03, R01 AG023686, R01 AG023686-02] Funding Source: Medline; NICHD NIH HHS [R01 HD 40787, K24 HD 01464, R01 HD040787, K24 HD001464, R01 HD 28016, R01 HD028016] Funding Source: Medline; NIDDK NIH HHS [R01 DK-49230, R01 DK049230] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD040787, R01HD028016] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K24HD001464] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006022, M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023686] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Boesch C, 2000, ANN NY ACAD SCI, V904, P25; Bonadonna RC, 2003, DIABETES, V52, P470, DOI 10.2337/diabetes.52.2.470; CAPRIO S, 1995, AM J PHYSIOL-ENDOC M, V269, pE118, DOI 10.1152/ajpendo.1995.269.1.E118; Dabelea D, 1999, ENDOCRIN METAB CLIN, V28, P709, DOI 10.1016/S0889-8529(05)70098-0; DEFRONZO RA, 1989, METABOLISM, V38, P387, DOI 10.1016/0026-0495(89)90129-7; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Edelstein SL, 1997, DIABETES, V46, P701, DOI 10.2337/diabetes.46.4.701; FINEGOOD DT, 1987, DIABETES, V36, P914, DOI 10.2337/diabetes.36.8.914; FRAYN KN, 1983, J APPL PHYSIOL, V55, P628, DOI 10.1152/jappl.1983.55.2.628; Greco AV, 2002, DIABETES, V51, P144, DOI 10.2337/diabetes.51.1.144; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Guo, 2002, VITAL HLTH STAT, V11, DOI DOI 10.1016/J.BBRC.2015.06.114; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kitagawa T, 1998, CLIN PEDIATR, V37, P111, DOI 10.1177/000992289803700208; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Montagne CT, 2000, DIABETES, V49, P883, DOI 10.2337/diabetes.49.6.883; Perseghin G, 1997, DIABETES, V46, P1001, DOI 10.2337/diabetes.46.6.1001; Robinson C, 1998, AM J PHYSIOL-ENDOC M, V274, pE737, DOI 10.1152/ajpendo.1998.274.4.E737; Rosenbloom AL, 1999, DIABETES CARE, V22, P345, DOI 10.2337/diacare.22.2.345; SCHICK F, 1993, MAGN RESON MED, V29, P158, DOI 10.1007/BF01769418; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; Sinha R, 2002, NEW ENGL J MED, V346, P802, DOI 10.1056/NEJMoa012578; Sinha R, 2002, DIABETES, V51, P1022, DOI 10.2337/diabetes.51.4.1022; Szczepaniak LS, 1999, AM J PHYSIOL-ENDOC M, V276, pE977, DOI 10.1152/ajpendo.1999.276.5.E977; TOFFOLO G, 1995, DIABETES, V44, P845, DOI 10.2337/diabetes.44.7.845; Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	32	346	357	0	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 20	2003	362	9388					951	957		10.1016/S0140-6736(03)14364-4	http://dx.doi.org/10.1016/S0140-6736(03)14364-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511928	Green Accepted			2022-12-28	WOS:000185489600009
J	Staller, P; Sulitkova, J; Liszlwan, J; Moch, H; Oakeley, EJ; Krek, W				Staller, P; Sulitkova, J; Liszlwan, J; Moch, H; Oakeley, EJ; Krek, W			Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL	NATURE			English	Article							INDUCIBLE FACTOR-I; RENAL-CELL CARCINOMA; HYPOXIA; CANCER; GENES; METASTASIS; PROTEIN; GROWTH; PHOSPHORYLATION; FACTOR-1-ALPHA	Organ-specific metastasis is governed, in part, by interactions between chemokine receptors on cancer cells and matching chemokines in target organs. For example, malignant breast cancer cells express the chemokine receptor CXCR4 and commonly metastasize to organs that are an abundant source of the CXCR4-specific ligand stromal cell-derived factor-1alpha (ref. 1). It is still uncertain how an evolving tumour cell is reprogrammed to express CXCR4, thus implementing the tendency to metastasize to specific organs. Here we show that the von Hippel-Lindau tumour suppressor protein pVHL negatively regulates CXCR4 expression owing to its capacity to target hypoxia-inducible factor (HIF) for degradation under normoxic conditions. This process is suppressed under hypoxic conditions, resulting in HIF-dependent CXCR4 activation. An analysis of clear cell renal carcinoma that manifests mutation of the VHL gene in most cases revealed an association of strong CXCR4 expression with poor tumour-specific survival. These results suggest a mechanism for CXCR4 activation during tumour cell evolution and imply that VHL inactivation acquired by incipient tumour cells early in tumorigenesis confers not only a selective survival advantage but also the tendency to home to selected organs.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Univ Basel, Inst Pathol, CH-4031 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; University of Basel	Krek, W (corresponding author), ETH Honggerberg, Inst Cell Biol, HPM F 42, CH-8093 Zurich, Switzerland.							Aebersold DM, 2001, CANCER RES, V61, P2911; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Liotta LA, 2001, NATURE, V410, P24, DOI 10.1038/35065180; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Moch H, 2000, CANCER, V89, P604, DOI 10.1002/1097-0142(20000801)89:3<604::AID-CNCR16>3.3.CO;2-H; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; OBERLEY LW, 1982, SUPEROXIDE DISMUTASE, V1, P1; PASTOREKOVA S, 1992, VIROLOGY, V187, P620, DOI 10.1016/0042-6822(92)90464-Z; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Rempel SA, 2000, CLIN CANCER RES, V6, P102; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wiesener MS, 2001, CANCER RES, V61, P5215	30	712	754	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					307	311		10.1038/nature01874	http://dx.doi.org/10.1038/nature01874			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679920				2022-12-28	WOS:000185370900048
J	Adachi, M; Saito, H; Kobayashi, H; Horie, Y; Kato, S; Yoshioka, M; Ishii, H				Adachi, M; Saito, H; Kobayashi, H; Horie, Y; Kato, S; Yoshioka, M; Ishii, H			Hepatic injury in 12 patients taking the herbal weight loss aids Chaso or Onshido	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATOTOXICITY; SUPPLEMENTS; REMEDIES	Background: The Chinese herbal dietary supplements Chaso and Onshido are marketed for weight loss in Japan. The safety of these weight loss aids is unknown. Objective: To describe patients who developed liver injury while taking Chaso or Onshido. Design: Case series. Setting: Keio University Hospital, Tokyo, Japan, and other hospitals in Japan. Patients: 6 patients who took Chaso and 6 patients who took Onshido before presenting with liver injury. Measurements: Pathologic, clinical, and laboratory evaluations and chemical analysis of the herbal weight loss aids. Results: All 12 patients developed acute liver injury characterized by a marked increase in serum liver chemistry values (mean alanine aminotransferase level, 1978 U/L [range, 283 to 4074 U/L]) after ingesting these products. Two patients developed fulminant hepatic failure: 1 patient required liver transplantation, and the other patient died. N-nitroso-fenfluramine, a variant of the appetite-depressant drug fenfluramine, was present in these products. Conclusions: The use of the weight loss aids Chaso and Onshido may be associated with acute liver injury. N-nitroso-fenfluramine is a possible hepatotoxic ingredient.	Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Ishii, H (corresponding author), Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.							Allison DB, 2001, CRIT REV FOOD SCI, V41, P1, DOI 10.1080/20014091091661; Barnes J, 1998, BRIT J CLIN PHARMACO, V45, P496, DOI 10.1046/j.1365-2125.1998.00715.x; Chitturi S, 2000, J GASTROEN HEPATOL, V15, P1093, DOI 10.1046/j.1440-1746.2000.02349.x; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6; ELIASON BC, 1994, J FAM PRACTICE, V38, P287; Favreau JT, 2002, ANN INTERN MED, V136, P590, DOI 10.7326/0003-4819-136-8-200204160-00008; HANAWA N, 2003, ACTAZ HEPATOLOGICA J, V44, P21; Hasegawa R, 1998, CANCER LETT, V123, P185, DOI 10.1016/S0304-3835(97)00417-5; Hutchins GM, 2001, NEW ENGL J MED, V344, P1095; KATO Y, 1979, Gastroenterologia Japonica, V14, P216; Nadir A, 1996, AM J GASTROENTEROL, V91, P1436; Shaw D, 1997, DRUG SAFETY, V17, P342, DOI 10.2165/00002018-199717050-00006; Sheikh NM, 1997, ARCH INTERN MED, V157, P913, DOI 10.1001/archinte.157.8.913; Trey C, 1970, Prog Liver Dis, V3, P282; Zimmerman H J, 2000, Clin Liver Dis, V4, P73, DOI 10.1016/S1089-3261(05)70097-0	16	59	60	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					488	492		10.7326/0003-4819-139-6-200309160-00012	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679326				2022-12-28	WOS:000185324100005
J	Ezzati, M; Lopez, AD				Ezzati, M; Lopez, AD			Estimates of global mortality attributable to smoking in 2000	LANCET			English	Article							LUNG-CANCER; RISK-FACTORS; DEVELOPED-COUNTRIES; TOBACCO; EXPOSURE; HAZARDS; DEATHS	Background Smoking is a risk factor for several diseases and has been increasing in many developing countries. Our aim was to estimate global and regional mortality in 2000 caused by smoking, including an analysis of uncertainty. Methods Following the methods of Peto and colleagues, we used lung-cancer mortality as an indirect marker for accumulated smoking risk. Never-smoker lung-cancer mortality was estimated based on the household use of coal with poor ventilation. Relative risks were taken from the American Cancer Society Cancer Prevention Study, phase II, and the retrospective proportional mortality analysis of Liu and colleagues in China. Relative risks were corrected for confounding and extrapolation to other regions. Results We estimated that in 2000, 4.83 (uncertainty range 3.94-5.93) million premature deaths in the world were attributable to smoking; 2.41 (1.80-3.15) million in developing countries and 2.43 (2.13-2.78) million in industrialised countries. 3.84 million of these deaths were in men. The leading causes of death from smoking were cardiovascular diseases (1.69 million deaths), chronic obstructive pulmonary disease (0.97 million deaths), and lung cancer (0.85 million deaths). Interpretation Smoking was an important cause of global mortality in 2000. In view of the expected demographic and epidemiological transitions and current smoking patterns in the developing world, the health loss due to smoking will grow even larger unless effective interventions and policies that reduce smoking among men and prevent increases among women in developing countries are implemented.	Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA; Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia	Harvard University; Harvard T.H. Chan School of Public Health; University of Queensland	Ezzati, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, 665 Huntington Ave, Boston, MA 02115 USA.	mezzati@hsph.harvard.edu	Lopez, Alan/AAA-2734-2022; Lopez, Alan D/F-1487-2010	Lopez, Alan D/0000-0001-5818-6512	NIA NIH HHS [1-PO1-AG17625] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG017625] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 2002, WORLD MORTALITY 2000; Bronnum-Hansen H, 2000, EPIDEMIOLOGY, V11, P422, DOI 10.1097/00001648-200007000-00010; Du YX, 1996, LUNG CANCER-J IASLC, V14, pS9, DOI 10.1016/S0169-5002(96)90208-1; ENGLISH DR, 1995, QUANTIFICATION DRU 2, P430; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Ezzati M, 2003, TOB CONTROL, V12, P79, DOI 10.1136/tc.12.1.79; Gajalakshmi V, 2003, LANCET, V362, P507, DOI 10.1016/S0140-6736(03)14109-8; GARFINKEL L, 1985, NCI MONOGRAPH, V67; Hirayama T, 1990, LIFE STYLE MORTALITY; JEDRYCHOWSKI W, 1990, J EPIDEMIOL COMMUN H, V44, P114, DOI 10.1136/jech.44.2.114; Jha P, 2002, AM J PUBLIC HEALTH, V92, P1002, DOI 10.2105/AJPH.92.6.1002; KAWACHI I, 1997, SMOKING TOBACCO CONT, V8; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; Lan Q, 2002, J NATL CANCER I, V94, P826, DOI 10.1093/jnci/94.11.826; Law MR, 1997, BMJ-BRIT MED J, V315, P973, DOI 10.1136/bmj.315.7114.973; Lee PN, 1996, REGUL TOXICOL PHARM, V24, P60, DOI 10.1006/rtph.1996.0064; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; Malarcher AM, 2000, AM J EPIDEMIOL, V152, P573, DOI 10.1093/aje/152.6.573; MATHERS CD, 2002, 50 GPE WHO GLOB PROG; Morgan M.G., 1990, UNCERTAINTY GUIDE DE; National Cancer Institute, 1997, SMOK TOB CONTR MON, V8; PARKIN DM, 1997, IARC SCI PUBLICATION, V143; PERCY C, 1989, AM J EPIDEMIOL, V129, P934, DOI 10.1093/oxfordjournals.aje.a115226; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; PETO R, 1986, TOBACCO MAJOR INT HL; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; STERLING TD, 1993, AM J EPIDEMIOL, V138, P128, DOI 10.1093/oxfordjournals.aje.a116835; Thun MJ, 2000, JAMA-J AM MED ASSOC, V284, P706, DOI 10.1001/jama.284.6.706; U.S. Department of Health and Human Services, 2001, WOM SMOK REP SURG GE; US Department of Health and Human Services, 1989, RED CONS SMOK 25 YEA; World Health Organization, 1997, TOB HLTH GLOB STAT R	31	856	911	0	59	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 13	2003	362	9387					847	852		10.1016/S0140-6736(03)14338-3	http://dx.doi.org/10.1016/S0140-6736(03)14338-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678970				2022-12-28	WOS:000185329400007
J	Kamaras, K; Itkis, ME; Hu, H; Zhao, B; Haddon, RC				Kamaras, K; Itkis, ME; Hu, H; Zhao, B; Haddon, RC			Covalent bond formation to a carbon nanotube metal	SCIENCE			English	Article									Univ Calif Riverside, Dept Chem, Ctr Nanoscale Sci & Engn, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Environm Chem & Engn, Riverside, CA 92521 USA; MTA SzFKI, Budapest, Hungary	University of California System; University of California Riverside; University of California System; University of California Riverside	Haddon, RC (corresponding author), Univ Calif Riverside, Dept Chem, Ctr Nanoscale Sci & Engn, Riverside, CA 92521 USA.		Haddon, Robert C/A-2528-2008; Kamaras, Katalin/A-3916-2009	Haddon, Robert C/0000-0002-7903-5139; Kamaras, Katalin/0000-0002-0390-3331				Boul PJ, 1999, CHEM PHYS LETT, V310, P367, DOI 10.1016/S0009-2614(99)00713-7; Chen J, 1998, SCIENCE, V282, P95, DOI 10.1126/science.282.5386.95; Crespi VH, 1997, PHYS REV LETT, V79, P2093, DOI 10.1103/PhysRevLett.79.2093; Frank S, 1998, SCIENCE, V280, P1744, DOI 10.1126/science.280.5370.1744; Itkis ME, 2002, NANO LETT, V2, P155, DOI 10.1021/nl0156639; Minot ED, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.156401; SEYFERTH D, 1972, ACCOUNTS CHEM RES, V5, P65, DOI 10.1021/ar50050a004; Ugawa A, 1999, PHYS REV B, V60, pR11305, DOI 10.1103/PhysRevB.60.R11305	8	250	264	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1501	1501		10.1126/science.1088083	http://dx.doi.org/10.1126/science.1088083			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970557				2022-12-28	WOS:000185255300039
J	Minniti, D; Borissova, J; Rejkuba, M; Alves, DR; Cook, KH; Freeman, KC				Minniti, D; Borissova, J; Rejkuba, M; Alves, DR; Cook, KH; Freeman, KC			Kinematic evidence for an old stellar halo in the Large Magellanic Cloud	SCIENCE			English	Article							RR LYRAE STARS; MACHO PROJECT; GLOBULAR-CLUSTERS; VARIABLE-STARS; OMEGA-CENTAURI; CARBON STARS; LMC; POPULATION; INVENTORY; DISTANCE	The oldest and most metal-poor Milky Way stars form a kinematically hot halo, which motivates the two major formation scenarios for our galaxy: extended hierarchical accretion and rapid collapse. RR Lyrae stars are excellent tracers of old and metal-poor populations. We measured the kinematics of 43 RR Lyrae stars in the inner regions of the nearby Large Magellanic Cloud (LMC) galaxy. The velocity dispersion equals 53 +/- 10 kilometers per second, which indicates that a kinematically hot metal-poor old halo also exists in the LMC. This result suggests that our galaxy and smaller late-type galaxies such as the LMC have similar early formation histories.	Pontificia Univ Catolica Chile, Dept Astron, Santiago 22, Chile; European So Observ, D-85748 Garching, Germany; Columbia Univ, Astrophys Lab, New York, NY 10027 USA; Lawrence Livermore Natl Lab, Inst Geophys & Planetary Phys, Livermore, CA 94550 USA; Australian Natl Univ, Mt Stromlo Observ, Res Sch Astron & Astrophys, Canberra, ACT, Australia	Pontificia Universidad Catolica de Chile; European Southern Observatory; Columbia University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Australian National University	Minniti, D (corresponding author), Pontificia Univ Catolica Chile, Dept Astron, Ave Vicuna Mackenna 4860,Casilla 306, Santiago 22, Chile.		Minniti, Dante/AAD-7251-2021	Minniti, Dante/0000-0002-7064-099X; Freeman, Kenneth/0000-0001-6280-1207; Rejkuba, Marina/0000-0002-6577-2787				Alcock C, 2000, ASTROPHYS J, V542, P281, DOI 10.1086/309512; Alcock C, 2000, ASTRON J, V119, P2194, DOI 10.1086/301326; Alcock C, 1997, ASTROPHYS J, V482, P89, DOI 10.1086/304120; Alcock C, 2000, ASTROPHYS J, V542, P257, DOI 10.1086/309530; ALCOCK C, 1997, APJ, V490, P59; Alves DR, 2000, ASTROPHYS J, V542, P789, DOI 10.1086/317023; Alves DR, 2002, ASTROPHYS J, V573, pL51, DOI 10.1086/341992; Clement CM, 2001, ASTRON J, V122, P2587, DOI 10.1086/323719; CLEMENTINI G, 1994, MON NOT R ASTRON SOC, V267, P83, DOI 10.1093/mnras/267.1.83; EGGEN OJ, 1962, ASTROPHYS J, V136, P748, DOI 10.1086/147433; FEAST MW, 1992, ASTR SOC P, V30, P143; FREEMAN KC, 1983, ASTROPHYS J, V272, P488, DOI 10.1086/161316; Graff DS, 2000, ASTROPHYS J, V540, P211, DOI 10.1086/309302; Gyuk G, 2000, ASTROPHYS J, V535, P90, DOI 10.1086/308834; Hardy E, 2001, ASTROPHYS SPACE SCI, V277, P471, DOI 10.1023/A:1012774916353; HUGHES SMG, 1991, ASTRON J, V101, P1304, DOI 10.1086/115767; Kaluzny J, 1997, ASTRON ASTROPHYS SUP, V122, P471, DOI 10.1051/aas:1997338; KINMAN TD, 1991, PUBL ASTRON SOC PAC, V103, P1279, DOI 10.1086/132947; Layden AC, 1998, ASTR SOC P, V136, P14; Mayor M, 1997, ASTRON J, V114, P1087, DOI 10.1086/118539; Minniti D, 1996, ASTROPHYS J, V467, pL13, DOI 10.1086/310189; Minniti D, 1996, ASTROPHYS J, V459, P175, DOI 10.1086/176879; NORRIS JE, 1997, ASTROPHYS J, V487, P187; Olszewski EW, 1996, ANNU REV ASTRON ASTR, V34, P511, DOI 10.1146/annurev.astro.34.1.511; SCHOMMER RA, 1992, ASTRON J, V103, P447, DOI 10.1086/116074; SEARLE L, 1978, ASTROPHYS J, V225, P358; SKILLEN I, 1993, MON NOT R ASTRON SOC, V265, P301, DOI 10.1093/mnras/265.2.301; Smith H., 1995, RR LYRAE STARS; STUBBS C, 2000, ASP C SERIES, V165, P503	31	60	60	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1508	1510		10.1126/science.1088529	http://dx.doi.org/10.1126/science.1088529			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970558	Green Submitted			2022-12-28	WOS:000185255300041
J	Kawas, CH				Kawas, CH			Early Alzheimer's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED-TRIAL; QUALITY STANDARDS SUBCOMMITTEE; ACADEMY-OF-NEUROLOGY; MILD COGNITIVE IMPAIRMENT; DOUBLE-BLIND TRIAL; MINI-MENTAL-STATE; PRACTICE PARAMETER; VASCULAR DEMENTIA; MEMORY COMPLAINTS		Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Kawas, CH (corresponding author), Univ Calif Irvine, Inst Brain Aging & Dementia, 1121 Gillespie, Irvine, CA 92697 USA.	ckawas@uci.edu		Kawas, Claudia/0000-0001-9577-230X	NATIONAL INSTITUTE ON AGING [P50AG016573, R01AG008325, R01AG021055] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG21055, P50 AG-16573, R01 AG08325] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aisen Paul S, 2002, Curr Neurol Neurosci Rep, V2, P405, DOI 10.1007/s11910-002-0066-6; Aisen PS, 2000, NEUROLOGY, V54, P588, DOI 10.1212/WNL.54.3.588; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Arenberg D, 1990, Adv Neurol, V51, P207; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BRODATY H, 1989, BMJ-BRIT MED J, V299, P1375, DOI 10.1136/bmj.299.6712.1375; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473; COCCARO EF, 1990, AM J PSYCHIAT, V147, P1640; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Cummings JL, 2002, AM FAM PHYSICIAN, V65, P2525; Cummings JL, 2002, AM FAM PHYSICIAN, V65, P2263; De Deyn PP, 1999, NEUROLOGY, V53, P946, DOI 10.1212/WNL.53.5.946; Doody RS, 2001, NEUROLOGY, V56, P1154, DOI 10.1212/WNL.56.9.1154; Erkinjuntti T, 2002, LANCET, V359, P1283, DOI 10.1016/S0140-6736(02)08267-3; Farlow M, 2000, EUR NEUROL, V44, P236, DOI 10.1159/000008243; Feldman H, 2003, J AM GERIATR SOC, V51, P737, DOI 10.1046/j.1365-2389.2003.51260.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frenchman I B, 1997, Int Psychogeriatr, V9, P431; Geerlings MI, 1999, AM J PSYCHIAT, V156, P531; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HEBERT R, 1994, ARCH GERONTOL GERIAT, V18, P1, DOI 10.1016/0167-4943(94)90043-4; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; Jonker C, 2000, INT J GERIATR PSYCH, V15, P983, DOI 10.1002/1099-1166(200011)15:11<983::AID-GPS238>3.0.CO;2-5; Katz IR, 1999, J CLIN PSYCHIAT, V60, P107, DOI 10.4088/JCP.v60n0207; Kawas C, 1999, ALZHEIMER DIS, P95; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; LARSON EB, 1986, ARCH INTERN MED, V146, P1917, DOI 10.1001/archinte.146.10.1917; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P1686, DOI 10.1176/appi.ajp.157.10.1686; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McKhann GM, 2001, ARCH NEUROL-CHICAGO, V58, P1803, DOI 10.1001/archneur.58.11.1803; Miller BL, 1997, NEUROLOGY, V48, P937, DOI 10.1212/WNL.48.4.937; MITTELMAN MS, 1995, GERONTOLOGIST, V35, P792, DOI 10.1093/geront/35.6.792; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; MOHIDE EA, 1990, J AM GERIATR SOC, V38, P446, DOI 10.1111/j.1532-5415.1990.tb03544.x; Mohs RC, 2001, NEUROLOGY, V57, P481, DOI 10.1212/WNL.57.3.481; MULNARD RA, 2000, JAMA-J AM MED ASSOC, V284, P2597; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; NYTH AL, 1990, BRIT J PSYCHIAT, V157, P894, DOI 10.1192/bjp.157.6.894; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Ostwald SK, 1999, GERONTOLOGIST, V39, P299, DOI 10.1093/geront/39.3.299; Petersen, 1999, ARCH NEUROL-CHICAGO, V56, P760; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Rabins P, 1997, AM J PSYCHIAT, V154, P1; Raskind MA, 2000, NEUROLOGY, V54, P2261, DOI 10.1212/WNL.54.12.2261; REIFLER BV, 1989, AM J PSYCHIAT, V146, P45; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; Rosler M, 2001, BRIT MED J, V322, P1456; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Schenk D, 2001, DNA CELL BIOL, V20, P679, DOI 10.1089/10445490152717532; Schofield PW, 1997, AM J PSYCHIAT, V154, P609; Shock NW, 1984, NIH PUBLICATION; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968; Taragano FE, 1997, PSYCHOSOMATICS, V38, P246, DOI 10.1016/S0033-3182(97)71461-0; Tariot PN, 2000, NEUROLOGY, V54, P2269, DOI 10.1212/WNL.54.12.2269; Teri, 2001, NEUROLOGY, V56, P426; Teri L, 2000, NEUROLOGY, V55, P1271, DOI 10.1212/WNL.55.9.1271; Winblad B, 2001, NEUROLOGY, V57, P489, DOI 10.1212/WNL.57.3.489; Winblad B, 1999, INT J GERIATR PSYCH, V14, P135, DOI 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; 1997, AM J PSYCHIAT, V154, P1180	70	68	72	2	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					1056	1063		10.1056/NEJMcp022295	http://dx.doi.org/10.1056/NEJMcp022295			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	719UH	12968090				2022-12-28	WOS:000185223100009
J	Yudkin, JS; Bayley, O; Elnour, S; Willott, C; Miranda, JJ				Yudkin, JS; Bayley, O; Elnour, S; Willott, C; Miranda, JJ			Introducing medical students to global health issues: a Bachelor of Science degree in international health	LANCET			English	Article									UCL, Int Hlth & Med Educ Ctr, London N19 5LW, England; Univ Leicester, Leicester Warwick Med Sch, Leicester, Leics, England; Univ Edinburgh, Coll Med & Vet Med, Edinburgh, Midlothian, Scotland	University of London; University College London; University of Leicester; University of Edinburgh	Yudkin, JS (corresponding author), UCL, Int Hlth & Med Educ Ctr, Holborn Union Bldg,Archway Campus,2-10 Highgate H, London N19 5LW, England.	ihmec@ucl.ac.uk	Miranda, J. Jaime/A-8482-2008; Yudkin, John S/C-1988-2008	Miranda, J. Jaime/0000-0002-4738-5468; Willott, Chris/0000-0003-0940-4215				[Anonymous], 2001, LANCET, V358, P1471; Bateman C, 2001, LANCET, V358, P1539, DOI 10.1016/S0140-6736(01)06586-2; Edwards R, 2001, MED EDUC, V35, P807, DOI 10.1046/j.1365-2923.2001.1014c.x; Haq C, 2000, FAM MED, V32, P566; Margolis CZ, 2002, LANCET, V359, P1253, DOI 10.1016/S0140-6736(02)08244-2; Miranda JJ, 2002, J EPIDEMIOL COMMUN H, V56, P719, DOI 10.1136/jech.56.9.719-a	6	23	23	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2003	362	9386					822	824		10.1016/S0140-6736(03)14276-6	http://dx.doi.org/10.1016/S0140-6736(03)14276-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678879				2022-12-28	WOS:000185188500024
J	Chen, LM; Friedman, RM; Roe, AW				Chen, LM; Friedman, RM; Roe, AW			Optical Imaging of a tactile illusion in area 3b of the primary somatosensory cortex	SCIENCE			English	Article							CUTANEOUS STIMULI; SQUIRREL-MONKEYS; PARIETAL CORTEX; BODY-SURFACE; POINT; SKIN; REPRESENTATIONS; ORGANIZATION; INTEGRATION; RESPONSES	In the tactile funneling illusion, the simultaneous presentation of brief stimuli at multiple points on the skin produces a single focal sensation at the center of the stimulus pattern even when no physical stimulus occurs at that site. Consistent with the funneling percept, we show with optical imaging in area 3b of the primary somatosensory cortex (SI) that simultaneous stimulation of two fingertips produces a single focal cortical activation between the single fingertip activation regions. Thus, in contrast to traditional views of the body map, topographic representation in the SI reflects the perceived rather than the physical location of peripheral stimulation.	Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06520 USA	Yale University; Yale University	Roe, AW (corresponding author), Vanderbilt Univ, Dept Psychol, 066 Wilson Hall,111 21st Ave S, Nashville, TN 37203 USA.		Chen, Li Min/C-3554-2011	Roe, Anna Wang/0000-0003-4146-9705				ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; Bonhoeffer Tobias, 1996, P55; Bringuier V, 1999, SCIENCE, V283, P695, DOI 10.1126/science.283.5402.695; Chen LM, 2001, J NEUROPHYSIOL, V86, P3011, DOI 10.1152/jn.2001.86.6.3011; GARDNER EP, 1981, J NEUROPHYSIOL, V46, P479, DOI 10.1152/jn.1981.46.3.479; GARDNER EP, 1972, J NEUROPHYSIOL, V35, P925, DOI 10.1152/jn.1972.35.6.925; GARDNER EP, 1972, J NEUROPHYSIOL, V35, P954, DOI 10.1152/jn.1972.35.6.954; GARDNER EP, 1980, J NEUROPHYSIOL, V43, P420, DOI 10.1152/jn.1980.43.2.420; Hashimoto I, 1999, NEUROREPORT, V10, P3201, DOI 10.1097/00001756-199910190-00014; IWAMURA Y, 1983, EXP BRAIN RES, V51, P315; Kapadia MK, 2000, J NEUROPHYSIOL, V84, P2048, DOI 10.1152/jn.2000.84.4.2048; MCKENNA TM, 1982, J NEUROPHYSIOL, V48, P289, DOI 10.1152/jn.1982.48.2.289; NELSON RJ, 1980, J COMP NEUROL, V192, P611, DOI 10.1002/cne.901920402; PONS TP, 1987, SOMATOSENS MOT RES, V4, P309, DOI 10.3109/07367228709144612; Ramsden BM, 2001, CEREB CORTEX, V11, P648, DOI 10.1093/cercor/11.7.648; SCHROEDER CE, 1995, J NEUROPHYSIOL, V74, P722, DOI 10.1152/jn.1995.74.2.722; SHERRICK CE, 1964, AM J PSYCHOL, V77, P42, DOI 10.2307/1419270; SUR M, 1982, J COMP NEUROL, V211, P177, DOI 10.1002/cne.902110207; Tommerdahl M, 1998, J NEUROPHYSIOL, V80, P3272, DOI 10.1152/jn.1998.80.6.3272; von Bekesy G, 1967, SENSORY INHIBITION	20	124	125	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					881	885		10.1126/science.1087846	http://dx.doi.org/10.1126/science.1087846			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14500850				2022-12-28	WOS:000186258000054
J	Ekstrom, G; Nettles, M; Abers, GA				Ekstrom, G; Nettles, M; Abers, GA			Glacial earthquakes	SCIENCE			English	Article							SUBDUCTION ZONE; WAVES; SLOW; MECHANISM; ALASKA; EVENT; FAULT; FLOW	We have detected dozens of previously unknown, moderate earthquakes beneath large glaciers. The seismic radiation from these earthquakes is depleted at high frequencies, explaining their nondetection by traditional methods. Inverse modeling of the long-period seismic waveforms from the best-recorded earthquake, in southern Alaska, shows that the seismic source is well represented by stick-slip, downhill sliding of a glacial ice mass. The duration of sliding in the Alaska earthquake is 30 to 60 seconds, about 15 to 30 times longer than for a regular tectonic earthquake of similar magnitude.	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Boston Univ, Dept Earth Sci, Boston, MA 02215 USA	Harvard University; Boston University	Ekstrom, G (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.		Nettles, Meredith/A-8638-2012; Ekstrom, Goran/C-9771-2012	Nettles, Meredith/0000-0003-4613-4162; Ekstrom, Goran/0000-0001-6410-275X				ABERS GA, 2002, SEISMOL RES LETT, V73, P219; ALLEY RB, 1993, J GLACIOL, V39, P447, DOI 10.3189/S0022143000016336; ANANDAKRISHNAN S, 1993, J GLACIOL, V39, P455, DOI 10.3189/S0022143000016348; Arvidsson R, 1998, B SEISMOL SOC AM, V88, P1003; BEROZA GC, 1990, J GEOPHYS RES-SOLID, V95, P2485, DOI 10.1029/JB095iB03p02485; Blankenship D. D., 1987, ANN GLACIOL, V9, P30; Dragert H, 2001, SCIENCE, V292, P1525, DOI 10.1126/science.1060152; DZIEWONSKI AM, 1981, J GEOPHYS RES, V86, P2825, DOI 10.1029/JB086iB04p02825; Ekstrom G, 2001, J GEOPHYS RES-SOL EA, V106, P26483, DOI 10.1029/2000JB000086; EKSTROM G, 2002, EOS, V83, pF1037; Heki K, 1997, NATURE, V386, P595, DOI 10.1038/386595a0; KAMB B, 1985, SCIENCE, V227, P469, DOI 10.1126/science.227.4686.469; KAMB B, 1991, J GEOPHYS RES-SOL EA, V96, P16585, DOI 10.1029/91JB00946; KANAMORI H, 1982, J GEOPHYS RES, V87, P5422, DOI 10.1029/JB087iB07p05422; KAWAKATSU H, 1989, J GEOPHYS RES-SOLID, V94, P12363, DOI 10.1029/JB094iB09p12363; Linde AT, 1996, NATURE, V383, P65, DOI 10.1038/383065a0; Miller MM, 2002, SCIENCE, V295, P2423, DOI 10.1126/science.1071193; Miyazaki S, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000456; Rignot E, 2002, SCIENCE, V297, P1502, DOI 10.1126/science.1073888; ROULAND D, 1992, B SEISMOL SOC AM, V82, P2448; SHEARER PM, 1994, J GEOPHYS RES-SOL EA, V99, P13713, DOI 10.1029/94JB00498; VANWORMER D, 1973, J GLACIOL, V12, P259; WOLF LW, 1986, B SEISMOL SOC AM, V76, P367; Zwally HJ, 2002, SCIENCE, V297, P218, DOI 10.1126/science.1072708	24	158	159	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					622	624		10.1126/science.1088057	http://dx.doi.org/10.1126/science.1088057			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14512505				2022-12-28	WOS:000186119900052
J	Gibson, EA; Paul, A; Wagner, N; Tobey, R; Gaudiosi, D; Backus, S; Christov, IP; Aquila, A; Gullikson, EM; Attwood, DT; Murnane, MM; Kapteyn, HC				Gibson, EA; Paul, A; Wagner, N; Tobey, R; Gaudiosi, D; Backus, S; Christov, IP; Aquila, A; Gullikson, EM; Attwood, DT; Murnane, MM; Kapteyn, HC			Coherent soft x-ray generation in the water window with quasi-phase matching	SCIENCE			English	Article							HIGH-HARMONIC-GENERATION; ATTOSECOND PULSES; IONIZATION; GASES	We demonstrate enhanced generation of coherent light in the "water window" region of the soft x-ray spectrum at 4.4 nanometers, using quasi-phase-matched frequency conversion of ultrafast laser pulses. By periodically modulating the diameter of a gas-filled hollow waveguide, the phase mismatch normally present between the laser light and the generated soft x-ray light can be partially compensated. This makes it possible to use neon gas as the nonlinear medium to coherently convert light up to the water window, illustrating that techniques of nonlinear optics can be applied effectively in the soft x-ray region of the spectrum. These results advance the prospects for compact coherent soft x-ray sources for applications in biomicroscopy and in chemical spectroscopy.	Univ Colorado, Dept Phys, Boulder, CO 80309 USA; Univ Colorado, Joint Inst Lab Astrophys, Boulder, CO 80309 USA; Univ Sofia, Dept Phys, BU-1126 Sofia, Bulgaria; Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Xray Opt, Berkeley, CA 94720 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Bulgarian Academy of Sciences; University of Sofia; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kapteyn, HC (corresponding author), Univ Colorado, Dept Phys, Boulder, CO 80309 USA.	kapteyn@jila.colorado.edu	Backus, Sterling/C-2506-2008; Christov, Ivan P/D-4446-2014; Wagner, Nicholas L/E-7437-2010; Kapteyn, Henry C/H-6559-2011	Christov, Ivan P/0000-0002-9146-6708; Wagner, Nicholas L/0000-0001-9936-1145; Kapteyn, Henry C/0000-0001-8386-6317; Aquila, Andrew/0000-0003-0358-2774				Ammosov M. V., 1986, Soviet Physics - JETP, V64, P1191; ATTWOOD D, 1992, PHYS TODAY, V45, P24, DOI 10.1063/1.881314; Backus S, 1997, OPT LETT, V22, P1256, DOI 10.1364/OL.22.001256; Bartels RA, 2002, SCIENCE, V297, P376, DOI 10.1126/science.1071718; Bauer M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.025501; Chang Z, 1998, PHYS REV A, V58, pR30, DOI 10.1103/PhysRevA.58.R30; Chang ZH, 1997, PHYS REV LETT, V79, P2967, DOI 10.1103/PhysRevLett.79.2967; Christov IP, 2000, OPT EXPRESS, V7, P362, DOI 10.1364/OE.7.000362; Christov IP, 1997, PHYS REV LETT, V78, P1251, DOI 10.1103/PhysRevLett.78.1251; Christov IP, 1998, PHYS REV A, V57, pR2285, DOI 10.1103/PhysRevA.57.R2285; Constant E, 1999, PHYS REV LETT, V82, P1668, DOI 10.1103/PhysRevLett.82.1668; Descamps D, 2000, OPT LETT, V25, P135, DOI 10.1364/OL.25.000135; FEJER MM, 1992, IEEE J QUANTUM ELECT, V28, P2631, DOI 10.1109/3.161322; FERRAY M, 1988, J PHYS B-AT MOL OPT, V21, pL31, DOI 10.1088/0953-4075/21/3/001; HAIGHT R, 1994, APPL PHYS LETT, V65, P517, DOI 10.1063/1.112283; Jacobsen C, 1999, TRENDS CELL BIOL, V9, P44, DOI 10.1016/S0962-8924(98)01424-X; Krainov VP, 1997, J OPT SOC AM B, V14, P425, DOI 10.1364/JOSAB.14.000425; KULANDER KC, 1993, NATO ADV SCI INST SE, V316, P95, DOI 10.1007/978-1-4615-7963-2_10; MACKLIN JJ, 1993, PHYS REV LETT, V70, P766, DOI 10.1103/PhysRevLett.70.766; MCPHERSON A, 1987, J OPT SOC AM B, V4, P595, DOI 10.1364/JOSAB.4.000595; Nugent-Glandorf L, 2002, J CHEM PHYS, V117, P6108, DOI 10.1063/1.1504084; Paul A, 2003, NATURE, V421, P51, DOI 10.1038/nature01222; Rundquist A, 1998, SCIENCE, V280, P1412, DOI 10.1126/science.280.5368.1412; Schneider G, 2002, SURF REV LETT, V9, P177, DOI 10.1142/S0218625X02001914; Schnurer M, 1999, PHYS REV LETT, V83, P722, DOI 10.1103/PhysRevLett.83.722; Schoenlein RW, 2000, SCIENCE, V287, P2237, DOI 10.1126/science.287.5461.2237; Scrinzi A, 1999, PHYS REV LETT, V83, P706, DOI 10.1103/PhysRevLett.83.706; Shin HJ, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.053407; Spielmann C, 1997, SCIENCE, V278, P661, DOI 10.1126/science.278.5338.661; WAHLSTROM CG, 1993, PHYS REV A, V48, P4709, DOI 10.1103/PhysRevA.48.4709; Zhou J, 1996, PHYS REV LETT, V76, P752, DOI 10.1103/PhysRevLett.76.752	31	294	301	5	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					95	98		10.1126/science.1088654	http://dx.doi.org/10.1126/science.1088654			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526077				2022-12-28	WOS:000185678500042
J	O'Brien, SJ; Murphy, WJ				O'Brien, SJ; Murphy, WJ			A dog's breakfast?	SCIENCE			English	Editorial Material							GENE-THERAPY; GENOMICS; RESOLUTION		NCI, Lab Genom Divers, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	O'Brien, SJ (corresponding author), NCI, Lab Genom Divers, Frederick, MD 21702 USA.		OBRIEN, STEPHEN/ABD-1346-2020	OBRIEN, STEPHEN/0000-0001-7857-0757	DIVISION OF BASIC SCIENCES - NCI [Z01BC010265] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Couzin J, 2003, SCIENCE, V301, P1176, DOI 10.1126/science.301.5637.1176; Eichler EE, 2003, SCIENCE, V301, P793, DOI 10.1126/science.1086132; Guyon R, 2003, P NATL ACAD SCI USA, V100, P5296, DOI 10.1073/pnas.0831002100; Kirkness EF, 2003, SCIENCE, V301, P1898, DOI 10.1126/science.1086432; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; MURPHY WJ, 2001, GENOME BIOL, V2, DOI DOI 10.1186/GB-2001-2-6-REVIEWS0005; Nash WG, 2001, CYTOGENET CELL GENET, V95, P210, DOI 10.1159/000059348; O'Brien SJ, 1999, SCIENCE, V286, P458, DOI 10.1126/science.286.5439.458; O'Brien SJ, 2001, SCIENCE, V292, P2264, DOI 10.1126/science.1059393; Ostrander EA, 2000, TRENDS GENET, V16, P117, DOI 10.1016/S0168-9525(99)01958-7; PATTERSON DF, 2002, CANINE GENETIC DIS I; Ponder KP, 2002, P NATL ACAD SCI USA, V99, P13102, DOI 10.1073/pnas.192353499; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	18	23	23	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1854	1855		10.1126/science.1090531	http://dx.doi.org/10.1126/science.1090531			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512608				2022-12-28	WOS:000185536700030
J	Guermonprez, P; Saveanu, L; Kleijmeer, M; Davoust, J; van Endert, P; Amigorena, S				Guermonprez, P; Saveanu, L; Kleijmeer, M; Davoust, J; van Endert, P; Amigorena, S			ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells	NATURE			English	Article							ANTIGEN PRESENTATION; MEMBRANE-PROTEINS; DEGRADATION; MOLECULES; TRANSPORT; COMPLEX; CYTOSOL	Induction of cytotoxic T-cell immunity requires the phagocytosis of pathogens, virus-infected or dead tumour cells by dendritic cells(1). Peptides derived from phagocytosed antigens are then presented to CD8(+) T lymphocytes on major histocompatibility complex (MHC) class I molecules, a process called "cross-presentation"(2,3). After phagocytosis, antigens are exported into the cytosol and degraded by the proteasome(4-6). The resulting peptides are thought to be translocated into the lumen of the endoplasmic reticulum (ER) by specific transporters associated with antigen presentation (TAP), and loaded onto MHC class I molecules by a complex "loading machinery" (which includes tapasin, calreticulin and Erp57)(7). Here we show that soon after or during formation, phagosomes fuse with the ER. After antigen export to the cytosol and degradation by the proteasome, peptides are translocated by TAP into the lumen of the same phagosomes, before loading on phagosomal MHC class I molecules. Therefore, cross-presentation in dendritic cells occurs in a specialized, self-sufficient, ER-phagosome mix compartment.	Inst Curie, INSERM, U520, F-75005 Paris, France; Inst Necker, INSERM, U580, F-75015 Paris, France; UMC Utrecht, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Genethon, CNRS, UMR 8115, F-91002 Evry 02, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Utrecht University; Utrecht University Medical Center; Centre National de la Recherche Scientifique (CNRS)	Amigorena, S (corresponding author), Inst Curie, INSERM, U520, 26 Rue Ulm, F-75005 Paris, France.	sebastian.amigorena@curie.fr	SAVEANU, Loredana/Q-1241-2019; Guermonprez, Pierre/ABE-7718-2020; Davoust, Jean/ABB-6720-2020; van Endert, Peter/R-4606-2017; Saveanu, Loredana/K-6821-2017	SAVEANU, Loredana/0000-0003-3138-7968; Guermonprez, Pierre/0000-0001-5621-2262; van Endert, Peter/0000-0003-3782-0750; Davoust, Jean/0000-0002-3098-7665; Amigorena, Sebastian/0000-0001-8583-8416				Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Daniel S, 1997, J IMMUNOL, V159, P2350; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Lemonnier FA, 2002, VIRUS RES, V82, P87; Norbury CC, 1997, EUR J IMMUNOL, V27, P280, DOI 10.1002/eji.1830270141; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Ramachandra L, 1998, J IMMUNOL METHODS, V213, P53, DOI 10.1016/S0022-1759(98)00017-9; RAPOSO G, 1997, HDB EXPT IMMUNOLOGY, P1; Reits E, 2003, IMMUNITY, V18, P97, DOI 10.1016/S1074-7613(02)00511-3; Rock KL, 2002, ADV IMMUNOL, V80, P1, DOI 10.1016/S0065-2776(02)80012-8; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3	22	589	613	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					397	402		10.1038/nature01911	http://dx.doi.org/10.1038/nature01911			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508489				2022-12-28	WOS:000185502300041
J	Ranero, CR; Morgan, JP; McIntosh, K; Reichert, C				Ranero, CR; Morgan, JP; McIntosh, K; Reichert, C			Bending-related faulting and mantle serpentinization at the Middle America trench	NATURE			English	Article							DEEP-FOCUS EARTHQUAKES; CONVERGENT MARGIN; SEISMIC-REFLECTION; SUBDUCTION; SEGMENTATION; PLATE; RIDGE; INTERMEDIATE; ZONES; WATER	The dehydration of subducting oceanic crust and upper mantle has been inferred both to promote the partial melting leading to arc magmatism and to induce intraslab intermediate-depth earthquakes, at depths of 50-300 km. Yet there is still no consensus about how slab hydration occurs or where and how much chemically bound water is stored within the crust and mantle of the incoming plate. Here we document that bending-related faulting of the incoming plate at the Middle America trench creates a pervasive tectonic fabric that cuts across the crust, penetrating deep into the mantle. Faulting is active across the entire ocean trench slope, promoting hydration of the cold crust and upper mantle surrounding these deep active faults. The along-strike length and depth of penetration of these faults are also similar to the dimensions of the rupture area of intermediate-depth earthquakes.	GEOMAR, D-24148 Kiel, Germany; SFB574, D-24148 Kiel, Germany; Univ Texas, Inst Geophys, Austin, TX 78759 USA; BGR, D-30655 Hannover, Germany	Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; University of Texas System; University of Texas Austin	Ranero, CR (corresponding author), GEOMAR, Wischhofstr 1-3, D-24148 Kiel, Germany.	cranero@geomar.de	Zhang, Junyuan/P-9292-2018; McIntosh, Kirk/G-6143-2010; Ranero, César R/B-9165-2009	Ranero, César R/0000-0002-5204-545X; Morgan, Jason/0000-0002-3100-0877				Barckhausen U, 2001, J GEOPHYS RES-SOL EA, V106, P19207, DOI 10.1029/2001JB000238; Barth GA, 1996, J GEOPHYS RES-SOL EA, V101, P17951, DOI 10.1029/96JB00814; Bock G, 2000, GEOPHYS RES LETT, V27, P3929, DOI 10.1029/2000GL011881; CARBOTTE SM, 1994, J GEOPHYS RES-SOL EA, V99, P13609, DOI 10.1029/93JB02971; Carbotte SM, 2000, J GEOPHYS RES-SOL EA, V105, P2737, DOI 10.1029/1999JB900245; CASSIDY JF, 2003, J GEOPHYS RES, V108, DOI DOI 10.1029/2002GL015511; CHAUVEL C, 1992, EARTH PLANET SC LETT, V110, P99, DOI 10.1016/0012-821X(92)90042-T; CHRISTENSEN DH, 1988, J GEOPHYS RES-SOLID, V93, P13421, DOI 10.1029/JB093iB11p13421; DETRICK RS, 1993, SCIENCE, V259, P499, DOI 10.1126/science.259.5094.499; Ernst WG, 1999, GEOLOGY, V27, P675, DOI 10.1130/0091-7613(1999)027<0675:HTCMEO>2.3.CO;2; FROHLICH C, 1989, ANNU REV EARTH PL SC, V17, P227, DOI 10.1146/annurev.ea.17.050189.001303; Gill J., 1981, OROGENIC ANDESITES P; Hacker B.R., 2003, J GEOPHYS RES, V108; HALLENBORG E, IN PRESS J GEOPHYS R; HASEGAWA A, 1994, J GEOPHYS RES-SOL EA, V99, P22295, DOI 10.1029/93JB02797; Jiao WJ, 2000, J GEOPHYS RES-SOL EA, V105, P28125, DOI 10.1029/2000JB900314; Kirby S. H., 1996, GEOPHYS MONOGR SER, V96, P195, DOI DOI 10.1029/GM096P0195; Kobayashi K, 1998, GEOPHYS J INT, V134, P356, DOI 10.1046/j.1365-246x.1998.00569.x; Langseth MG, 1996, GEOPHYS RES LETT, V23, P891, DOI 10.1029/96GL00733; LI C, 1995, MAR GEOPHYS RES, V17, P97, DOI 10.1007/BF01268052; LYNNES CS, 1988, J GEOPHYS RES-SOLID, V93, P13407, DOI 10.1029/JB093iB11p13407; MACDONALD AH, 1985, TECTONOPHYSICS, V116, P123, DOI 10.1016/0040-1951(85)90225-2; MASSON DG, 1991, MAR GEOPHYS RES, V13, P209, DOI 10.1007/BF00369150; MEADE C, 1991, SCIENCE, V252, P68, DOI 10.1126/science.252.5002.68; MOORE JC, 1992, REV GEOPHYS, V30, P113, DOI 10.1029/92RG00201; MORGAN JP, 1994, MAGMATIC SYSTEMS, P139; MORTON JL, 1985, J GEOPHYS RES-SOLID, V90, P1345, DOI 10.1029/JB090iB13p11345; Nicolas A., 1989, STRUCTURES OPHIOLITE; PEACOCK SM, 1990, SCIENCE, V248, P329, DOI 10.1126/science.248.4953.329; Peacock SM, 2001, GEOLOGY, V29, P299, DOI 10.1130/0091-7613(2001)029<0299:ATLPOD>2.0.CO;2; PHIPPSMORGAN J, 1993, J GEOPHYS RES, V98, P6283; PORCELLI D, 1995, GEOCHIM COSMOCHIM AC, V59, P4921, DOI 10.1016/0016-7037(95)00336-3; Protti M., 1995, SPEC PAP GEOL SOC AM, V295, P309, DOI DOI 10.1130/SPE295-P309; RALEIGH CB, 1965, J GEOPHYS RES, V70, P3965, DOI 10.1029/JZ070i016p03965; Ranero CR, 2000, NATURE, V404, P748, DOI 10.1038/35008046; Ranero CR, 1997, J GEOPHYS RES-SOL EA, V102, P10185, DOI 10.1029/97JB00101; Ranero CR, 1997, GEOLOGY, V25, P499, DOI 10.1130/0091-7613(1997)025<0499:ROCFAA>2.3.CO;2; Rupke LH, 2002, GEOLOGY, V30, P1035, DOI 10.1130/0091-7613(2002)030<1035:ATRVIC>2.0.CO;2; SAVAGE JC, 1969, TECTONOPHYSICS, V8, P115, DOI 10.1016/0040-1951(69)90085-7; Schmidt MW, 1998, EARTH PLANET SC LETT, V163, P361, DOI 10.1016/S0012-821X(98)00142-3; Seno T., 1996, SUBDUCTION TOP BOTTO, DOI [10.1029/GM096p0347, DOI 10.1029/GM096P0347]; SIBSON RH, 1981, NATURE, V289, P665, DOI 10.1038/289665a0; Tibi R, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000361; ULMER P, 1995, SCIENCE, V268, P858, DOI 10.1126/science.268.5212.858; von Huene R, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001569; vonHuene R, 1997, TECTONICS, V16, P474, DOI 10.1029/96TC03703; Yamano M, 1990, SCI RESULTS, V112, P653, DOI 10.2973/odp.proc.sr.112.171.1990	47	687	696	7	137	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					367	373		10.1038/nature01961	http://dx.doi.org/10.1038/nature01961			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508480				2022-12-28	WOS:000185502300032
J	Little, J; Khoury, MJ				Little, J; Khoury, MJ			Mendelian randomisation: a new spin or real progress?	LANCET			English	Editorial Material							METHYLENETETRAHYDROFOLATE REDUCTASE MTHFR; POPULATION STRATIFICATION; LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; C677T POLYMORPHISM; ENZYME-ACTIVITY; HUMAN-GENOME; DISEASE; SUSCEPTIBILITY; HOMOCYSTEINE		Ctr Dis Control & Prevent, Off Genom & Dis Prevent, Atlanta, GA 30341 USA; Univ Aberdeen, Dept Med & Therapeut, Epidemiol Grp, Aberdeen, Scotland	Centers for Disease Control & Prevention - USA; University of Aberdeen	Little, J (corresponding author), Ctr Dis Control & Prevent, Off Genom & Dis Prevent, Atlanta, GA 30341 USA.		Little, Julian/AAR-6117-2020	Little, Julian/0000-0001-5026-5531				Andreassi MG, 2003, HUM GENET, V112, P171, DOI 10.1007/s00439-002-0859-3; Ardlie KG, 2002, NAT REV GENET, V3, P299, DOI 10.1038/nrg777; Ardlie KG, 2002, AM J HUM GENET, V71, P304, DOI 10.1086/341719; Cardon LR, 2003, LANCET, V361, P598, DOI 10.1016/S0140-6736(03)12520-2; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Crott JW, 2001, CARCINOGENESIS, V22, P1019, DOI 10.1093/carcin/22.7.1019; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; KHOURY MJ, 1987, AM J EPIDEMIOL, V126, P561, DOI 10.1093/oxfordjournals.aje.a114695; Lievers KJA, 2001, J MOL MED-JMM, V79, P522, DOI 10.1007/s001090100253; Little J, 2003, AM J EPIDEMIOL, V157, P667, DOI 10.1093/aje/kwg048; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Nallamothu BK, 2000, ARCH INTERN MED, V160, P3406, DOI 10.1001/archinte.160.22.3406; NARAYANAN S, 2001, THESIS U ABERDEEN AB; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; Rozen R, 1997, THROMB HAEMOSTASIS, V78, P523; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Strachan T., 2004, HUM MOL GENET, V3; Thomas DC, 2002, CANCER EPIDEM BIOMAR, V11, P505; van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825; Wacholder S, 2002, CANCER EPIDEM BIOMAR, V11, P513; Weisberg I, 1998, MOL GENET METAB, V64, P169, DOI 10.1006/mgme.1998.2714; 2003, LANCET, V361, P357	23	51	52	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					930	931		10.1016/S0140-6736(03)14396-6	http://dx.doi.org/10.1016/S0140-6736(03)14396-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511923				2022-12-28	WOS:000185489600004
J	van der Marel, D; Molegraaf, HJA; Zaanen, J; Nussinov, Z; Carbone, F; Damascelli, A; Eisaki, H; Greven, M; Kes, PH; Li, M				van der Marel, D; Molegraaf, HJA; Zaanen, J; Nussinov, Z; Carbone, F; Damascelli, A; Eisaki, H; Greven, M; Kes, PH; Li, M			Quantum critical behaviour in a high-T-c superconductor	NATURE			English	Article							OPTICAL CONDUCTIVITY; PSEUDOGAP STATE; ANISOTROPY; TRANSPORT; YBA2CU3O7; CRYSTALS	Quantum criticality is associated with a system composed of a nearly infinite number of interacting quantum degrees of freedom at zero temperature, and it implies that the system looks on average the same regardless of the time- and length scale on which it is observed. Electrons on the atomic scale do not exhibit such symmetry, which can only be generated as a collective phenomenon through the interactions between a large number of electrons. In materials with strong electron correlations a quantum phase transition at zero temperature can occur, and a quantum critical state has been predicted(1,2), which manifests itself through universal power-law behaviours of the response functions. Candidates have been found both in heavy-fermion systems(3) and in the high-transition temperature (high-Tc) copper oxide superconductors(4), but the reality and the physical nature of such a phase transition are still debated(5-7). Here we report a universal behaviour that is characteristic of the quantum critical region. We demonstrate that the experimentally measured phase angle agrees precisely with the exponent of the optical conductivity. This points towards a quantum phase transition of an unconventional kind in the high-Tc superconductors.	Univ Groningen, Ctr Mat Sci, NL-9747 AG Groningen, Netherlands; Leiden Univ, Leiden Inst Phys, NL-2300 RA Leiden, Netherlands; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94305 USA	University of Groningen; Leiden University; Leiden University - Excl LUMC; Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	van der Marel, D (corresponding author), Univ Geneva, Dept Phys Mat Condensee, 24 Quai E Ansermet, CH-1211 Geneva 4, Switzerland.	dirk.vandermarel@physics.unige.ch	van der Marel, Dirk/G-4618-2012; Eisaki, Hiroshi/F-6317-2018; damascelli, andrea/P-6329-2014; Carbone, Fabrizio/A-2969-2012	van der Marel, Dirk/0000-0001-5266-9847; Eisaki, Hiroshi/0000-0002-8299-6416; damascelli, andrea/0000-0001-9895-2226; 				Anderson PW, 1997, PHYS REV B, V55, P11785, DOI 10.1103/PhysRevB.55.11785; ASPNES DE, 1980, J OPT SOC AM, V70, P1275, DOI 10.1364/JOSA.70.001275; Bernhoeft N, 2001, J PHYS-CONDENS MAT, V13, pR771, DOI 10.1088/0953-8984/13/39/201; Damle K, 1997, PHYS REV B, V56, P8714, DOI 10.1103/PhysRevB.56.8714; ELAZRAK A, 1994, PHYS REV B, V49, P9846, DOI 10.1103/PhysRevB.49.9846; FISHER MPA, 1990, PHYS REV LETT, V64, P587, DOI 10.1103/PhysRevLett.64.587; Ioffe LB, 1998, PHYS REV B, V58, P11631, DOI 10.1103/PhysRevB.58.11631; Kaminski A, 2002, NATURE, V416, P610, DOI 10.1038/416610a; Li M, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.024502; LITTLEWOOD PB, 1991, J APPL PHYS, V69, P4979, DOI 10.1063/1.348195; Liu Y., 1994, Modern Physics Letters B, V8, P277, DOI 10.1142/S0217984994000297; Molegraaf HJA, 2002, SCIENCE, V295, P2239, DOI 10.1126/science.1069947; Mook HA, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.144513; Orenstein J, 2000, SCIENCE, V288, P468, DOI 10.1126/science.288.5465.468; Prelovsek P, 2001, EUROPHYS LETT, V53, P228, DOI 10.1209/epl/i2001-00141-0; Puchkov AV, 1996, J PHYS-CONDENS MAT, V8, P10049, DOI 10.1088/0953-8984/8/48/023; Quijada MA, 1999, PHYS REV B, V60, P14917, DOI 10.1103/PhysRevB.60.14917; Sachdev S., 1999, QUANTUM PHASE TRANSI; Santander-Syro AF, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.097005; Saxena SS, 2000, NATURE, V406, P587, DOI 10.1038/35020500; SCHLESINGER Z, 1990, PHYS REV LETT, V65, P801, DOI 10.1103/PhysRevLett.65.801; TAJIMA S, 1993, PHYS REV B, V48, P16164, DOI 10.1103/PhysRevB.48.16164; Tallon JL, 2001, PHYSICA C, V349, P53, DOI 10.1016/S0921-4534(00)01524-0; van der Marel D, 1999, PHYS REV B, V60, pR765, DOI 10.1103/PhysRevB.60.R765; Varma CM, 2002, PHYS REP, V361, P267, DOI 10.1016/S0370-1573(01)00060-6	25	251	252	1	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					271	274		10.1038/nature01978	http://dx.doi.org/10.1038/nature01978			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679910	Green Published, Green Submitted			2022-12-28	WOS:000185370900038
J	Morris, CA; Avorn, J				Morris, CA; Avorn, J			Internet marketing of herbal products	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	19th International Conference on Pharmacoepidermiology/Annual Meeting of the International-Society-for-Pharmacoepidemiology	AUG   22, 2003	PHILADELPHIA, PENNSYLVANIA	Internat Soc Pharmacoepidemiol			DIETARY-SUPPLEMENTS; UNITED-STATES; HEALTH; MEDICINE; NEED; WEB	Context Passage of the Dietary Supplement Health and Education Act in 1994 restricted the Food and Drug Administration's control over dietary supplements, leading to enormous growth in their promotion. The Internet is often used by consumers as a source of information on such therapies. Objective To assess the information presented and indications claimed on the Internet for the 8 best-selling herbal products. Data Sources We searched the Internet using the 5 most commonly used search engines. For each, we entered the names of the 8 most widely used herbal supplements (ginkgo biloba, St John's wort, echinacea, ginseng, garlic, saw palmetto, kava kava, and valerian root). We analyzed the health content of all Web sites listed on the first page of the search results. Study Selection We analyzed all accessible, English-language Web sites that pertained to oral herbal supplements. A total of 522 Web sites were identified; of these, 443 sites met inclusion criteria for the analysis. Data Extraction The nature of the Web site (retail or nonretail), whether it was a sponsored link, and all references, indications, claims, and disclaimers were recorded. Two reviewers independently categorized medical claims as disease or nondisease according to Food and Drug Administration criteria. Data Synthesis Among 443 Web sites, 338 (76%) were retail sites either selling product or directly linked to a vendor. A total of 273 (81%) of the 338 retail Web sites made 1 or more health claims; of these, 149 (55%) claimed to treat, prevent, diagnose, or cure specific diseases. More than half (153/292; 52%) of sites with a health claim omitted the standard federal disclaimer. Nonretail sites were more likely than retail sites to include literature references, although only 52 (12%) of the 443 Web sites provided referenced information without a link to a distributor or vendor. Conclusions Consumers maybe misled, by vendors' claims that herbal products can treat, prevent, diagnose, or cure specific diseases, despite regulations prohibiting such statements. Physicians should be aware of this widespread and easily accessible information. More effective regulation is required to put this class of therapeutics on the same evidence-based footing as other medicinal products.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Morris, CA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.							Blendon RJ, 2001, ARCH INTERN MED, V161, P805, DOI 10.1001/archinte.161.6.805; Bonakdar RA, 2002, FAM MED, V34, P522; CHALLENER C, 2002, CHEM MARKET REP 0617, pFR11; Drazen JM, 2003, NEW ENGL J MED, V348, P777, DOI 10.1056/NEJMp030021; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Fontanarosa PB, 2003, JAMA-J AM MED ASSOC, V289, P1568, DOI 10.1001/jama.289.12.1568; *FOOD DRUG ADM, CONS ADV KAV DIET SU; *FOOD DRUG ADM, FDA ADV DIET SUPPL M; Fox S., 2002, VITAL DECISIONS INTE; *GEN ACC OFF, 2002, 83177 GEN ACC OFF; JELLIN JM, 2002, PHARM LETT PRESCRIBE; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Lipman MM, 2003, NEW ENGL J MED, V348, P1498; Marcus DM, 2002, NEW ENGL J MED, V347, P2073, DOI 10.1056/NEJMsb022858; Palmer ME, 2003, LANCET, V361, P101, DOI 10.1016/S0140-6736(03)12227-1; Slater MD, 2002, JAMA-J AM MED ASSOC, V288, P316, DOI 10.1001/jama.288.3.316; SULLIVAN D, 2002, JUPITER MEDIA METRIX; Troger U, 1998, BMJ-BRIT MED J, V317, P1069, DOI 10.1136/bmj.317.7165.1069; *US DEP COMM, 2002, NAT ONL AM AR EXP TH; Waxman H, COMMUNICATION; Wilson P, 2002, BMJ-BRIT MED J, V324, P598, DOI 10.1136/bmj.324.7337.598; Wilt TJ, 1998, JAMA-J AM MED ASSOC, V280, P1604, DOI 10.1001/jama.280.18.1604; 2002, NUTR BUSINESS J  MAY, P1; 2001, FED REG, V65, P56035	25	172	178	0	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1505	1509		10.1001/jama.290.11.1505	http://dx.doi.org/10.1001/jama.290.11.1505			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RE	13129992				2022-12-28	WOS:000185329000034
J	Ashcroft, B; Elstein, M; Boreham, N; Holm, S				Ashcroft, B; Elstein, M; Boreham, N; Holm, S			Prospective semistructured observational study to identify risk attributable to staff deployment, training, and updating opportunities for midwives	BRITISH MEDICAL JOURNAL			English	Article								Objective To identify potential risk or mishap in the system of intrapartum care, relating to the deployment of midwives. Design Prospective semistructured observational study. Setting Labour wards of seven maternity units in the north west of England. Participants All midwives working on the labour ward during the observation period in 2000. Main outcome measure "Latent failures" within the system relating to midwifery staffing levels, deployment, and training or updating opportunities. Results Despite the exemplary dedication of midwives, potential risk of mishap due to their deployment occurred within the system of care. A shortfall of midwives existed in all seven maternity units and was most acute in the largest units. Six units relied on bank midwives to maintain minimum staffing levels. High risk practices (oxytocin administration and epidural blockades) continued during midwifery shortfalls in all units. Some adverse events and "near misses" were attributable to midwifery shortages in all units, and near misses remained unreported in all units. Uptake of opportunities for training or updating in interpretation of cardiotocographs and obstetric emergency management remained low owing to midwifery shortages in all units. A poor skill mix of midwives occurred at times in all units. In six units midwives spent time away from clinical areas performing clerical duties. In three units learn midwifery systems were reported to erode labour ward skills and confidence. Conclusion Midwives are fundamental components in the system of intrapartum care, and the system cannot operate safely and effectively when the number of midwives is inadequate, midwives are poorly deployed, and they are unable to engage in opportunities for training and updating.	Univ Salford, Sch Hlth Care Profess, Manchester M6 6PU, Lancs, England; Univ Manchester, Inst Med Law & Bioeth, Manchester, Lancs, England; Univ Sterling, Inst Educ, Stirling, Scotland	University of Salford; University of Manchester; University of Stirling	Ashcroft, B (corresponding author), Univ Salford, Sch Hlth Care Profess, Manchester M6 6PU, Lancs, England.			Holm, Soren/0000-0002-7200-5607				Barach P, 2000, BMJ-BRIT MED J, V320, P759, DOI 10.1136/bmj.320.7237.759; Department of Health, 1993, CHANGING CHILDBIRTH; Department of Health, 1998, WHY MOTH DIE REP CON; DIMOND B, 1998, BRIT J MIDWIFERY, V6, P755; ENNIS M, 1990, BRIT MED J, V300, P1365, DOI 10.1136/bmj.300.6736.1365; Maternal and Child Health Research Consortium, 1997, CONF ENQ STILLB DEAT; *NAT HLTH SERV LIT, 2000, CLIN NEGL SCHEM TRUS; *NAT RES COUNC, 1980, IMPR AIRCR SAF FAA C; *NHS MAN EX, 1993, RISK MAN NHS; *OBST AN ASS, 1998, REC MIN STAND OBST A; Reason JT, 1997, MANAGING RISKS ORG A, P126; *ROYAL COLL OBST G, 1999, SAF CHILDB MIN STAND; *UK CENTR COUNC NU, 1998, STAT AN UKCCS PROF R, P9; VANDERSHAFF TW, 1991, NEAR MISS REPORTING; WILSON J, 1996, APPL CLIN RISK MAN M	15	24	25	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					584	586A		10.1136/bmj.327.7415.584	http://dx.doi.org/10.1136/bmj.327.7415.584			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969921	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000185358700014
J	Fogel, M; Gutwein, P; Mechtersheimer, S; Riedle, S; Stoeck, A; Smirnov, A; Edler, L; Ben-Arie, A; Huszar, M; Altevogt, P				Fogel, M; Gutwein, P; Mechtersheimer, S; Riedle, S; Stoeck, A; Smirnov, A; Edler, L; Ben-Arie, A; Huszar, M; Altevogt, P			L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas	LANCET			English	Article							CELL-ADHESION MOLECULE; MALIGNANT-MELANOMA; MEDIATED RELEASE; SEROUS CARCINOMA; PROTEINS; METALLOPROTEASE; ECTODOMAIN; INTEGRIN; FAMILY; METASTASIS	Background Ovarian and uterine carcinomas are the most common cause of cancer-related deaths in gynecological malignant diseases. We aimed to assess whether the L1 adhesion molecule, an important mediator for cell migration for neural and tumour cells, is expressed in these carcinomas, Methods We investigated L1 expression by immunohistochemistry, RT-PCR, and Western blot analysis of tumour samples. Soluble L1 in the serum was detected by ELISA and immunoprecipitation. Findings We detected the L1 adhesion molecule in ovarian and uterine tumours in a stage-dependent manner. In a retrospective study L1 was found in 46 of 58 ovarian carcinomas and 20 of 72 uterine adenocarcinomas. L1 expression was an excellent predictor of poor outlook (p<0.00001). Patients with L1 positive uterine tumours were at high risk for progression even in the endometrioid-type tumours, which usually have a favourable prognosis. In uterine tumours, expression of L1 in curettage samples enabled us to identify aggressive tumours before the operation. Soluble L1 was specifically detected in serum samples from patients with ovarian and uterine tumours. ADAM10, which was implicated in previous studies as L1 sheddase, was expressed in tumours in which soluble L1 was present in the serum. Interpretation L1 is overexpressed in ovarian and uterine carcinomas and is associated with short survival. L1 can serve as a new marker for prediction of clinical outcome and could be helpful to identify patients with uterine tumours who are at high risk for recurrent disease. L1 expression and cleavage could promote dissemination of tumours by facilitating cell migration.	German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany; German Canc Res Ctr, Biostat Grp R0700, D-69120 Heidelberg, Germany; Kaplan Hosp, Dept Pathol, IL-76100 Rehovot, Israel; Kaplan Hosp, Dept Gynecol, IL-76100 Rehovot, Israel	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Kaplan Medical Center	Altevogt, P (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, G0100,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	P.Altevogt@dkfz-heidelberg.de		Smirnov, Asya/0000-0003-4767-1680				Beer S, 1999, J CELL SCI, V112, P2667; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Creasman W T, 2001, J Epidemiol Biostat, V6, P47; Ebeling O, 1996, EUR J IMMUNOL, V26, P2508, DOI 10.1002/eji.1830261035; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Friedlander ML, 1998, SEMIN ONCOL, V25, P305; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Heintz A P, 2001, J Epidemiol Biostat, V6, P107; HENDRICKSON M, 1982, AM J SURG PATHOL, V6, P93, DOI 10.1097/00000478-198203000-00002; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Hulley P, 1998, J NEUROSCI RES, V53, P129, DOI 10.1002/(SICI)1097-4547(19980715)53:2<129::AID-JNR1>3.0.CO;2-9; Kamiguchi H, 1998, MOL CELL NEUROSCI, V12, P48, DOI 10.1006/mcne.1998.0702; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; Ohnishi T, 1998, CANCER RES, V58, P2935; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Schaefer AW, 2002, J CELL BIOL, V157, P1223, DOI 10.1083/jcb.200203024; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; SHERMAN ME, 1992, AM J SURG PATHOL, V16, P600, DOI 10.1097/00000478-199206000-00008; Thelen K, 2002, J NEUROSCI, V22, P4918, DOI 10.1523/JNEUROSCI.22-12-04918.2002; Thies A, 2002, EUR J CANCER, V38, P1708, DOI 10.1016/S0959-8049(02)00105-3; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026	29	228	248	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 13	2003	362	9387					869	875		10.1016/S0140-6736(03)14342-5	http://dx.doi.org/10.1016/S0140-6736(03)14342-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678974				2022-12-28	WOS:000185329400011
J	Jaggy, C; von Overbeck, J; Ledergerber, B; Schwarz, C; Egger, M; Rickenbach, M; Furrer, HJ; Telenti, A; Battegay, M; Flepp, M; Vernazza, P; Bernasconi, E; Hirschel, B				Jaggy, C; von Overbeck, J; Ledergerber, B; Schwarz, C; Egger, M; Rickenbach, M; Furrer, HJ; Telenti, A; Battegay, M; Flepp, M; Vernazza, P; Bernasconi, E; Hirschel, B		Swiss HIV Cohort Study	Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population	LANCET			English	Article								Because of high death rates in the past, patients with HIV-1 cannot obtain life insurance. We measured mortality rates in the Swiss HIV Cohort Study (SHCS) from 1997 to 2001 and compared them with those of the Swiss reference population. In patients who were successfully treated with highly active anti-retroviral therapy (HAART), and who were not also infected with the hepatitis C virus, excess death rates were below five per thousand per year. Patients with successfully treated cancer have much the same excess death rates but are not excluded from life insurance policies.	Univ Hosp, Div Infect Dis, CH-1211 Geneva, Switzerland; Swiss Re, Zurich, Switzerland; Univ Zurich Hosp, CH-8091 Zurich, Switzerland; Univ Hosp Bern, Div Infect Dis, Bern, Switzerland; Univ Lausanne Hosp, Div Infect Dis, Lausanne, Switzerland; Univ Basel Hosp, Div Infect Dis, CH-4031 Basel, Switzerland; Cantonal Hosp St Gallen, St Gallen, Switzerland; Cantonal Hosp Lugano, Lugano, Switzerland; Dept Social & Prevent Med, Bern, Switzerland	University of Geneva; University of Zurich; University Zurich Hospital; University of Bern; University Hospital of Bern; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Basel; Kantonsspital St. Gallen	Hirschel, B (corresponding author), Univ Hosp, Div Infect Dis, CH-1211 Geneva, Switzerland.		SHCS, social sciences/G-4093-2011; Telenti, Amalio/AAY-1674-2021; Furrer, Hansjakob/G-6768-2013; Ledergerber, Bruno/B-5656-2009; VALLET, Yannick/F-9979-2011	Furrer, Hansjakob/0000-0002-1375-3146; Ledergerber, Bruno/0000-0002-6881-4401; Egger, Matthias/0000-0001-7462-5132				FRIISMOLLER N, 2003, 10 C RETR OPP INF BO; Kendall M.G., 1973, ADV THEORY STAT, V2; LEW EA, 1990, MED RISKS TRENDS MOR, V1; Mocroft A, 2002, AIDS, V16, P1663, DOI 10.1097/00002030-200208160-00012; SUDRE P, 2000, SCHWEIZ MED WOCHENSC, V130, P1500	5	89	92	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					877	878		10.1016/S0140-6736(03)14307-3	http://dx.doi.org/10.1016/S0140-6736(03)14307-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678976				2022-12-28	WOS:000185329400013
J	Richter, J; Hatz, C; Haussinger, D				Richter, J; Hatz, C; Haussinger, D			Ultrasound in tropical and parasitic diseases	LANCET			English	Review							SCHISTOSOMIASIS-MANSONI; ECHINOCOCCOSIS; EVOLUTION	Context Migration and worldwide travel mean that western clinicians and radiologists more and more face imported tropical diseases. Diseases with unclear signs and symptoms are likely to be investigated with ultrasound Many tropical diseases have particular ultrasonographic features that are not familiar to the examiner and which may lead to further unnecessary or even harmful diagnostic investigations. In developing countries, ultrasound machines are becoming more widely distributed and are fairly cheap. Portable devices allow field use of ultrasound for population studies and individual diagnosis of tropical diseases Starting point Recently, WHO introduced a standardised classification of ultrasonographic images of cystic echinococcosis (Acta Trop 2003; 85: 253-61), to obtain comparable results in patients worldwide and to link disease status with each morphological type of echinococcosis cyst. WHO also defined guidelines for the puncture, aspiration, injection of ethanol, and re-aspiration of such cysts. Ultrasound allows diagnosis of schistosomiasis-induced periportal fibrosis and bladder abnormalities. Liver abscesses can be differentiated from other focal lesions such as cysts or neoplasms. For amoebic abscesses, invasive procedures are usually not required. In doubtful cases ultrasound-guided puncture can give adequate material for microscopy and culture. Helminths (eg, ascaris), flukes, and filariae can be seen directly with ultrasound. Filaria-induced damage also includes hypoechogenic splenic foci and ultrasonographic abnormalities due to tropical hypereosinophilia. Where next? Classification of cysts and procedures that are less invasive than conventional surgery are being developed further for cystic echinococcosis. Novel methods are needed for the assessment of polycystic and alveolar echinococcosis. Ultrasound protocols for schistosomiasis are being evaluated for interobserver reliability, relation to clinical disease status, and power to predict complications. A WHO expert-group is also developing a standardised protocol for Asian schistosomiasis. International consensus on an algorithm for managing amoebic liver abscesses,is needed.	Univ Dusseldorf, Univ Clin, Clin Gastroenterol Hepatol & Infect Dis, D-4000 Dusseldorf, Germany; Swiss Trop Inst, CH-4002 Basel, Switzerland	Heinrich Heine University Dusseldorf; University of Basel; Swiss Tropical & Public Health Institute	Richter, J (corresponding author), Univ Dusseldorf, Klin Gastroenterol Hepatol & Infektiol, Tropenmed Ambulanz, D-40225 Dusseldorf, Germany.							ACQUATELLA H, 1983, CIRCULATION, V67, P1219, DOI 10.1161/01.CIR.67.6.1219; AMARAL F, 1994, AM J TROP MED HYG, V50, P753, DOI 10.4269/ajtmh.1994.50.753; Bartholomot B, 2002, AM J TROP MED HYG, V66, P23, DOI 10.4269/ajtmh.2002.66.23; Brunetti E, 2001, LANCET, V358, P1464, DOI 10.1016/S0140-6736(01)06518-7; Burchard GD, 1996, CLIN INFECT DIS, V23, P979, DOI 10.1093/clinids/23.5.979; CERRI GG, 1984, RADIOLOGY, V153, P777, DOI 10.1148/radiology.153.3.6387793; DAlessandro A, 1997, ACTA TROP, V67, P43, DOI 10.1016/S0001-706X(97)00048-X; Hatz CF, 1998, AM J TROP MED HYG, V59, P775, DOI 10.4269/ajtmh.1998.59.775; King CH, 2003, TROP MED INT HEALTH, V8, P109, DOI 10.1046/j.1365-3156.2003.00994.x; LEICHSENRING M, 1990, AM J TROP MED HYG, V43, P380, DOI 10.4269/ajtmh.1990.43.380; Macpherson CNL, 2003, ACTA TROP, V85, P253, DOI 10.1016/S0001-706X(02)00213-9; MUELLER PR, 1985, RADIOLOGY, V155, P627, DOI 10.1148/radiology.155.3.3890001; Niamey Working Group, 2000, ULTR SCHIST PRACT GU; Richter J, 1999, TROP MED INT HEALTH, V4, P774, DOI 10.1046/j.1365-3156.1999.00482.x; *WHO, 1995, MAN DIAGN ULTR; *WHO, 1998, WHO TECH REP SER, V875; WHO Informal Working Group on Echinococcosis (WHO-IGWE), 2001, PAIR PUNCT ASP INJ R	17	64	65	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					900	902		10.1016/S0140-6736(03)14334-6	http://dx.doi.org/10.1016/S0140-6736(03)14334-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678978				2022-12-28	WOS:000185329400023
J	Riley, SG; Chess, J; Donovan, KL; Williams, JD				Riley, SG; Chess, J; Donovan, KL; Williams, JD			Lesson of the week - Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RENAL-FAILURE		Univ Wales Hosp, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Riley, SG (corresponding author), Univ Wales Hosp, Inst Nephrol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	steveriley65@hotmail.com						ANSELL D, 2000, UK RENAL REGISTRY RE; Coles GA, 1998, KIDNEY INT, V54, P2234, DOI 10.1046/j.1523-1755.1998.00183.x; Gokal R, 2002, KIDNEY INT, V62, pS62, DOI 10.1046/j.1523-1755.62.s81.9.x; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Mehmet S, 2001, DIABETIC MED, V18, P679, DOI 10.1046/j.0742-3071.2001.00556.x; Ritz E, 1999, AM J KIDNEY DIS, V34, P795, DOI 10.1016/S0272-6386(99)70035-1; Wens R, 1998, PERITON DIALYSIS INT, V18, P603; Wilkie ME, 1997, PERITON DIALYSIS INT, V17, P84	8	22	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	2003	327	7415					608	609		10.1136/bmj.327.7415.608	http://dx.doi.org/10.1136/bmj.327.7415.608			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969932	Green Published			2022-12-28	WOS:000185358700028
J	Becker, H; Walker, RJ				Becker, H; Walker, RJ			Efficient mixing of the solar nebula from uniform Mo isotopic composition of meteorites	NATURE			English	Article							ABUNDANCES; SYSTEM; OXYGEN; FRACTIONATION; NITROGEN; ELEMENTS	The abundances of elements and their isotopes in our Galaxy show wide variations, reflecting different nucleosynthetic processes in stars and the effects of Galactic evolution(1). These variations contrast with the uniformity of stable isotope abundances for many elements in the Solar System(2,3), which implies that processes efficiently homogenized dust and gas from different stellar sources within the young solar nebula. However, isotopic heterogeneity has been recognized on the subcentimetre scale in primitive meteorites(4,5), indicating that these preserve a compositional memory of their stellar sources. Small differences in the abundance of stable molybdenum isotopes in bulk rocks of some primitive(6-8) and differentiated(7,9) meteorites, relative to terrestrial Mo, suggest large-scale Mo isotopic heterogeneity between some inner Solar System bodies, which implies physical conditions that did not permit efficient mixing of gas and dust. Here we report Mo isotopic data for bulk samples of primitive and differentiated meteorites that show no resolvable deviations from terrestrial Mo. This suggests efficient mixing of gas and dust in the solar nebula at least to 3 AU from the Sun, possibly induced by magnetohydrodynamic instabilities(10). These mixing processes must have occurred before isotopic fractionation of gas-phase elements and volatility-controlled chemical fractionations were established.	Univ Maryland, Dept Geol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Becker, H (corresponding author), Univ Maryland, Dept Geol, College Pk, MD 20742 USA.	hbecker@geol.umd.edu	Walker, Richard/K-6869-2016	Walker, Richard/0000-0003-0348-2407				ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; Becker H, 2003, CHEM GEOL, V196, P43, DOI 10.1016/S0009-2541(02)00406-0; Becker H, 2001, GEOCHIM COSMOCHIM AC, V65, P3379, DOI 10.1016/S0016-7037(01)00676-7; BECKER H, 2002, LPS, V33, P1018; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; Clayton RN, 2002, NATURE, V415, P860, DOI 10.1038/415860b; Dauphas N, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014237; Dauphas N, 2002, ASTROPHYS J, V569, pL139, DOI 10.1086/340580; Dauphas N, 2002, ASTROPHYS J, V565, P640, DOI 10.1086/324597; HARPER CL, 1993, NUCLEI IN THE COSMOS, P113; Lee T, 1998, ASTROPHYS J, V506, P898, DOI 10.1086/306284; LEWIS RS, 1983, NATURE, V305, P767, DOI 10.1038/305767a0; Lu Q, 2001, ORIGIN OF ELEMENTS IN THE SOLAR SYSTEM, P385; MCCULLOCH MT, 1978, ASTROPHYS J, V220, pL15, DOI 10.1086/182628; NIEDERER FR, 1985, GEOCHIM COSMOCHIM AC, V49, P835, DOI 10.1016/0016-7037(85)90176-0; NIER AO, 1950, PHYS REV, V77, P789, DOI 10.1103/PhysRev.77.789; PERNICKA E, 1987, GEOCHIM COSMOCHIM AC, V51, P1717, DOI 10.1016/0016-7037(87)90350-4; QILU, 1994, INT J MASS SPECTROM, V130, P65, DOI 10.1016/0168-1176(93)03900-7; RUSSELL WA, 1978, GEOCHIM COSMOCHIM AC, V42, P1075, DOI 10.1016/0016-7037(78)90105-9; SCHONBACHLER M, 2002, LUNAR PLANET SCI, V33, P1283; SHUKOLYUKOV A, 2003, LUNAR PLANET SCI, V34, P1279; Stone J. M., 2000, Protostars and planets 4, P589; SUESS HE, 1956, REV MOD PHYS, V28, P53, DOI 10.1103/RevModPhys.28.53; THIEMENS MH, 1983, SCIENCE, V219, P1073, DOI 10.1126/science.219.4588.1073; Wallerstein G, 1997, REV MOD PHYS, V69, P995, DOI 10.1103/RevModPhys.69.995; Yin QZ, 2002, NATURE, V415, P881, DOI 10.1038/415881a	28	43	44	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					152	155		10.1038/nature01975	http://dx.doi.org/10.1038/nature01975			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968172				2022-12-28	WOS:000185236000034
J	Ekstrom, AD; Kahana, MJ; Caplan, JB; Fields, TA; Isham, EA; Newman, EL; Fried, I				Ekstrom, AD; Kahana, MJ; Caplan, JB; Fields, TA; Isham, EA; Newman, EL; Fried, I			Cellular networks underlying human spatial navigation	NATURE			English	Article							HUMAN HIPPOCAMPUS; HEAD DIRECTION; SINGLE-NEURON; CELLS; RESPONSES	Place cells of the rodent hippocampus constitute one of the most striking examples of a correlation between neuronal activity and complex behaviour in mammals(1,2). These cells increase their firing rates when the animal traverses specific regions of its surroundings, providing a context-dependent map of the environment(3-5). Neuroimaging studies implicate the hippocampus and the parahippocampal region in human navigation(6-8). However, these regions also respond selectively to visual stimuli(9-13). It thus remains unclear whether rodent place coding has a homologue in humans or whether human navigation is driven by a different, visually based neural mechanism. We directly recorded from 317 neurons in the human medial temporal and frontal lobes while subjects explored and navigated a virtual town. Here we present evidence for a neural code of human spatial navigation based on cells that respond at specific spatial locations and cells that respond to views of landmarks. The former are present primarily in the hippocampus, and the latter in the parahippocampal region. Cells throughout the frontal and temporal lobes responded to the subjects' navigational goals and to conjunctions of place, goal and view.	Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA; Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Tel Aviv Med Ctr, Funct Neurosurg Unit, IL-69978 Tel Aviv, Israel	Brandeis University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Kahana, MJ (corresponding author), Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA.	kahana@brandeis.edu; ifried@mednet.ucla.edu	Ekstrom, Arne/A-1329-2013	Newman, Ehren/0000-0001-7006-4112; Ekstrom, Arne/0000-0002-6812-2368				Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Aguirre GK, 1998, NEURON, V21, P373, DOI 10.1016/S0896-6273(00)80546-2; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Cameron KA, 2001, NEURON, V30, P289, DOI 10.1016/S0896-6273(01)00280-X; Caplan JB, 2003, J NEUROSCI, V23, P4726; Epstein R, 2003, NEURON, V37, P865, DOI 10.1016/S0896-6273(03)00117-X; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; Frank LM, 2000, NEURON, V27, P169, DOI 10.1016/S0896-6273(00)00018-0; Fried I, 1999, J NEUROSURG, V91, P697, DOI 10.3171/jns.1999.91.4.0697; Fried I, 1997, NEURON, V18, P753, DOI 10.1016/S0896-6273(00)80315-3; Georges-Francois P, 1999, CEREB CORTEX, V9, P197, DOI 10.1093/cercor/9.3.197; Kreiman G, 2000, NAT NEUROSCI, V3, P946, DOI 10.1038/78868; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; MARKUS EJ, 1995, J NEUROSCI, V15, P7079; Matsumura N, 1999, J NEUROSCI, V19, P2381; MULLER RU, 1987, J NEUROSCI, V7, P1951; MULLER RU, 1987, J NEUROSCI, V7, P1935; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Ojemann GA, 2002, NAT NEUROSCI, V5, P64, DOI 10.1038/nn785; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1978, EXP BRAIN RES, V31, P573; QUIRK GJ, 1992, J NEUROSCI, V12, P1945; Robertson RG, 1999, HIPPOCAMPUS, V9, P206, DOI 10.1002/(SICI)1098-1063(1999)9:3<206::AID-HIPO2>3.0.CO;2-H; Skaggs W., 1993, ADV NEURAL INFORM PR, V5, P1030; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; Witter M., 2002, PARAHIPPOCAMPAL REGI, P3, DOI DOI 10.1093/ACPROF:OSO/9780198509172.001.0001	27	806	831	5	153	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					184	187		10.1038/nature01964	http://dx.doi.org/10.1038/nature01964			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968182				2022-12-28	WOS:000185236000044
J	O'Grady, G				O'Grady, G			Death of the teaching autopsy	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-EDUCATION; ATTITUDES; STUDENTS		New Zealand Med Students Assoc, Wellington, New Zealand		O'Grady, G (corresponding author), New Zealand Med Students Assoc, 55A Rugby St,Mt Cook, Wellington, New Zealand.							ANDERSON RE, 1989, AM J CLIN PATHOL, V92, pS31; BENBOW EW, 1990, J CLIN PATHOL, V43, P969, DOI 10.1136/jcp.43.12.969; Botega NJ, 1997, J CLIN PATHOL, V50, P64, DOI 10.1136/jcp.50.1.64; Chariot P, 2000, ARCH PATHOL LAB MED, V124, P739; CHARLTON R, 1994, J ROY SOC MED, V87, P232; CODDINGTON D, 2002, N S MAGAZINE     JUN, P28; Galloway M, 1999, HOSP MED, V60, P756, DOI 10.12968/hosp.1999.60.10.1223; GELLER SA, 1984, ARCH PATHOL LAB MED, V108, P494; GOLDMAN L, 1984, ARCH PATHOL LAB MED, V108, P501; HARTMANN HRF, 1984, ARCH PATHOL LAB MED, V108, P522; Hill RB, 1996, ARCH PATHOL LAB MED, V120, P702; HILL RB, 1991, ACAD MED, V66, P97, DOI 10.1097/00001888-199102000-00011; Kingsford DPW, 1995, MED SCI LAW, V35, P347, DOI 10.1177/002580249503500413; Kirch W, 1996, MEDICINE, V75, P29, DOI 10.1097/00005792-199601000-00004; Loughrey MB, 2000, ULSTER MED J, V69, P83; LUNDBERG GD, 1984, ARCH PATHOL LAB MED, V108, P449; Sanchez H, 2001, ACAD MED, V76, P530, DOI 10.1097/00001888-200105000-00067; SANNER MA, 1994, ARCH PATHOL LAB MED, V118, P878; SHERWOOD SJ, 1995, MED EDUC, V29, P231, DOI 10.1111/j.1365-2923.1995.tb02836.x; Welsh TS, 1998, MAYO CLIN PROC, V73, P802, DOI 10.4065/73.8.802	20	73	74	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					802	803		10.1136/bmj.327.7418.802	http://dx.doi.org/10.1136/bmj.327.7418.802			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525883	Green Published			2022-12-28	WOS:000185805100027
J	Englund, C; Loren, CE; Grabbe, C; Varshney, GK; Deleuil, F; Hallberg, B; Palmer, RH				Englund, C; Loren, CE; Grabbe, C; Varshney, GK; Deleuil, F; Hallberg, B; Palmer, RH			Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion	NATURE			English	Article							NON-HODGKINS-LYMPHOMA; DROSOPHILA-MELANOGASTER; GENE; EMBRYOGENESIS	The Drosophila melanogaster gene Anaplastic lymphoma kinase (Alk) is homologous to mammalian Alk, a member of the Alk/Ltk family of receptor tyrosine kinases (RTKs)(1). We have previously shown that the Drosophila Alk RTK is crucial for visceral mesoderm development during early embryogenesis(2). Notably, observed Alk visceral mesoderm defects are highly reminiscent of the phenotype reported for the secreted molecule Jelly belly (Jeb)(3). Here we show that Drosophila Alk is the receptor for Jeb in the developing visceral mesoderm, and that Jeb binding stimulates an Alk-driven, extracellular signal-regulated kinase-mediated signalling pathway, which results in the expression of the downstream gene duf (also known as kirre)(4,5)-needed for muscle fusion. This new signal transduction pathway drives specification of the muscle founder cells, and the regulation of Duf expression by the Drosophila Alk RTK explains the visceral-mesoderm-specific muscle fusion defects observed in both Alk and jeb mutant animals.	Umea Univ, Umea Ctr Mol Pathogenesis, S-90187 Umea, Sweden; Umea Univ, Dept Med Biosci, S-90187 Umea, Sweden	Umea University; Umea University	Palmer, RH (corresponding author), Umea Univ, Umea Ctr Mol Pathogenesis, S-90187 Umea, Sweden.	Ruth.Palmer@ucmp.umu.se	Varshney, Gaurav/L-5261-2014	Varshney, Gaurav K./0000-0002-0429-1904				BATE M, 1990, DEVELOPMENT, V110, P791; Baylies MK, 2001, CURR OPIN GENET DEV, V11, P431, DOI 10.1016/S0959-437X(00)00214-8; Campos-Ortega J, 1997, EMBRYONIC DEV DROSOP; CARMENA A, 1995, GENE DEV, V9, P2373, DOI 10.1101/gad.9.19.2373; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Dworak HA, 2002, BIOESSAYS, V24, P591, DOI 10.1002/bies.10115; Fujioka H, 2002, CHEM IMMUNOL, V80, P1; Gabay L, 1997, DEVELOPMENT, V124, P3535; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Klapper R, 2002, MECH DEVELOP, V110, P85, DOI 10.1016/S0925-4773(01)00567-6; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Loren CE, 2003, EMBO REP, V4, P781, DOI 10.1038/sj.embor.embor897; Loren CE, 2001, GENES CELLS, V6, P531, DOI 10.1046/j.1365-2443.2001.00440.x; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Palmer RH, 1999, J BIOL CHEM, V274, P35621, DOI 10.1074/jbc.274.50.35621; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; Ruiz-Gomez M, 2000, CELL, V102, P189, DOI 10.1016/S0092-8674(00)00024-6; San Martin B, 2001, DEVELOPMENT, V128, P3331; Strunkelnberg M, 2001, DEVELOPMENT, V128, P4229; Weiss JB, 2001, CELL, V107, P387, DOI 10.1016/S0092-8674(01)00540-2	23	121	122	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2003	425	6957					512	516		10.1038/nature01950	http://dx.doi.org/10.1038/nature01950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523447				2022-12-28	WOS:000185648100045
J	Hirshfeld, JW				Hirshfeld, JW			Invasive cardiovascular procedures - Optimizing patient safety	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Hirshfeld, JW (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1311	1312		10.1056/NEJMp038140	http://dx.doi.org/10.1056/NEJMp038140			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523137				2022-12-28	WOS:000185644000003
J	Moses, JW; Leon, MB; Popma, JJ; Fitzgerald, PJ; Holmes, DR; O'Shaughnessy, C; Caputo, RP; Kereiakes, DJ; Williams, DO; Teirstein, PS; Jaeger, JL; Kuntz, RE				Moses, JW; Leon, MB; Popma, JJ; Fitzgerald, PJ; Holmes, DR; O'Shaughnessy, C; Caputo, RP; Kereiakes, DJ; Williams, DO; Teirstein, PS; Jaeger, JL; Kuntz, RE		SIRIUS Investigators	Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GAMMA-RADIATION THERAPY; BALLOON ANGIOPLASTY; INTRAVASCULAR ULTRASOUND; NEOINTIMAL PROLIFERATION; INTIMAL HYPERPLASIA; DIABETES-MELLITUS; FOLLOW-UP/; RESTENOSIS; DELIVERY; IMPLANTATION	BACKGROUND: Preliminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous coronary revascularization. METHODS: We conducted a randomized, double-blind trial comparing a sirolimus-eluting stent with a standard stent in 1058 patients at 53 centers in the United States who had a newly diagnosed lesion in a native coronary artery. The coronary disease in these patients was complex because of the frequent presence of diabetes (in 26 percent of patients), the high percentage of patients with longer lesions (mean, 14.4 mm), and small vessels (mean, 2.80 mm). The primary end point was failure of the target vessel (a composite of death from cardiac causes, myocardial infarction, and repeated percutaneous or surgical revascularization of the target vessel) within 270 days. RESULTS: The rate of failure of the target vessel was reduced from 21.0 percent with a standard stent to 8.6 percent with a sirolimus-eluting stent (P<0.001) -- a reduction that was driven largely by a decrease in the frequency of the need for revascularization of the target lesion (16.6 percent in the standard-stent group vs. 4.1 percent in the sirolimus-stent group, P<0.001). The frequency of neointimal hyperplasia within the stent was also decreased in the group that received sirolimus-eluting stents, as assessed by both angiography and intravascular ultrasonography. Subgroup analyses revealed a reduction in the rates of angiographic restenosis and target-lesion revascularization in all subgroups examined. CONCLUSIONS: In this randomized clinical trial involving patients with complex coronary lesions, the use of a sirolimus-eluting stent had a consistent treatment effect, reducing the rates of restenosis and associated clinical events in all subgroups analyzed.	Lenox Hill Heart & Vasc Inst New York, New York, NY USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Stanford Univ, Med Ctr, Stanford, CA 94305 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; N Ohio Heart Ctr, Elyria, OH USA; St Josephs Hosp, Syracuse, NY USA; Christ Hosp Lindner Res Ctr, Cincinnati, OH USA; Rhode Isl Hosp, Providence, RI USA; Scripps Clin, La Jolla, CA USA; Cordis, Warren, NJ USA	Lenox Hill Heart & Vascular Institute of New York; Harvard University; Brigham & Women's Hospital; Stanford University; Mayo Clinic; Christ Hospital - Ohio; Lifespan Health Rhode Island; Rhode Island Hospital; Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA	Moses, JW (corresponding author), Cardiovasc Res Fdn, 130 E 77th St,Black Hall,9th Fl, New York, NY 10021 USA.	jmoses@lenoxhill.net						Abizaid A, 1998, J AM COLL CARDIOL, V32, P584, DOI 10.1016/S0735-1097(98)00286-1; Akiyama T, 1998, J AM COLL CARDIOL, V32, P1610, DOI 10.1016/S0735-1097(98)00444-6; BAIM DS, 1993, AM J CARDIOL, V71, P364, DOI 10.1016/0002-9149(93)90813-R; Dauerman HL, 1998, CIRCULATION, V98, P22; de Feyter PJ, 2000, Curr Interv Cardiol Rep, V2, P326; Drachman DE, 2000, J AM COLL CARDIOL, V36, P2325, DOI 10.1016/S0735-1097(00)01020-2; DUSSAILLANT GR, 1995, J AM COLL CARDIOL, V26, P720, DOI 10.1016/0735-1097(95)00249-4; Elezi S, 1998, J AM COLL CARDIOL, V32, P1866, DOI 10.1016/S0735-1097(98)00467-7; Elezi S, 1998, CIRCULATION, V98, P1875, DOI 10.1161/01.CIR.98.18.1875; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Heldman AW, 2001, CIRCULATION, V103, P2289; Herdeg C, 2000, J AM COLL CARDIOL, V35, P1969, DOI 10.1016/S0735-1097(00)00614-8; Holmes DR, 2002, CIRCULATION, V106, P1243, DOI 10.1161/01.CIR.0000028335.31300.DA; Kastrati A, 1999, AM J CARDIOL, V83, P1617, DOI 10.1016/S0002-9149(99)00165-4; Kimura T, 1996, NEW ENGL J MED, V334, P561, DOI 10.1056/NEJM199602293340903; Kobayashi Y, 1999, J AM COLL CARDIOL, V34, P651, DOI 10.1016/S0735-1097(99)00303-4; Kutryk MJB, 2002, J AM COLL CARDIOL, V39, P281, DOI 10.1016/S0735-1097(01)01741-7; Leon MB, 2001, NEW ENGL J MED, V344, P250, DOI 10.1056/NEJM200101253440402; Marx SO, 2001, CIRCULATION, V104, P852, DOI 10.1161/01.CIR.104.8.852; Mehran R, 1996, AM J CARDIOL, V78, P618, DOI 10.1016/S0002-9149(96)00381-5; Mehran R, 1999, CIRCULATION, V100, P1872, DOI 10.1161/01.CIR.100.18.1872; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Park SJ, 2003, NEW ENGL J MED, V348, P1537, DOI 10.1056/NEJMoa021007; Rankin JM, 1999, NEW ENGL J MED, V341, P1957, DOI 10.1056/NEJM199912233412602; Rensing BJ, 2001, EUR HEART J, V22, P2125, DOI 10.1053/euhj.2001.2892; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; Sousa JE, 2001, CIRCULATION, V104, P2007, DOI 10.1161/hc4201.098056; Sousa JE, 2001, CIRCULATION, V103, P192; Suzuki T, 2001, CIRCULATION, V104, P1188, DOI 10.1161/hc3601.093987; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201; Waksman R, 2000, CIRCULATION, V101, P2165, DOI 10.1161/01.CIR.101.18.2165; Wilensky RL, 2000, AM HEART J, V139, P1061, DOI 10.1067/mhj.2000.106614	35	3290	3596	1	146	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1315	1323		10.1056/NEJMoa035071	http://dx.doi.org/10.1056/NEJMoa035071			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523139				2022-12-28	WOS:000185644000005
J	Staal, M; Meysman, FJR; Stal, LJ				Staal, M; Meysman, FJR; Stal, LJ			Temperature excludes N-2-fixing heterocystous cyanobacteria in the tropical oceans	NATURE			English	Article							NITROGEN-FIXATION; N-2 FIXATION; BALTIC SEA; PHOTOSYNTHESIS; TRICHODESMIUM; OXYGEN	Whereas the non-heterocystous cyanobacteria Trichodesmium spp. are the dominant N-2-fixing organisms in the tropical oceans(1), heterocystous species dominate N-2 fixation in freshwater lakes and brackish environments such as the Baltic Sea(2). So far no satisfactory explanation for the absence of heterocystous cyanobacteria in the pelagic of the tropical oceans has been given, even though heterocysts would seem to represent an ideal strategy for protecting nitrogenase from being inactivated by O-2, thereby enabling cyanobacteria to fix N-2 and to perform photosynthesis simultaneously. Trichodesmium is capable of N-2 fixation, apparently without needing to differentiate heterocysts(3). Here we show that differences in the temperature dependence of O-2 flux, respiration and N-2 fixation activity explain how Trichodesmium performs better than heterocystous species at higher temperatures. Our results also explain why Trichodesmium is not successful in temperate or cold seas. The absence of heterocystous cyanobacteria in the pelagic zone of temperate and cold seas, however, requires another explanation.	NIOO KNAW, Dept Marine Microbiol, NL-4400 AC Yerseke, Netherlands; NIOO KNAW, Dept Ecosyst Studies, NL-4400 AC Yerseke, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW)	Staal, M (corresponding author), NIOO KNAW, Dept Marine Microbiol, POB 140, NL-4400 AC Yerseke, Netherlands.		Stal, Lucas J/B-3334-2011; Meysman, Filip JR/C-9585-2009	Meysman, Filip JR/0000-0001-5334-7655				Bergman B, 1997, FEMS MICROBIOL REV, V19, P139, DOI 10.1016/S0168-6445(96)00028-9; Berman-Frank I, 2001, LIMNOL OCEANOGR, V46, P1249, DOI 10.4319/lo.2001.46.6.1249; Berman-Frank I, 2001, SCIENCE, V294, P1534, DOI 10.1126/science.1064082; Carpenter EJ, 2001, PHYCOLOGIA, V40, P105; Chen YB, 1996, J PHYCOL, V32, P916, DOI 10.1111/j.0022-3646.1996.00916.x; DAVISON IR, 1991, J PHYCOL, V27, P2, DOI 10.1111/j.0022-3646.1991.00002.x; Hoffmann L, 1999, EUR J PHYCOL, V34, P371; KANA TM, 1993, LIMNOL OCEANOGR, V38, P18, DOI 10.4319/lo.1993.38.1.0018; KANGATHARALINGAM N, 1991, J PHYCOL, V27, P680, DOI 10.1111/j.0022-3646.1991.00680.x; Karl D, 2002, BIOGEOCHEMISTRY, V57, P47, DOI 10.1023/A:1015798105851; Laamanen MJ, 1997, J PLANKTON RES, V19, P1385, DOI 10.1093/plankt/19.10.1385; MURRY MA, 1989, ARCH MICROBIOL, V151, P469, DOI 10.1007/BF00454860; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sanudo-Wilhelmy SA, 2001, NATURE, V411, P66, DOI 10.1038/35075041; Staal M, 2001, ENVIRON MICROBIOL, V3, P343, DOI 10.1046/j.1462-2920.2001.00201.x; Staal M, 2002, APPL ENVIRON MICROB, V68, P4679, DOI 10.1128/AEM.68.9.4679-4683.2002; Stal LJ, 2000, EUR J PHYCOL, V35, P97, DOI 10.1080/09670260010001735681; TALLING J. F., 1957, NEW PHYTOL, V56, P29, DOI 10.1111/j.1469-8137.1957.tb07447.x; WALSBY A E, 1985, Proceedings of the Royal Society of London Series B Biological Sciences, V226, P345, DOI 10.1098/rspb.1985.0099; Wolk C.P., 1994, MOL BIOL CYANOBACTER, P770	20	123	130	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					504	507		10.1038/nature01999	http://dx.doi.org/10.1038/nature01999			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523445				2022-12-28	WOS:000185648100043
J	Powers, M				Powers, M			Commentary: communicating risk in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Editorial Material									ADR Chambers, London WC2A 3UP, England		Powers, M (corresponding author), ADR Chambers, Lincolns Inn, London WC2A 3UP, England.							*BRIT ROYAL INF IN, 2001, INQ MAN CAR CHILDR R; *DOH, MAK AM CONS PAP SETT	2	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	2003	327	7417					735	736		10.1136/bmj.327.7417.735	http://dx.doi.org/10.1136/bmj.327.7417.735			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728FZ	14512486	Green Published			2022-12-28	WOS:000185708300026
J	Garrett, C				Garrett, C			Internal tides and ocean mixing	SCIENCE			English	Editorial Material							HAWAIIAN RIDGE; DEEP-OCEAN		Univ Victoria, Dept Phys & Astron, Victoria, BC V8W 3P6, Canada	University of Victoria	Garrett, C (corresponding author), Univ Victoria, Dept Phys & Astron, POB 3055, Victoria, BC V8W 3P6, Canada.							Alford M. H., 2003, GEOPHYS RES LETT, V30; Cartwright David Edgar, 1999, TIDES SCI HIST; DICKEY JO, 1994, SCIENCE, V265, P482, DOI 10.1126/science.265.5171.482; Egbert GD, 2001, J GEOPHYS RES-OCEANS, V106, P22475, DOI 10.1029/2000JC000699; Merrifield MA, 2001, GEOPHYS RES LETT, V28, P559, DOI 10.1029/2000GL011749; MOROZOV EG, 1995, DEEP-SEA RES PT I, V42, P135, DOI 10.1016/0967-0637(95)92886-C; Munk W, 1998, DEEP-SEA RES PT I, V45, P1977, DOI 10.1016/S0967-0637(98)00070-3; Polzin KL, 1997, SCIENCE, V276, P93, DOI 10.1126/science.276.5309.93; Ray RD, 1997, PROG OCEANOGR, V40, P135, DOI 10.1016/S0079-6611(97)00025-6; RIPPETH TP, 2002, J GEOPHYS RES, V107; Rudnick DL, 2003, SCIENCE, V301, P355, DOI 10.1126/science.1085837; St Laurent L, 2002, J PHYS OCEANOGR, V32, P2882, DOI 10.1175/1520-0485(2002)032<2882:TROITI>2.0.CO;2; St Laurent LC, 2001, J PHYS OCEANOGR, V31, P3476, DOI 10.1175/1520-0485(2001)031<3476:BFBTAR>2.0.CO;2; Webb DJ, 2001, NATURE, V409, P37, DOI 10.1038/35051171; WAVES OCEANOGRAPHY S	15	145	158	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1858	1859						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512611				2022-12-28	WOS:000185536700033
J	Fecko, CJ; Eaves, JD; Loparo, JJ; Tokmakoff, A; Geissler, PL				Fecko, CJ; Eaves, JD; Loparo, JJ; Tokmakoff, A; Geissler, PL			Ultrafast hydrogen-bond dynamics in the infrared spectroscopy of water	SCIENCE			English	Article							SOLVATION DYNAMICS; LIQUID WATER; PHOTON-ECHO; TIME; SHIFT; 3RD-ORDER	We investigated rearrangements of the hydrogen-bond network in water by measuring fluctuations in the OH-stretching frequency of HOD in liquid D2O with femtosecond infrared spectroscopy. Using simulations of an atomistic model of water, we relate these frequency fluctuations to intermolecular dynamics. The model reveals that OH frequency shifts arise from changes in the molecular electric field that acts on the proton. At short times, vibrational dephasing reflects an underdamped oscillation of the hydrogen bond with a period of 170 femtoseconds. At longer times, vibrational correlations decay on a 1.2-picosecond time scale because of collective structural reorganizations.	MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, George R Harrison Spect Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Tokmakoff, A (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	tokmakof@mit.edu		EAVES, JOEL/0000-0002-9371-1703				BAGCHI B, 1984, CHEM PHYS, V86, P257, DOI 10.1016/0301-0104(84)80014-2; Bakker HJ, 2002, J CHEM PHYS, V116, P2592, DOI 10.1063/1.1432687; BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038; CASTNER EW, 1995, J CHEM PHYS, V102, P653, DOI 10.1063/1.469177; CHO M, 1994, J CHEM PHYS, V100, P6672, DOI 10.1063/1.467027; Cho MH, 1996, J PHYS CHEM-US, V100, P11944, DOI 10.1021/jp9601983; de Boeij WP, 1998, ANNU REV PHYS CHEM, V49, P99, DOI 10.1146/annurev.physchem.49.1.99; Errington JR, 2001, NATURE, V409, P318, DOI 10.1038/35053024; Gale GM, 1999, PHYS REV LETT, V82, P1068, DOI 10.1103/PhysRevLett.82.1068; Georgievskii Y, 2001, J PHYS CHEM A, V105, P2281, DOI 10.1021/jp0036700; JARZEBA W, 1988, J PHYS CHEM-US, V92, P7039, DOI 10.1021/j100336a002; JIMENEZ R, 1994, NATURE, V369, P471, DOI 10.1038/369471a0; Joo TH, 1996, J CHEM PHYS, V104, P6089, DOI 10.1063/1.471276; LAENEN R, 2002, J PHYS CHEM B, V106; Lang MJ, 1999, J CHEM PHYS, V110, P5884, DOI 10.1063/1.478488; Lawrence CP, 2003, J CHEM PHYS, V118, P264, DOI 10.1063/1.1525802; OHMINE I, 1993, CHEM REV, V93, P2545, DOI 10.1021/cr00023a011; Ohta K, 2001, J CHEM PHYS, V114, P8020, DOI 10.1063/1.1359241; Oxtoby D. W., 1979, ADV CHEM PHYS, V40, P1; PIRYATINSKI A, 2003, J CHEM PHYS, V118; REIMERS JR, 1984, MOL PHYS, V52, P357, DOI 10.1080/00268978400101271; Rey R, 2002, J PHYS CHEM A, V106, P11993, DOI 10.1021/jp026419o; Song XY, 1996, J PHYS CHEM-US, V100, P11954, DOI 10.1021/jp960887e; Stenger J, 2002, J PHYS CHEM A, V106, P2341, DOI 10.1021/jp013104k; Stenger J, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.027401; STILLINGER FH, 1975, ADV CHEM PHYS, V31, P1; Sung JY, 2001, J CHEM PHYS, V115, P9266, DOI 10.1063/1.1413979; Woutersen S, 1999, PHYS REV LETT, V83, P2077, DOI 10.1103/PhysRevLett.83.2077; Yeremenko S, 2003, CHEM PHYS LETT, V369, P107, DOI 10.1016/S0009-2614(02)02001-8	29	822	833	14	319	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1698	1702		10.1126/science.1087251	http://dx.doi.org/10.1126/science.1087251			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500975				2022-12-28	WOS:000185387700037
J	Marrucci, G				Marrucci, G			Polymers go with the flow	SCIENCE			English	Editorial Material							DYNAMICS; SYSTEMS		Univ Naples, Dept Chem Engn, I-80125 Naples, Italy	University of Naples Federico II	Marrucci, G (corresponding author), Univ Naples, Dept Chem Engn, I-80125 Naples, Italy.	marrucci@cds.unina.it						Bent J, 2003, SCIENCE, V301, P1691, DOI 10.1126/science.1086952; DOI M, 1978, J CHEM SOC FARAD T 2, V74, P1789, DOI 10.1039/f29787401789; DOI M, 1979, J CHEM SOC FARAD T 2, V75, P38, DOI 10.1039/f29797500038; Doi M., 1988, THEORY POLYM DYNAMIC; EDWARDS SF, 1967, P PHYS SOC LOND, V92, P9, DOI 10.1088/0370-1328/92/1/303; Likhtman AE, 2000, PHYS REV LETT, V85, P4550, DOI 10.1103/PhysRevLett.85.4550; Marrucci G, 1996, J NON-NEWTON FLUID, V62, P279, DOI 10.1016/0377-0257(95)01407-1; Mead DW, 1998, MACROMOLECULES, V31, P7895, DOI 10.1021/ma980127x; ROUSE PE, 1953, J CHEM PHYS, V21, P1272, DOI 10.1063/1.1699180; Tanner R.I., 1998, RHEOLOGY HIST PERSPE; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462; [No title captured]	12	8	8	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1681	1682		10.1126/science.1088553	http://dx.doi.org/10.1126/science.1088553			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500970				2022-12-28	WOS:000185387700031
J	Beckerman, KP				Beckerman, KP			Long-term findings of HIVNET 012: the next steps	LANCET			English	Editorial Material							MOTHER-TO-CHILD; CONTROLLED TRIAL; HIV-1; TRANSMISSION; NEVIRAPINE; ZIDOVUDINE; RESISTANCE; COMBINATION; LAMIVUDINE; PREVENTION		NYU, Bellevue Hosp Ctr, Sch Med, New York, NY 10016 USA	Bellevue Hospital Center; New York University	Beckerman, KP (corresponding author), NYU, Bellevue Hosp Ctr, Sch Med, New York, NY 10016 USA.							Antinori A, 2002, AIDS RES HUM RETROV, V18, P835, DOI 10.1089/08892220260190308; BECKER E, 2003, NY TIMES        0831; Bloland P, 1996, AM J TROP MED HYG, V55, P82, DOI 10.4269/ajtmh.1996.55.82; *CDCP, 2003, PUBL HLTH SERV TASK; *COL U MAILM SCH P, MTCT PLUS EXPANDING; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196; KANTOR R, 2003, 2 IAS C HIV PATH TRE; Mandelbrot L, 2001, JAMA-J AM MED ASSOC, V285, P2083, DOI 10.1001/jama.285.16.2083; MCNEIL DG, 2003, NY TIMES        0903; Nakiyingi JS, 2003, AIDS, V17, P1827, DOI 10.1097/00002030-200308150-00012; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Saba J, 2002, LANCET, V359, P1178; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7	16	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					842	843		10.1016/S0140-6736(03)14345-0	http://dx.doi.org/10.1016/S0140-6736(03)14345-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678965				2022-12-28	WOS:000185329400002
J	Shennan, AH				Shennan, AH			Recent developments in obstetrics	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SPONTANEOUS PRETERM BIRTH; BACTERIAL VAGINOSIS; UTERINE RUPTURE; CERVICAL LENGTH; INCREASED RISK; VAGINAL BIRTH; WOMEN; DELIVERY; PREECLAMPSIA; PREVENTION		St Thomas Hosp, Guys Kings & St Thomass Sch Med, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Shennan, AH (corresponding author), St Thomas Hosp, Guys Kings & St Thomass Sch Med, London SE1 7EH, England.			Shennan, Andrew/0000-0001-5273-3132				Althuisius SM, 2000, AM J OBSTET GYNECOL, V183, P823, DOI 10.1067/mob.2000.108874; Carey JC, 2000, NEW ENGL J MED, V342, P534, DOI 10.1056/NEJM200002243420802; Chappell LC, 1999, LANCET, V354, P810, DOI 10.1016/S0140-6736(99)80010-5; Coleman MAG, 2000, ULTRASOUND OBST GYN, V15, P7, DOI 10.1046/j.1469-0705.2000.00014.x; *CONF ENQ MAT DEAT, 2001, WHY MOTH DIE REP 199; Coomarasamy A, 2001, OBSTET GYNECOL, V98, P861, DOI 10.1016/S0029-7844(01)01569-1; da Fonseca EB, 2003, AM J OBSTET GYNECOL, V188, P419, DOI 10.1067/mob.2003.41; Davis G, 2000, AM J OBSTET GYNECOL, V183, P836, DOI 10.1067/mob.2000.108837; DULEY L, 1995, LANCET, V345, P1455; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; Duley L, 2001, BMJ-BRIT MED J, V322, P329, DOI 10.1136/bmj.322.7282.329; Esposito MA, 2000, AM J OBSTET GYNECOL, V183, P1180, DOI 10.1067/mob.2000.109046; Guzman ER, 2000, AM J OBSTET GYNECOL, V183, P1108, DOI 10.1067/mob.2000.108875; Hannah ME, 2000, LANCET, V356, P1375, DOI 10.1016/S0140-6736(00)02840-3; Hassan SS, 2000, AM J OBSTET GYNECOL, V182, P1458, DOI 10.1067/mob.2000.106851; Heath VCF, 2000, BRIT J OBSTET GYNAEC, V107, P1276, DOI 10.1111/j.1471-0528.2000.tb11620.x; Hofmeyr GJ, 2002, COCHRANE DB SYST REV; HOFMEYR GJ, 2002, DATABASE SYST REV; Howell C.J, 2000, COCHRANE DB SYST REV; Impey L, 1998, OBSTET GYNECOL, V92, P799, DOI 10.1016/S0029-7844(98)00279-8; Kenyon SL, 2001, LANCET, V357, P979, DOI 10.1016/S0140-6736(00)04233-1; Knight M., 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000492; Lydon-Rochelle M, 2001, NEW ENGL J MED, V345, P3, DOI 10.1056/NEJM200107053450101; MacArthur C, 2001, LANCET, V358, P19; Meis PJ, 2003, NEW ENGL J MED, V348, P2379, DOI 10.1056/NEJMoa035140; Mires GJ, 1998, AM J OBSTET GYNECOL, V179, P1317, DOI 10.1016/S0002-9378(98)70154-1; Odendaal HJ, 2002, SAMJ S AFR MED J, V92, P231; Olsen SF, 2000, BRIT J OBSTET GYNAEC, V107, P382, DOI 10.1111/j.1471-0528.2000.tb13235.x; Shah NR, 2000, AM J OBSTET GYNECOL, V182, P465, DOI 10.1016/S0002-9378(00)70240-7; Shennan A, 2001, BRIT MED J, V323, P244, DOI 10.1136/bmj.323.7307.244; Sims EJ, 2001, AM J OBSTET GYNECOL, V184, P1122, DOI 10.1067/mob.2001.115278; Ugwumadu A, 2003, LANCET, V361, P983, DOI 10.1016/S0140-6736(03)12823-1; Worldwide Atosiban versus Beta-agonists Study Group, 2001, BJOG, V108, P133; Zelop CM, 2000, AM J OBSTET GYNECOL, V183, P1184, DOI 10.1067/mob.2000.109048; [No title captured]	35	16	18	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	2003	327	7415					604	608		10.1136/bmj.327.7415.604	http://dx.doi.org/10.1136/bmj.327.7415.604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969931	Green Published			2022-12-28	WOS:000185358700027
J	Sollima, S; Corbellino, M; Castelnuovo, B; Tosoni, A; Antinori, S				Sollima, S; Corbellino, M; Castelnuovo, B; Tosoni, A; Antinori, S			Red herrings	LANCET			English	Editorial Material							HIV-INFECTION; TUBERCULOSIS		Univ Milan, Inst Infect & Trop Dis, I-20157 Milan, Italy; L Sacco Hosp Vialba, Pathol Unit, I-20157 Milan, Italy	University of Milan; University of Milan; Luigi Sacco Hospital	Sollima, S (corresponding author), Univ Milan, Inst Infect & Trop Dis, I-20157 Milan, Italy.		Antinori, Spinello/E-7936-2017	Antinori, Spinello/0000-0003-0569-9407				ABOS J, 1991, AIDS, V5, P461, DOI 10.1097/00002030-199104000-00021; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; GALLANT JE, 1992, AIDS, V6, P889, DOI 10.1097/00002030-199208000-00025; SIMPSON DM, 1994, ANN INTERN MED, V121, P769, DOI 10.7326/0003-4819-121-10-199411150-00008; WHITEMAN M, 1995, AM J NEURORADIOL, V16, P1319	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					876	876		10.1016/S0140-6736(03)14343-7	http://dx.doi.org/10.1016/S0140-6736(03)14343-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678975				2022-12-28	WOS:000185329400012
J	McMurray, JJV; Ostergren, J; Swedberg, K; Granger, CB; Held, P; Michelson, EL; Olofsson, B; Yusuf, S; Pfeffer, MA				McMurray, JJV; Ostergren, J; Swedberg, K; Granger, CB; Held, P; Michelson, EL; Olofsson, B; Yusuf, S; Pfeffer, MA		CHARM Investigators Comm	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial	LANCET			English	Article							RECEPTOR BLOCKER; FORMING PATHWAYS; ACE-INHIBITORS; GUIDELINES; THERAPY; MANAGEMENT; ENALAPRIL	Background Angiotensin II type 1 receptor blockers have favourable effects on haemodynamic measurements, neurohumoral activity, and left-ventricular remodelling when added to angiotensin-converting-enzyme (ACE) inhibitors in patients with chronic heart failure (CHF). We aimed to find out Whether these drugs improve clinical outcome. Methods Between March, 1999, and November, 1999, we enrolled 2548 patients with New York Heart Association functional class II-IV CHF and left-ventricular ejection fraction 40% or lower, and who were being treated with ACE inhibitors. We randomly assigned patients candesartan (n=1276, target dose 32 mg once daily) or placebo (n=1272). At baseline, 55% of patients were also treated with P blockers and 17% with spironolactone. The primary outcome of the study was the composite of cardiovascular death or hospital admission for CHF. Analysis was done by intention to treat. Findings The median follow-up was 41 months. 483 (38%) patients in the candesartan group and 538 (42%) in the placebo group experienced the primary outcome (unadjusted hazard ratio 0.85 [95% CI 0.75-0.96], p=0.011; covariate adjusted p=0.010). Candesartan reduced each of the components of the primary outcome significantly, as well as the total number of hospital admissions for CHF. The benefits of candesartan were similar in all predefined subgroups, including patients receiving baseline beta blocker treatment. Interpretation The addition of candesartan to ACE inhibitor and other treatment leads to a further clinically important reduction in relevant cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction.	Univ Glasgow, Glasgow, Lanark, Scotland; Karolinska Hosp, S-10401 Stockholm, Sweden; Sahlgrenska Univ Hosp Ostra, Gothenburg, Sweden; Duke Univ, Med Ctr, Durham, NC USA; AstraZeneca, R&D Molndal, Molndal, Sweden; AstraZeneca LP, Wilmington, DE USA; Hamilton Hlth Sci, Hamilton, ON, Canada; McMaster Univ, Hamilton, ON, Canada; Brigham & Womens Hosp, Boston, MA 02115 USA	University of Glasgow; Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital; Duke University; AstraZeneca; AstraZeneca; McMaster University; McMaster University; Harvard University; Brigham & Women's Hospital	McMurray, JJV (corresponding author), Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland.		mcmurray, John/B-2467-2013; Swedberg, Karl/B-2475-2008; Granger, Christopher B/D-3458-2014	mcmurray, John/0000-0002-6317-3975; Granger, Christopher B/0000-0002-0045-3291; Yusuf, Salim/0000-0003-4776-5601				Baruch L, 1999, CIRCULATION, V99, P2658, DOI 10.1161/01.CIR.99.20.2658; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Hamroff G, 1999, CIRCULATION, V99, P990, DOI 10.1161/01.CIR.99.8.990; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Jorde UP, 2000, CIRCULATION, V101, P844, DOI 10.1161/01.CIR.101.8.844; McDonald JE, 2001, CIRCULATION, V104, P1805, DOI 10.1161/hc4001.097220; MCKELVIE R, IN PRESS EUR HEART J; McKelvie RS, 1999, CIRCULATION, V100, P1056, DOI 10.1161/01.CIR.100.10.1056; McMurray J, 2003, EUR J HEART FAIL, V5, P261, DOI 10.1016/S1388-9842(03)00052-7; McMurray J, 2001, EUR J HEART FAIL, V3, P495, DOI 10.1016/S1388-9842(01)00173-8; Mehra MR, 2003, J AM COLL CARDIOL, V41, P1606, DOI 10.1016/S0735-1097(03)00245-6; Petrie MC, 2001, J AM COLL CARDIOL, V37, P1056, DOI 10.1016/S0735-1097(01)01111-1; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; Remme WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/euhj.2001.2783; Stewart S, 2002, EUR J HEART FAIL, V4, P361, DOI 10.1016/S1388-9842(01)00198-2; Stewart S, 2001, EUR HEART J, V22, P209, DOI 10.1053/euhj.2000.2291; Swedberg K, 1999, J Card Fail, V5, P276, DOI 10.1016/S1071-9164(99)90013-1; URATA H, 1990, CIRC RES, V66, P883, DOI 10.1161/01.RES.66.4.883; Witherow FN, 2002, J AM COLL CARDIOL, V40, P961, DOI 10.1016/S0735-1097(02)02061-2; Witherow FN, 2001, CIRCULATION, V104, P2177, DOI 10.1161/hc4301.098252; Wolny A, 1997, CIRC RES, V80, P219, DOI 10.1161/01.RES.80.2.219; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	22	1334	1406	1	33	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					767	771		10.1016/S0140-6736(03)14283-3	http://dx.doi.org/10.1016/S0140-6736(03)14283-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678869				2022-12-28	WOS:000185188500008
J	Zhou, Q; Renard, JP; Le Friec, G; Brochard, V; Beaujean, N; Cherifi, Y; Fraichard, A; Cozzi, J				Zhou, Q; Renard, JP; Le Friec, G; Brochard, V; Beaujean, N; Cherifi, Y; Fraichard, A; Cozzi, J			Generation of fertile cloned rats by regulating oocyte activation	SCIENCE			English	Article									INRA, Dev Biol & Reprod Unit, Jouy En Josas, France; Chinese Acad Sci, Inst Zool, Beijing, Peoples R China; GenOway, Lyon, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Chinese Academy of Sciences; Institute of Zoology, CAS	Renard, JP (corresponding author), INRA, Dev Biol & Reprod Unit, Jouy En Josas, France.		Beaujean, Nathalie/C-9883-2011	Beaujean, Nathalie/0000-0003-0188-9190				Hirabayashi M, 2003, CLONING STEM CELLS, V5, P35, DOI 10.1089/153623003321512148; Jabob H. J., 2002, NATURE REV GENET, V3, P33; Josefsberg LBY, 2000, BIOL REPROD, V62, P1270, DOI 10.1095/biolreprod62.5.1270; Zan YH, 2003, NAT BIOTECHNOL, V21, P645, DOI 10.1038/nbt830; ZERNICKAGOETZ M, 1991, MOL REPROD DEV, V28, P169, DOI 10.1002/mrd.1080280210	5	300	378	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1179	1179		10.1126/science.1088313	http://dx.doi.org/10.1126/science.1088313			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14512506	Green Submitted			2022-12-28	WOS:000186544300044
J	Ansley, SJ; Badano, JL; Blacque, OE; Hill, J; Hoskins, BE; Leitch, CC; Kim, JC; Ross, AJ; Eichers, ER; Teslovich, TM; Mah, AK; Johnsen, RC; Cavender, JC; Lewis, RA; Leroux, MR; Beales, PL; Katsanis, N				Ansley, SJ; Badano, JL; Blacque, OE; Hill, J; Hoskins, BE; Leitch, CC; Kim, JC; Ross, AJ; Eichers, ER; Teslovich, TM; Mah, AK; Johnsen, RC; Cavender, JC; Lewis, RA; Leroux, MR; Beales, PL; Katsanis, N			Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome	NATURE			English	Article							HUMAN OBESITY SYNDROME; C-ELEGANS; INTRAFLAGELLAR TRANSPORT; TRIALLELIC INHERITANCE; KIDNEY-DISEASE; PROTEIN; CILIA; GENE; IDENTIFICATION; MUTATIONS	Bardet-Biedl syndrome (BBS) is a genetically heterogeneous disorder characterized primarily by retinal dystrophy, obesity, polydactyly, renal malformations and learning disabilities. Although five BBS genes have been cloned(1-6), the molecular basis of this syndrome remains elusive. Here we show that BBS is probably caused by a defect at the basal body of ciliated cells. We have cloned a new BBS gene, BBS8, which encodes a protein with a prokaryotic domain, pilF, involved in pilus formation and twitching mobility. In one family, a homozygous null BBS8 mutation leads to BBS with randomization of left-right body axis symmetry, a known defect of the nodal cilium. We have also found that BBS8 localizes specifically to ciliated structures, such as the connecting cilium of the retina and columnar epithelial cells in the lung. In cells, BBS8 localizes to centrosomes and basal bodies and interacts with PCM1, a protein probably involved in ciliogenesis. Finally, we demonstrate that all available Caenorhabditis elegans BBS homologues are expressed exclusively in ciliated neurons, and contain regulatory elements for RFX, a transcription factor that modulates the expression of genes associated with ciliogenesis and intraflagellar transport.	Johns Hopkins Univ, Inst Med Genet, Baltimore, MD 21287 USA; Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; UCL, Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; King Khalid Eye Specialist Hosp, Riyadh 11462, Saudi Arabia	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Simon Fraser University; University of London; University College London; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; King Khaled Eye Specialist Hospital	Katsanis, N (corresponding author), Johns Hopkins Univ, Inst Med Genet, Baltimore, MD 21287 USA.	katsanis@jhmi.edu	Katsanis, Nicholas/E-1837-2012; Beales, Philip L/C-7367-2009; Blacque, Oliver/AAL-8860-2021	Blacque, Oliver/0000-0003-1598-2695; Katsanis, Nicholas/0000-0002-2480-0171; Badano, Jose/0000-0002-0706-8652				Badano JL, 2002, NAT REV GENET, V3, P779, DOI 10.1038/nrg910; Badano JL, 2003, AM J HUM GENET, V72, P650, DOI 10.1086/368204; Beales PL, 1999, J MED GENET, V36, P437; Beales PL, 2003, AM J HUM GENET, V72, P1187, DOI 10.1086/375178; BRENNER S, 1974, GENETICS, V77, P71; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Fujiwara M, 1999, DEVELOPMENT, V126, P4839; Haycraft CJ, 2001, DEVELOPMENT, V128, P1493; Hobert O, 2002, BIOTECHNIQUES, V32, P728, DOI 10.2144/02324bm01; Hou XY, 2002, J CLIN INVEST, V109, P533, DOI 10.1172/JC1200214099; Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525; Katsanis N, 2002, AM J HUM GENET, V71, P22, DOI 10.1086/341031; Katsanis N, 2000, NAT GENET, V26, P67, DOI 10.1038/79201; Kubo A, 1999, J CELL BIOL, V147, P969, DOI 10.1083/jcb.147.5.969; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; MAURER L, 1987, J BACTERIOL, V169, P640, DOI 10.1128/jb.169.2.640-645.1987; Merz AJ, 2000, NATURE, V407, P98, DOI 10.1038/35024105; Morgan D, 2002, HUM MOL GENET, V11, P3345, DOI 10.1093/hmg/11.26.3345; Mykytyn K, 2002, NAT GENET, V31, P435, DOI 10.1038/ng935; Mykytyn K, 2001, NAT GENET, V28, P188, DOI 10.1038/88925; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nishimura DY, 2001, HUM MOL GENET, V10, P865, DOI 10.1093/hmg/10.8.865; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; Pazour GJ, 2002, J CELL BIOL, V157, P103, DOI 10.1083/jcb.200107108; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Slavotinek AM, 2000, NAT GENET, V26, P15, DOI 10.1038/79116; Swoboda P, 2000, MOL CELL, V5, P411, DOI 10.1016/S1097-2765(00)80436-0; Watanabe D, 2003, DEVELOPMENT, V130, P1725, DOI 10.1242/dev.00407	29	496	527	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					628	633		10.1038/nature02030	http://dx.doi.org/10.1038/nature02030			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14520415				2022-12-28	WOS:000185801000040
J	Beck, RD; Maroni, P; Papageorgopoulos, DC; Dang, TT; Schmid, MP; Rizzo, TR				Beck, RD; Maroni, P; Papageorgopoulos, DC; Dang, TT; Schmid, MP; Rizzo, TR			Vibrational mode-specific reaction of methane on a nickel surface	SCIENCE			English	Article							DISSOCIATIVE CHEMISORPTION; CH4 DISSOCIATION; EXCITED METHANE; ACTIVATION; 2-NU(3); DESIGN; NI	The dissociation of methane on a nickel catalyst is a key step in steam reforming of natural gas for hydrogen production. Despite substantial effort in both experiment and theory, there is still no atomic-scale description of this important gas-surface reaction. We report quantum state-resolved studies, using pulsed laser and molecular beam techniques, of vibrationally excited methane reacting on the nickel (100) surface. For doubly deuterated methane (CD2H2), we observed that the reaction probability with two quanta of excitation in one C-H bond was greater (by as much as a factor of 5) than with one quantum in each of two C-H bonds. These results clearly exclude the possibility of statistical models correctly describing the mechanism of this process and attest to the importance of full-dimensional calculations of the reaction dynamics.	Ecole Polytech Fed Lausanne, Lab Chim Phys Mol, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Beck, RD (corresponding author), Ecole Polytech Fed Lausanne, Lab Chim Phys Mol, CH-1015 Lausanne, Switzerland.	rainer.beck@epfl.ch	Dang, Tung Thanh/B-8479-2012; Beck, Rainer D/A-4422-2012; Rizzo, Thomas R/D-1554-2011	Beck, Rainer D/0000-0002-8152-8290; Rizzo, Thomas R/0000-0003-2796-905X				Besenbacher F, 1998, SCIENCE, V279, P1913, DOI 10.1126/science.279.5358.1913; Bukoski A, 2003, J CHEM PHYS, V118, P9762, DOI 10.1063/1.1570393; Busch K. W., 1999, ACS S SERIES, V720; Carre MN, 1998, J CHEM PHYS, V108, P3722, DOI 10.1063/1.475766; CHILD MS, 1984, ADV CHEM PHYS, V57, P1, DOI 10.1002/9780470142813.ch1; Duncan JL, 1997, SPECTROCHIM ACTA A, V53, P1445, DOI 10.1016/S1386-1425(97)01815-5; Halonen L, 2001, J CHEM PHYS, V115, P5611, DOI 10.1063/1.1398075; Higgins J, 2001, J CHEM PHYS, V114, P5277, DOI 10.1063/1.1349895; HOLMBLAD PM, 1995, J CHEM PHYS, V102, P8255, DOI 10.1063/1.468955; Juurlink LBF, 1999, PHYS REV LETT, V83, P868, DOI 10.1103/PhysRevLett.83.868; Kim ZH, 2001, J AM CHEM SOC, V123, P12714, DOI 10.1021/ja017180c; Kroes GJ, 2002, ACCOUNTS CHEM RES, V35, P193, DOI 10.1021/ar010104u; Larsen JH, 1999, SURF SCI REP, V35, P165; LEE MB, 1987, J CHEM PHYS, V87, P2724, DOI 10.1063/1.453060; LUNTZ AC, 1995, J CHEM PHYS, V102, P8264, DOI 10.1063/1.468956; Maxwell IE, 1996, STUD SURF SCI CATAL, V101, P1; Milot R, 2000, PHYS REV B, V61, P15657, DOI 10.1103/PhysRevB.61.15657; Mortensen H, 2002, J CHEM PHYS, V116, P5781, DOI 10.1063/1.1456509; RETTNER CT, 1985, PHYS REV LETT, V54, P2716, DOI 10.1103/PhysRevLett.54.2716; Schmid MP, 2003, REV SCI INSTRUM, V74, P4110, DOI 10.1063/1.1599064; Schmid MP, 2002, J CHEM PHYS, V117, P8603, DOI 10.1063/1.1519860; Spath P.L., 2001, TECHNICAL REPORT, DOI 10.2172/764485; UKRAINTSEV VA, 1994, J CHEM PHYS, V101, P1564, DOI 10.1063/1.468476; Watanabe K, 1996, J CHEM PHYS, V104, P5974, DOI 10.1063/1.471329; Xiang Y, 2003, J CHEM PHYS, V118, P8954, DOI 10.1063/1.1567716; YANG H, 1992, J CHEM PHYS, V96, P5529, DOI 10.1063/1.462690; Yoon S, 2002, J CHEM PHYS, V116, P10744, DOI 10.1063/1.1476318	27	213	213	2	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					98	100		10.1126/science.1088996	http://dx.doi.org/10.1126/science.1088996			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526078				2022-12-28	WOS:000185678500043
J	Mechoulam, R; Lichtman, AH				Mechoulam, R; Lichtman, AH			Stout guards of the central nervous system	SCIENCE			English	Editorial Material							ANANDAMIDE; BRAIN; NEUROPROTECTION; CANNABINOIDS; PROTECTS; INJURY		Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol Toxicol, Richmond, VA 23298 USA	Hebrew University of Jerusalem; Virginia Commonwealth University	Mechoulam, R (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel.	mechou@cc.huji.ac.il; alichtma@hsc.vcu.edu						Clement AB, 2003, J NEUROSCI, V23, P3916; Grundy RI, 2002, EXPERT OPIN INV DRUG, V11, P1365, DOI 10.1517/13543784.11.10.1365; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HH, 2002, J NEUROCHEM, V82, P154, DOI 10.1046/j.1471-4159.2002.00961.x; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; KARLER R, 1981, J CLIN PHARMACOL, V21, P437; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Mechoulam R, 1986, CANNABINOIDS THERAPE, P1; Nagayama T, 1999, J NEUROSCI, V19, P2987; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001	12	55	58	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					65	+		10.1126/science.1091256	http://dx.doi.org/10.1126/science.1091256			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526067				2022-12-28	WOS:000185678500031
J	Aalto, R; Maurice-Bourgoin, L; Dunne, T; Montgomery, DR; Nittrouer, CA; Guyot, JL				Aalto, R; Maurice-Bourgoin, L; Dunne, T; Montgomery, DR; Nittrouer, CA; Guyot, JL			Episodic sediment accumulation on Amazonian flood plains influenced by El Nino/Southern Oscillation	NATURE			English	Article							RIVER SEDIMENT; CENTRAL ANDES; FLOODPLAINS; PATTERNS; PB-210; BASIN; AVULSION; INSIGHTS; CLIMATE; RATES	Continental-scale rivers with a sandy bed sequester a significant proportion of their sediment load in flood plains. The spatial extent and depths of such deposits have been described(1,2), and flood-plain accumulation has been determined at decadal time-scales(3-5), but it has not been possible to identify discrete events or to resolve deposition on near-annual timescales. Here we analyse Pb-210 activity profiles from sediment cores taken in the pristine Beni and Mamore river basins, which together comprise 720,000 km(2) of the Amazon basin, to investigate sediment accumulation patterns in the Andean-Amazonian foreland. We find that in most locations, sediment stratigraphy is dominated by discrete packages of sediments of uniform age, which are typically 20-80 cm thick, with system-wide recurrence intervals of about 8 yr, indicating relatively rare episodic deposition events. Ocean temperature and stream flow records link these episodic events to rapidly rising floods associated with La Nina events, which debouch extraordinary volumes of sediments from the Andes. We conclude that transient processes driven by the El Nino/Southern Oscillation cycle control the formation of the Bolivian flood plains and modulate downstream delivery of sediments as well as associated carbon, nutrients and pollutants to the Amazon main stem.	Univ Washington, Quaternary Res Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; Inst Rech Dev, UMR Lab Mecan Transfert Geol, BR-71619970 Brasilia, DF, Brazil; Univ Calif Santa Barbara, Dept Geol Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Donald Bren Sch Environm Sci & Management, Santa Barbara, CA 93106 USA; Univ Toulouse 3, IRD, CNRS, UMR LMTG, F-31400 Toulouse, France	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Institut de Recherche pour le Developpement (IRD); University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD)	Aalto, R (corresponding author), Univ Washington, Quaternary Res Ctr, Seattle, WA 98195 USA.		Dunne, Thomas/B-6374-2014; Maurice, Laurence/H-5763-2015; Guyot, Jean Loup/A-4193-2010; Maurice, Laurence/T-2636-2019	Dunne, Thomas/0000-0002-5281-6517; Guyot, Jean Loup/0000-0001-6298-7806; Maurice, Laurence/0000-0003-3482-3892				AALTO R, IN PRESS J GEOL; AALTO R, UNPUB GEOL SOC AM B; AALTO R, 2002, THESIS U WASHINGTON, P365; AALTO R, UNPUB SEDIMENT GEOL; ACEITUNO P, 1988, MON WEATHER REV, V116, P505, DOI 10.1175/1520-0493(1988)116<0505:OTFOTS>2.0.CO;2; Allison MA, 1998, GEOLOGY, V26, P175, DOI 10.1130/0091-7613(1998)026<0175:IOFPSF>2.3.CO;2; Aslan A, 1999, J SEDIMENT RES, V69, P800, DOI 10.2110/jsr.69.800; Baby P, 1997, GEOLOGY, V25, P883, DOI 10.1130/0091-7613(1997)025<0883:NSCTCT>2.3.CO;2; Coelho CAS, 2002, THEOR APPL CLIMATOL, V71, P185, DOI 10.1007/s007040200004; Dunne T, 1998, GEOL SOC AM BULL, V110, P450, DOI 10.1130/0016-7606(1998)110<0450:EOSBTF>2.3.CO;2; Goodbred SL, 1998, SEDIMENT GEOL, V121, P239, DOI 10.1016/S0037-0738(98)00082-7; Guyot JL, 1999, J S AM EARTH SCI, V12, P401, DOI 10.1016/S0895-9811(99)00030-9; GUYOT JL, 1993, COLLECTION ETUDES TH; He Q, 1996, EARTH SURF PROCESSES, V21, P141, DOI 10.1002/(SICI)1096-9837(199602)21:2&lt;141::AID-ESP572&gt;3.0.CO;2-9; Horton BK, 2001, GEOL SOC AM BULL, V113, P1387, DOI 10.1130/0016-7606(2001)113<1387:PSSITA>2.0.CO;2; Horton BK, 1997, GEOLOGY, V25, P895, DOI 10.1130/0091-7613(1997)025<0895:TMFBSA>2.3.CO;2; HOWARD AD, 1992, LOWLAND FLOODPLAIN R; JAMES CS, 1985, J HYDRAUL RES, V23, P435, DOI 10.1080/00221688509499337; KESEL RH, 1992, EARTH SURF PROCESSES, V17, P711, DOI 10.1002/esp.3290170707; MAURICEBOURGOIN L, 2003, EOS AGI T SPRING; MERTES LAK, 1994, GEOLOGY, V22, P171, DOI 10.1130/0091-7613(1994)022<0171:ROFPSO>2.3.CO;2; Mertes LAK, 1997, WATER RESOUR RES, V33, P1749, DOI 10.1029/97WR00658; Meyers SD, 1999, MON WEATHER REV, V127, P1599, DOI 10.1175/1520-0493(1999)127<1599:ROMSIT>2.0.CO;2; Nicholas AP, 1997, GEOMORPHOLOGY, V19, P133, DOI 10.1016/S0169-555X(96)00043-8; Nie YH, 2001, LIMNOL OCEANOGR, V46, P1425, DOI 10.4319/lo.2001.46.6.1425; PIZZUTO JE, 1987, SEDIMENTOLOGY, V34, P301, DOI 10.1111/j.1365-3091.1987.tb00779.x; Richey JE, 2002, NATURE, V416, P617, DOI 10.1038/416617a; Ronchail J, 1998, B I FRANCAIS ETUDES, V27, P687; Slingerland R, 1998, GEOLOGY, V26, P435, DOI 10.1130/0091-7613(1998)026<0435:NCFAMR>2.3.CO;2; SMITH ND, 1989, SEDIMENTOLOGY, V36, P1, DOI 10.1111/j.1365-3091.1989.tb00817.x	30	230	231	4	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					493	497		10.1038/nature02002	http://dx.doi.org/10.1038/nature02002			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523442				2022-12-28	WOS:000185648100040
J	Friedrich, R; Panizzi, P; Fuentes-Prior, P; Richter, K; Verhamme, I; Anderson, PJ; Kawabata, SI; Huber, R; Bode, W; Bock, PE				Friedrich, R; Panizzi, P; Fuentes-Prior, P; Richter, K; Verhamme, I; Anderson, PJ; Kawabata, SI; Huber, R; Bode, W; Bock, PE			Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation	NATURE			English	Article							BINDING-PROTEIN; STREPTOCOCCUS-AGALACTIAE; STAPHYLOCOCCUS-AUREUS; CRYSTAL-STRUCTURE; GENOME SEQUENCE; THROMBIN; STREPTOKINASE; PROTHROMBIN; PLASMINOGEN; FIBRONECTIN	Many bacterial pathogens secrete proteins that activate host trypsinogen-like enzyme precursors, most notably the proenzymes of the blood coagulation and fibrinolysis systems(1,2). Staphylococcus aureus, an important human pathogen implicated in sepsis and endocarditis(3), secretes the cofactor staphylocoagulase, which activates prothrombin, without the usual proteolytic cleavages, to directly initiate blood clotting(4,5). Here we present the 2.2 Angstrom crystal structures of human alpha-thrombin and prethrombin-2 bound to a fully active staphylocoagulase variant. The cofactor consists of two domains, each with three-helix bundles; this is a novel fold that is distinct from known serine proteinase activators, particularly the streptococcal plasminogen activator streptokinase(6). The staphylocoagulase fold is conserved in other bacterial plasma-protein-binding factors and extracellular-matrix-binding factors(7-9). Kinetic studies confirm the importance of isoleucine 1 and valine 2 at the amino terminus of staphylocoagulase for zymogen activation. In addition to making contacts with the 148 loop and (pro)exosite I of pre-thrombin-2, staphylocoagulase inserts its N-terminal peptide into the activation pocket of bound prethrombin-2, allosterically inducing functional catalytic machinery. These investigations demonstrate unambiguously the validity of the zymogen-activation mechanism known as 'molecular sexuality'(10).	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Tech Univ Munich, Lehrstuhl Biotechnol, D-85747 Garching, Germany; Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan	Max Planck Society; Vanderbilt University; Technical University of Munich; Kyushu University	Bode, W (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany.		Richter, Klaus/A-2673-2010; Panizzi, Peter/A-6072-2019	Richter, Klaus/0000-0002-8952-9642; Panizzi, Peter/0000-0003-0141-8807; Fuentes-Prior, Pablo/0000-0002-6618-3204	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL094533] Funding Source: NIH RePORTER; NHLBI NIH HHS [R00 HL094533] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Bjerketorp J, 2002, MICROBIOL-SGM, V148, P2037, DOI 10.1099/00221287-148-7-2037; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Boxrud PD, 2001, J BIOL CHEM, V276, P26084, DOI 10.1074/jbc.M101966200; Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; CHEUNG AI, 1995, INFECT IMMUN, V63, P1914, DOI 10.1128/IAI.63.5.1914-1920.1995; Glaser P, 2002, MOL MICROBIOL, V45, P1499, DOI 10.1046/j.1365-2958.2002.03126.x; HEMKER HC, 1975, BIOCHIM BIOPHYS ACTA, V379, P180, DOI 10.1016/0005-2795(75)90020-3; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; Jeng A, 2003, J BACTERIOL, V185, P1208, DOI 10.1128/JB.185.4.1208-1217.2003; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; KAWABATA SI, 1987, J PROTEIN CHEM, V6, P17; Khan AR, 1998, PROTEIN SCI, V7, P815; Lahteenmaki K, 2001, FEMS MICROBIOL REV, V25, P531, DOI 10.1111/j.1574-6976.2001.tb00590.x; Mylonakis E, 2001, NEW ENGL J MED, V345, P1318, DOI 10.1056/NEJMra010082; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; TAGER M, 1965, ANN NY ACAD SCI, V128, P92, DOI 10.1111/j.1749-6632.1965.tb11632.x; Tettelin H, 2002, P NATL ACAD SCI USA, V99, P12391, DOI 10.1073/pnas.182380799; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662	25	194	214	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					535	539		10.1038/nature01962	http://dx.doi.org/10.1038/nature01962			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523451				2022-12-28	WOS:000185648100050
J	Klugman, KP; Madhi, SA; Huebner, RE; Kohberger, R; Mbelle, N; Pierce, N				Klugman, KP; Madhi, SA; Huebner, RE; Kohberger, R; Mbelle, N; Pierce, N		Vaccine Trialists Grp	A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-TRACT INFECTIONS; NASOPHARYNGEAL CARRIAGE; IMMUNOGENICITY; DISEASE; BURDEN; IMPACT; RESISTANCE	BACKGROUND: Acute respiratory tract infections caused by Streptococcus pneumoniae are a leading cause of morbidity and mortality in young children. We evaluated the efficacy of a 9-valent pneumococcal conjugate vaccine in a randomized, double-blind study in Soweto, South Africa. METHODS: At 6, 10, and 14 weeks of age, 19,922 children received the 9-valent pneumococcal polysaccharide vaccine conjugated to a noncatalytic cross-reacting mutant of diphtheria toxin (CRM197), and 19,914 received placebo. All children received Haemophilus influenzae type b conjugate vaccine. Efficacy and safety were analyzed according to the intention-to-treat principle. RESULTS: Among children without human immunodeficiency virus (HIV) infection, the vaccine reduced the incidence of a first episode of invasive pneumococcal disease due to serotypes included in the vaccine by 83 percent (95 percent confidence interval, 39 to 97; 17 cases among controls and 3 among vaccine recipients). Among HIV-infected children, the efficacy was 65 percent (95 percent confidence interval, 24 to 86; 26 and 9 cases, respectively). Among children without HIV infection, the vaccine reduced the incidence of first episodes of radiologically confirmed alveolar consolidation by 20 percent (95 percent confidence interval, 2 to 35; 212 cases in the control group and 169 in the vaccinated group) in the intention-to-treat analysis and by 25 percent (95 percent confidence interval, 4 to 41; 158 and 119 cases, respectively) in the per-protocol analysis (i.e., among fully vaccinated children). The incidence of invasive pneumococcal disease caused by penicillin-resistant strains was reduced by 67 percent (95 percent confidence interval, 19 to 88; 21 cases in the control group and 7 in the vaccinated group), and that caused by strains resistant to trimethoprim-sulfamethoxazole was reduced by 56 percent (95 percent confidence interval, 16 to 78; 32 and 14 cases, respectively). CONCLUSIONS: Vaccination with a 9-valent pneumococcal conjugate vaccine reduced the incidence of radiologically confirmed pneumonia. The vaccine also reduced the incidence of vaccine-serotype and antibiotic-resistant invasive pneumococcal disease among children with and those without HIV infection.	Emory Univ, Rollins Sch Publ Hlth, Dept Int Hlth, Atlanta, GA 30322 USA; Univ Witwatersrand, MRC, Natl Inst Communicable Dis, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa; Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA; Wyeth Ayerst Res, Pearl River, NY USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Emory University; Rollins School Public Health; National Institute for Communicable Diseases (NICD); University of Witwatersrand; Emory University; Pfizer; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Klugman, KP (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Int Hlth, 1518 Clifton Rd,764, Atlanta, GA 30322 USA.	kklugma@sph.emory.edu		Mbelle, Nontombi/0000-0001-8890-2663				[Anonymous], 2000, MMWR Recomm Rep, V49, P1; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Black SB, 2002, PEDIATR INFECT DIS J, V21, P810, DOI 10.1097/00006454-200209000-00005; Breslow N E, 1987, IARC Sci Publ, P1; Dagan R, 1996, J INFECT DIS, V174, P1271, DOI 10.1093/infdis/174.6.1271; Destefano F, 2002, PEDIATR INFECT DIS J, V21, P498, DOI 10.1097/00006454-200206000-00004; Feikin DR, 2002, CLIN INFECT DIS, V35, P547, DOI 10.1086/341896; French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1; Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608; Huebner RE, 2002, PEDIATR INFECT DIS J, V21, P1004, DOI 10.1097/00006454-200211000-00006; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; Madhi SA, 2000, CLIN INFECT DIS, V31, P170, DOI 10.1086/313925; Madhi SA, 2002, PEDIATR INFECT DIS J, V21, P393, DOI 10.1097/00006454-200205000-00009; Madhi SA, 2000, J PEDIATR-US, V137, P78, DOI 10.1067/mpd.2000.105350; Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009; Mulholland K, 1999, VACCINE, V17, pS79, DOI 10.1016/S0264-410X(99)00112-7; Mulholland K, 1997, LANCET, V350, P524; National Committee for Clinical Laboratory Standards, 2002, M100S12 NAT COMM CLI; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; *PNEUM VACC TRIAL, 2001, WHOVB0135; SANTOSHAM M, 2001, INT J TUBERC LUNG S1, V5, pS27; von Hertzen LC, 2000, ANN MED, V32, P397, DOI 10.3109/07853890008995946; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0	26	757	822	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1341	1348		10.1056/NEJMoa035060	http://dx.doi.org/10.1056/NEJMoa035060			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523142				2022-12-28	WOS:000185644000008
J	Pollock, AM; Price, D				Pollock, AM; Price, D			The public health implications of world trade negotiations on the general agreement on trade in services and public services	LANCET			English	Editorial Material							ORGANIZATION; POLICIES; CARE	Trade ministries from the World Trade Organization's (WTO's) 144 member states are presently deciding which public services to open to foreign competition under the complex liberalisation rules of the general agreement on trade in services (GATS). A frequent criticism of the WTO system is that it reduces national autonomy over public policy. However, respect for national sovereignty is asserted in the GATS treaty. Here, we examine claims made by the WTO and others that GATS exempts public services and does not require their privatisation. We discuss trade treaty processes that can subject public services to commercial rules, the treaty's flexibility with respect to national autonomy, and the effect of GATS in situations in which national autonomy is not protected. We conclude that national autonomy over health policy is not preserved under GATS, and that accordingly, there is a role for international standards that protect public services from the adverse effect of trade and market forces.	UCL, Sch Publ Policy, Publ Hlth Policy Unit, London WC1H 9QU, England	University of London; University College London	Pollock, AM (corresponding author), UCL, Sch Publ Policy, Publ Hlth Policy Unit, 29-30 Tavistock Sq, London WC1H 9QU, England.	allyson.pollock@ucl.ac.uk		pollock, allyson/0000-0002-7388-3110				Adlung R, 2001, LANCET, V357, P1626, DOI 10.1016/S0140-6736(00)04773-5; BRAITHWAITE J, 2000, GLOBAL BUSINESS REGU, P211; Correa CM, 2000, J WORLD TRADE, V34, P89; Driesen David M., 2000, VA J INT L, V41, P279; *DTI HM GOV, 1999, GATS 2000 HLTH ED SE; *DTI HM GOV, 2002, LIB TRAD SERV NEW CO; EEKHOUT P, 2001, EU WTO, P211; ELLISJONES M, 2002, SERVING NATION GUIDE; *EUR COMM, TRAD SERV WTO MEMB R; Howse R, 2000, MICH LAW REV, V98, P2329, DOI 10.2307/1290307; Kapp C, 2003, LANCET, V361, P315, DOI 10.1016/S0140-6736(03)12366-5; Krajewski M., 2001, PUBLIC SERVICES SCOP; KRAJEWSKI M, PUBLIC SERVICES TRAD; Leibfried S., 2000, POLICY MAKING EUROPE; *NZ GOV MIN FOR AF, GATS NEG PUBL CONS N; Oxfam, 2002, RIGG RUL DOUBL STAND; Pollock AM, 2003, BRIT MED J, V326, P236, DOI 10.1136/bmj.326.7383.236; Price D, 1999, LANCET, V354, P1889, DOI 10.1016/S0140-6736(99)11060-2; Price D, 2002, BRIT MED J, V325, P293, DOI 10.1136/bmj.325.7359.293; TRACHTMAN J, 2002, AP GROUP SERV WORKSH; World Health Organization, 2002, WTO AGR PUBL HLTH JO; *WORLD TRAD ORG, APPL NEC TEST ISS CO; *WORLD TRAD ORG, 2001, TRAD POL REV CAM; *WORLD TRAD ORG, 1999, LEG TEXTS, P286; *WORLD TRAD ORG, GATS FACT FICT; *WORLD TRAD ORG, 2000, WTDS135R WORLD TRAD; *WORLD TRAD ORG, 1998, TRAD POL REV ARG; World Trade Organization, 2002, TRAD POL REV PAK; 2001, DOHA MINISTERIAL BRE; 2003, LANCET, V361, P269	30	30	30	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 27	2003	362	9389					1072	1075		10.1016/S0140-6736(03)14419-4	http://dx.doi.org/10.1016/S0140-6736(03)14419-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	725WD	14522540				2022-12-28	WOS:000185564600027
J	Rivas, P; Polo, J; de Gorgolas, M; Fernandez-Guerrero, ML				Rivas, P; Polo, J; de Gorgolas, M; Fernandez-Guerrero, ML			Drug points - Fatal lactic acidosis associated with tenofovir	BRITISH MEDICAL JOURNAL			English	Article							MITOCHONDRIAL TOXICITY; NUCLEOSIDE		Univ Autonoma Madrid, Fdn Jimenez Diaz, Div Infect Dis, Madrid 28040, Spain	Autonomous University of Madrid	Rivas, P (corresponding author), Univ Autonoma Madrid, Fdn Jimenez Diaz, Div Infect Dis, Avda Reyes Catolicos 2, Madrid 28040, Spain.							Birkus G, 2002, ANTIMICROB AGENTS CH, V46, P716, DOI 10.1128/AAC.46.3.716-723.2002; CHENG A, 2002, 1J INT AIDS C BARC J; *FDA, 2002, FDA CONSUM, V36, P5; Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3; KEARNEY BP, 2002, 14 INT AIDS C BARC J	5	21	22	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	2003	327	7417					711	711		10.1136/bmj.327.7417.711	http://dx.doi.org/10.1136/bmj.327.7417.711			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728FZ	14512477	Green Published, Bronze			2022-12-28	WOS:000185708300016
J	Gumbsch, P				Gumbsch, P			Modeling strain hardening the hard way	SCIENCE			English	Editorial Material									Fraunhofer Inst Werkstoffmech, D-79108 Freiburg, Germany; Univ Karlsruhe, Inst Zuverlassigkeit Bauteilen & Syst, Karlsruhe, Germany	Fraunhofer Gesellschaft; Helmholtz Association; Karlsruhe Institute of Technology	Gumbsch, P (corresponding author), Fraunhofer Inst Werkstoffmech, D-79108 Freiburg, Germany.		Gumbsch, Peter/E-5879-2012	Gumbsch, Peter/0000-0001-7995-228X				DEHM G, 2002, Z METALLKD, V93, P5; GILSEVILLANO J, 1993, MAT SCI TECHNOLOGY, V6, P19; Hirth J. P., 1972, THEORY DISLOCATIONS; Madec R, 2003, SCIENCE, V301, P1879, DOI 10.1126/science.1085477; Madec R, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.255508; Zaiser M, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.224102	6	3	3	2	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1857	1858		10.1126/science.1090482	http://dx.doi.org/10.1126/science.1090482			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512610				2022-12-28	WOS:000185536700032
J	Liu, QH; Rand, TA; Kalidas, S; Du, FH; Kim, HE; Smith, DP; Wang, XD				Liu, QH; Rand, TA; Kalidas, S; Du, FH; Kim, HE; Smith, DP; Wang, XD			R2D2, a bridge between the initiation and effector steps of the Drosophila RNAi pathway	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; GENETIC INTERFERENCE; MESSENGER-RNA; C-ELEGANS; REQUIREMENTS	The RNA interference (RNAi) pathway is initiated by processing long double-stranded RNA into small interfering RNA (siRNA). The siRNA-generating enzyme was puriFIed from Drosophila S2 cells and consists of two stoichiometric subunits: Dicer-2 (DCR-2) and a previously unknown protein that we named R2D2. R2D2 is homologous to the Caenorhabditis elegans RNAi protein RDE-4. Association with R2D2 does not affect the enzymatic activity of DCR-2. Rather, the DCR-2/R2D2 complex, but not DCR-2 alone, binds to siRNA and enhances sequence-specific messenger RNA degradation mediated by the RNA-initiated silencing complex(RISC). These results indicate that R2D2 bridges the initiation and effector steps of the Drosophila RNAi pathway by facilitating siRNA passage from Dicer to RISC.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, XD (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA.		Kim, Hyun-Eui/GOV-5988-2022	Kim, Hyun-Eui/0000-0003-1495-1993; Wang, Xiaodong/0000-0001-9885-356X; Smith, Dean/0000-0002-4271-0436	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002539] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC02539] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; KALIDAS S, UNPUB; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zenobi, UNPUB	16	537	586	5	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1921	1925		10.1126/science.1088710	http://dx.doi.org/10.1126/science.1088710			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512631				2022-12-28	WOS:000185536700055
J	Dodd, RY				Dodd, RY			Emerging infections, transfusion safety, and epidemiologic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Amer Red Cross, Jerome H Holland Lab Biomed Sci, Transmissible Dis Dept, Rockville, MD 20855 USA	American Red Cross	Dodd, RY (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, Transmissible Dis Dept, Rockville, MD 20855 USA.								0	66	66	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2003	349	13					1205	1206		10.1056/NEJMp038138	http://dx.doi.org/10.1056/NEJMp038138			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LJ	14500807				2022-12-28	WOS:000185488800002
J	Glasgow, NJ; Posonby, AL; Yates, R; Beilby, J; Dugdale, P				Glasgow, NJ; Posonby, AL; Yates, R; Beilby, J; Dugdale, P			Proactive asthma care in childhood: general practice based randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; CHILDREN; QUALITY; ISSUES	Objectives To assess the feasibility and effectiveness of a general practice based, proactive system of asthma care in children. Design Randomised controlled trial with cluster sampling by general practice. Setting General practices in the northern region of the Australian Capital Territory Participants 174 children with moderate to severe asthma who attended 24 general practitioners. Intervention System of structured asthma care (the 3+ visit plan), with participating families reminded to attend the general practitioner. Main outcome measures Process measures: rates for asthma consultations with general practitioner, written asthma plans, completion of the 3+ visit plan; clinical measures: rates for emergency department visits for asthma, days absent from school, symptom-free days, symptoms over the past year, activity limitation over the past year, and asthma drug use over the past year; spirometric lung function measures before and after cold air challenge. Results Intervention group children had significantly more asthma related consultations (odds ratio for three or more asthma related consultations 3.8 (95% confidence interval 1.9 to 7.6; P = 0.0001), written asthma plans (2.2 (1.2 to 4.1); P = 0.01), and completed 3+ visit plans (24.2 (5.7 to 103.2); P = 0.0001) than control children and a mean reduction in measurements of forced expiratory volume in one second after cold air challenge of 2.6% (1.7 to 3.5); P = 0.0001) less than control children. The number needed to treat (benefit) for one additional written asthma action plan was 5 (3 to 41) children. Intervention group children had lower emergency department attendance rates for asthma (odds ratio 0.4 (0.2 to 1.04); P = 0.06) and less speech limiting wheeze (0.2 (0.1 to 0.4); P = 0.0001) than control children and were more likely to use a spacer (2.8 (1.6 to 4.7); P = 0.0001). No differences occurred in number of days absent from school or symptom-free day scores. Conclusions Proactive care with active recall for children with moderate to severe asthma is feasible in general practice and seems to be beneficial.	Univ Sydney, Canberra Clin Sch, Acad Unit Gen Practice & Community Care, Canberra, ACT 2614, Australia; Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia; Univ Adelaide, Dept Gen Practice, Adelaide, SA 5005, Australia	University of Sydney; Australian National University; University of Adelaide	Glasgow, NJ (corresponding author), Univ Sydney, Canberra Clin Sch, Acad Unit Gen Practice & Community Care, POB 254, Canberra, ACT 2614, Australia.	Nicholas.Glasgow@calvary-act.com.au	Beilby, Justin/M-5147-2019; Glasgow, Nicholas J/G-3521-2010; Dugdale, Paul/GYJ-7351-2022	Glasgow, Nicholas J/0000-0002-1994-3565; Dugdale, Paul/0000-0002-2315-5051; Ponsonby, Anne-Louise/0000-0002-6581-3657				Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; [Anonymous], 2002, ASTHM MAN HDB; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Campbell M, 2000, J Health Serv Res Policy, V5, P12; Comino EJ, 1996, MED J AUSTRALIA, V164, P403, DOI 10.5694/j.1326-5377.1996.tb122087.x; Edwards SJL, 1999, BMJ-BRIT MED J, V318, P1407, DOI 10.1136/bmj.318.7195.1407; Fardy H J, 1999, Aust Fam Physician, V28, P95; Feder G, 1999, BRIT MED J, V318, P1522, DOI 10.1136/bmj.318.7197.1522; Gibson PG, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001117], 10.1002/14651858.CD001117]; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Neville RG, 1999, THORAX, V54, P813, DOI 10.1136/thx.54.9.813; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; PIERCE R, 1995, SPIROMETRY MEASUREME; Ponsonby AL, 2002, CHEST, V121, P135, DOI 10.1378/chest.121.1.135; Ponsonby AL, 2001, CLIN EXP ALLERGY, V31, P1205, DOI 10.1046/j.1365-2222.2001.01168.x; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391	21	43	44	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2003	327	7416					659	663		10.1136/bmj.327.7416.659	http://dx.doi.org/10.1136/bmj.327.7416.659			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724AC	14500440	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000185463100024
J	Scharko, AM; Perlman, SB; Pyzalski, RW; Graziano, FM; Sosman, J; Pauza, CD				Scharko, AM; Perlman, SB; Pyzalski, RW; Graziano, FM; Sosman, J; Pauza, CD			Whole-body positron emission tomography in patients with HIV-1 infection	LANCET			English	Article							RHESUS MACAQUES	Positron emission tomography with fluorine-18-deoxyglucose (FDG-PET) detects active lymphoid tissues during HIV-1 infection in man. We used FDG-PET to study anatomical correlates of HIV-1 infection in man. Whole-body FDG-PET images from 15 patients with HIV-1 showed distinct lymphoid tissue activation in the head and neck during acute disease, a generalised pattern of peripheral lymph-node activation at mid-stages, and involvement of abdominal lymph nodes during late disease. Unexpectedly, HIV-1 progression was evident by distinct anatomical correlates, suggesting that lymphoid tissues are engaged in a predictable sequence. Understanding the anatomy of HIV-1 infection could encourage use of surgical or radiological interventions to supplement chemotherapy.	Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA; Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA; Univ Wisconsin, Dept Nucl Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University System of Maryland; University of Maryland Baltimore; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Pauza, CD (corresponding author), Univ Maryland, Inst Biotechnol, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA.				NIAID NIH HHS [AI41977] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041977] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GARCIA CF, 1986, AM J CLIN PATHOL, V86, P706, DOI 10.1093/ajcp/86.6.706; Pantaleo G, 1998, NAT MED, V4, P341, DOI 10.1038/nm0398-341; PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x; Scharko AM, 1996, P NATL ACAD SCI USA, V93, P6425, DOI 10.1073/pnas.93.13.6425; Wallace M, 2000, VIROLOGY, V274, P255, DOI 10.1006/viro.2000.0479	5	65	66	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					959	961		10.1016/S0140-6736(03)14366-8	http://dx.doi.org/10.1016/S0140-6736(03)14366-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511930				2022-12-28	WOS:000185489600011
J	Kim, M; Carman, CV; Springer, TA				Kim, M; Carman, CV; Springer, TA			Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins	SCIENCE			English	Article							INSIDE-OUT ACTIVATION; ALPHA-SUBUNIT; AFFINITY; TAILS; LFA-1; FLOW; ALPHA-IIB-BETA-3; ADHESIVENESS; CHEMOKINES; REVEALS	Although critical for development, immunity, wound healing, and metastasis, integrins represent one of the few classes of plasma membrane receptors for which the basic signaling mechanism remains a mystery. We investigated cytoplasmic conformational changes in the integrin LFA-1 (alpha(L)beta(2)) in living cells by measuring fluorescence resonance energy transfer between cyan fluorescent protein - fused and yellow fluorescent protein - fused alpha(L) and beta(2) cytoplasmic domains. In the resting state these domains were close to each other, but underwent significant spatial separation upon either intracellular activation of integrin adhesiveness (inside-out signaling) or ligand binding (outside-in signaling). Thus, bidirectional integrin signaling is accomplished by coupling extracellular conformational changes to an unclasping and separation of the alpha and beta cytoplasmic domains, a distinctive mechanism for transmitting information across the plasma membrane.	Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Springer, TA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	springeroffice@cbr.med.harvard.edu	Carman, Christopher V./AAX-8995-2020; Carman, Christopher/L-8108-2016	Carman, Christopher V./0000-0001-7358-2548; Carman, Christopher/0000-0001-7358-2548	NCI NIH HHS [CA31798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031798, R37CA031798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adair BD, 2002, P NATL ACAD SCI USA, V99, P14059, DOI 10.1073/pnas.212498199; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Liu SC, 2000, J CELL SCI, V113, P3563; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 1997, J IMMUNOL, V159, P268; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Lub M, 1997, MOL BIOL CELL, V8, P719, DOI 10.1091/mbc.8.4.719; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Ulmer TS, 2001, BIOCHEMISTRY-US, V40, P7498, DOI 10.1021/bi010338l; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Weljie AM, 2002, P NATL ACAD SCI USA, V99, P5878, DOI 10.1073/pnas.092515799; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	31	611	631	3	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1720	1725		10.1126/science.1084174	http://dx.doi.org/10.1126/science.1084174			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500982				2022-12-28	WOS:000185387700044
J	Gutman, JD; Harris, NL; Pingree, RG; Kratz, A; Kotton, CN				Gutman, JD; Harris, NL; Pingree, RG; Kratz, A; Kotton, CN			Case 29-2003: A 60-year-old man with fever, rigors, and sweats - Infection with Babesia microti (the agent that causes babesiosis) and Borrelia burgdorferi (the agent that causes Lyme disease)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EHRLICHIOSIS; ZOONOSES		Family Med Associates, S Attleboro, MA 02703 USA; Brown Univ, Dept Family Med, Providence, RI 02912 USA; Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Brown University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Gutman, JD (corresponding author), Family Med Associates, S Attleboro, MA 02703 USA.			Kotton, Camille/0000-0001-7320-2234				Bain B. J., 2002, BLOOD CELLS PRACTICA, P52; DOOLEY JR, 1980, LANCET, V2, P1237; Filbin MR, 2001, J EMERG MED, V20, P21, DOI 10.1016/S0736-4679(00)00289-4; GELFAND JA, 2000, MANDELL DOUGLAS BENN, V2, P2899; Graham R, 2002, JAMA-J AM MED ASSOC, V288, P1097, DOI 10.1001/jama.288.9.1097; Green LA, 2001, NEW ENGL J MED, V344, P2021, DOI 10.1056/NEJM200106283442611; Homer MJ, 2000, CLIN MICROBIOL REV, V13, P451, DOI 10.1128/CMR.13.3.451-469.2000; Krause PJ, 1996, JAMA-J AM MED ASSOC, V275, P1657, DOI 10.1001/jama.275.21.1657; Krause PJ, 2000, NEW ENGL J MED, V343, P1454, DOI 10.1056/NEJM200011163432004; Krause PJ, 2002, CLIN INFECT DIS, V34, P1184, DOI 10.1086/339813; Krause PJ, 2002, MED CLIN N AM, V86, P361, DOI 10.1016/S0025-7125(03)00092-0; Taege AJ, 2000, CLEV CLIN J MED, V67, P241; Thompson C, 2001, CLIN INFECT DIS, V33, P676, DOI 10.1086/322681	13	8	8	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1168	1175		10.1056/NEJMcpc030025	http://dx.doi.org/10.1056/NEJMcpc030025			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679532				2022-12-28	WOS:000185369700012
J	Aylward, RB; Acharya, A; England, S; Agocs, M; Linkins, J				Aylward, RB; Acharya, A; England, S; Agocs, M; Linkins, J			Global health goals: lessons from the worldwide effort to eradicate poliomyelitis	LANCET			English	Article							POLIO ERADICATION; IMPACT	The Global Polio Eradication Initiative was launched in 1988. Assessment of the politics, production, financing, and economics of this international effort has suggested six lessons that might be pertinent to the pursuit of other global health goals. First, such goals should be based on technically sound strategies with proven operational feasibility in a large geographical area. Second, before launching an initiative, an informed collective decision must be negotiated and agreed in an appropriate international forum to keep to a minimum long-term risks in financing and implementation. Third, if substantial community engagement is envisaged, efficient deployment of sufficient resources at that level necessitates a defined, time-limited input by the community within a properly managed partnership. Fourth, although the so-called fair-share concept is arguably the best way to finance such goals, its limitations must be recognised early and alternative strategies developed for settings where it does not work. Fifth, international health goals must be designed and pursued within existing health systems if they are to secure and sustain broad support. Finally, countries, regions, or populations most likely to delay the achievement of a global health goal should be identified at the outset to ensure provision of sufficient resources and attention. The greatest threats to poliomyelitis eradication are a financing gap of US$210 million and difficulties in strategy implementation in at most five countries.	WHO, Dept Vaccines & Biol, Global Polio Eradicat Initiat, CH-1211 Geneva 27, Switzerland; WHO, Communicable Dis Cluster, Stop TB Dept, Stop TB Partnership Secretariat, CH-1211 Geneva 27, Switzerland; Univ Sussex, Inst Dev Studies, Brighton, E Sussex, England; US Ctr Dis Control & Prevent, Polio Eradicat Branch, Global Immunizat Div, Natl Immunizat Program, Atlanta, GA USA	World Health Organization; World Health Organization; University of Sussex; Centers for Disease Control & Prevention - USA	Aylward, RB (corresponding author), WHO, Dept Vaccines & Biol, Global Polio Eradicat Initiat, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	aylwardb@who.int		Agocs, Mary/0000-0002-7710-708X; England, Sarah/0000-0002-0953-8136				ACHARYA A, 2001, PRODUCTION GLOBAL PU; Andrus JK, 2001, AM J PUBLIC HEALTH, V91, P146, DOI 10.2105/AJPH.91.1.146; [Anonymous], 2001, Wkly Epidemiol Rec, V76, P95; [Anonymous], 2000, LANCET, V356, P521; [Anonymous], 1982, Rev Infect Dis, V4, P912; [Anonymous], 1990, WORLD DECL SURV PROT; Arora NK, 1999, PULSE POLIO IMMUNIZA; *ASS HEADS STAT GO, 1996, YAOUND DECL POL ER A; Aylward B, 2000, AM J PUBLIC HEALTH, V90, P1515, DOI 10.2105/AJPH.90.10.1515; Aylward RB, 1997, J INFECT DIS, V175, pS268, DOI 10.1093/infdis/175.Supplement_1.S268; Bart KJ, 1996, B WORLD HEALTH ORGAN, V74, P35; Ching P, 2000, AM J PUBLIC HEALTH, V90, P1526, DOI 10.2105/AJPH.90.10.1526; DEQUADROS CA, 1992, ANNU REV PUBL HEALTH, V13, P239, DOI 10.1146/annurev.publhealth.13.1.239; DOWDLE WR, IN PRESS PICORNAVIRU; *EXP PROGR IMM, 2002, WKLY EP REC, V77, P81; *EXP PROGR IMM, 2001, WKLY EPIDEMIOL REC, V76, P319; *EXP PROGR IMM, 2000, WKLY EPIDEMIOL REC, V75, P213; *EXP PROGR IMM, 2002, WKLY EPIDEMIOL REC, V77, P97; *EXP PROGR IMM, 2000, WKLY EP REC, V76, P299; *EXP PROGR IMM, 2001, WKLY EP REC, V76, P158; *EXP PROGR IMM, 1996, WKLY EP REC, V71, P329; *EXP PROGR IMM, 2002, WKLY EP REC, V77, P299; *EXP PROGR VACC IM, 1998, WHOEPIGEN9810; Expanded Programme on Immunization. Progress toward poliomyelitis eradication 1990-1996, 1996, WEEKLY EPIDEMIOLOGIC, V71, P377; Feachem RGA, 2002, NATURE, V417, P695, DOI 10.1038/417695a; FENNER F, 1988, SMALLPOX ERADICATION, P421; *GLOB POL ER IN, POL ER; Goodman T, 2000, B WORLD HEALTH ORGAN, V78, P305; *GOV CAN, G8 AFR ACT PLAN; HORSTMANN DM, 1984, REV INFECT DIS S2, V6; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; JACOBS L, IN PRESS NEW GENERAT; Kaul I., 1999, GLOBAL PUBLIC GOODS; Kew O, 2002, SCIENCE, V296, P356, DOI 10.1126/science.1068284; Loevinsohn B, 2002, AM J PUBLIC HEALTH, V92, P19, DOI 10.2105/AJPH.92.1.19; MacAulay C, 1999, GLOBAL POLIO LAB NET; MOGEDAL S, 2000, M IMP TARG PROGR HLT; Musgrove P, 1988, Bull Pan Am Health Organ, V22, P1; Nsubuga P, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-27; Orenstein W, 2002, CLIN INFECT DIS, V34, P72, DOI 10.1086/338262; Pablos-Mendez A, 2002, B WORLD HEALTH ORGAN, V80, P489; Sachs JD, 2001, MACR HLTH INV HLTH E; Smith R., 2003, GLOBAL PUBLIC GOODS; Tangermann RH, 1997, J INFECT DIS, V175, pS272, DOI 10.1093/infdis/175.Supplement_1.S272; *TASK FORC CHILD S, 1988, PROT WORLDS CHILDR A; *TAYL COMM, 1995, 1995000003 TAYL COMM; Taylor AL, 2000, B WORLD HEALTH ORGAN, V78, P920; Taylor CE, 1997, AM J PUBLIC HEALTH, V87, P922, DOI 10.2105/AJPH.87.6.922; *WHO, 2002, HTPPOLIO0209 WHO; WHO, 2002, 7 M TECHN CONS GROUP; *WHO, 2001, WHOPOLIO0105; *WHO, 2002, WHOCDSSTB200113; *WHO, 2002, EBPDC83 WHO; *WHO, 2001, 6 M GLOB TECHN CONS; WOODWARD D, 2002, COMMUNICABLE DIS CON; *WORLD BANK, 2001, WORLD DEV IND 2001; World Health Assembly, 1988, GLOB ER POL YEAR 200; World Health Organization, 2000, M IMP TARG PROGR HLT; Yach D, 1998, AM J PUBLIC HEALTH, V88, P735, DOI 10.2105/AJPH.88.5.735	59	40	41	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 13	2003	362	9387					909	914		10.1016/S0140-6736(03)14337-1	http://dx.doi.org/10.1016/S0140-6736(03)14337-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	721RH	13678981	Green Published, Bronze			2022-12-28	WOS:000185329400026
J	Mallam, KM; Metcalf, BS; Kirkby, J; Voss, LD; Wilkin, TJ				Mallam, KM; Metcalf, BS; Kirkby, J; Voss, LD; Wilkin, TJ			Contribution of timetabled physical education to total physical activity in primary school children: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							ACTIVITY MONITOR		Derriford Hosp, Peninsula Med Sch, Dept Endocrinol & Metab, Plymouth PL6 8DH, Devon, England	Derriford Hospital; University of Plymouth	Wilkin, TJ (corresponding author), Derriford Hosp, Peninsula Med Sch, Dept Endocrinol & Metab, Plymouth PL6 8DH, Devon, England.							Ekelund U, 2001, MED SCI SPORT EXER, V33, P275; Metcalf BS, 2002, MED SCI SPORT EXER, V34, P1533, DOI 10.1097/00005768-200209000-00022; MURPHY MJ, IN PRESS PEDIATRICS; Rowe N, 2000, YOUNG PEOPLE SPORT N	4	84	84	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					592	593		10.1136/bmj.327.7415.592	http://dx.doi.org/10.1136/bmj.327.7415.592			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969924	Green Published, Bronze			2022-12-28	WOS:000185358700020
J	Arpigny, C; Jehin, E; Manfroid, J; Hutsemekers, D; Schulz, R; Stuwe, JA; Zucconi, JM; Ilyin, I				Arpigny, C; Jehin, E; Manfroid, J; Hutsemekers, D; Schulz, R; Stuwe, JA; Zucconi, JM; Ilyin, I			Anomalous nitrogen isotope ratio in comets	SCIENCE			English	Article							ABUNDANCE RATIO; PRESOLAR GRAINS; INTERSTELLAR; NUCLEOSYNTHESIS; PHOTOLYSIS; CHEMISTRY; ORIGIN; CN	High-resolution spectra of the CN B-2 Sigma(+)- X-2 Sigma(+) (0,0) band at 390 nanometers yield isotopic ratios for comets C/ 1995 O1 (Hale-Bopp) and C/ 2000 WM1 (LINEAR) as follows: 165 +/- 40 and 115 +/- 20 for C-12/C-13, 140 +/- 35 and 140 +/- 30 for N-14/N-15. Our N isotopic measurements are lower than the terrestrial N-14/N-15 = 272 and the ratio for Hale-Bopp from measurements of HCN, the presumed parent species of CN. This isotopic anomaly suggests the existence of other parent(s) of CN, with an even lower N isotopic ratio. Organic compounds like those found in interplanetary dust particles are good candidates.	Inst Astrophys & Geophys, B-4000 Liege, Belgium; European So Observ, Santiago 19, Chile; European Space Technol Ctr, European Space Agcy, RSSD, NL-2200 AG Noordwijk, Netherlands; Leiden Observ, NL-2300 RA Leiden, Netherlands; Observ Besancon, F-25010 Besancon, France; Univ Oulu, Astron Div, FIN-90014 Oulu, Finland	European Southern Observatory; European Space Agency; Leiden University; Leiden University - Excl LUMC; University of Oulu	Arpigny, C (corresponding author), Inst Astrophys & Geophys, Sart Tilman,Batiment B5c, B-4000 Liege, Belgium.	Claude.Arpigny@ulg.ac.be						AHEARN MF, 1986, NATURE, V324, P649, DOI 10.1038/324649a0; ALEON J, IN PRESS GEOCHIM COS; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; ARPIGNY C, 2000, B AM ASTRON SOC, V32, P1074; BERNSTEIN MP, 1995, ASTROPHYS J, V454, P327, DOI 10.1086/176485; Bernstein MP, 2002, ASTROPHYS J, V576, P1115, DOI 10.1086/341863; Charnley SB, 2002, ASTROPHYS J, V569, pL133, DOI 10.1086/340484; Chin YN, 1999, ASTROPHYS J, V512, pL143, DOI 10.1086/311875; Clayton DD, 1997, ASTROPHYS J, V486, P824, DOI 10.1086/304545; Cochran AL, 2002, ICARUS, V157, P297, DOI 10.1006/icar.2002.6850; Cochran AL, 2000, ICARUS, V146, P583, DOI 10.1006/icar.2000.6413; DAHMEN G, 1995, ASTRON ASTROPHYS, V295, P194; Dekker H, 2000, P SOC PHOTO-OPT INS, V4008, P534, DOI 10.1117/12.395512; FLOSS C, 2003, LUNAR PLANET SCI, V34, P1234; Hashizume K, 2000, SCIENCE, V290, P1142, DOI 10.1126/science.290.5494.1142; Henkel C, 1999, ESO ASTROPHY SYMP, P103; Hoppe P, 1997, ASTROPHYS J, V487, pL101, DOI 10.1086/310869; Ikeda M, 2002, ASTROPHYS J, V575, P250, DOI 10.1086/341287; Jessberger EK, 1999, SPACE SCI REV, V90, P91, DOI 10.1023/A:1005233727874; Jessberger EK, 2001, ASTR AST LI, P253; Jewitt DC, 1997, SCIENCE, V278, P90, DOI 10.1126/science.278.5335.90; Kallenbach R, 1998, ASTROPHYS J, V507, pL185, DOI 10.1086/311702; KELLER LP, 1998, LUNAR PLANET SCI, V28, P1811; KLAVETTER JJ, 2000, ICARUS, V146, P583; KLEINE M, 1995, ASTROPHYS J, V439, P1021, DOI 10.1086/175239; Lucas R, 1998, ASTRON ASTROPHYS, V337, P246; Meier R, 1999, SPACE SCI REV, V90, P33, DOI 10.1023/A:1005269208310; Messenger S, 2000, NATURE, V404, P968, DOI 10.1038/35010053; Mostefaoui S, 2002, EARTH PLANET SC LETT, V204, P89, DOI 10.1016/S0012-821X(02)00964-0; Owen T, 2001, ASTROPHYS J, V553, pL77, DOI 10.1086/320501; Rauer H, 2003, ASTRON ASTROPHYS, V397, P1109, DOI 10.1051/0004-6361:20021550; RETTIG TW, 1992, ASTROPHYS J, V393, P398; Terzieva R, 2000, MON NOT R ASTRON SOC, V317, P563, DOI 10.1046/j.1365-8711.2000.03618.x; Woodney LM, 2002, ICARUS, V157, P193, DOI 10.1006/icar.2001.6798; Wyckoff S, 2000, ASTROPHYS J, V535, P991, DOI 10.1086/308863; Zinner E, 1998, ANNU REV EARTH PL SC, V26, P147, DOI 10.1146/annurev.earth.26.1.147; Ziurys LM, 1999, ASTROPHYS J, V527, pL67, DOI 10.1086/312388; ZUCCONI JM, 1985, ASTRON ASTROPHYS, V150, P180	38	85	85	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1522	1524		10.1126/science.1086711	http://dx.doi.org/10.1126/science.1086711			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970562				2022-12-28	WOS:000185255300046
J	Hoffmeister, KM; Josefsson, EC; Isaac, NA; Clausen, H; Hartwig, JH; Stossel, TP				Hoffmeister, KM; Josefsson, EC; Isaac, NA; Clausen, H; Hartwig, JH; Stossel, TP			Glycosylation restores survival of chilled blood platelets	SCIENCE			English	Article							GLYCOPROTEIN IB-ALPHA; CARBOHYDRATE MOIETY; COLLAGEN ADHESION; RECEPTOR; ERYTHROCYTES; GLYCOCALICIN; COMPLEX; CLONING	Cooling of blood platelets clusters the von Willebrand factor receptor complex. Macrophage alpha(M)beta(2) integrins bind to the GPIbalpha subunit of the clustered complex, resulting in rapid clearance of transfused, cooled platelets. This precludes refrigeration of platelets for transfusion, but the current practice of room temperature storage has major drawbacks. We document that alpha(M)beta(2) is a lectin that recognizes exposed beta-N-acetylglucosamine residues of N-linked glycans on GPIbalpha. Enzymatic galactosylation of chilled platelets blocks alpha(M)beta(2) recognition, prolonging the circulation of functional cooled platelets. Platelet-associated galactosyltransferase produces efficient galactosylation when uridine diphosphate - galactose is added, affording a potentially simple method for storing platelets in the cold.	Harvard Univ, Sch Med, Dept Med, Div Hematol, Boston, MA 02115 USA; Univ Gothenburg, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden; Univ Copenhagen, Sch Dent, Dept Oral Diag, Copenhagen, Denmark; Zymequest Inc, Beverly, MA 01915 USA	Harvard University; Harvard Medical School; University of Gothenburg; University of Copenhagen	Hoffmeister, KM (corresponding author), Harvard Univ, Sch Med, Dept Med, Div Hematol, Boston, MA 02115 USA.	khoffmeister@rics.bwh.harvard.edu	clausen, henrik/AAD-8016-2021	Clausen, Henrik/0000-0002-0915-5055; Josefsson, Emma/0000-0001-6478-5204	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL019429, R01HL019429, P01HL056949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19429, HL56949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARTHUR PG, 1991, J PEDIATR GASTR NUTR, V13, P260, DOI 10.1097/00005176-199110000-00004; BARBER AJ, 1971, BIOCHIM BIOPHYS ACTA, V252, P533, DOI 10.1016/0304-4165(71)90156-5; BECKER GA, 1973, TRANSFUSION, V13, P61, DOI 10.1111/j.1537-2995.1973.tb05442.x; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; BERRY GT, 1995, LANCET, V346, P1073, DOI 10.1016/S0140-6736(95)91745-4; Blajchman MA, 2001, TRANSFUS APHER SCI, V24, P245, DOI 10.1016/S1473-0502(01)00063-5; Ellies LG, 2002, P NATL ACAD SCI USA, V99, P10042, DOI 10.1073/pnas.142005099; Fotinopoulou A, 2003, BIOTECHNOL APPL BIOC, V37, P1, DOI 10.1042/BA20020023; Hoffmeister KM, 2003, CELL, V112, P87, DOI 10.1016/S0092-8674(02)01253-9; HOPPER KE, 1986, BLOOD, V68, P167; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; JAMIESON GA, 1971, NATURE-NEW BIOL, V234, P5, DOI 10.1038/newbio234005a0; KORREL SAM, 1988, FEBS LETT, V228, P321, DOI 10.1016/0014-5793(88)80024-3; Kuehnert MJ, 2001, TRANSFUSION, V41, P1493, DOI 10.1046/j.1537-2995.2001.41121493.x; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; MCCULLOUGH J, 2003, BLOOD PRINCIPLES PRA, P2011; Mi YL, 2002, J CLIN INVEST, V109, P269, DOI 10.1172/JCI13997; *NAT BLOOD DAT RES, 2001, COMPR REP BLOOD COLL, P3; Park EI, 2003, J BIOL CHEM, V278, P4597, DOI 10.1074/jbc.M210612200; RENDU F, 1984, THROMB RES, V36, P447, DOI 10.1016/0049-3848(84)90301-3; ROBBINS PW, 1992, GENE, V111, P69, DOI 10.1016/0378-1119(92)90604-N; ROSS GD, 1985, J IMMUNOL, V134, P3307; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Thornton BP, 1996, J IMMUNOL, V156, P1235; TSUJI T, 1987, J BIOCHEM-TOKYO, V101, P241, DOI 10.1093/oxfordjournals.jbchem.a121897; TSUJI T, 1983, J BIOL CHEM, V258, P6335; VAYSSE J, 1986, P NATL ACAD SCI USA, V83, P1339, DOI 10.1073/pnas.83.5.1339; WARD C, 1996, BIOCHEMISTRY-US, V28, P8326	30	190	207	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1531	1534		10.1126/science.1085322	http://dx.doi.org/10.1126/science.1085322			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970565				2022-12-28	WOS:000185255300049
J	Zagotta, WN; Olivier, NB; Black, KD; Young, EC; Olson, R; Gouaux, E				Zagotta, WN; Olivier, NB; Black, KD; Young, EC; Olson, R; Gouaux, E			Structural basis for modulation and agonist specificity of HCN pacemaker channels	NATURE			English	Article							NUCLEOTIDE-GATED CHANNELS; CAMP MODULATION; MOLECULAR-MECHANISM; BINDING DOMAIN; PROTEIN-KINASE; STOICHIOMETRY; ACTIVATION; DEPENDENCE; SUBUNIT; K+	The family of hyperpolarization-activated, cyclic nucleotide-modulated (HCN) channels are crucial for a range of electrical signalling, including cardiac and neuronal pacemaker activity, setting resting membrane electrical properties and dendritic integration(1). These nonselective cation channels, underlying the I-f, I-h and I-q currents of heart and nerve cells, are activated by membrane hyperpolarization and modulated by the binding of cyclic nucleotides such as cAMP and cGMP(2). The cAMP-mediated enhancement of channel activity is largely responsible for the increase in heart rate caused by beta-adrenergic agonists(3). Here we have investigated the mechanism underlying this modulation by studying a carboxy-terminal fragment of HCN2 containing the cyclic nucleotide-binding domain (CNBD) and the C-linker region that connects the CNBD to the pore. X-ray crystallographic structures of this C-terminal fragment bound to cAMP or cGMP, together with equilibrium sedimentation analysis, identify a tetramerization domain and the mechanism for cyclic nucleotide specificity, and suggest a model for ligand-dependent channel modulation. On the basis of amino acid sequence similarity to HCN channels, the cyclic nucleotide-gated, and eag- and KAT1-related families of channels are probably related to HCN channels in structure and mechanism.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Seattle, WA 98195 USA; Columbia Univ, Howard Hughes Med Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Columbia University; Howard Hughes Medical Institute	Gouaux, E (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 650 W 168th St, New York, NY 10032 USA.	zagotta@u.washington.edu; jeg52@columbia.edu	Gouaux, Eric/Y-4370-2019	Gouaux, Eric/0000-0002-8549-2360; Young, Edgar C./0000-0002-8453-088X	NATIONAL EYE INSTITUTE [R01EY010329] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY010329, R01 EY010329-10] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Guerrero SA, 2001, APPL MICROBIOL BIOT, V56, P718, DOI 10.1007/s002530100690; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Johnson JP, 2001, NATURE, V412, P917, DOI 10.1038/35091089; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KUMAR VD, 1992, BIOCHEMISTRY-US, V31, P4643, DOI 10.1021/bi00134a015; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Matulef K, 1999, NEURON, V24, P443, DOI 10.1016/S0896-6273(00)80857-0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Rothberg BS, 2002, J GEN PHYSIOL, V119, P83, DOI 10.1085/jgp.119.1.83; Shin KS, 2001, J GEN PHYSIOL, V117, P91, DOI 10.1085/jgp.117.2.91; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Ulens C, 2003, BIOPHYS J, V84, p137A; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Wang J, 2001, J GEN PHYSIOL, V118, P237, DOI 10.1085/jgp.118.3.237; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	30	458	476	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					200	205		10.1038/nature01922	http://dx.doi.org/10.1038/nature01922			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968185				2022-12-28	WOS:000185236000048
J	Alaszewski, A; Horlick-Jones, T				Alaszewski, A; Horlick-Jones, T			How can doctors communicate information about risk more effectively?	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Effective communication of risk can improve both individual and national health, and there has been substantial investment in such communication. Has this yielded the anticipated improvements in health?	Univ Kent, Ctr Hlth Studies, Canterbury CT2 7NF, Kent, England; Cardiff Univ, Sch Social Sci, Cardiff CF10 3WT, S Glam, Wales	University of Kent; Cardiff University	Alaszewski, A (corresponding author), Univ Kent, Ctr Hlth Studies, Allen Wing, Canterbury CT2 7NF, Kent, England.	a.m.alaszewski@kent.ac.uk						BERRY C, 2002, RISKY HLTH; Bloor M., 1995, SOCIOLOGY HIV TRANSM; CALMAN KC, 1999, HEALTH RISK SOC, V1, P107, DOI DOI 10.1080/13698579908407010; Coleman LM, 2002, HEALTH RISK SOC, V4, P77, DOI 10.1080/13698570210291; Denscombe M, 2001, BRIT J SOCIOL, V52, P157, DOI 10.1080/00071310020023082; DIBBEN MR, IN PRESS HLTH RISK S; FREWER LJ, IN PRESS HLTH RISK S; Grmek M. D., 1990, HIST AIDS EMERGENCE; Hall Christopher., 1999, TALK WORK I ORDER DI, P293; Hill CA, 1997, PERS RELATIONSHIP, V4, P15, DOI 10.1111/j.1475-6811.1997.tb00127.x; HOBSONWEST P, IN PRESS HLTH RISK S; HORLICKJONES T, 2002, SOCIAL AMPLIFICATION; Leventhal H., 1997, PERCEPTIONS HLTH ILL, V2, P19; Myhre SL, 2000, J HEALTH COMMUN, V5, P29, DOI 10.1080/10810730050019546; Philo G., 1999, MESSAGE RECEIVED GLA; Pidgeon N., 1992, ROYALSOCIETY STUDY G, P89; PIDGEON N, 2003, PERCEPTIONS TRUST HL; Prochaska J. O., 1994, CHANGING GOOD; REILLY J, 1999, MESSAGE RECEIVED GLA; Slovic P, 2000, PERCEPTION RISK; Wallman S, 2000, HEALTH RISK SOC, V2, P189, DOI 10.1080/713670157; Williams G., 1994, CHALLENGING MED, P118; Witte K, 2000, HEALTH EDUC BEHAV, V27, P591, DOI 10.1177/109019810002700506	23	92	94	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 27	2003	327	7417					728	731		10.1136/bmj.327.7417.728	http://dx.doi.org/10.1136/bmj.327.7417.728			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	728FZ	14512483	Green Published			2022-12-28	WOS:000185708300023
J	Sharma, R; Boon, A; Harnden, A				Sharma, R; Boon, A; Harnden, A			Interactive case report - A 2 year old child with rash and fever	BRITISH MEDICAL JOURNAL			English	Article									Inst Hlth Sci, Dept Primary Hlth Care, Oxford OX3 7LF, England; Royal Berkshire Hosp, Reading RG1 5AN, Berks, England	University of Oxford; Royal Berkshire Hospital	Harnden, A (corresponding author), Inst Hlth Sci, Dept Primary Hlth Care, Oxford OX3 7LF, England.								0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	2003	327	7417					720	720		10.1136/bmj.327.7417.720	http://dx.doi.org/10.1136/bmj.327.7417.720			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728FZ	14512480	Green Published			2022-12-28	WOS:000185708300019
J	Dueber, JE; Yeh, BJ; Chak, K; Lim, WA				Dueber, JE; Yeh, BJ; Chak, K; Lim, WA			Reprogramming control of an allosteric signaling switch through modular recombination	SCIENCE			English	Article							WASP-FAMILY PROTEINS; ARP2/3 COMPLEX; SH3 DOMAINS; N-WASP; ACTIVATION; BINDING; SYSTEMS; CDC42	Many eukaryotic signaling proteins are composed of simple modular binding domains, yet they can display sophisticated behaviors such as allosteric gating and multi-input signal integration, properties essential for complex cellular circuits. To understand how such behavior can emerge from combinations of simple domains, we engineered variants of the actin regulatory protein N-WASP (neuronal Wiskott-Aldrich syndrome protein) in which the "output" domain of N-WASP was recombined with heterologous autoinhibitory "input" domains. Synthetic switch proteins were created with diverse gating behaviors in response to nonphysiological inputs. Thus, this type of modular framework can facilitate the evolution or engineering of cellular signaling circuits.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biol Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Chem & Chem Biol Grad Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	wlim@itsa.ucsf.edu						Buck M, 2001, BIOCHEMISTRY-US, V40, P14115, DOI 10.1021/bi0157215; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lim WA, 2002, CURR OPIN STRUC BIOL, V12, P61, DOI 10.1016/S0959-440X(02)00290-7; Mayer BJ, 2001, J CELL SCI, V114, P1253; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; Mullins RD, 2000, METHOD ENZYMOL, V325, P214; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Pawson T, 2000, GENE DEV, V14, P1027; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zalevsky J, 2001, CURR BIOL, V11, P1903, DOI 10.1016/S0960-9822(01)00603-0; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8	18	231	240	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1904	1908		10.1126/science.1085945	http://dx.doi.org/10.1126/science.1085945			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512628				2022-12-28	WOS:000185536700050
J	Kirkness, EF; Bafna, V; Halpern, AL; Levy, S; Remington, K; Rusch, DB; Delcher, AL; Pop, M; Wang, W; Fraser, CM; Venter, JC				Kirkness, EF; Bafna, V; Halpern, AL; Levy, S; Remington, K; Rusch, DB; Delcher, AL; Pop, M; Wang, W; Fraser, CM; Venter, JC			The dog genome: Survey sequencing and comparative analysis	SCIENCE			English	Article							PLACENTAL MAMMALS; MOUSE; MAP; SUPERFAMILY; DIVERSITY; GENETICS; LOCUS; AGE	A survey of the dog genome sequence (6.22 million sequence reads; 1.5X coverage) demonstrates the power of sample sequencing for comparative analysis of mammalian genomes and the generation of species-specific resources. More than 650 million base pairs (>25%) of dog sequence align uniquely to the human genome, including fragments of putative orthologs for 18,473 of 24,567 annotated human genes. Mutation rates, conserved synteny, repeat content, and phylogeny can be compared among human, mouse, and dog. A variety of polymorphic elements are identified that will be valuable for mapping the genetic basis of diseases and traits in the dog.	Inst Genom Res, Rockville, MD 20850 USA; Ctr Advancement Genom, Rockville, MD 20850 USA	J. Craig Venter Institute; J. Craig Venter Institute	Bafna, V (corresponding author), Inst Genom Res, Rockville, MD 20850 USA.		Pop, Mihai/A-7987-2013	Pop, Mihai/0000-0001-9617-5304; Fraser, Claire/0000-0003-1462-2428; Bafna, Vineet/0000-0002-5810-6241				Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Breen M, 2001, GENOME RES, V11, P1784, DOI 10.1101/gr.189401; Brouillette JA, 2000, MAMM GENOME, V11, P1079, DOI 10.1007/s003350010220; Chase K, 2002, P NATL ACAD SCI USA, V99, P9930, DOI 10.1073/pnas.152333099; Davies PA, 2003, J BIOL CHEM, V278, P712, DOI 10.1074/jbc.M208814200; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Guyon R, 2003, P NATL ACAD SCI USA, V100, P5296, DOI 10.1073/pnas.0831002100; LANDER E S, 1988, Genomics, V2, P231; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Lowe JK, 2003, GENOMICS, V82, P86, DOI 10.1016/S0888-7543(03)00078-8; Madsen O, 2001, NATURE, V409, P610, DOI 10.1038/35054544; MINNICK MF, 1992, GENE, V110, P235, DOI 10.1016/0378-1119(92)90654-8; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; O'Brien SJ, 1999, SCIENCE, V286, P458, DOI 10.1126/science.286.5439.458; Ostrander EA, 2000, TRENDS GENET, V16, P117, DOI 10.1016/S0168-9525(99)01958-7; Patterson DF, 2000, J VET INTERN MED, V14, P1, DOI 10.1892/0891-6640(2000)14[1:CAMITA]2.0.CO;2; PATTERSON DF, 2001, CANINE GENETIIC DIS; Rodriguez I, 2002, NAT NEUROSCI, V5, P134, DOI 10.1038/nn795; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Vassetzky NS, 2002, MAMM GENOME, V13, P50, DOI 10.1007/s00335-001-2111-1; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vinogradov AE, 1998, CYTOMETRY, V31, P100, DOI 10.1002/(SICI)1097-0320(19980201)31:2<100::AID-CYTO5>3.0.CO;2-Q; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800	28	403	430	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1898	1903		10.1126/science.1086432	http://dx.doi.org/10.1126/science.1086432			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512627				2022-12-28	WOS:000185536700049
J	Kiselev, SI; Sankey, JC; Krivorotov, IN; Emley, NC; Schoelkopf, RJ; Buhrman, RA; Ralph, DC				Kiselev, SI; Sankey, JC; Krivorotov, IN; Emley, NC; Schoelkopf, RJ; Buhrman, RA; Ralph, DC			Microwave oscillations of a nanomagnet driven by a spin-polarized current	NATURE			English	Article							FERROMAGNETIC-RESONANCE; MAGNETIC-ANISOTROPY	The recent discovery that a spin-polarized electrical current can apply a large torque to a ferromagnet, through direct transfer of spin angular momentum, offers the possibility of manipulating magnetic-device elements without applying cumbersome magnetic fields(1-16). However, a central question remains unresolved: what type of magnetic motions can be generated by this torque? Theory predicts that spin transfer may be able to drive a nanomagnet into types of oscillatory magnetic modes not attainable with magnetic fields alone(1-3), but existing measurement techniques have provided only indirect evidence for dynamical states(4,6-8,12,14-16). The nature of the possible motions has not been determined. Here we demonstrate a technique that allows direct electrical measurements of microwave-frequency dynamics in individual nanomagnets, propelled by a d.c. spin-polarized current. We show that spin transfer can produce several different types of magnetic excitation. Although there is no mechanical motion, a simple magnetic-multilayer structure acts like a nanoscale motor; it converts energy from a d.c. electrical current into high-frequency magnetic rotations that might be applied in new devices including microwave sources and resonators.	Cornell Univ, Ithaca, NY 14853 USA; Yale Univ, Dept Phys & Appl Phys, New Haven, CT 06511 USA	Cornell University; Yale University	Ralph, DC (corresponding author), Cornell Univ, Ithaca, NY 14853 USA.	ralph@ccmr.cornell.edu	Ralph, Daniel C/G-3251-2010; Krivorotov, Ilya/Q-5760-2019; Sankey, Jack C/H-1373-2012; Sankey, Jack C/K-5072-2012; Schoelkopf, Robert J/J-8178-2012	Krivorotov, Ilya/0000-0002-1658-2565; Childress (Sankey), Jack/0000-0002-7997-8727				ALBERT FJ, 2003, THESIS CORNELL U; BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; Bauer GEW, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.094421; Bazaliy YB, 2001, J APPL PHYS, V89, P6793, DOI 10.1063/1.1362642; Bazaliy YB, 1998, PHYS REV B, V57, pR3213, DOI 10.1103/PhysRevB.57.R3213; Berger L, 1996, PHYS REV B, V54, P9353, DOI 10.1103/PhysRevB.54.9353; Grollier J, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.174402; Grollier J, 2001, APPL PHYS LETT, V78, P3663, DOI 10.1063/1.1374230; Johnson MT, 1996, REP PROG PHYS, V59, P1409, DOI 10.1088/0034-4885/59/11/002; Katine JA, 2000, PHYS REV LETT, V84, P3149, DOI 10.1103/PhysRevLett.84.3149; Kittel C., 1996, INTRO SOLID STATE PH, P505; LEE CH, 1990, PHYS REV B, V42, P1066, DOI 10.1103/PhysRevB.42.1066; Li Z, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.024404; Myers EB, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.196801; Myers EB, 1999, SCIENCE, V285, P867, DOI 10.1126/science.285.5429.867; Nazarov AV, 2002, APPL PHYS LETT, V81, P4559, DOI 10.1063/1.1521578; Ozyilmaz B, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.067203; POLIANSKI M, 2003, CURRENT INDUCED TRAN; POZAR DM, 1995, MICROWAVE ENG, P566; Rippard WH, 2003, APPL PHYS LETT, V82, P1260, DOI 10.1063/1.1556168; Slonczewski JC, 1996, J MAGN MAGN MATER, V159, pL1, DOI 10.1016/0304-8853(96)00062-5; Stiles MD, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.014407; SUHL H, 1957, J PHYS CHEM SOLIDS, V1, P209, DOI 10.1016/0022-3697(57)90010-0; Sun JZ, 2000, PHYS REV B, V62, P570, DOI 10.1103/PhysRevB.62.570; Sun JZ, 1999, J MAGN MAGN MATER, V202, P157, DOI 10.1016/S0304-8853(99)00289-9; Sun JZ, 2002, APPL PHYS LETT, V81, P2202, DOI 10.1063/1.1506794; Tsoi M, 2000, NATURE, V406, P46, DOI 10.1038/35017512; Tsoi M, 1998, PHYS REV LETT, V81, P493, DOI 10.1103/PhysRevLett.81.493; URAZHDIN S, 2003, CURRENT DRIVEN MAGNE; Wegrowe JE, 2002, APPL PHYS LETT, V80, P3775, DOI 10.1063/1.1476065	30	1672	1731	9	341	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					380	383		10.1038/nature01967	http://dx.doi.org/10.1038/nature01967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508483	Green Submitted			2022-12-28	WOS:000185502300035
J	Tunis, SR; Stryer, DB; Clancy, CM				Tunis, SR; Stryer, DB; Clancy, CM			Practical clinical trials - Increasing the value of clinical research for decision making in clinical and health policy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; LIPID-LOWERING TREATMENT; OBSTRUCTIVE PULMONARY-DISEASE; BENIGN PROSTATIC HYPERPLASIA; ACUTE MYOCARDIAL-INFARCTION; ABDOMINAL AORTIC-ANEURYSMS; LOW-BACK-PAIN; MEDICAL LITERATURE; USERS GUIDES; PRIMARY-CARE	Decision makers in health care are increasingly interested in using high-quality scientific evidence to support clinical and health policy choices; however, the quality of available scientific evidence is often found to be inadequate. Reliable evidence is essential to improve health care quality and to support efficient use of limited resources. The widespread gaps in evidence-based knowledge suggest that systematic flaws exist in the production of scientific evidence, in part because there is no consistent effort to conduct clinical trials designed to meet the needs of decision makers. Clinical trials for which the hypothesis and study design are developed specifically to answer the questions faced by decision makers are called pragmatic or practical clinical trials (PCTs). The characteristic features of PCTs are that they (1) select clinically relevant alternative interventions to compare, (2) include a diverse population of study participants, (3) recruit participants from heterogeneous practice settings, and (4) collect data on a broad range of health outcomes. The supply of PCTs is limited primarily because the major funders of clinical research, the National Institutes of Health and the-medical products industry, do not focus on supporting such trials. Increasing the supply of PCTs will depend on the development of a mechanism to establish priorities for these studies, significant expansion of an infrastructure to conduct clinical research within the health care delivery system, more reliance on high-quality evidence by health care decision makers, and a substantial increase in public and private funding for these studies. For these changes to occur, clinical and health policy decision makers will need to become more involved in all aspects of clinical research, including priority, setting, infrastructure development, and funding.	Ctr Medicare Serv, Off Clin Stand & Qual, Baltimore, MD 21244 USA; Ctr Medicaid Serv, Off Clin Stand & Qual, Baltimore, MD 21244 USA; Agcy Healthcare Res & Qual, Rockville, MD USA	Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services; Agency for Healthcare Research & Quality	Tunis, SR (corresponding author), Ctr Medicare Serv, Off Clin Stand & Qual, 7500 Secur Blvd,Mailstop 53-02-01, Baltimore, MD 21244 USA.							Altman SH, 2002, NEW ENGL J MED, V346, P855, DOI 10.1056/NEJM200203143461113; Antman K, 2001, NEW ENGL J MED, V344, P762, DOI 10.1056/NEJM200103083441010; Bach PB, 2001, ANN INTERN MED, V134, P600, DOI 10.7326/0003-4819-134-7-200104030-00016; Baigent C, 1998, BMJ-BRIT MED J, V316, P1337, DOI 10.1136/bmj.316.7141.1337; BARRY MJ, 1993, J UROLOGY, V150, P351, DOI 10.1016/S0022-5347(17)35482-4; Brady AR, 2002, NEW ENGL J MED, V346, P1445; BURING JE, 1995, TOOLS EVALUATING HLT; Califf RM, 2002, CIRCULATION, V106, P1172, DOI 10.1161/01.CIR.0000023218.39412.32; Califf RM, 2002, CIRCULATION, V106, P1015, DOI 10.1161/01.CIR.0000023260.78078.BB; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; *CTR MED MED COV, AIR FLUID BEDS PRESS; Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545; DeAngelis CD, 2003, JAMA-J AM MED ASSOC, V289, P1492, DOI 10.1001/jama.289.12.1492; Delaney BC, 2001, BRIT MED J, V322, P898, DOI 10.1136/bmj.322.7291.898; Djulbegovic B, 2001, JAMA-J AM MED ASSOC, V285, P1206, DOI 10.1001/jama.285.9.1206; Dolor RJ, 2001, JAMA-J AM MED ASSOC, V286, P3097, DOI 10.1001/jama.286.24.3097; EDDY DM, 1988, HEALTH AFFAIR, V7, P19, DOI 10.1377/hlthaff.7.1.19; Field MJ, 1990, CLIN PRACTICE GUIDEL; FITZGIBBONS RJ, GRANTS ON LINE DATAB; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Garber AM, 2001, HEALTH AFFAIR, V20, P62, DOI 10.1377/hlthaff.20.5.62; GETZ K, 2003, CTR WATCH, V10, P4; Greenland S, 1990, Epidemiology, V1, P421, DOI 10.1097/00001648-199011000-00003; Grimm RH, 2001, HYPERTENSION, V37, P19, DOI 10.1161/01.HYP.37.1.19; Guyatt G., 2015, USERS GUIDES MED LIT; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; KOLATA G, 2002, NY TIMES        0824, pA9; Lederle FA, 2002, NEW ENGL J MED, V346, P1437, DOI 10.1056/NEJMoa012573; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; LILIFORD R, 2003, BRIT MED J, V326, P980; LOMAS J, 1988, JAMA-J AM MED ASSOC, V259, P3001, DOI 10.1001/jama.259.20.3001; McNeil BJ, 2001, NEW ENGL J MED, V345, P1612, DOI 10.1056/NEJMsa011810; Mello MM, 2001, HEALTH AFFAIR, V20, P101, DOI 10.1377/hlthaff.20.5.101; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; *MTOPS RES GROUP, 2002, AM UR ASS ANN M MAY; MULROW CD, 1999, AHCPR PUBLICATION; Nathan DG, 2000, NAT MED, V6, P1201, DOI 10.1038/81282; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P554, DOI 10.1001/jama.275.7.554; *NIH, MIN INV SURG THER TR; *NIH, 2003, HLTH NEWS DAILY, V15, P5; Rafuse J, 1996, CAN MED ASSOC J, V155, P463; Rizzo JD, 1999, PHARMACOECONOMICS, V15, P339; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; Schein OD, 2000, NEW ENGL J MED, V342, P168, DOI 10.1056/NEJM200001203420304; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; Simon GE, 1996, JAMA-J AM MED ASSOC, V275, P1897, DOI 10.1001/jama.275.24.1897; Siris ES, 2001, JAMA-J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815; Snow V, 2001, ANN INTERN MED, V134, P595, DOI 10.7326/0003-4819-134-7-200104030-00015; Snow V, 2000, ANN INTERN MED, V132, P738, DOI 10.7326/0003-4819-132-9-200005020-00010; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Steiner CA, 1997, MED CARE, V35, P472, DOI 10.1097/00005650-199705000-00005; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; TAKARO T, 1976, CIRCULATION, V54, P107; Tunis SKA., 2002, ROLE PURCHASERS PAYE; Tunis SR, 2001, HEALTH AFFAIR, V20, P83, DOI 10.1377/hlthaff.20.5.83; *US FDA, IMPR INN MED TECHN 2; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; Williams JW, 2000, JAMA-J AM MED ASSOC, V284, P1519, DOI 10.1001/jama.284.12.1519; WOOSLEY RL, 1994, CLIN PHARMACOL THER, V55, P249, DOI 10.1038/clpt.1994.24	65	1305	1325	0	92	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	2003	290	12					1624	1632		10.1001/jama.290.12.1624	http://dx.doi.org/10.1001/jama.290.12.1624			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	723ZK	14506122				2022-12-28	WOS:000185461300028
J	Strack, B; Calistri, A; Craig, S; Popova, E; Gottlinger, HG				Strack, B; Calistri, A; Craig, S; Popova, E; Gottlinger, HG			AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding	CELL			English	Article							LATE ASSEMBLY DOMAIN; ROUS-SARCOMA-VIRUS; GAG PROTEIN; MULTIVESICULAR-BODY; SACCHAROMYCES-CEREVISIAE; PARTICLE-PRODUCTION; TERMINAL DOMAIN; ESCRT-I; UBIQUITIN; TSG101	HIV-1 and other retroviruses exit infected cells by budding from the plasma membrane, a process requiring membrane fission. The primary late assembly (L) domain in the p6 region of HIV-1 Gag mediates the detachment of the virion by recruiting host Tsg101, a component of the class E vacuolar protein sorting (Vps) machinery. We now show that HIV Gag p6 contains a second region involved in L domain function that binds AIP1, a homolog of the yeast class E Vps protein Bro1. Further, AIP1 interacts with Tsg101 and homologs of a subunit of the yeast class E Vps protein complex ESCRT-III. AIP1 also binds to the L domain in EIAV p9, and this binding correlates perfectly with L domain function. These observations identify AIP1 as a component of the viral budding machinery, which serves to link a distinct region in the L domain of HIV-1 p6 and EIAV p9 to ESCRT-III.	Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Gottlinger, HG (corresponding author), Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA.			Gottlinger, Heinrich/0000-0003-4124-5824; Calistri, Arianna/0000-0002-6881-7936; Popova, Elena/0000-0001-8470-8994	NIAID NIH HHS [AI29873] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029873, R37AI029873] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; Accola MA, 1999, J VIROL, V73, P9992, DOI 10.1128/JVI.73.12.9992-9999.1999; Alexander L, 2000, J VIROL, V74, P4361, DOI 10.1128/JVI.74.9.4361-4376.2000; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Borsetti A, 1998, J VIROL, V72, P9313, DOI 10.1128/JVI.72.11.9313-9317.1998; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002; Forsberg H, 2001, GENETICS, V158, P973; Freed EO, 2002, J VIROL, V76, P4679, DOI 10.1128/JVI.76.10.4679-4687.2002; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Howard TL, 2001, J CELL SCI, V114, P2395; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Le Blanc I, 2002, J VIROL, V76, P10024, DOI 10.1128/JVI.76.19.10024-10029.2002; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; PARENT LJ, 1995, J VIROL, V69, P5455, DOI 10.1128/JVI.69.9.5455-5460.1995; Puffer BA, 1998, J VIROL, V72, P10218, DOI 10.1128/JVI.72.12.10218-10221.1998; Puffer BA, 1997, J VIROL, V71, P6541, DOI 10.1128/JVI.71.9.6541-6546.1997; Springael JY, 2002, FEBS LETT, V517, P103, DOI 10.1016/S0014-5793(02)02586-3; Strack B, 2002, J VIROL, V76, P5472, DOI 10.1128/JVI.76.11.5472-5479.2002; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Vincent O, 2003, MOL CELL BIOL, V23, P1647, DOI 10.1128/MCB.23.5.1647-1655.2003; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vogt VM, 2000, P NATL ACAD SCI USA, V97, P12945, DOI 10.1073/pnas.97.24.12945; WILLS JW, 1994, J VIROL, V68, P6605, DOI 10.1128/JVI.68.10.6605-6618.1994; Xiang Y, 1996, J VIROL, V70, P5695, DOI 10.1128/JVI.70.8.5695-5700.1996; Yasuda J, 1998, J VIROL, V72, P4095, DOI 10.1128/JVI.72.5.4095-4103.1998; Yuan B, 1999, EMBO J, V18, P4700, DOI 10.1093/emboj/18.17.4700; Yuan B, 2000, J VIROL, V74, P7250, DOI 10.1128/JVI.74.16.7250-7260.2000	40	634	650	2	17	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 19	2003	114	6					689	699		10.1016/S0092-8674(03)00653-6	http://dx.doi.org/10.1016/S0092-8674(03)00653-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505569	Bronze			2022-12-28	WOS:000185464000007
J	Kaufman, AJ; Xiao, SH				Kaufman, AJ; Xiao, SH			High CO2 levels in the Proterozoic atmosphere estimated from analyses of individual microfossils	NATURE			English	Article							CARBON ISOTOPIC COMPOSITION; GROWTH-RATE	Solar luminosity on the early Earth was significantly lower than today. Therefore, solar luminosity models suggest that, in the atmosphere of the early Earth, the concentration of greenhouse gases such as carbon dioxide and methane must have been much higher(1,2). However, empirical estimates of Proterozoic levels of atmospheric carbon dioxide concentrations have not hitherto been available. Here we present ion microprobe analyses of the carbon isotopes in individual organic-walled microfossils extracted from a Proterozoic (similar to1.4-gigayear-old) shale in North China. Calculated magnitudes of the carbon isotope fractionation in these large, morphologically complex microfossils suggest elevated levels of carbon dioxide in the ancient atmosphere-between 10 and 200 times the present atmospheric level. Our results indicate that carbon dioxide was an important greenhouse gas during periods of lower solar luminosity, probably dominating over methane after the atmosphere and hydrosphere became pervasively oxygenated between 2 and 2.2 gigayears ago.	Univ Maryland, Dept Geol, College Pk, MD 20742 USA; Tulane Univ, Dept Earth & Environm Sci, New Orleans, LA 70118 USA	University System of Maryland; University of Maryland College Park; Tulane University	Kaufman, AJ (corresponding author), Univ Maryland, Dept Geol, College Pk, MD 20742 USA.	kaufman@geol.umd.edu; xiao@vt.edu	Xiao, Shuhai/A-2190-2009	Xiao, Shuhai/0000-0003-4655-2663				Bidigare RR, 1999, GLOBAL BIOGEOCHEM CY, V13, P251, DOI 10.1029/1998GB900011; Brasier MD, 1998, GEOLOGY, V26, P555, DOI 10.1130/0091-7613(1998)026<0555:ABYOES>2.3.CO;2; Cristy SS, 2000, PRACT SPECTROSC SERI, V23, P159; Farquhar J, 1999, EARTH PLANET SC LETT, V171, P607, DOI 10.1016/S0012-821X(99)00177-6; GROTZINGER JP, 1993, J GEOL, V101, P235, DOI 10.1086/648218; Habicht KS, 2002, SCIENCE, V298, P2372, DOI 10.1126/science.1078265; Hayes JM, 1999, CHEM GEOL, V161, P103, DOI 10.1016/S0009-2541(99)00083-2; Holland H. D., 1994, EARLY LIFE EARTH, V84, P237; House CH, 2000, GEOLOGY, V28, P707, DOI 10.1130/0091-7613(2000)28<707:CICOIP>2.0.CO;2; Javaux EJ, 2001, NATURE, V412, P66, DOI 10.1038/35083562; Karhu JA, 1996, GEOLOGY, V24, P867, DOI 10.1130/0091-7613(1996)024<0867:CIATRO>2.3.CO;2; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; KNOLL AH, 1984, J PALEONTOL, V58, P131; Laws EA, 1997, LIMNOL OCEANOGR, V42, P1552, DOI 10.4319/lo.1997.42.7.1552; LAWS EA, 1995, GEOCHIM COSMOCHIM AC, V59, P1131, DOI 10.1016/0016-7037(95)00030-4; Pavlov AA, 2003, GEOLOGY, V31, P87, DOI 10.1130/0091-7613(2003)031<0087:MRPA>2.0.CO;2; Popp BN, 1998, GEOCHIM COSMOCHIM AC, V62, P69, DOI 10.1016/S0016-7037(97)00333-5; RYE R, 1995, NATURE, V378, P603, DOI 10.1038/378603a0; Schulz HN, 1999, SCIENCE, V284, P493, DOI 10.1126/science.284.5413.493; SHIVELY JM, 1991, VARIATIONS AUTOTROPH, P1; Ueno Y, 2001, INT GEOL REV, V43, P196, DOI 10.1080/00206810109465008; Xiao SH, 1997, PRECAMBRIAN RES, V84, P197, DOI 10.1016/S0301-9268(97)00029-6	22	124	137	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2003	425	6955					279	282		10.1038/nature01902	http://dx.doi.org/10.1038/nature01902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679912				2022-12-28	WOS:000185370900040
J	Sheppard, CRC				Sheppard, CRC			Predicted recurrences of mass coral mortality in the Indian Ocean	NATURE			English	Article							REEFS; RECOVERY; FUTURE; EVENT	In 1998, more than 90% of shallow corals were killed on most Indian Ocean reefs(1). High sea surface temperature (SST) was a primary cause(2,3), acting directly or by interacting with other factors(3-7). Mean SSTs have been forecast to rise above the 1998 values in a few decades(2,3); however, forecast SSTs rarely flow seamlessly from historical data, or may show erroneous seasonal oscillations, precluding an accurate prediction of when lethal SSTs will recur. Differential acclimation by corals in different places complicates this further(3,7,8). Here I scale forecast SSTs at 33 Indian Ocean sites where most shallow corals died in 1998 (ref. 1) to identify geographical patterns in the timing of probable repeat occurrences. Reefs located 10-15degrees south will be affected every 5 years by 2010-2025. North and south from this, dates recede in a pattern not directly related to present SSTs; paradoxically, some of the warmest sites may be affected last. Temperatures lethal to corals vary in this region by 6degreesC, and acclimation of a modest 2degreesC by corals could prolong their survival by nearly 100 years.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick	Sheppard, CRC (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.			sheppard, charles/0000-0002-2579-5124				CESAR HSJ, 2000, EC CORAL REEFS, P244; Cubasch U., 2001, PROJECTIONS FUTURE C, P525; Douglas AE, 2003, MAR POLLUT BULL, V46, P385, DOI 10.1016/S0025-326X(03)00037-7; Gates RD, 1999, AM ZOOL, V39, P30; Harrison P.L., 1990, CORAL REEFS, V25, P133; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; LINDEN O, 2002, CORAL REEF DEGRADATI, P284; McAvaney BJ, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P471; McClanahan TR, 2000, MAR POLLUT BULL, V40, P587, DOI 10.1016/S0025-326X(00)00064-3; Nakamura T, 2001, MAR ECOL PROG SER, V212, P301, DOI 10.3354/meps212301; Pittock AB, 1999, AM ZOOL, V39, P10; RAYNER NA, IN PRESS J GEOPHYS R; Riegl B, 2002, MAR BIOL, V140, P29, DOI 10.1007/s002270100676; Sheppard C, 2002, MAR POLLUT BULL, V44, P303, DOI 10.1016/S0025-326X(02)00059-0; Sheppard C, 2001, MAR POLLUT BULL, V42, P1199, DOI 10.1016/S0025-326X(01)00238-7; Sheppard Charles, 2002, Aquatic Ecosystem Health & Management, V5, P395, DOI 10.1080/14634980290002020; SHEPPARD CRC, 1988, J NAT HIST, V22, P263, DOI 10.1080/00222938800770201; Sheppard CRC, 2002, AMBIO, V31, P40, DOI 10.1639/0044-7447(2002)031[0040:EVROCR]2.0.CO;2; SHEPPARD CRC, 1991, FAUNA SAUDI ARABIA, V12, P7; Spencer T, 2000, MAR POLLUT BULL, V40, P569, DOI 10.1016/S0025-326X(00)00026-6; Turner J., 2000, CORAL REEF DEGRADATI, P94; Veron J. E., 2000, CORALS WORLD, V1; Wilkinson C, 1999, AMBIO, V28, P188; WILKINSON C, 2000, SEAS MILLENNIUM ENV, V3, P43	24	272	287	6	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					294	297		10.1038/nature01987	http://dx.doi.org/10.1038/nature01987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679917				2022-12-28	WOS:000185370900045
J	Yoshida, S; Shidoh, M; Shimoya, Y; Ohta, Y				Yoshida, S; Shidoh, M; Shimoya, Y; Ohta, Y			Brenner tumour	LANCET			English	Editorial Material									Muroran City Gen Hosp, Dept Radiol, Muroran, Hokkaido 0518512, Japan; Muroran City Gen Hosp, Dept Gynaecol, Muroran, Hokkaido 0518512, Japan		Yoshida, S (corresponding author), Muroran City Gen Hosp, Dept Radiol, Yamatechou 3-8-1, Muroran, Hokkaido 0518512, Japan.								0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					858	858		10.1016/S0140-6736(03)14340-1	http://dx.doi.org/10.1016/S0140-6736(03)14340-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678972				2022-12-28	WOS:000185329400009
J	Cashmore, AR				Cashmore, AR			Cryptochromes: Enabling plants and animals to determine circadian time	CELL			English	Review							ARABIDOPSIS CRYPTOCHROMES; DNA PHOTOLYASE; LIGHT; CLOCK; MELANOPSIN; RESPONSES; PROTEIN; PHOTORECEPTORS; BLIND; GENE	Cryptochromes are flavin-containing blue light photoreceptors related to photolyases -they are found in both plants and animals and have recently been described for bacteria. In plants, cryptochromes perform a variety of functions including the entrainment of circadian rhythms. They serve a similar role in Drosophila and mammals, where the cryptochromes also perform an additional function as an essential component of the circadian clock.	Univ Penn, Sch Arts & Sci, Inst Plant Sci, Dept Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Cashmore, AR (corresponding author), Univ Penn, Sch Arts & Sci, Inst Plant Sci, Dept Biol, Philadelphia, PA 19104 USA.							AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Brudler R, 2003, MOL CELL, V11, P59, DOI 10.1016/S1097-2765(03)00008-X; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Hall JC, 2000, CURR OPIN NEUROBIOL, V10, P456, DOI 10.1016/S0959-4388(00)00117-3; Harmer SL, 2001, ANNU REV CELL DEV BI, V17, P215, DOI 10.1146/annurev.cellbio.17.1.215; Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761; Helfrich-Forster C, 2001, NEURON, V30, P249, DOI 10.1016/S0896-6273(01)00277-X; Kleine T, 2003, PLANT J, V35, P93, DOI 10.1046/j.1365-313X.2003.01787.x; Krishnan B, 2001, NATURE, V411, P313, DOI 10.1038/35077094; Lin CT, 2003, ANNU REV PLANT BIOL, V54, P469, DOI 10.1146/annurev.arplant.54.110901.160901; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; Lin FJ, 2001, MOL CELL BIOL, V21, P7287, DOI 10.1128/MCB.21.21.7287-7294.2001; Long JC, 1998, PLANT CELL, V10, P2077, DOI 10.1105/tpc.10.12.2077; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rosato E, 2001, CURR BIOL, V11, P909, DOI 10.1016/S0960-9822(01)00259-7; Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Selby CP, 2000, P NATL ACAD SCI USA, V97, P14697, DOI 10.1073/pnas.260498597; Shalitin D, 2002, NATURE, V417, P763, DOI 10.1038/nature00815; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Thompson CL, 2001, P NATL ACAD SCI USA, V98, P11708, DOI 10.1073/pnas.201301498; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Van Gelder RN, 2003, SCIENCE, V299, P222, DOI 10.1126/science.1079536; Van Gelder RN, 2002, J BIOL RHYTHM, V17, P110, DOI 10.1177/074873002129002401; Wang HY, 2001, SCIENCE, V294, P154, DOI 10.1126/science.1063630; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; YANG MH, 2001, KLU INT S VIDEO COMP, V1, P1	35	249	271	0	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	2003	114	5					537	543		10.1016/j.cell.2003.08.004	http://dx.doi.org/10.1016/j.cell.2003.08.004			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678578				2022-12-28	WOS:000185193100004
J	Roovers, JPWR; van der Bom, JG; van der Vaart, CH; Heintz, APM				Roovers, JPWR; van der Bom, JG; van der Vaart, CH; Heintz, APM		Hysterectomy Vaginal Versus Abdomi	Hysterectomy and sexual wellbeing: prospective observational study of vaginal hysterectomy, subtotal abdominal hysterectomy, and total abdominal hysterectomy	BRITISH MEDICAL JOURNAL			English	Article							OUTCOMES; URINARY; WOMEN		Univ Med Ctr Utrecht, Dept Obstet & Gynaecol, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Roovers, JPWR (corresponding author), Univ Med Ctr Utrecht, Dept Obstet & Gynaecol, NL-3584 CX Utrecht, Netherlands.		van der Bom, Johanna G./G-1965-2018	van der Bom, Johanna G./0000-0001-9095-2475				Butler-Manuel SA, 2000, CANCER-AM CANCER SOC, V89, P834, DOI 10.1002/1097-0142(20000815)89:4<834::AID-CNCR16>3.0.CO;2-7; Davies A, 1998, AM J OBSTET GYNECOL, V179, P1008, DOI 10.1016/S0002-9378(98)70207-8; *DEP HLTH, 1998, HOSP EP STAT; HELSTROM I, 1998, OBSTET GYNECOL, V81, P357; HELSTROM L, 1993, OBSTET GYNECOL, V81, P357; HELSTROM L, 1995, ACTA OBSTET GYN SCAN, V74, P142, DOI 10.3109/00016349509008924; Hoogendoorn D, 1984, Ned Tijdschr Geneeskd, V128, P1937; KILKKU P, 1983, ACTA OBSTET GYN SCAN, V62, P147, DOI 10.3109/00016348309155779; Kovac SR, 2000, OBSTET GYNECOL, V95, P787, DOI 10.1016/S0029-7844(99)00641-9; PARYS BT, 1989, BR J UROL, V64, P4594; POLIVY J, 1974, AM J OBSTET GYNECOL, V118, P417, DOI 10.1016/S0002-9378(16)33802-9; Rhodes JC, 1999, JAMA-J AM MED ASSOC, V282, P1934, DOI 10.1001/jama.282.20.1934; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SLOAN D, 1978, AM J OBSTET GYNECOL, V131, P598, DOI 10.1016/0002-9378(78)90817-7; SMITH PH, 1968, BRIT J SURG, V55, P929, DOI 10.1002/bjs.1800551212; SULTAN AH, 1994, BRIT J OBSTET GYNAEC, V101, P22, DOI 10.1111/j.1471-0528.1994.tb13005.x; Thakar R, 2002, NEW ENGL J MED, V347, P1318, DOI 10.1056/NEJMoa013336; Van den Eeden SK, 1998, AM J OBSTET GYNECOL, V178, P91, DOI 10.1016/S0002-9378(98)70633-7; VIRTANEN H, 1993, BRIT J UROL, V72, P868, DOI 10.1111/j.1464-410X.1993.tb16288.x; Vroege JA, 1998, EUR UROL, V34, P25, DOI 10.1159/000019673; Vroege JA, 2001, J SEX MARITAL THER, V27, P237, DOI 10.1080/00926230152052058	21	110	121	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					774	777		10.1136/bmj.327.7418.774	http://dx.doi.org/10.1136/bmj.327.7418.774			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525872	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000185805100016
J	Fischle, W; Wang, YM; Allis, CD				Fischle, W; Wang, YM; Allis, CD			Binary switches and modification cassettes in histone biology and beyond	NATURE			English	Article							POSITION-EFFECT VARIEGATION; MAMMALIAN-CELLS; LYSINE METHYLATION; MOLECULAR-BASIS; H3; HP1; CHROMATIN; PHOSPHORYLATION; CORE; IDENTIFICATION	An immense number of post-translational modifications on histone proteins have been described and additional sites of modification are still being uncovered. Whereas many direct and indirect connections between certain histone modifications and distinct biological phenomena have now been established, concepts for comprehending the extreme density and variety of these covalent modifications are lacking. Here, we formally introduce localized 'binary switches' and 'modification cassettes' as new concepts in histone biology, elucidating mechanisms that might govern the biological readout of distinct modification patterns. Specifically, our hypotheses provide missing models for the dynamic readout of stable histone modifications and offer explanations for several long-standing questions embedded in the literature. Our ideas might also apply to non-histone proteins and are open to direct experimental examination.	Rockefeller Univ, Lab Chromat Biol, New York, NY 10021 USA	Rockefeller University	Allis, CD (corresponding author), Rockefeller Univ, Lab Chromat Biol, 1230 York Ave, New York, NY 10021 USA.			Wang, Yanming/0000-0002-0710-043X				Appella E, 2000, PATHOL BIOL, V48, P227; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Baarends WM, 1999, DEV BIOL, V207, P322, DOI 10.1006/dbio.1998.9155; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; DAVIE JR, 1991, BIOCHEM CELL BIOL, V69, P66, DOI 10.1139/o91-009; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; FUJITAKI JM, 1981, BIOCHEMISTRY-US, V20, P3658, DOI 10.1021/bi00515a055; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; KELLUM R, 1995, J CELL SCI, V108, P1407; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Li YH, 2003, DEVELOPMENT, V130, P1817, DOI 10.1242/dev.00405; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Ng HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI 10.1073/pnas.0437846100; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Park JH, 2002, NAT GENET, V32, P273, DOI 10.1038/ng982; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thompson JS, 2003, GENETICS, V163, P447; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; WATERBORG JH, 1990, J BIOL CHEM, V265, P17157; Zhang KL, 2002, ANAL BIOCHEM, V306, P259, DOI 10.1006/abio.2002.5719; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	38	522	535	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					475	479		10.1038/nature02017	http://dx.doi.org/10.1038/nature02017			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523437				2022-12-28	WOS:000185648100035
J	Yanagisawa, S; Yoo, SD; Sheen, J				Yanagisawa, S; Yoo, SD; Sheen, J			Differential regulation of EIN3 stability by glucose and ethylene signalling in plants	NATURE			English	Article							INDUCIBLE GENE-EXPRESSION; PROTEASOME PATHWAY; RESPONSE PATHWAY; ABSCISIC-ACID; ARABIDOPSIS; PROTEIN; LIGHT; TRANSDUCTION; MAIZE; ETHYLENE-INSENSITIVE3	Glucose is a global regulator of growth and metabolism that is evolutionarily conserved from unicellular microorganisms to multicellular animals and plants(1). In photosynthetic plants, glucose shows hormone-like activities and modulates many essential processes, including embryogenesis, germination, seedling development, vegetative growth, reproduction and senescence(2,3). Genetic and phenotypic analyses of Arabidopsis mutants with glucose-insensitive (gin) and glucose-oversensitive (glo) phenotypes have identified an unexpected antagonistic interaction between glucose and the plant stress hormone ethylene. The ethylene-insensitive etr1 and ein2 mutants have glo phenotypes, whereas the constitutive ethylene signalling mutant ctr1 is allelic to gin4 (refs 4, 5). The precise molecular mechanisms underlying the complex signalling network that governs plant growth and development in response to nutrients and plant hormones are mostly unknown. Here we show that glucose enhances the degradation of ETHYLENE-INSENSITIVE3 (EIN3), a key transcriptional regulator in ethylene signalling(6,7), through the plant glucose sensor hexokinase(8). Ethylene, by contrast, enhances the stability of EIN3. The ein3 mutant has a glo phenotype, and overexpression of EIN3 in transgenic Arabidopsis decreases glucose sensitivity.	Okayama Univ, Bioresources Res Inst, Kurashiki, Okayama 7100046, Japan; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Genet,Dept Mol Biol, Boston, MA 02114 USA	Okayama University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Yanagisawa, S (corresponding author), Okayama Univ, Bioresources Res Inst, Chuo 2-20-1, Kurashiki, Okayama 7100046, Japan.	yanagi-s@rib.okayama-u.ac.jp						Alonso JM, 1999, SCIENCE, V284, P2148, DOI 10.1126/science.284.5423.2148; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Chang CC, 1999, PLANT CELL, V11, P911, DOI 10.1105/tpc.11.5.911; Chao QM, 1997, CELL, V89, P1133, DOI 10.1016/S0092-8674(00)80300-1; Cheng WH, 2002, PLANT CELL, V14, P2723, DOI 10.1105/tpc.006494; Fujimoto SY, 2000, PLANT CELL, V12, P393, DOI 10.1105/tpc.12.3.393; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; He JX, 2002, P NATL ACAD SCI USA, V99, P10185, DOI 10.1073/pnas.152342599; Hwang I, 2001, NATURE, V413, P383, DOI 10.1038/35096500; JANG JC, 1994, PLANT CELL, V6, P1665, DOI 10.1105/tpc.6.11.1665; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kosugi S, 2000, NUCLEIC ACIDS RES, V28, P960, DOI 10.1093/nar/28.4.960; Kovtun Y, 1998, NATURE, V395, P716, DOI 10.1038/27240; Lopez-Molina L, 2001, P NATL ACAD SCI USA, V98, P4782, DOI 10.1073/pnas.081594298; Moore B, 2003, SCIENCE, V300, P332, DOI 10.1126/science.1080585; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Rolland F, 2002, PLANT CELL, V14, pS185, DOI 10.1105/tpc.010455; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; SHEEN J, 1993, EMBO J, V12, P3497, DOI 10.1002/j.1460-2075.1993.tb06024.x; SHEEN JY, 1986, EMBO J, V5, P3417, DOI 10.1002/j.1460-2075.1986.tb04663.x; Smeekens S, 2000, ANNU REV PLANT PHYS, V51, P49, DOI 10.1146/annurev.arplant.51.1.49; Solano R, 1998, GENE DEV, V12, P3703, DOI 10.1101/gad.12.23.3703; Vierstra RD, 2003, TRENDS PLANT SCI, V8, P135, DOI 10.1016/S1360-1385(03)00014-1; Wang KLC, 2002, PLANT CELL, V14, pS131, DOI 10.1105/tpc.001768; Yanagisawa S, 1998, PLANT CELL, V10, P75, DOI 10.1105/tpc.10.1.75; Zhou L, 1998, P NATL ACAD SCI USA, V95, P10294, DOI 10.1073/pnas.95.17.10294; Zuo JR, 2000, PLANT J, V24, P265, DOI 10.1046/j.1365-313x.2000.00868.x	30	377	413	4	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2003	425	6957					521	525		10.1038/nature01984	http://dx.doi.org/10.1038/nature01984			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523448				2022-12-28	WOS:000185648100047
J	Nathoo, S; Serghides, L; Kain, KC				Nathoo, S; Serghides, L; Kain, KC			Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes	LANCET			English	Article							MALARIA	In response to the HIV/AIDS pandemic, antiretroviral treatment is currently being implemented in sub-Saharan Africa, where malaria and HIV-1 co-infections are highly prevalent. The effectiveness and tolerability of antiretrovirals in patients with malaria and HIV-1 co-infection have not been investigated. Antiretrovirals decrease CD36 surface concentrations in vivo, which might impair receptor function and affect parasite-host interactions. Thus, we investigated the effects of these drugs on CD36-mediated cytoadherence and non-opsonic phagocytosis of Plasmodium falciparum parasitised erythrocytes in vitro. The protease-inhibitor class of antiretrovirals particularly impairs CD36-mediated cytoadherence and non-opsonic phagocytosis of parasitised erythrocytes by human macrophages. Such treatment might therefore contribute to altered malaria disease outcomes in co-infected patients.	Toronto Gen Hosp, Trop Dis Unit, Div Infect Dis, Dept Med,Univ Hlth Network, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto	Kain, KC (corresponding author), Toronto Gen Hosp, Trop Dis Unit, Div Infect Dis, Dept Med,Univ Hlth Network, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	kevin.kain@uhn.on.ca	Serghides, Lena/C-7968-2018	Serghides, Lena/0000-0002-2817-6134; Kain, Kevin/0000-0001-6068-1272				Aitman TJ, 2000, NATURE, V405, P1015, DOI 10.1038/35016636; Corbett EL, 2002, LANCET, V359, P2177, DOI 10.1016/S0140-6736(02)09095-5; Rogerson SJ, 1999, AM J TROP MED HYG, V61, P467, DOI 10.4269/ajtmh.1999.61.467; Serghides L, 2001, J IMMUNOL, V166, P6742, DOI 10.4049/jimmunol.166.11.6742; Serghides L, 2002, AIDS, V16, P353, DOI 10.1097/00002030-200202150-00006	5	51	52	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2003	362	9389					1039	1041		10.1016/S0140-6736(03)14414-5	http://dx.doi.org/10.1016/S0140-6736(03)14414-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522535				2022-12-28	WOS:000185564600012
J	Kamal, A; Thao, L; Sensintaffar, J; Zhang, L; Boehm, MF; Fritz, LC; Burrows, FJ				Kamal, A; Thao, L; Sensintaffar, J; Zhang, L; Boehm, MF; Fritz, LC; Burrows, FJ			A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors	NATURE			English	Article							HEAT-SHOCK PROTEINS; ATP BINDING; GELDANAMYCIN; CHAPERONE; DEGRADATION; EXPRESSION; DESTABILIZATION; HYDROLYSIS; CAPACITOR; RECEPTOR	Heat shock protein 90 (Hsp90) is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signalling proteins, including HER-2/ErbB2, Akt, Raf-1, Bcr-Abl and mutated p53(1-7). Hsp90 inhibitors bind to Hsp90, and induce the proteasomal degradation of Hsp90 client proteins(6,8-11). Although Hsp90 is highly expressed in most cells, Hsp90 inhibitors selectively kill cancer cells compared to normal cells, and the Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG) is currently in phase I clinical trials(12,13). However, the molecular basis of the tumour selectivity of Hsp90 inhibitors is unknown. Here we report that Hsp90 derived from tumour cells has a 100-fold higher binding affinity for 17-AAG than does Hsp90 from normal cells. Tumour Hsp90 is present entirely in multi-chaperone complexes with high ATPase activity, whereas Hsp90 from normal tissues is in a latent, uncomplexed state. In vitro reconstitution of chaperone complexes with Hsp90 resulted in increased binding affinity to 17-AAG, and increased ATPase activity. These results suggest that tumour cells contain Hsp90 complexes in an activated, high-affinity conformation that facilitates malignant progression, and that may represent a unique target for cancer therapeutics.	Conforma Therapeut Corp, San Diego, CA 92121 USA		Burrows, FJ (corresponding author), Conforma Therapeut Corp, 9393 Towne Ctr dr,Suite 240, San Diego, CA 92121 USA.	fburrows@conformacorp.com						An WG, 2000, CELL GROWTH DIFFER, V11, P355; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Chiosis G, 2003, MOL CANCER THER, V2, P123; Chiosis G, 2001, CHEM BIOL, V8, P289, DOI 10.1016/S1074-5521(01)00015-1; EGORIN MJ, 1999, P AM ASSOC CANC RES, V40, P3409; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; GRESS TM, 1994, CANCER RES, V54, P547; Guermonprez P, 2003, NATURE, V425, P397, DOI 10.1038/nature01911; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; MILLER P, 1994, CANCER RES, V54, P2724; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SCHUH S, 1985, J BIOL CHEM, V260, P4292; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; Solit DB, 2002, CLIN CANCER RES, V8, P986; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Workman P, 2003, MOL CANCER THER, V2, P131; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yano M, 1996, JPN J CANCER RES, V87, P908, DOI 10.1111/j.1349-7006.1996.tb02119.x	32	1124	1191	12	141	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					407	410		10.1038/nature01913	http://dx.doi.org/10.1038/nature01913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508491				2022-12-28	WOS:000185502300043
J	Tancredi, DN; Shannon, MW; Goldstein, JN; Kosowsky, J; Lai, M; Singh, MK				Tancredi, DN; Shannon, MW; Goldstein, JN; Kosowsky, J; Lai, M; Singh, MK			A man with sudden alteration of mental status - Ingestion of 1,4-butanediol, resulting in gamma-hydroxybutyrate intoxication	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MANAGEMENT; WITHDRAWAL; OVERDOSE; DEATH		Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Emergency Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Tancredi, DN (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.		Goldstein, Joshua N/H-8953-2016					Bond GR, 2002, ANN EMERG MED, V39, P273, DOI 10.1067/mem.2002.122058; Boyer EW, 2001, NEW ENGL J MED, V345, P469, DOI 10.1056/NEJM200108093450619; Chin RL, 1998, ANN EMERG MED, V31, P716, DOI 10.1016/S0196-0644(98)70230-6; Doyon Suzanne, 1994, Emergency Medicine Clinics of North America, V12, P301; Dyer JE, 2001, ANN EMERG MED, V37, P147, DOI 10.1067/mem.2001.112985; Grierson R, 2000, ANN EMERG MED, V35, P435, DOI 10.1067/mem.2000.105931; HOLLANDER JE, 1995, NEW ENGL J MED, V333, P1267, DOI 10.1056/NEJM199511093331907; Lev Roneet, 1994, Journal of Emergency Medicine, V12, P499, DOI 10.1016/0736-4679(94)90347-6; Li J, 1998, ANN EMERG MED, V31, P723, DOI 10.1016/S0196-0644(98)70231-8; Mycyk MB, 2001, ANN EMERG MED, V38, P345, DOI 10.1067/mem.2001.117499; Quang LS, 2002, LIFE SCI, V71, P771, DOI 10.1016/S0024-3205(02)01744-7; QUANG LS, 2002, ANN NY ACAD SCI, V965, P1; Sakles JC, 1998, ANN EMERG MED, V31, P325, DOI 10.1016/S0196-0644(98)70342-7; Schneidereit T., 2000, INT J MED TOXICOL, V3, P1; Stratton SJ, 2001, AM J EMERG MED, V19, P187, DOI 10.1053/ajem.2001.22665; Vale J A, 1997, J Toxicol Clin Toxicol, V35, P711; Zvosec DL, 2001, NEW ENGL J MED, V344, P87, DOI 10.1056/NEJM200101113440202	17	9	9	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2003	349	13					1267	1275		10.1056/NEJMcpc030021	http://dx.doi.org/10.1056/NEJMcpc030021			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	724LJ	14507952				2022-12-28	WOS:000185488800010
J	Iyengar, S; Chin, B; Margolick, JB; Sabundayo, BP; Schwartz, DH				Iyengar, S; Chin, B; Margolick, JB; Sabundayo, BP; Schwartz, DH			Anatomical loci of HIV-associated immune activation and association with viraemia	LANCET			English	Article							POSITRON-EMISSION-TOMOGRAPHY; HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; STANDARDIZED UPTAKE VALUES; CYTOTOXIC T-LYMPHOCYTES; LYMPHOID-TISSUES; RHESUS MACAQUES; CELL DEPLETION; BODY-WEIGHT; INFECTION	Background Lymphocyte activation, associated with vaccination or infection, can be measured by positron emission tomography (PET). We investigated the ability of PET to detect and measure magnitude of lymph-node activation among asymptomatic HIV-1-infected individuals. Methods Initially we assessed PET response in eight HIV-1-uninfected individuals who had received licensed killed influenza vaccine. In an urban teaching hospital, we recruited 12 patients recently infected with HIV-1 (<18 months since seroconversion) and 11 chronic long-term HIV-1 patients who had stable viraemia by RT-PCR (non-progressors). After injection with fluorine-18-labelled fluorodeoxyglucose, patients underwent PET. We correlated summed PET signal from nodes with viral load by linear regression on log-transformed values. Findings Node activation was more localised after vaccination than after HIV-1 infection. In early and chronic HIV-1 disease, node activation was greater in cervical and axillary than in inguinal and iliac chains (p<0.0001), and summed PET signal correlated with viraemia across a 4 log range (r(2)=0.98, p<0.0001). Non-progressors had small numbers of persistently active nodes, most of which were surgically accessible. Interpretation The anatomical restriction we noted may reflect microenvironmental niche selection, and tight correlation of PET signal with viraemia suggests target-cell activation determines steady-state viral replication.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Div Nucl Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Schwartz, DH (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.		Chin, Bennett/T-6591-2017; Chin, Bennett B/M-6554-2015	Chin, Bennett/0000-0002-2907-5968; Chin, Bennett B/0000-0002-2907-5968	NIAID NIH HHS [R21-AI 44725, AI 41532, P30-AI42855] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041532, P30AI042855, R21AI044725] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams S, 1998, J NUCL MED, V39, P1155; Akhurst, 2000, Clin Positron Imaging, V3, P57, DOI 10.1016/S1095-0397(00)00041-8; Anthony KB, 2003, JAIDS-J ACQ IMM DEF, V33, P125, DOI 10.1097/00126334-200306010-00002; BENTAL M, 1993, MAGN RESON MED, V29, P317, DOI 10.1002/mrm.1910290307; Blattman JN, 2000, J IMMUNOL, V165, P6081, DOI 10.4049/jimmunol.165.11.6081; Brand KA, 1997, FASEB J, V11, P388, DOI 10.1096/fasebj.11.5.9141507; Brodie SJ, 2000, J CLIN INVEST, V105, P1407, DOI 10.1172/JCI8707; Chen G, 2001, BLOOD, V98, P156, DOI 10.1182/blood.V98.1.156; Chen JJY, 2002, J LEUKOCYTE BIOL, V72, P271; d'Ettorre G, 2002, AIDS, V16, P1877, DOI 10.1097/00002030-200209270-00004; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Hazenberg MD, 2002, AIDS, V16, P1287, DOI 10.1097/00002030-200206140-00013; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724; Hosmalin A, 2001, BLOOD, V97, P2695, DOI 10.1182/blood.V97.9.2695; Iyengar S, 1999, J IMMUNOL, V162, P6263; KAUR A, 2002, VIR INF 9 C RETR OPP; KIM CK, 1994, J NUCL MED, V35, P164; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; Krzysiek R, 2001, BLOOD, V98, P3169, DOI 10.1182/blood.V98.10.3169; Kwan A, 2001, ANTICANCER RES, V21, P701; MARJANOVIC S, 1991, EXP CELL RES, V193, P425, DOI 10.1016/0014-4827(91)90116-C; Mohri H, 2001, J EXP MED, V194, P1277, DOI 10.1084/jem.194.9.1277; Schacker T, 2001, J INFECT DIS, V183, P555, DOI 10.1086/318524; Scharko AM, 1996, P NATL ACAD SCI USA, V93, P6425, DOI 10.1073/pnas.93.13.6425; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; THOMAS MB, 2000, CLIN POSITRON IMAGIN, V3, P176; WAHL RL, 1993, J CLIN ONCOL, V11, P2101, DOI 10.1200/JCO.1993.11.11.2101; Wallace M, 2000, VIROLOGY, V274, P255, DOI 10.1006/viro.2000.0479; Yasuda Seiei, 1998, Tokai Journal of Experimental and Clinical Medicine, V23, P241; ZASADNY KR, 1993, RADIOLOGY, V189, P847, DOI 10.1148/radiology.189.3.8234714	32	55	58	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					945	950		10.1016/S0140-6736(03)14363-2	http://dx.doi.org/10.1016/S0140-6736(03)14363-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511927				2022-12-28	WOS:000185489600008
J	Davidson, AJ; Ernst, P; Wang, Y; Dekens, MPS; Kingsley, PD; Palis, J; Korsmeyer, SJ; Daley, GQ; Zon, LI				Davidson, AJ; Ernst, P; Wang, Y; Dekens, MPS; Kingsley, PD; Palis, J; Korsmeyer, SJ; Daley, GQ; Zon, LI			cdx4 mutants fail to specify blood progenitors and can be rescued by multiple hox genes	NATURE			English	Article							HOMEOBOX GENE; HEMATOPOIETIC-CELLS; MYELOID-LEUKEMIA; CAUDAL HOMOLOG; TAIL FORMATION; STEM-CELL; EXPRESSION; MICE; DROSOPHILA; EXPANSION	Organogenesis is dependent on the formation of distinct cell types within the embryo. Important to this process are the hox genes, which are believed to confer positional identities to cells along the anteroposterior axis(1-3). Here, we have identified the caudal-related gene cdx4 as the locus mutated in kugelig (kgg), a zebrafish mutant with an early defect in haematopoiesis that is associated with abnormal anteroposterior patterning and aberrant hox gene expression. The blood deficiency in kgg embryos can be rescued by overexpressing hoxb7a or hoxa9a but not hoxb8a, indicating that the haematopoietic defect results from perturbations in specific hox genes. Furthermore, the haematopoietic defect in kgg mutants is not rescued by scl overexpression, suggesting that cdx4 and hox genes act to make the posterior mesoderm competent for blood development. Overexpression of cdx4 during zebrafish development or in mouse embryonic stem cells induces blood formation and alters hox gene expression. Taken together, these findings demonstrate that cdx4 regulates hox genes and is necessary for the specification of haematopoietic cell fate during vertebrate embryogenesis.	Childrens Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02115 USA; Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Max Planck Inst Entwicklungsbiol, Genet Abt, D-72076 Tubingen, Germany; Univ Rochester, Dept Pediat, Ctr Human Genet & Mol Pediat Dis, Rochester, NY 14642 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Max Planck Society; University of Rochester	Zon, LI (corresponding author), Childrens Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02115 USA.			Palis, James/0000-0001-7324-1049; Ernst, Patricia/0000-0001-7638-2939; Dekens, Marcus P.S./0000-0003-1689-3491; wang, Yuan/0000-0002-0939-1269				Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Bjornsson JM, 2003, MOL CELL BIOL, V23, P3872, DOI 10.1128/MCB.23.11.3872-3883.2003; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Charite J, 1998, DEVELOPMENT, V125, P4349; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Chen F, 1998, MECH DEVELOP, V77, P49, DOI 10.1016/S0925-4773(98)00126-9; Edgar LG, 2001, DEV BIOL, V229, P71, DOI 10.1006/dbio.2000.9977; Gering M, 1998, EMBO J, V17, P4029, DOI 10.1093/emboj/17.14.4029; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; Hunter CP, 1999, DEVELOPMENT, V126, P805; JOLY JS, 1992, DIFFERENTIATION, V50, P75, DOI 10.1111/j.1432-0436.1992.tb00488.x; Kappen C, 2000, AM J HEMATOL, V65, P111, DOI 10.1002/1096-8652(200010)65:2<111::AID-AJH4>3.0.CO;2-Z; Katsuyama Y, 1999, DEV BIOL, V213, P257, DOI 10.1006/dbio.1999.9403; Kingsley PD, 2001, DEV GROWTH DIFFER, V43, P133; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Tamai Y, 1999, CANCER RES, V59, P2965; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; van den Akker E, 2002, DEVELOPMENT, V129, P2181	30	197	213	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					300	306		10.1038/nature01973	http://dx.doi.org/10.1038/nature01973			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679919				2022-12-28	WOS:000185370900047
J	McKeever, J; Boca, A; Boozer, AD; Buck, JR; Kimble, HJ				McKeever, J; Boca, A; Boozer, AD; Buck, JR; Kimble, HJ			Experimental realization of a one-atom laser in the regime of strong coupling	NATURE			English	Article							ION-TRAP LASER; PHOTON STATISTICS; SINGLE ATOMS	Conventional lasers (from table-top systems to microscopic devices) typically operate in the so-called weak-coupling regime, involving large numbers of atoms and photons; individual quanta have a negligible impact on the system dynamics. However, this is no longer the case when the system approaches the regime of strong coupling for which the number of atoms and photons can become quite small. Indeed, the lasing properties of a single atom in a resonant cavity have been extensively investigated theoretically(1-11). Here we report the experimental realization of a one-atom laser operated in the regime of strong coupling. We exploit recent advances(12) in cavity quantum electrodynamics that allow one atom to be isolated in an optical cavity in a regime for which one photon is sufficient to saturate the atomic transition. The observed characteristics of the atom-cavity system are qualitatively different from those of the familiar many-atom case. Specifically, our measurements of the intracavity photon number versus pump intensity indicate that there is no threshold for lasing, and we infer that the output flux from the cavity mode exceeds that from atomic fluorescence by more than tenfold. Observations of the second-order intensity correlation function demonstrate that our one-atom laser generates manifestly quantum (nonclassical) light, typified by photon anti-bunching and sub-poissonian photon statistics.	CALTECH, Norman Bridge Lab Phys 12 33, Pasadena, CA 91125 USA	California Institute of Technology	Kimble, HJ (corresponding author), CALTECH, Norman Bridge Lab Phys 12 33, Pasadena, CA 91125 USA.							An KW, 1997, PHYS REV A, V56, P1662, DOI 10.1103/PhysRevA.56.1662; Boiron D, 1996, PHYS REV A, V53, pR3734, DOI 10.1103/PhysRevA.53.R3734; BOOZER AD, UNPUB PHYS REV A; Carmichael H. J., 1999, STAT METHODS QUANTUM, V1; CHANG RK, 1996, OPTICAL PROCESSES MI; Corwin KL, 1999, PHYS REV LETT, V83, P1311, DOI 10.1103/PhysRevLett.83.1311; Gardiner C. W., 1991, QUANTUM NOISE; GINZEL C, 1993, PHYS REV A, V48, P732, DOI 10.1103/PhysRevA.48.732; Haken H., 1984, LASER THEORY; HORAK P, 1995, PHYS REV A, V51, P3257, DOI 10.1103/PhysRevA.51.3257; Jones B, 1999, PHYS REV A, V60, P3267, DOI 10.1103/PhysRevA.60.3267; Kilin SY, 2002, J EXP THEOR PHYS+, V95, P805, DOI 10.1134/1.1528672; Kimble HJ, 1998, PHYS SCRIPTA, VT76, P127, DOI 10.1238/Physica.Topical.076a00127; Loffler M, 1997, PHYS REV A, V55, P3923, DOI 10.1103/PhysRevA.55.3923; Mandel L, 1995, OPTICAL COHERENCE QU; McKeever J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.133602; Metcalf HJ., 1999, LASER COOLING TRAPPI; Meyer GM, 1998, PHYS REV A, V58, P3210, DOI 10.1103/PhysRevA.58.3210; Meyer GM, 1997, PHYS REV A, V56, pR1099, DOI 10.1103/PhysRevA.56.R1099; Meyer GM, 1997, EUROPHYS LETT, V37, P317, DOI 10.1209/epl/i1997-00150-y; MEYSTRE P, 1992, PROG OPTICS, V30, P261, DOI 10.1016/S0079-6638(08)70100-8; MU Y, 1992, PHYS REV A, V46, P5944, DOI 10.1103/PhysRevA.46.5944; PELLIZZARI T, 1994, PHYS REV LETT, V72, P3973, DOI 10.1103/PhysRevLett.72.3973; PELLIZZARI T, 1994, J MOD OPTIC, V41, P609, DOI 10.1080/09500349414550601; Raithel G., 1994, CAVITY QUANTUM ELECT, P57; RICE PR, 1994, PHYS REV A, V50, P4318, DOI 10.1103/PhysRevA.50.4318; SARGENT M, 1974, LASER PHYSICS; Vahala KJ, 2003, NATURE, V424, P839, DOI 10.1038/nature01939; Ye J, 1999, PHYS REV LETT, V83, P4987, DOI 10.1103/PhysRevLett.83.4987; [No title captured]	30	487	499	3	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					268	271		10.1038/nature01974	http://dx.doi.org/10.1038/nature01974			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679909	Green Accepted			2022-12-28	WOS:000185370900037
J	Wilson, JF				Wilson, JF			How cloning could change medicine	ANNALS OF INTERNAL MEDICINE			English	Article													Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136					0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					535	538		10.7326/0003-4819-139-6-200309160-00036	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00036			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679343				2022-12-28	WOS:000185324100026
J	Jackson, JB; Musoke, P; Fleming, T; Guay, LA; Bagenda, D; Allen, M; Nakabiito, C; Sherman, J; Bakaki, P; Owor, M; Ducar, C; Deseyve, M; Mwatha, A; Emel, L; Duefield, C; Mirochnick, M; Fowler, MG; Mofenson, L; Miotti, P; Gigliotti, M; Bray, D; Mmiro, F				Jackson, JB; Musoke, P; Fleming, T; Guay, LA; Bagenda, D; Allen, M; Nakabiito, C; Sherman, J; Bakaki, P; Owor, M; Ducar, C; Deseyve, M; Mwatha, A; Emel, L; Duefield, C; Mirochnick, M; Fowler, MG; Mofenson, L; Miotti, P; Gigliotti, M; Bray, D; Mmiro, F			Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VERTICAL TRANSMISSION; RECEIVING NEVIRAPINE; ORAL ZIDOVUDINE; COTE-DIVOIRE; WOMEN; REGIMEN; PHARMACOKINETICS; PROPHYLAXIS; COMBINATION	Background In 1999, we reported safety and efficacy data for short-course nevirapine from a Ugandan perinatal HIV-1 prevention trial when 496 babies were followed up to age 14-16 weeks. Safety and efficacy data are now presented for all babies followed up to 18 months of age. Methods From November, 1997, to April, 1999, HIV-1 infected pregnant women in Kampala, Uganda, were randomly assigned nevirapine (200 mg at labour onset and 2 mg/kg for babies within 72 h of birth; regimen A) or zidovudine (600 mg orally at labour onset and 300 mg every 3 h until delivery, and 4 mg/kg orally twice daily for babies for 7 days, regimen B). Infant HIV-1 testing was done at birth, age 6-8 and 14-16 weeks, and age 12 months by HIV-1 RNA PCR, and by HIV-1 antibody at 18 months. HIV-1 transmission and HIV-1-free survival were assessed using Kaplan-Meier analysis. We recorded adverse experiences through 6-8 weeks postpartum for mothers, and 18 months for babies. Efficacy analyses were by intention to treat. Findings We enrolled 645 mothers to the study: 313 were assigned regimen A, 313 regimen B, and 19 placebo. Eight mothers were lost to follow-up before delivery. 99% of babies were breastfed (median duration 9 months). Estimated risks of HIV-1 transmission in the zidovudine and nevirapine groups were 10.3% and 8.1% at birth (p=0.35); 20.0% and 11.8% by age 6-8 weeks (p=0.0063); 22.1% and 13.5% by age 14-16 weeks (p=0.0064); and 25.8% and 15.7% by age 18 months (p=0.0023). Nevirapine was associated with a 41% (95% CI 16-59) reduction in relative risk of transmission through to age 18 months. Both regimens were well-tolerated with few serious side-effects. Interpretation Intrapartum/neonatal nevirapine significantly lowered HIV-1 transmission risk in a breastfeeding population in Uganda compared with a short intrapartum/neonatal zidovudine regimen. The absolute 8.2% reduction in transmission at 6-8 weeks was sustained at age 18 months (10.1% [95% CI 3.5-16.6]). This simple, inexpensive, well-tolerated regimen has the potential to significantly decrease HIV-1 perinatal transmission in less-developed countries.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; Makerere Univ, Dept Pediat, Kampala, Uganda; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, Seattle, WA 98104 USA; Makerere Univ, Dept Obstet & Gynaecol, Kampala, Uganda; Family Hlth Int, Durham, NC USA; Boston Univ, Dept Pediat, Boston, MA 02215 USA; NIAID, Pediat Adolescent & Maternal AIDS Branch, NIH, Bethesda, MD 20892 USA; Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA; GlaxoWellcome, London, England	Johns Hopkins University; Makerere University; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Makerere University; Boston University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Boehringer Ingelheim; GlaxoSmithKline	Jackson, JB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Carnegie Bldg Room 420,600 N Wolfe St, Baltimore, MD 21287 USA.	BJACKSO@jhmi.edu	Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808; jackson, brooks/0000-0001-9458-135X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045200, N01AI035173, U01AI048054, U01AI046745] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-35173, N01-AI-45200, U01-AI-46745, U01-AI-48054, N0I-AI-35173-417] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benn PD, 2001, LANCET, V357, P687, DOI 10.1016/S0140-6736(00)04139-8; Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; *CDCP, 2001, MMWR-MORBID MORTAL W, V49, P1153, DOI DOI 10.1097/01.INF.0000035031.50613.44; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; Coutsoudis A, 2001, AIDS, V15, P379, DOI 10.1097/00002030-200102160-00011; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; Dorenbaum A, 2002, JAMA-J AM MED ASSOC, V288, P189, DOI 10.1001/jama.288.2.189; Dunn DT, 1998, AIDS, V12, P2211, DOI 10.1097/00002030-199816000-00017; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Jackson JB, 2000, AIDS, V14, pF111, DOI 10.1097/00002030-200007280-00001; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; Marseille E, 1999, LANCET, V354, P803, DOI 10.1016/S0140-6736(99)80009-9; Miotti PG, 1999, JAMA-J AM MED ASSOC, V282, P744, DOI 10.1001/jama.282.8.744; Mirochnick M, 1998, J INFECT DIS, V178, P368, DOI 10.1086/515641; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; Musoke P, 1999, AIDS, V13, P479, DOI 10.1097/00002030-199903110-00006; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pollard RB, 1998, CLIN THER, V20, P1071, DOI 10.1016/S0149-2918(98)80105-7; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; Saba J, 2002, LANCET, V359, P1178; Sha BE, 2000, JAMA-J AM MED ASSOC, V284, P2723; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; SOUSSELIER M, 2000, 13 INT AIDS C DURB S; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Stringer JSA, 2003, AIDS, V17, P1659, DOI 10.1097/00002030-200307250-00010; Stringer JSA, 2003, JAIDS-J ACQ IMM DEF, V32, P506, DOI 10.1097/00126334-200304150-00007; *UNAIDS, 2002, AIDS EP UPD DEC 2002; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9	33	370	379	0	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 13	2003	362	9387					859	868		10.1016/S0140-6736(03)14341-3	http://dx.doi.org/10.1016/S0140-6736(03)14341-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678973				2022-12-28	WOS:000185329400010
J	Lassen, A; Hallas, J; de Muckadell, OBS				Lassen, A; Hallas, J; de Muckadell, OBS			Eradication of Helicobacter pylori and use of antisecretory drugs: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		Odense Univ Hosp, Dept Med Gastroenterol, DK-5000 Odense, Denmark; Odense Univ Hosp, Dept Internal Med, DK-5000 Odense, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital	Lassen, A (corresponding author), Odense Univ Hosp, Dept Med Gastroenterol, DK-5000 Odense, Denmark.		Lassen, Annmarie/AAA-5816-2019	Schaffalitzky de Muckadell, Ove B/0000-0003-1969-2329; Hallas, Jesper/0000-0002-8097-8708; Lassen, Annmarie/0000-0003-4942-6152				De Boer WA, 2001, GUT, V48, P567, DOI 10.1136/gut.48.4.567; Frank L, 2000, SCIENCE, V287, P2398, DOI 10.1126/science.287.5462.2398; Gaist D, 1997, DAN MED BULL, V44, P445; Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P167, DOI 10.1046/j.1365-2036.2002.01169.x; McColl KEL, 2000, AM J GASTROENTEROL, V95, P101	5	10	11	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					603	603		10.1136/bmj.327.7415.603	http://dx.doi.org/10.1136/bmj.327.7415.603			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969930	Green Published, Bronze			2022-12-28	WOS:000185358700026
J	Leanhardt, AE; Pasquini, TA; Saba, M; Schirotzek, A; Shin, Y; Kielpinski, D; Pritchard, DE; Ketterle, W				Leanhardt, AE; Pasquini, TA; Saba, M; Schirotzek, A; Shin, Y; Kielpinski, D; Pritchard, DE; Ketterle, W			Cooling Bose-Einstein condensates below 500 picokelvin	SCIENCE			English	Article							MAGNETIC TRAP; NEUTRAL ATOMS; NOBEL LECTURE; REFLECTION; SUPERFLUID; CESIUM; LASER; COHERENCE; ROTATION; SURFACE	Spin-polarized gaseous Bose-Einstein condensates were confined by a combination of gravitational and magnetic forces. The partially condensed atomic vapors were adiabatically decompressed by weakening the gravito-magnetic trap to a mean frequency of 1 hertz, then evaporatively reduced in size to 2500 atoms. This lowered the peak condensate density to 5 x 10(10) atoms per cubic centimeter and cooled the entire cloud in all three dimensions to a kinetic temperature of 450 +/- 80 picokelvin. Such spin-polarized, dilute, and ultracold gases are important for spectroscopy, metrology, and atom optics.	MIT, MIT Harvard Ctr Ultracold Atoms, Dept Phys, Cambridge, MA 02139 USA; MIT, Elect Res Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Leanhardt, AE (corresponding author), MIT, MIT Harvard Ctr Ultracold Atoms, Dept Phys, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ael@mit.edu	Saba, Michele/M-4239-2013; Shin, Yong-il/B-1955-2008	Saba, Michele/0000-0001-6416-3122; Shin, Yong-il/0000-0003-0481-9841; Kielpinski, David/0000-0002-2816-6892				ANDERSON A, 1986, PHYS REV A, V34, P3513, DOI 10.1103/PhysRevA.34.3513; Avenel O, 1997, PHYS REV LETT, V78, P3602, DOI 10.1103/PhysRevLett.78.3602; BERKHOUT JJ, 1989, PHYS REV LETT, V63, P1689, DOI 10.1103/PhysRevLett.63.1689; Chu S, 1998, REV MOD PHYS, V70, P685, DOI 10.1103/RevModPhys.70.685; Cohen-Tannoudji CN, 1998, REV MOD PHYS, V70, P707, DOI 10.1103/RevModPhys.70.707; Cornell EA, 2002, REV MOD PHYS, V74, P875, DOI 10.1142/S0217979202014681; Dalfovo F, 1999, REV MOD PHYS, V71, P463, DOI 10.1103/RevModPhys.71.463; Darrow KK, 1940, REV MOD PHYS, V12, P0257, DOI 10.1103/RevModPhys.12.257; DeMarco B, 1999, SCIENCE, V285, P1703, DOI 10.1126/science.285.5434.1703; Donley EA, 2002, NATURE, V417, P529, DOI 10.1038/417529a; GOTT YV, 1962, NUCL FUSION S, V3, P1045; Gustavson TL, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.020401; KASEVICH M, 1992, PHYS REV LETT, V69, P1741, DOI 10.1103/PhysRevLett.69.1741; KASTBERG A, 1995, PHYS REV LETT, V74, P1542, DOI 10.1103/PhysRevLett.74.1542; Ketterle W, 2002, REV MOD PHYS, V74, P1131, DOI [10.1103/RevModPhys.74.1131, 10.1142/S0217979202014668]; Mewes MO, 1996, PHYS REV LETT, V77, P416, DOI 10.1103/PhysRevLett.77.416; Oja AS, 1997, REV MOD PHYS, V69, P1, DOI 10.1103/RevModPhys.69.1; Phillips WD, 1998, REV MOD PHYS, V70, P721, DOI 10.1103/RevModPhys.70.721; PRITCHARD DE, 1983, PHYS REV LETT, V51, P1336, DOI 10.1103/PhysRevLett.51.1336; REICHEL J, 1995, PHYS REV LETT, V75, P4575, DOI 10.1103/PhysRevLett.75.4575; Saubamea B, 1997, PHYS REV LETT, V79, P3146, DOI 10.1103/PhysRevLett.79.3146; Schwab K, 1997, NATURE, V386, P585, DOI 10.1038/386585a0; Shimizu F, 2001, PHYS REV LETT, V86, P987, DOI 10.1103/PhysRevLett.86.987; SILVER AH, 1965, PHYS REV LETT, V15, P888, DOI 10.1103/PhysRevLett.15.888; Smith HG, 1935, REV MOD PHYS, V7, P0237, DOI 10.1103/RevModPhys.7.237; Treutlein P, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.051401; Udem T, 2002, NATURE, V416, P233, DOI 10.1038/416233a; Weber T, 2003, SCIENCE, V299, P232, DOI 10.1126/science.1079699	28	163	166	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1513	1515		10.1126/science.1088827	http://dx.doi.org/10.1126/science.1088827			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970559				2022-12-28	WOS:000185255300043
J	Sung, NS; Gordon, JI; Rose, GD; Getzoff, ED; Kron, SJ; Mumford, D; Onuchic, JN; Scherer, NF; Sumners, DL; Kopell, NJ				Sung, NS; Gordon, JI; Rose, GD; Getzoff, ED; Kron, SJ; Mumford, D; Onuchic, JN; Scherer, NF; Sumners, DL; Kopell, NJ			Science education - Educating future scientists	SCIENCE			English	Editorial Material									Boston Univ, Dept Math & Stat, Boston, MA 02215 USA; Burroughs Wellcome Fund, Res Triangle Pk, NC 27709 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Johns Hopkins Univ, Dept Biophys, Baltimore, MD 21218 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Chicago, Dept Chem, Chicago, IL 60637 USA; Brown Univ, Div Appl Math, Providence, RI 02912 USA; Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA; Florida State Univ, Dept Math, Tallahassee, FL 32306 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Boston University; Burroughs Wellcome Fund; Washington University (WUSTL); Johns Hopkins University; Scripps Research Institute; University of Chicago; Brown University; University of California System; University of California San Diego; State University System of Florida; Florida State University; University of Chicago	Kopell, NJ (corresponding author), Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.								0	36	37	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1485	1485		10.1126/science.1086133	http://dx.doi.org/10.1126/science.1086133			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	720HL	12970550				2022-12-28	WOS:000185255300032
J	Hope, RL				Hope, RL			Paying in potatoes: community-based health insurance for the rural and informal sector	LANCET			English	Article									UCL, Int Hlth & Med Educ Ctr, London, England	University of London; University College London	Hope, RL (corresponding author), UCL, Int Hlth & Med Educ Ctr, London, England.	rl_hope@hotmail.com						CRIEL B, 1998, DISTRICT BASED HLTH; Desmet M, 1999, SOC SCI MED, V48, P925, DOI 10.1016/S0277-9536(98)00393-1; Dror DM, 2001, B WORLD HEALTH ORGAN, V79, P672; NOLAN B, 1993, COST RECOVERY PUBLIC; TOONAN J, 1995, 337 KIT ROYAL TROP I	5	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					827	829		10.1016/S0140-6736(03)14279-1	http://dx.doi.org/10.1016/S0140-6736(03)14279-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	719DN	13678882				2022-12-28	WOS:000185188500027
J	Tkachev, D; Mimmack, ML; Ryan, MM; Wayland, M; Freeman, T; Jones, PB; Starkey, M; Webster, MJ; Yolken, RH; Bahn, S				Tkachev, D; Mimmack, ML; Ryan, MM; Wayland, M; Freeman, T; Jones, PB; Starkey, M; Webster, MJ; Yolken, RH; Bahn, S			Oligodendrocyte dysfunction in schizophrenia and bipolar disorder	LANCET			English	Article							GENE-EXPRESSION; PSYCHIATRIC-DISORDERS; UP-REGULATION; TARGET GENES; BRAIN; MYELIN; MICROARRAY; SUSCEPTIBILITY; PATHOLOGY; PROTEINS	Background Results of array studies have suggested abnormalities in expression of lipid and myelin-related genes in schizophrenia. Here, we investigated oligodendrocyte-specific and myelination-associated gene expression in schizophrenia and bipolar affective disorder. Methods We used samples from the Stanley brain collection, consisting of 15 schizophrenia, 15 bipolar affective disorder, and 15 control brains. Indexing-based differential display PCR was done to screen for differences in gene expression in schizophrenia patients versus controls. Results were cross-validated with quantitative PCR,, which was also used to investigate expression profiles of 16 other oligodendrocyte and myelin genes in schizophrenia and bipolar disorder. These genes were further investigated with an ongoing microarray analysis. Findings Results of differential display and quantitative PCR analysis showed a reduction of key oligodendrocyte-related and myelin-related genes in schizophrenia and bipolar patients; expression changes for both disorders showed a high degree of overlap. Microarray results of the same genes investigated by quantitative PCR correlated well overall. Interpretation Schizophrenia and bipolar brains showed downregulation of key oligodendrocyte and myelination genes, including transcription factors that regulate these genes, compared with control brains. These results lend support to and extend observations from other microarray investigations. Our study also showed similar expression changes to the schizophrenia group in bipolar brains, which thus lends support to the notion that the disorders share common causative and pathophysiological pathways.	Babraham Inst, Dept Neurobiol, Cambridge, England; UK Human Genome Mapping Project Resource Ctr, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England; Uniformed Serv Univ Hlth Sci, Dept Psychiat, Stanley Lab Brain Res, Bethesda, MD 20814 USA; Johns Hopkins Univ, Sch Med, Stanley Div Dev Neurovirol, Baltimore, MD USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Uniformed Services University of the Health Sciences - USA; Johns Hopkins University	Bahn, S (corresponding author), Univ Cambridge, Dept Psychiat, Cambridge CB2 2QQ, England.		Wayland, Matthew/V-6751-2019; yolken, robert/AAW-2556-2021	Wayland, Matthew/0000-0002-8095-858X; Jones, Peter Brian/0000-0002-0387-880X				Bahn S, 2002, LANCET, V359, P310, DOI 10.1016/S0140-6736(02)07497-4; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; BENES FM, 1986, ARCH GEN PSYCHIAT, V43, P31; Bertolino A, 2001, BIOL PSYCHIAT, V49, P39, DOI 10.1016/S0006-3223(00)00997-5; Bertolino A, 1998, BIOL PSYCHIAT, V43, P641, DOI 10.1016/S0006-3223(97)00555-6; Buchsbaum MS, 1998, NEUROREPORT, V9, P425, DOI 10.1097/00001756-199802160-00013; Colantuoni C, 2001, NEUROBIOL DIS, V8, P847, DOI 10.1006/nbdi.2001.0428; CONNOR JR, 1994, DEV NEUROSCI-BASEL, V16, P233, DOI 10.1159/000112115; Erikson KM, 1997, J NUTR, V127, P2030, DOI 10.1093/jn/127.10.2030; Foong J, 2000, J NEUROL NEUROSUR PS, V68, P70, DOI 10.1136/jnnp.68.1.70; Garbern JY, 2002, BRAIN, V125, P551, DOI 10.1093/brain/awf043; GOTTESMAN II, 1987, SCHIZOPHRENIA BULL, V13, P23, DOI 10.1093/schbul/13.1.23; Hakak Y, 2001, P NATL ACAD SCI USA, V98, P4746, DOI 10.1073/pnas.081071198; Hata R, 2001, BIOCHEM BIOPH RES CO, V284, P310, DOI 10.1006/bbrc.2001.4968; Ho L, 2001, NEUROSCI LETT, V298, P191, DOI 10.1016/S0304-3940(00)01753-5; Hof PR, 2002, NEUROCHEM RES, V27, P1193, DOI 10.1023/A:1020981510759; Horrobin DF, 1999, PROSTAG LEUKOTR ESS, V60, P141, DOI 10.1054/plef.1999.0027; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lim KO, 1999, ARCH GEN PSYCHIAT, V56, P367, DOI 10.1001/archpsyc.56.4.367; Lu QR, 2001, P NATL ACAD SCI USA, V98, P10851, DOI 10.1073/pnas.181340798; Marcus J, 2002, J CELL BIOL, V156, P567, DOI 10.1083/jcb.200111047; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Mayfield RD, 2002, J NEUROCHEM, V81, P802, DOI 10.1046/j.1471-4159.2002.00860.x; Maziade M, 1997, AM J MED GENET, V74, P311, DOI 10.1002/(SICI)1096-8628(19970531)74:3<311::AID-AJMG13>3.3.CO;2-C; Mimmack ML, 2002, P NATL ACAD SCI USA, V99, P4680, DOI 10.1073/pnas.032069099; Pongrac J, 2002, NEUROCHEM RES, V27, P1049, DOI 10.1023/A:1020904821237; Snider JV, 2001, DRUG DISCOV TODAY, V6, P1062, DOI 10.1016/S1359-6446(01)01988-2; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Torrey EF, 2000, SCHIZOPHR RES, V44, P151, DOI 10.1016/S0920-9964(99)00192-9; Uranova N, 2001, BRAIN RES BULL, V55, P597, DOI 10.1016/S0361-9230(01)00528-7; Whitney LW, 1999, ANN NEUROL, V46, P425; Wood JN, 2000, J PAIN, V1, P19, DOI 10.1054/jpai.2000.9807a; Wurmbach E, 2001, J BIOL CHEM, V276, P47195, DOI 10.1074/jbc.M108716200; Yool DA, 2000, HUM MOL GENET, V9, P987, DOI 10.1093/hmg/9.6.987; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	36	723	752	1	36	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					798	805		10.1016/S0140-6736(03)14289-4	http://dx.doi.org/10.1016/S0140-6736(03)14289-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678875				2022-12-28	WOS:000185188500014
J	Marks, AR				Marks, AR			Sirolimus for the prevention of in-stent restenosis in a coronary artery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CELL-CYCLE; REGULATORS		Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, Ctr Mol Cardiol, New York, NY 10032 USA	Columbia University	Marks, AR (corresponding author), Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, Ctr Mol Cardiol, New York, NY 10032 USA.							Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Lemos PA, 2003, CIRCULATION, V108, P257, DOI 10.1161/01.CIR.0000083366.33686.11; Luo Y, 1996, MOL CELL BIOL, V16, P6744; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; Poon M, 1996, J CLIN INVEST, V98, P2277, DOI 10.1172/JCI119038	5	66	72	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1307	1309		10.1056/NEJMp038141	http://dx.doi.org/10.1056/NEJMp038141			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523135				2022-12-28	WOS:000185644000001
J	Rogerson, S				Rogerson, S			HIV-1, antiretroviral therapy, and malaria	LANCET			English	Editorial Material							FALCIPARUM-INFECTED ERYTHROCYTES; PLASMODIUM-FALCIPARUM; ADHESION; DISEASE; CD36		Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; University of Melbourne	Rogerson, S (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia.	sroger@unimelb.edu.au		Rogerson, Stephen/0000-0003-4287-1982				Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582; Chandramohan D, 1998, INT J EPIDEMIOL, V27, P296, DOI 10.1093/ije/27.2.296; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; GRIMWADE K, IN PRESS AIDS; Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; McGilvray ID, 2000, BLOOD, V96, P3231, DOI 10.1182/blood.V96.9.3231; Newbold C, 1997, AM J TROP MED HYG, V57, P389, DOI 10.4269/ajtmh.1997.57.389; Serghides L, 2002, AIDS, V16, P353, DOI 10.1097/00002030-200202150-00006; Steketee RW, 1996, AM J TROP MED HYG, V55, P42, DOI 10.4269/ajtmh.1996.55.42; Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900; van Eijk AM, 2003, AIDS, V17, P595, DOI 10.1097/00002030-200303070-00015; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6	14	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2003	362	9389					1008	1009		10.1016/S0140-6736(03)14447-9	http://dx.doi.org/10.1016/S0140-6736(03)14447-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522527				2022-12-28	WOS:000185564600004
J	Van Damme, P; Banatvala, J; Fay, O; Iwarson, S; McMahon, B; Van Herck, K; Shouval, D; Bonanni, P; Connor, B; Cooksley, G; Leroux-Roels, G; Von Sonnenburg, F				Van Damme, P; Banatvala, J; Fay, O; Iwarson, S; McMahon, B; Van Herck, K; Shouval, D; Bonanni, P; Connor, B; Cooksley, G; Leroux-Roels, G; Von Sonnenburg, F		Int Consensus Grp Hepatitis A Viru	Hepatitis A booster vaccination: is there a need?	LANCET			English	Article							FOLLOW-UP; CHILDHOOD VACCINATION; VIRUS-VACCINE; IMMUNOGENICITY; SAFETY; CHILDREN; IMMUNIZATION; TRIAL; PROTECTION; ANTIBODIES	Hepatitis A is one of the most common vaccine-preventable infectious diseases in the world. Effective vaccines against hepatitis A have been available since 1992, and they provide long-term immunity against the infection. However, there is no worldwide consensus on how long protection will last or whether there will be a need for hepatitis A virus (HAV) booster vaccinations in the future. In most countries, booster-vaccination policy is guided by manufacturers' recommendations, national authorities, or both. In June, 2002, a panel of international experts met to review the long-term immunogenicity and protection conferred by HAV vaccine in different population groups. Data have shown that after a full primary vaccination course, protective antibody amounts persist beyond 10 years in healthy individuals, and underlying immune memory provides protection far beyond the duration of anti-HAV antibodies. The group concluded that there is no evidence to lend support to HAV booster vaccination after a full primary vaccination course in a healthy individual. However, further investigations are needed before deciding if boosters can be omitted in special patient-groups.	Univ Instelling Antwerp, Ctr Evaluat Vaccinat, WHO,Unit Epidemiol & Social Med, Collaborating Ctr Control & Prevent Viral Hepatit, B-2610 Antwerp, Belgium	University of Antwerp; World Health Organization	Van Damme, P (corresponding author), Univ Instelling Antwerp, Ctr Evaluat Vaccinat, WHO,Unit Epidemiol & Social Med, Collaborating Ctr Control & Prevent Viral Hepatit, B-2610 Antwerp, Belgium.	pierre.vandamme@ua.ac.be	Bonanni, Paolo/AAB-9823-2019; Van Herck, Koen/G-5223-2013; cooksley, william ge/G-7742-2011; van damme, pierre/I-4846-2013; Bonanni, Paolo/A-7580-2012; Shouval, Daniel/U-2779-2017; Van Herck, Koen/L-2549-2019; Connor, Bradley/AAX-6032-2020	Van Herck, Koen/0000-0003-0717-2406; Shouval, Daniel/0000-0002-0512-6513; Van Herck, Koen/0000-0003-0717-2406; van damme, pierre/0000-0002-8642-1249				Abarca K, 2001, ARCH MED RES, V32, P468, DOI 10.1016/S0188-4409(01)00309-5; *ACIP, 2001, MMWR MORB MORTALY WK, V50, P19; *ACIP, 2001, MMWR-MORBID MORTAL W, V50, P7; Andre Francis, 2002, Expert Rev Vaccines, V1, P9, DOI 10.1586/14760584.1.1.9; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 2000, Wkly Epidemiol Rec, V75, P38; Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6; Banatvala J, 2000, VACCINE, V19, P877, DOI 10.1016/S0264-410X(00)00224-3; Beran J, 1999, EUR J EPIDEMIOL, V15, P805, DOI 10.1023/A:1007625715665; Beran J, 2000, J TRAVEL MED, V7, P246, DOI 10.2310/7060.2000.00073; BRIEM H, 1994, J MED VIROL, V44, P443, DOI 10.1002/jmv.1890440424; BULKOW LR, 1993, J INFECT DIS, V168, P1017, DOI 10.1093/infdis/168.4.1017; Cederna JB, 1999, VACCINE, V18, P892, DOI 10.1016/S0264-410X(99)00342-4; Chan CY, 1999, VACCINE, V17, P369, DOI 10.1016/S0264-410X(98)00200-X; CHEN X, 1996, IMMUNE RESPONSE HEPA; Crowcroft N S, 2001, Commun Dis Public Health, V4, P213; Dagan R, 2000, PEDIATR INFECT DIS J, V19, P1045, DOI 10.1097/00006454-200011000-00004; Dagan R, 1999, VACCINE, V17, P1919, DOI 10.1016/S0264-410X(98)00461-7; DAGAN R, 2002, P 20 ANN M EUR SOC P, P14; Fan PC, 1998, VACCINE, V16, P232, DOI 10.1016/S0264-410X(97)00179-5; Findor, 1996, J Travel Med, V3, P156, DOI 10.1111/j.1708-8305.1996.tb00730.x; FIORE AE, 2001, P 39 ANN M INF DIS S, P378; Fishman RHB, 1998, LANCET, V352, P888, DOI 10.1016/S0140-6736(05)60023-2; Ginsberg GM, 2001, J HEPATOL, V34, P92, DOI 10.1016/S0168-8278(00)00007-6; *GLAX, HEP A EP; HADLER SC, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P14; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; Iwarson S, 2002, SCAND J INFECT DIS, V34, P110, DOI 10.1080/00365540110077362; Iwarson S, 2002, VACCINE, V20, P2017, DOI 10.1016/S0264-410X(02)00050-6; Joines RW, 2001, VACCINE, V19, P4710, DOI 10.1016/S0264-410X(01)00240-7; Kallinowski B, 2000, VACCINE, V19, P16, DOI 10.1016/S0264-410X(00)00166-3; Kanra G, 2000, TURKISH J PEDIATR, V42, P105; Keeffe EB, 1998, HEPATOLOGY, V27, P881, DOI 10.1002/hep.510270336; Koff RS, 1999, NEW ENGL J MED, V340, P644, DOI 10.1056/NEJM199902253400810; Koff RS, 1998, LANCET, V351, P1643, DOI 10.1016/S0140-6736(98)01304-X; Landry P, 2000, VACCINE, V19, P399, DOI 10.1016/S0264-410X(00)00188-2; Lee SD, 1997, J MED VIROL, V52, P215, DOI 10.1002/(SICI)1096-9071(199706)52:2&lt;215::AID-JMV16&gt;3.0.CO;2-J; LEMON SM, 1993, J HEPATOL, V18, pS15, DOI 10.1016/S0168-8278(05)80372-1; Leroux-Roels G, 2002, VIRAL HEPATITIS LIVE, P41; Lopalco PL, 2000, VACCINE, V19, P470, DOI 10.1016/S0264-410X(00)00193-6; Loscher T, 1999, J TRAVEL MED, V6, P107, DOI 10.1111/j.1708-8305.1999.tb00841.x; LOUTAN L, 1994, LANCET, V343, P322, DOI 10.1016/S0140-6736(94)91162-2; NALIN DR, 1993, J HEPATOL, V18, pS51, DOI 10.1016/S0168-8278(05)80379-4; Neilsen GA, 1997, J INFECT DIS, V176, P1064, DOI 10.1086/516512; NORDENFELT E, 1997, VIRAL HEPATITIS LIVE, P545; Piazza M, 1999, VACCINE, V17, P585, DOI 10.1016/S0264-410X(98)00237-0; PRIKAZSKY V, 1994, J MED VIROL, V44, P457, DOI 10.1002/jmv.1890440427; PURCELL RH, 1992, VACCINE, V10, pS148, DOI 10.1016/0264-410X(92)90572-2; Salleras L, 2000, VACCINE, V18, pS80, DOI 10.1016/S0264-410X(99)00472-7; SHAW FE, 1990, AM J PUBLIC HEALTH, V80, P1091, DOI 10.2105/AJPH.80.9.1091; Thoelen S, 1999, VACCINE, V17, P1657, DOI 10.1016/S0264-410X(98)00421-6; Troisi CL, 1997, VACCINE, V15, P1613, DOI 10.1016/S0264-410X(97)00199-0; Van Damme P, 2001, VACCINE, V19, P2407, DOI 10.1016/S0264-410X(00)00464-3; Van Damme P, 2001, J MED VIROL, V65, P6, DOI 10.1002/jmv.1094; Van Damme P, 2002, P 3 EUR C TRAV MED 2, P50; Van Herck K, 2001, J MED VIROL, V63, P1, DOI 10.1002/1096-9071(200101)63:1&lt;1::AID-JMV1000&gt;3.0.CO;2-U; VANDAMME P, 1994, J MED VIROL, V44, P435, DOI 10.1002/jmv.1890440422; VANHERCK K, 2002, VIRAL HEPATITIS LIVE, P56; *VHPB, 1999, VIRAL HEPATITIS, V8, P12; Webster G, 2001, BRIT MED J, V322, P1194, DOI 10.1136/bmj.322.7296.1194; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; Werzberger A, 2002, VACCINE, V20, P1699, DOI 10.1016/S0264-410X(02)00042-7; Werzberger A, 1998, NEW ENGL J MED, V338, P1160, DOI 10.1056/NEJM199804163381615; Wiens BL, 1996, J MED VIROL, V49, P235, DOI 10.1002/(SICI)1096-9071(199607)49:3&lt;235::AID-JMV13&gt;3.0.CO;2-B; WILLIAMS J, 2000, ANTIVIR THER, V13, P5; ZACHOVAL R, 1990, J INFECT DIS, V161, P353, DOI 10.1093/infdis/161.2.353-a; ZANETTI A, 1997, VIRAL HEPATITIS LIVE, P551	67	153	156	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2003	362	9389					1065	1071		10.1016/S0140-6736(03)14418-2	http://dx.doi.org/10.1016/S0140-6736(03)14418-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522539				2022-12-28	WOS:000185564600026
J	Alon, U				Alon, U			Biological networks: The tinkerer as an engineer	SCIENCE			English	Editorial Material							TRANSCRIPTIONAL REGULATION; GENE-REGULATION; ROBUSTNESS; MOTIFS; ORGANIZATION; EVOLUTION	This viewpoint comments on recent advances in understanding the design principles of biological networks. It highlights the surprising discovery of "good-engineering" principles in biochemical circuitry that evolved by random tinkering.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Alon, U (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	urialon@weizmann.ac.il						Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; Arkin A, 1997, SCIENCE, V277, P1275, DOI 10.1126/science.277.5330.1275; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BRAY D, 1990, J THEOR BIOL, V143, P215, DOI 10.1016/S0022-5193(05)80268-1; Conant GC, 2003, NAT GENET, V34, P264, DOI 10.1038/ng1181; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eldar A, 2002, NATURE, V419, P304, DOI 10.1038/nature01061; Fell D., 1997, UNDERSTANDING CONTRO; Gardner TS, 2003, SCIENCE, V301, P102, DOI 10.1126/science.1081900; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; KACSER H, 1973, S SOC EXP BIOL, V32, P65; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lipson H, 2002, EVOLUTION, V56, P1549, DOI 10.1111/j.0014-3820.2002.tb01466.x; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; MYERS CR, 2003, CONDMAT0305575; Rao CV, 2001, ANNU REV BIOMED ENG, V3, P391, DOI 10.1146/annurev.bioeng.3.1.391; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Ronen M, 2002, P NATL ACAD SCI USA, V99, P10555, DOI 10.1073/pnas.152046799; Rosenfeld N, 2002, J MOL BIOL, V323, P785, DOI 10.1016/S0022-2836(02)00994-4; Savageau M, 1976, BIOCH SYSTEMS ANAL S; SAVAGEAU MA, 1971, NATURE, V229, P542, DOI 10.1038/229542a0; Setty Y, 2003, P NATL ACAD SCI USA, V100, P7702, DOI 10.1073/pnas.1230759100; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; WAGNER A, 2003, SCI STKE, pPE41; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896	34	410	429	5	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1866	1867		10.1126/science.1089072	http://dx.doi.org/10.1126/science.1089072			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512615				2022-12-28	WOS:000185536700037
J	Hu, FS; Kaufman, D; Yoneji, S; Nelson, D; Shemesh, A; Huang, Y; Tian, J; Bond, G; Clegg, B; Brown, T				Hu, FS; Kaufman, D; Yoneji, S; Nelson, D; Shemesh, A; Huang, Y; Tian, J; Bond, G; Clegg, B; Brown, T			Cyclic variation and solar forcing of Holocene climate in the Alaskan subarctic	SCIENCE			English	Article							NORTH-ATLANTIC; LATE-QUATERNARY; BIOGENIC-SILICA; ICE CORE; OXYGEN ISOTOPES; YOUNGER-DRYAS; RECORD; VEGETATION; TUNDRA; POLLEN	High-resolution analyses of lake sediment from southwestern Alaska reveal cyclic variations in climate and ecosystems during the Holocene. These variations occurred with periodicities similar to those of solar activity and appear to be coherent with time series of the cosmogenic nuclides C-14 and Be-10 as well as North Atlantic drift ice. Our results imply that small variations in solar irradiance induced pronounced cyclic changes in northern high-latitude environments. They also provide evidence that centennial-scale shifts in the Holocene climate were similar between the subpolar regions of the North Atlantic and North Pacific, possibly because of Sun-ocean-climate linkages.	Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA; Univ Illinois, Program Ecol & Evolutionary Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Geol, Urbana, IL 61801 USA; No Arizona Univ, Dept Geol, Flagstaff, AZ 86011 USA; No Arizona Univ, Dept Environm Sci, Flagstaff, AZ 86011 USA; Weizmann Inst Sci, Dept Environm Sci, IL-76100 Rehovot, Israel; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94551 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Northern Arizona University; Northern Arizona University; Weizmann Institute of Science; Brown University; Columbia University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Hu, FS (corresponding author), Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA.		Nelson, David/AAP-9412-2020; Nelson, David M/D-5596-2009; Kaufman, Darrell/A-2471-2008	Nelson, David/0000-0003-2755-5535; Nelson, David M/0000-0003-2755-5535; Kaufman, Darrell/0000-0002-7572-1414; Brown, Tom/0000-0001-9984-7647				ANDERSON PM, 1991, J BIOGEOGR, V18, P565, DOI 10.2307/2845692; ANDERSON PM, 1994, QUATERNARY SCI REV, V13, P71, DOI 10.1016/0277-3791(94)90125-2; Barker PA, 2001, SCIENCE, V292, P2307, DOI 10.1126/science.1059612; BEER J, 1988, NATURE, V331, P675, DOI 10.1038/331675a0; Bond G, 2001, SCIENCE, V294, P2130, DOI 10.1126/science.1065680; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; Brubaker LB, 2001, QUATERNARY SCI REV, V20, P175, DOI 10.1016/S0277-3791(00)00124-4; Carslaw KS, 2002, SCIENCE, V298, P1732, DOI 10.1126/science.1076964; CHAPIN FS, 1995, ECOLOGY, V76, P694, DOI 10.2307/1939337; Chapman MR, 2000, HOLOCENE, V10, P287, DOI 10.1191/095968300671253196; ESTEP MF, 1980, GEOCHIM COSMOCHIM AC, V44, P1197, DOI 10.1016/0016-7037(80)90073-3; Finkel RC, 1997, J GEOPHYS RES-OCEANS, V102, P26699, DOI 10.1029/97JC01282; Fleitmann D, 2003, SCIENCE, V300, P1737, DOI 10.1126/science.1083130; Foukal P, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015474; Gupta AK, 2003, NATURE, V421, P354, DOI 10.1038/nature01340; Haigh JD, 1996, SCIENCE, V272, P981, DOI 10.1126/science.272.5264.981; Hodell DA, 2001, SCIENCE, V292, P1367, DOI 10.1126/science.1057759; Hu FS, 2003, QUATERNARY RES, V59, P379, DOI 10.1016/S0033-5894(03)00056-5; Huang YS, 2002, GEOLOGY, V30, P1103, DOI 10.1130/0091-7613(2002)030<1103:HIROPA>2.0.CO;2; KAUFMAN DS, IN PRESS J PALEOLIMN; Lean JL, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015880; Liston GE, 2002, GLOBAL CHANGE BIOL, V8, P17, DOI 10.1046/j.1354-1013.2001.00416.x; LOZHKIN AV, 1993, QUATERNARY RES, V39, P314, DOI 10.1006/qres.1993.1038; Meyers PA, 1999, J PALEOLIMNOL, V21, P345, DOI 10.1023/A:1008073732192; Mikolajewicz U, 1997, NATURE, V387, P384, DOI 10.1038/387384a0; Muscheler R, 2000, NATURE, V408, P567, DOI 10.1038/35046041; Oswald WW, 2003, J BIOGEOGR, V30, P521, DOI 10.1046/j.1365-2699.2003.00870.x; Rietti-Shati M, 1998, SCIENCE, V281, P980, DOI 10.1126/science.281.5379.980; Rind D, 2002, SCIENCE, V296, P673, DOI 10.1126/science.1069562; Schiller A, 1997, CLIM DYNAM, V13, P325, DOI 10.1007/s003820050169; SHEMESH A, 1992, SCIENCE, V256, P1434, DOI 10.1126/science.256.5062.1434; Shindell D, 1999, SCIENCE, V284, P305, DOI 10.1126/science.284.5412.305; Shindell DT, 2001, SCIENCE, V294, P2149, DOI 10.1126/science.1064363; STUIVER M, 1993, RADIOCARBON, V35, P137; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Stuiver M, 1995, QUATERNARY RES, V44, P341, DOI 10.1006/qres.1995.1079; Sturm M, 2001, NATURE, V411, P546, DOI 10.1038/35079180; Sturm M, 2001, J CLIMATE, V14, P336, DOI 10.1175/1520-0442(2001)014<0336:SSIIAT>2.0.CO;2; Verschuren D, 2000, NATURE, V403, P410, DOI 10.1038/35000179; Wetzel RG., 2001, LIMNOLOGY LAKE RIVER, V3, DOI DOI 10.1046/J.1529-8817.2001.37602.X; Yiou F, 1997, J GEOPHYS RES-OCEANS, V102, P26783, DOI 10.1029/97JC01265	41	241	256	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1890	1893		10.1126/science.1088568	http://dx.doi.org/10.1126/science.1088568			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512624				2022-12-28	WOS:000185536700046
J	Hayes, RA; Feenstra, BJ				Hayes, RA; Feenstra, BJ			Video-speed electronic paper based on electrowetting	NATURE			English	Article							VOLTAGE; DISPLAYS	In recent years, a number of different technologies have been proposed for use in reflective displays(1-3). One of the most appealing applications of a reflective display is electronic paper, which combines the desirable viewing characteristics of conventional printed paper with the ability to manipulate the displayed information electronically. Electronic paper based on the electrophoretic motion of particles inside small capsules has been demonstrated(1) and commercialized; but the response speed of such a system is rather slow, limited by the velocity of the particles. Recently, we have demonstrated that electrowetting is an attractive technology for the rapid manipulation of liquids on a micrometre scale(4). Here we show that electrowetting can also be used to form the basis of a reflective display that is significantly faster than electrophoretic displays, so that video content can be displayed. Our display principle utilizes the voltage-controlled movement of a coloured oil film adjacent to a white substrate. The reflectivity and contrast of our system approach those of paper. In addition, we demonstrate a colour concept, which is intrinsically four times brighter than reflective liquid-crystal displays(5) and twice as bright as other emerging technologies(1-3). The principle of microfluidic motion at low voltages is applicable in a wide range of electro-optic devices.	Philips Res Eindhoven, NL-5656 AA Eindhoven, Netherlands	Philips; Philips Research	Hayes, RA (corresponding author), Philips Res Eindhoven, Prof Holstlaan 4, NL-5656 AA Eindhoven, Netherlands.							BENI G, 1981, APPL PHYS LETT, V38, P207, DOI 10.1063/1.92322; Berge B, 2000, EUR PHYS J E, V3, P159, DOI 10.1007/s101890070029; Comiskey B, 1998, NATURE, V394, P253, DOI 10.1038/28349; GRUPP J, 2002, EUR DIG 2002, P35; Moon H, 2002, J APPL PHYS, V92, P4080, DOI 10.1063/1.1504171; PODOJIL GM, 1998, SID98 DIG, P51; Pollack MG, 2000, APPL PHYS LETT, V77, P1725, DOI 10.1063/1.1308534; Prins MWJ, 2001, SCIENCE, V291, P277, DOI 10.1126/science.291.5502.277; Quilliet C, 2001, CURR OPIN COLLOID IN, V6, P34, DOI 10.1016/S1359-0294(00)00085-6; RITTER J, 2001, IDW01 DIG SOC INF DI, P343; Seyrat E, 2001, J APPL PHYS, V90, P1383, DOI 10.1063/1.1383583; SHERIDON NK, 1997, P IDRC97, pL82; Welters WJJ, 1998, LANGMUIR, V14, P1535, DOI 10.1021/la971153b	13	852	1019	18	396	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					383	385		10.1038/nature01988	http://dx.doi.org/10.1038/nature01988			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508484				2022-12-28	WOS:000185502300036
J	Pealer, LN; Marfin, AA; Petersen, LR; Lanciotti, RS; Page, PL; Stramer, SL; Stobierski, MG; Signs, K; Newman, B; Kapoor, H; Goodman, JL; Chamberland, ME				Pealer, LN; Marfin, AA; Petersen, LR; Lanciotti, RS; Page, PL; Stramer, SL; Stobierski, MG; Signs, K; Newman, B; Kapoor, H; Goodman, JL; Chamberland, ME		W Nile Virus Transmission Investig	Transmission of West Nile virus through blood transfusion in the United States in 2002	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-CITY; ENCEPHALITIS; EPIDEMIC; INFECTION; RISK	BACKGROUND: During the 2002 West Nile virus epidemic in the United States, patients were identified whose West Nile virus illness was temporally associated with the receipt of transfused blood and blood components. METHODS: Patients with laboratory evidence of recent West Nile virus infection within four weeks after receipt of a blood component from a donor with viremia were considered to have a confirmed transfusion-related infection. We interviewed the donors of these components, asking them whether they had had symptoms compatible with the presence of a viral illness before or after their donation; blood specimens retained from the time of donation and collected at follow-up were tested for West Nile virus. RESULTS: Twenty-three patients were confirmed to have acquired West Nile virus through transfused leukoreduced and nonleukoreduced red cells, platelets, or fresh-frozen plasma. Of the 23 recipients, 10 (43 percent) were immunocompromised owing to transplantation or cancer and 8 (35 percent) were at least 70 years of age. Immunocompromised recipients tended to have longer incubation periods than nonimmunocompromised recipients and infected persons in mosquito-borne community outbreaks. Sixteen donors with evidence of viremia at donation were linked to the 23 infected recipients; of these donors, 9 reported viral symptoms before or after donation, 5 were asymptomatic, and 2 were lost to follow-up. Fever, new rash, and painful eyes were independently associated with being an implicated donor with viremia rather than a donor without viremia. All 16 donors were negative for West Nile virus-specific IgM antibody at donation. CONCLUSIONS: Transfused red cells, platelets, and fresh-frozen plasma can transmit West Nile virus. Screening of potential donors with the use of nucleic acid-based assays for West Nile virus may reduce this risk.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; CDC, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA; Amer Red Cross, Blood Serv, Biomed Headquarters, Washington, DC 20006 USA; Amer Red Cross, Blood Serv, Sci Support Off, Gaithersburg, MD USA; Michigan Dept Community Hlth, Bur Labs, Lansing, MI USA; Amer Red Cross, Blood Serv, Detroit, MI USA; US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; American Red Cross; American Red Cross; MDHHS - Michigan Department of Health & Human Services; American Red Cross; US Food & Drug Administration (FDA)	Pealer, LN (corresponding author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, 1600 Clifton Rd,D-18, Atlanta, GA 30333 USA.			Basile, Alison Jane/0000-0002-5646-1557				[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P833; [Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P790; Biggerstaff BJ, 2002, TRANSFUSION, V42, P1019, DOI 10.1046/j.1537-2995.2002.00167.x; Campbell GL, 2002, LANCET INFECT DIS, V2, P519, DOI 10.1016/S1473-3099(02)00368-7; *CDCP, 2003, EP EP W NIL VIR US R; Chamberland ME, 2002, CLIN INFECT DIS, V34, P797, DOI 10.1086/338787; *FOOD DRUG ADM, 2003, GUID IND REV REC ASS; Harrington T, 2003, TRANSFUSION, V43, P1018, DOI 10.1046/j.1537-2995.2003.00481.x; Huang CN, 2002, EMERG INFECT DIS, V8, P1367, DOI 10.3201/eid0812.020532; Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987; Lanciotti RS, 2000, J CLIN MICROBIOL, V38, P4066, DOI 10.1128/JCM.38.11.4066-4071.2000; Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000; Mostashari F, 2001, LANCET, V358, P261, DOI 10.1016/S0140-6736(01)05480-0; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; Petersen LR, 2002, ANN INTERN MED, V137, P173, DOI 10.7326/0003-4819-137-3-200208060-00009; Roehrig JT, 2002, CURR TOP MICROBIOL, V267, P223; SOUTHAM CM, 1954, AM J TROP MED HYG, V3, P19, DOI 10.4269/ajtmh.1954.3.19; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; 2003, MMWR MORB MORTAL WKL, V52, P769; 2001, MMWR MORB MORTAL WKL, V50, P37; 2002, MMWR MORB MORTAL WKL, V51, P1129; 2000, MMWR MORB MORTAL WKL, V50, P101; 2002, MMWR MORB MORTAL WKL, V51, P929	23	434	464	0	19	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2003	349	13					1236	1245		10.1056/NEJMoa030969	http://dx.doi.org/10.1056/NEJMoa030969			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LJ	14500806				2022-12-28	WOS:000185488800006
J	Barnes, PF; Cave, MD				Barnes, PF; Cave, MD			Molecular epidemiology of tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DRUG-RESISTANT TUBERCULOSIS; CENTRAL LOS-ANGELES; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; EXOGENOUS REINFECTION; SAN-FRANCISCO; TRANSMISSION DYNAMICS; BEIJING GENOTYPE; OUTBREAK; STRAIN		Univ Texas Hlth Ctr, CPIDC, Dept Med, Tyler, TX 75708 USA; Univ Texas Hlth Ctr, CPIDC, Dept Microbiol, Tyler, TX 75708 USA; Univ Texas Hlth Ctr, CPIDC, Dept Immunol, Tyler, TX 75708 USA; Univ Arkansas Med Sci, Dept Anat, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Neurobiol, Little Rock, AR 72205 USA; Cent Arkansas Vet Healthcare Syst, Med Res Serv, Little Rock, AR USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Barnes, PF (corresponding author), Univ Texas Hlth Ctr, CPIDC, Dept Med, 11937 US Hwy 271, Tyler, TX 75708 USA.	peter.barnes@uthct.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044935] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44935] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; Allos BM, 1996, ANN INTERN MED, V125, P114, DOI 10.7326/0003-4819-125-2-199607150-00007; Anh DD, 2000, EMERG INFECT DIS, V6, P302; Bandera A, 2001, J CLIN MICROBIOL, V39, P2213, DOI 10.1128/JCM.39.6.2213-2218.2001; Barnes PF, 1998, JAMA-J AM MED ASSOC, V280, P1702, DOI 10.1001/jama.280.19.1702; Barnes PF, 1997, JAMA-J AM MED ASSOC, V278, P1159, DOI 10.1001/jama.278.14.1159; Barnes PF, 1999, AM J RESP CRIT CARE, V159, P1081, DOI 10.1164/ajrccm.159.4.9807153; Beggs ML, 2000, J CLIN MICROBIOL, V38, P2923, DOI 10.1128/JCM.38.8.2923-2928.2000; Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6; Bifani PJ, 1999, JAMA-J AM MED ASSOC, V282, P2321, DOI 10.1001/jama.282.24.2321; Bishai WR, 1998, JAMA-J AM MED ASSOC, V280, P1679, DOI 10.1001/jama.280.19.1679; Borgdorff MW, 2000, INT J TUBERC LUNG D, V4, P287; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; Burgos M., 2001, 36 TUB LEPR RES C AB, P206; Burman WJ, 2000, CLIN INFECT DIS, V31, P1390, DOI 10.1086/317504; Caminero JA, 2001, AM J RESP CRIT CARE, V164, P1165, DOI 10.1164/ajrccm.164.7.2101031; Caminero JA, 2001, AM J RESP CRIT CARE, V163, P717, DOI 10.1164/ajrccm.163.3.2003070; Chin DP, 2000, JAMA-J AM MED ASSOC, V283, P2968, DOI 10.1001/jama.283.22.2968; Dale JW, 2001, INT J TUBERC LUNG D, V5, P216; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; Friedman CR, 1997, J INFECT DIS, V176, P478, DOI 10.1086/514067; Frothingham R, 1998, MICROBIOL-UK, V144, P1189, DOI 10.1099/00221287-144-5-1189; Garcia-Garcia MD, 2000, ARCH INTERN MED, V160, P630, DOI 10.1001/archinte.160.5.630; Glynn JR, 1999, AM J EPIDEMIOL, V149, P366, DOI 10.1093/oxfordjournals.aje.a009822; Godfrey-Faussett P, 2000, LANCET, V356, P1066, DOI 10.1016/S0140-6736(00)02730-6; Golub JE, 2001, ARCH INTERN MED, V161, P2254, DOI 10.1001/archinte.161.18.2254; Jasmer RM, 1999, ANN INTERN MED, V130, P971, DOI 10.7326/0003-4819-130-12-199906150-00004; Jones TF, 1999, ANN INTERN MED, V131, P557, DOI 10.7326/0003-4819-131-8-199910190-00002; Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907, DOI 10.1128/JCM.35.4.907-914.1997; Kimerling ME, 1999, INT J TUBERC LUNG D, V3, P613; KLINE SE, 1995, NEW ENGL J MED, V333, P222, DOI 10.1056/NEJM199507273330404; Klovdahl AS, 2001, SOC SCI MED, V52, P681, DOI 10.1016/S0277-9536(00)00170-2; Kremer K, 1999, J CLIN MICROBIOL, V37, P2607, DOI 10.1128/JCM.37.8.2607-2618.1999; Kruuner A, 2001, J CLIN MICROBIOL, V39, P3339, DOI 10.1128/JCM.39.9.3339-3345.2001; Manca C, 1999, J IMMUNOL, V162, P6740; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; Mazars E, 2001, P NATL ACAD SCI USA, V98, P1901, DOI 10.1073/pnas.98.4.1901; MIDDLEBROOK G, 1953, SCIENCE, V118, P297, DOI 10.1126/science.118.3063.297; SAFI H, 2003, KEYSTONE S, V63; Schluger NW, 1999, INT J TUBERC LUNG D, V3, P281; Siminel M., 1979, B INT UNION TUBERC, V54, P263; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1985, AM REV RESPIR DIS, V132, P125; Soini H, 2000, J CLIN MICROBIOL, V38, P669, DOI 10.1128/JCM.38.2.669-676.2000; Supply P, 2001, J CLIN MICROBIOL, V39, P3563, DOI 10.1128/JCM.39.10.3563-3571.2001; Valway SE, 1998, NEW ENGL J MED, V338, P1783; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; van Soolingen D, 1999, J INFECT DIS, V180, P726, DOI 10.1086/314930; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1995, J CLIN MICROBIOL, V33, P3234, DOI 10.1128/JCM.33.12.3234-3238.1995; Weis SE, 2002, AM J RESP CRIT CARE, V166, P36, DOI 10.1164/rccm.2109089; Yaganehdoost A, 1999, J INFECT DIS, V180, P1245, DOI 10.1086/314991; Yang ZH, 1998, J CLIN MICROBIOL, V36, P1003, DOI 10.1128/JCM.36.4.1003-1007.1998; Zhang M, 1999, J INFECT DIS, V179, P1213, DOI 10.1086/314738	54	251	274	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1149	1156		10.1056/NEJMra021964	http://dx.doi.org/10.1056/NEJMra021964			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679530				2022-12-28	WOS:000185369700010
J	Gaucher, EA; Thomson, JM; Burgan, MF; Benner, SA				Gaucher, EA; Thomson, JM; Burgan, MF; Benner, SA			Inferring the palaeoenvironment of ancient bacteria on the basis of resurrected proteins	NATURE			English	Article							ELONGATION-FACTOR TU; COMMON ANCESTOR; EVOLUTION; THERMOSTABILITY; RIBONUCLEASE; DIVERSITY; SEQUENCES; LIFE	Features of the physical environment surrounding an ancestral organism can be inferred by reconstructing sequences(1-9) of ancient proteins made by those organisms, resurrecting these proteins in the laboratory, and measuring their properties. Here, we resurrect candidate sequences for elongation factors of the Tu family (EF-Tu) found at ancient nodes in the bacterial evolutionary tree, and measure their activities as a function of temperature. The ancient EF-Tu proteins have temperature optima of 55-65degreesC. This value seems to be robust with respect to uncertainties in the ancestral reconstruction. This suggests that the ancient bacteria that hosted these particular genes were thermophiles, and neither hyperthermophiles nor mesophiles. This conclusion can be compared and contrasted with inferences drawn from an analysis of the lengths of branches in trees joining proteins from contemporary bacteria(10), the distribution of thermophily in derived bacterial lineages(11), the inferred G+C content of ancient ribosomal RNA(12), and the geological record combined with assumptions concerning molecular clocks(13). The study illustrates the use of experimental palaeobiochemistry and assumptions about deep phylogenetic relationships between bacteria to explore the character of ancient life.	Univ Florida, NASA, Astrobiol Inst, Gainesville, FL 32611 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32611 USA; Univ Florida, Dept Chem, Gainesville, FL 32611 USA	National Aeronautics & Space Administration (NASA); State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Gaucher, EA (corresponding author), Univ Florida, NASA, Astrobiol Inst, Gainesville, FL 32611 USA.		Gaucher, Eric/I-7313-2013	Green, Michelle/0000-0002-6055-4342				Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; ADEY NB, 1994, P NATL ACAD SCI USA, V91, P1569, DOI 10.1073/pnas.91.4.1569; ARAI KI, 1972, J BIOL CHEM, V247, P7029; Benner SA, 2002, SCIENCE, V296, P864, DOI 10.1126/science.1069863; Brochier C, 2002, NATURE, V417, P244, DOI 10.1038/417244a; Cavalier-Smith T, 2002, INT J SYST EVOL MICR, V52, P7, DOI 10.1099/00207713-52-1-7; Chandrasekharan UM, 1996, SCIENCE, V271, P502, DOI 10.1126/science.271.5248.502; Chang BSW, 2002, MOL BIOL EVOL, V19, P1483, DOI 10.1093/oxfordjournals.molbev.a004211; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Galtier N, 1999, SCIENCE, V283, P220, DOI 10.1126/science.283.5399.220; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Gaucher EA, 2001, P NATL ACAD SCI USA, V98, P548, DOI 10.1073/pnas.98.2.548; Golding GB, 1998, MOL BIOL EVOL, V15, P355, DOI 10.1093/oxfordjournals.molbev.a025932; Gromiha MM, 1999, BIOPHYS CHEM, V82, P51, DOI 10.1016/S0301-4622(99)00103-9; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; Miyazaki J, 2001, J BIOCHEM-TOKYO, V129, P777, DOI 10.1093/oxfordjournals.jbchem.a002919; NOCK S, 1995, EUR J BIOCHEM, V234, P132, DOI 10.1111/j.1432-1033.1995.00132.x; PAULING L, 1963, ACTA CHEM SCAND, V17, pS9; Sanangelantoni AM, 1996, MICROBIOL-UK, V142, P2525, DOI 10.1099/00221287-142-9-2525; STACKHOUSE J, 1990, FEBS LETT, V262, P104, DOI 10.1016/0014-5793(90)80164-E; SWOFFORD DL, 2002, PAUP PHYLOGENETIC AN; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG Z, 1999, COMPUT APPL BIOSCI, V13, P555; YANG ZH, 1995, GENETICS, V141, P1641; Zhang JZ, 2002, P NATL ACAD SCI USA, V99, P5486, DOI 10.1073/pnas.072626199	30	180	188	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					285	288		10.1038/nature01977	http://dx.doi.org/10.1038/nature01977			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679914				2022-12-28	WOS:000185370900042
J	McMahon, BJ; Hennessy, TW; Bensler, JM; Bruden, DL; Parkinson, AJ; Morris, JM; Reasonover, AL; Hurlburt, DA; Bruce, MG; Sacco, F; Butler, JC				McMahon, BJ; Hennessy, TW; Bensler, JM; Bruden, DL; Parkinson, AJ; Morris, JM; Reasonover, AL; Hurlburt, DA; Bruce, MG; Sacco, F; Butler, JC			The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections	ANNALS OF INTERNAL MEDICINE			English	Article							ANTIBIOTIC-RESISTANCE; METRONIDAZOLE RESISTANCE; TRIPLE THERAPIES; HIGH PREVALENCE; UNITED-STATES; RISK-FACTORS; CLARITHROMYCIN; ERADICATION; SUSCEPTIBILITY; POPULATION	Background: The relationship between previous antimicrobial treatments and infection with drug-resistant Helicobacter pylori is unknown. Objectives: To determine whether previous use of antimicrobial agents predicts subsequent antibiotic resistance of H. pylori and whether resistance affects treatment outcome. Design: Retrospective cohort analysis of adults recruited sequentially from a clinical practice. Setting: A referral hospital in Anchorage, Alaska. Patients: 125 adults infected with H. pylori. Measurements: Medical records were reviewed for antimicrobial agents prescribed in the 10 years before diagnosis with H. pylori infection. Antimicrobial susceptibility of H. pylori isolates obtained from endoscopic gastric biopsy was determined by using agar dilution, Cure was determined by using the urea breath test 2 months after antimicrobial treatment. Results: Among the 125 patients, 37 (30%) were found to have H. pylori isolates resistant to clarithromycin and 83 (66%) were found to have H. pylori isolates resistant to metronidazole. Resistance to clarithromycin was associated with previous use of any macrolide antibiotic (P < 0.001), and resistance to metronidazole was associated with previous use of metronidazole (P < 0.001). The odds of isolates being resistant to clarithromycin increased in relation to the number of courses of macrolides received (P < 0.001). Among 53 persons treated with clarithromycin-based regimens, treatment failed in 77% of those carrying clarithromycin-resistant H. pylori (10 of 13) and 13% of those with clarithromycin-susceptible strains (5 of 40) (relative risk, 6.2 [95% Cl, 1.9 to 37.1]; P < 0.001). Conclusions: Previous use of macrolides and metronidazole is associated with H. pylori resistant to these antimicrobial agents. Clarithromycin resistance is associated with a greater risk for failure with clarithromycin-based treatments.	CDCP, Arctic Invest Program, Natl Ctr Infect Dis, Anchorage, AK 99508 USA; Alaska Native Med Ctr, Anchorage, AK USA	Alaska Native Medical Center	McMahon, BJ (corresponding author), CDCP, Arctic Invest Program, Natl Ctr Infect Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.	bdm9@cdc.gov						Alarcon T, 1999, INT J ANTIMICROB AG, V12, P19, DOI 10.1016/S0924-8579(99)00051-5; BANATVALA N, 1994, GUT, V35, P1562, DOI 10.1136/gut.35.11.1562; Bardhan PK, 1997, CLIN INFECT DIS, V25, P973, DOI 10.1086/516067; Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954; BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; Blaser MJ, 1997, J CLIN INVEST, V100, P759, DOI 10.1172/JCI119588; Blecker U, 1997, PEDIATR INFECT DIS J, V16, P391, DOI 10.1097/00006454-199704000-00011; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056/NEJM199812243392602; CASELLA G, 1986, CAN J STAT, V14, P113, DOI 10.2307/3314658; Centers for Disease Control and Prevention (CDC), 2016, DEV WAT MAN PROGR RE; Dore MP, 2000, DIGEST DIS SCI, V45, P68, DOI 10.1023/A:1005457226341; Dowell SF, 1998, PEDIATRICS, V101, P163; Falk GW, 1997, CLEV CLIN J MED, V64, P187, DOI 10.3949/ccjm.64.4.187; Fraser AG, 1999, AUST NZ J MED, V29, P512, DOI 10.1111/j.1445-5994.1999.tb00752.x; Gonzales R, 2001, ANN INTERN MED, V134, P479, DOI 10.7326/0003-4819-134-6-200103200-00013; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; Greenberg PD, 1999, ARCH INTERN MED, V159, P2283, DOI 10.1001/archinte.159.19.2283; Hoshiya S, 2000, J GASTROENTEROL, V35, P10; Katelaris PH, 2002, GASTROENTEROLOGY, V123, P1763, DOI 10.1053/gast.2002.37051; Laine L, 2001, ANN INTERN MED, V134, P361, DOI 10.7326/0003-4819-134-5-200103060-00008; Lautenbach E, 2001, CLIN INFECT DIS, V32, P1162, DOI 10.1086/319757; Leach AJ, 1997, CLIN INFECT DIS, V24, P356, DOI 10.1093/clinids/24.3.356; Mandell Lionel A., 2000, Clinical Infectious Diseases, V31, P383, DOI 10.1086/313959; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; McColl K, 1998, NEW ENGL J MED, V339, P1869, DOI 10.1056/NEJM199812243392601; Megraud F, 1999, ANTIMICROB AGENTS CH, V43, P2747, DOI 10.1128/AAC.43.11.2747; Meyer JM, 2002, ANN INTERN MED, V136, P13, DOI 10.7326/0003-4819-136-1-200201010-00008; Miehlke S, 2001, Semin Gastrointest Dis, V12, P167; Miyaji H, 1997, ALIMENT PHARM THERAP, V11, P1131, DOI 10.1046/j.1365-2036.1997.00258.x; Moayyedi P, 2000, LANCET, V355, P1665, DOI 10.1016/S0140-6736(00)02236-4; Moayyedi P, 1998, J GASTROENTEROL, V33, P62; MORRIS JG, 1995, ANN INTERN MED, V123, P250, DOI 10.7326/0003-4819-123-4-199508150-00002; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; Osato MS, 1999, INT J ANTIMICROB AG, V12, P341, DOI 10.1016/S0924-8579(99)00079-5; Osato MS, 2001, ARCH INTERN MED, V161, P1217, DOI 10.1001/archinte.161.9.1217; Parkinson AJ, 2000, CLIN DIAGN LAB IMMUN, V7, P885, DOI 10.1128/CDLI.7.6.885-888.2000; PETERSON WL, 1993, AM J GASTROENTEROL, V88, P1860; Pilotto A, 1999, ALIMENT PHARM THER, V13, P667; Pilotto A, 2000, DIGEST LIVER DIS, V32, P763, DOI 10.1016/S1590-8658(00)80352-7; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; RICHARD P, 1994, J INFECT DIS, V170, P377, DOI 10.1093/infdis/170.2.377; Rozynek E, 1997, EUR J CLIN MICROBIOL, V16, P943, DOI 10.1007/BF01700566; Taylor DE, 1998, CAN J GASTROENTEROL, V12, P295, DOI 10.1155/1998/672746; TYTGAT GNJ, 1990, GASTROENTEROL CLIN N, V19, P183; van der Hulst RWM, 1998, GUT, V42, P166, DOI 10.1136/gut.42.2.166; Wolle K, 1998, EUR J CLIN MICROBIOL, V17, P519, DOI 10.1007/BF01691138; Xia HHX, 1997, AM J GASTROENTEROL, V92, P1780; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65; 2000, PERFORMANCE STANDARD, V20, P1	49	143	151	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					463	469		10.7326/0003-4819-139-6-200309160-00008	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679322				2022-12-28	WOS:000185324100001
J	Schoofs, MWCJ; van der Klift, M; Hofman, A; de Laet, CEDH; Herings, RMC; Stijnen, T; Pols, HAP; Stricker, BHC				Schoofs, MWCJ; van der Klift, M; Hofman, A; de Laet, CEDH; Herings, RMC; Stijnen, T; Pols, HAP; Stricker, BHC			Thiazide diuretics and the risk for hip fracture	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MINERAL DENSITY; NORMAL POSTMENOPAUSAL WOMEN; OSTEOPOROTIC FRACTURES; CONTROLLED-TRIAL; LONG-TERM; ROTTERDAM; MEN; HYDROCHLOROTHIAZIDE; QUESTIONNAIRE; EPIDEMIOLOGY	Background: Since most hip fractures are related to osteoporosis, treating accelerated bone loss can be an important strategy to prevent hip fractures. Thiazides have been associated with reduced age-related bone loss by decreasing urinary calcium excretion. Objective: To examine the association between dose and duration of thiazide diuretic use and the risk for hip fracture and to study the consequences of discontinuing use. Design: Prospective population-based cohort study. Setting: The Rotterdam Study. Participants: 7891 individuals 55 years of age and older. Measurements: Hip fractures were reported by the general practitioners and verified by trained research assistants. Details of all dispensed drugs were available on a day-to-day basis. Exposure to thiazides was divided into 7 mutually exclusive categories: never use, current use for 1 to 42 days, current use for 43 to 365 days, current use for more than 365 days, discontinuation of use since 1 to 60 days, discontinuation of use since 61 to 120 days, and discontinuation of use since more than 120 days. Results: 281 hip fractures occurred. Relative to nonuse, current use of thiazides for more than 365 days was statistically significantly associated with a lower risk for hip fracture (hazard ratio, 0.46 [95% Cl, 0.21 to 0.96]). There was no clear dose dependency. This lower risk disappeared approximately 4 months after thiazide use was discontinued. Conclusions: Thiazide diuretics protect against hip fracture, but this protective effect disappears within 4 months after use is discontinued.	Erasmus Univ, Ctr Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Stricker, BHC (corresponding author), Erasmus Univ, Ctr Med, Dept Epidemiol & Biostat, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Herings, Ron/AAE-4096-2021	Herings, Ron/0000-0002-2561-8734; De Laet, Chris/0000-0002-1951-2079				Adams JS, 1999, ANN INTERN MED, V130, P658, DOI 10.7326/0003-4819-130-8-199904200-00012; ADLANDDAVENPORT P, 1985, AM J OBSTET GYNECOL, V152, P630, DOI 10.1016/S0002-9378(85)80035-1; [Anonymous], 1992, INT STAT CLASS DIS R, V1-3; Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756-3282(95)00486-6; Aubin R, 1996, KIDNEY INT, V50, P1476, DOI 10.1038/ki.1996.461; BURGER H, 1994, BONE MINER, V25, P1, DOI 10.1016/S0169-6009(08)80203-6; Burger H, 1998, AM J EPIDEMIOL, V147, P871, DOI 10.1093/oxfordjournals.aje.a009541; CAULEY JA, 1993, ANN INTERN MED, V118, P666, DOI 10.7326/0003-4819-118-9-199305010-00002; COX DR, 1972, J R STAT SOC B, V34, P187; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; DUARTE CG, 1971, NEW ENGL J MED, V284, P828, DOI 10.1056/NEJM197104152841506; FELSON DT, 1991, JAMA-J AM MED ASSOC, V265, P370, DOI 10.1001/jama.265.3.370; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; HALE WE, 1984, NEW ENGL J MED, V310, P926; HEIDRICH FE, 1991, ANN INTERN MED, V115, P1, DOI 10.7326/0003-4819-115-1-1; Herings RMC, 1996, J CLIN EPIDEMIOL, V49, P115, DOI 10.1016/0895-4356(95)00552-8; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; LaCroix AZ, 2000, ANN INTERN MED, V133, P516, DOI 10.7326/0003-4819-133-7-200010030-00010; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; Lajeunesse D, 2000, J BONE MINER RES, V15, P894, DOI 10.1359/jbmr.2000.15.5.894; Meijer WT, 1998, ARTERIOSCL THROM VAS, V18, P185, DOI 10.1161/01.ATV.18.2.185; MELTON LJ, 1993, BONE, V14, pS1; MORTON DJ, 1994, AM J EPIDEMIOL, V139, P1107, DOI 10.1093/oxfordjournals.aje.a116954; Moser M, 1998, JAMA-J AM MED ASSOC, V279, P1813, DOI 10.1001/jama.279.22.1813; Onder G, 2001, J HUM HYPERTENS, V15, P291, DOI 10.1038/sj.jhh.1001176; PEH CA, 1993, J AM GERIATR SOC, V41, P513, DOI 10.1111/j.1532-5415.1993.tb01887.x; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; RASHIQ S, 1986, BRIT MED J, V292, P861, DOI 10.1136/bmj.292.6524.861; RAY WA, 1989, LANCET, V1, P687; Reid IR, 2000, AM J MED, V109, P362, DOI 10.1016/S0002-9343(00)00510-6; Savage PJ, 1998, ARCH INTERN MED, V158, P741, DOI 10.1001/archinte.158.7.741; Sigurdsson G, 2001, J INTERN MED, V250, P51, DOI 10.1046/j.1365-2796.2001.00850.x; TRANSBOL I, 1982, METABOLISM, V31, P383, DOI 10.1016/0026-0495(82)90115-9; Twisk J, 2002, J CLIN EPIDEMIOL, V55, P329, DOI 10.1016/S0895-4356(01)00476-0; VANDERKUY A, 2000, FARMACOTHERAPEUTISCH, P523; WASNICH RD, 1986, OBSTET GYNECOL, V67, P457; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; *WHO COLL CTR DRUG, 1993, AN THER CHEM IND; *WHO COLL CTR DRUG, 1992, AN THER CHEM IND INC; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	42	146	155	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					476	482		10.7326/0003-4819-139-6-200309160-00010	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679324	Green Published			2022-12-28	WOS:000185324100003
J	Sjolund, M; Wreiber, K; Andersson, DI; Blaser, MJ; Engstrand, L				Sjolund, M; Wreiber, K; Andersson, DI; Blaser, MJ; Engstrand, L			Long-term persistence of resistant enterococcus species after antibiotics to eradicate Helicobacter pylori	ANNALS OF INTERNAL MEDICINE			English	Article							GROUP-A STREPTOCOCCI; BIOLOGICAL COST; MACROLIDE RESISTANCE; DETERMINANTS; PCR	Background: Antibiotic treatment selects for resistance not only in the pathogen to which it is directed but also in the indigenous microflora. Objective: To determine whether a widely used regimen (clarithromycin, metronidazole, and omeprazole) for Helicobacter pylori eradication affects resistance development in enterococci. Design: Cohort study. Setting: Endoscopy units at 3 community hospitals in Sweden. Patients: 5 consecutive dyspeptic patients who were colonized with H. pylori, had endoscopy-confirmed duodenal ulcer, and received antibiotic treatment, and 5 consecutive controls with dyspepsia but no ulcer who did not receive treatment. Measurements: Fecal samples were obtained from patients and controls before, immediately after, 1 year after, and 3 years after treatment. From each patient and sample, enterococci were isolated and analyzed for DNA fingerprint, clarithromycin susceptibility, and presence of the erm(B) gene. Results: in treated patients, all enterococci isolated immediately after treatment showed high-level clarithromycin resistance due to erm(B). In 3 patients, resistant enterococci persisted for 1 to 3 years after treatment. No resistance developed among controls. Conclusion: A common H. pylori treatment selects for highly resistant enterococci that can persist for at least 3 years without further selection.	Swedish Inst Infect Dis Control, Dept Bacteriol, SE-17182 Solna, Sweden	Swedish Institute for Infectious Disease Control	Engstrand, L (corresponding author), Swedish Inst Infect Dis Control, Dept Bacteriol, SE-17182 Solna, Sweden.	lars.engstrand@smi.ki.se		Andersson, Dan/0000-0001-6640-2174	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063270] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM63270] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson DI, 1999, CURR OPIN MICROBIOL, V2, P489, DOI 10.1016/S1369-5274(99)00005-3; Bjorkholm B, 2001, P NATL ACAD SCI USA, V98, P14607, DOI 10.1073/pnas.241517298; Bjorkman J, 1998, P NATL ACAD SCI USA, V95, P3949, DOI 10.1073/pnas.95.7.3949; Cresti S, 2002, ANTIMICROB AGENTS CH, V46, P1816, DOI 10.1128/AAC.46.6.1816-1822.2002; Descheemaeker P, 1997, INT J SYST BACTERIOL, V47, P555, DOI 10.1099/00207713-47-2-555; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; KUIPERS EJ, 1995, ALIMENT PHARM THERAP, V9, P59; Levy SB, 2002, J ANTIMICROB CHEMOTH, V49, P25, DOI 10.1093/jac/49.1.25; Maiden MCJ, 1998, CLIN INFECT DIS, V27, pS12, DOI 10.1086/514917; Martinez JL, 2000, ANTIMICROB AGENTS CH, V44, P1771, DOI 10.1128/AAC.44.7.1771-1777.2000; Megraud F, 2000, GASTROENTEROL CLIN N, V29, P759, DOI 10.1016/S0889-8553(05)70145-X; Murray BE, 1999, P ASSOC AM PHYSICIAN, V111, P328, DOI 10.1046/j.1525-1381.1999.99241.x; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; Nagaev I, 2001, MOL MICROBIOL, V40, P433, DOI 10.1046/j.1365-2958.2001.02389.x; Portillo A, 2000, ANTIMICROB AGENTS CH, V44, P967, DOI 10.1128/AAC.44.4.967-971.2000; Sander P, 2002, ANTIMICROB AGENTS CH, V46, P1204, DOI 10.1128/AAC.46.5.1204-1211.2002; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; Shoemaker NB, 2001, APPL ENVIRON MICROB, V67, P561, DOI 10.1128/AEM.67.2.561-568.2001; Sutcliffe J, 1996, ANTIMICROB AGENTS CH, V40, P2562, DOI 10.1128/AAC.40.11.2562	20	109	124	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					483	487		10.7326/0003-4819-139-6-200309160-00011	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679325				2022-12-28	WOS:000185324100004
J	Coupland, C; Hippisley-Cox, J; Kendrick, D; Groom, L; Cross, E; Savelyich, B				Coupland, C; Hippisley-Cox, J; Kendrick, D; Groom, L; Cross, E; Savelyich, B			Severe traffic injuries to children, Trent, 1992-7: time trend analysis	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham, Div Primary Care, Nottingham NG7 2RD, England	University of Nottingham	Coupland, C (corresponding author), Univ Nottingham, Div Primary Care, Nottingham NG7 2RD, England.		Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Kendrick, Denise/0000-0003-3603-6542; Coupland, Carol/0000-0002-2327-3306				Cryer PC, 2000, PUBLIC HEALTH, V114, P232; Hippisley-Cox J, 2002, BRIT MED J, V324, P1132, DOI 10.1136/bmj.324.7346.1132; *OFF NAT STAT, 2001, MORT STAT INJ POIS; THOMPSON DC, 1999, COCHRANE LIB; Towner E, 2001, Inj Prev, V7, P161, DOI 10.1136/ip.7.2.161	5	9	10	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					593	594		10.1136/bmj.327.7415.593	http://dx.doi.org/10.1136/bmj.327.7415.593			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969925	Green Published, Bronze			2022-12-28	WOS:000185358700021
J	Hayashi, YK				Hayashi, YK			Membrane-repair machinery and muscular dystrophy	LANCET			English	Editorial Material							DYSFERLIN; EXPRESSION; EXOCYTOSIS; LYSOSOMES		Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo 1878502, Japan	National Center for Neurology & Psychiatry - Japan	Hayashi, YK (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo 1878502, Japan.							Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; Ikezeo K, 2003, ACTA NEUROPATHOL, V105, P603, DOI 10.1007/s00401-003-0686-1; Jaiswal JK, 2002, J CELL BIOL, V159, P625, DOI 10.1083/jcb.200208154; Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761; Piccolo F, 2000, ANN NEUROL, V48, P902, DOI 10.1002/1531-8249(200012)48:6<902::AID-ANA11>3.3.CO;2-Q; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Selcen D, 2001, NEUROLOGY, V56, P1472, DOI 10.1212/WNL.56.11.1472; Tagawa K, 2003, J NEUROL SCI, V211, P23, DOI 10.1016/S0022-510X(03)00041-8	10	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					843	844		10.1016/S0140-6736(03)14346-2	http://dx.doi.org/10.1016/S0140-6736(03)14346-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678966				2022-12-28	WOS:000185329400003
J	Frumkin, A; Shimron, A; Rosenbaum, J				Frumkin, A; Shimron, A; Rosenbaum, J			Radiometric dating of the Siloam Tunnel, Jerusalem	NATURE			English	Article							SYSTEM	The historical credibility of texts from the Bible is often debated when compared with Iron Age archaeological finds (refs. 1, 2 and references therein). Modern scientific methods may, in principle, be used to independently date structures that seem to be mentioned in the biblical text, to evaluate its historical authenticity. In reality, however, this approach is extremely difficult because of poor archaeological preservation, uncertainty in identification, scarcity of datable materials, and restricted scientific access into well-identified worship sites. Because of these problems, no well-identified Biblical structure has been radiometrically dated until now. Here we report radiocarbon and U-Th dating of the Siloam Tunnel(3-10), proving its Iron Age II date; we conclude that the Biblical text presents an accurate historic record of the Siloam Tunnel's construction. Being one of the longest ancient water tunnels lacking intermediate shafts(11,12), dating the Siloam Tunnel is a key to determining where and when this technological breakthrough took place. Siloam Tunnel dating also refutes a claim(13) that the tunnel was constructed in the second century BC.	Hebrew Univ Jerusalem, Dept Geog, IL-91905 Jerusalem, Israel; Geol Survey Israel, IL-95501 Jerusalem, Israel; Univ Reading, Postgrad Res Inst Sedimentol, Reading RG6 6AB, Berks, England	Hebrew University of Jerusalem; Geological Survey Israel; University of Reading	Frumkin, A (corresponding author), Hebrew Univ Jerusalem, Dept Geog, IL-91905 Jerusalem, Israel.							ABELLS Z, 1995, CITY D WATER SYSTEMS; Amiran R., 1976, JERUSALEM REVEALED, P75; AMIT D, 2002, J ROMAN ARCHAEOL S; BRONKRAMSEY C, 1995, RADIOCARBON, V37, P425; Finkelstein Israel, 2001, BIBLE UNEARTHED ARCH; Frumkin A, 1999, QUATERNARY RES, V51, P317, DOI 10.1006/qres.1998.2031; FRUMKIN A, 1986, 9 C INT ESP UN INT E, P264; FRUMKIN A, 2001, 11 INT C WAT ANT TEL, P4; GILL D, 1991, SCIENCE, V254, P1467, DOI 10.1126/science.254.5037.1467; GILL D, 1996, EXCAVATIONS CITY DAV, P1; HACKETT JA, 1997, BIBL ARCHAEOL RE MAR, P41; HEDGES REM, 1989, ARCHAEOMETRY, V31, P99, DOI 10.1111/j.1475-4754.1989.tb01007.x; ISSAR A, 1976, ISRAEL EXPLOR J, V26, P130; Kaufman A, 1998, EARTH PLANET SC LETT, V156, P141, DOI 10.1016/S0012-821X(98)00002-8; Levi della Vida G., 1968, MEMORIAM P KAHLE MEMORIAM P KAHLE, P162; MAZAR A, 2000, HIST JERUSALEM BIBLI, P195; Montgomery J. A., 1951, INT CRITICAL COMMENT; Reich R., 2002, B AM SCH ORIENT RES, V325, P75; Rogerson J, 1996, BIBLIC ARCHAEOL, V59, P138, DOI 10.2307/3210545; Sasson V, 1982, PALEST EXPLOR Q, V114, P111; SHAHEEN N, 1979, PALESTINE EXPLOR JAN, P103; SHIMRON A, 2000, GEOL SURV ISRAEL CUR, V12, P247; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; TSUK T, 2000, ANCIENT WATER SYSTEM; Ussishkin D., 1976, LEVANT, V8, P82; Vincent L.-H., 1911, UNDERGROUND JERUSALE	26	26	26	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2003	425	6954					169	171		10.1038/nature01875	http://dx.doi.org/10.1038/nature01875			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	719ZT	12968177				2022-12-28	WOS:000185236000039
J	White, HD				White, HD			Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION		Green Lane Hosp, Dept Cardiol, Auckland 3, New Zealand		White, HD (corresponding author), Green Lane Hosp, Dept Cardiol, Auckland 3, New Zealand.							Alpert JS, 2000, EUR HEART J, V21, P1502, DOI 10.1053/euhj.2000.2305; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Talbot P, 2000, NEW ENGL J MED, V342, P748; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N; Yusuf S, 2000, NEW ENGL J MED, V342, P145	6	30	30	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					755	757		10.1016/S0140-6736(03)14295-X	http://dx.doi.org/10.1016/S0140-6736(03)14295-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678865				2022-12-28	WOS:000185188500004
J	Smith, S; Pfeifer, SM; Collins, JA				Smith, S; Pfeifer, SM; Collins, JA			Diagnosis and management of female infertility	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLOMIPHENE CITRATE; INTRAUTERINE INSEMINATION; GONADOTROPIN THERAPY; CONTROLLED TRIAL; ENDOMETRIOSIS; WOMEN; PREGNANCIES; IVF		Johns Hopkins Med Inst, Dept Obstet & Gynecol, Baltimore, MD 21205 USA; Univ Penn, Sch Med, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA; McMaster Univ, Dept Obstet & Gynecol, Hamilton, ON, Canada	Johns Hopkins University; Johns Hopkins Medicine; University of Pennsylvania; McMaster University	Collins, JA (corresponding author), 400 Maders Cove Rd,RR 1, Mahone Bay, NS B3J 2E0, Canada.	collinsj@auracom.com						ADAMSON GD, 1994, AM J OBSTET GYNECOL, V171, P1488, DOI 10.1016/0002-9378(94)90392-1; Amer Soc Reprod Med, 2002, FERTIL STERIL, V78, P918; *ASRM PRACT COMM, 2000, OPT EV INF FEM, P1; BALASCH J, 1992, HUM REPROD, V7, P973, DOI 10.1093/oxfordjournals.humrep.a137782; CALLAHAN TL, 1994, NEW ENGL J MED, V331, P244, DOI 10.1056/NEJM199407283310407; COLLINS J, 1993, TREATMENT INFERTILIT, V10, P233; Collins JA, 2002, HUM REPROD UPDATE, V8, P265, DOI 10.1093/humupd/8.3.265; DEATON JL, 1990, FERTIL STERIL, V54, P1083; Farquhar CM, 2002, FERTIL STERIL, V78, P404, DOI 10.1016/S0015-0282(02)03225-9; FLUKER MR, 1994, OBSTET GYNECOL, V83, P189; Guzick DS, 1999, NEW ENGL J MED, V340, P177, DOI 10.1056/NEJM199901213400302; HUGHES EG, 1993, FERTIL STERIL, V59, P963; HUGHES EG, 2002, 48 ANN M CAN FERT AN; Hunault CC, 2002, FERTIL STERIL, V78, P500, DOI 10.1016/S0015-0282(02)03244-2; Imani B, 2002, FERTIL STERIL, V77, P91, DOI 10.1016/S0015-0282(01)02929-6; Marcoux S, 1997, NEW ENGL J MED, V337, P217, DOI 10.1056/NEJM199707243370401; Oei SG, 1998, BRIT MED J, V317, P502; Parazzini F, 1999, HUM REPROD, V14, P1332; Perri T, 2001, J ASSIST REPROD GEN, V18, P245, DOI 10.1023/A:1016614217411; Stephen EH, 1998, FERTIL STERIL, V70, P30, DOI 10.1016/S0015-0282(98)00103-4; Strandell A, 2001, HUM REPROD, V16, P2403, DOI 10.1093/humrep/16.11.2403; Touraine F, 2001, ACTA OBSTET GYN SCAN, V80, P162, DOI 10.1034/j.1600-0412.2001.080002162.x; U.S. Congress Office of Technology Assessment, 1988, INF MED SOC CHOIC; *US BUR CENS, 1997, STAT ABSTR US, V117	24	126	136	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1767	1770		10.1001/jama.290.13.1767	http://dx.doi.org/10.1001/jama.290.13.1767			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519712				2022-12-28	WOS:000185606100027
J	de Jonge, E; Schultz, MJ; Spanjaard, L; Bossuyt, PMM; Vroom, MB; Dankert, J; Kesecioglu, J				de Jonge, E; Schultz, MJ; Spanjaard, L; Bossuyt, PMM; Vroom, MB; Dankert, J; Kesecioglu, J			Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial	LANCET			English	Article							VENTILATOR-ASSOCIATED PNEUMONIA; CRITICALLY ILL PATIENTS; DOUBLE-BLIND; ANTIBIOTIC-PROPHYLAXIS; NOSOCOMIAL INFECTION; SURGICAL PATIENTS; CLINICAL-TRIAL; PREVENTION; UNIT; COLONIZATION	Background Selective decontamination of the digestive tract (SDD) is an infection-prevention regimen used in critically ill patients. We assessed the effects of SDD on intensive-care-unit (ICU) and hospital mortality, and on the acquisition of resistant bacteria in adult patients admitted to intensive care. Methods We did a prospective, controlled, randomised, unblinded clinical trial, 934 patients admitted to a surgical and medical ICU were randomly assigned oral and enteral polymyxin E, tobramycin, and amphotericin B combined with an initial 4-day course of intravenous cefotaxime (SDD group n=466), or standard treatment (controls n=468). Primary endpoints were ICU and hospital mortality and the acquisition of resistant bacteria. Findings In the SDD group 69 (15%) patients died in the ICU compared with 107 (23%) in the control group (p=0.002). Hospital mortality was lower in the SDD groups than in the control group (113 [24%] vs 146 [31%], p=0.02). During their stay in intensive care, colonisation with gram-negative bacteria resistant to ceftazidime, ciprofloxacin, imipenem, polymyxin E, or tobramycin occurred in 61 (16%) of 378 SDD patients and in 104 (26%) of 395 patients in the control group (p=0.001). Colonisation with vancomycin-resistant enterococcus occurred in five (1%) SDD patients and in four (1%) controls (p=1.0). No patient in either group was colonised with meticillin-resistant Staphylococcus aureus. Interpretation In a setting with low prevalence of vancomycin-resistant enterococcus and meticillin-resistant S aureus, SDD can decrease ICU and hospital mortality and colonisation with resistant gram-negative aerobic bacteria.	Univ Amsterdam, Acad Med Ctr, Dept Intens Care, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Univ Med Ctr, Dept Anaesthesiol & Intens Care, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center	de Jonge, E (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Intens Care, POB 22660, NL-1100 DD Amsterdam, Netherlands.		Schultz, Marcus/AAB-6379-2021; Bossuyt, Patrick M./B-4557-2016; Bossuyt, Patrick M/AAR-1183-2021	Schultz, Marcus/0000-0003-3969-7792; Bossuyt, Patrick M./0000-0003-4427-0128; Bossuyt, Patrick M/0000-0003-4427-0128				AERDTS SJA, 1993, BRIT MED J, V307, P525; AERDTS SJA, 1991, CHEST, V100, P783, DOI 10.1378/chest.100.3.783; Arts D, 2002, INTENS CARE MED, V28, P656, DOI 10.1007/s00134-002-1272-z; Bergmans DCJJ, 2001, AM J RESP CRIT CARE, V164, P382, DOI 10.1164/ajrccm.164.3.2005003; BLAIR P, 1991, SURGERY, V110, P303; Bonten MJM, 2000, J ANTIMICROB CHEMOTH, V46, P351, DOI 10.1093/jac/46.3.351; Bou G, 2000, ANTIMICROB AGENTS CH, V44, P428, DOI 10.1128/AAC.44.2.428-432.2000; COCKERILL FR, 1992, ANN INTERN MED, V117, P545, DOI 10.7326/0003-4819-117-7-545; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; Ebner W, 2000, EUR J CLIN MICROBIOL, V19, P243, DOI 10.1007/s100960050470; Garcia MS, 1998, AM J RESP CRIT CARE, V158, P908, DOI 10.1164/ajrccm.158.3.9712079; Jacobs S., 1992, CLIN INTENSIVE CARE, V3, P52; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; Kollef MH, 1996, CRIT CARE MED, V24, P177, DOI 10.1097/00003246-199601000-00032; KORINEK AM, 1993, CRIT CARE MED, V21, P1466, DOI 10.1097/00003246-199310000-00013; Krueger WA, 2002, AM J RESP CRIT CARE, V166, P1029, DOI 10.1164/rccm.2105141; Lingnau W, 1998, J HOSP INFECT, V39, P195, DOI 10.1016/S0195-6701(98)90258-4; LIVERMORE DM, 1995, CLIN MICROBIOL REV, V8, P557, DOI 10.1128/CMR.8.4.557; Nathens AB, 1999, ARCH SURG-CHICAGO, V134, P170, DOI 10.1001/archsurg.134.2.170; Palomar M., 1997, CLIN INTENSIVE CARE, V8, P228, DOI [10.3109/tcic.8.5.228.235, DOI 10.3109/TCIC.8.5.228.235]; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; ROCHA LA, 1992, INTENS CARE MED, V18, P398, DOI 10.1007/BF01694341; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; van Nieuwenhoven CA, 2001, JAMA-J AM MED ASSOC, V286, P335, DOI 10.1001/jama.286.3.335; Verwaest C, 1997, CRIT CARE MED, V25, P63, DOI 10.1097/00003246-199701000-00014; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; WINTER R, 1992, J ANTIMICROB CHEMOTH, V30, P73, DOI 10.1093/jac/30.1.73	30	404	414	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 27	2003	362	9389					1011	1016		10.1016/S0140-6736(03)14409-1	http://dx.doi.org/10.1016/S0140-6736(03)14409-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522530				2022-12-28	WOS:000185564600007
J	Bockenstedt, P				Bockenstedt, P			D-dimer in venous thromboembolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DEEP-VEIN THROMBOSIS		Univ Michigan, Med Ctr, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Bockenstedt, P (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.							Cogo A, 1998, BRIT MED J, V316, P17, DOI 10.1136/bmj.316.7124.17; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X	2	35	37	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2003	349	13					1203	1204		10.1056/NEJMp030084	http://dx.doi.org/10.1056/NEJMp030084			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LJ	14507947				2022-12-28	WOS:000185488800001
J	Houde, M; Bertholet, S; Gagnon, E; Brunet, S; Goyette, G; Laplante, A; Princiotta, MF; Thibault, P; Sacks, D; Desjardins, M				Houde, M; Bertholet, S; Gagnon, E; Brunet, S; Goyette, G; Laplante, A; Princiotta, MF; Thibault, P; Sacks, D; Desjardins, M			Phagosomes are competent organelles for antigen cross-presentation	NATURE			English	Article							MHC CLASS-I; CD8(+) T-CELLS; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; COMPLEX; PHAGOCYTOSIS; ACTIVATION; PATHWAY; CYTOSOL; LOCALIZATION	The ability to process microbial antigens and present them at the surface of cells is an important aspect of our innate ability to clear infections. It is generally accepted that antigens in the cytoplasm are loaded in the endoplasmic reticulum and presented at the cell surface on major histocompatibility complex (MHC) class I molecules, whereas peptides present in endo/phagocytic compartments are presented on MHC class II molecules(1,2). Despite the apparent segregation of the class I and class II pathways, antigens from intracellular pathogens including mycobacteria, Escherichia coli, Salmonella typhimurium, Brucella abortus and Leishmania, have been shown to elicit an MHCclass-I-dependent CD8(+) T-cell response(3-7), a process referred to as cross-presentation(2). The cellular mechanisms allowing the cross-presentation pathway are poorly understood. Here we show that phagosomes display the elements and properties needed to be self-sufficient for the cross-presentation of exogenous antigens, a newly ascribed function linked to phagocytosis mediated by the endoplasmic reticulum.	Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3C 3J7, Canada; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Caprion Pharmaceut Inc, Montreal, PQ H45 2C8, Canada	Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Desjardins, M (corresponding author), Univ Montreal, Dept Pathol & Biol Cellulaire, CP6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.			Desjardins, Michel/0000-0002-5684-5980; Thibault, Pierre/0000-0001-5993-0331; Goyette, Guillaume/0000-0003-3277-568X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000494, ZIAAI000658, Z01AI000658, Z01AI000494] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belkaid Y, 2002, J IMMUNOL, V168, P3992, DOI 10.4049/jimmunol.168.8.3992; Brooks P, 2000, BIOCHEM J, V352, P611, DOI 10.1042/0264-6021:3520611; Canaday DH, 1999, J IMMUNOL, V162, P372; Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Hazes B, 1997, BIOCHEMISTRY-US, V36, P11051, DOI 10.1021/bi971383p; Heath WR, 2001, NAT REV IMMUNOL, V1, P126, DOI 10.1038/35100512; KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Lennon-Dumenil AM, 2002, J EXP MED, V196, P529, DOI 10.1084/jem.20020327; MacAry PA, 2001, P NATL ACAD SCI USA, V98, P3982, DOI 10.1073/pnas.071477498; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Muno D, 2000, FEBS LETT, V478, P178, DOI 10.1016/S0014-5793(00)01849-4; OLIVEIRA SC, 1995, EUR J IMMUNOL, V25, P2551, DOI 10.1002/eji.1830250922; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Ramachandra L, 1999, J IMMUNOL, V162, P3263; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203; Tirosh B, 2003, J BIOL CHEM, V278, P6664, DOI 10.1074/jbc.M210158200; Turner J, 1996, IMMUNOLOGY, V87, P339, DOI 10.1046/j.1365-2567.1996.512590.x; Watts C, 2001, SEMIN IMMUNOL, V13, P373; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	27	565	583	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					402	406		10.1038/nature01912	http://dx.doi.org/10.1038/nature01912			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508490				2022-12-28	WOS:000185502300042
J	Berkley, S				Berkley, S			Thorny issues in the ethics of AIDS vaccine trials	LANCET			English	Editorial Material									IAVI, New York, NY 10013 USA	International AIDS Vaccine Initiative	Berkley, S (corresponding author), IAVI, New York, NY 10013 USA.							*IAVI, 2001, NEW ACC PAR PUBL SEC; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916	2	23	24	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					992	992		10.1016/S0140-6736(03)14371-1	http://dx.doi.org/10.1016/S0140-6736(03)14371-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	724LT	14513850				2022-12-28	WOS:000185489600024
J	Chen, EH; Pryce, BA; Tzeng, JA; Gonzalez, GA; Olson, EN				Chen, EH; Pryce, BA; Tzeng, JA; Gonzalez, GA; Olson, EN			Control of myoblast fusion by a guanine nucleotide exchange factor, loner, and its effector ARF6	CELL			English	Article							ADP-RIBOSYLATION FACTOR; DROSOPHILA EMBRYOGENESIS; ACTIN CYTOSKELETON; TRANSCRIPTION FACTOR; MUSCLE DEVELOPMENT; GENETIC-ANALYSIS; ROLLING-PEBBLES; PROTEIN; MEMBRANE; MYOGENESIS	Myoblast fusion is essential for the formation and regeneration of skeletal muscle. In a genetic screen for regulators of muscle development in Drosophila, we discovered a gene encoding a guanine nucleotide exchange factor, called loner, which is required for myoblast fusion. Loner localizes to subcellular sites of fusion and acts downstream of cell surface fusion receptors by recruiting the small GTPase ARF6 and stimulating guanine nucleotide exchange. Accordingly, a dominant-negative ARF6 disrupts myoblast fusion in Drosophila embryos and in mammalian myoblasts in culture, mimicking the fusion defects caused by loss of Loner. Loner and ARF6, which also control the proper membrane localization of another small GTPase, Rac, are key components of a cellular apparatus required for myoblast fusion and muscle development. In muscle cells, this fusigenic mechanism is coupled to fusion receptors; in other fusion-competent cell types it may be triggered by different upstream signals.	Univ Texas, SW Med Ctr, Dept Biol Mol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Biol Mol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.							Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Artero RD, 2001, DEVELOPMENT, V128, P4251; Bate Michael, 1993, P1013; Baylies MK, 2001, CURR OPIN GENET DEV, V11, P431, DOI 10.1016/S0959-437X(00)00214-8; Baylies MK, 1998, CELL, V93, P921, DOI 10.1016/S0092-8674(00)81198-8; Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Bour BA, 2000, GENE DEV, V14, P1498; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen EH, 2001, DEV CELL, V1, P705, DOI 10.1016/S1534-5807(01)00084-3; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Doberstein SK, 1997, J CELL BIOL, V136, P1249, DOI 10.1083/jcb.136.6.1249; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Dworak HA, 2002, BIOESSAYS, V24, P591, DOI 10.1002/bies.10115; Dworak HA, 2001, DEVELOPMENT, V128, P4265; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Frasch M, 2000, CELL, V102, P127, DOI 10.1016/S0092-8674(00)00016-7; Frasch M, 1999, CURR OPIN GENET DEV, V9, P522, DOI 10.1016/S0959-437X(99)00014-3; Fuerstenberg S, 1998, DEV BIOL, V201, P66, DOI 10.1006/dbio.1998.8944; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; Hakeda-Suzuki S, 2002, NATURE, V416, P438, DOI 10.1038/416438a; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Keller CA, 1997, DEV BIOL, V181, P197, DOI 10.1006/dbio.1996.8434; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; KNUDSEN KA, 1992, MEMBRANE FUSION, P601; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Menon SD, 2001, DEV CELL, V1, P691, DOI 10.1016/S1534-5807(01)00075-2; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; Paululat A, 1999, MECH DEVELOP, V83, P17, DOI 10.1016/S0925-4773(99)00029-5; Radhakrishna H, 1999, J CELL SCI, V112, P855; Rau A, 2001, DEVELOPMENT, V128, P5061; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Ruiz-Gomez M, 2000, CELL, V102, P189, DOI 10.1016/S0092-8674(00)00024-6; RuizGomez M, 1997, DEVELOPMENT, V124, P3407; Rusconi JC, 1998, MECH DEVELOP, V79, P39, DOI 10.1016/S0925-4773(98)00170-1; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; Someya A, 2001, P NATL ACAD SCI USA, V98, P2413, DOI 10.1073/pnas.051634798; Strunkelnberg M, 2001, DEVELOPMENT, V128, P4229; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Taylor MV, 2002, CURR BIOL, V12, pR224, DOI 10.1016/S0960-9822(02)00757-1; WAKELAM MJO, 1985, BIOCHEM J, V228, P1	61	128	132	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 19	2003	114	6					751	762		10.1016/S0092-8674(03)00720-7	http://dx.doi.org/10.1016/S0092-8674(03)00720-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505574	Bronze			2022-12-28	WOS:000185464000012
J	Ouzounov, DG; Ahmad, FR; Muller, D; Venkataraman, N; Gallagher, MT; Thomas, MG; Silcox, J; Koch, KW; Gaeta, AL				Ouzounov, DG; Ahmad, FR; Muller, D; Venkataraman, N; Gallagher, MT; Thomas, MG; Silcox, J; Koch, KW; Gaeta, AL			Generation of megawatt optical solitons in hollow-core photonic band-gap fibers	SCIENCE			English	Article							FEMTOSECOND LASER-PULSES; SELF-FREQUENCY SHIFT; ANOMALOUS-DISPERSION; MICROSTRUCTURED FIBERS; CRYSTAL FIBERS; AIR; GUIDANCE; NM	The measured dispersion of a low-loss, hollow-core photonic band-gap fiber is anomalous throughout most of the transmission band, and its variation with wavelength is large compared with that of a conventional step-index fiber. For an air-filled fiber, femtosecond self-frequency-shifted fundamental solitons with peak powers greater than 2 megawatts can be supported. For Xe-filled fibers, nonfrequency-shifted temporal solitons with peak powers greater than 5.5 megawatts can be generated, representing an increase in the power that can be propagated in an optical fiber of two orders of magnitude. The results demonstrate a unique capability to deliver high-power pulses in a single spatial mode over distances exceeding 200 meters.	Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; Corning Inc, Corning, NY 14831 USA	Cornell University; Corning Inc; State University of New York (SUNY) System; SUNY Community College	Gaeta, AL (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.	a.gaeta@cornell.edu	Muller, David/A-7745-2010; Gaeta, Alexander/AAE-2095-2019	Muller, David/0000-0003-4129-0473; 	NCI NIH HHS [R44CA88391-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R44CA088391] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MJ, 1981, INTRO OPTICAL WAVEGU, P245; AGRAWAL GP, 2001, NONLINEAR FIBER OPTI, P120; Allan DC, 2001, NATO SCI SER II-MATH, V563, P305; Atherton BW, 1998, P SOC PHOTO-OPT INS, V3269, P22, DOI 10.1117/12.580605; Benabid F, 2002, SCIENCE, V298, P399, DOI 10.1126/science.1076408; Cregan RF, 1999, SCIENCE, V285, P1537, DOI 10.1126/science.285.5433.1537; DIANOV EM, 1985, JETP LETT+, V41, P294; GORDON JP, 1986, OPT LETT, V11, P662, DOI 10.1364/OL.11.000662; HASEGAWA A, 1973, APPL PHYS LETT, V23, P142, DOI 10.1063/1.1654836; JACKSON JD, 1975, CLASSICAL ELECTRODYN, P343; Knight JC, 2000, IEEE PHOTONIC TECH L, V12, P807, DOI 10.1109/68.853507; Knight JC, 1998, SCIENCE, V282, P1476, DOI 10.1126/science.282.5393.1476; MITSCHKE FM, 1986, OPT LETT, V11, P659, DOI 10.1364/OL.11.000659; MOLLENAUER LF, 1980, PHYS REV LETT, V45, P1095, DOI 10.1103/PhysRevLett.45.1095; Nibbering ETJ, 1997, J OPT SOC AM B, V14, P650, DOI 10.1364/JOSAB.14.000650; Ouzounov D, 2002, OPT COMMUN, V205, P227, DOI 10.1016/S0030-4018(02)01359-7; Ouzounov D, 2001, OPT COMMUN, V192, P219, DOI 10.1016/S0030-4018(01)01185-3; Ouzounov DG, 2002, OPT LETT, V27, P1513, DOI 10.1364/OL.27.001513; Price JHV, 2002, J OPT SOC AM B, V19, P1286, DOI 10.1364/JOSAB.19.001286; Ranka JK, 2000, OPT LETT, V25, P796, DOI 10.1364/OL.25.000796; Ranka JK, 2000, OPT LETT, V25, P25, DOI 10.1364/OL.25.000025; RANKA JK, 1997, OPT LETT, V22, P1934; Smith CM, 2003, NATURE, V424, P657, DOI 10.1038/nature01849; VENKATARAMAN N, 2002, EUR C OPT COMM; Wadsworth WJ, 2000, ELECTRON LETT, V36, P53, DOI 10.1049/el:20000134; Washburn BR, 2001, ELECTRON LETT, V37, P1510, DOI 10.1049/el:20011047	26	416	440	1	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1702	1704		10.1126/science.1088387	http://dx.doi.org/10.1126/science.1088387			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500976				2022-12-28	WOS:000185387700038
J	Kearns, GL; Abdel-Rahman, SM; Alander, SW; Blowey, DL; Leeder, JS; Kauffman, RE				Kearns, GL; Abdel-Rahman, SM; Alander, SW; Blowey, DL; Leeder, JS; Kauffman, RE			Developmental pharmacology - Drug disposition, action, and therapy in infants and children	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BLOOD-FLOW-VELOCITY; HUMAN LIVER; METABOLIZING-ENZYMES; CIRCULATORY ADAPTATION; NEWBORN-INFANTS; GESTATIONAL-AGE; RENAL-FUNCTION; PHARMACOKINETICS; PRETERM; ONTOGENY		Childrens Mercy Hosp & Clin, Dept Pediat, Div Pediat Pharmacol & Med Toxicol, Kansas City, MO 64108 USA; Childrens Mercy Hosp & Clin, Div Emergency Med, Kansas City, MO 64108 USA; Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA; Univ Missouri, Dept Pharmacol, Kansas City, MO 64110 USA; Univ Missouri, Dept Pharm Practice, Kansas City, MO 64110 USA; Childrens Mercy Hosp & Clin, Div Nephrol, Kansas City, MO 64108 USA	Children's Mercy Hospital; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; Children's Mercy Hospital	Kearns, GL (corresponding author), Childrens Mercy Hosp & Clin, Dept Pediat, Div Pediat Pharmacol & Med Toxicol, 2401 Gillham Rd, Kansas City, MO 64108 USA.	gkearns@cmh.edu	Leeder, James Steven/ABD-5438-2021	Leeder, James Steven/0000-0001-6688-0504	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD044239, U01HD031313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058883] Funding Source: NIH RePORTER; NICHD NIH HHS [U01 HD044239-01, 5 U01 HD31313-10] Funding Source: Medline; NIEHS NIH HHS [R01 ES10855-04] Funding Source: Medline; NIGMS NIH HHS [R01 GM58883-04] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUNOD M, 1969, AM J DIG DIS, V14, P400, DOI 10.1007/BF02239360; Alcorn J, 2002, CLIN PHARMACOKINET, V41, P1077, DOI 10.2165/00003088-200241130-00005; AMATO M, 1992, AM J PERINAT, V9, P431, DOI 10.1055/s-2007-999282; ARANDA JV, 1979, ARCH DIS CHILD, V54, P946, DOI 10.1136/adc.54.12.946; ARANT BS, 1978, J PEDIATR-US, V92, P705, DOI 10.1016/S0022-3476(78)80133-4; Bajpai M, 1996, DRUG METAB DISPOS, V24, P1401; Barrett DA, 1996, BRIT J CLIN PHARMACO, V41, P531, DOI 10.1046/j.1365-2125.1996.03539.x; BERSETH CL, 1989, J PEDIATR-US, V115, P646, DOI 10.1016/S0022-3476(89)80302-6; Blanco JG, 2000, DRUG METAB DISPOS, V28, P379; BOURGEOIS BFD, 1983, NEUROLOGY, V33, P173, DOI 10.1212/WNL.33.2.173; BRION LP, 1991, PEDIATR NEPHROL, V5, P675, DOI 10.1007/BF00857868; CARRY MR, 1986, MUSCLE NERVE, V9, P445, DOI 10.1002/mus.880090510; Chen H, 2000, DRUG METAB DISPOS, V28, P1051; CHIBA K, 1980, J PEDIATR-US, V96, P479; Coulthard KP, 1998, J PAEDIATR CHILD H, V34, P425, DOI 10.1046/j.1440-1754.1998.00267.x; de Wildt SN, 2003, CLIN DRUG INVEST, V23, P27, DOI 10.2165/00044011-200323010-00004; de Wildt SN, 1999, CLIN PHARMACOKINET, V37, P485, DOI 10.2165/00003088-199937060-00004; DILORENZO C, 1995, J PEDIATR-US, V127, P593, DOI 10.1016/S0022-3476(95)70120-6; EHRNEBO M, 1971, EUR J CLIN PHARMACOL, V3, P189, DOI 10.1007/BF00565004; Engel G, 1996, CLIN PHARMACOL THER, V59, P613, DOI 10.1016/S0009-9236(96)90001-6; Fluhr JW, 2000, PEDIATR DERMATOL, V17, P436, DOI 10.1046/j.1525-1470.2000.01815.x; FREDHOLM BB, 1975, PEDIATR RES, V9, P26, DOI 10.1203/00006450-197509010-00005; FRIISHANSEN B, 1983, ACTA PAEDIATR SCAND, P7; Gibbs JP, 1999, DRUG METAB DISPOS, V27, P1466; GRAND RJ, 1976, GASTROENTEROLOGY, V70, P790; GREENBLATT DJ, 1976, NEW ENGL J MED, V295, P542; GUPTA M, 1978, PEDIATRICS, V62, P26; Hall Stephen D., 1999, Drug Metabolism and Disposition, V27, P161; Halpern S, 1988, AM PEDIAT SOCIAL DYN, P52; HEIMANN G, 1980, EUR J CLIN PHARMACOL, V18, P43, DOI 10.1007/BF00561477; Hines RN, 2002, J PHARMACOL EXP THER, V300, P355, DOI 10.1124/jpet.300.2.355; HUANG NN, 1953, J PEDIATR-US, V42, P657, DOI 10.1016/S0022-3476(53)80422-1; ITTMANN PI, 1992, DIGEST DIS SCI, V37, P14, DOI 10.1007/BF01308336; Jadcherla SR, 2002, J PEDIATR GASTR NUTR, V34, P16, DOI 10.1097/00005176-200201000-00005; James LP, 2000, J CLIN PHARMACOL, V40, P1298; James LP, 1998, J CLIN PHARMACOL, V38, P1089; KAFETZIS DA, 1979, ACTA PAEDIATR SCAND, V68, P419, DOI 10.1111/j.1651-2227.1979.tb05030.x; Kauffman R E, 2000, Paediatr Drugs, V2, P411, DOI 10.2165/00128072-200002060-00001; Kearns GL, 2000, J ALLERGY CLIN IMMUN, V106, pS128; KERR BM, 1994, BIOCHEM PHARMACOL, V47, P1969, DOI 10.1016/0006-2952(94)90071-X; Kinirons MT, 1999, CLIN PHARMACOL THER, V66, P224, DOI 10.1016/S0009-9236(99)70029-9; KITADA M, 1987, J BIOL CHEM, V262, P13534; KRAUS DM, 1993, CLIN PHARMACOL THER, V54, P351, DOI 10.1038/clpt.1993.160; Lacroix D, 1997, EUR J BIOCHEM, V247, P625, DOI 10.1111/j.1432-1033.1997.00625.x; LAMBERT GH, 1986, DEV PHARMACOL THERAP, V9, P375, DOI 10.1159/000457262; Leeder J. S., 2002, Pharmacogenomics Journal, V2, P141, DOI 10.1038/sj.tpj.6500104; Leeder JS, 2001, CURR THER RES CLIN E, V62, P900, DOI 10.1016/S0011-393X(01)80094-1; Lin JH, 2003, CLIN PHARMACOKINET, V42, P59, DOI 10.2165/00003088-200342010-00003; LINDAY L, 1987, PEDIATRICS, V79, P544; LOUGHNAN PM, 1977, ARCH DIS CHILD, V52, P302, DOI 10.1136/adc.52.4.302; Marshall J, 2000, J CLIN PHARMACOL, V40, P578; Marshall JD, 1999, CLIN PHARMACOL THER, V66, P66, DOI 10.1016/S0009-9236(99)70055-X; Martinussen M, 1996, PEDIATR RES, V39, P275, DOI 10.1203/00006450-199602000-00015; MARTINUSSEN M, 1994, PEDIATR RES, V36, P334, DOI 10.1203/00006450-199409000-00011; McCarver DG, 2002, J PHARMACOL EXP THER, V300, P361, DOI 10.1124/jpet.300.2.361; MILAVETZ G, 1986, J PEDIATR-US, V109, P351, DOI 10.1016/S0022-3476(86)80403-6; MILLER RP, 1976, CLIN PHARMACOL THER, V19, P284; MORSELLI PL, 1977, DRUG DISPOSITION DEV, P311; MURRY DJ, 1995, DRUG METAB DISPOS, V23, P1110; OKAH FA, 1995, PEDIATRICS, V96, P688; PAINTER MJ, 1981, NEUROLOGY, V31, P1107, DOI 10.1212/WNL.31.9.1107; POLEY JR, 1964, J LAB CLIN MED, V63, P838; Pui CH, 2001, LANCET ONCOL, V2, P597, DOI 10.1016/S1470-2045(01)00516-2; PYNNONEN S, 1977, EUR J CLIN PHARMACOL, V11, P129, DOI 10.1007/BF00562904; RITSCHEL WA, 1999, HDB BASIC PHARMACOKI, P318; RITSCHEL WA, 1980, HDB BASIC PHARMACOKI, P296; RIVA R, 1985, CLIN PHARMACOKINET, V10, P524, DOI 10.2165/00003088-198510060-00005; Robillard JE, 1999, PEDIAT NEPHROLOGY, P21; RODBRO PAUL, 1967, SCAND J GASTROENTEROL, V2, P209; RUTTER N, 1987, CLIN PERINATOL, V14, P911, DOI 10.1016/S0095-5108(18)30740-1; SCHILLERSCOTLAND CF, 1994, TOXICOL LETT, V72, P137, DOI 10.1016/0378-4274(94)90020-5; Scott CS, 1999, J PEDIATR-US, V135, P423, DOI 10.1016/S0022-3476(99)70163-0; Sharer JE, 1996, DRUG METAB DISPOS, V24, P487; SHENG KT, 1964, ANTIMICROBIAL AGENTS, P200; SIBER GR, 1975, J INFECT DIS, V132, P637, DOI 10.1093/infdis/132.6.637; Silver L, 2001, VOICES, V27, P37; Sonnier M, 1998, EUR J BIOCHEM, V251, P893, DOI 10.1046/j.1432-1327.1998.2510893.x; Stahl G, 1999, HUNG J IND CHEM, V27, P9; Steinbrook R, 2002, NEW ENGL J MED, V347, P1462, DOI 10.1056/NEJMhpr021646; Stratchunsky L S, 1991, Eur J Drug Metab Pharmacokinet, VSpec No 3, P321; SUCHY FJ, 1981, GASTROENTEROLOGY, V80, P1037; SZEFLER SJ, 1980, J PEDIATR-US, V97, P312, DOI 10.1016/S0022-3476(80)80506-3; Takahashi H, 2000, CLIN PHARMACOL THER, V68, P541, DOI 10.1067/mcp.2000.110977; Taketomo CH, 2000, PEDIAT DOSAGE HDB; Thorsson L, 2001, BRIT J CLIN PHARMACO, V52, P529, DOI 10.1046/j.0306-5251.2001.01493.x; TRELUYER JM, 1991, EUR J BIOCHEM, V202, P583, DOI 10.1111/j.1432-1033.1991.tb16411.x; Treluyer JM, 1997, PHARMACOGENETICS, V7, P441, DOI 10.1097/00008571-199712000-00002; Tsai C, 2000, PEDIATR RES, V47, p436A; van Lingen RA, 1999, ARCH DIS CHILD-FETAL, V80, pF59, DOI 10.1136/fn.80.1.F59; vandenAnker JN, 1995, CLIN PHARMACOL THER, V58, P650, DOI 10.1016/0009-9236(95)90021-7; VANDENANKER JN, 1994, PEDIATR RES, V36, P578, DOI 10.1203/00006450-199411000-00006; Vieira I, 1996, EUR J BIOCHEM, V238, P476, DOI 10.1111/j.1432-1033.1996.0476z.x; WEAVER LT, 1991, GUT, V32, P1321, DOI 10.1136/gut.32.11.1321; WEISS CF, 1960, NEW ENGL J MED, V262, P787, DOI 10.1056/NEJM196004212621601; WEST DP, 1981, J INVEST DERMATOL, V76, P147, DOI 10.1111/1523-1747.ep12525553; WINDORFE.A, 1974, EUR J CLIN PHARMACOL, V7, P227, DOI 10.1007/BF00560385; Yanowitz TD, 1999, J APPL PHYSIOL, V87, P370, DOI 10.1152/jappl.1999.87.1.370; YOUNG WS, 1978, J PHARMACOL EXP THER, V204, P203	98	1455	1511	3	88	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1157	1167		10.1056/NEJMra035092	http://dx.doi.org/10.1056/NEJMra035092			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679531				2022-12-28	WOS:000185369700011
J	Thompson, JW; Ryan, KW; Pinidiya, SD; Bost, JE				Thompson, JW; Ryan, KW; Pinidiya, SD; Bost, JE			Quality of care for children in commercial and Medicaid managed care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-INSURANCE-PROGRAM; FOR-PROFIT; PLAN QUALITY; STATE; ENROLLMENT; HMOS	Context Many states have turned to commercial health plans to serve Medic. aid beneficiaries and to achieve cost-containment goals. Assumptions that the quality of care provided to Medicaid beneficiaries through these programs is acceptable have not been tested. Objective To compare the quality of care provided to children and adolescents in commercial and Medicaid managed care in the United States. Design, Setting, and Population Using 1999 data collected through the Health Plan Employer Data and Information Set, we examined reported quality-of-care indicators for children and adolescents. Results from 423 commercial and 169 Medicaid plans were compared. Matched pairs analyses were performed using data from each of the 81 companies serving both populations to control for corporate differences. Correlation coefficients and regression procedures were used to examine observed variations in health plan performance. Main Outcome Measures Quality indicators including prenatal care, childhood immunizations, well-child visits, adolescent immunizations, and myringotomy and tonsillectomy rates. Results Using standard indicators of clinical performance, children and adolescents enrolled in Medicaid received worse care compared with their commercial counterparts. For most of the 81 health plans serving both populations, Medicaid enrollees had statistically significantly (P<.001) lower rates than commercial plans for clinical quality indicators (eg, childhood immunization rates of 69% vs 54%); for clinical access indicators (eg, well-child visits in the first 15 months of life, 53% vs 31 %); and for common procedures (eg, myringotomies for children aged 0-4 years, 35 vs 2 per 1000 members). Conversely, some plans demonstrated equal and high-quality care for both populations. Regression models failed to identify consistent plan characteristics that explained the observed differences in quality of care. Conclusions Most commercial health plans do not deliver high-quality care on a number of performance indicators for children enrolled in Medicaid. Policy makers and the public need plan-specific quality information to inform purchasing decisions.	Univ Arkansas Med Sci, Arkansas Ctr Hlth Improvement, Dept Pediat, Coll Med, Little Rock, AR 72204 USA; Univ Arkansas Med Sci, Coll Publ Hlth, Dept Biostat, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Thompson, JW (corresponding author), Univ Arkansas Med Sci, Arkansas Ctr Hlth Improvement, Dept Pediat, Coll Med, 5800 W 10th St,Suite 410, Little Rock, AR 72204 USA.							*AG HEALTHC RES QU, AHRQ LEAD EFF DEV NA; Angell M, 1996, NEW ENGL J MED, V335, P883, DOI 10.1056/NEJM199609193351209; [Anonymous], 1999, SAS SOFTW COMP PROGR; Bost J E, 2001, Manag Care Interface, V14, P50; Coughlin TA, 1999, HEALTH SERV RES, V34, P281; *CTR MED MED, 2003, HOSP QUAL INF IN; *CTR MED MED SERV, 2002, 2002 CMS STAT; Epstein AM, 1997, JAMA-J AM MED ASSOC, V278, P1617, DOI 10.1001/jama.278.19.1617; Epstein AM, 2000, JAMA-J AM MED ASSOC, V283, P1884, DOI 10.1001/jama.283.14.1884; Epstein AM, 1998, JAMA-J AM MED ASSOC, V279, P1691, DOI 10.1001/jama.279.21.1691; Gabel J, 1997, HEALTH AFFAIR, V16, P134, DOI 10.1377/hlthaff.16.3.134; Halfon N, 1998, HEALTH SERV RES, V33, P955; Himmelstein DU, 1999, JAMA-J AM MED ASSOC, V282, P159, DOI 10.1001/jama.282.2.159; Holahan J, 1998, HEALTH AFFAIR, V17, P43, DOI 10.1377/hlthaff.17.3.43; Homer CJ, 1998, HEALTH SERV RES, V33, P1091; Iglehart JK, 1996, NEW ENGL J MED, V335, P995, DOI 10.1056/NEJM199609263351322; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Kuhlthau K, 1998, HEALTH AFFAIR, V17, P42, DOI 10.1377/hlthaff.17.4.42; Landon BE, 1998, JAMA-J AM MED ASSOC, V279, P211, DOI 10.1001/jama.279.3.211; Landon BE, 1999, JAMA-J AM MED ASSOC, V282, P1769, DOI 10.1001/jama.282.18.1769; Landon BE, 2001, HEALTH AFFAIR, V20, P162, DOI 10.1377/hlthaff.20.3.162; Mangione-Smith R, 1998, HEALTH SERV RES, V33, P1059; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; *NAT COMM QUAL ASS, 1998, HEDIS 3 0 TECHN SPEC, V2; *NAT COMM QUAL ASS, 2002, HEDIS SPEC SURV MEAS, V3; *NAT COMM QUAL ASS, 2000, HEDIS 3 0 TECHN SPEC, V2; *NAT CTR HLTH STAT, 2001, HLTH PEOP 2000; Nudelman PM, 1996, NEW ENGL J MED, V334, P1057, DOI 10.1056/NEJM199604183341611; Oleske DM, 1998, HEALTH SERV RES, V33, P55; Rosenbaum S, 1998, HEALTH AFFAIR, V17, P75, DOI 10.1377/hlthaff.17.1.75; Selden TM, 1999, HEALTH AFFAIR, V18, P126, DOI 10.1377/hlthaff.18.2.126; Silberman P, 2002, HEALTH AFFAIR, V21, P255, DOI 10.1377/hlthaff.21.4.255; Sisk JE, 1998, MILBANK Q, V76, P687, DOI 10.1111/1468-0009.00110; STOOL SE, 1994, PEDIATRICS, V94, P766; Thompson JW, 2003, AM J PREV MED, V24, P62, DOI 10.1016/S0749-3797(02)00569-X; Voelker R, 1997, JAMA-J AM MED ASSOC, V278, P1559, DOI 10.1001/jama.278.19.1559; Weinick RM, 2000, HEALTH AFFAIR, V19, P178, DOI 10.1377/hlthaff.19.3.178; Zaslavsky AM, 2000, MED CARE, V38, P981, DOI 10.1097/00005650-200010000-00002; 2002, LEADERSHIP EXAMPLE C	40	55	55	0	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1486	1493		10.1001/jama.290.11.1486	http://dx.doi.org/10.1001/jama.290.11.1486			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	721RE	13129989	Bronze			2022-12-28	WOS:000185329000031
J	Lederle, FA				Lederle, FA			Ultrasonographic screening for abdominal aortic aneurysms	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; COST-EFFECTIVENESS; UNITED-STATES; PSYCHOLOGICAL MORBIDITY; PHYSICAL-EXAMINATION; DOUBLE-BLIND; GROWTH-RATE; AGE 65; MORTALITY; MEN	Abdominal aortic aneurysms (AAAs) occur in 1 of 20 older men, remain asymptomatic for many years, and, if left untreated, cause death from rupture in about one third of patients. Ultrasonography is a suitable screening test for AAA, and elective repair can prevent rupture. Although these features suggest a promising target for a screening program, evidence of benefit from AAA screening has only recently become available. Four randomized trials of ultrasonographic screening involving more than 125 000 men have been reported, and each trial observed a reduction in AAA-related mortality (which was statistically significant in 2 trials), ranging from 21% to 68%. One trial in women found no benefit. Other studies indicate that screening can begin in men older than 65 years of age and does not need to be repeated if results are negative. An AAA larger than 5.5 cm in diameter should be considered for elective open or endovascular repair. Most aneurysms detected at screening are smaller and should be kept under surveillance with periodic imaging measurement. Widespread elective repair of small AAAs could reduce the benefits and increase the costs of screening. No medical treatments have been proven to reduce the enlargement rate. If elective repair is reserved for larger AAAs, one-time ultrasonographic screening for AAA can be recommended for men 65 to 79 years of age who have never smoked.	Vet Affairs Med Ctr, Minneapolis, MN 55417 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Lederle, FA (corresponding author), Vet Affairs Med Ctr, Minneapolis, MN 55417 USA.	frank.lederle@med.va.gov						Adam DJ, 1999, J VASC SURG, V30, P922, DOI 10.1016/S0741-5214(99)70018-2; Ashton HA, 2002, LANCET, V360, P1531, DOI 10.1016/S0140-6736(02)11522-4; Ashton HA, 2002, BMJ-BRIT MED J, V325, P1135; Barnett SB, 2000, ULTRASOUND MED BIOL, V26, P355, DOI 10.1016/S0301-5629(00)00204-0; Bayly PJM, 2001, BRIT J SURG, V88, P687, DOI 10.1046/j.0007-1323.2001.01778.x; Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167; Black WC, 2002, J NATL CANCER I, V94, P865, DOI 10.1093/jnci/94.11.865; Boll APM, 1998, BRIT J SURG, V85, P1090, DOI 10.1046/j.1365-2168.1998.00814.x; Bosch JL, 2002, RADIOLOGY, V225, P337, DOI 10.1148/radiol.2252011687; Brady AR, 2003, BRIT J SURG, V90, P492; Bruce CJ, 2000, J AM SOC ECHOCARDIOG, V13, P674, DOI 10.1067/mje.2000.107797; BURTON TM, 2003, WALL STREET J   0113, pA1; CABELLON S, 1983, AM J SURG, V146, P575, DOI 10.1016/0002-9610(83)90290-8; CHESLER E, 1999, CLIN CARDIOLOGY ELDE; COCHRANE AL, 1971, BRIT MED BULL, V27, P3, DOI 10.1093/oxfordjournals.bmb.a070810; Crow P, 2001, BRIT J SURG, V88, P941, DOI 10.1046/j.0007-1323.2001.01822.x; Darling RC, 1977, CIRCULATION S, V56, pII161; Fink HA, 2000, ARCH INTERN MED, V160, P833, DOI 10.1001/archinte.160.6.833; Fisher D, 2003, J FAM PRACTICE, V52, P272; Forbes JF, 1998, LANCET, V352, P1656; Frame P S, 1975, J Fam Pract, V2, P29; GILLUM RF, 1995, J CLIN EPIDEMIOL, V48, P1289, DOI 10.1016/0895-4356(95)00045-3; GRIMSHAW GM, 1994, EUR J VASCULAR SURG, V8, P741, DOI 10.1016/S0950-821X(05)80656-5; Gueyffier F, 1997, ANN INTERN MED, V126, P761, DOI 10.7326/0003-4819-126-10-199705150-00002; HARRIS PL, 1991, CMAJ, V145, P783; Heather BP, 2000, BRIT J SURG, V87, P750, DOI 10.1046/j.1365-2168.2000.01476.x; Heather BP, 2002, BRIT J SURG, V89, P518; Hoyert D L, 2001, Natl Vital Stat Rep, V49, P1; Huber TS, 2001, J VASC SURG, V33, P304, DOI 10.1067/mva.2001.112703; Khaira HS, 1998, ANN ROY COLL SURG, V80, P341; Laupacis A, 2002, J VASC SURG, V35, P72, DOI 10.1067/mva.2002.121308; Lawrence PF, 1999, J VASC SURG, V30, P632, DOI 10.1016/S0741-5214(99)70102-3; LEDERLE FA, 1995, J VASC SURG, V21, P945, DOI 10.1016/S0741-5214(95)70222-9; Lederle FA, 1999, JAMA-J AM MED ASSOC, V281, P77, DOI 10.1001/jama.281.1.77; Lederle FA, 2000, ARCH INTERN MED, V160, P1117, DOI 10.1001/archinte.160.8.1117; Lederle FA, 2000, ARCH INTERN MED, V160, P1425, DOI 10.1001/archinte.160.10.1425; Lederle FA, 2002, JAMA-J AM MED ASSOC, V287, P2968, DOI 10.1001/jama.287.22.2968; Lederle FA, 2001, J VASC SURG, V34, P122, DOI 10.1067/mva.2001.115275; LEDERLE FA, 1988, ARCH INTERN MED, V148, P1753, DOI 10.1001/archinte.148.8.1753; Lederle FA, 2002, NEW ENGL J MED, V346, P1437, DOI 10.1056/NEJMoa012573; Lederle FA, 1997, ANN INTERN MED, V126, P441, DOI 10.7326/0003-4819-126-6-199703150-00004; Lederle FA, 1996, J GEN INTERN MED, V11, P774, DOI 10.1007/BF02599000; LEDERLE FA, 1990, J CLIN EPIDEMIOL, V43, P101, DOI 10.1016/0895-4356(90)90062-T; Lee TY, 2002, SURGERY, V132, P399, DOI 10.1067/msy.2002.126510; Lindholt JS, 1998, J PUBLIC HEALTH MED, V20, P211, DOI 10.1093/oxfordjournals.pubmed.a024745; Lindholt JS, 1997, BRIT J SURG, V84, P40; Lindholt JS, 2002, EUR J VASC ENDOVASC, V23, P55, DOI 10.1053/ejvs.2001.1534; Lucarotti ME, 1997, EUR J VASC ENDOVASC, V14, P499, DOI 10.1016/S1078-5884(97)80131-1; MACSWEENEY STR, 1994, LANCET, V344, P651, DOI 10.1016/S0140-6736(94)92087-7; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; Merenstein D, 1999, ARCH FAM MED, V8, P354, DOI 10.1001/archfami.8.4.354; Mosorin M, 2001, J VASC SURG, V34, P606, DOI 10.1067/mva.2001.117891; Nagashima H, 2002, J VASC SURG, V36, P158, DOI 10.1067/mva.2002.123680; Nakahashi TK, 2002, ARTERIOSCL THROM VAS, V22, P2017, DOI 10.1161/01.ATV.0000042082.38014.EA; Norman PE, 2003, BRIT J SURG, V90, P492; NUSBAUM JW, 1971, ARCH SURG-CHICAGO, V102, P385; Owens DK, 1998, J GEN INTERN MED, V13, P716, DOI 10.1046/j.1525-1497.1998.00211.x; Powell JT, 1998, LANCET, V352, P1649; SANTIAGO F, 1987, JAMA-J AM MED ASSOC, V258, P1732, DOI 10.1001/jama.1987.03400130046020; Santilli SM, 2002, J VASC SURG, V35, P666, DOI 10.1067/mva.2002.121572; SCHILLING FJ, 1974, J CHRON DIS, V27, P37, DOI 10.1016/0021-9681(74)90006-X; SCOTT RAP, 1995, BRIT J SURG, V82, P1066, DOI 10.1002/bjs.1800820821; Scott RAP, 2001, EUR J VASC ENDOVASC, V21, P535, DOI 10.1053/ejvs.2001.1368; Scott RAP, 2002, BRIT J SURG, V89, P283, DOI 10.1046/j.0007-1323.2001.02014.x; Spencer CA, 2000, J MED SCREEN, V7, P209, DOI 10.1136/jms.7.4.209; StewartBrown S, 1997, BRIT MED J, V314, P533, DOI 10.1136/bmj.314.7080.533; Vammen S, 2001, BRIT J SURG, V88, P1066, DOI 10.1046/j.0007-1323.2001.01845.x; Vardulaki KA, 2002, BRIT J SURG, V89, P861, DOI 10.1046/j.1365-2168.2002.02133.x; Wilmink A.B.M., 2002, BRIT J SURG, V87, P499, DOI [10.1046/j.1365-2168.2000.01420-23.x, DOI 10.1046/J.1365-2168.2000.01420-23.X]; Wilmink TBM, 1999, J VASC SURG, V30, P203, DOI 10.1016/S0741-5214(99)70129-1; 1996, US PREVENTIVE SERVIC, P67	71	39	43	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					516	522		10.7326/0003-4819-139-6-200309160-00016	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00016			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679330				2022-12-28	WOS:000185324100009
J	Alsdorf, DE; Lettenmaier, DP				Alsdorf, DE; Lettenmaier, DP			Tracking fresh water from space	SCIENCE			English	Editorial Material							GRAVITY-FIELD		Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA; Univ Washington, Dept Civil & Environm Engn, Seattle, WA 98195 USA	University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle	Alsdorf, DE (corresponding author), Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA.		lettenmaier, dennis p/F-8780-2011	lettenmaier, dennis p/0000-0003-3317-1327				Alsdorf D., 2003, EOS T AM GEOPHYS UN, V84, P269; Alsdorf DE, 2000, NATURE, V404, P174, DOI 10.1038/35004560; BIRKETT CM, 2002, J GEOPHYS RES, V107; Lammers R., 2002, EOS T AM GEOPHYS UNI, V83, P13, DOI [10.1029/2002EO000007, DOI 10.1029/2002EO000007]; Ohmura A, 2002, SCIENCE, V298, P1345, DOI 10.1126/science.1078972; Prigent C, 2001, GEOPHYS RES LETT, V28, P4631, DOI 10.1029/2001GL013263; Roads J, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002583; Rodell M, 1999, WATER RESOUR RES, V35, P2705, DOI 10.1029/1999WR900141; Rosenqvist A, 2002, INT J REMOTE SENS, V23, P1215, DOI 10.1080/014311602753569773; Smith LC, 1997, HYDROL PROCESS, V11, P1427, DOI 10.1002/(SICI)1099-1085(199708)11:10&lt;1427::AID-HYP473&gt;3.0.CO;2-S; TAPLEY BD, COMMUNICATION; Vorosmarty CJ, 2000, SCIENCE, V289, P284, DOI 10.1126/science.289.5477.284; Wahr J, 1998, J GEOPHYS RES-SOL EA, V103, P30205, DOI 10.1029/98JB02844	13	197	210	8	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1491	+		10.1126/science.1089802	http://dx.doi.org/10.1126/science.1089802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970554				2022-12-28	WOS:000185255300036
J	Waters, AP				Waters, AP			Guilty until proven otherwise	SCIENCE			English	Editorial Material							PLASMODIUM-FALCIPARUM; GENOME SEQUENCE; LIFE-CYCLE; VAR GENES; MALARIA; EXPRESSION		Leiden Univ, Med Ctr, Dept Parasitol, Malaria Grp, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Waters, AP (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, Malaria Grp, NL-2300 RA Leiden, Netherlands.	Waters@lumc.nl	Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982				Al-Olayan EM, 2002, SCIENCE, V295, P677, DOI 10.1126/science.1067159; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Clare Amanda, 2002, In Silico Biology, V2, P511; Fischer K, 1997, MOL CELL BIOL, V17, P3679, DOI 10.1128/MCB.17.7.3679; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Hayward RE, 2000, MOL MICROBIOL, V35, P6, DOI 10.1046/j.1365-2958.2000.01730.x; HernandezRivas R, 1997, MOL CELL BIOL, V17, P604, DOI 10.1128/MCB.17.2.604; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Mamoun CB, 2001, MOL MICROBIOL, V39, P26, DOI 10.1046/j.1365-2958.2001.02222.x; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418	13	4	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1487	1488		10.1126/science.1089799	http://dx.doi.org/10.1126/science.1089799			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970551				2022-12-28	WOS:000185255300033
J	Fan, MJ; Ryan, PD; Shannon, KM; Haber, DA; Smith, BL; Harris, NL				Fan, MJ; Ryan, PD; Shannon, KM; Haber, DA; Smith, BL; Harris, NL			Case 28-2003: A 51-year-old premenopausal woman with newly diagnosed breast cancer and a strong family history of breast cancer - Infiltrating lobular carcinoma of the right breast, two separate foci. Ductal carcinoma in situ of the right breast. Lobular carcinoma in situ and atypical ductal hyperplasia in both breasts. Mutation (6174delT) in the BRCA2 gene.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BILATERAL PROPHYLACTIC MASTECTOMY; WOMEN; OOPHORECTOMY; PATHOLOGY; CARRIERS; RISK		Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc Risk Anal, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Fan, MJ (corresponding author), Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02114 USA.							Agoff SN, 2002, AM J SURG PATHOL, V26, P171, DOI 10.1097/00000478-200202000-00003; Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.3.CO;2-E; Armes JE, 2002, PATHOLOGY, V34, P309, DOI 10.1080/00313020220147113; Blackwood MA, 1998, J CLIN ONCOL, V16, P1969, DOI 10.1200/JCO.1998.16.5.1969; Colgan TJ, 2001, AM J SURG PATHOL, V25, P1283, DOI 10.1097/00000478-200110000-00009; Frost MH, 2000, JAMA-J AM MED ASSOC, V284, P319, DOI 10.1001/jama.284.3.319; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1997, LANCET, V349, P1505; Marcus JN, 1997, BREAST CANCER RES TR, V44, P275, DOI 10.1023/A:1005830230664; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Thompson D, 2001, AM J HUM GENET, V68, P410, DOI 10.1086/318181; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3	16	1	1	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					1076	1082		10.1056/NEJMcpc030018	http://dx.doi.org/10.1056/NEJMcpc030018			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719UH	12968092				2022-12-28	WOS:000185223100011
J	Vinnikov, KY; Grody, NC				Vinnikov, KY; Grody, NC			Global warming trend of mean tropospheric temperature observed by satellites	SCIENCE			English	Article							MICROWAVE SOUNDING UNIT; SURFACE AIR-TEMPERATURE; TEMPORAL HOMOGENIZATION; MSU	We have analyzed the global tropospheric temperature for 1978 to 2002 with the use of passive microwave sounding data from the NOAA series of polar orbiters and the Earth Observing System Aqua satellite. To accurately retrieve the climatic trend, we combined the satellite data with an analytic model of temperature that contains three different time scales: a linear trend and functions that de. ne the seasonal and diurnal cycles. Our analysis shows a trend of +0.22degrees to 0.26degreesC per 10 years, consistent with the global warming trend derived from surface meteorological stations.	Univ Maryland, Dept Meteorol, College Pk, MD 20742 USA; NOAA, Natl Environm Satellite Data & Informat Serv, Camp Springs, MD 20746 USA	University System of Maryland; University of Maryland College Park; National Oceanic Atmospheric Admin (NOAA) - USA	Vinnikov, KY (corresponding author), Univ Maryland, Dept Meteorol, College Pk, MD 20742 USA.	kostya@atmos.umd.edu	Vinnikov, Konstantin/F-9348-2010					Balling RC, 1996, J GEOPHYS RES-ATMOS, V101, P12827, DOI 10.1029/96JD00446; Christy JR, 2000, J ATMOS OCEAN TECH, V17, P1153, DOI 10.1175/1520-0426(2000)017<1153:MTTDCA>2.0.CO;2; Christy JR, 2003, J ATMOS OCEAN TECH, V20, P613, DOI 10.1175/1520-0426(2003)20<613:EEOVOM>2.0.CO;2; Christy JR, 1998, J CLIMATE, V11, P2016, DOI 10.1175/1520-0442-11.8.2016; Grody N, 2001, J GEOPHYS RES-ATMOS, V106, P2943, DOI 10.1029/2000JD900616; GRODY NC, 1983, J CLIM APPL METEOROL, V22, P609, DOI 10.1175/1520-0450(1983)022<0609:SSOUTM>2.0.CO;2; Hansen J, 1999, J GEOPHYS RES-ATMOS, V104, P30997, DOI 10.1029/1999JD900835; Hansen J, 2002, SCIENCE, V295, P275; HOUGHTON JT, 2001, CLIMATE CHANGE 2001; IGNATOV AA, UNPUB; Jones PD, 2003, J CLIMATE, V16, P206, DOI 10.1175/1520-0442(2003)016<0206:HALSSA>2.0.CO;2; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; KARL TR, 1993, B AM METEOROL SOC, V74, P1007, DOI 10.1175/1520-0477(1993)074<1007:ANPORG>2.0.CO;2; Lanzante JR, 2003, J CLIMATE, V16, P224, DOI 10.1175/1520-0442(2003)016<0224:THOMRT>2.0.CO;2; Lanzante JR, 2003, J CLIMATE, V16, P241, DOI 10.1175/1520-0442(2003)016<0241:THOMRT>2.0.CO;2; MANABE S, 1991, J CLIMATE, V4, P785, DOI 10.1175/1520-0442(1991)004<0785:TROACO>2.0.CO;2; MEARS CA, 2003, GEOPHYS RES ABSTR, V5, P7241; Mo T, 2001, J GEOPHYS RES-ATMOS, V106, P10145, DOI 10.1029/2001JD900027; National Research Council, 2000, REC OBS GLOB TEMP CH; OORT AH, 1993, J CLIMATE, V6, P292, DOI 10.1175/1520-0442(1993)006<0292:UATTOT>2.0.CO;2; Prabhakara C, 1998, GEOPHYS RES LETT, V25, P1927, DOI 10.1029/98GL01300; Santer BD, 2003, SCIENCE, V300, P1280, DOI 10.1126/science.1082393; SPENCER RW, 1990, SCIENCE, V247, P1558, DOI 10.1126/science.247.4950.1558; SPENCER RW, 1990, J CLIMATE, V3, P1111, DOI 10.1175/1520-0442(1990)003<1111:GATMWS>2.0.CO;2; Vinnikov KY, 1996, GEOPHYS RES LETT, V23, P1801, DOI 10.1029/96GL01736; VINNIKOV KY, 2002, J GEOPHYS RES, V107; VINNIKOV KY, 2002, GEOPHYS RES LETT, V29; Wentz FJ, 1998, NATURE, V394, P661, DOI 10.1038/29267	28	118	129	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					269	272		10.1126/science.1087910	http://dx.doi.org/10.1126/science.1087910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	12970572				2022-12-28	WOS:000185825900037
J	Bellaby, P				Bellaby, P			Communication and miscommunication of risk: understanding UK parents' attitudes to combined MMR vaccination	BRITISH MEDICAL JOURNAL			English	Article							CREUTZFELDT-JAKOB-DISEASE; RUBELLA VACCINE; TREND ANALYSIS; MEASLES; MUMPS; IMMUNIZATION; CHILDREN; ENGLAND; AUTISM; POLICY	In this article on the public perception of risks Paul Bellaby considers three examples of risks to children in the UK-an insignificant risk (autism caused by MMR vaccine), a real but probably small risk (vCJD from BSE), and a real and demonstrably larger risk (injuries from road crashes) and contrasts the perceptions of the risks by parents.	Univ Salford, Inst Publ Hlth Res & Policy, Salford M5 4QA, Greater Manches, England	University of Salford	Bellaby, P (corresponding author), Univ Salford, Inst Publ Hlth Res & Policy, Salford M5 4QA, Greater Manches, England.							Adams J, 1998, INTERDISCIPL SCI REV, V23, P146; Bartlett DMC, 1998, CRIME LAW SOCIAL CH, V30, P237, DOI 10.1023/A:1008386621333; BEDFORD H, 2003, BMJ-BRIT MED J, V326, P718; BOBO JK, 1993, PEDIATRICS, V91, P308; Boulianne N, 2003, CAN J PUBLIC HEALTH, V94, P218, DOI 10.1007/BF03405070; Brown P, 2001, EMERG INFECT DIS, V7, P6, DOI 10.3201/eid0701.010102; Cousens S, 2003, STAT METHODS MED RES, V12, P235, DOI 10.1191/0962280203sm332ra; DiGuiseppi C, 1997, BRIT MED J, V314, P710, DOI 10.1136/bmj.314.7082.710; Durbach N, 2000, SOC HIST MED, V13, P45, DOI 10.1093/shm/13.1.45; Evans M, 2001, BRIT J GEN PRACT, V51, P904; Ghani AC, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-4; Hennock EP, 1998, SOC HIST MED, V11, P49, DOI 10.1093/shm/11.1.49; HILLMAN M, 1990, ONE FALSE MOVE STUDY; Huxley RR, 2000, BRIT J NUTR, V84, P247, DOI 10.1017/S0007114500001483; Kaye JA, 2001, BRIT MED J, V322, P460, DOI 10.1136/bmj.322.7284.460; Lutwick SM, 2000, PEDIATR CLIN N AM, V47, P427, DOI 10.1016/S0031-3955(05)70215-7; Marks L., 1996, METROPOLITAN MATERNI; Middleton E, 2003, BMJ-BRIT MED J, V326, P854, DOI 10.1136/bmj.326.7394.854; Mullany L, 2003, AM J MANAG CARE, V9, pS23; *OFF NAT STAT, 2003, ANN ABSTR STAT; Petrovic M, 2001, BRIT MED J, V322, P82, DOI 10.1136/bmj.322.7278.82; Ramsay ME, 2002, BRIT J GEN PRACT, V52, P912; *SCI MED CTR, 2002, MMR LEARN LESS; Szreter Simon, 1988, SOCIAL SCI MED, V1, P1, DOI DOI 10.1145/1073943.1073950; Taylor B, 2002, BRIT MED J, V324, P393, DOI 10.1136/bmj.324.7334.393; Vernon JG, 2003, BRIT J GEN PRACT, V53, P399; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; 2003, INDEPENDENT     0731, P16; 2003, INDEPENDENT     0731, P4	29	64	64	0	24	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	2003	327	7417					725	728		10.1136/bmj.327.7417.725	http://dx.doi.org/10.1136/bmj.327.7417.725			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	728FZ	14512482	Green Published			2022-12-28	WOS:000185708300022
J	Jackson, H; Hubbard, R				Jackson, H; Hubbard, R			Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article									City Hosp Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital	Hubbard, R (corresponding author), City Hosp Nottingham, Div Epidemiol & Publ Hlth, Hucknall Rd, Nottingham NG5 1PB, England.							ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; British Medical Association, 2003, INV GEN PRACT NEW GE; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Nolan D, 1999, THORAX, V54, P468, DOI 10.1136/thx.54.5.468d; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	5	56	57	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 20	2003	327	7416					653	654		10.1136/bmj.327.7416.653	http://dx.doi.org/10.1136/bmj.327.7416.653			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724AC	14500437	Bronze, Green Published			2022-12-28	WOS:000185463100021
J	Koekkoek, SKE; Hulscher, HC; Dortland, BR; Hensbroek, RA; Elgersma, Y; Ruigrok, TJH; De Zeeuw, CI				Koekkoek, SKE; Hulscher, HC; Dortland, BR; Hensbroek, RA; Elgersma, Y; Ruigrok, TJH; De Zeeuw, CI			Cerebellar LTD and learning-dependent timing of conditioned eyelid responses	SCIENCE			English	Article							LONG-TERM DEPRESSION; KINASE-C INHIBITOR; MUTANT MICE; VESTIBULOOCULAR REFLEX; EXPRESSION; ADAPTATION	Mammals can be trained to make a conditioned movement at a precise time, which is correlated to the interval between the conditioned stimulus and unconditioned stimulus during the learning. This learning-dependent timing has been shown to depend on an intact cerebellar cortex, but which cellular process is responsible for this form of learning remains to be demonstrated. Here, we show that protein kinase C-dependent long-term depression in Purkinje cells is necessary for learning-dependent timing of Pavlovian-conditioned eyeblink responses.	Erasmus MC, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	De Zeeuw, CI (corresponding author), Erasmus MC, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands.	c.dezeeuw@erasmusmc.nl	Elgersma, Ype/F-5164-2013	Elgersma, Ype/0000-0002-3758-1297				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; Aizenman CD, 1998, NEURON, V21, P827, DOI 10.1016/S0896-6273(00)80598-X; BUONOMANO DV, 1994, NEURAL COMPUT, V6, P38, DOI 10.1162/neco.1994.6.1.38; De Zeeuw CI, 1998, NEURON, V20, P495, DOI 10.1016/S0896-6273(00)80990-3; Gao WC, 2003, J NEUROSCI, V23, P1859; Garcia KS, 1998, NEUROPHARMACOLOGY, V37, P471, DOI 10.1016/S0028-3908(98)00055-0; Garcia KS, 1999, J NEUROSCI, V19, P10940, DOI 10.1523/JNEUROSCI.19-24-10940.1999; Goossens J, 2001, J NEUROSCI, V21, P5813, DOI 10.1523/JNEUROSCI.21-15-05813.2001; Hansel C, 2000, NEURON, V26, P473, DOI 10.1016/S0896-6273(00)81179-4; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Kistler WM, 2003, CEREBELLUM, V2, P44, DOI 10.1080/14734220309426; Koekkoek SKE, 2002, J NEUROPHYSIOL, V88, P2124, DOI 10.1152/jn.2002.88.4.2124; Medina JF, 2002, NATURE, V416, P330, DOI 10.1038/416330a; Miyata M, 2001, EUR J NEUROSCI, V13, P1945, DOI 10.1046/j.0953-816x.2001.01570.x; PERRETT SP, 1993, J NEUROSCI, V13, P1708; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; van Alphen AM, 2002, EUR J NEUROSCI, V16, P486, DOI 10.1046/j.1460-9568.2002.02094.x; Yeo CH, 1998, TRENDS COGN SCI, V2, P322, DOI 10.1016/S1364-6613(98)01219-4	18	213	219	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1736	1739		10.1126/science.1088383	http://dx.doi.org/10.1126/science.1088383			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500987				2022-12-28	WOS:000185387700049
J	Thornton, JW; Need, E; Crews, D				Thornton, JW; Need, E; Crews, D			Resurrecting the ancestral steroid receptor: Ancient origin of estrogen signaling	SCIENCE			English	Article							REPRODUCTIVE-SYSTEM; OCTOPUS-VULGARIS; EVOLUTION; MECHANISMS; INDUCTION; BINDING; GENOME; FEMALE; GENE	Receptors for sex and adrenal steroid hormones are absent from fully sequenced invertebrate genomes and have not been recovered from other invertebrates. Here we report the isolation of an estrogen receptor ortholog from the mollusk Aplysia californica and the reconstruction, synthesis, and experimental characterization of functional domains of the ancestral protein from which all extant steroid receptors (SRs) evolved. Our findings indicate that SRs are extremely ancient and widespread, having diversified from a primordial gene before the origin of bilaterally symmetric animals, and that this ancient receptor had estrogen receptor - like functionality. This gene was lost in the lineage leading to arthropods and nematodes and became independent of hormone regulation in the Aplysia lineage.	Univ Oregon, Ctr Ecol & Evolutionary Biol, Eugene, OR 97403 USA; Univ Texas, Sect Integrat Biol, Austin, TX 78712 USA	University of Oregon; University of Texas System; University of Texas Austin	Thornton, JW (corresponding author), Univ Oregon, Ctr Ecol & Evolutionary Biol, Eugene, OR 97403 USA.	joet@uoregon.edu	Thornton, Joseph/GSN-4190-2022		PHS HHS [41770] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baker ME, 2003, BIOESSAYS, V25, P396, DOI 10.1002/bies.10252; Bentley P., 1998, COMP VERTEBRATE ENDO; Benton MJ, 2003, SCIENCE, V300, P1698, DOI 10.1126/science.1077795; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Di Cosmo A, 2002, MOL REPROD DEV, V61, P367, DOI 10.1002/mrd.10014; Di Cosmo A, 2001, J EXP ZOOL, V289, P33, DOI 10.1002/1097-010X(20010101/31)289:1<33::AID-JEZ4>3.0.CO;2-A; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; MAGLICH JM, 2001, GENOME BIOL, V2; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Oberdorster E, 2002, MAR ENVIRON RES, V54, P715, DOI 10.1016/S0141-1136(02)00118-6; Peterson KJ, 2001, EVOL DEV, V3, P170, DOI 10.1046/j.1525-142x.2001.003003170.x; Suzuki Y, 2002, P NATL ACAD SCI USA, V99, P16138, DOI 10.1073/pnas.212646199; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; *US EPA, 2003, END DISR SCREEN TEST; ZILLIACUS J, 1994, P NATL ACAD SCI USA, V91, P4175, DOI 10.1073/pnas.91.10.4175	19	484	507	4	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1714	1717		10.1126/science.1086185	http://dx.doi.org/10.1126/science.1086185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500980				2022-12-28	WOS:000185387700042
J	Cook, D; Rocker, G; Marshall, J; Sjokvist, P; Dodek, P; Griffith, L; Freitag, A; Varon, J; Bradley, C; Levy, M; Finfer, S; Hamielec, C; McMullin, J; Weaver, B; Walter, S; Guyatt, G				Cook, D; Rocker, G; Marshall, J; Sjokvist, P; Dodek, P; Griffith, L; Freitag, A; Varon, J; Bradley, C; Levy, M; Finfer, S; Hamielec, C; McMullin, J; Weaver, B; Walter, S; Guyatt, G		Level Care Study Investigators; Canadian Critical Care Trials Grp	Withdrawal of mechanical ventilation in anticipation of death in the intensive care unit	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-SUSTAINING TREATMENTS; CRITICALLY ILL; CARDIOPULMONARY-RESUSCITATION; DECISION-MAKING; SUPPORT; PHYSICIAN; PREFERENCES; END; DIRECTIVES; HOSPITALS	BACKGROUND: In critically ill patients who are receiving mechanical ventilation, the factors associated with physicians' decisions to withdraw ventilation in anticipation of death are unclear. The objective of this study was to examine the clinical determinants that were associated with the withdrawal of mechanical ventilation. METHODS: We studied adults who were receiving mechanical ventilation in 15 intensive care units, recording base-line physiological characteristics, daily Multiple Organ Dysfunction Scores, the patient's decision-making ability, the type of life support administered, the use of do-not-resuscitate orders, the physician's prediction of the patient's status, and the physician's perceptions of the patient's preferences about the use of life support. We examined the relation between these factors and withdrawal of mechanical ventilation, using Cox proportional-hazards regression analysis. RESULTS: Of 851 patients who were receiving mechanical ventilation, 539 (63.3 percent) were successfully weaned, 146 (17.2 percent) died while receiving mechanical ventilation, and 166 (19.5 percent) had mechanical ventilation withdrawn. The need for inotropes or vasopressors was associated with withdrawal of the ventilator (hazard ratio, 1.78; 95 percent confidence interval, 1.20 to 2.66; P=0.004), as were the physician's prediction that the patient's likelihood of survival in the intensive care unit was less than 10 percent (hazard ratio, 3.49; 95 percent confidence interval, 1.39 to 8.79; P=0.002), the physician's prediction that future cognitive function would be severely impaired (hazard ratio, 2.51; 95 percent confidence interval, 1.28 to 4.94; P=0.04), and the physician's perception that the patient did not want life support used (hazard ratio, 4.19; 95 percent confidence interval, 2.57 to 6.81; P<0.001). CONCLUSIONS: Rather than age or the severity of the illness and organ dysfunction, the strongest determinants of the withdrawal of ventilation in critically ill patients were the physician's perception that the patient preferred not to use life support, the physician's predictions of a low likelihood of survival in the intensive care unit and a high likelihood of poor cognitive function, and the use of inotropes or vasopressors.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Dalhousie Univ, Dept Med, Halifax, NS, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Huddinge Univ, Dept Anesthesia & Intens Care, Stockholm, Sweden; Univ British Columbia, Program Crit Care Med, Vancouver, BC V5Z 1M9, Canada; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Brown Univ, Dept Med, Providence, RI 02912 USA; Univ Sydney, Royal N Shore Hosp, Intens Therapy Unit, Sydney, NSW 2006, Australia; Toronto Hosp, Toronto, ON M5T 2S8, Canada; London Hlth Sci Ctr, London, ON, Canada; Hamilton Hlth Sci Ctr, Hamilton, ON, Canada	McMaster University; McMaster University; Dalhousie University; University of Toronto; University of British Columbia; Baylor College of Medicine; Brown University; Royal North Shore Hospital; University of Sydney; University of Toronto; University Toronto Affiliates; University Health Network Toronto; London Health Sciences Centre; McMaster University	Cook, D (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.		Varon, Joseph/R-5198-2019; Walter, Stephen/AAB-5548-2022; Varon, Joseph/T-9481-2019	Walter, Stephen/0000-0003-4157-8928; Finfer, Simon/0000-0002-2785-5864; Varon, Joseph/0000-0002-7622-9974				Asch DA, 1996, MED CARE, V34, P103, DOI 10.1097/00005650-199602000-00002; CHRISTAKIS NA, 1993, LANCET, V342, P642, DOI 10.1016/0140-6736(93)91759-F; CHRISTAKIS NA, 1995, J GEN INTERN MED, V10, P491, DOI 10.1007/BF02602399; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Cook DJ, 2001, LANCET, V358, P1941, DOI 10.1016/S0140-6736(01)06960-4; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DETSKY AS, 1981, NEW ENGL J MED, V305, P667, DOI 10.1056/NEJM198109173051204; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; Esteban A, 2001, INTENS CARE MED, V27, P1744, DOI 10.1007/s00134-001-1111-7; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Hall RI, 2000, CHEST, V118, P1424, DOI 10.1378/chest.118.5.1424; Hamel Mary Beth, 1995, JAMA (Journal of the American Medical Association), V273, P1842, DOI 10.1001/jama.273.23.1842; JAYES RL, 1993, JAMA-J AM MED ASSOC, V270, P2213, DOI 10.1001/jama.270.18.2213; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; Keenan SP, 1998, CRIT CARE MED, V26, P245, DOI 10.1097/00003246-199802000-00018; Keenan SP, 1997, CRIT CARE MED, V25, P1324, DOI 10.1097/00003246-199708000-00019; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANKEN PN, 1991, ANN INTERN MED, V115, P478; LEE DKP, 1994, JAMA-J AM MED ASSOC, V271, P1358, DOI 10.1001/jama.271.17.1358; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; McLean RF, 2000, CRIT CARE MED, V28, P100, DOI 10.1097/00003246-200001000-00016; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; SLOMKA J, 1992, SOC SCI MED, V35, P251, DOI 10.1016/0277-9536(92)90021-H; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Smucker WD, 2000, MED DECIS MAKING, V20, P271, DOI 10.1177/0272989X0002000303; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042; WOOD GG, 1995, CAN J ANAESTH, V42, P186, DOI 10.1007/BF03010673	36	298	304	0	19	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1123	1132		10.1056/NEJMoa030083	http://dx.doi.org/10.1056/NEJMoa030083			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679526	Bronze			2022-12-28	WOS:000185369700005
J	Manisty, C; Waxman, J				Manisty, C; Waxman, J			For and against - Doctors should not discuss resuscitation with terminally ill patients - For	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC-ARREST; CANCER		Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Canc Med, London W12 0NN, England	Imperial College London	Waxman, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Canc Med, Hammersmith Campus, London W12 0NN, England.		Manisty, Charlotte/AAN-3723-2021	Manisty, Charlotte/0000-0003-0245-7090				BMA Resuscitation Council UK and Royal College of Nursing, DEC REL CARD RES; Ewer MS, 2001, CANCER, V92, P1905, DOI 10.1002/1097-0142(20011001)92:7<1905::AID-CNCR1708>3.0.CO;2-6; Haidet P, 1998, AM J MED, V105, P222, DOI 10.1016/S0002-9343(98)00242-3; Varon J, 1998, RESUSCITATION, V36, P165, DOI 10.1016/S0300-9572(98)00015-X	4	20	21	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					614	615		10.1136/bmj.327.7415.614	http://dx.doi.org/10.1136/bmj.327.7415.614			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969934	Green Published			2022-12-28	WOS:000185358700030
J	Bunce, M; Worthy, TH; Ford, T; Hoppitt, W; Willerslev, E; Drummond, A; Cooper, A				Bunce, M; Worthy, TH; Ford, T; Hoppitt, W; Willerslev, E; Drummond, A; Cooper, A			Extreme reversed sexual size dimorphism in the extinct New Zealand moa Dinornis	NATURE			English	Article							DNA; SEQUENCES; EVOLUTION	The ratite moa(Aves; Dinornithiformes) were massive graviportal browsers weighing up to 250 kg (ref. 1) that dominated the New Zealand biota until their extinction approximately 500 yr ago. Despite an extensive Quaternary fossil record, moa taxonomy remains problematic(1-4) and currently 11 species are recognized. Three Dinornis species were found throughout New Zealand and differed markedly in size(1-2 m height at back) and mass (from similar to34 to 242 kg)(1). Surprisingly, ancient mitochondrial DNA sequences show that the three species were genetically indistinguishable within each island, but formed separate North and South Island clades. Here we show, using the first sex-linked nuclear sequences from an extinct species, that on each island the three morphological forms actually represent just one species, whose size varied markedly according to sex and habitat. The largest females in this example of extreme reversed sexual size dimorphism were about 280% the weight and 150% the height of the largest males, which is unprecedented among birds and terrestrial mammals. The combination of molecular and palaeontological data highlights the difficulties of analysing extinct groups, even those with detailed fossil records.	Univ Oxford, Dept Zool, Henry Wellcome Ancient Biomol Ctr, Oxford OX1 3PS, England; Palaeofaunal Surveys, Masterton, New Zealand; Univ Copenhagen, Inst Zool, Dept Evolutionary Biol, DK-2100 Copenhagen, Denmark; Univ Oxford, Dept Stat, Oxford OX1 3TG, England	University of Oxford; University of Copenhagen; University of Oxford	Cooper, A (corresponding author), Univ Oxford, Dept Zool, Henry Wellcome Ancient Biomol Ctr, S Parks Rd, Oxford OX1 3PS, England.	alan.cooper@zoo.ox.ac.uk	Hoppitt, William/A-8216-2008; Willerslev, Eske/A-9619-2011; Drummond, Alexei J/A-3209-2010; Cooper, Alan/E-8171-2012; Willerslev, Eske/AAA-5686-2019; Worthy, Trevor/B-3781-2012	Hoppitt, William/0000-0003-0815-5720; Willerslev, Eske/0000-0002-7081-6748; Drummond, Alexei J/0000-0003-4454-2576; Cooper, Alan/0000-0002-7738-7851; Worthy, Trevor/0000-0001-7047-4680; Bunce, Michael/0000-0002-0302-4206; Ford, Tom/0000-0002-1131-8335				Andersson Malte, 1994; Archey G., 1941, Bull Aukland Inst Mus, Vno. 1, P1; ATKINSON IAE, 1989, NEW ZEAL J ECOL, V12, P67; Barnes I, 2002, SCIENCE, V295, P2267, DOI 10.1126/science.1067814; BERTRAM B.C.R., 1979, P 17 INT ORN C S ALT, P890; Cooper A, 2000, SCIENCE, V289, P1139; Cooper A, 2001, NATURE, V409, P704, DOI 10.1038/35055536; CRACRAFT J, 1976, Paleobiology, V2, P166; Davies S.J.J.F., 2002, RATITES TINAMOUS; Drummond AJ, 2002, GENETICS, V161, P1307; Greenwood AD, 1999, MOL BIOL EVOL, V16, P1466, DOI 10.1093/oxfordjournals.molbev.a026058; HJELMQVIST L, 1995, FEBS LETT, V367, P306, DOI 10.1016/0014-5793(95)00554-M; Hutton FW, 1892, T P NZ I, V24, P93; Huynen L, 2002, MOL ECOL, V11, P851, DOI 10.1046/j.1365-294X.2002.01483.x; LEWIS KB, 1994, MAR GEOL, V116, P293, DOI 10.1016/0025-3227(94)90047-7; MARCHANG M, 1990, HDB AUSTR NZ ANTARCT; Oliver W. R. B., 1949, Dominion Mus. Bull. Wellington N.Z., V15, P1; Owen, 1879, MEMOIRS EXTINCT WING; Owen R, 1840, P ZOOL SOC LOND, VVII, P169, DOI [10.1080/00222934009496800, DOI 10.1080/00222934009496800]; Shetty S, 1999, CHROMOSOME RES, V7, P289, DOI 10.1023/A:1009278914829; SHINE R, 1989, Q REV BIOL, V64, P419, DOI 10.1086/416458; WORTHY T H, 1987, National Museum of New Zealand Records, V3, P59; WORTHY TH, 1994, NEW ZEAL J ZOOL, V21, P113, DOI 10.1080/03014223.1994.9517981; WORTHY TH, 2002, LOST WORLD MOA	24	135	143	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					172	175		10.1038/nature01871	http://dx.doi.org/10.1038/nature01871			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968178				2022-12-28	WOS:000185236000040
J	Gillberg, C; Soderstrorn, H				Gillberg, C; Soderstrorn, H			Learning disability	LANCET			English	Review							SELF-INJURIOUS-BEHAVIOR; FRAGILE-X-SYNDROME; MENTAL-RETARDATION; INTELLECTUAL DISABILITY; DOWN-SYNDROME; FOLLOW-UP; DOUBLE-BLIND; DEVELOPMENTAL-DISABILITIES; PSYCHIATRIC-DISORDERS; SPECTRUM DISORDERS	Learning disability is common, affecting 1-2.5% of the general population in the Western world, and encompasses many different conditions. It usually leads to major functional impairment and lifelong need for support and interventions, not the least important of which are medical and health-care services. Rapid progress is being made in the understanding of the cause and pathogenesis of many learning disability syndromes, and these advances are likely to improve targeted interventions in the next decade. Many countries have abolished a learning disability specialty for medical professionals, but there is a great need to revive this niche of medical knowledge. We know little about quality of life and effects on families of people with learning disability, and research is needed to address these issues.	Univ Gothenburg, Dept Child & Adolescent Psychiat, SE-41119 Gothenburg, Sweden; St Georges Med Sch, London, England	University of Gothenburg; St Georges University London	Gillberg, C (corresponding author), Univ Gothenburg, Dept Child & Adolescent Psychiat, Kungsgatan 12, SE-41119 Gothenburg, Sweden.	christopher.gillberg@pediat.gu.se						Akefeldt A, 1999, J AM ACAD CHILD PSY, V38, P761, DOI 10.1097/00004583-199906000-00025; Aman MG, 2002, AM J PSYCHIAT, V159, P1337, DOI 10.1176/appi.ajp.159.8.1337; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Amir RE, 2000, AM J MED GENET, V97, P147, DOI 10.1002/1096-8628(200022)97:2<147::AID-AJMG6>3.0.CO;2-O; Anderson M, 2001, J CHILD PSYCHOL PSYC, V42, P287, DOI 10.1017/S0021963001007016; Andersson HW, 2001, SCAND J PSYCHOL, V42, P437, DOI 10.1111/1467-9450.00256; Aronson M, 1997, DEV MED CHILD NEUROL, V39, P583; Autti-Ramo I, 2000, DEV MED CHILD NEUROL, V42, P406, DOI 10.1017/S0012162200000748; Avchen RN, 2001, AM J EPIDEMIOL, V154, P895, DOI 10.1093/aje/154.10.895; Bailey A, 2001, J INTELL DISABIL RES, V45, P344, DOI 10.1046/j.1365-2788.2001.00339.x; Baker E, 2002, AM J MED GENET, V107, P285, DOI 10.1002/ajmg.10159; Ballaban-Gil K, 2000, MENT RETARD DEV D R, V6, P300, DOI 10.1002/1098-2779(2000)6:4<300::AID-MRDD9>3.0.CO;2-R; Bedford H, 2001, BRIT MED J, V323, P533, DOI 10.1136/bmj.323.7312.533; Benn PA, 2002, CLIN CHIM ACTA, V323, P1, DOI 10.1016/S0009-8981(02)00186-9; Benzacken B, 2002, HUM REPROD, V17, P1154, DOI 10.1093/humrep/17.5.1154; Berkson G, 2000, RES DEV DISABIL, V21, P13, DOI 10.1016/S0891-4222(99)00027-X; Bohmer CJM, 2001, J INTELL DISABIL RES, V45, P212, DOI 10.1046/j.1365-2788.2001.00300.x; Bolton PF, 2001, AM J MED GENET, V105, P675, DOI 10.1002/ajmg.1551; Bolton PF, 1997, LANCET, V349, P392, DOI 10.1016/S0140-6736(97)80012-8; Bowley C, 2000, J INTELL DISABIL RES, V44, P529, DOI 10.1046/j.1365-2788.2000.00270.x; Brylewski J, 2003, COCHRANE DATABASE SY, V3, DOI [10. 1002/14651858.cd000377, DOI 10.1002/14651858.CD000377]; Buck GM, 2000, PAEDIATR PERINAT EP, V14, P324, DOI 10.1046/j.1365-3016.2000.00276.x; CARR J, 1994, J CHILD PSYCHOL PSYC, V35, P425, DOI 10.1111/j.1469-7610.1994.tb01732.x; Carvill S, 2001, J INTELL DISABIL RES, V45, P467, DOI 10.1046/j.1365-2788.2001.00366.x; Chapman DA, 2002, AM J MENT RETARD, V107, P46, DOI 10.1352/0895-8017(2002)107<0046:ERFFMR>2.0.CO;2; Chelly J, 2001, NAT REV GENET, V2, P669, DOI 10.1038/35088558; Clarke DJ, 2000, AM J MENT RETARD, V105, P25, DOI 10.1352/0895-8017(2000)105<0025:PBAWQA>2.0.CO;2; Clarkson B, 2002, AM J MED GENET, V107, P267, DOI 10.1002/ajmg.10240; Croen LA, 2002, J AUTISM DEV DISORD, V32, P207, DOI 10.1023/A:1015453830880; Cumella S, 2000, J INTELL DISABIL RES, V44, P45, DOI 10.1046/j.1365-2788.2000.00252.x; Deb S, 2001, J INTELL DISABIL RES, V45, P495, DOI 10.1046/j.1365-2788.2001.00374.x; Delaney-Black V, 2002, ARCH PEDIAT ADOL MED, V156, P280, DOI 10.1001/archpedi.156.3.280; Dimitropoulos A, 2001, AM J MENT RETARD, V106, P39, DOI 10.1352/0895-8017(2001)106<0039:EOCBAT>2.0.CO;2; Down J L, 1995, Ment Retard, V33, P54; Duff M, 2001, J INTELL DISABIL RES, V45, P219, DOI 10.1046/j.1365-2788.2001.00302.x; Dyken PR, 2001, MENT RETARD DEV D R, V7, P217, DOI 10.1002/mrdd.1030; Dykens EM, 2000, J CHILD PSYCHOL PSYC, V41, P407, DOI 10.1017/S0021963000005667; Emerson E, 2000, AM J MENT RETARD, V105, P81, DOI 10.1352/0895-8017(2000)105<0081:QACOCR>2.0.CO;2; FERNELL E, 1997, LAKARTIDNINGEN, V94, P2360; Finlay WML, 2002, MENT RETARD, V40, P14, DOI 10.1352/0047-6765(2002)040<0014:AIIWPW>2.0.CO;2; Fombonne E, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e58; Futagi Y, 2002, PEDIATR NEUROL, V27, P111, DOI 10.1016/S0887-8994(02)00395-8; Ghaziuddin M, 2000, J INTELL DISABIL RES, V44, P562, DOI 10.1046/j.1365-2788.2000.00271.x; Gillberg C, 1999, DEV PSYCHOPATHOL, V11, P567, DOI 10.1017/S0954579499002217; GILLBERG C, 1986, BRIT J PSYCHIAT, V149, P68, DOI 10.1192/bjp.149.1.68; Gillberg C, 1999, ACTA PSYCHIAT SCAND, V99, P399, DOI 10.1111/j.1600-0447.1999.tb00984.x; Gillberg C, 1997, J CHILD PSYCHOL PSYC, V38, P889, DOI 10.1111/j.1469-7610.1997.tb01608.x; GILLBERG C, 1983, PSYCHIAT RES, V10, P21, DOI 10.1016/0165-1781(83)90025-2; Gillberg C, 1997, ARCH GEN PSYCHIAT, V54, P857; GILLBERG C, 1987, J AUTISM DEV DISORD, V17, P273, DOI 10.1007/BF01495061; Gillberg C., 1995, CLIN CHILD NEUROPSYC; Gillberg C, 2000, BIOL AUTISTIC SYNDRO, V3rd; Gleeson JG, 2001, MENT RETARD DEV D R, V7, P167, DOI 10.1002/mrdd.1024; Goodman R, 1996, BRIT MED J, V312, P1065; GOODMAN R, 1995, EUR CHILD ADOLES PSY, V4, P187, DOI 10.1007/BF01980457; Gravestock S, 2000, J INTELL DISABIL RES, V44, P625, DOI 10.1046/j.1365-2788.2000.00308.x; Guerri C, 2001, NEUROTOXICOLOGY, V22, P593, DOI 10.1016/S0161-813X(01)00037-7; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; HAGBERG B, 1983, BRAIN DEV-JPN, V5, P441, DOI 10.1016/S0387-7604(83)80072-2; Hall S, 2001, AM J MENT RETARD, V106, P189, DOI 10.1352/0895-8017(2001)106<0189:EDOSIB>2.0.CO;2; Harris JC, 1995, DEV NEUROPSYCHIATRY; Hellings JA, 2001, J CHILD ADOL PSYCHOP, V11, P229, DOI 10.1089/10445460152595559; HODGINS S, 1992, ARCH GEN PSYCHIAT, V49, P476, DOI 10.1001/archpsyc.1992.01820060056009; Hoffbuhr KC, 2002, MENT RETARD DEV D R, V8, P99, DOI 10.1002/mrdd.10026; Holland T, 2002, J INTELL DISABIL RES, V46, P6, DOI 10.1046/j.1365-2788.2002.00001.x; Hornig M, 2001, MENT RETARD DEV D R, V7, P200, DOI 10.1002/mrdd.1028; HOWLIN P, 1995, DEV MED CHILD NEUROL, V37, P406; Jones RSP, 2002, AM J MENT RETARD, V107, P99, DOI 10.1352/0895-8017(2002)107<0099:MRAMFS>2.0.CO;2; Kahng S, 2002, AM J MENT RETARD, V107, P212, DOI 10.1352/0895-8017(2002)107<0212:BTOSIT>2.0.CO;2; Kau ASM, 2000, AM J MENT RETARD, V105, P286, DOI 10.1352/0895-8017(2000)105<0286:EBSOPP>2.0.CO;2; Kelly L., 1992, CHILD ABUSE REV, V1, P157; Kemper TL, 1998, J NEUROPATH EXP NEUR, V57, P645, DOI 10.1097/00005072-199807000-00001; Kennedy CH, 2001, AM J MENT RETARD, V106, P503; Khalifa MM, 2002, CLIN GENET, V61, P49, DOI 10.1034/j.1399-0004.2001.610110.x; Kingma A, 2002, J PEDIAT HEMATOL ONC, V24, P106, DOI 10.1097/00043426-200202000-00010; Krajewski J, 2000, MENT RETARD, V38, P154, DOI 10.1352/0047-6765(2000)038<0154:AOHSST>2.0.CO;2; Kroll L, 2002, LANCET, V359, P1975, DOI 10.1016/S0140-6736(02)08829-3; Lorenz JM, 2001, SEMIN PERINATOL, V25, P348, DOI 10.1053/sper.2001.27164; Lott IT, 2001, MENT RETARD DEV D R, V7, P172, DOI 10.1002/mrdd.1025; LOVAAS OI, 1987, J CONSULT CLIN PSYCH, V55, P3, DOI 10.1037/0022-006X.55.1.3; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; LYNAM D, 1993, J ABNORM PSYCHOL, V102, P187, DOI 10.1037/0021-843X.102.2.187; Maes B, 2000, MENT RETARD, V38, P207, DOI 10.1352/0047-6765(2000)038<0207:PCTSFF>2.0.CO;2; MAKRIDES M, 1995, LANCET, V345, P1463, DOI 10.1016/S0140-6736(95)91035-2; Mank D, 2000, MENT RETARD, V38, P506, DOI 10.1352/0047-6765(2000)038<0506:DSISEA>2.0.CO;2; Martin C S, 2000, Prev Sci, V1, P107, DOI 10.1023/A:1010042231697; McCarthy J, 2001, J INTELL DISABIL RES, V45, P99, DOI 10.1046/j.1365-2788.2001.00335.x; MCGIMSEY JF, 1988, J AUTISM DEV DISORD, V18, P167, DOI 10.1007/BF02211944; Milberger S, 1997, BIOL PSYCHIAT, V41, P65, DOI 10.1016/0006-3223(95)00653-2; MOFFITT TE, 1994, CRIMINOLOGY, V32, P277, DOI 10.1111/j.1745-9125.1994.tb01155.x; Moffitt TE, 1991, NEUROPSYCHOLOGY AGGR, P67; Molteno G, 2001, J INTELL DISABIL RES, V45, P515, DOI 10.1046/j.1365-2788.2001.00368.x; Moreira LMD, 2000, J INTELL DISABIL RES, V44, P91, DOI 10.1046/j.1365-2788.2000.00246.x; Murphy DGM, 2002, ARCH GEN PSYCHIAT, V59, P885, DOI 10.1001/archpsyc.59.10.885; Niklasson L, 2002, DEV MED CHILD NEUROL, V44, P44, DOI 10.1017/S0012162201001645; Nottestad JA, 2001, J INTELL DISABIL RES, V45, P121, DOI 10.1046/j.1365-2788.2001.00332.x; O'Brien G, 2001, DEV MED CHILD NEUROL, V43, P634, DOI 10.1017/S0012162201001153; OBRIEN G, 2002, CLIN DEV MED, V157; Oliver C, 2000, AM J MENT RETARD, V105, P455, DOI 10.1352/0895-8017(2000)105<0455:CDIAWD>2.0.CO;2; Olney JW, 2001, MENT RETARD DEV D R, V7, P267, DOI 10.1002/mrdd.1037; Olsson MB, 2001, J INTELL DISABIL RES, V45, P535, DOI 10.1046/j.1365-2788.2001.00372.x; ORBAN P, 1993, FORENSIC PSYCHIAT CL, P286; Patja K, 2001, J INTELL DISABIL RES, V45, P300, DOI 10.1046/j.1365-2788.2001.00322.x; Patja K, 2001, J INTELL DISABIL RES, V45, P30, DOI 10.1046/j.1365-2788.2001.00290.x; Pearson H, 2002, NATURE, V417, P10, DOI 10.1038/417010a; Pellock JM, 2000, MENT RETARD DEV D R, V6, P309, DOI 10.1002/1098-2779(2000)6:4<309::AID-MRDD10>3.0.CO;2-I; Philippe A, 1999, HUM MOL GENET, V8, P805, DOI 10.1093/hmg/8.5.805; Puri BK, 2001, INT J CLIN PRACT, V55, P442; QUERSHI H, 1993, RES PRACTICES, P89; RAPIN I, 1996, DEF LANGUAGE DISORDE; REID AH, 1989, RES DEV DISABIL, V10, P241, DOI 10.1016/0891-4222(89)90013-9; Roberts JE, 2001, AM J MENT RETARD, V106, P216, DOI 10.1352/0895-8017(2001)106<0216:RAECDO>2.0.CO;2; Roizen NJ, 2001, MENT RETARD DEV D R, V7, P38, DOI 10.1002/1098-2779(200102)7:1<38::AID-MRDD1006>3.0.CO;2-C; Ronen GM, 2000, DEV MED CHILD NEUROL, V42, P751, DOI 10.1017/S0012162200001390; Rosa A, 2001, J INTELL DISABIL RES, V45, P416, DOI 10.1046/j.1365-2788.2001.00351.x; Rosenhall U, 1999, J AUTISM DEV DISORD, V29, P349, DOI 10.1023/A:1023022709710; ROURKE BP, 1978, J ABNORM CHILD PSYCH, V6, P121, DOI 10.1007/BF00915788; Rowe D, 2000, J INTELL DISABIL RES, V44, P638, DOI 10.1046/j.1365-2788.2000.00304.x; Saigal S, 2000, Semin Neonatol, V5, P107, DOI 10.1053/siny.1999.0003; Schull W J, 1986, Adv Space Res, V6, P223, DOI 10.1016/0273-1177(86)90296-6; Schwartzman JS, 2001, NEUROPEDIATRICS, V32, P162, DOI 10.1055/s-2001-16620; Simonoff E, 1996, J CHILD PSYCHOL PSYC, V37, P259, DOI 10.1111/j.1469-7610.1996.tb01404.x; Siponmaa L, 2001, J AM ACAD PSYCHIATRY, V29, P420; Smith T, 2000, AM J MENT RETARD, V105, P269, DOI 10.1352/0895-8017(2000)105<0269:RTOIEI>2.0.CO;2; SODERSTROM H, 2002, NEUROPSYCHIATRIC BAC; Stafstrom CE, 2000, MENT RETARD DEV D R, V6, P281, DOI 10.1002/1098-2779(2000)6:4<281::AID-MRDD7>3.0.CO;2-9; Steffenburg S, 1996, PEDIATR NEUROL, V14, P131, DOI 10.1016/0887-8994(96)00011-2; Steffenburg S, 1996, ARCH NEUROL-CHICAGO, V53, P904, DOI 10.1001/archneur.1996.00550090114017; Steinhausen HC, 1998, ALCOHOL CLIN EXP RES, V22, P334, DOI 10.1111/j.1530-0277.1998.tb03657.x; STROMLAND K, 1994, DEV MED CHILD NEUROL, V36, P351; Strydom A, 2001, J INTELL DISABIL RES, V45, P146, DOI 10.1046/j.1365-2788.2001.00329.x; Sudhalter V, 2001, AM J MENT RETARD, V106, P389, DOI 10.1352/0895-8017(2001)106<0389:CCOCWF>2.0.CO;2; SWEIN J, 1996, BR J LEARN DISABIL, V24, P58; Swillen A, 2001, GENET COUNSEL, V12, P309; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Temple V, 2001, J INTELL DISABIL RES, V45, P47, DOI 10.1046/j.1365-2788.2001.00299.x; THOMPSON T, 1994, AM J MENT RETARD, V99, P85; TURK J, 1992, BRIT J PSYCHIAT, V160, P24, DOI 10.1192/bjp.160.1.24; Tyrrell J, 2001, INT J GERIATR PSYCH, V16, P1168, DOI 10.1002/gps.502; Udwin O, 2001, DEV MED CHILD NEUROL, V43, P823, DOI 10.1017/S0012162201001499; Ulovec Z, 2002, COLLEGIUM ANTROPOL, V26, P119; Van Amelsvoort T, 2001, BRIT J PSYCHIAT, V178, P412; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; WALDROP MF, 1971, EXCEPTIONAL INFANT S, P343; Warburg M, 2001, ACTA OPHTHALMOL SCAN, V79, P450, DOI 10.1034/j.1600-0420.2001.790504.x; WHO, 1992, ICD10 CLASS MENT BEH; Whybrow Peter C., 1996, P866; Wilsher Colin R, 1994, Eur Child Adolesc Psychiatry, V3, P59, DOI 10.1007/BF01977668; WINCHEL RM, 1991, AM J PSYCHIAT, V148, P306; Wing L, 1996, BRIT MED J, V312, P327; Yamaki K, 2002, MENT RETARD, V40, P132, DOI 10.1352/0047-6765(2002)040<0132:EAISOA>2.0.CO;2; Yeargin-Allsopp M, 2002, MOL PSYCHIATR, V7, pS9, DOI 10.1038/sj.mp.4001164; Zappella M, 1998, J AUTISM DEV DISORD, V28, P519, DOI 10.1023/A:1026052128305; Zarcone JR, 2001, AM J MENT RETARD, V106, P525, DOI 10.1352/0895-8017(2001)106<0525:EOROAB>2.0.CO;2	154	68	69	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2003	362	9386					811	821		10.1016/S0140-6736(03)14275-4	http://dx.doi.org/10.1016/S0140-6736(03)14275-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	719DN	13678878				2022-12-28	WOS:000185188500023
J	John, K				John, K			Democracy, accountability, and international health: Westminister from a medical perspective	LANCET			English	Article									UCL, Int Hlth & Med Educ Ctr, London WC1E 6BT, England	University of London; University College London	John, K (corresponding author), 2 Mazenod Ave, London NW6 4LR, England.	john_katrina@hotmail.com							0	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					826	827		10.1016/S0140-6736(03)14278-X	http://dx.doi.org/10.1016/S0140-6736(03)14278-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	719DN	13678881				2022-12-28	WOS:000185188500026
J	Gibbons, DL; Erk, I; Reilly, B; Navaza, J; Kielian, M; Rey, FA; Lepault, J				Gibbons, DL; Erk, I; Reilly, B; Navaza, J; Kielian, M; Rey, FA; Lepault, J			Visualization of the target-membrane-inserted fusion protein of Semliki Forest virus by combined electron microscopy and crystallography	CELL			English	Article							BORNE ENCEPHALITIS-VIRUS; CELL-CELL FUSION; INFLUENZA HEMAGGLUTININ; CHOLESTEROL DEPENDENCE; ENVELOPE GLYCOPROTEIN; CONFORMATIONAL-CHANGE; LOW-PH; BINDING; ENTRY; ACTIVATION	Semliki Forest virus enters cells by receptor-mediated endocytosis. The acidic environment of the endosome triggers a membrane fusion reaction that is mediated by the E1 glycoprotein. During fusion, E1 rearranges from an E1/E2 heterodimer to a highly stable, membrane-inserted E1 homotrimer (E1HT). In this study, we analyzed E1HT by a combination of electron cryomicroscopy, electron crystallography of negatively stained 2D crystals, and fitting of the available X-ray structure of the monomeric E1 ectodomain into the resulting 3D reconstruction. The visualized E1HT reveals that the ectodomain has reoriented vertically and inserted the distal tip of domain II into the lipid bilayer. Our data allow the visualization of a viral fusion protein inserted in its target membrane and demonstrate that insertion is a cooperative process, resulting in rings composed of five to six homotrimers.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; CNRS, INRA, UMR 2472 1157, F-91198 Gif Sur Yvette, France	Yeshiva University; Albert Einstein College of Medicine; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay	Kielian, M (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	kielian@aecom.yu.edu; mem-vms@gv.cnrs-gif.fr	Lepault, Jean/AAN-8859-2020; Rey, Felix/B-6497-2012	Rey, Felix/0000-0002-9953-7988; Kielian, Margaret/0000-0002-7395-4791	NCI NIH HHS [P30-CA13330] Funding Source: Medline; NIGMS NIH HHS [T32 GM07288, R01 GM52929] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052929, T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn A, 2002, J VIROL, V76, P3267, DOI 10.1128/JVI.76.7.3267-3275.2002; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; Chatterjee PK, 2002, J VIROL, V76, P12712, DOI 10.1128/JVI.76.24.12712-12722.2002; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; GAROFF H, 1980, NATURE, V288, P236, DOI 10.1038/288236a0; Gaudin Y, 1996, J VIROL, V70, P7371, DOI 10.1128/JVI.70.11.7371-7378.1996; Gibbons DL, 2000, J VIROL, V74, P7772, DOI 10.1128/JVI.74.17.7772-7780.2000; Gibbons DL, 2002, J VIROL, V76, P1194, DOI 10.1128/JVI.76.3.1194-1205.2002; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; HARTER C, 1989, J BIOL CHEM, V264, P6459; HELENIUS A, 1977, J CELL BIOL, V75, P866, DOI 10.1083/jcb.75.3.866; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; KAARIAINEN L, 1969, ANN MED EXP BIOL FEN, V47, P235; Kanaseki T, 1997, J CELL BIOL, V137, P1041, DOI 10.1083/jcb.137.5.1041; Kielian M, 1996, J CELL BIOL, V134, P863, DOI 10.1083/jcb.134.4.863; Kielian M, 2000, Subcell Biochem, V34, P409; KIELIAN M, 1985, J CELL BIOL, V101, P2284, DOI 10.1083/jcb.101.6.2284; KLIMJACK MR, 1994, J VIROL, V68, P6940, DOI 10.1128/JVI.68.11.6940-6946.1994; LEPAULT J, 1983, J MICROSC-OXFORD, V129, P89, DOI 10.1111/j.1365-2818.1983.tb04163.x; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; Markovic I, 2001, J CELL BIOL, V155, P833, DOI 10.1083/jcb.200103005; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Navaza J, 2002, ACTA CRYSTALLOGR D, V58, P1820, DOI 10.1107/S0907444902013707; Pletnev SV, 2001, CELL, V105, P127, DOI 10.1016/S0092-8674(01)00302-6; Plonsky I, 1996, J CELL BIOL, V135, P1831, DOI 10.1083/jcb.135.6.1831; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Roche S, 2002, VIROLOGY, V297, P128, DOI 10.1006/viro.2002.1429; SCHLESINGER S, 2001, FIELDS VIROLOGY, P895; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Stiasny K, 2001, J VIROL, V75, P7392, DOI 10.1128/JVI.75.16.7392-7398.2001; Vashishtha M, 1998, J CELL BIOL, V140, P91, DOI 10.1083/jcb.140.1.91; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Wengler G, 1999, VIROLOGY, V257, P472, DOI 10.1006/viro.1999.9661; WILSCHUT J, 1995, MOL MEMBR BIOL, V12, P143, DOI 10.3109/09687689509038510; Yeager M, 1999, Methods Enzymol, V294, P135; Zhang W, 2002, J VIROL, V76, P11645, DOI 10.1128/JVI.76.22.11645-11658.2002	45	92	92	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	2003	114	5					573	583		10.1016/S0092-8674(03)00683-4	http://dx.doi.org/10.1016/S0092-8674(03)00683-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678581	Bronze			2022-12-28	WOS:000185193100007
J	Ambinder, R				Ambinder, R			Infection and lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University	Ambinder, R (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.							Murray PG, 1998, BLOOD, V92, P2477, DOI 10.1182/blood.V92.7.2477.2477_2477_2483	1	13	15	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1309	1311		10.1056/NEJMp030083	http://dx.doi.org/10.1056/NEJMp030083			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523136				2022-12-28	WOS:000185644000002
J	Garcia-Garcia, MJ; Anderson, KV				Garcia-Garcia, MJ; Anderson, KV			Essential role of glycosaminoglycans in Fgf signaling during mouse gastrulation	CELL			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; UDP-GLUCOSE DEHYDROGENASE; ENDOTHELIAL-CELL PRECURSORS; ANTERIOR PRIMITIVE ENDODERM; SURFACE PROTEOGLYCAN; TARGETED DISRUPTION; MOLECULAR-CLONING; GROWTH-FACTORS; GENE ENCODES; TOUT-VELU	In vitro studies have suggested that proteoglycans facilitate signaling by mammalian growth factors, but genetic evidence supporting this role has been lacking. Here, we characterize the ENU-induced mutation lazy mesoderm (Izme), which disrupts the single mouse gene encoding UDP-glucose dehydrogenase (Ugdh), an enzyme required for the synthesis of the glycosaminoglycan (GAG) side chains of proteoglycans. lzme mutants arrest during gastrulation with defects in migration of mesoderm and endoderm, a phenotype similar to that of mutants in the fibroblast growth factor (Fgf) pathway. Analysis of the expression of molecular markers indicates that Fgf signaling is blocked in lzme mutant embryos. In contrast, signaling by the growth factors Nodal and Wnt3, which are also essential during mouse gastrulation, appears to be normal in lzme embryos. The results demonstrate that proteoglycans are required during mouse gastrulation specifically to promote Fgf signaling.	Sloan Kettering Inst, Dev Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Anderson, KV (corresponding author), Sloan Kettering Inst, Dev Biol Program, 1275 York Ave, New York, NY 10021 USA.	k-anderson@ski.mskcc.org		Anderson, Kathryn/0000-0003-1657-2161	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD035455, R37HD035455] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD035455] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35455] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Baeg GH, 2001, DEVELOPMENT, V128, P87; Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bellosta P, 2001, MOL CELL BIOL, V21, P5946, DOI 10.1128/MCB.21.17.5946-5957.2001; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Binari RC, 1997, DEVELOPMENT, V124, P2623; Brennan J, 2001, NATURE, V411, P965, DOI 10.1038/35082103; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P7012, DOI 10.1021/bi000181h; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; Chapman DL, 1998, NATURE, V391, P695, DOI 10.1038/35624; Chiao E, 2002, DEV BIOL, V243, P185, DOI 10.1006/dbio.2001.0554; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Costell M, 2002, CIRC RES, V91, P158, DOI 10.1161/01.RES.0000026056.81424.DA; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DAMJANOV I, 1986, DEV BIOL, V116, P194, DOI 10.1016/0012-1606(86)90056-4; DasGupta R, 1999, DEVELOPMENT, V126, P4557; De Cat B, 2001, SEMIN CELL DEV BIOL, V12, P117, DOI 10.1006/scdb.2000.0240; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Furukawa K, 2002, BBA-GEN SUBJECTS, V1573, P377, DOI 10.1016/S0304-4165(02)00406-3; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; HOGAN BLM, 1994, DEVELOPMENT, P53; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kasarskis A, 1998, P NATL ACAD SCI USA, V95, P7485, DOI 10.1073/pnas.95.13.7485; Kelly RG, 2001, DEV CELL, V1, P435, DOI 10.1016/S1534-5807(01)00040-5; Li YF, 1997, MATRIX BIOL, V16, P49, DOI 10.1016/S0945-053X(97)90071-8; Lin XH, 1999, DEVELOPMENT, V126, P3715; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; MAKOVER A, 1989, DIFFERENTIATION, V40, P17, DOI 10.1111/j.1432-0436.1989.tb00809.x; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Minowada G, 1999, DEVELOPMENT, V126, P4465; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; Ornitz DM, 2001, GENOME BIOL, V2; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; Saga Y, 1999, DEVELOPMENT, V126, P3437; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; Sun X, 1999, GENE DEV, V13, P1834, DOI 10.1101/gad.13.14.1834; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; Wang YL, 2000, GENOMICS, V66, P333, DOI 10.1006/geno.2000.6221; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032	69	96	97	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					727	737		10.1016/S0092-8674(03)00715-3	http://dx.doi.org/10.1016/S0092-8674(03)00715-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505572	Bronze			2022-12-28	WOS:000185464000010
J	Eugster, EA; Pescovitz, OH				Eugster, EA; Pescovitz, OH			New revelations about the role of STATS in stature	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Indiana Univ, Sch Med,Riley Hosp Children, Dept Pediat, Sect Pediat Endocrinol & Diabetol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Eugster, EA (corresponding author), Indiana Univ, Sch Med,Riley Hosp Children, Dept Pediat, Sect Pediat Endocrinol & Diabetol, Indianapolis, IN 46202 USA.								0	6	7	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1110	1112		10.1056/NEJMp038134	http://dx.doi.org/10.1056/NEJMp038134			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679524				2022-12-28	WOS:000185369700003
J	Fenistein, D; van Hecke, M				Fenistein, D; van Hecke, M			Kinematics - Wide shear zones in granular bulk flow	NATURE			English	Editorial Material							STRESS FLUCTUATIONS; MICROSTRUCTURE; BANDS		Leiden Univ, Kamerlingh Onnes Lab, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Fenistein, D (corresponding author), Leiden Univ, Kamerlingh Onnes Lab, POB 9506, NL-2300 RA Leiden, Netherlands.			van Hecke, Martin/0000-0002-9550-6607				Daerr A, 1999, NATURE, V399, P241, DOI 10.1038/20392; DURAN J, 1997, SAND POWDERS GRAINS; Hartley RR, 2003, NATURE, V421, P928, DOI 10.1038/nature01394; Howell D, 1999, PHYS REV LETT, V82, P5241, DOI 10.1103/PhysRevLett.82.5241; Jaeger HM, 1996, REV MOD PHYS, V68, P1259, DOI 10.1103/RevModPhys.68.1259; LATZEL M, PREPRINT; Losert W, 2000, PHYS REV LETT, V85, P1428, DOI 10.1103/PhysRevLett.85.1428; Mueth DM, 2000, NATURE, V406, P385, DOI 10.1038/35019032; MUHLHAUS HB, 1987, GEOTECHNIQUE, V37, P271; Nedderman R.M., 1992, STATICS KINEMATICS G; Oda M, 1998, GEOTECHNIQUE, V48, P465, DOI 10.1680/geot.1998.48.4.465; Pouliquen O, 1996, PHYS REV E, V53, P552, DOI 10.1103/PhysRevE.53.552; Scott DR, 1996, NATURE, V381, P592, DOI 10.1038/381592a0	13	135	135	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					256	256		10.1038/425256a	http://dx.doi.org/10.1038/425256a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679907	Bronze			2022-12-28	WOS:000185370900034
J	Feinberg, EH; Hunter, CP				Feinberg, EH; Hunter, CP			Transport of dsRNA into cells by the transmembrane protein SID-1	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; C-ELEGANS; CAENORHABDITIS-ELEGANS; GENETIC INTERFERENCE; IDENTIFICATION; RECEPTOR; RDE-1	RNA interference (RNAi) spreads systemically in plants and nematodes to silence gene expression distant from the site of initiation. We previously identified a gene, sid-1, essential for systemic but not cell-autonomous RNAi in Caenorhabditis elegans. Here, we demonstrate that SID-1 is a multispan transmembrane protein that sensitizes Drosophila cells to soaking RNAi with a potency that is dependent on double-stranded RNA ( dsRNA) length. Further analyses revealed that SID-1 enables passive cellular uptake of dsRNA. These data indicate that systemic RNAi in C. elegans involves SID-1-mediated intercellular transport of dsRNA.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Hunter, CP (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.				NIGMS NIH HHS [R01 GM069891] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069891] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FEINBERG EH, UNPUB; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Han K, 2001, MOL CELLS, V12, P267; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Shibuya A, 2000, NAT IMMUNOL, V1, P441, DOI 10.1038/80886; SILHAVY TJ, 1985, MICROBIOL REV, V49, P398, DOI 10.1128/MMBR.49.4.398-418.1985; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Worby C A, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.95.pl1	21	387	421	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1545	1547		10.1126/science.1087117	http://dx.doi.org/10.1126/science.1087117			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970568				2022-12-28	WOS:000185255300053
J	White, HD				White, HD			Candesartan and heart failure: the allure of CHARM	LANCET			English	Editorial Material							RANDOMIZED TRIAL; MORTALITY; CAPTOPRIL; LOSARTAN		Green Lane Hosp, Dept Cardiol, Auckland 3, New Zealand		White, HD (corresponding author), Green Lane Hosp, Dept Cardiol, Auckland 3, New Zealand.							Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Dickstein K, 2002, LANCET, V360, P752, DOI 10.1016/S0140-6736(02)09895-1; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3	3	13	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					754	755		10.1016/S0140-6736(03)14294-8	http://dx.doi.org/10.1016/S0140-6736(03)14294-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678864				2022-12-28	WOS:000185188500003
J	Fang, Z; Nagaosa, N; Takahashi, KS; Asamitsu, A; Mathieu, R; Ogasawara, T; Yamada, H; Kawasaki, M; Tokura, Y; Terakura, K				Fang, Z; Nagaosa, N; Takahashi, KS; Asamitsu, A; Mathieu, R; Ogasawara, T; Yamada, H; Kawasaki, M; Tokura, Y; Terakura, K			The anomalous Hall effect and magnetic monopoles in momentum space	SCIENCE			English	Article							PHASE-FACTORS	Efforts to find the magnetic monopole in real space have been made in cosmic rays and in particle accelerators, but there has not yet been any firm evidence for its existence because of its very heavy mass, similar to10(16) giga-electron volts. We show that the magnetic monopole can appear in the crystal momentum space of solids in the accessible low-energy region (similar to0.1 to 1 electron volts) in the context of the anomalous Hall effect. We report experimental results together with first-principles calculations on the ferromagnetic crystal SrRuO3 that provide evidence for the magnetic monopole in the crystal momentum space.	Natl Inst Adv Ind Sci & Techonl, Japan Sci & Technol Corp, ERATO, Tsukuba, Ibaraki 3058562, Japan; Chinese Acad Sci, Inst Phys, Beijing 100080, Peoples R China; Correlated Electron Res Ctr, Tsukuba, Ibaraki 3058562, Japan; Univ Tokyo, Dept Appl Phys, Bunkyo Ku, Tokyo 1138562, Japan; Univ Geneva, Dept Condensed Matter Phys, CH-1211 Geneva 4, Switzerland; Univ Tokyo, Cryogen Ctr, Tokyo 1130032, Japan; Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan; Res Inst Computat Sci, Tsukuba, Ibaraki 3058568, Japan	Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST); Chinese Academy of Sciences; Institute of Physics, CAS; National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo; University of Geneva; University of Tokyo; Tohoku University; National Institute of Advanced Industrial Science & Technology (AIST)	Fang, Z (corresponding author), Natl Inst Adv Ind Sci & Techonl, Japan Sci & Technol Corp, ERATO, Tsukuba Cent 4, Tsukuba, Ibaraki 3058562, Japan.	z.fang@aist.go.jp	Nagaosa, Naoto/G-7057-2012; Tokura, Yoshinori/C-7352-2009; Ogasawara, Takeshi/K-7406-2018; TAKAHASHI, Kei/B-2498-2013; Fang, Zhong/D-4132-2009; Kawasaki, Masashi/B-5826-2008; Yamada, Hiroyuki/L-6862-2018; Yamada, Hiroyuki/AAR-8332-2020	Tokura, Yoshinori/0000-0002-2732-4983; Ogasawara, Takeshi/0000-0001-5993-6119; Yamada, Hiroyuki/0000-0001-9847-5431; Yamada, Hiroyuki/0000-0001-9847-5431; Mathieu, Roland/0000-0002-5261-2047				Berger L, 1970, PHYS REV B-SOLID ST, V2, P4559, DOI 10.1103/PhysRevB.2.4559; BERRY MV, 1984, PROC R SOC LON SER-A, V392, P45, DOI 10.1098/rspa.1984.0023; Dirac PAM, 1931, P R SOC LOND A-CONTA, V133, P60, DOI 10.1098/rspa.1931.0130; Jungwirth T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.207208; KARPLUS R, 1954, PHYS REV, V95, P1154, DOI 10.1103/PhysRev.95.1154; KINGSMITH RD, 1993, PHYS REV B, V47, P1651, DOI 10.1103/PhysRevB.47.1651; KOHN W, 1957, PHYS REV, V108, P590, DOI 10.1103/PhysRev.108.590; LUTTINGER JM, 1958, PHYS REV, V112, P739, DOI 10.1103/PhysRev.112.739; MARTIN RM, 1972, PHYS REV B, V5, P1607, DOI 10.1103/PhysRevB.5.1607; Murakami S, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.057002; Ohno H, 1998, SCIENCE, V281, P951, DOI 10.1126/science.281.5379.951; Onoda M, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.206601; POLYAKOV AM, 1974, JETP LETT+, V20, P194; Shapere A., 1989, GEOMETRIC PHASES PHY; SHIKANO M, 1994, SOLID STATE COMMUN, V90, P115, DOI 10.1016/0038-1098(94)90942-3; Sinova J, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.235203; SMIT J, 1958, PHYSICA, V24, P39, DOI 10.1016/S0031-8914(58)93541-9; Taguchi Y, 2001, SCIENCE, V291, P2573, DOI 10.1126/science.1058161; THOOFT G, 1974, NUCL PHYS B, VB 79, P276; THOULESS DJ, 1982, PHYS REV LETT, V49, P405, DOI 10.1103/PhysRevLett.49.405; WU TT, 1975, PHYS REV D, V12, P3845, DOI 10.1103/PhysRevD.12.3845	21	727	741	22	315	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					92	95		10.1126/science.1089408	http://dx.doi.org/10.1126/science.1089408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526076	Green Submitted			2022-12-28	WOS:000185678500041
J	Limelette, P; Georges, A; Jerome, D; Wzietek, P; Metcalf, P; Honig, JM				Limelette, P; Georges, A; Jerome, D; Wzietek, P; Metcalf, P; Honig, JM			Universality and critical behavior at the Mott transition	SCIENCE			English	Article							METAL-INSULATOR TRANSITIONS; INFINITE DIMENSIONS; DOPED V2O3; MODEL	We report conductivity measurements of Cr-doped V2O3 using a variable pressure technique. The critical behavior of the conductivity near the Mott insulator to metal critical endpoint is investigated in detail as a function of pressure and temperature. The critical exponents are determined, as well as the scaling function associated with the equation of state. The universal properties of a liquid-gas transition are found. This is potentially a generic description of the Mott critical endpoint in correlated electron materials.	Univ Paris 11, Phys Solides Lab, CNRS, URA 8502, F-91405 Orsay, France; Ecole Normale Super, CNRS, UMR 8549, Phys Theor Lab, F-75231 Paris 05, France; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Sorbonne Universite; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Limelette, P (corresponding author), Univ Paris 11, Phys Solides Lab, CNRS, URA 8502, Batiment 510, F-91405 Orsay, France.	limelette@lps.u-psud.fr	Georges, Antoine/H-4855-2012	Georges, Antoine/0000-0001-9479-9682; Wzietek, Pawel/0000-0002-5498-5533				CASTELLANI C, 1979, PHYS REV LETT, V43, P1957, DOI 10.1103/PhysRevLett.43.1957; Georges A, 1996, REV MOD PHYS, V68, P13, DOI 10.1103/RevModPhys.68.13; HARRISON HR, 1980, MATER RES BULL, V15, P571, DOI 10.1016/0025-5408(80)90136-1; Imada M, 1998, REV MOD PHYS, V70, P1039, DOI 10.1103/RevModPhys.70.1039; Jayaraman A, 1970, PHYS REV B-SOLID ST, V2, P3751, DOI 10.1103/PhysRevB.2.3751; KADANOFF LP, 1967, REV MOD PHYS, V39, P395, DOI 10.1103/RevModPhys.39.395; KERLIN AL, 1973, SOLID STATE COMMUN, V13, P1125, DOI 10.1016/0038-1098(73)90547-4; Kotliar G, 2000, PHYS REV LETT, V84, P5180, DOI 10.1103/PhysRevLett.84.5180; KUWAMOTO H, 1980, PHYS REV B, V22, P2626, DOI 10.1103/PhysRevB.22.2626; MAJUMDAR P, 1994, PHYS REV LETT, V73, P1525, DOI 10.1103/PhysRevLett.73.1525; McWhan DB, 1970, PHYS REV B-SOLID ST, V2, P3734, DOI 10.1103/PhysRevB.2.3734; MCWHAN DB, 1973, PHYS REV B, V7, P1920, DOI 10.1103/PhysRevB.7.1920; Mott N.F., 1990, METAL INSULATOR TRAN; MOTT NF, 1949, P PHYS SOC LOND A, V62, P416, DOI 10.1088/0370-1298/62/7/303; Rozenberg MJ, 1999, PHYS REV LETT, V83, P3498, DOI 10.1103/PhysRevLett.83.3498	16	288	289	0	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					89	92		10.1126/science.1088386	http://dx.doi.org/10.1126/science.1088386			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526075	Green Submitted			2022-12-28	WOS:000185678500040
J	Jin, RC; Cao, YC; Hao, EC; Metraux, GS; Schatz, GC; Mirkin, CA				Jin, RC; Cao, YC; Hao, EC; Metraux, GS; Schatz, GC; Mirkin, CA			Controlling anisotropic nanoparticle growth through plasmon excitation	NATURE			English	Article							DISCRETE-DIPOLE APPROXIMATION; SILVER NANODISKS; SEMICONDUCTOR NANOCRYSTALS; METAL NANOPARTICLES; OPTICAL-PROPERTIES; GOLD NANORODS; II-VI; PARTICLES; SHAPE; SIZE	Inorganic nanoparticles exhibit size-dependent properties that are of interest for applications ranging from biosensing(1-5) and catalysis(6) to optics(7) and data storage(8). They are readily available in a wide variety of discrete compositions and sizes(9-14). Shape-selective synthesis strategies now also yield shapes other than nanospheres, such as anisotropic metal nanostructures with interesting optical properties(15-23). Here we demonstrate that the previously described photoinduced method(23) for converting silver nanospheres into triangular silver nanocrystals-so-called nanoprisms-can be extended to synthesize relatively mono-disperse nanoprisms with desired edge lengths in the 30-120 nm range. The particle growth process is controlled using dual-beam illumination of the nanoparticles, and appears to be driven by surface plasmon excitations. We find that, depending on the illumination wavelengths chosen, the plasmon excitations lead either to fusion of nanoprisms in an edge-selective manner or to the growth of the nanoprisms until they reach their light-controlled final size.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Inst Nanotechnol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Schatz, GC (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.		Mirkin, Chad A/E-3911-2010; Schatz, George C./ABF-1341-2020; Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Mirkin, Chad/0000-0002-6634-7627				Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Brust M, 2002, COLLOID SURFACE A, V202, P175, DOI 10.1016/S0927-7757(01)01087-1; Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536; Chang SS, 1999, LANGMUIR, V15, P701, DOI 10.1021/la980929l; Chen SH, 2002, J PHYS CHEM B, V106, P10777, DOI 10.1021/jp026376b; DRAINE BT, 1994, J OPT SOC AM A, V11, P1491, DOI 10.1364/JOSAA.11.001491; Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228; Hao EC, 2002, J AM CHEM SOC, V124, P15182, DOI 10.1021/ja028336r; Henglein A, 1999, LANGMUIR, V15, P6738, DOI 10.1021/la9901579; Jin RC, 2001, SCIENCE, V294, P1901, DOI 10.1126/science.1066541; Kamat PV, 2002, J PHYS CHEM B, V106, P7729, DOI 10.1021/jp0209289; Kelly KL, 2003, J PHYS CHEM B, V107, P668, DOI 10.1021/jp026731y; Korgel BA, 1998, ADV MATER, V10, P661, DOI 10.1002/(SICI)1521-4095(199806)10:9<661::AID-ADMA661>3.0.CO;2-L; Link S, 1999, J PHYS CHEM A, V103, P1165, DOI 10.1021/jp983141k; Maillard M, 2003, J PHYS CHEM B, V107, P2466, DOI 10.1021/jp022357q; Maillard M, 2002, ADV MATER, V14, P1084, DOI 10.1002/1521-4095(20020805)14:15<1084::AID-ADMA1084>3.0.CO;2-L; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; Pastoriza-Santos I, 2002, NANO LETT, V2, P903, DOI 10.1021/nl025638i; Peng XG, 1998, J AM CHEM SOC, V120, P5343, DOI 10.1021/ja9805425; Penn RL, 1998, SCIENCE, V281, P969, DOI 10.1126/science.281.5379.969; SCHMID G, 1992, CHEM REV, V92, P1709, DOI 10.1021/cr00016a002; Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989; Sun YG, 2003, ADV MATER, V15, P695, DOI 10.1002/adma.200304652; Sun YG, 2002, SCIENCE, V298, P2176, DOI 10.1126/science.1077229; Talapin DV, 2002, J AM CHEM SOC, V124, P5782, DOI 10.1021/ja0123599; Tang ZY, 2002, SCIENCE, V297, P237, DOI 10.1126/science.1072086; Wang JF, 2001, SCIENCE, V293, P1455, DOI 10.1126/science.1062340; YANG WH, 1995, J CHEM PHYS, V103, P869, DOI 10.1063/1.469787	30	1494	1531	20	936	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					487	490		10.1038/nature02020	http://dx.doi.org/10.1038/nature02020			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523440				2022-12-28	WOS:000185648100038
J	Miller, RF; Cloutier, R; Turner, S				Miller, RF; Cloutier, R; Turner, S			The oldest articulated chondrichthyan from the Early Devonian period	NATURE			English	Article							BRAINCASE; INTERRELATIONSHIPS; EVOLUTION; SHARKS	Chondrichthyans (including living sharks, skates, rays and chimaeras) have a fossil record of scales and dermal denticles perhaps dating back to the Late Ordovician period, about 455 million years ago(1,2). Their fossil tooth record extends to the earliest Devonian period, almost 418 million years ago(3), whereas the oldest known articulated shark remains date from the Early Devonian period(4), about 394 million years ago(5). Here we report the discovery of an articulated shark that is almost 409 million years old 5 from the Early Devonian (early Emsian) period of New Brunswick, Canada. The specimen, identified as Doliodus problematicus (Woodward)(6), sheds light on the earliest chondrichthyans and their interrelationships with basal jawed vertebrates. This species has been truly problematic(7). Previously known only from isolated teeth(2,6,8), it has been identified as an acanthodian and a chondrichthyan. This specimen is the oldest shark showing the tooth families in situ, and preserves one of the oldest chondrichthyan braincases. More notably, it shows the presence of paired pectoral fin-spines, previously unknown in cartilaginous fishes.	New Brunswick Museum, Steinhammer Palaeontol Lab, St John, NB E2K 1E5, Canada; Univ Quebec, Lab Biol Evolut, Rimouski, PQ G5L 3A1, Canada; Monash Univ, Sch Geosci, Clayton, Vic 3088, Australia; Queensland Museum, Brisbane, Qld 4101, Australia	University of Quebec; Monash University; Queensland Museum	Miller, RF (corresponding author), New Brunswick Museum, Steinhammer Palaeontol Lab, St John, NB E2K 1E5, Canada.		Turner, Susan/AAS-6992-2021	Turner, Susan/0000-0003-2308-158X; Cloutier, Richard/0000-0001-5780-3304				Blieck Alain, 2000, Courier Forschungsinstitut Senckenberg, V223, P223; Coates MI, 2001, SYST ASSOC SPEC VOL, V61, P241; Coates MI, 1998, T ROY SOC EDIN-EARTH, V89, P63, DOI 10.1017/S026359330000701X; Compagno L.J.V., 1988, SHARKS ORDER CARCHAR; Denison R., 1979, Handbook of Paleoichthyology, V5, P1; DINELEY DL, 1968, CAN J EARTH SCI, V5, P945, DOI DOI 10.1139/E68-091; Forey P.L., 1992, Bulletin of the British Museum (Natural History) Geology, V48, P25; Gensel P. G., 1984, PLANT LIFE DEVONIAN; Heidtke Ulrich H.J., 2001, Mainzer Geowissenschaftliche Mitteilungen, V30, P105; Janvier P., 1986, Bulletin de l'Institut Francais d'Etudes Andines, V15, P73; Janvier P., 1996, EARLY VERTEBRATES; KEPPIE JD, 1999, GEOLOGICAL SOC AM SP, V336, P267; Long John A., 1995, Records of the Western Australian Museum, V17, P287; Mader H., 1986, GOTTINGER ARB GEOL P, V28, P1; MAISEY J G, 1986, Cladistics, V2, P201, DOI 10.1111/j.1096-0031.1986.tb00462.x; Maisey JG, 2001, J VERTEBR PALEONTOL, V21, P702, DOI 10.1671/0272-4634(2001)021[0702:APCBFT]2.0.CO;2; Maisey JG, 2001, SYST ASSOC SPEC VOL, V61, P263; REIF WE, 1982, EVOL BIOL, V15, P287; Shear WA, 1996, NATURE, V384, P555, DOI 10.1038/384555a0; Smith MM, 2001, SYST ASSOC SPEC VOL, V61, P223; Traquair RH, 1893, GEOLOGICAL MAGAZINE, V10, P145; Tucker RD, 1998, EARTH PLANET SC LETT, V158, P175, DOI 10.1016/S0012-821X(98)00050-8; TURNER S, RECENT ADV ORIGIN EA; WHITEAVES JF, 1881, CANADIAN NATURALIST, V10, P93; Williams G.L., 1985, LEXICON CANADIAN STR, VVI; Woodward A.S., 1892, GEOL MAG, P1, DOI [10.1017/S0016756800188533, DOI 10.1017/S0016756800188533]; YOUNG GC, 1982, PALAEONTOLOGY, V25, P817; Zangerl R., 1981, Handbook of Paleoichthyology, V3, P1; Zhu M, 2001, SYST ASSOC SPEC VOL, V61, P289; Zhu M, 1999, NATURE, V397, P607, DOI 10.1038/17594	30	119	126	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					501	504		10.1038/nature02001	http://dx.doi.org/10.1038/nature02001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523444				2022-12-28	WOS:000185648100042
J	Rumpker, G; Ryberg, T; Bock, G				Rumpker, G; Ryberg, T; Bock, G		Desert Seismology Grp	Boundary-layer mantle flow under the Dead Sea transform fault inferred from seismic anisotropy	NATURE			English	Article							SHEAR; BENEATH; RIFT; DEFORMATION; TECTONICS; EVOLUTION; PLATE	Lithospheric-scale transform faults play an important role in the dynamics of global plate motion. Near-surface deformation fields for such faults are relatively well documented by satellite geodesy, strain measurements and earthquake source studies(1,2), and deeper crustal structure has been imaged by seismic profiling(3). Relatively little is known, however, about deformation taking place in the subcrustal lithosphere-that is, the width and depth of the region associated with the deformation, the transition between deformed and undeformed lithosphere and the interaction between lithospheric and asthenospheric mantle flow at the plate boundary. Here we present evidence for a narrow, approximately 20-km-wide, subcrustal anisotropic zone of fault-parallel mineral alignment beneath the Dead Sea transform, obtained from an inversion of shear-wave splitting observations along a dense receiver profile. The geometry of this zone and the contrast between distinct anisotropic domains suggest subhorizontal mantle flow within a vertical boundary layer that extends through the entire lithosphere and accommodates the transform motion between the African and Arabian plates within this relatively narrow zone.	Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany; Univ Potsdam, Potsdam, Germany; Nat Resources Author, Amman, Jordan; Tel Aviv Univ, IL-69978 Tel Aviv, Israel; Ah Najah Natl Univ, Nablus, Palestine Autho, Israel; Hebrew Univ Jerusalem, Jerusalem, Israel; Geophys Inst Israel, Lod, Israel	Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; University of Potsdam; Tel Aviv University; Hebrew University of Jerusalem	Rumpker, G (corresponding author), Geoforschungszentrum Potsdam, Telegrafenberg, D-14473 Potsdam, Germany.		Weber, Michael/D-8330-2013; Ryberg, Trond/H-4329-2013	Ryberg, Trond/0000-0001-7129-5596; Rumpker, Georg/0000-0002-5348-9888				Bartov Y., 1998, GEOL SURV ISR CURR R, V11, P27; BENMENAHEM A, 1976, PHYS EARTH PLANET IN, V12, P1, DOI 10.1016/0031-9201(76)90005-4; CRAMPIN S, 1987, NATURE, V328, P491, DOI 10.1038/328491a0; *DES TEAM, 2000, EOS, V81, P609; *DES TEAM, 2000, EOS, V81, P616; FREUND R, 1970, PHILOS T R SOC S-A, V267, P107, DOI 10.1098/rsta.1970.0027; GARFUNKEL Z, 1981, TECTONOPHYSICS, V80, P81, DOI 10.1016/0040-1951(81)90143-8; Herquel G, 1999, GEOPHYS RES LETT, V26, P3225, DOI 10.1029/1999GL005387; HIRN A, 1995, NATURE, V375, P571, DOI 10.1038/375571a0; Holt W.E., 2000, GEOPHYS MONOGR SER, V121, P113, DOI [DOI 10.1029/GM121P0113, 10.1029/gm121p0113]; KIND R, 1985, NATURE, V318, P358, DOI 10.1038/318358a0; MART Y, 1986, TECTONOPHYSICS, V124, P85, DOI 10.1016/0040-1951(86)90139-3; MCKENZIE DP, 1969, NATURE, V224, P125, DOI 10.1038/224125a0; MCNAMARA DE, 1994, J GEOPHYS RES-SOL EA, V99, P13655, DOI 10.1029/93JB03406; Nicolas A., 1987, FORMATION ANISOTROPY, DOI DOI 10.1029/GD016P0111; Quennell A.M., 1958, Q J GEOL SOC LOND, V114, P2; REINECKER J, 2003, 2003 RELEASE WORLD S; Savage MK, 1999, REV GEOPHYS, V37, P65, DOI 10.1029/98RG02075; SAVAGE MK, 1997, GEOPHYS RES LETT, V24, P3289; SHACHAK P, 2002, GEOPHYS RES LETT, V29; SILVER PG, 1988, NATURE, V335, P34, DOI 10.1038/335034a0; Silver PG, 1996, ANNU REV EARTH PL SC, V24, P385, DOI 10.1146/annurev.earth.24.1.385; SOBOLEV SV, UNPUB EARTH PLANET S; Stern TA, 1998, TECTONOPHYSICS, V286, P63, DOI 10.1016/S0040-1951(97)00255-2; Tommasi A, 1999, EARTH PLANET SC LETT, V168, P173, DOI 10.1016/S0012-821X(99)00046-1; VANECK T, 1989, GEOPHYS J INT, V99, P605, DOI 10.1111/j.1365-246X.1989.tb02045.x; Wolfe CJ, 1999, GEOPHYS RES LETT, V26, P779, DOI 10.1029/1999GL900056; ZHANG SQ, 1995, NATURE, V375, P774, DOI 10.1038/375774a0	28	58	60	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					497	501		10.1038/nature01982	http://dx.doi.org/10.1038/nature01982			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523443				2022-12-28	WOS:000185648100041
J	Murray, CJL; Shengelia, B; Gupta, N; Moussavi, S; Tandon, A; Thieren, M				Murray, CJL; Shengelia, B; Gupta, N; Moussavi, S; Tandon, A; Thieren, M			Validity of reported vaccination coverage in 45 countries	LANCET			English	Article							SAMPLE SELECTION BIAS; CHILD VACCINATION; MOTHERS REPORTS; ACCURACY	Background Monitoring and assessment of coverage rates in national health programmes is becoming increasingly important, We aimed to assess the accuracy of officially reported coverage rates of vaccination with diphtheria-tetanus-pertussis vaccine (DTP3), which is commonly used to monitor child health interventions. Methods We compared officially reported national data for DTP3 coverage with those from the household Demographic and Health Surveys (DHS) in 45 countries between :1990 and 2000. We adjusted survey data to reflect the number of valid vaccinations (ie, those administered in accordance with the schedule recommended by WHO) using a probit model with sample selection. The model predicted the probability of valid vaccinations for children, including those without documented vaccinations, after correcting for bias from differences between the children with and without documented information on vaccination. We then assessed the extent of survey bias and differences between officially reported data and those from DHS estimates. Findings Our results suggest that officially reported DTP3 coverage is higher than that reported from household surveys. This size of the difference increases with the rate of reported coverage of DTP3. Results of time-trend analysis show that changes in reported coverage are not correlated with changes reported from household surveys. Interpretation Although reported data might be the most widely available information for assessment of vaccination coverage, their validity for measuring changes in coverage over time is highly questionable. Household surveys can be used to validate data collected by service providers. Strategies for measurement of the coverage of all health interventions should be grounded in careful assessments of the validity of data derived from various sources.	WHO, Dept Hlth Serv Provis Evidence & Informat Policy, CH-1211 Geneva 27, Switzerland	World Health Organization	Shengelia, B (corresponding author), WHO, Dept Hlth Serv Provis Evidence & Informat Policy, CH-1211 Geneva 27, Switzerland.	shengeliab@who.int		Gupta, Neeru/0000-0002-3806-4435				Angelillo IF, 1999, B WORLD HEALTH ORGAN, V77, P224; BENNETT P, 1992, HEALTH EDUC RES, V7, P341, DOI 10.1093/her/7.3.341; BERK RA, 1983, AM SOCIOL REV, V48, P386, DOI 10.2307/2095230; Bhattacharya N, 1990, Indian J Public Health, V34, P220; Boerma J, 1994, DHS METHODOLOGICAL R; BORGDORFF MW, 1988, J TROP MED HYG, V91, P35; BROWN J, 2002, MEASURE EVALUATION W; Brugha R, 2002, LANCET, V359, P435, DOI 10.1016/S0140-6736(02)07607-9; CUTTS FT, 1993, B WORLD HEALTH ORGAN, V71, P633; GAREABALLAH ET, 1989, B WORLD HEALTH ORGAN, V67, P669; George K, 1990, Indian J Pediatr, V57, P588, DOI 10.1007/BF02726779; Guerin N, 1998, VACCINE, V16, pS81, DOI 10.1016/S0264-410X(98)00304-1; HECKMAN JJ, 1979, ECONOMETRICA, V47, P153, DOI 10.2307/1912352; Langsten R, 1998, SOC SCI MED, V46, P1205, DOI 10.1016/S0277-9536(97)10049-1; *LATH CONS, 2001, IMM DAT QUAL AUD EV; LEWIS T, 1988, AM J DIS CHILD, V142, P283, DOI 10.1001/archpedi.1988.02150030053018; *MACR INT, 1996, SAMPL MAN DHS 3 BAS; *ORC MACR, 2001, MOD A QUEST MEASURE; Ramakrishnan R, 1999, Indian Pediatr, V36, P881; Singh R, 1976, Indian J Pediatr, V43, P118, DOI 10.1007/BF02749242; Suarez L, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e3; *UNICEF, ROUT IMM EST IMM COV; VALADEZ JJ, 1992, AM J PUBLIC HEALTH, V82, P120, DOI 10.2105/AJPH.82.1.120; VANDEVEN WPMM, 1981, J ECONOMETRICS, V17, P229, DOI 10.1016/0304-4076(81)90028-2; *WHO, 1999, WHOVB9906 DEP VACC B; *WHO, 1991, WHOEPIMLM9110 EXP PR; *WHO, 1996, WHOGPVGEN9503 GLOB P; *WHO, 2000, WHOVB0032 DEP VACC B; Wittet S, 2000, VACCINE, V19, P385, DOI 10.1016/S0264-410X(00)00196-1	29	154	161	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2003	362	9389					1022	1027		10.1016/S0140-6736(03)14411-X	http://dx.doi.org/10.1016/S0140-6736(03)14411-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	725WD	14522532				2022-12-28	WOS:000185564600009
J	Paling, J				Paling, J			Strategies to help patients understand risks	BRITISH MEDICAL JOURNAL			English	Article							INFORMED CONSENT; COMMUNICATION	Explaining risks to patients in an effective way is an essential part of ensuring that consent is "informed." A consultant in risk communication discusses the strategies that can help doctors to communicate risks clearly, and thereby also build closer relationships with their patients.	Risk Commun Inst, Gainesville, FL 32653 USA		Paling, J (corresponding author), Risk Commun Inst, 5822 NW 91 Blvd, Gainesville, FL 32653 USA.							Aristotle, RHETORIC; Bennett P., 1999, RISK COMMUNICATION P, P3; Berry DC, 2003, DRUG SAFETY, V26, P1, DOI 10.2165/00002018-200326010-00001; Calman KC, 1996, BRIT MED J, V313, P799; David Ropeik, 2002, RISK PRACTICAL GUIDE; Edwards A, 1998, FAM PRACT, V15, P296, DOI 10.1093/fampra/15.4.296; Edwards A, 2002, BMJ-BRIT MED J, V324, P827, DOI 10.1136/bmj.324.7341.827; Gigerenzer G, 2003, BMJ-BRIT MED J, V327, P741, DOI 10.1136/bmj.327.7417.741; Grimes DA, 1999, OBSTET GYNECOL, V93, P910, DOI 10.1016/S0029-7844(98)00567-5; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Lloyd A, 2001, MED DECIS MAKING, V21, P141, DOI 10.1177/0272989X0102100207; MALENKA DJ, 1993, J GEN INTERN MED, V8, P543, DOI 10.1007/BF02599636; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; MERZ JF, 1991, MED DECIS MAKING, V11, P273, DOI 10.1177/0272989X9101100405; Nightingale F, 1858, NOTES MATTERS AFFECT; Paling J., 1997, YOUR ARMPITS ALLIGAT; PALING J, IN PRESS MEDICS ARE; Ross Sir David, 1964, ARISTOTLE; Roter DL, 2002, JAMA-J AM MED ASSOC, V288, P756, DOI 10.1001/jama.288.6.756; SMALL PA, COMMUNICATING RISKS; SPENCE J, 2003, EXCELLENCE DESIGN LE; Stallings SP, 2001, OBSTET GYNECOL, V98, P345, DOI 10.1016/S0029-7844(00)01182-0; WONG DL, 1988, PEDIAT NURSING, V141, P9	23	327	329	0	37	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	2003	327	7417					745	748		10.1136/bmj.327.7417.745	http://dx.doi.org/10.1136/bmj.327.7417.745			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728FZ	14512489	Green Published			2022-12-28	WOS:000185708300029
J	Vincent, JL				Vincent, JL			Selective digestive decontamination: for everyone, everywhere?	LANCET			English	Editorial Material							INTENSIVE-CARE UNITS; MECHANICALLY VENTILATED PATIENTS; RANDOMIZED CONTROLLED TRIALS; MULTIPLE-TRAUMA PATIENTS; ANTIMICROBIAL RESISTANCE; NOSOCOMIAL INFECTIONS; DOUBLE-BLIND; TRACT; PNEUMONIA; COLONIZATION		Free Univ Brussels, Hop Erasme, Dept Intens Care, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vincent, JL (corresponding author), Free Univ Brussels, Hop Erasme, Dept Intens Care, 808 Route Lennik, B-1070 Brussels, Belgium.			Vincent, Jean-Louis/0000-0001-6011-6951				AERDTS SJA, 1993, BRIT MED J, V307, P525; Bergmans DCJJ, 2001, AM J RESP CRIT CARE, V164, P382, DOI 10.1164/ajrccm.164.3.2005003; Bonten MJM, 2000, J ANTIMICROB CHEMOTH, V46, P351, DOI 10.1093/jac/46.3.351; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; Ebner W, 2000, EUR J CLIN MICROBIOL, V19, P243, DOI 10.1007/s100960050470; Garcia MS, 1998, AM J RESP CRIT CARE, V158, P908, DOI 10.1164/ajrccm.158.3.9712079; GarrousteOrgeas M, 1997, AM J RESP CRIT CARE, V156, P1647, DOI 10.1164/ajrccm.156.5.96-04076; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; HAMMOND JMJ, 1995, CRIT CARE MED, V23, P637, DOI 10.1097/00003246-199504000-00010; KAUFHOLD A, 1992, LANCET, V339, P1411, DOI 10.1016/0140-6736(92)91228-Z; Kollef MH, 2000, CRIT CARE, V4, P327, DOI 10.1186/cc716; Legras A, 1998, INTENS CARE MED, V24, P1040, DOI 10.1007/s001340050713; Leone M, 2003, CRIT CARE MED, V31, P2090, DOI 10.1097/01.CCM.0000079606.16776.C5; Nathens AB, 1999, ARCH SURG-CHICAGO, V134, P170, DOI 10.1001/archsurg.134.2.170; Silvestri L, 1999, J HOSP INFECT, V42, P125, DOI 10.1053/jhin.1998.0550; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; van Nieuwenhoven CA, 2001, JAMA-J AM MED ASSOC, V286, P335, DOI 10.1001/jama.286.3.335; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; Verwaest C, 1997, CRIT CARE MED, V25, P63, DOI 10.1097/00003246-199701000-00014; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Vincent JL, 2003, LANCET, V361, P2068, DOI 10.1016/S0140-6736(03)13644-6	21	22	23	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 27	2003	362	9389					1006	1007		10.1016/S0140-6736(03)14445-5	http://dx.doi.org/10.1016/S0140-6736(03)14445-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522525				2022-12-28	WOS:000185564600002
J	Allan, RS; Smith, CM; Belz, GT; van Lint, AL; Wakim, LM; Heath, WR; Carbone, FR				Allan, RS; Smith, CM; Belz, GT; van Lint, AL; Wakim, LM; Heath, WR; Carbone, FR			Epidermal viral immunity induced by CD8 alpha(+) dendritic cells but not by Langerhans cells	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS-1; TUMOR-NECROSIS-FACTOR; DRAINING LYMPH-NODE; SURFACE PHENOTYPE; STEADY-STATE; MOUSE; SKIN; ANTIGEN; SPLEEN; INFECTION	The classical paradigm for dendritic cell function derives from the study of Langerhans cells, which predominate within skin epidermis. After an encounter with foreign agents, Langerhans cells are thought to migrate to draining lymph nodes, where they initiate T cell priming. Contrary to this, we show here that infection of murine epidermis by herpes simplex virus did not result in the priming of virus-specific cytotoxic T lymphocytes by Langerhans cells. Rather, the priming response required a distinct CD8alpha(+) dendritic cell subset. Thus, the traditional view of Langerhans cells in epidermal immunity needs to be revisited to accommodate a requirement for other dendritic cells in this response.	Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia; Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Cooperat Res Vaccine Technol, Melbourne, Vic 3050, Australia	University of Melbourne; Walter & Eliza Hall Institute; Walter & Eliza Hall Institute	Heath, WR (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia.		Carbone, Francis/ABF-2141-2020; Belz, Gabrielle T/C-9350-2013	Belz, Gabrielle T/0000-0002-9660-9587; Heath, William/0000-0001-9670-259X; Wakim, Linda/0000-0003-1752-9579; Allan, Rhys/0000-0003-0906-2980				ALLAN RJ, UNPUB; Austyn JM, 1996, J EXP MED, V183, P1287, DOI 10.1084/jem.183.4.1287; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Coles RM, 2002, J IMMUNOL, V168, P834, DOI 10.4049/jimmunol.168.2.834; CUMBERBATCH M, 1995, IMMUNOLOGY, V84, P31; Hemmi H, 2001, INT IMMUNOL, V13, P695, DOI 10.1093/intimm/13.5.695; Henri S, 2001, J IMMUNOL, V167, P741, DOI 10.4049/jimmunol.167.2.741; HOEFSMIT ECM, 1982, IMMUNOBIOLOGY, V161, P255, DOI 10.1016/S0171-2985(82)80081-8; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; MAURER D, 2001, DENDRITIC CELLS, V2, pCH5; Merad M, 2002, NAT IMMUNOL, V3, P1135, DOI 10.1038/ni852; MOLL H, 1993, EUR J IMMUNOL, V23, P1595, DOI 10.1002/eji.1830230730; Mueller SN, 2002, IMMUNOL CELL BIOL, V80, P156, DOI 10.1046/j.1440-1711.2002.01071.x; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; O'Keeffe M, 2002, J EXP MED, V196, P1307, DOI 10.1084/jem.20021031; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; ROMANI N, 1989, J EXP MED, V169, P1169, DOI 10.1084/jem.169.3.1169; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; SILBERBERGSINAKIN I, 1976, CELL IMMUNOL, V25, P137, DOI 10.1016/0008-8749(76)90105-2; Smith CM, 2003, J IMMUNOL, V170, P4437, DOI 10.4049/jimmunol.170.9.4437; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; VREMEC D, 1992, J EXP MED, V176, P47, DOI 10.1084/jem.176.1.47; Zhao XY, 2003, J EXP MED, V197, P153, DOI 10.1084/jem.20021109	24	464	474	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1925	1928		10.1126/science.1087576	http://dx.doi.org/10.1126/science.1087576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512632				2022-12-28	WOS:000185536700056
J	Tedford, RH; Harington, CR				Tedford, RH; Harington, CR			An Arctic mammal fauna from the Early Pliocene of North America	NATURE			English	Article								A peat deposit on Ellesmere Island(1), Nunavut, Canada, allows a unique glimpse of the Early Pliocene terrestrial biota north of the Arctic Circle. The peat accumulated in a beaver pond surrounded by boreal larch forest near regional tree line(2) in coastal hills close to the Arctic Ocean. The ecological affinities of the plant and beetle remains(3) contained in the peat indicate that winter temperatures on Ellesmere Island were nearly 15degreesC higher and summer temperatures 10degreesC higher than they are today. Here we show that the mammalian remains buried in the peat represent mainly taxa of Eurasiatic zoogeographic and phyletic affinities, including the first North American occurrence of a meline badger (Arctomeles). This deposit contains direct evidence of the composition of an Early Pliocene (4-5 million years ago) arctic mammalian fauna during an active period of interchange between Asia and North America.	Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA; Canadian Museum Nat Paleobiol, Ottawa, ON K1P 6P4, Canada	American Museum of Natural History (AMNH)	Tedford, RH (corresponding author), Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA.	tedford@amnh.org						BJORK PR, 1970, T AM PHILOS SOC, V60, P3, DOI 10.2307/1006119; Dompierre H., 1997, Journal of Vertebrate Paleontology, V17, p43A; Dowsett H. J., 1999, 99535 US GEOL SURV; Elias SA, 2002, CAN J EARTH SCI, V39, P911, DOI 10.1139/E01-096; FYLES JG, 1989, CURR RES GEOL SURV C, V89, P101; Harington C.R., 2001, MERIDIAN         FAL, P11; Hulbert RC, 1999, PALAEONTOLOGY, V42, P1017; Hutchison JH, 2002, CAN J EARTH SCI, V39, P439, DOI 10.1139/E01-078; Lindsay E, 2002, J VERTEBR PALEONTOL, V22, P429, DOI 10.1671/0272-4634(2002)022[0429:ROTHBB]2.0.CO;2; MATTHEWS JV, 1990, ARCTIC, V43, P364; PETTER G, 1971, Mammalia, V35, P567, DOI 10.1515/mamm.1971.35.4.567; ROSHCHIN AD, 1949, T ODESKOGO GOSUD U, V60, P97; Rybczynski N., 1997, Journal of Vertebrate Paleontology, V17, p72A; SHER AV, 1986, PALAEONTOGRAPHICA IT, V74, P77; Shi N, 1994, STRIAE, V36, P1; Stach J., 1951, Acta Geologica Polonica, V2, P129; Tedford R.H., 1991, Journal of Vertebrate Paleontology, V11, P519; Teilhard de Chardin P., 1945, I GEOBIOL PEKING, V12, P1; VIRET J, 1934, TRAV LAB GEOL FS LYO, V2, P7; Zakrzewski R. J., 2001, Journal of Vertebrate Paleontology, V21, p116A	20	64	67	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					388	390		10.1038/nature01892	http://dx.doi.org/10.1038/nature01892			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508486				2022-12-28	WOS:000185502300038
J	Buljevac, D; Hop, WCJ; Reedeker, W; Janssens, ACJW; van der Meche, FGA; van Doorn, PA; Hintzen, RQ				Buljevac, D; Hop, WCJ; Reedeker, W; Janssens, ACJW; van der Meche, FGA; van Doorn, PA; Hintzen, RQ			Self reported stressful life events and exacerbations in multiple sclerosis: prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PSYCHOLOGICAL STRESS; EMOTIONAL-STRESS; DISEASE; MS; INFECTIONS; MODELS	Objective To study the relation between self reported stressful life events not related to multiple sclerosis and the occurrence of exacerbations in relapsing-remitting multiple sclerosis. Design Longitudinal, prospective cohort study. Setting Outpatient clinic of a department of neurology in the Netherlands. Participants Patients aged 18-55 with relapsing-remitting multiple sclerosis who could walk with a cane or better (score of 0-6.0 on the expanded disability status scale) and had had at least two exacerbations in 24 months before inclusion in the study. Patients with other serious conditions were excluded. Main outcome measure The risk of increased disease activity as measured by the occurrence of exacerbations after weeks with stressful events. Results Seventy out of 73 included patients (96%) reported at least one stressful event. In total, 457 stressful life events were reported that were not related to multiple sclerosis. Average follow up time was 1.4 years. Throughout the study, 134 exacerbations occurred in 56 patients and 136 infections occurred in 57 patients. Cox regression. analysis with time dependent variables showed that the occurrence of stress was associated with a doubling of the exacerbation rate (relative risk 2.2, 95% confidence interval 1.2 to 4.0, P = 0.014) during the subsequent four weeks. Infections were associated with a threefold increase in the risk of exacerbation, but this effect was found to be independent of experienced stress. Conclusion Stressful events were associated with increased exacerbations in relapsing-remitting multiple sclerosis. This association was independent of die triggering effect of infections on exacerbations of multiple sclerosis.	Erasmus MC, Dept Neurol, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Dept Epidemiol & Biostat, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Dept Med Psychol & Psychotherapy, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Hintzen, RQ (corresponding author), Erasmus MC, Dept Neurol, Postbox 2040, NL-3000 CA Rotterdam, Netherlands.	rhintzen@xs4all.nl	janssens, cecile c/L-1075-2015	Janssens, A Cecile/0000-0002-6153-4976				Antel JP, 1999, J NEUROIMMUNOL, V100, P181, DOI 10.1016/S0165-5728(99)00186-1; Buljevac D, 2002, BRAIN, V125, P952, DOI 10.1093/brain/awf098; Charnley J, 1979, LOW FRICTION ARTHROP, P157; CHELMICKASCHORR E, 1994, ANN NEUROL, V36, pS29, DOI 10.1002/ana.410360710; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; COX DR, 1972, J R STAT SOC B, V34, P187; Franklin GM, 1988, J NEUROL REHABIL, V2, P7; Goodin DS, 1999, NEUROLOGY, V52, P1737, DOI 10.1212/WNL.52.9.1737; GRANT I, 1989, J NEUROL NEUROSUR PS, V52, P8, DOI 10.1136/jnnp.52.1.8; Jafarian-Tehrani M, 1999, J NEUROIMMUNOL, V100, P13, DOI 10.1016/S0165-5728(99)00207-6; JANSSENS ACJ, 2003, IN PRESS ACTA NEUROL; Kroencke DC, 1999, MULT SCLER J, V5, P89, DOI 10.1177/135245859900500204; Mohr DC, 2000, NEUROLOGY, V55, P55, DOI 10.1212/WNL.55.1.55; NISIPEANU P, 1993, NEUROLOGY, V43, P1311, DOI 10.1212/WNL.43.7.1311; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; RABINS PV, 1986, BRAIN, V109, P585, DOI 10.1093/brain/109.4.585; SCHUMACHER GA, 1965, ANN NY ACAD SCI, V122, P552; Schwartz CE, 1999, BEHAV MED, V25, P110, DOI 10.1080/08964289909596740; SHERIDAN JF, 1994, CLIN MICROBIOL REV, V7, P200, DOI 10.1128/CMR.7.2.200-212.1994; SIBLEY WA, 1985, LANCET, V1, P1313; SIBLEY WA, 1997, MULTIPLE SCLEROSIS C, P141; Sternberg EM, 2001, J ENDOCRINOL, V169, P429, DOI 10.1677/joe.0.1690429; WARREN S, 1982, J CHRON DIS, V35, P821, DOI 10.1016/0021-9681(82)90047-9; WARREN S, 1991, J PSYCHOSOM RES, V35, P37, DOI 10.1016/0022-3999(91)90005-9	25	100	101	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2003	327	7416					646	+		10.1136/bmj.327.7416.646	http://dx.doi.org/10.1136/bmj.327.7416.646			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	724AC	14500435	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000185463100015
J	Lawthom, C; Durdey, P; Hughes, T				Lawthom, C; Durdey, P; Hughes, T			Constipation as a presenting symptom	LANCET			English	Editorial Material							MULTIPLE-SCLEROSIS; DYSFUNCTION		Univ Wales Hosp, Dept Neurol, Cardiff CF14 4XW, S Glam, Wales; Bristol Royal Infirm & Gen Hosp, Dept Surg, Bristol BS2 8HW, Avon, England	Cardiff University; Bristol Royal Infirmary	Hughes, T (corresponding author), Univ Wales Hosp, Dept Neurol, Heath Pk, Cardiff CF14 4XW, S Glam, Wales.							Chia YW, 1996, J NEUROL NEUROSUR PS, V60, P31, DOI 10.1136/jnnp.60.1.31; HINDS JP, 1990, GASTROENTEROLOGY, V98, P1538, DOI 10.1016/0016-5085(90)91087-M; MATHERS SE, 1990, J NEUROL NEUROSUR PS, V53, P955, DOI 10.1136/jnnp.53.11.955; SULLIVAN SN, 1983, GASTROENTEROLOGY, V84, P1640	4	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					958	958		10.1016/S0140-6736(03)14365-6	http://dx.doi.org/10.1016/S0140-6736(03)14365-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511929				2022-12-28	WOS:000185489600010
J	Wu, WJ; Tu, S; Cerione, RA				Wu, WJ; Tu, S; Cerione, RA			Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation	CELL			English	Article							TYROSINE KINASE; BINDING PARTNERS; GROWTH; RHO; RAC; REGULATOR; GTPASES; FAMILY; ENDOCYTOSIS; PROTEINS	Cdc42 is a Ras-related protein that has been implicated in the control of normal cell growth, and when improperly regulated, in cellular transformation and invasiveness. A variety of extracellular stimuli, including epidermal growth factor (EGF), activate Cdc42. Here, we show that activation of Cdc42 protects the EGF receptor from the negative regulatory activity of the c-CbI ubiquitin ligase. Activated Cdc42 binds to p85Cool-1 (for cloned-out-of-library)/beta-Pix (for Pak-interactive exchange factor), a protein that directly associates with c-CbI. This inhibits the binding of CbI by the EGF receptor and thus prevents CbI from catalyzing receptor ubiquitination. The role played by Cdc42 in regulating the timing of EGIF receptor-CbI interactions is underscored by the fact that constitutively active Cdc42(F28L), by persistently blocking the binding of CbI to these receptors, leads to their aberrant accumulation and sustained EGF-stimulated ERK activation, thus resulting in cellular transformation.	Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu		Tu, S. Sean/0000-0003-0391-8186	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654, R01GM047458] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47458, GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Feng QY, 2002, J BIOL CHEM, V277, P5644, DOI 10.1074/jbc.M107704200; Flanders JA, 2003, FEBS LETT, V550, P119, DOI 10.1016/S0014-5793(03)00853-6; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PAVELIC K, 1993, ANTICANCER RES, V13, P1133; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Tu S, 2001, J BIOL CHEM, V276, P19656, DOI 10.1074/jbc.M009838200; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WHITEHEAD IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P11; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	34	156	159	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					715	725		10.1016/S0092-8674(03)00688-3	http://dx.doi.org/10.1016/S0092-8674(03)00688-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505571	Bronze			2022-12-28	WOS:000185464000009
J	Wellman, CH; Osterloff, PL; Mohiuddin, U				Wellman, CH; Osterloff, PL; Mohiuddin, U			Fragments of the earliest land plants	NATURE			English	Article							WELSH BORDERLAND; SPORE MASSES; MICROFOSSIL RECORD; VASCULAR PLANTS; SPORANGIA; ULTRASTRUCTURE; ORDOVICIAN; BRYOPHYTES; ECOSYSTEMS; TETRADS	The earliest fossil evidence for land plants comes from microscopic dispersed spores(1-3). These microfossils are abundant and widely distributed in sediments, and the earliest generally accepted reports are from rocks of mid-Ordovician age (Llanvirn, 475 million years ago)(4). Although distribution, morphology and ultrastructure of the spores indicate that they are derived from terrestrial plants, possibly early relatives of the bryophytes, this interpretation remains controversial 5 as there is little in the way of direct evidence for the parent plants. An additional complicating factor is that there is a significant hiatus between the appearance of the first dispersed spores and fossils of relatively complete land plants (megafossils)(6): spores predate the earliest megafossils (Late Silurian, 425 million year ago) by some 50 million years(7). Here we report the description of spore-containing plant fragments from Ordovician rocks of Oman. These fossils provide direct evidence for the nature of the spore-producing plants. They confirm that the earliest spores developed in large numbers within sporangia, providing strong evidence that they are the fossilized remains of bona fide land plants. Furthermore, analysis of spore wall ultrastructure supports liverwort affinities.	Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; Petr Dev Oman LLC, Muscat 113, Oman	University of Sheffield	Wellman, CH (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Alfred Denny Bldg,Western Bank, Sheffield S10 2TN, S Yorkshire, England.							BANKS HP, 1975, REV PALAEOBOT PALYNO, V20, P13, DOI 10.1016/0034-6667(75)90004-4; Brown R.C., 1990, MICROSPORES EVOLUTIO, P55; Droste H.H., 1997, GEOARABIA, V2, P419; Edwards D, 1999, BOT J LINN SOC, V130, P111, DOI 10.1006/bojl.1998.0243; EDWARDS D, 1995, NATURE, V374, P635, DOI 10.1038/374635a0; Edwards D, 1996, REV PALAEOBOT PALYNO, V90, P159, DOI 10.1016/0034-6667(95)00081-X; EDWARDS D, 1980, NATURE, V287, P41, DOI 10.1038/287041a0; EDWARDS D, 1995, NATURE, V377, P329, DOI 10.1038/377329a0; Edwards D., 2001, PLANTS INVADE LAND E, P3; Graham L, 1993, ORIGIN LAND PLANTS; GRAY J, 1971, SCIENCE, V173, P918, DOI 10.1126/science.173.4000.918; GRAY J, 1985, PHILOS T ROY SOC B, V309, P167, DOI 10.1098/rstb.1985.0077; Kenrick P, 2000, PHILOS T R SOC B, V355, P847, DOI 10.1098/rstb.2000.0619; Kenrick P., 1997, ORIGIN EARLY DIVERSI; Kroken SB, 1996, AM J BOT, V83, P1241, DOI 10.2307/2446108; MOHIUDDIN U, THESIS U SHEFFIELD; Nickrent DL, 2000, MOL BIOL EVOL, V17, P1885, DOI 10.1093/oxfordjournals.molbev.a026290; Pacini E, 1990, MICROSPORES EVOLUTIO, P213, DOI DOI 10.1016/B978-0-12-103458-0.50014-6; Qiu YL, 2000, J PHYCOL, V36, P799, DOI 10.1046/j.1529-8817.2000.03653.x; Richardson J. B., 1988, SUBSURFACE PALYNOSTR, P89; Steemans P, 1999, GEOBIOS-LYON, V32, P341, DOI 10.1016/S0016-6995(99)80048-5; Strother PK, 1996, GEOLOGY, V24, P55, DOI 10.1130/0091-7613(1996)024<0055:NEFLPF>2.3.CO;2; Taylor WA, 2002, REV PALAEOBOT PALYNO, V119, P325, DOI 10.1016/S0034-6667(01)00136-1; TAYLOR WA, 1995, NATURE, V373, P391, DOI 10.1038/373391b0; Wellman CH, 2000, PHILOS T R SOC B, V355, P717, DOI 10.1098/rstb.2000.0612; Wellman CH, 1998, PHILOS T ROY SOC B, V353, P1983, DOI 10.1098/rstb.1998.0349; Wellman CH, 1998, BOT J LINN SOC, V127, P117, DOI 10.1111/j.1095-8339.1998.tb02092.x	27	385	413	0	170	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					282	285		10.1038/nature01884	http://dx.doi.org/10.1038/nature01884			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679913	Green Accepted			2022-12-28	WOS:000185370900041
J	Hennessy, S; Bilker, WB; Zhou, L; Weber, AL; Brensinger, C; Wang, YL; Strom, BL				Hennessy, S; Bilker, WB; Zhou, L; Weber, AL; Brensinger, C; Wang, YL; Strom, BL			Retrospective drug utilization review, prescribing errors, and clinical outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICARE BENEFICIARIES; INTERVENTION; DATABASES; DISEASE	Context Retrospective drug utilization review is required of all state Medicaid programs and is performed by most private-sector prescription programs. However, it has not been shown to improve clinical outcomes or reduce the rate of potential prescribing errors, known as "exceptions." Objective To look for an effect of retrospective drug utilization review on the rate of exceptions and of clinical outcomes in patients with an exception. Design, Setting, and Participants Longitudinal ecologic study of the rate of exceptions, controlling for preintervention trends and calendar time; and a cohort study of all-cause and cause-specific hospitalizations in patients with an exception, controlling for potential individual-level confounders in 6 Medicaid programs using the same software in the mid-1990s. Main Outcome Measures The rate of exceptions was examined as a function of retrospective drug utilization review implementation. In addition, before-after comparisons were made of the incidence of all-cause and cause-specific hospitalization in patients with exceptions. Results We found no reduction in the rate of exceptions coincident with retrospective drug utilization review implementation (rate increase, 0.064 exceptions per 1000 prescriptions per month; 95% confidence interval [CI], -0.006 to 0.133). We also found no effect of retrospective drug utilization review on the incidence of all-cause hospitalization (odds ratio, 0.99; 95% Cl, 0.98-1.00) or cause-specific hospitalization. These results persisted in multiple subgroup analyses. Study states intervened using physician alerts in between 1% and 25% of exceptions. Conclusions We were unable to identify an effect of retrospective drug utilization review on the rate of exceptions or on clinical outcomes. Given the lack of evidence for effectiveness, and suggestions from previous research of possible harm, policy-makers should consider withdrawing the legislative mandate for retrospective drug utilization review.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Hennessy, S (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, 803 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.		Bilker, Warren/AAS-3515-2021		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG000987, R01AG014601] Funding Source: NIH RePORTER; AHRQ HHS [U18-HS10399] Funding Source: Medline; NIA NIH HHS [1K23AG000987, 1R01 AG14601] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*ABT ASS INC, 1998, EV DRUG US REV DEM P; Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Carson JL, 2000, PHARMACOEPIDEM DR S, P307; CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; Coleman CI, 2003, AM J HEALTH-SYST PH, V60, P1142, DOI 10.1093/ajhp/60.11.1142; Hennessey S, 2000, PHARMACOEPIDEM DR S, P505; Hennessy S, 2003, PHARMACOEPIDEM DR S, V12, P103, DOI 10.1002/pds.765; JAY DE, 1991, MED CAL THERAPEUTIC; Kleinbaum D. G., 1998, APPL REGRESSION ANAL; Krumholz HM, 1998, J AM COLL CARDIOL, V31, P957, DOI 10.1016/S0735-1097(98)00106-5; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Raiford DS, 1996, EPIDEMIOLOGY, V7, P101, DOI 10.1097/00001648-199601000-00018; Ray WA, 1997, ANN INTERN MED, V127, P712, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00055; Smith DH, 1998, MED CARE, V36, P1013, DOI 10.1097/00005650-199807000-00008; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; STROM BL, 1995, AM J MED, V99, P282, DOI 10.1016/S0002-9343(99)80161-2; STROM BL, 1990, EPIDEMIOL REV, V12, P87, DOI 10.1093/oxfordjournals.epirev.a036064; Strom BL, 1997, ARCH INTERN MED, V157, P2626, DOI 10.1001/archinte.157.22.2626; *US CTR MED MED SE, MED DUALL EL POP; *US CTR MED MED SE, MED ENR BEN SEL FISC; West SL, 2000, PHARMACOEPIDEMIOLOGY, V3rd edn, P661; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; ZIMMERMAN DR, 1994, INQUIRY-J HEALTH CAR, V31, P89; 1969, FINAL REPORT TASK FO	27	38	40	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1494	1499		10.1001/jama.290.11.1494	http://dx.doi.org/10.1001/jama.290.11.1494			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RE	13129990				2022-12-28	WOS:000185329000032
J	Huynen, L; Millar, CD; Scofield, RP; Lambert, DM				Huynen, L; Millar, CD; Scofield, RP; Lambert, DM			Nuclear DNA sequences detect species limits in ancient moa	NATURE			English	Article							MITOCHONDRIAL-DNA; GENOME SEQUENCES; SEX; BIRDS; GENE	Ancient DNA studies have typically used multi-copy mitochondrial DNA sequences(1,2). This is largely because single-locus nuclear genes have been difficult to recover from sub-fossil material(3), restricting the scope of ancient DNA research. Here, we have isolated single-locus nuclear DNA markers to assign the sex of 115 extinct moa and, in combination with a mitochondrial DNA phylogeny, tested competing hypotheses about the specific status of moa taxa. Moa were large ratite birds that showed extreme size variation both within and among species(4). For some taxa, this large variation was hypothesized to represent sexual dimorphism, while for others it was argued to reflect the existence of different species(5). Our results show that moa were characterized by extreme reverse sexual dimorphism and as a result we have been able to clarify the number of moa species. For example, we show that the three recognized 'species' of Dinornis comprised only two monophyletic groups and that two of these 'species' comprised individuals of one sex only. This study also illustrates that single-locus nuclear DNA sequences can be consistently recovered from ancient material.	Univ Auckland, Sch Biol Sci, Allan Wilson Ctr Mol Ecol & Evolut, Auckland 1, New Zealand; Canterbury Museum, Christchurch 8001, New Zealand	Massey University; University of Auckland	Lambert, DM (corresponding author), Massey Univ, Inst Mol Biosci, Allan Wilson Ctr Mol Ecol & Evolut, Private Bag 102 904, Palmerston North, New Zealand.	D.M.Lambert@massey.ac.nz	Scofield, R. Paul/A-4271-2011	Scofield, R. Paul/0000-0002-7510-6980; Lambert, David/0000-0002-5821-3637				ANDERSON AJ, 1989, PRODIGIIOUS BIRDS MO; ANSARI HA, 1988, CYTOGENET CELL GENET, V47, P185, DOI 10.1159/000132545; Asfaw B, 2002, NATURE, V416, P317, DOI 10.1038/416317a; Clinton M, 1999, CELL MOL LIFE SCI, V55, P876, DOI 10.1007/s000180050341; Cooper A, 1998, CURR OPIN BIOTECH, V9, P49, DOI 10.1016/S0958-1669(98)80083-9; Cooper A, 2001, NATURE, V409, P704, DOI 10.1038/35055536; Cooper Alan, 1997, P345, DOI 10.1016/B978-012498315-1/50019-4; Cracraft J., 1976, Smithsonian Contributions to Paleobiology, VNo. 27, P189; Ellegren H, 1996, P ROY SOC B-BIOL SCI, V263, P1635, DOI 10.1098/rspb.1996.0239; GRIFFITHS R, 1995, NATURE, V375, P454, DOI 10.1038/375454a0; Griffiths R, 1998, MOL ECOL, V7, P1071, DOI 10.1046/j.1365-294x.1998.00389.x; Haddrath O, 2001, P ROY SOC B-BIOL SCI, V268, P939, DOI 10.1098/rspb.2001.1587; HERMANN B, 1993, ANCIENNT DNA; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; Hofreiter M, 2001, NAT REV GENET, V2, P353, DOI 10.1038/35072071; Holdaway RN, 2000, SCIENCE, V287, P2250, DOI 10.1126/science.287.5461.2250; Huynen L, 2002, MOL ECOL, V11, P851, DOI 10.1046/j.1365-294X.2002.01483.x; Lambert DM, 2002, SCIENCE, V295, P2270, DOI 10.1126/science.1068105; Leonard JA, 2002, SCIENCE, V298, P1613, DOI 10.1126/science.1076980; Owen R., 1839, P ZOOL SOC LOND, V7, P169; PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2; Polack J. S., 1838, NZ BEING NARRATIVE T, V1; PRANGE HD, 1979, AM NAT, V113, P103, DOI 10.1086/283367; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; Taberlet P, 1999, BIOL J LINN SOC, V68, P41, DOI 10.1111/j.1095-8312.1999.tb01157.x; Taberlet P, 1996, NUCLEIC ACIDS RES, V24, P3189, DOI 10.1093/nar/24.16.3189; Wiens JJ, 2002, SYST BIOL, V51, P69, DOI 10.1080/106351502753475880; Worthy T.H., 1988, NATL MUSEUM NZ MISCE, V17, P1; Worthy T. H., 2002, LOST WORLD MOA PREHI	30	96	100	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					175	178		10.1038/nature01838	http://dx.doi.org/10.1038/nature01838			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968179				2022-12-28	WOS:000185236000041
J	Rao, VR; Finkbeiner, S				Rao, VR; Finkbeiner, S			Secrets of a secretase: N-cadherin proteolysis regulates CBP function	CELL			English	Editorial Material							APP	Presenilin (PS-1) is part of the protease gamma-secretase that cleaves the membrane proteins APP and Notch. In this issue of Cell, Marambaud et al. report that PS-1 cleaves the cell adhesion molecule N-cadherin, releasing a C-terminal fragment that promotes degradation of the transcriptional coactivator CBP. Mutations in PS-1 associated with Alzheimer's disease interfere with CBP proteolysis, leading to abnormal transcription.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, Dept Neurol, San Francisco, CA 94103 USA; Univ Calif San Francisco, Gladstone Inst Neurol Dis, Dept Physiol, San Francisco, CA 94103 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes	Rao, VR (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, Dept Neurol, San Francisco, CA 94103 USA.							Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159	7	4	4	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					533	535		10.1016/S0092-8674(03)00686-X	http://dx.doi.org/10.1016/S0092-8674(03)00686-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678577	Bronze			2022-12-28	WOS:000185193100003
J	Berman, DM; Karhadkar, SS; Maitra, A; de Oca, RM; Gerstenblith, MR; Briggs, K; Parker, AR; Shimada, Y; Eshleman, JR; Watkins, DN; Beachy, PA				Berman, DM; Karhadkar, SS; Maitra, A; de Oca, RM; Gerstenblith, MR; Briggs, K; Parker, AR; Shimada, Y; Eshleman, JR; Watkins, DN; Beachy, PA			Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours	NATURE			English	Article							INHIBITION; PATHWAY; CANCER; MOUSE; MEDULLOBLASTOMA; CARCINOGENESIS; CYCLOPAMINE; MODULATION; SIGNALS	Activation of the Hedgehog (Hh) signalling pathway by sporadic mutations or in familial conditions such as Gorlin's syndrome is associated with tumorigenesis in skin, the cerebellum and skeletal muscle(1,2). Here we show that a wide range of digestive tract tumours, including most of those originating in the oesophagus, stomach, biliary tract and pancreas, but not in the colon, display increased Hh pathway activity, which is suppressible by cyclopamine, a Hh pathway antagonist. Cyclopamine also suppresses cell growth in vitro and causes durable regression of xenograft tumours in vivo. Unlike in Gorlin's syndrome tumours, pathway activity and cell growth in these digestive tract tumours are driven by endogenous expression of Hh ligands, as indicated by the presence of Sonic hedgehog and Indian hedgehog transcripts, by the pathway- and growth-inhibitory activity of a Hh-neutralizing antibody, and by the dramatic growth-stimulatory activity of exogenously added Hh ligand. Our results identify a group of common lethal malignancies in which Hh pathway activity, essential for tumour growth, is activated not by mutation but by ligand expression.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; Kyoto Univ, Dept Surg, Kyoto 6068507, Japan	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Kyoto University	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.		Karhadkar, Sunil/Y-9235-2019; Watkins, David N/I-6113-2013; berman, david/HIR-4177-2022	Karhadkar, Sunil/0000-0001-7943-0203; berman, david/0000-0001-5985-3698				Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Chen XX, 2001, CARCINOGENESIS, V22, P1119, DOI 10.1093/carcin/22.8.1119; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hebrok M, 2003, MECH DEVELOP, V120, P45, DOI 10.1016/S0925-4773(02)00331-3; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Lowenfels AB, 2002, HEMATOL ONCOL CLIN N, V16, P1, DOI 10.1016/S0889-8588(01)00003-X; Peek RM, 2002, J GASTROENTEROL, V37, P10, DOI 10.1007/BF02990093; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; van den Brink GR, 2001, GASTROENTEROLOGY, V121, P317, DOI 10.1053/gast.2001.26261; Wang LC, 2000, J INVEST DERMATOL, V114, P901, DOI 10.1046/j.1523-1747.2000.00951.x; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385	23	1056	1168	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					846	851		10.1038/nature01972	http://dx.doi.org/10.1038/nature01972			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14520411				2022-12-28	WOS:000186118500047
J	Karst, M; Salim, K; Burstein, S; Conrad, I; Hoy, L; Schneider, U				Karst, M; Salim, K; Burstein, S; Conrad, I; Hoy, L; Schneider, U			Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AJULEMIC ACID; DELTA-9-TETRAHYDROCANNABINOL; MARIJUANA; TRAIL; CT3	Context 1',1'Dimethylheptyl-Delta(8)-tetrahydrocannabinol-11-oic acid (CT-3), a potent analog of THC-11-oic acid, produces marked antiallodynic and analgesic effects in. animals without evoking the typical effects described in models of cannabinoids. Therefore, CT-3 may be an effective analgesic for poorly controlled resistant neuropathic pain. Objective To examine the analgesic efficacy and safety of CT-3 in chronic neuropathic pain in humans. Design and Setting Randomized, placebo-controlled, double-blind crossover trial conducted in Germany from May-September 2002. Participants Twenty-one patients (8 women and 13 men) aged 29 to 65 years (mean, 51 years) who had a clinical presentation and examination consistent with chronic neuropathic pain (for at least 6 months) with hyperalgesia (n=21) and allodynia (n=7). Interventions Patients were randomized to two 7-day treatment orders in a crossover design. Two daily doses of CT-3 (four 10-mg capsules per day) or identical placebo capsules were given during the first 4 days and 8 capsules per day were given in 2 daily doses in the following 3 days. After a washout and baseline period of 1 week each, patients crossed over to the second 7-day treatment period. Main Outcome Measures Visual analog scale (VAS) and verbal rating scale scores for pain; vital sign, hematologic and blood chemistry, and electrocardiogram measurements; scores on the Trail-Making Test and the Addiction Research Center Inventory-Marijuana scale; and adverse effects. Results The mean differences overtime for the VAS values in the CT-3-placebo sequence measured 3 hours after intake of study drug differed significantly from those in the placebo-CT-3 sequence (mean. [SD], -11.54 [14.16] vs 9.86 [21.43]; P=.02). Eight hours after intake of the drug, the pain scale differences between groups were less marked. No dose response was observed. Adverse effects, mainly transient dry mouth and tiredness, were reported significantly more often during CT-3 treatment (mean LSD] difference, -0.67 [0.50] for CT-3-placebo sequence vs 0.10 [0.74] for placebo-CT-3 sequence; P=.02). There were no significant differences with respect to vital signs, blood tests, electrocardiogram, Trail-Making Test, and Addiction Research Center Inventory-Marijuana scale. No carryover or period effects were observed except on the Trail-Making Test. Conclusions In this preliminary study, CT-3 was effective in reducing chronic neuropathic pain compared with placebo. No major adverse effects were observed.	Hannover Med Sch, Dept Anesthesiol, Pain Clin, D-30623 Hannover, Germany; Hannover Med Sch, Dept Biometr, D-30623 Hannover, Germany; Hannover Med Sch, Dept Clin Psychiat & Psychotherapy, D-30623 Hannover, Germany; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA USA	Hannover Medical School; Hannover Medical School; Hannover Medical School; University of Massachusetts System; University of Massachusetts Worcester	Karst, M (corresponding author), Hannover Med Sch, Dept Anesthesiol, Pain Clin, D-30623 Hannover, Germany.							Ashton CH, 1999, BRIT J ANAESTH, V83, P637, DOI 10.1093/bja/83.4.637; BRADLEY DA, 1992, IFAC WORKSHOP MOTION, P45; Burstein SH, 1998, LIFE SCI, V63, P161, DOI 10.1016/S0024-3205(98)00256-2; Burstein SH, 2000, CURR PHARM DESIGN, V6, P1339, DOI 10.2174/1381612003399473; Campbell FA, 2001, BMJ-BRIT MED J, V323, P1; CHAIT LD, 1985, DRUG ALCOHOL DEPEN, V15, P229, DOI 10.1016/0376-8716(85)90002-X; GAUDINO EA, 1995, J CLIN EXP NEUROPSYC, V17, P529, DOI 10.1080/01688639508405143; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; Horton AM, 2002, INT J NEUROSCI, V112, P429, DOI 10.1080/00207450290025563; Liu JL, 2003, MOL PHARMACOL, V63, P983, DOI 10.1124/mol.63.5.983; Martin WJ, 1999, PAIN, V82, P199, DOI 10.1016/S0304-3959(99)00045-7; MARTIN WJ, 1999, IASP NEWSLETTER  SUM, P3; MARTIN WR, 1971, CLIN PHARMACOL THER, V12, P245; MAURER M, 1990, EUR ARCH PSY CLIN N, V240, P1, DOI 10.1007/BF02190083; NOYES R, 1975, CLIN PHARMACOL THER, V18, P84; NOYES R, 1975, J CLIN PHARMACOL, V15, P139, DOI 10.1002/j.1552-4604.1975.tb02348.x; Sharpe P, 2000, ANESTH ANALG, V90, P237, DOI 10.1097/00000539-200002000-00001; Tramer MR, 2001, BMJ-BRIT MED J, V323, P16, DOI 10.1136/bmj.323.7303.16; Wachtel SR, 2002, PSYCHOPHARMACOLOGY, V161, P331, DOI 10.1007/s00213-002-1033-2; Weber C, 1998, ANASTH INTENSIV NOTF, V33, P475, DOI 10.1055/s-2007-994794; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0	21	231	251	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1757	1762		10.1001/jama.290.13.1757	http://dx.doi.org/10.1001/jama.290.13.1757			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519710				2022-12-28	WOS:000185606100025
J	Budowle, B; Schutzer, SE; Einseln, A; Kelley, LC; Walsh, AC; Smith, JAL; Marrone, BL; Robertson, J; Campos, J				Budowle, B; Schutzer, SE; Einseln, A; Kelley, LC; Walsh, AC; Smith, JAL; Marrone, BL; Robertson, J; Campos, J			Building microbial forensics as a response to bioterrorism	SCIENCE			English	Editorial Material									Fed Bur Invest, Lab Div, Quantico, VA 22135 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA; USDA, Russell Res Ctr, Athens, GA 30604 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Childrens Natl Med Ctr, Dept Lab Med, Washington, DC 20010 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; United States Department of Agriculture (USDA); State University of New York (SUNY) System; Wadsworth Center; United States Department of Energy (DOE); Los Alamos National Laboratory; Children's National Health System	Budowle, B (corresponding author), Fed Bur Invest, Lab Div, Quantico, VA 22135 USA.							BUDOWLE B, 1995, CRIME LAB DIGEST, V22, P21; BUDOWLE B, IN PRESS MICROBIAL F; Carus WS, 2001, BIOTERRORISM BIOCRIM; *FBI, 1998, QUAL ASS STAND FOR D; Fleming DO., 2000, BIOL SAFETY PRINCIPL; Hawley RJ, 2001, ANNU REV MICROBIOL, V55, P235, DOI 10.1146/annurev.micro.55.1.235; *INT STAND ORG, 1999, ISOIEC17025 AM NAT S; Lederberg J, 2000, SCIENCE, V288, P287, DOI 10.1126/science.288.5464.287; *NAT RES COUNC COM, 2002, MAK NAT SAF ROL SCI; *US DEP HHS, 1999, BIOS MICR BIOM LAB	10	88	98	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1852	1853		10.1126/science.1090083	http://dx.doi.org/10.1126/science.1090083			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512607				2022-12-28	WOS:000185536700029
J	Finkelstein, JS; Hayes, A; Hunzelman, JL; Wyland, JJ; Lee, H; Neer, RM				Finkelstein, JS; Hayes, A; Hunzelman, JL; Wyland, JJ; Lee, H; Neer, RM			The effects of parathyroid hormone, alendronate, or both in men with osteoporosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; RANDOMIZED CONTROLLED TRIAL; GROWTH FACTOR-I; POSTMENOPAUSAL WOMEN; OVARIECTOMIZED RATS; ESTROGEN DEFICIENCY; VERTEBRAL FRACTURES; RESORPTION; MARKERS; MASS	BACKGROUND: Because parathyroid hormone increases both bone formation and bone resorption, it is possible that combining parathyroid hormone with an antiresorptive agent will enhance its effect on bone mineral density. METHODS: We randomly assigned 83 men who were 46 to 85 years of age and had low bone density to receive alendronate (10 mg daily; 28 men), parathyroid hormone (40 microg subcutaneously daily; 27 men), or both (28 men). Alendronate therapy was given for 30 months; parathyroid hormone therapy was begun at month 6. The bone mineral density of the lumbar spine, proximal femur, radial shaft, and total body was measured every six months with the use of dual-energy x-ray absorptiometry. Trabecular bone mineral density of the lumbar spine was measured at base line and month 30 by means of quantitative computed tomography. Serum alkaline phosphatase levels were measured every six months. The primary end point was the rate of change in the bone mineral density at the posteroanterior spine. RESULTS: The bone mineral density at the lumbar spine increased significantly more in men treated with parathyroid hormone alone than in those in the other groups (P<0.001 for both comparisons). The bone mineral density at the femoral neck increased significantly more in the parathyroid hormone group than in the alendronate group (P<0.001) or the combination-therapy group (P=0.01). The bone mineral density of the lumbar spine increased significantly more in the combination-therapy group than in the alendronate group (P<0.001). At 12 months, changes in the serum alkaline phosphatase level were significantly greater in the parathyroid hormone group than in the alendronate group or the combination-therapy group (P<0.001 for both comparisons). CONCLUSIONS: Alendronate impairs the ability of parathyroid hormone to increase the bone mineral density at the lumbar spine and the femoral neck in men. This effect may be attributable to an attenuation of parathyroid hormone-induced stimulation of bone formation by alendronate.	Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Finkelstein, JS (corresponding author), Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Bulfinch 327,55 Fruit St, Boston, MA 02114 USA.		Finkelstein, Joel/M-6463-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR044855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002759] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline; NIAMS NIH HHS [5 P50 AR44855] Funding Source: Medline; NIDDK NIH HHS [K24 DK02759] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUMANN BD, 1995, BONE, V16, P247, DOI 10.1016/8756-3282(94)00036-Y; Bikle DD, 1997, AM J MED, V103, P427, DOI 10.1016/S0002-9343(97)00137-X; Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Body JJ, 2002, J CLIN ENDOCR METAB, V87, P4528, DOI 10.1210/jc.2002-020334; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; Cosman F, 1998, J BONE MINER RES, V13, P1051, DOI 10.1359/jbmr.1998.13.6.1051; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756-3282(95)00113-R; Ettinger B, 2002, J BONE MINER RES, V17, pS157; FINKELSTEIN JS, 1994, NEW ENGL J MED, V331, P1618, DOI 10.1056/NEJM199412153312404; Finkelstein JS, 1998, JAMA-J AM MED ASSOC, V280, P1067, DOI 10.1001/jama.280.12.1067; FINKELSTEIN JS, 1996, PRINCIPLES BONE BIOL, V2, P993; Finkelstein JS, 2000, CECIL TXB MED, P1366; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110; HOCK JM, 1989, J BONE MINER RES, V4, P449; Hodsman AB, 1997, J CLIN ENDOCR METAB, V82, P620, DOI 10.1210/jc.82.2.620; HODSMAN AB, 1991, BONE MINER, V14, P67, DOI 10.1016/0169-6009(91)90103-7; Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; Ma YFL, 2003, ENDOCRINOLOGY, V144, P2008, DOI 10.1210/en.2002-221061; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; Melton 3rd LJ, 1999, OSTEOPOROSIS MEN EFF, V1 st, P1, DOI [10.1016/B978-012528640-4/50002-2, DOI 10.1016/B978-012528640-4/50002-2]; Neer R, 2002, J BONE MINER RES, V17, pS135; NEER R, 1990, OSTEOPOROSIS 1990, V3, P1314; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9; Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902; Ringe JD, 2001, J CLIN ENDOCR METAB, V86, P5252, DOI 10.1210/jc.86.11.5252; Roe EB, 1999, J BONE MINER RES, V14, pS137; ROSENTHAL DI, 1985, INVEST RADIOL, V20, P306, DOI 10.1097/00004424-198505000-00014; SLOVIK DM, 1986, J BONE MINER RES, V1, P377; Taylor A, 1997, J BONE MINER RES, V12, P652, DOI 10.1359/jbmr.1997.12.4.652; WRONSKI TJ, 1993, ENDOCRINOLOGY, V132, P823, DOI 10.1210/en.132.2.823	37	576	611	0	13	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2003	349	13					1216	1226		10.1056/NEJMoa035725	http://dx.doi.org/10.1056/NEJMoa035725			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LJ	14500805	Bronze			2022-12-28	WOS:000185488800004
J	Fitzgerald, DW; Pape, JW; Wasserheit, JN; Counts, GW; Corey, L				Fitzgerald, DW; Pape, JW; Wasserheit, JN; Counts, GW; Corey, L			Provision of treatment in HIV-1 vaccine trials in developing countries	LANCET			English	Editorial Material							AIDS		HVTN, Seattle, WA 98109 USA		Fitzgerald, DW (corresponding author), HVTN, Seattle, WA 98109 USA.							Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; *CIOMS, 2002, INT ETH GUID BIOM RE; UNAIDS and WHO, 2000, ETH CONS HIV PREV VA; World Health Organization, 2002, SCAL ANT THER RES LT	5	26	29	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					993	994		10.1016/S0140-6736(03)14372-3	http://dx.doi.org/10.1016/S0140-6736(03)14372-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	724LT	14513852				2022-12-28	WOS:000185489600025
J	Heckenberger, MJ; Kuikuro, A; Kuikuro, UT; Russell, JC; Schmidt, M; Fausto, C; Franchetto, B				Heckenberger, MJ; Kuikuro, A; Kuikuro, UT; Russell, JC; Schmidt, M; Fausto, C; Franchetto, B			Amazonia 1492: Pristine forest or cultural parkland?	SCIENCE			English	Article							LANDSCAPE; SCALE	Archaeology and indigenous history of Native Amazonian peoples in the Upper Xingu region of Brazil reveal unexpectedly complex regional settlement patterns and large-scale transformations of local landscapes over the past millennium. Mapping and excavation of archaeological structures document pronounced human-induced alteration of the forest cover, particularly in relation to large, dense late-prehistoric settlements ( circa 1200 to 1600 A. D.). The findings contribute to debates on human carrying capacity, population size and settlement patterns, anthropogenic impacts on the environment, and the importance of indigenous knowledge, as well as contributing to the pride of place of the native peoples in this part of the Amazon.	Univ Florida, Dept Anthropol, Gainesville, FL 32611 USA; Univ Florida, Land Use & Environm Change Inst, Gainesville, FL 32611 USA; Univ Florida, Dept Geog, Gainesville, FL 32611 USA; Associacao Indigena kuikuro Alto Xingu, Parque Indigena Xingu, Mato Grosso, Brazil; Univ Fed Rio de Janeiro, Museu nacl, Dept Anthropol, BR-20940040 Rio De Janeiro, Brazil	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Universidade Federal do Rio de Janeiro	Heckenberger, MJ (corresponding author), Univ Florida, Dept Anthropol, Gainesville, FL 32611 USA.	mheckenb@anthro.ufl.edu	Fausto, Carlos/I-4550-2013	Fausto, Carlos/0000-0002-0617-6643				Balee W., 1989, Advances in Economic Botany, V7, P1; CARNEIRO R, 1957, SUBSISTENCE SOCIAL S; Carneiro R., 1984, ADAPTIVE RESPONSES N, P65, DOI [10.1016/B978-0-12-321250-4.50007-5, DOI 10.1016/B978-0-12-321250-4.50007-5]; Denevan W.M., 1992, J STEWARD ANTHR SOC, V20, P153; Denevan William M., 2001, CULTIVATED LANDSCAPE; DENEVAN WM, 1992, ANN ASSOC AM GEOGR, V82, P369, DOI 10.1111/j.1467-8306.1992.tb01965.x; Erickson CL, 2000, NATURE, V408, P190, DOI 10.1038/35041555; HECKENBERGER M, 2001, COMP ARAWAK HIST RET, P99; HECKENBERGER M, 2001, OS POVOS INDIGENAS A, P77; Heckenberger MJ, 1998, ANTIQUITY, V72, P633, DOI 10.1017/S0003598X00087056; Heckenberger MJ, 1999, LAT AM ANTIQ, V10, P353, DOI 10.2307/971962; Lathrap DW, 1970, UPPER AMAZON; Mann CC, 2000, SCIENCE, V287, P786, DOI 10.1126/science.287.5454.786; MANN CC, 2002, ATLANTIC MONTHLY MAR, P41; METRAUX A, 1948, B BUR AM ETHNOL, V143, P349; Peterson J.B., 2001, UNKNOWN AMAZON CULTU, P86; Roosevelt AC., 1999, ARCHEOLOGICAL PAPERS, V9, P2, DOI DOI 10.1525/AP3A.1999.9.1.13; Smith N.J.H., 1995, AMAZONIA RESILIENCY; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; TAMBIAH S, 1985, RITUAL PERFORMANCE T; Woods W.I., 1999, YB C LAT AM GEOGR, V25, P7; 2002, AM BROADCASTING 0919; 2002, BRIT BROADCASTI 1219	23	310	332	3	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1710	1714		10.1126/science.1086112	http://dx.doi.org/10.1126/science.1086112			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500979				2022-12-28	WOS:000185387700041
J	Yuan, JP; Kiselyov, K; Shin, DM; Chen, J; Shcheynikov, N; Kang, SH; Dehoff, MH; Schwarz, MK; Seeburg, PH; Muallem, S; Worley, PF				Yuan, JP; Kiselyov, K; Shin, DM; Chen, J; Shcheynikov, N; Kang, SH; Dehoff, MH; Schwarz, MK; Seeburg, PH; Muallem, S; Worley, PF			Homer binds TRPC family channels and is required for gating of TRPC1 by IP3 receptors	CELL			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; OPERATED HTRP3 CHANNELS; PROLINE-RICH MOTIF; EVH1 DOMAIN; PROTEINS; CELLS; CALCIUM; COMPLEX; ASSOCIATION	Receptor signaling at the plasma membrane often releases calcium from intracellular stores. For example, inositol triphosphate (IP3) produced by receptor-coupled phospholipase C activates an intracellular store calcium channel, the IP3R. Conversely, stores can induce extracellular calcium to enter the cell through plasma membrane channels, too. How this "reverse" coupling works was unclear, but store IP(3)Rs were proposed to bind and regulate plasma membrane TRIP cation channels. Here, we demonstrate that the adaptor protein, termed Homer, facilitates a physical association between TRPC1 and the IP3R that is required for the TRP channel to respond to signals. The TRPC1-Homer-IP3R complex is dynamic and its disassembly parallels TRPC1 channel activation. Homer's action depends on its ability to crosslink and is blocked by the dominant-negative immediate early gene form, H1a. Since H1a is transcriptionally regulated by cellular activity, this mechanism can affect both short and long-term regulation of TRPC1 function.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Yonsei Univ, Dept Oral Biol, Brain Korea 21 Project Med Sci, Seoul 120752, South Korea; Max Planck Inst Med Res, Dept Mol Neurobiol, D-69120 Heidelberg, Germany	Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yonsei University; Max Planck Society	Worley, PF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	shmuel.muallem@utsouthwestern.edu; pworley@jhmi.edu		Shin, Dong Min/0000-0001-6042-0435; Kiselyov, Kirill/0000-0001-6683-2895				Baltensperger H, 1997, J BIOL CHEM, V272, P10151; Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; FAGNI L, 2002, SCI STKE; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Irie K, 2002, J MOL BIOL, V318, P1117, DOI 10.1016/S0022-2836(02)00170-5; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Klingelhofer J, 2003, ONCOGENE, V22, P1181, DOI 10.1038/sj.onc.1206245; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C., 2001, SCI STKE; Nucifora FC, 1996, MOL BIOL CELL, V7, P949, DOI 10.1091/mbc.7.6.949; Putney JW, 2001, NATURE, V410, P648, DOI 10.1038/35070704; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Shin DM, 2003, J CELL BIOL, V162, P293, DOI 10.1083/jcb.200210109; Soloviev MM, 2000, EUR J BIOCHEM, V267, P634, DOI 10.1046/j.1432-1327.2000.01078.x; Soloviev MM, 2000, J MOL BIOL, V295, P1185; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Vaca L, 2002, J BIOL CHEM, V277, P42178, DOI 10.1074/jbc.M204531200; Vazdarjanova A, 2002, J NEUROSCI, V22, P10067; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Vennekens R, 2002, CELL CALCIUM, V31, P253, DOI 10.1016/S0143-4160(02)00055-6; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8	33	399	417	1	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					777	789		10.1016/S0092-8674(03)00716-5	http://dx.doi.org/10.1016/S0092-8674(03)00716-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505576	Bronze			2022-12-28	WOS:000185464000014
J	Sinclair, ARE; Mduma, S; Brashares, JS				Sinclair, ARE; Mduma, S; Brashares, JS			Patterns of predation in a diverse predator-prey system	NATURE			English	Article							TROPHIC CASCADES; BOTTOM-UP; FOOD WEBS; TOP-DOWN; COMPETITION; COMMUNITY; HETEROGENEITY; ECOSYSTEM	There are many cases where animal populations are affected by predators and resources in terrestrial ecosystems(1-3),but the factors that determine when one or the other predominates remain poorly understood(4-5). Here we show, using 40 years of data from the highly diverse mammal community of the Serengeti ecosystem, East Africa, that the primary cause of mortality for adults of a particular species is determined by two factors-the species diversity of both the predators and prey and the body size of that prey species relative to other prey and predators. Small ungulates in Serengeti are exposed to more predators, owing to opportunistic predation, than are larger ungulates; they also suffer greater predation rates, and experience strong predation pressure. A threshold occurs at prey body sizes of similar to150 kg, above which ungulate species have few natural predators and exhibit food limitation. Thus, biodiversity allows both predation (top-down) and resource limitation (bottom-up) to act simultaneously to affect herbivore populations. This result may apply generally in systems where there is a diversity of predators and prey.	Univ British Columbia, Ctr Biodivers Res, Vancouver, BC V6T 1Z4, Canada; Tanzania Wildlife Res Inst, Arusha, Tanzania	University of British Columbia	Sinclair, ARE (corresponding author), Univ British Columbia, Ctr Biodivers Res, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.							[Anonymous], 1999, WALKERS MAMMALS WORL; Bertram B. C. B., 1979, SERENGETI DYNAMICS E, P221; BRASHARES JS, IN PRESS MAMMALS AFR; BROTEN M, 1995, SERENGETI, V2, P169; CAMPBELL K, 1995, SERENGETI, V2, P117; Dunne JA, 2002, ECOL LETT, V5, P558, DOI 10.1046/j.1461-0248.2002.00354.x; Dyer LA, 2003, ECOL LETT, V6, P60, DOI 10.1046/j.1461-0248.2003.00398.x; Dyer LA, 1999, P NATL ACAD SCI USA, V96, P5072, DOI 10.1073/pnas.96.9.5072; ELLIOTT JP, 1977, CAN J ZOOL, V55, P1811, DOI 10.1139/z77-235; HAIRSTON NG, 1960, AM NAT, V94, P421, DOI 10.1086/282146; Heinisch O., 1963, PREIS S BIOM J, V1965, P203, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; Hofer H., 1995, SERENGETI, P332, DOI DOI 10.1186/1471-2148-9-253; HUNTER MD, 1992, ECOLOGY, V73, P724; JOLLY G M, 1969, East African Agricultural and Forestry Journal, V34, P46; Kruuk H., 1972, SPOTTED HYENA STUDY; LAMPRECHT J, 1978, Z SAUGETIERKD, V43, P210; Mduma SAR, 1999, J ANIM ECOL, V68, P1101, DOI 10.1046/j.1365-2656.1999.00352.x; MDUMA SAR, 1995, SERENGETI, V2, P220; Persson L, 1999, OIKOS, V85, P385, DOI 10.2307/3546688; Polis GA, 1999, OIKOS, V86, P3, DOI 10.2307/3546565; Post E, 1999, NATURE, V401, P905, DOI 10.1038/44814; Schaller G. B., 1972, SERENGETI LION STUDY; Scheel, 1995, SERENGETI; Schoener TW, 1996, NATURE, V381, P691, DOI 10.1038/381691a0; Sinclair A. R. E., 1979, SERENGETI DYNAMICS E, P82; Sinclair A.R.E., 1979, SERENGETI DYNAMICS E; Sinclair ARE, 2000, OIKOS, V89, P313, DOI 10.1034/j.1600-0706.2000.890213.x; SINCLAIR ARE, 1985, J ANIM ECOL, V54, P899, DOI 10.2307/4386; SINCLAIR ARE, 1995, SERENGETI, V2, P194; Terborgh J, 2001, SCIENCE, V294, P1923, DOI 10.1126/science.1064397	30	526	537	4	314	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					288	290		10.1038/nature01934	http://dx.doi.org/10.1038/nature01934			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679915				2022-12-28	WOS:000185370900043
J	Higginson, I				Higginson, I			For and against - Doctors should not discuss resuscitation with terminally ill patients - Against	BRITISH MEDICAL JOURNAL			English	Article							CARE; PHYSICIANS; LIFE; COMMUNICATION; PREFERENCES; CANCER; END		Kings Coll London, Weston Educ Ctr, Dept Palliat Care & Policy, London SE5 9RJ, England	University of London; King's College London	Higginson, I (corresponding author), Kings Coll London, Weston Educ Ctr, Dept Palliat Care & Policy, London SE5 9RJ, England.	irene.higginson@kcl.ac.uk	Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313				Davies E, 2003, SUPPORT CARE CANCER, V11, P21, DOI 10.1007/s00520-002-0392-x; Edmonds P, 2003, CLIN MED, V3, P149, DOI 10.7861/clinmedicine.3-2-149; Fallowfield LJ, 2002, PALLIATIVE MED, V16, P297, DOI 10.1191/0269216302pm575oa; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; GYSELS M, 2003, IMPROVING SUPPORTIVE; Koffman J, 2001, PALLIATIVE MED, V15, P337, DOI 10.1191/026921601678320322; MURRAY E, 2001, BRIT MED J, V323, P496; *NAT CANC RES I, 2002, STRAT AN 2002 OV CAN; Perron NJ, 2002, SWISS MED WKLY, V132, P562; Silvestri G, 1998, BRIT MED J, V317, P771, DOI 10.1136/bmj.317.7161.771; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; Teno JM, 1998, J GEN INTERN MED, V13, P439, DOI 10.1046/j.1525-1497.1998.00132.x	12	12	13	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					615	616		10.1136/bmj.327.7415.615	http://dx.doi.org/10.1136/bmj.327.7415.615			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969935	Green Published			2022-12-28	WOS:000185358700031
J	Bayley, O				Bayley, O			Improvement of sexual and reproductive health requires focusing on adolescents	LANCET			English	Article									UCL, Int Hlth & Med Educ Ctr, London WC1E 6BT, England	University of London; University College London	Bayley, O (corresponding author), 19 Shelley St, Leicester LE2 3EH, Leics, England.	koib1@le.ac.uk						MPANGILE GS, 1993, REPROD HEALTH MATTER, V1, P21; Singh S, 1998, STUD FAMILY PLANN, V29, P117, DOI 10.2307/172154; *UNPF, 1999, ANN REP 1999; *WHO, 1998, 2 DEC IMPR AD HLTH D; World Health Organization, 1998, WORLD HLTH DAY SAF M	5	8	8	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2003	362	9386					830	831		10.1016/S0140-6736(03)14281-X	http://dx.doi.org/10.1016/S0140-6736(03)14281-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	719DN	13678884				2022-12-28	WOS:000185188500029
J	Whitney, D; Goltz, HC; Thomas, CG; Gati, JS; Menon, RS; Goodale, MA				Whitney, D; Goltz, HC; Thomas, CG; Gati, JS; Menon, RS; Goodale, MA			Flexible retinotopy: Motion-dependent position coding in the visual cortex	SCIENCE			English	Article							PERCEIVED POSITION; STRIATE CORTEX; ATTENTION; REPRESENTATION; PERCEPTION; FIELD; OBJECTS; MONKEYS; NEURONS; HUMANS	Although the visual cortex is organized retinotopically, it is not clear whether the cortical representation of position necessarily reflects perceived position. Using functional magnetic resonance imaging (fMRI), we show that the retinotopic representation of a stationary object in the cortex was systematically shifted when visual motion was present in the scene. Whereas the object could appear shifted in the direction of the visual motion, the representation of the object in the visual cortex was always shifted in the opposite direction. The results show that the representation of position in the primary visual cortex, as revealed by fMRI, can be dissociated from perceived location.	Univ Western Ontario, Dept Psychol, London, ON N6A 5C2, Canada; John P Robarts Res Inst, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Whitney, D (corresponding author), Univ Western Ontario, Dept Psychol, London, ON N6A 5C2, Canada.		Menon, Ravi/ABA-8654-2020; Goodale, Melvyn A/M-5907-2013; Menon, Ravi S/K-5500-2013; Gati, Joseph S/K-5476-2013	Menon, Ravi/0000-0002-7916-0263; Goodale, Melvyn A/0000-0001-6748-0561; Menon, Ravi S/0000-0002-7916-0263; Thomas, Christopher/0000-0002-5209-8797; Goltz, Herbert/0000-0002-6496-754X	NATIONAL EYE INSTITUTE [F32EY013899] Funding Source: NIH RePORTER; NEI NIH HHS [F32 EY013899-01, F32 EY013899, F32 EY013899-03, F32 EY013899-02] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BATTAGLINI PP, 1993, ARCH ITAL BIOL, V131, P303; Berry MJ, 1999, NATURE, V398, P334, DOI 10.1038/18678; BEX PJ, 1995, VISION RES, V35, P2539, DOI 10.1016/0042-6989(95)00060-D; Brefczynski JA, 1999, NAT NEUROSCI, V2, P370, DOI 10.1038/7280; BURR D, 1980, NATURE, V284, P164, DOI 10.1038/284164a0; CAVANAGH P, 1992, SCIENCE, V257, P1563, DOI 10.1126/science.1523411; DANIEL PM, 1961, J PHYSIOL-LONDON, V159, P203, DOI 10.1113/jphysiol.1961.sp006803; DEVALOIS RL, 1991, VISION RES, V31, P1619, DOI 10.1016/0042-6989(91)90138-U; Fu YX, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-20-j0003.2001; Georgeson MA, 2002, P ROY SOC B-BIOL SCI, V269, P1429, DOI 10.1098/rspb.2002.2029; Kirschfeld K, 1999, VISION RES, V39, P3702, DOI 10.1016/S0042-6989(99)00089-9; LAMME VAF, 1993, NATURE, V363, P541, DOI 10.1038/363541a0; Musseler J, 1998, PERCEPT PSYCHOPHYS, V60, P683, DOI 10.3758/BF03206055; Nishida S, 1999, NATURE, V397, P610, DOI 10.1038/17600; RAMACHAN.VS, 1974, PERCEPTION, V3, P97, DOI 10.1068/p030097; RAMACHANDRAN VS, 1990, PERCEPTION, V19, P611, DOI 10.1068/p190611; Reppas JB, 1997, NATURE, V388, P175, DOI 10.1038/40633; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Snowden RJ, 1998, CURR BIOL, V8, P1343, DOI 10.1016/S0960-9822(07)00567-2; Somers DC, 1999, P NATL ACAD SCI USA, V96, P1663, DOI 10.1073/pnas.96.4.1663; Stasheff SF, 2002, J NEUROPHYSIOL, V88, P1026, DOI 10.1152/jn.2002.88.2.1026; TOOTELL RBH, 1982, SCIENCE, V218, P902, DOI 10.1126/science.7134981; Tootell RBH, 1998, NEURON, V21, P1409, DOI 10.1016/S0896-6273(00)80659-5; Tootell RBH, 1998, P NATL ACAD SCI USA, V95, P811, DOI 10.1073/pnas.95.3.811; Verstraten FAJ, 2000, VISION RES, V40, P3651, DOI 10.1016/S0042-6989(00)00213-3; VIRSU V, 1979, EXP BRAIN RES, V37, P475; Whitaker D, 1999, VISION RES, V39, P2999, DOI 10.1016/S0042-6989(99)00010-3; Whitney D, 2000, NAT NEUROSCI, V3, P954, DOI 10.1038/78878; WILSON JR, 1976, J NEUROPHYSIOL, V39, P512, DOI 10.1152/jn.1976.39.3.512	29	98	98	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					878	881		10.1126/science.1087839	http://dx.doi.org/10.1126/science.1087839			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14500849	Green Accepted			2022-12-28	WOS:000186258000053
J	He, K; Merchant, A; Rimin, EB; Rosner, BA; Starripler, M; Willett, WC; Ascherio, A				He, K; Merchant, A; Rimin, EB; Rosner, BA; Starripler, M; Willett, WC; Ascherio, A			Dietary fat intake and risk of stroke in male US healthcare professionals: 14 year prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							FOOD FREQUENCY QUESTIONNAIRE; CORONARY-HEART-DISEASE; UNITED-STATES; CHOLESTEROL; ACID; MEN; ATHEROSCLEROSIS; REPRODUCIBILITY; PROTECTION; VALIDITY		Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	He, K (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Robles-Sardin, Alma E/M-7714-2015; Merchant, Anwar/B-5233-2009	Robles-Sardin, Alma E/0000-0003-2044-7793; 	NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; DECATERINA R, 1994, ARTERIOSCLER THROMB, V14, P1829, DOI 10.1161/01.ATV.14.11.1829; DRISS F, 1984, THROMB RES, V36, P389, DOI 10.1016/0049-3848(84)90295-0; ENIG MG, 1983, J AM OIL CHEM SOC, V60, P1788, DOI 10.1007/BF02680357; Gillman MW, 1997, JAMA-J AM MED ASSOC, V278, P2145, DOI 10.1001/jama.278.24.2145; He K, 2002, JAMA-J AM MED ASSOC, V288, P3130, DOI 10.1001/jama.288.24.3130; HEBERT PR, 1995, ARCH INTERN MED, V155, P50, DOI 10.1001/archinte.155.1.50; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; Iso H, 2002, STROKE, V33, P2086, DOI 10.1161/01.STR.0000023890.25066.50; Iso H, 2001, CIRCULATION, V103, P856, DOI 10.1161/01.CIR.103.6.856; KEANEY JF, 1995, PROG CARDIOVASC DIS, V38, P129, DOI 10.1016/S0033-0620(05)80003-9; KEARNEY JF, 1995, PROG CARDIOVASC DIS, V38, P129; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; LaBiche R, 2001, STROKE, V32, P855, DOI 10.1161/01.STR.32.4.855; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Qizilbash N, 1995, LANCET, V346, P1647; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1992, AM J EPIDEMIOL, V135, P1127, DOI [DOI 10.1093/OXFORDJOURNALS.AJE.A116211, DOI 10.1093/OXFORDJOUMALS.AJE.A116211]; SASAKI S, 1995, STROKE, V26, P783, DOI 10.1161/01.STR.26.5.783; SIMON JA, 1995, STROKE, V26, P778, DOI 10.1161/01.STR.26.5.778; SIMON JA, 1995, STROKE, V26, P788; SLOVER HT, 1985, J AM OIL CHEM SOC, V62, P775, DOI 10.1007/BF03028753; TELL GS, 1994, AM J EPIDEMIOL, V139, P979, DOI 10.1093/oxfordjournals.aje.a116947; Walker AE, 1981, STROKE S1, V12, P13; Weinfeld, 1981, STROKE S1, V12, pI13; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	28	131	136	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					777	781		10.1136/bmj.327.7418.777	http://dx.doi.org/10.1136/bmj.327.7418.777			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525873	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000185805100017
J	Guo, FQ; Okamoto, M; Crawford, NM				Guo, FQ; Okamoto, M; Crawford, NM			Identification of a plant nitric oxide synthase gene involved in hormonal signaling	SCIENCE			English	Article							ABSCISIC-ACID; STOMATAL CLOSURE; GENERATION; PROTEIN; NO	Nitric oxide ( NO) serves as a signal in plants. An Arabidopsis mutant (Atnos1) was identified that had impaired NO production, organ growth, and abscisic acid-induced stomatal movements. Expression of AtNOS1 with a viral promoter in Atnos1 mutant plants resulted in overproduction of NO. Purified AtNOS1 protein used the substrates arginine and nicotinamide adenine dinucleotide phosphate and was activated by Ca2+ and calmodulin-like mammalian endothelial nitric oxide synthase and neuronal nitric oxide synthase, yet it is a distinct enzyme with no sequence similarities to any mammalian isoform. Thus, AtNOS1 encodes a distinct nitric oxide synthase that regulates growth and hormonal signaling in plants.	Univ Calif San Diego, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Crawford, NM (corresponding author), Univ Calif San Diego, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA.	ncrawford@ucsd.edu	Okamoto, Mamoru/AAF-4265-2019; Bruening, Stefan/B-8505-2011	Okamoto, Mamoru/0000-0002-2989-607X; Guo, Fang-Qing/0000-0001-6889-394X	NIGMS NIH HHS [GM 40672] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040672, R29GM040672] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Beck KF, 1999, J EXP BIOL, V202, P645; Butt YKC, 2003, PLANTA, V216, P762, DOI 10.1007/s00425-002-00926-y; Chandok MR, 2003, CELL, V113, P469, DOI 10.1016/S0092-8674(03)00350-7; CHEN YJ, 1995, J BACTERIOL, V177, P5122, DOI 10.1128/jb.177.17.5122-5128.1995; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; Desikan R, 2002, P NATL ACAD SCI USA, V99, P16314, DOI 10.1073/pnas.252461999; Forstermann U, 1998, FASEB J, V12, P773; Garcia-Mata C, 2003, TRENDS PLANT SCI, V8, P20, DOI 10.1016/S1360-1385(02)00009-2; Garcia-Mata C, 2002, PLANT PHYSIOL, V128, P790, DOI 10.1104/pp.011020; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Huang S, 1997, J NEUROCHEM, V69, P2516; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Lamattina L, 2003, ANNU REV PLANT BIOL, V54, P109, DOI 10.1146/annurev.arplant.54.031902.134752; Neill SJ, 2003, NEW PHYTOL, V159, P11, DOI 10.1046/j.1469-8137.2003.00804.x; Neill SJ, 2002, PLANT PHYSIOL, V128, P13, DOI 10.1104/pp.010707; Stohr C, 2002, J EXP BOT, V53, P2293, DOI 10.1093/jxb/erf110; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Wendehenne D, 2001, TRENDS PLANT SCI, V6, P177, DOI 10.1016/S1360-1385(01)01893-3	22	652	730	6	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					100	103		10.1126/science.1086770	http://dx.doi.org/10.1126/science.1086770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526079				2022-12-28	WOS:000185678500044
J	Parker, GA; Chubb, JC; Ball, MA; Roberts, GN				Parker, GA; Chubb, JC; Ball, MA; Roberts, GN			Evolution of complex life cycles in helminth parasites	NATURE			English	Article							REPRODUCTION; GROWTH	The fundamental question of how complex life cycles-where there is typically more than one host-evolve in host-parasite systems remains largely unexplored. We suggest that complex cycles in helminths without penetrative infective stages evolve by two essentially different processes, depending on where in the cycle a new host is inserted. In 'upward incorporation', a new definitive host, typically higher up a food web and which preys on the original definitive host, is added. Advantages to the parasite are avoidance of mortality due to the predator, greater body size at maturity and higher fecundity. The original host typically becomes an intermediate host, in which reproduction is suppressed. In 'downward incorporation', a new intermediate host is added at a lower trophic level; this reduces mortality and facilitates transmission to the original definitive host. These two processes should also apply in helminths with penetrative infective stages, although the mathematical conditions differ.	Univ Liverpool, Sch Biol Sci, Populat & Evolut Biol Res Grp, Liverpool L69 7ZB, Merseyside, England; Univ Liverpool, Dept Math Sci, Div Appl Math, Liverpool L69 3BX, Merseyside, England	University of Liverpool; University of Liverpool	Parker, GA (corresponding author), Univ Liverpool, Sch Biol Sci, Populat & Evolut Biol Res Grp, Liverpool L69 7ZB, Merseyside, England.	gap@liverpool.ac.uk	Parker, Geoff/C-4337-2008	Parker, Geoff/0000-0003-4795-6352				Anderson R. C., 2000, Nematode parasites of vertebrates: their development and transmission., DOI 10.1079/9780851994215.0000; BAER JG, 1952, ECOLOGY ANIMAL PARAS; BRIAND F, 1987, SCIENCE, V238, P956, DOI 10.1126/science.3672136; Brooks DR, 1993, PARASCRIPT PARASITES; Brown SP, 2001, J EVOLUTION BIOL, V14, P815, DOI 10.1046/j.1420-9101.2001.00318.x; Charnov Eric L., 1993, P1; EBERMAN B, 1992, AM NAT, V139, P990; Fernandez J.C, 1993, FUNCTIONAL BIOL PARA; Gemmill AW, 1999, J EVOLUTION BIOL, V12, P1148, DOI 10.1046/j.1420-9101.1999.00117.x; HARVEY PH, 1991, PHILOS T R SOC B, V332, P31, DOI 10.1098/rstb.1991.0030; KOZLOWSKI J, 1992, TRENDS ECOL EVOL, V7, P15, DOI 10.1016/0169-5347(92)90192-E; MACKIEWICZ JS, 1972, EXP PARASITOL, V31, P417, DOI 10.1016/0014-4894(72)90103-8; Matsuno K, 1996, J THEOR BIOL, V180, P105, DOI 10.1006/jtbi.1996.0085; MOLNAR K, 1968, FOLIA PARASIT, V14, P83; Morand S, 1996, FUNCT ECOL, V10, P210, DOI 10.2307/2389845; MORAND S, 1995, J ANIM ECOL, V64, P256, DOI 10.2307/5760; Moravec F., 1994, Parasitic nematodes of freshwater fishes of Europe.; Nickol B.B, 1985, BIOL ACANTHOCEPHALA; Parker GA, 2003, J EVOLUTION BIOL, V16, P47, DOI 10.1046/j.1420-9101.2003.00504.x; Poulin R, 2002, TRENDS PARASITOL, V18, P176, DOI 10.1016/S1471-4922(02)02262-6; POULIN R, 1998, EVOLUTIONARY ECOLOGY; Price P. W., 1980, EVOLUTIONARY BIOL PA; REDI F, 1671, EXPT CIRC GENERATION; Roff Derek A., 1992; STUNKARD HW, 1946, BIOL REV, V21, P148, DOI 10.1111/j.1469-185X.1946.tb00321.x; [No title captured]	26	153	158	0	64	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 2	2003	425	6957					480	484		10.1038/nature02012	http://dx.doi.org/10.1038/nature02012			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523438				2022-12-28	WOS:000185648100036
J	Loong, TW				Loong, TW			Understanding sensitivity and specificity with the right side of the brain	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Natl Univ Singapore, Dept Community Occupat & Family Med, Singapore 117548, Singapore	National University of Singapore	Loong, TW (corresponding author), King Georges Med Ctr, Block 803,King Georges Ave 01-144, Singapore 200803, Singapore.	tzewey@singnet.com.sg						BOEY M L, 1992, SMJ Singapore Medical Journal, V33, P291; JOHNSON AE, 1995, ARTHRITIS RHEUM, V38, P551, DOI 10.1002/art.1780380415	2	218	221	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 27	2003	327	7417					716	719		10.1136/bmj.327.7417.716	http://dx.doi.org/10.1136/bmj.327.7417.716			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728FZ	14512479	Green Published			2022-12-28	WOS:000185708300018
J	Serbina, NV; Pamer, EG				Serbina, NV; Pamer, EG			Giving credit where credit is due	SCIENCE			English	Editorial Material							CELLS IN-VIVO; CD8(-) DENDRITIC CELLS; CD4 T-CELLS; LANGERHANS CELLS; ANTIGEN; MONOCYTES; SKIN		Mem Sloan Kettering Canc Ctr, Infect Dis Serv, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Serbina, NV (corresponding author), Mem Sloan Kettering Canc Ctr, Infect Dis Serv, 1275 York Ave, New York, NY 10021 USA.							Allan RS, 2003, SCIENCE, V301, P1925, DOI 10.1126/science.1087576; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Garg S, 2003, NAT IMMUNOL, V4, P907, DOI 10.1038/ni962; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4; Langerhans P, 1868, VIRCHOWS ARCH PATHOL, V44, P325, DOI [DOI 10.1007/BF01959006, 10.1007/BF01959006]; Merad M, 2002, NAT IMMUNOL, V3, P1135, DOI 10.1038/ni852; Pooley JL, 2001, J IMMUNOL, V166, P5327, DOI 10.4049/jimmunol.166.9.5327; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7; Zhao XY, 2003, J EXP MED, V197, P153, DOI 10.1084/jem.20021109	12	12	12	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1856	1857		10.1126/science.1090613	http://dx.doi.org/10.1126/science.1090613			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512609				2022-12-28	WOS:000185536700031
J	Caudy, AA; Ketting, RF; Hammond, SM; Denli, AM; Bathoorn, AMP; Tops, BBJ; Silva, JM; Myers, MM; Hannon, GJ; Plasterk, RHA				Caudy, AA; Ketting, RF; Hammond, SM; Denli, AM; Bathoorn, AMP; Tops, BBJ; Silva, JM; Myers, MM; Hannon, GJ; Plasterk, RHA			A micrococcal nuclease homologue in RNAi effector complexes	NATURE			English	Article							STAPHYLOCOCCAL NUCLEASE; INTERFERENCE; COACTIVATOR; CELLS; ELEGANS; PROTEIN; P100; TRANSCRIPTION; CLEAVAGE; SIRNAS	RNA interference (RNAi) regulates gene expression by the cleavage of messenger RNA, by mRNA degradation and by preventing protein synthesis. These effects are mediated by a ribonucleoprotein complex known as RISC (RNA-induced silencing complex)(1). We have previously identified four Drosophila components (short interfering RNAs1, Argonaute 2 (ref. 2), VIG and FXR3) of a RISC enzyme that degrades specific mRNAs in response to a double-stranded-RNA trigger. Here we show that Tudor-SN (tudor staphylococcal nuclease)-a protein containing five staphylococcal/micrococcal nuclease domains and a tudor domain-is a component of the RISC enzyme in Caenorhabditis elegans, Drosophila and mammals. Although Tudor-SN contains non-canonical active-site sequences, we show that purified Tudor-SN exhibits nuclease activity similar to that of other staphylococcal nucleases. Notably, both purified Tudor-SN and RISC are inhibited by a specific competitive inhibitor of micrococcal nuclease. Tudor-SN is the first RISC subunit to be identified that contains a recognizable nuclease domain, and could therefore contribute to the RNA degradation observed in RNAi.	Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands; Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Cold Spring Harbor Laboratory	Hannon, GJ (corresponding author), Hubrecht Lab, Ctr Biomed Genet, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		Hannon, Gregory/AAB-3568-2019; Tops, Bastiaan/L-4697-2015	Ketting, Rene/0000-0001-6161-5621; Tops, Bastiaan/0000-0002-1699-8210; Caudy, Amy/0000-0001-6307-8137				Avalos RT, 1997, J VIROL, V71, P2947, DOI 10.1128/JVI.71.4.2947-2958.1997; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Callebaut I, 1997, BIOCHEM J, V321, P125, DOI 10.1042/bj3210125; Capodici J, 2002, J IMMUNOL, V169, P5196, DOI 10.4049/jimmunol.169.9.5196; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; CUATRECA.P, 1967, J BIOL CHEM, V242, P3063; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hirayoshi K, 1999, METHOD ENZYMOL, V304, P351; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Keenan TW, 2000, BBA-GEN SUBJECTS, V1523, P84, DOI 10.1016/S0304-4165(00)00106-9; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Ponting CP, 1997, PROTEIN SCI, V6, P459; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; TONG X, 1995, MOL CELL BIOL, V15, P4735	30	348	380	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					411	414		10.1038/nature01956	http://dx.doi.org/10.1038/nature01956			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508492				2022-12-28	WOS:000185502300044
J	Grein, T; Checchi, F; Escriba, JM; Tamrat, A; Karunakara, U; Stokes, C; Brown, V; Legros, D				Grein, T; Checchi, F; Escriba, JM; Tamrat, A; Karunakara, U; Stokes, C; Brown, V; Legros, D			Mortality among displaced former UNITA members and their families in Angola: a retrospective cluster survey	BRITISH MEDICAL JOURNAL			English	Article							NUTRITIONAL-STATUS; CONFLICT; CHILDREN; REFUGEE; FAMINE	Objective To measure retrospectively mortality among a previously inaccessible population of former UNTIA members and their families displaced within Angola, before and after their arrival in resettlement camps after ceasefire of 4 April 2002. Design Three stage cluster sampling for interviews. Recall period for mortality assessment was from 21 June 2001 to 15-31 August 2002. Setting Eleven resettlement camps over four provinces of Angola (Bie, Cuando Cubango, Huila, and Malange) housing 149 000 former UNITA members and their families. Participants 900 consenting family heads of households, or most senior household members, corresponding to an intended sample size of 4500 individuals. Main outcome measures Crude mortality and proportional mortality, overall and by period (monthly, and before and after arrival in camps). Results Final sample included 6599 people. The 390 deaths reported during the recall period corresponded to an average crude mortality of 1.5/10 000/day (95% confidence interval 1.3 to 1.8), and, among children under 5 years old, to 4.1/10 000/day (3.3 to 5.2). Monthly crude mortality rose gradually to a peak in March 2002 and remained above emergency thresholds thereafter. Malnutrition was the leading cause of death (34%), followed by fever or malaria (24%) and war or violence (18%). Most war victims and people who had disappeared were women and children. Conclusions This population of displaced Angolans experienced global and child mortality greatly in excess of normal levels, both before and after the 2002 ceasefire. Malnutrition deaths reflect the extent of the food crisis affecting this population. Timely humanitarian assistance must be made available to all populations in such conflicts.	Epictr, F-75011 Paris, France; Med Sans Frontieres, Barcelona 08001, Spain; Med Sans Frontieres, CH-1207 Geneva, Switzerland; Med Sans Frontieres, NL-1001 EA Amsterdam, Netherlands; Med Sans Frontieres, B-1090 Brussels, Belgium	Doctors Without Borders; Doctors Without Borders; Doctors Without Borders; Doctors Without Borders	Legros, D (corresponding author), Epictr, 8 Rue St Sabin, F-75011 Paris, France.			Checchi, Francesco/0000-0001-9030-5382				Aaby P, 1999, BRIT MED J, V319, P878, DOI 10.1136/bmj.319.7214.878; Bhutta ZA, 2002, BMJ-BRIT MED J, V324, P349, DOI 10.1136/bmj.324.7333.349; BOREL T, 2002, MORTALITY NUTR MEASL; BOSS LP, 1994, JAMA-J AM MED ASSOC, V272, P371, DOI 10.1001/jama.272.5.371; BROWN V, 2002, EVALUATION SITUATION; BURKHOLDER BT, 1995, LANCET, V346, P1012, DOI 10.1016/S0140-6736(95)91694-6; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Chandramohan D, 1998, TROP MED INT HEALTH, V3, P436, DOI 10.1046/j.1365-3156.1998.00255.x; de Mul E, 2002, LANCET, V360, P335, DOI 10.1016/S0140-6736(02)09574-0; Ford N, 2002, LANCET, V360, P334, DOI 10.1016/S0140-6736(02)09559-4; GREIN T, 2002, MORTALITY INTERNALLY; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; Murray CJL, 2002, BRIT MED J, V324, P346, DOI 10.1136/bmj.324.7333.346; *NAT RES COUNC, 2002, DEM ASS TECHN COMPL; Robinson WC, 1999, LANCET, V354, P291, DOI 10.1016/S0140-6736(99)02266-7; Salama P, 2001, JAMA-J AM MED ASSOC, V286, P563, DOI 10.1001/jama.286.5.563; Stokes C, 2000, LANCET, V356, P2093, DOI 10.1016/S0140-6736(00)03415-2; Toole MJ, 1997, ANNU REV PUBL HEALTH, V18, P283, DOI 10.1146/annurev.publhealth.18.1.283; *UN OFF COORD HUM, HUM SIT ANG Q AN AUG; *UN OFF COORD HUM, 2002, HUM SIT ANG Q AN AUG; World Health Organization, 1999, RAP HLTH ASS PROT EM; SPHERE PROJECT HUMAN; 2002, LANCET, V359, P2125	23	22	22	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 20	2003	327	7416					650	653		10.1136/bmj.327.7416.650	http://dx.doi.org/10.1136/bmj.327.7416.650			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724AC	14500436	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000185463100020
J	Gunnell, D; Middleton, N				Gunnell, D; Middleton, N			National suicide rates as an indicator of the effect of suicide on premature mortality	LANCET			English	Article								The health strategies of many nations include targets to reduce suicide rates. In several countries, because suicide rates are rising in young men but failing or unchanging in most other groups, achievement of target reductions might mask rises in potential years of life lost (PYLL). Analysis of routine mortality and census data for England and Wales, UK, shows that although age-standardised suicide rates fell by 18% (95% CI 15-21) between 1981 and 1998, the PYLL before age 65 years increased by 5% (4-6). National suicide reduction targets should focus on PYLL and overall suicide rates.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Gunnell, D (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.		Gunnell, David/ABE-6653-2020; Middleton, Nicos/E-8408-2011	Gunnell, David/0000-0002-0829-6470; Middleton, Nicos/0000-0001-6358-8591				Cantor C. H., 2000, INT HDB SUICIDE ATTE; Department of Health, 2002, NAT SUIC PREV STRAT; Gunnell D, 2003, BRIT J PSYCHIAT, V182, P164, DOI 10.1192/bjp.182.2.164; Taylor SJ, 1997, ACTA PSYCHIAT SCAND, V95, P457, DOI 10.1111/j.1600-0447.1997.tb10132.x	4	44	44	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					961	962		10.1016/S0140-6736(03)14367-X	http://dx.doi.org/10.1016/S0140-6736(03)14367-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	724LT	14511931				2022-12-28	WOS:000185489600012
J	Overgaard, J; Hansen, HS; Specht, L; Overgaard, M; Grau, C; Andersen, E; Bentzen, J; Bastholt, L; Hansen, O; Johansen, J; Andersen, L; Evensen, JF				Overgaard, J; Hansen, HS; Specht, L; Overgaard, M; Grau, C; Andersen, E; Bentzen, J; Bastholt, L; Hansen, O; Johansen, J; Andersen, L; Evensen, JF		Danish Head Neck Canc Study Grp	Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial	LANCET			English	Article							GROWTH-FACTOR RECEPTOR; SPLIT-COURSE RADIOTHERAPY; ACCELERATED FRACTIONATION; ALTERED FRACTIONATION; PHARYNX CARCINOMA; PHASE-III; CANCER; LARYNX; HYPERFRACTIONATION; ONCOLOGY	Background Although head and neck cancer can be cured by radiotherapy, the optimum treatment time for locoregional control is unclear. We aimed to find out whether shortening of treatment time by use of six instead of five radiotherapy fractions per week improves the tumour response in squamous-cell carcinoma. Methods We did a multicentre, controlled, randomised trial. Between January, 1992, and December, 1999, of 1485 patients treated with primary radiotherapy alone, 1476 eligible patients were randomly assigned five (n=726) or six (n=750) fractions per week at the same total dose and fraction number (66-68 Gy in 33-34 fractions to all tumour sites except well-differentiated T1 glottic tumours, which were treated with 62 Gy). All patients, except those with glottic cancers, also received the hypoxic radiosensitiser nimorazole. Analysis was by intention to treat. Findings More than 97% of the patients received the planned total dose. Median overall treatment times were 39 days (six-fraction group) and 46 days (five-fraction group). Overall 5-year locoregional control rates were 70% and 60% for the six-fraction and five-fraction groups, respectively (p=0.0005). The whole benefit of shortening of treatment time was seen for primary tumour control (76 vs 64% for six and five fractions, p=0.0001), but was non-significant for neck-node control. Six compared with five fractions per week improved preservation of the voice among patients with laryngeal cancer (80 vs 68%, p=0.007). Disease-specific survival improved (73 vs 66% for six and five fractions, p=0.01) but not overall survival. Acute morbidity was significantly more frequent with six than with five fractions, but was transient. Interpretation The shortening of overall treatment time by increase of the weekly number of fractions is beneficial in patients with head and neck cancer. The six-fractions-weekly regimen has become the standard treatment in Denmark.	Aarhus Univ Hosp, Dept Expt Clin Oncol, DK-8000 Aarhus C, Denmark; Rigshosp, Finsen Ctr, Dept Oncol, DK-2100 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus C, Denmark; Herlev Hosp, Dept Oncol, Copenhagen, Denmark; Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark; Aaborg Hosp, Dept Oncol, Aaborg, Denmark; Norwegian Radium Hosp, Oslo, Norway	Aarhus University; Rigshospitalet; University of Copenhagen; Aarhus University; University of Copenhagen; Herlev & Gentofte Hospital; University of Southern Denmark; Odense University Hospital; University of Oslo	Overgaard, J (corresponding author), Aarhus Univ Hosp, Dept Expt Clin Oncol, Norrebrogade 44,Bldg 5, DK-8000 Aarhus C, Denmark.		Grau, Cai/I-8161-2014; Andersen, Elo/A-1639-2016; Johansen, Jørgen/I-6816-2013; Specht, Lena/J-6422-2019; Hansen, Olfred/D-1432-2012	Grau, Cai/0000-0003-3548-3527; Andersen, Elo/0000-0002-2476-1037; Johansen, Jørgen/0000-0003-3911-3929; Specht, Lena/0000-0002-6902-2190; Bastholt, Lars/0000-0001-5478-9826; Hansen, Olfred/0000-0003-0396-1424				Ang KK, 2002, CANCER RES, V62, P7350; Bernier J, 2003, EUR J CANCER, V39, P560, DOI 10.1016/S0959-8049(02)00838-9; Bourhis J., 2002, International Journal of Radiation Oncology Biology Physics, V54, P71, DOI 10.1016/S0360-3016(02)03180-2; BOURHIS J, 2000, P AN M AM SOC CLIN, V19, pA412; Cummings BJ, 1999, ACTA ONCOL, V38, P131, DOI 10.1080/028418699431528; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; Dische S, 1997, RADIOTHER ONCOL, V44, P123, DOI 10.1016/S0167-8140(97)00094-7; Dobrowsky W, 2000, RADIOTHER ONCOL, V57, P119, DOI 10.1016/S0167-8140(00)00233-4; ERIKSEN JG, IN PRESS INT J RAD O; Fu KK, 2000, INT J RADIAT ONCOL, V48, P7, DOI 10.1016/S0360-3016(00)00663-5; Groome PA, 2003, J CLIN ONCOL, V21, P496, DOI 10.1200/JCO.2003.10.106; Hansen O, 1997, RADIOTHER ONCOL, V43, P47, DOI 10.1016/S0167-8140(97)01904-X; Hliniak A, 2002, RADIOTHER ONCOL, V62, P1, DOI 10.1016/S0167-8140(01)00494-7; HORIOT JC, 1992, RADIOTHER ONCOL, V25, P231, DOI 10.1016/0167-8140(92)90242-M; Horiot JC, 1997, RADIOTHER ONCOL, V44, P111, DOI 10.1016/S0167-8140(97)00079-0; Jackson SM, 1997, RADIOTHER ONCOL, V43, P39, DOI 10.1016/S0167-8140(97)01944-0; Kaanders JHAM, 2002, LANCET ONCOL, V3, P728, DOI 10.1016/S1470-2045(02)00929-4; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Nguyen LN, 2002, LANCET ONCOL, V3, P693, DOI 10.1016/S1470-2045(02)00906-3; OVERGAARD J, 1989, INT J RADIAT ONCOL, V16, P1065, DOI 10.1016/0360-3016(89)90917-6; Overgaard J, 1996, SEMIN RADIAT ONCOL, V6, P10, DOI 10.1016/S1053-4296(96)80032-4; Overgaard J, 1998, RADIOTHER ONCOL, V46, P135, DOI 10.1016/S0167-8140(97)00220-X; OVERGAARD J, 1988, ACTA ONCOL, V27, P147, DOI 10.3109/02841868809090334; OVERGAARD J, 1986, INT J RADIAT ONCOL, V12, P515, DOI 10.1016/0360-3016(86)90058-1; Overgaard Jens, 2000, Rays (Rome), V25, P313; Peters, 1992, Semin Radiat Oncol, V2, P180, DOI 10.1016/1053-4296(92)90007-8; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Poulsen MG, 2001, RADIOTHER ONCOL, V60, P113, DOI 10.1016/S0167-8140(01)00347-4; Skladowski K, 2000, RADIOTHER ONCOL, V55, P101, DOI 10.1016/S0167-8140(00)00139-0; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333	30	493	501	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					933	940		10.1016/S0140-6736(03)14361-9	http://dx.doi.org/10.1016/S0140-6736(03)14361-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511925				2022-12-28	WOS:000185489600006
J	Krummel, EM; Macdonald, RW; Kimpe, LE; Gregory-Eaves, I; Demers, MJ; Smol, JP; Finney, B; Blais, JM				Krummel, EM; Macdonald, RW; Kimpe, LE; Gregory-Eaves, I; Demers, MJ; Smol, JP; Finney, B; Blais, JM			Delivery of pollutants by spawning salmon - Fish dump toxic industrial compounds in Alaskan lakes on their return from the ocean.	NATURE			English	Editorial Material							POLYCHLORINATED-BIPHENYLS; PACIFIC SALMON; SEDIMENTS; IMPACTS		Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada; Inst Ocean Sci, Dept Fisheries & Oceans, Sidney, BC V8L 4B2, Canada; Queens Univ, Dept Biol, Paleoecol Environm Assessment & Res Lab, Kingston, ON K7L 3N6, Canada; Univ Alaska, Inst Marine Sci, Fairbanks, AK 99775 USA	University of Ottawa; Fisheries & Oceans Canada; Queens University - Canada; University of Alaska System; University of Alaska Fairbanks	Krummel, EM (corresponding author), Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada.	jblais@science.ottawa.ca	Blais, Jules/AAV-2321-2020; Macdonald, Robie W/A-7896-2012; Smol, John P/A-8838-2015; Gregory-Eaves, Irene/U-9325-2019	Blais, Jules/0000-0002-7188-3598; Macdonald, Robie W/0000-0002-1141-8520; Gregory-Eaves, Irene/0000-0002-0380-5061; Smol, John/0000-0002-2499-6696				Arkoosh MR, 1998, J AQUAT ANIM HEALTH, V10, P182, DOI 10.1577/1548-8667(1998)010&lt;0182:EOPOFD&gt;2.0.CO;2; Blais JM, 2003, ENVIRON TOXICOL CHEM, V22, P126, DOI [10.1002/etc.5620220116, 10.1897/1551-5028(2003)022&lt;0126:AACOPB&gt;2.0.CO;2]; Burgner R.L., 1991, P1; Ewald G, 1998, ARCTIC, V51, P40; Finney BP, 2000, SCIENCE, V290, P795, DOI 10.1126/science.290.5492.795; *IND NO AFF, 2003, CAN ARCT CONT ASS RE; IWATA H, 1993, ENVIRON SCI TECHNOL, V27, P1080, DOI 10.1021/es00043a007; MacDonald RW, 2000, SCI TOTAL ENVIRON, V254, P93, DOI 10.1016/S0048-9697(00)00434-4; Muir DCG, 1996, ENVIRON SCI TECHNOL, V30, P3609, DOI 10.1021/es960393v; Naiman RJ, 2002, ECOSYSTEMS, V5, P399, DOI 10.1007/s10021-001-0083-3	10	103	108	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					255	256		10.1038/425255a	http://dx.doi.org/10.1038/425255a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679906				2022-12-28	WOS:000185370900033
J	Goldacre, MJ; Roberts, SE; Yeates, D				Goldacre, MJ; Roberts, SE; Yeates, D			Case fatality rates for meningococcal disease in an English population, 1963-98: database study	BRITISH MEDICAL JOURNAL			English	Article							ACUTE BACTERIAL-MENINGITIS		Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.							Booy R, 2001, ARCH DIS CHILD, V85, P386, DOI 10.1136/adc.85.5.386; GOLDACRE MJ, 1976, INT J EPIDEMIOL, V5, P343, DOI 10.1093/ije/5.4.343; GOLDACRE MJ, 1976, LANCET, V1, P28; Sorensen HT, 1998, EUR J CLIN MICROBIOL, V17, P690, DOI 10.1007/s100960050162; Wylie PAL, 1997, BRIT MED J, V315, P774, DOI 10.1136/bmj.315.7111.774	5	40	40	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					596	597		10.1136/bmj.327.7415.596	http://dx.doi.org/10.1136/bmj.327.7415.596			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969927	Green Published, Bronze			2022-12-28	WOS:000185358700023
J	Khalaf, Y				Khalaf, Y			ABC of subfertility - Tubal subfertility	BRITISH MEDICAL JOURNAL			English	Review							SELECTIVE SALPINGOGRAPHY; PREGNANCY		Guys & St Thomass NHS Hosp Trust, London, England; Guys & St Thomass Assisted Concept Unit, London, England		Khalaf, Y (corresponding author), Guys & St Thomass NHS Hosp Trust, London, England.							*CDCP, 1991, MMWR-MORBID MORTAL W, P1; COLLINS JA, 1983, NEW ENGL J MED, V309, P1201, DOI 10.1056/NEJM198311173092001; HULL MGR, 1985, BRIT MED J, V291, P1693, DOI 10.1136/bmj.291.6510.1693; KARANDE VC, 1995, FERTIL STERIL, V64, P1070, DOI 10.1016/S0015-0282(16)57962-X; WOOLCOTT R, 1995, HUM REPROD, V10, P1423, DOI 10.1093/HUMREP/10.6.1423	5	27	30	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					610	613		10.1136/bmj.327.7415.610	http://dx.doi.org/10.1136/bmj.327.7415.610			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969933	Green Published			2022-12-28	WOS:000185358700029
J	Strano, MS; Dyke, CA; Usrey, ML; Barone, PW; Allen, MJ; Shan, HW; Kittrell, C; Hauge, RH; Tour, JM; Smalley, RE				Strano, MS; Dyke, CA; Usrey, ML; Barone, PW; Allen, MJ; Shan, HW; Kittrell, C; Hauge, RH; Tour, JM; Smalley, RE			Electronic structure control of single-walled carbon nanotube functionalization	SCIENCE			English	Article							DEPENDENCE; DISPERSION; SEPARATION	Diazonium reagents functionalize single-walled carbon nanotubes suspended in aqueous solution with high selectivity and enable manipulation according to electronic structure. For example, metallic species are shown to react to the near exclusion of semiconducting nanotubes under controlled conditions. Selectivity is dictated by the availability of electrons near the Fermi level to stabilize a charge-transfer transition state preceding bond formation. The chemistry can be reversed by using a thermal treatment that restores the pristine electronic structure of the nanotube.	Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA; Rice Univ, Ctr Nanoscale Sci & Technol, Dept Chem, Houston, TX 77005 USA; Rice Univ, Ctr Biol & Environm Nanotechnol, Houston, TX 77005 USA; Rice Univ, Dept Mech Engn & Mat Sci, Houston, TX 77005 USA; Rice Univ, Dept Phys, Houston, TX 77005 USA	University of Illinois System; University of Illinois Urbana-Champaign; Rice University; Rice University; Rice University; Rice University	Strano, MS (corresponding author), Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA.	strano@uiuc.edu; tour@rice.edu	Hauge, Robert H/A-7008-2011	Hauge, Robert H/0000-0002-3656-0152; Tour, James/0000-0002-8479-9328				Avouris P, 2002, ACCOUNTS CHEM RES, V35, P1026, DOI 10.1021/ar010152e; Bachilo SM, 2002, SCIENCE, V298, P2361, DOI 10.1126/science.1078727; Bahr JL, 2001, J AM CHEM SOC, V123, P6536, DOI 10.1021/ja010462s; Bahr JL, 2002, J MATER CHEM, V12, P1952, DOI 10.1039/b201013p; Bravo-Diaz C, 1998, LANGMUIR, V14, P5098, DOI 10.1021/la9708142; Bronikowski MJ, 2001, J VAC SCI TECHNOL A, V19, P1800, DOI 10.1116/1.1380721; Chattopadhyay D, 2003, J AM CHEM SOC, V125, P3370, DOI 10.1021/ja028599l; Chen ZF, 2003, CHEMPHYSCHEM, V4, P93, DOI 10.1002/cphc.200390015; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Dyke CA, 2003, J AM CHEM SOC, V125, P1156, DOI 10.1021/ja0289806; Itkis ME, 2002, NANO LETT, V2, P155, DOI 10.1021/nl0156639; MIYOGI S, 2002, ACCOUNTS CHEM RES, V35, P1105; O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631; Reich S, 2000, PHYS REV B, V62, P4273, DOI 10.1103/PhysRevB.62.4273; Saito R., 1998, PHYS PROPERTIES CARB; Strano MS, 2003, J PHYS CHEM B, V107, P6979, DOI 10.1021/jp027664a; Strano MS, 2003, NANO LETT, V3, P1091, DOI 10.1021/nl034196n; Strano MS, 2003, J NANOSCI NANOTECHNO, V3, P81, DOI 10.1166/jnn.2003.194; Zheng M, 2003, NAT MATER, V2, P338, DOI 10.1038/nmat877	19	1187	1255	1	399	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1519	1522		10.1126/science.1087691	http://dx.doi.org/10.1126/science.1087691			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970561				2022-12-28	WOS:000185255300045
J	Galun, R; Yoi, OKOM				Galun, R; Yoi, OKOM			Thomas Risley Odhiambo (1931-2003) - Obituary	NATURE			English	Biographical-Item									Hebrew Univ Jerusalem, Dept Parasitol, IL-91905 Jerusalem, Israel; ICIPE, Nairobi, Kenya	Hebrew University of Jerusalem; International Centre of Insect Physiology & Ecology (ICIPE)	Galun, R (corresponding author), Hebrew Univ Jerusalem, Dept Parasitol, IL-91905 Jerusalem, Israel.							ODHIAMBO TR, PUBLICATION LIST	1	0	0	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2003	425	6954					142	142		10.1038/425142a	http://dx.doi.org/10.1038/425142a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968167	Bronze			2022-12-28	WOS:000185236000030
J	Yu, YL; Nakano, M; Ikeda, T				Yu, YL; Nakano, M; Ikeda, T			Directed bending of a polymer film by light - Miniaturizing a simple photomechanical system could expand its range of applications.	NATURE			English	Editorial Material									Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yu, YL (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	tikeda@res.titech.ac.jp						EISENBACH CD, 1980, POLYMER, V21, P1175, DOI 10.1016/0032-3861(80)90083-X; Finkelmann H, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.015501; Hogan PM, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041720; Ikeda T, 2003, ADV MATER, V15, P201, DOI 10.1002/adma.200390045; IKEDA T, 1995, SCIENCE, V268, P1873, DOI 10.1126/science.268.5219.1873; IKEDA TJ, 2000, MATER CHEM, V13, P2037; Li MH, 2003, ADV MATER, V15, P569, DOI 10.1002/adma.200304552; MATEJKA L, 1981, POLYMER, V22, P1511, DOI 10.1016/0032-3861(81)90321-9; SMETS G, 1974, PURE APPL CHEM, V39, P225, DOI 10.1351/pac197439010225; VANDERVE.G, 1971, NATURE-PHYS SCI, V230, P70, DOI 10.1038/physci230070a0	10	1700	1776	29	715	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					145	145		10.1038/425145a	http://dx.doi.org/10.1038/425145a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968169	Bronze			2022-12-28	WOS:000185236000031
J	Deffenbaugh, AE; Scaglione, KM; Zhang, LX; Moore, JM; Buranda, T; Sklar, LA; Skowyra, D				Deffenbaugh, AE; Scaglione, KM; Zhang, LX; Moore, JM; Buranda, T; Sklar, LA; Skowyra, D			Release of ubiquitin-charged Cdc34-S similar to Ub from the RING domain is essential for ubiquitination of the SCFCdc4-bound substrate Sic1	CELL			English	Article							CDC34 SELF-ASSOCIATION; CONJUGATING ENZYME; MULTIUBIQUITIN CHAIN; LIGASE COMPLEX; SACCHAROMYCES-CEREVISIAE; STRUCTURAL BASIS; TERMINAL DOMAIN; E2 ENZYME; F-BOX; SCF	The S. cerevisiae SCFCdc4 is a prototype of RING-type SCF E3s, which recruit substrates for polyubiquitination by the Cdc34 ubiquitin-conjugating enzyme. Current models propose that Cdc34 ubiquitinates the substrate while remaining bound to the RING domain. In contrast, we found that the formation of a ubiquitin thiol ester regulates the Cdc34/SCFCdc4 binding equilibrium by increasing the dissociation rate constant, with only a minor effect on the association rate. By using a F72VCdc34 mutant with increased affinity for the RING domain, we demonstrate that release of ubiquitin-charged Cdc34-Ssimilar toUb from the RING is essential for ubiquitination of the SCFCdc4-bound substrate Sic1. Release of ubiquitin-charged E2 from E3 prior to ubiquitin transfer is a previously unrecognized step in ubiquitination, which can explain both the modification of multiple lysines on the recruited substrate and the extension of polyubiquitin chains. We discuss implications of this finding for function of other ubiquitin ligases.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA	Saint Louis University; University of New Mexico	Skowyra, D (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.			Scaglione, Kenneth/0000-0002-3858-9418	NCI NIH HHS [CA88339] Funding Source: Medline; NIGMS NIH HHS [GM60799/EB00264, GM65267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA088339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065267, R24GM060799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; Buranda T, 1999, J PHYS CHEM B, V103, P3399, DOI 10.1021/jp983842h; Buranda T, 2001, ANAL BIOCHEM, V298, P151, DOI 10.1006/abio.2001.5363; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; FELDMAN RM, 1997, CELL, V91, P149; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GOEBL MG, 1994, MOL CELL BIOL, V14, P3022, DOI 10.1128/MCB.14.5.3022; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PTAK C, 1994, J BIOL CHEM, V269, P26539; Ptak C, 2001, MOL CELL BIOL, V21, P6537, DOI 10.1128/MCB.21.19.6537-6548.2001; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Ulrich HD, 2003, J BIOL CHEM, V278, P7051, DOI 10.1074/jbc.M212195200; VanDemark AP, 2002, CURR OPIN STRUC BIOL, V12, P822, DOI 10.1016/S0959-440X(02)00389-5; Varelas X, 2003, MOL CELL BIOL, V23, P5388, DOI 10.1128/MCB.23.15.5388-5400.2003; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	48	75	76	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					611	622		10.1016/S0092-8674(03)00641-X	http://dx.doi.org/10.1016/S0092-8674(03)00641-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678584	Bronze			2022-12-28	WOS:000185193100010
J	Herrera, E; Brown, L; Aruga, J; Rachel, RA; Dolen, G; Mikoshiba, K; Brown, S; Mason, CA				Herrera, E; Brown, L; Aruga, J; Rachel, RA; Dolen, G; Mikoshiba, K; Brown, S; Mason, CA			Zic2 patterns binocular vision by specifying the uncrossed retinal projection	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; LIM HOMEOBOX GENES; OPTIC CHIASM; AXON DIVERGENCE; GANGLION-CELLS; TRANSCRIPTIONAL CODES; ALBINO FERRETS; VISUAL-SYSTEM; SPINAL-CORD; EXPRESSION	During CNS development, combinatorial expression of transcription factors controls neuronal subtype identity and subsequent axonal trajectory. Regulatory genes designating the routing of retinal ganglion cell (RGC) axons at the optic chiasm to the appropriate hemisphere, a pattern critical for proper binocular vision, have not been identified. Here, we show that the zinc finger transcription factor Zic2, a vertebrate homolog of the Drosophila gene odd-paired, is expressed in RGCs with an uncrossed trajectory during the period when this subpopulation grows from the ventrotemporal retina toward the optic chiasm. Loss-and gain-of-function analyses indicate that Zic2 is necessary and sufficient to regulate RGC axon repulsion by cues at the optic chiasm midline. Moreover, Zic2 expression reflects the extent of binocularity in different species, suggesting that Zic2 is an evolutionarily conserved determinant of RGCs that project ipsilaterally. These data provide evidence for transcriptional coding of axon pathfinding at the midline.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan	Columbia University; Columbia University; Columbia University; RIKEN	Mason, CA (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	cam4@columbia.edu	Herrera, Eloísa/A-5377-2008; Aruga, Jun/H-5837-2011; Mikoshiba, Katsuhiko/N-7943-2015; Dolen, Gul/J-3073-2015	Herrera, Eloísa/0000-0001-9525-5441; Aruga, Jun/0000-0001-7936-1375; Dolen, Gul/0000-0003-1780-995X	NATIONAL EYE INSTITUTE [T32EY013933, R01EY015290, R01EY012736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042730] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY012736, EY12736, R01 EY015290, T32 EY013933] Funding Source: Medline; NINDS NIH HHS [NS42730] Funding Source: Medline; PHS HHS [P030532] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Aruga J, 2002, J NEUROSCI, V22, P218, DOI 10.1523/JNEUROSCI.22-01-00218.2002; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; BENEDYK MJ, 1994, GENE DEV, V8, P105, DOI 10.1101/gad.8.1.105; Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; Brown LY, 2001, HUM MOL GENET, V10, P791, DOI 10.1093/hmg/10.8.791; BROWN LY, 2003, MECH DEVELOP, V3, P361; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chalupa LM, 1998, J COMP NEUROL, V392, P35, DOI 10.1002/(SICI)1096-9861(19980302)392:1<35::AID-CNE3>3.0.CO;2-Q; Chung KY, 2000, DEVELOPMENT, V127, P2673; COLELLO RJ, 1990, DEVELOPMENT, V108, P515; CUCCHIARO JB, 1991, J COMP NEUROL, V312, P193, DOI 10.1002/cne.903120203; DEITCHER DL, 1994, J NEUROSCI, V14, P486; DRAGER UC, 1985, PROC R SOC SER B-BIO, V224, P57, DOI 10.1098/rspb.1985.0021; Erskine L, 2000, J NEUROSCI, V20, P4975; GalliResta L, 1997, J NEUROSCI, V17, P7831; GUILLERY RW, 1995, J NEUROSCI, V15, P4727; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; HOSKINS SG, 1985, J NEUROSCI, V5, P911; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Kandel E., 2000, PRINCIPLES NEURAL SC; Kania A, 2000, CELL, V102, P161, DOI 10.1016/S0092-8674(00)00022-2; Kania A, 2003, NEURON, V38, P581, DOI 10.1016/S0896-6273(03)00292-7; Kitaguchi T, 2000, DEVELOPMENT, V127, P4787; Lee KJ, 1999, ANNU REV NEUROSCI, V22, P261, DOI 10.1146/annurev.neuro.22.1.261; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Lustig M, 2001, J COMP NEUROL, V434, P13, DOI 10.1002/cne.1161; Mann F, 2001, BIOESSAYS, V23, P319, DOI 10.1002/bies.1046; Marcus RC, 2000, DEV BIOL, V221, P132, DOI 10.1006/dbio.2000.9660; MARCUS RC, 1995, J NEUROSCI, V15, P3716; Marcus RC, 1996, DEVELOPMENT, V122, P859; Mason C, 2000, J NEUROBIOL, V44, P260, DOI 10.1002/1097-4695(200008)44:2<260::AID-NEU14>3.0.CO;2-H; Nagai T, 2000, P NATL ACAD SCI USA, V97, P1618, DOI 10.1073/pnas.97.4.1618; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; Nakagawa S, 2000, NEURON, V25, P599, DOI 10.1016/S0896-6273(00)81063-6; OLEARY DDM, 1983, DEV BRAIN RES, V10, P93, DOI 10.1016/0165-3806(83)90124-4; Pierani A, 2001, NEURON, V29, P367, DOI 10.1016/S0896-6273(01)00212-4; Plump AS, 2002, NEURON, V33, P219, DOI 10.1016/S0896-6273(01)00586-4; Polyak S., 1957, VERTEBRATE VISUAL SY; Purandare SM, 2002, DEVELOPMENT, V129, P2293; Rachel RA, 2002, J NEUROSCI, V22, P4249, DOI 10.1523/JNEUROSCI.22-11-04249.2002; RICE DS, 1995, J COMP NEUROL, V354, P459, DOI 10.1002/cne.903540312; Rubin JB, 2002, DEVELOPMENT, V129, P2223; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schulte D, 1999, NEURON, V24, P541, DOI 10.1016/S0896-6273(00)81111-3; Shirasaki R, 2002, ANNU REV NEUROSCI, V25, P251, DOI 10.1146/annurev.neuro.25.112701.142916; Thanos S, 2001, BRAIN RES REV, V35, P205, DOI 10.1016/S0165-0173(01)00049-2; THOMPSON ID, 1993, EUR J NEUROSCI, V5, P341, DOI 10.1111/j.1460-9568.1993.tb00502.x; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wang LC, 1995, NEURON, V15, P1349, DOI 10.1016/0896-6273(95)90013-6; Warner SJ, 2003, DEV DYNAM, V226, P702, DOI 10.1002/dvdy.10262; WILLIAMS SE, 2003, IN PRESS NEURON, V39; XIANG MQ, 1995, J NEUROSCI, V15, P4762	55	197	199	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	2003	114	5					545	557		10.1016/S0092-8674(03)00684-6	http://dx.doi.org/10.1016/S0092-8674(03)00684-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678579	Bronze			2022-12-28	WOS:000185193100005
J	Hirota, T; Kunitoku, N; Sasayama, T; Marumoto, T; Zhang, DW; Nitta, M; Hatakeyama, K; Saya, H				Hirota, T; Kunitoku, N; Sasayama, T; Marumoto, T; Zhang, DW; Nitta, M; Hatakeyama, K; Saya, H			Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells	CELL			English	Article							CHROMOSOME SEGREGATION; DEPENDENT MANNER; MAMMALIAN-CELLS; KINASE; CENTROSOMES; MATURATION; SPINDLE; MICROTUBULES; CHECKPOINT; DIVISION	Aurora family kinases contribute to regulation of mitosis. Using RNA interference in synchronized HeLa cells, we now show that Aurora-A is required for mitotic entry. We found that initial activation of Aurora-A in late G2 phase of the cell cycle is essential for recruitment of the cyclin B1-Cdk1 complex to centrosomes, where it becomes activated and commits cells to mitosis. A two-hybrid screen identified the LIM protein Ajuba as an Aurora-A binding protein. Ajuba and Aurora-A interact in mitotic cells and become phosphorylated as they do so. In vitro analyses revealed that Ajuba induces the autophosphorylation and consequent activation of Aurora-A. Depletion of Ajuba prevented activation of Aurora-A at centrosomes in late G2 phase and inhibited mitotic entry. Overall, our data suggest that Ajuba is an essential activator of Aurora-A in mitotic commitment.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Dept Surg, Niigata 9518510, Japan	Kumamoto University; Niigata University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.		Saya, Hideyuki/J-4325-2013	Sasayama, Takashi/0000-0002-5593-9045				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andreu V, 1998, COMPUTAT STUDIES, V2, P17; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Pines J, 2001, NAT CELL BIOL, V3, pE3, DOI 10.1038/35050676; Roghi C, 1998, J CELL SCI, V111, P557; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847	22	513	537	1	23	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					585	598		10.1016/S0092-8674(03)00642-1	http://dx.doi.org/10.1016/S0092-8674(03)00642-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678582	Bronze			2022-12-28	WOS:000185193100008
J	Lee, KS; Zhan, XM; Gao, JJ; Ji, Q; Feng, YA; Meganathan, R; Cohen, SN; Georgiou, G				Lee, KS; Zhan, XM; Gao, JJ; Ji, Q; Feng, YA; Meganathan, R; Cohen, SN; Georgiou, G			RraA: a protein inhibitor of RNase E activity that globally modulates RNA abundance in E. coli	CELL			English	Article							DISULFIDE BOND FORMATION; ESCHERICHIA-COLI; MESSENGER-RNA; RIBONUCLEASE-E; GENE-EXPRESSION; RIBOSOMAL-RNA; IN-VIVO; CATALYTIC DOMAIN; DNA MICROARRAY; TERMINAL HALF	Ribonuclease E (RNase E) has a key role in mRNA degradation and the processing of catalytic and structural RNAs in E. coli. We report the discovery of an evolutionarily conserved 17.4 kDa protein, here named RraA (regulator of ribonuclease activity A) that binds to RNase E and inhibits RNase E endonucleolytic cleavages without altering cleavage site specificity or interacting detectably with substrate RNAs. Overexpression of RraA circumvents the effects of an autoregulatory mechanism that normally maintains the RNase E cellular level within a narrow range, resulting in the genome-wide accumulation of RNase E-targeted transcripts. While not required for RraA action the C-terminal RNase E region that serves as a scaffold for formation of a multiprotein degradosome complex modulates the inhibition of RNase E catalytic activity by RraA. Our results reveal a possible mechanism for the dynamic regulation of RNA decay and processing by inhibitory RNase binding proteins.	Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA; Univ Texas, Dept Chem Engn, Austin, TX 78712 USA; Univ Texas, Dept Biomed Engn, Austin, TX 78712 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; No Illinois Univ, Dept Biol Sci, De Kalb, IL 60115 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Stanford University; Stanford University; Northern Illinois University	Georgiou, G (corresponding author), Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA.		Meganathan, R./A-6878-2009		NIGMS NIH HHS [GM55090, GM 54158, GM64511-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM064511, R01GM054158, R01GM055090] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bernstein JA, 2002, P NATL ACAD SCI USA, V99, P9697, DOI 10.1073/pnas.112318199; Bessette PH, 2001, J BACTERIOL, V183, P980, DOI 10.1128/JB.183.3.980-988.2001; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; ELISH ME, 1988, J GEN MICROBIOL, V134, P1355; Feng Y, 2001, J BIOL CHEM, V276, P31651, DOI 10.1074/jbc.M102855200; Feng YA, 2002, P NATL ACAD SCI USA, V99, P14746, DOI 10.1073/pnas.202590899; GEORGELLIS D, 1993, MOL MICROBIOL, V9, P375, DOI 10.1111/j.1365-2958.1993.tb01698.x; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GUREVITZ M, 1983, P NATL ACAD SCI-BIOL, V80, P4450, DOI 10.1073/pnas.80.14.4450; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; Jain C, 2002, MOL MICROBIOL, V43, P1053, DOI 10.1046/j.1365-2958.2002.02808.x; JAIN C, 1995, GENE DEV, V9, P84, DOI 10.1101/gad.9.1.84; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kalapos MP, 1997, BIOCHIMIE, V79, P493, DOI 10.1016/S0300-9084(97)82741-1; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P12170, DOI 10.1073/pnas.220414297; Kido M, 1996, J BACTERIOL, V178, P3917, DOI 10.1128/jb.178.13.3917-3925.1996; Lee K, 2003, MOL MICROBIOL, V48, P349, DOI 10.1046/j.1365-2958.2003.03435.x; Lee K, 2002, MOL MICROBIOL, V43, P1445, DOI 10.1046/j.1365-2958.2002.02848.x; Leroy A, 2002, MOL MICROBIOL, V45, P1231, DOI 10.1046/j.1365-2958.2002.03104.x; Li ZW, 2002, RNA, V8, P97, DOI 10.1017/S1355838202014929; Li ZW, 1999, EMBO J, V18, P2878, DOI 10.1093/emboj/18.10.2878; Lin-Chao S, 1999, P NATL ACAD SCI USA, V96, P12406, DOI 10.1073/pnas.96.22.12406; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; Liou GG, 2001, P NATL ACAD SCI USA, V98, P63, DOI 10.1073/pnas.011535498; Lopez PJ, 1999, MOL MICROBIOL, V33, P188, DOI 10.1046/j.1365-2958.1999.01465.x; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MEGANATHAN R, 1996, ESCHERICHIA COLI SAL, P642; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; Ow MC, 2002, GENE DEV, V16, P1102, DOI 10.1101/gad.983502; Ow MC, 2000, MOL MICROBIOL, V38, P854, DOI 10.1046/j.1365-2958.2000.02186.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Qiu J, 1998, APPL ENVIRON MICROB, V64, P4891; Raynal LC, 1999, MOL MICROBIOL, V32, P765, DOI 10.1046/j.1365-2958.1999.01394.x; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Scott DJ, 2000, BIOCHEM J, V352, P539, DOI 10.1042/0264-6021:3520539; Steege DA, 2000, RNA, V6, P1079, DOI 10.1017/S1355838200001023; Sun WM, 2001, BIOCHEMISTRY-US, V40, P5102, DOI 10.1021/bi010022d; TARASEVICIENE L, 1995, J BIOL CHEM, V270, P26391, DOI 10.1074/jbc.270.44.26391; Tsao KL, 1996, GENE, V169, P59, DOI 10.1016/0378-1119(95)00762-8; Vanzo NF, 1998, GENE DEV, V12, P2770, DOI 10.1101/gad.12.17.2770; Walsh AP, 2001, NUCLEIC ACIDS RES, V29, P1864, DOI 10.1093/nar/29.9.1864; ZHAN X, 2002, THESIS U TEXAS AUSTI	62	117	119	6	23	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					623	634		10.1016/j.cell.2003.08.003	http://dx.doi.org/10.1016/j.cell.2003.08.003			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678585	Bronze			2022-12-28	WOS:000185193100011
J	Pinnaduwage, LA; Gehl, A; Hedden, DL; Muralidharan, G; Thundat, T; Lareau, RT; Sulchek, T; Manning, L; Rogers, B; Jones, M; Adams, JD				Pinnaduwage, LA; Gehl, A; Hedden, DL; Muralidharan, G; Thundat, T; Lareau, RT; Sulchek, T; Manning, L; Rogers, B; Jones, M; Adams, JD			A microsensor for trinitrotoluene vapour	NATURE			English	Editorial Material							MICROCANTILEVERS; SENSORS		Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA; Univ Tennessee, Dept Phys, Knoxville, TN 37996 USA; Transportat Secur Adm, US Dept Homeland Secur, Atlantic City, NJ 08405 USA; Univ Nevada, Dept Mech Engn, Reno, NV 89557 USA; Univ Nevada, Nevada Ventures Nanosci Program, Reno, NV 89557 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Pinnaduwage, LA (corresponding author), Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA.			Thundat, Thomas/0000-0003-1721-1181				Colton RJ, 2003, SCIENCE, V299, P1324, DOI 10.1126/science.1080688; Czarnik AW, 1998, NATURE, V394, P417, DOI 10.1038/28728; Furton KG, 2001, TALANTA, V54, P487, DOI 10.1016/S0039-9140(00)00546-4; Khayamian T, 2003, TALANTA, V59, P327, DOI 10.1016/S0039-9140(02)00521-0; Lang HP, 1998, APPL PHYS LETT, V72, P383, DOI 10.1063/1.120749; Minne SC, 1995, APPL PHYS LETT, V67, P3918, DOI 10.1063/1.115317; Muralidharan G, 2003, ULTRAMICROSCOPY, V97, P433, DOI 10.1016/S0304-3991(03)00071-8; ROGERS B, IN PRESS REV SCI INS; THUNDAT T, 1995, ANAL CHEM, V67, P519, DOI 10.1021/ac00099a006	9	154	165	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					474	474		10.1038/425474a	http://dx.doi.org/10.1038/425474a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523436				2022-12-28	WOS:000185648100034
J	Norris, JM; Barriga, K; Klingensmith, G; Hoffman, M; Eisenbarth, GS; Erlich, HA; Rewers, M				Norris, JM; Barriga, K; Klingensmith, G; Hoffman, M; Eisenbarth, GS; Erlich, HA; Rewers, M			Timing of initial cereal exposure in infancy and risk of islet autoimmunity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT DIABETES-MELLITUS; BETA-CELL AUTOIMMUNITY; CELIAC-DISEASE; COWS MILK; YOUNG DAISY; AUTOANTIBODIES; INSULIN; CHILDHOOD; IDDM; ASSOCIATION	Context Dietary exposures in infancy have been implicated, albeit inconsistently, in the etiology of type 1 diabetes mellitus (DM). Objective To examine the association between cereal exposures in the infant diet and appearance of islet autoimmunity (IA). Design Birth cohort study conducted from 1994 to 2002 with a mean follow-up of 4 years. Setting Newborn screening for HLA was done at St Joseph's Hospital in Denver, Colo. First-degree relatives of type 1 DM individuals were recruited from the Denver metropolitan area. Participants We enrolled 1183 children at increased type 1 DM risk, defined as either HLA genotype or having a first-degree relative with type 1 DM, at birth and followed them prospectively. We obtained exposure and outcome measures for 76% of enrolled children. Participants had variable lengths of follow-up (9 months to 9 years). Main Outcome Measures Blood draws for the detection of insulin autoantibody, glutamic acid decarboxylase autoantibody, or IA-2 autoantibody were performed at 9, 15, and 24 months and annually thereafter. Children with A (n=34) were defined as those testing positive for at least 1 of the autoantibodies on 2 or more consecutive visits and who tested positive or had diabetes on their most recent visit. Results Children initially exposed to cereals between ages 0 and 3 months (hazard ratio [HR], 4.32; 95% confidence interval [CI], 2.0-9.35) and those who were exposed at 7 months or older (HR, 5.36; 95% Cl, 2.08-13.8) had increased hazard of A compared with those who were exposed during the fourth through sixth month, after adjustment for HLA genotype, family history of type 1 DM, ethnicity, and maternal age. In children who were positive for the HLA-DRB1*03/04,DQB8 genotype, adjusted HRs Were 5.55 (95% Cl, 1.92-16.03) and 12.53 (95% Cl, 3.19-49.23) for initial cereal exposure between ages 0 to 3 months and at 7 months or older, respectively. Conclusion There maybe a window of exposure to cereals in infancy outside which initial exposure increases A risk in susceptible children.	Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA; Roche Mol Syst Inc, Dept Human Genet, Alameda, CA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Roche Holding	Norris, JM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, 4200 E 9th Ave,Box B119, Denver, CO 80262 USA.				NIDDK NIH HHS [R01-DK32493, R01-DK49654] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049654, R01DK032493] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allison P. D, 1995, SURVIVAL ANAL USING; Ascher H, 2001, ACTA PAEDIATR, V90, P1217, DOI 10.1080/080352501317130209; BJORK E, 1992, DIABETOLOGIA, V35, P490, DOI 10.1007/BF02342450; Couper JJ, 1999, DIABETES, V48, P2145, DOI 10.2337/diabetes.48.11.2145; Haglund B, 1996, DIABETES CARE, V19, P873, DOI 10.2337/diacare.19.8.873; HAYWARD AR, 1992, J LAB CLIN MED, V119, P503; Ho E, 2001, EXP BIOL MED, V226, P103, DOI 10.1177/153537020122600207; Hummel M, 2002, DIABETES CARE, V25, P1111, DOI 10.2337/diacare.25.7.1111; Hummel M, 2000, DIABETES CARE, V23, P969, DOI 10.2337/diacare.23.7.969; Hypponen E, 1999, DIABETES CARE, V22, P1961, DOI 10.2337/diacare.22.12.1961; Ivarsson A, 2002, AM J CLIN NUTR, V75, P914, DOI 10.1093/ajcn/75.5.914; Kimpimaki T, 2001, DIABETOLOGIA, V44, P63, DOI 10.1007/s001250051581; KLEINMAN RE, 1998, PEDIAT NUTR HDB, P43; Knekt P, 1999, J INTERN MED, V245, P99, DOI 10.1046/j.1365-2796.1999.00416.x; KOSTRABA JN, 1993, DIABETES, V42, P288, DOI 10.2337/diabetes.42.2.288; KOSTRABA JN, 1992, EPIDEMIOLOGY, V3, P232, DOI 10.1097/00001648-199205000-00008; LaGasse JM, 2002, DIABETES CARE, V25, P505, DOI 10.2337/diacare.25.3.505; Leslie RDG, 1999, DIABETOLOGIA, V42, P3, DOI 10.1007/s001250051105; MacFarlane AJ, 2003, J BIOL CHEM, V278, P54, DOI 10.1074/jbc.M210636200; Meloni T, 1997, DIABETES CARE, V20, P340, DOI 10.2337/diacare.20.3.340; Norris JM, 1999, J ENDOCRINOL INVEST, V22, P568, DOI 10.1007/BF03343611; Norris JM, 1996, JAMA-J AM MED ASSOC, V276, P609, DOI 10.1001/jama.276.8.609; PEREZBRAVO E, 1996, J MOL MED, V74, P105; Rewers M, 1996, DIABETOLOGIA, V39, P807, DOI 10.1007/s001250050514; Roll U, 1996, DIABETES, V45, P967, DOI 10.2337/diabetes.45.7.967; Scott FW, 2002, DIABETES, V51, P73, DOI 10.2337/diabetes.51.1.73; Ventura A, 2000, J PEDIATR-US, V137, P263, DOI 10.1067/mpd.2000.107160; Verge CF, 1996, DIABETES, V45, P926, DOI 10.2337/diabetes.45.7.926; VIRTANEN SM, 1993, DIABETES, V42, P1786, DOI 10.2337/diabetes.42.12.1786; Yu LP, 2000, P NATL ACAD SCI USA, V97, P1701, DOI 10.1073/pnas.040556697; Yu LP, 1996, J CLIN ENDOCR METAB, V81, P4264, DOI 10.1210/jc.81.12.4264; Zhao HX, 2001, DIABETIC MED, V18, P709, DOI 10.1046/j.1464-5491.2001.00554.x	32	344	351	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1713	1720		10.1001/jama.290.13.1713	http://dx.doi.org/10.1001/jama.290.13.1713			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519705	Bronze			2022-12-28	WOS:000185606100020
J	Saiman, L; Marshall, BC; Mayer-Hamblett, N; Burns, JL; Quittner, AL; Cibene, DA; Coquillette, S; Fieberg, AY; Accurso, FJ; Campbel, PW				Saiman, L; Marshall, BC; Mayer-Hamblett, N; Burns, JL; Quittner, AL; Cibene, DA; Coquillette, S; Fieberg, AY; Accurso, FJ; Campbel, PW		Macrolide Study Grp	Azithromycin in, patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM AZITHROMYCIN; QUALITY-OF-LIFE; CHILDREN; DISEASE; MYCOBACTERIA; ERYTHROMYCIN; VALIDATION; PROTEIN; SPUTUM	Context Treatment strategies for cystic fibrosis (CF) lung disease include antibiotics, mucolytics, and anti-inflammatory therapies. Increasing evidence suggests that macrolide antibiotics might be beneficial in patients with CF. Objective To determine if an association between azithromycin use and pulmonary function exists in patients with CF. Design and Setting A multicenter, randomized, double-blind, placebo-controlled trial conducted from December 15, 2000, to May 2, 2002, at 23 CF care centers in the United States. Participants Of the 251 screened participants with a diagnosis of CF, 185 (74%) were randomized. Eligibility criteria included age 6 years or older, infection with Pseudomonas aeruginosa for 1 or more years, and a forced expiratory volume in 1 second (FEV1) of 30% or more. Participants were stratified by FEV1 (greater than or equal to60% predicted vs <60% predicted), weight of less than 40 kg vs 40 kg or more, and CF center. Intervention The active group (n=87) received 250 mg (weight <40 kg) or 500 mg (weight greater than or equal to40 kg) of oral azithromycin 3 days a week for 168 days; placebo group (n=98) received identically packaged tablets. Main Outcome Measures Change in FEV1 from day 0 to completion of therapy at day 168 and determination of safety. Secondary outcomes included pulmonary exacerbations and weight gain. Results The azithromycin group had a mean 0.097-L (SD, 0.26) increase in FEV1 at day 168 compared with 0.003 L (SID, 0.23) in the placebo group (mean difference, 0.094 L; 95% confidence interval [CI], 0.023-0.165; P=.009). Nausea occurred in 17% more participatns in the azithromycin group (P =.01), diarrhea in 15% more (P =.009), and wheezing in 13% more (P =.007). Participants in the azithromycin group had less risk of experiencing an exacerbation than participants in the placebo group (hazard ratio, 0.65; 95% Cl, 0.44-0.95; P=.03) and weighed at the end of the study an average 0.7 kg more than participants receiving placebo (95% Cl, 0.1-1.4 kg; P=.02). Conclusion Azithromycin treatment was associated with improvement in clinically relevant end points and should be considered for patients with CF who are 6 years or older and chronically infected with P aeruginosa.	Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Cyst Fibrosis Therapeut Dev Network Coordinating, Seattle, WA USA; Cyst Fibrosis Therapeut Dev Network Resource Ctr, Seattle, WA USA; Univ Florida, Dept Pediat, Dept Clin & Hlth Psychol, Gainesville, FL USA; Univ Colorado, Dept Pediat, Denver, CO 80202 USA; Cyst Fibrosis Therapeut Dev Network Resource Ctr, Denver, CO USA; Cyst Fibrosis Fdn, Bethesda, MD USA	Columbia University; Utah System of Higher Education; University of Utah; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; State University System of Florida; University of Florida; University of Colorado System; University of Colorado Denver; Cystic Fibrosis Foundation	Saiman, L (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pediat, 650 W 168th St,BB4-427, New York, NY 10032 USA.	ls5@columbia.edu						Altschuler EL, 1998, LANCET, V351, P1286, DOI 10.1016/S0140-6736(05)79350-8; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; ANSTEAD MI, 1999, PEDIAT PULMONOL, V19, P283; APP EM, 2000, AM J RESP CRIT CARE, V161, P758; Burns JL, 1998, CLIN INFECT DIS, V27, P158, DOI 10.1086/514631; DIGGLE P, 2002, OXFORD STAT SCI SERI, P117; Equi A, 2002, LANCET, V360, P978, DOI 10.1016/S0140-6736(02)11081-6; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; Ichimiya T, 1996, CHEMOTHERAPY, V42, P186, DOI 10.1159/000239440; IGLEWSKI BH, 2002, PEDIATR PULM, V24, P146; Jaffe A, 1998, LANCET, V351, P420, DOI 10.1016/S0140-6736(05)78360-4; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; KONSTAN MW, 1995, NEW ENGL J MED, V332, P848, DOI 10.1056/NEJM199503303321303; Koyama H, 1997, THORAX, V52, P915, DOI 10.1136/thx.52.10.915; Kudoh S, 1998, AM J RESP CRIT CARE, V157, P1829, DOI 10.1164/ajrccm.157.6.9710075; Labro M. T., 1998, Journal of Antimicrobial Chemotherapy, V41, P37, DOI 10.1093/jac/41.suppl_2.37; Liou TG, 2001, AM J EPIDEMIOL, V153, P345, DOI 10.1093/aje/153.4.345; Modi AC, 2003, J PEDIATR PSYCHOL, V28, P535, DOI 10.1093/jpepsy/jsg044; Olivier KN, 2003, AM J RESP CRIT CARE, V167, P828, DOI 10.1164/rccm.200207-678OC; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Quittner AL, 2000, J PEDIATR PSYCHOL, V25, P403, DOI 10.1093/jpepsy/25.6.403; QUITTNER AL, 2002, QUAL LIFE RES, V11, P661; Ramsey BW, 1999, NEW ENGL J MED, V340, P23, DOI 10.1056/NEJM199901073400104; Ramsey BW, 1996, NEW ENGL J MED, V335, P179, DOI 10.1056/NEJM199607183350307; Sagel SD, 2001, AM J RESP CRIT CARE, V164, P1425, DOI 10.1164/ajrccm.164.8.2104075; Saiman L, 2002, ANTIMICROB AGENTS CH, V46, P1105, DOI 10.1128/AAC.46.4.1105-1107.2002; SHEPARD RM, 1991, J CHROMATOGR-BIOMED, V565, P321, DOI 10.1016/0378-4347(91)80393-Q; Tai S, 1999, PEDIATR PULM, V19, P264; Tateda K, 1996, ANTIMICROB AGENTS CH, V40, P2271, DOI 10.1128/AAC.40.10.2271; Welsh MJ, 2001, METABOLIC MOL BASES, P521; WHITTIER S, 1993, J CLIN MICROBIOL, V31, P861, DOI 10.1128/JCM.31.4.861-864.1993; Wolter J, 2002, THORAX, V57, P212, DOI 10.1136/thorax.57.3.212; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	33	705	724	1	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1749	1756		10.1001/jama.290.13.1749	http://dx.doi.org/10.1001/jama.290.13.1749			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519709	Bronze			2022-12-28	WOS:000185606100024
J	Gigerenzer, G; Edwards, A				Gigerenzer, G; Edwards, A			Simple tools for understanding risks: from innumeracy to insight	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FREQUENCY; BENEFITS; CANCER; WOMEN	Bad presentation of medical statistics such as the risks associated with a particular intervention can lead to patients making poor decisions on treatment Particularly confusing are single event probabilities, conditional probabilities (such as sensitivity and specificity), and relative risks. How can doctors improve the presentation of statistical information so that patients can make well informed decisions?	Max Planck Inst Human Dev, Ctr Adapt Behav & Cognit, D-14195 Berlin, Germany; Univ Coll Swansea, Swansea Clin Sch, Primary Care Grp, Swansea SA2 8PP, W Glam, Wales	Max Planck Society; Swansea University	Gigerenzer, G (corresponding author), Max Planck Inst Human Dev, Ctr Adapt Behav & Cognit, Lentzeallee 94, D-14195 Berlin, Germany.	gigerenzer@mpib-berlin.mpg.de	Gigerenzer, Gerd/A-6250-2012; Gigerenzer, Gerd/M-5595-2013	Gigerenzer, Gerd/0000-0002-6163-5419; 				CASSCELLS W, 1978, NEW ENGL J MED, V299, P999, DOI 10.1056/NEJM197811022991808; Cosmides L, 1996, COGNITION, V58, P1, DOI 10.1016/0010-0277(95)00664-8; Edwards A, 2002, BMJ-BRIT MED J, V324, P827, DOI 10.1136/bmj.324.7341.827; Edwards A, 2001, J HEALTH COMMUN, V6, P61, DOI 10.1080/10810730150501413; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; GIGCRENZER G, 2002, CALCULATED RISKS KNO; GIGERENZER G, 1995, PSYCHOL REV, V102, P684, DOI 10.1037/0033-295X.102.4.684; Gigerenzer G., 1999, SIMPLE HEURISTICS MA, P3; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; Heller RF, 2000, BRIT MED J, V321, P950, DOI 10.1136/bmj.321.7266.950; Hoffrage U, 1998, ACAD MED, V73, P538, DOI 10.1097/00001888-199805000-00024; Hoffrage U, 2000, SCIENCE, V290, P2261, DOI 10.1126/science.290.5500.2261; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; Kuhberger A, 1998, ORGAN BEHAV HUM DEC, V75, P23, DOI 10.1006/obhd.1998.2781; Lipkus I M, 1999, J Natl Cancer Inst Monogr, P149; MAZUR DJ, 1994, THEOR SURG, V9, P129; Nystrom L, 1996, J Med Screen, V3, P85; Paling J, 2003, BRIT MED J, V327, P745, DOI 10.1136/bmj.327.7417.745; Sarfati D, 1998, J MED SCREEN, V5, P137, DOI 10.1136/jms.5.3.137; Schapira MM, 2001, MED DECIS MAKING, V21, P459, DOI 10.1177/02729890122062811; Slaytor EK, 1998, BRIT MED J, V317, P263, DOI 10.1136/bmj.317.7153.263; WILSON D K, 1988, Health Education Research, V3, P161, DOI 10.1093/her/3.2.161; Woloshin S, 1999, Eff Clin Pract, V2, P176; Wright P, 2000, ADV LEARN INS SERIES, P31	24	478	484	1	61	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 27	2003	327	7417					741	744		10.1136/bmj.327.7417.741	http://dx.doi.org/10.1136/bmj.327.7417.741			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	728FZ	14512488	Green Submitted, Green Published			2022-12-28	WOS:000185708300028
J	van der Werf, TS; Stinear, T; Stienstra, Y; van der Graaf, WTA; Small, PL				van der Werf, TS; Stinear, T; Stienstra, Y; van der Graaf, WTA; Small, PL			Mycolactones and Mycobacterium ulcerans disease	LANCET			English	Review							BURULI ULCER; BOVIS BCG; INFECTION; MICE; VIRULENCE; RIFAMPIN; GHANA; TOXIN; PCR		Univ Groningen, Med Ctr, Dept Internal Med, NL-9700 RB Groningen, Netherlands; Inst Pasteur, Unite Genet Bacterienne, Paris, France; Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA	University of Groningen; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Tennessee System; University of Tennessee Knoxville	van der Werf, TS (corresponding author), Univ Groningen, Med Ctr, Dept Internal Med, POB 30001, NL-9700 RB Groningen, Netherlands.		van der Graaf, Winette T/A-5006-2014; Stienstra, Ymkje/F-2222-2010	van der Graaf, Winette T/0000-0001-7549-3338; Stienstra, Ymkje/0000-0002-8844-8859; van der Werf, Tjip/0000-0002-4824-1642; Stinear, Timothy/0000-0003-0150-123X				Amofah G, 2002, EMERG INFECT DIS, V8, P167, DOI 10.3201/eid0802.010119; Aujoulat I, 2003, TROP MED INT HEALTH, V8, P750, DOI 10.1046/j.1365-3156.2003.01089.x; Dega H, 2000, ANTIMICROB AGENTS CH, V44, P2367, DOI 10.1128/AAC.44.9.2367-2372.2000; Dega H, 2002, ANTIMICROB AGENTS CH, V46, P3193, DOI 10.1128/AAC.46.10.3193-3196.2002; Dhople AM, 2003, J CHEMOTHERAPY, V15, P47, DOI 10.1179/joc.2003.15.1.47; Dobos KM, 2001, INFECT IMMUN, V69, P7182, DOI 10.1128/IAI.69.11.7182-7186.2001; Ellen DE, 2003, TROP MED INT HEALTH, V8, P90, DOI 10.1046/j.1365-3156.2003.00976.x; Espey David K., 2002, International Journal of Infectious Diseases, V6, P60, DOI 10.1016/S1201-9712(02)90138-4; ETUAFUL S, 2003, 6 WHO ADV GROUP M BU; Fidanze S, 2001, J AM CHEM SOC, V123, P10117, DOI 10.1021/ja011824z; George KM, 1999, SCIENCE, V283, P854, DOI 10.1126/science.283.5403.854; George KM, 2000, INFECT IMMUN, V68, P877, DOI 10.1128/IAI.68.2.877-883.2000; Gooding TM, 2003, CLIN INFECT DIS, V36, P1076, DOI 10.1086/368315; Guimaraes-Peres A, 1999, J CLIN MICROBIOL, V37, P206, DOI 10.1128/JCM.37.1.206-208.1999; *I PAST, MYC ULC; Marsollier L, 2003, ANTIMICROB AGENTS CH, V47, P1228, DOI 10.1128/AAC.47.4.1228-1232.2003; Marsollier L, 2002, APPL ENVIRON MICROB, V68, P4623, DOI 10.1128/AEM.68.9.4623-4628.2002; MARSOLLIER L, 2003, 6 WHO ADV GROUP M BU; Mve-Obiang A, 2003, INFECT IMMUN, V71, P774, DOI 10.1128/IAI.71.2.774-783.2003; Portaels F, 2002, CLIN DIAGN LAB IMMUN, V9, P1389, DOI 10.1128/CDLI.9.6.1389-1391.2002; Portaels F, 2001, REV SCI TECH OIE, V20, P252, DOI 10.20506/rst.20.1.1270; Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859; Snyder DS, 2003, MICROB PATHOGENESIS, V34, P91, DOI 10.1016/S0882-4010(02)00210-3; Stienstra Y, 2003, J CLIN MICROBIOL, V41, P794, DOI 10.1128/JCM.41.2.794-797.2003; Stienstra Y, 2002, AM J TROP MED HYG, V67, P207, DOI 10.4269/ajtmh.2002.67.207; STIENSTRA Y, 2001, TROP MED INT HEALTH, V6, P1; Stinear T, 1999, J CLIN MICROBIOL, V37, P1018, DOI 10.1128/JCM.37.4.1018-1023.1999; Stinear TP, 2000, J BACTERIOL, V182, P6322, DOI 10.1128/JB.182.22.6322-6330.2000; Tanghe A, 2001, INFECT IMMUN, V69, P5403, DOI 10.1128/IAI.69.9.5403-5411.2001; Teelken MA, 2003, ACTA TROP, V88, P51, DOI 10.1016/S0001-706X(03)00170-0; van der Werf TS, 1999, LANCET, V354, P1013, DOI 10.1016/S0140-6736(99)01156-3	31	64	69	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 27	2003	362	9389					1062	1064		10.1016/S0140-6736(03)14417-0	http://dx.doi.org/10.1016/S0140-6736(03)14417-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522538				2022-12-28	WOS:000185564600025
J	Lilic, M; Galkin, VE; Orlova, A; VanLoock, MS; Egelman, EH; Stebbins, CE				Lilic, M; Galkin, VE; Orlova, A; VanLoock, MS; Egelman, EH; Stebbins, CE			Salmonella SipA polymerizes actin by stapling filaments with nonglobular protein arms	SCIENCE			English	Article							BINDING PROTEIN	Like many bacterial pathogens, Salmonella spp. use a type III secretion system to inject virulence proteins into host cells. The Salmonella invasion protein A ( SipA) binds host actin, enhances its polymerization near adherent extracellular bacteria, and contributes to cytoskeletal rearrangements that internalize the pathogen. By combining x-ray crystallography of SipA with electron microscopy and image analysis of SipA-actin. laments, we show that SipA functions as a "molecular staple," in which a globular domain and two nonglobular "arms" mechanically stabilize the. lament by tethering actin subunits in opposing strands. Deletion analysis of the tethering arms provides strong support for this model.	Rockefeller Univ, Lab Struct Microbiol, New York, NY 10021 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Rockefeller University; University of Virginia	Stebbins, CE (corresponding author), Rockefeller Univ, Lab Struct Microbiol, 1230 York Ave, New York, NY 10021 USA.	stebbins@rockefeller.edu	Stebbins, Erec/N-2565-2018; Galkin, Vitold/AAD-2844-2019; Egelman, Edward H/A-2488-2009	Stebbins, Erec/0000-0001-6229-5308; Egelman, Edward/0000-0003-4844-5212				Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Galkin VE, 2002, NAT STRUCT BIOL, V9, P518, DOI 10.1038/nsb811; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lukoyanova N, 2002, CURR BIOL, V12, P383, DOI 10.1016/S0960-9822(02)00678-4; McGhie EJ, 2001, EMBO J, V20, P2131, DOI 10.1093/emboj/20.9.2131; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitra K, 2000, FEBS LETT, V482, P81, DOI 10.1016/S0014-5793(00)02040-8; PANG T, 1995, TRENDS MICROBIOL, V3, P253, DOI 10.1016/S0966-842X(00)88937-4; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; Torok TJ, 1997, JAMA-J AM MED ASSOC, V278, P389, DOI 10.1001/jama.278.5.389; Tsolis RM, 2000, INFECT IMMUN, V68, P3158, DOI 10.1128/IAI.68.6.3158-3163.2000; Zhang SP, 2002, INFECT IMMUN, V70, P3843, DOI 10.1128/IAI.70.7.3843-3855.2002; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092	18	90	94	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1918	1921		10.1126/science.1088433	http://dx.doi.org/10.1126/science.1088433			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512630				2022-12-28	WOS:000185536700054
J	Beltrami, AP; Barlucchi, L; Torella, D; Baker, M; Limana, F; Chimenti, S; Kasahara, H; Rota, M; Musso, E; Urbanek, K; Leri, A; Kajstura, J; Nadal-Ginard, B; Anversa, P				Beltrami, AP; Barlucchi, L; Torella, D; Baker, M; Limana, F; Chimenti, S; Kasahara, H; Rota, M; Musso, E; Urbanek, K; Leri, A; Kajstura, J; Nadal-Ginard, B; Anversa, P			Adult cardiac stem cells are multipotent and support myocardial regeneration	CELL			English	Article							PROGENITOR CELLS; HEART; LINEAGE; TRANSPLANTATION; EXPRESSION; INFARCTION; MYOCYTES; PROLIFERATION; CHIMERISM; FAILURE	The notion of the adult heart as terminally differentiated organ without self-renewal potential has been undermined by the existence of a subpopulation of replicating myocytes in normal and pathological states. The origin and significance of these cells has remained obscure for lack of a proper biological context. We report the existence of Lin(-) c-kit(POS) cells with the properties of cardiac stem cells. They are self-renewing, clonogenic, and multipotent, giving rise to myocytes, smooth muscle, and endothelial cells. When injected into an ischemic heart, these cells or their clonal progeny reconstitute well-differentiated myocardium, formed by blood-carrying new vessels and myocytes with the characteristics of young cells, encompassing similar to70% of the ventricle. Thus, the adult heart, like the brain, is mainly composed of terminally differentiated cells, but is not a terminally differentiated organ because it contains stem cells supporting its regeneration. The existence of these cells opens new opportunities for myocardial repair.	New York Med Coll, Dept Med, Inst Cardiovasc Res, Valhalla, NY 10595 USA; Univ Florida, Dept Physiol & Funct Genom, Gainesville, FL 32611 USA	New York Medical College; State University System of Florida; University of Florida	Anversa, P (corresponding author), New York Med Coll, Dept Med, Inst Cardiovasc Res, Valhalla, NY 10595 USA.	piero_anversa@nymc.edu	Beltrami, Antonio/C-5291-2008	Beltrami, Antonio/0000-0002-0679-2710; TORELLA, Daniele/0000-0002-4915-5084	NHLBI NIH HHS [HL-66923, HL-65573, HL-39902, HL-65557, HL-38132] Funding Source: Medline; NIA NIH HHS [AG-17042, AG-15756] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065573, R01HL066923, R01HL038132, R01HL039902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015756, R01AG017042] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alison MR, 2003, J CELL SCI, V116, P599, DOI 10.1242/jcs.00269; Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; Anversa P, 2002, CIRCULATION, V106, pE129, DOI 10.1161/01.CIR.0000035926.40150.D0; Anversa P, 2002, NATURE, V415, P240, DOI 10.1038/415240a; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Frangogiannis NG, 1998, CIRCULATION, V98, P687, DOI 10.1161/01.CIR.98.7.687; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Glaser R, 2002, CIRCULATION, V106, P17, DOI 10.1161/01.CIR.0000021923.58307.8F; Hellermann JP, 2002, AM J MED, V113, P324, DOI 10.1016/S0002-9343(02)01185-3; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; Kasahara H, 1998, CIRC RES, V82, P936, DOI 10.1161/01.RES.82.9.936; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kosaka M, 1998, EXP CELL RES, V245, P245, DOI 10.1006/excr.1998.4211; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kunisada T, 1998, DEVELOPMENT, V125, P2915; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Mahmud N, 2001, BLOOD, V97, P3061, DOI 10.1182/blood.V97.10.3061; MCDONNELL TJ, 1984, CELL TISSUE RES, V235, P583; Mikawa T, 1999, HEART DEV, P19; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Muller P, 2002, CIRCULATION, V106, P31, DOI 10.1161/01.CIR.0000022405.68464.CA; Nadal-Ginard B, 2003, CIRC RES, V92, P139, DOI 10.1161/01.RES.0000053618.86362.DF; Nadin BM, 2003, BLOOD, V102, P2436, DOI 10.1182/blood-2003-01-0118; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Rosenthal N, 2003, NEW ENGL J MED, V349, P267, DOI 10.1056/NEJMra020849; RUMYANTSEV PP, 1987, BIOMED BIOCHIM ACTA, V46, pS610; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Sellers SE, 2001, BLOOD, V97, P1888, DOI 10.1182/blood.V97.6.1888; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Teyssier-Le Discorde M, 1999, BRIT J HAEMATOL, V107, P247, DOI 10.1046/j.1365-2141.1999.01725.x; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3; Urbanek K, 2003, P NATL ACAD SCI USA, V100, P10440, DOI 10.1073/pnas.1832855100; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387	44	2619	2917	3	340	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					763	776		10.1016/S0092-8674(03)00687-1	http://dx.doi.org/10.1016/S0092-8674(03)00687-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505575	Bronze			2022-12-28	WOS:000185464000013
J	Kim, PW; Sun, ZYJ; Blacklow, SC; Wagner, G; Eck, MJ				Kim, PW; Sun, ZYJ; Blacklow, SC; Wagner, G; Eck, MJ			A zinc clasp structure tethers Lck to T cell coreceptors CD4 and CD8	SCIENCE			English	Article							TYROSINE-PROTEIN-KINASE; AMINO-TERMINAL DOMAIN; CYTOPLASMIC TAIL; SERINE PHOSPHORYLATION; DOWN-REGULATION; COATED PITS; P56LCK; P56(LCK); ANTIGEN; COMPLEX	The T cell coreceptors CD4 and CD8 both associate via their cytoplasmic tails with the N-terminus of the Src-family tyrosine kinase Lck. These interactions require zinc and are critical for T cell development and activation. We examined the folding and solution structures of ternary CD4-Lck-Zn2+ and CD8alpha-LckZn(2+) complexes. The coreceptor tails and the Lck N-terminus are unstructured in isolation but assemble in the presence of zinc to form compactly folded heterodimeric domains. The cofolded complexes have similar "zinc clasp" cores that are augmented by distinct structural elements. A dileucine motif required for clathrin-mediated endocytosis of CD4 is masked by Lck.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Eck, MJ (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.	eck@red.dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA080942] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061001] Funding Source: NIH RePORTER; NCI NIH HHS [CA080942] Funding Source: Medline; NHLBI NIH HHS [HL61001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; COLLINS TL, 1992, J IMMUNOL, V148, P2159; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; Huse M, 1998, J BIOL CHEM, V273, P18729, DOI 10.1074/jbc.273.30.18729; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Kim Philip, UNPUB; Lin RS, 1998, J BIOL CHEM, V273, P32878, DOI 10.1074/jbc.273.49.32878; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; PELCHENMATTHEWS A, 1993, J EXP MED, V178, P1209, DOI 10.1084/jem.178.4.1209; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALGHETTI S, 1995, P NATL ACAD SCI USA, V92, P349, DOI 10.1073/pnas.92.2.349; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SLECKMAN BP, 1992, P NATL ACAD SCI USA, V89, P7566, DOI 10.1073/pnas.89.16.7566; Trobridge PA, 2001, J IMMUNOL, V166, P809, DOI 10.4049/jimmunol.166.2.809; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEYAND CM, 1987, J IMMUNOL, V138, P1351; Wray V, 1998, BIOCHEMISTRY-US, V37, P8527, DOI 10.1021/bi9723111	26	179	188	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1725	1728		10.1126/science.1085643	http://dx.doi.org/10.1126/science.1085643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500983				2022-12-28	WOS:000185387700045
J	Drazen, JM				Drazen, JM			Decisions at the end of life	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material													Drazen, Jeffrey M/E-5841-2012	Drazen, Jeffrey/0000-0003-2715-9890					0	18	20	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1109	1110		10.1056/NEJMp038146	http://dx.doi.org/10.1056/NEJMp038146			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679523				2022-12-28	WOS:000185369700002
J	Duan, XF; Niu, CM; Sahi, V; Chen, J; Parce, JW; Empedocles, S; Goldman, JL				Duan, XF; Niu, CM; Sahi, V; Chen, J; Parce, JW; Empedocles, S; Goldman, JL			High-performance thin-film transistors using semiconductor nanowires and nanoribbons	NATURE			English	Article							DISPLAYS; CHANNEL	Thin-film transistors (TFTs) are the fundamental building blocks for the rapidly growing field of macroelectronics(1,2). The use of plastic substrates is also increasing in importance owing to their light weight, flexibility, shock resistance and low cost(3,4). Current polycrystalline-Si TFT technology is difficult to implement on plastics because of the high process temperatures required(1,2). Amorphous-Si and organic semiconductor(5,6) TFTs, which can be processed at lower temperatures, but are limited by poor carrier mobility. As a result, applications that require even modest computation, control or communication functions on plastics cannot be addressed by existing TFT technology. Alternative semiconductor materials(7,8) that could form TFTs with performance comparable to or better than polycrystalline or single-crystal Si, and which can be processed at low temperatures over large-area plastic substrates, should not only improve the existing technologies, but also enable new applications in flexible, wearable and disposable electronics. Here we report the fabrication of TFTs using oriented Si nanowire thin films or CdS nanoribbons as semiconducting channels. We show that high-performance TFTs can be produced on various substrates, including plastics, using a low-temperature assembly process. Our approach is general to a broad range of materials including high-mobility materials (such as InAs or InP).	Nanosys Inc, Adv Res Ctr, Medford, MA 02155 USA; Nanosys Inc, Palo Alto, CA 94304 USA		Duan, XF (corresponding author), Nanosys Inc, Adv Res Ctr, 200 Boston Ave, Medford, MA 02155 USA.	xduan@nanosysinc.com	Duan, Xiangfeng/AAQ-9674-2020; Duan, Xiangfeng/E-7522-2011	Duan, Xiangfeng/0000-0002-4321-6288; Duan, Xiangfeng/0000-0002-4321-6288				Cui Y, 2003, NANO LETT, V3, P149, DOI 10.1021/nl025875l; Cui Y, 2001, APPL PHYS LETT, V78, P2214, DOI 10.1063/1.1363692; Dimitrakopoulos CD, 2001, IBM J RES DEV, V45, P11, DOI 10.1147/rd.451.0011; DUAN X, 2003, MOL NANOELECTRONICS; Duan XF, 2003, NATURE, V421, P241, DOI 10.1038/nature01353; Duan XF, 2000, ADV MATER, V12, P298, DOI 10.1002/(SICI)1521-4095(200002)12:4<298::AID-ADMA298>3.0.CO;2-Y; Duan XF, 2001, NATURE, V409, P66, DOI 10.1038/35051047; GARNIER F, 1994, SCIENCE, V265, P1684, DOI 10.1126/science.265.5179.1684; Hastas NA, 2002, IEEE T ELECTRON DEV, V49, P1552, DOI 10.1109/TED.2002.802622; Horowitz P., 2015, ART ELECT; Huang Y, 2001, SCIENCE, V291, P630, DOI 10.1126/science.291.5504.630; Javey A, 2002, NAT MATER, V1, P241, DOI 10.1038/nmat769; Kagan CR, 1999, SCIENCE, V286, P945, DOI 10.1126/science.286.5441.945; Lauhon LJ, 2002, NATURE, V420, P57, DOI 10.1038/nature01141; Lee MJ, 2000, SOLID STATE ELECTRON, V44, P1431, DOI 10.1016/S0038-1101(00)00067-8; Madelung O., 2000, TECHNOLOGY APPL AMOR; MADELUNG O, 1987, LANDOLTBORNSTEIN NEW, V3, P407; Mizuno T, 2001, IEEE T ELECTRON DEV, V48, P1612, DOI 10.1109/16.936571; Ridley BA, 1999, SCIENCE, V286, P746, DOI 10.1126/science.286.5440.746; Rogers JA, 2001, P NATL ACAD SCI USA, V98, P4835, DOI 10.1073/pnas.091588098; Rosenblatt S, 2002, NANO LETT, V2, P869, DOI 10.1021/nl025639a; Sirringhaus H, 2000, SCIENCE, V290, P2123, DOI 10.1126/science.290.5499.2123; SZE SM, 1981, PHYSICS SEMICONDUCTO; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; TAO A, 2003, NANO LETT       0802, DOI DOI 10.102/N1344209; Uchikoga S, 2002, MRS BULL, V27, P881, DOI 10.1557/mrs2002.277; WEIMER PK, 1962, P IRE, V50, P1462, DOI 10.1109/JRPROC.1962.288190; WHANG D, 2003, NANO LETT       0805, DOI DOI 10.102/N10345062; Xia YN, 1996, ADV MATER, V8, P1015, DOI 10.1002/adma.19960081217; Yeh CF, 1999, IEEE ELECTR DEVICE L, V20, P223, DOI 10.1109/55.761021	30	840	955	6	617	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2003	425	6955					274	278		10.1038/nature01996	http://dx.doi.org/10.1038/nature01996			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679911				2022-12-28	WOS:000185370900039
J	Weyand, CM; Goronzy, JJ				Weyand, CM; Goronzy, JJ			Giant-cell arteritis and polymyalgia rheumatica	ANNALS OF INTERNAL MEDICINE			English	Review							ERYTHROCYTE SEDIMENTATION-RATE; POLYMERASE-CHAIN-REACTION; PLACEBO-CONTROLLED TRIAL; VARICELLA-ZOSTER-VIRUS; TEMPORAL ARTERITIS; CHLAMYDIA-PNEUMONIAE; DENDRITIC CELLS; DOUBLE-BLIND; AORTIC-ANEURYSM; PARVOVIRUS B19	Giant-cell arteritis is an immune-mediated disease characterized by granulomatous infiltrates in the wall of medium-size and large arteries. The immunopathology consists of 2 components. Excessive cytokine production (for example, of interleukin-1 and interleukin-6) induces systemic inflammation with an exuberant acute-phase response. In parallel, interferon-gamma, which is released by T cells captured in the arterial wall, activates tissue-injurious macrophages. In response to the immune injury, the artery generates hyperplasia of the intima that leads to luminal occlusion and subsequent tissue ischemia. Despite the systemic character of the disease, distinct vascular territories are preferentially affected. on the basis of the predominant involvement, clinical subtypes can be distinguished: cranial giant-cell arteritis with ischemic complications in the eye, the face, and the central nervous system; large-vessel giant-cell arteritis with occlusions in the subclavian or axillary vessels; aortic giant-cell arteritis; giant-cell arteritis presenting as an intense systemic inflammatory syndrome with nonstenosing vasculitis; and "isolated" polymyalgia rheumatica with myalgias, systemic inflammation, and subclinical vasculitis. Temporal artery biopsy remains the diagnostic procedure of choice to detect arteritis in cranial vessels. In other vascular territories, giant-cell arteritis is most commonly diagnosed by vascular imaging. Laboratory studies characteristically document the marked elevations of nonspecific acute-phase reactants, such as C-reactive protein and erythrocyte sedimentation rate. Cytokines, such as interleukin-6, that induce the acute-phase reaction are currently being explored as more sensitive biological markers of disease activity. Corticosteroids are highly effective in suppressing systemic inflammation, but they do not eliminate the immune responses in the vessel wall. In general, the clinical outcome of giant-cell arteritis is excellent, and efforts must now concentrate on tailoring therapies to the needs of the individual patient.	Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Weyand, CM (corresponding author), Mayo Clin, Guggenheim 401,200 1st St, Rochester, MN 55905 USA.	weyand.cornelia@mayo.edu	Weyand, Cornelia/AAH-3343-2021	Goronzy, Jorg/0000-0001-7670-1856	NEI NIH HHS [R01 EY11916] Funding Source: Medline; NHLBI NIH HHS [R01 HL 63919] Funding Source: Medline; NIAID NIH HHS [R01 AI44142] Funding Source: Medline; NIAMS NIH HHS [R01 AR42527, R01 AR41974] Funding Source: Medline; NIA NIH HHS [R01 AG15043] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011916] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042527, R01AR041974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015043] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Achkar AA, 1998, ANN INTERN MED, V128, P410, DOI 10.7326/0003-4819-128-5-199803010-00016; Agard C, 2002, JOINT BONE SPINE, V69, P367, DOI 10.1016/S1297-319X(02)00412-8; AIELLO PD, 1993, OPHTHALMOLOGY, V100, P550; ALBERT DM, 1976, ARCH OPHTHALMOL-CHIC, V94, P2072; ALBERT DM, 1982, OPHTHALMOLOGY, V89, P1111; ANDERSSON R, 1986, ACTA MED SCAND, V220, P365; Atalay MK, 2001, CURR OPIN RHEUMATOL, V13, P41, DOI 10.1097/00002281-200101000-00007; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barton GM, 2002, CURR TOP MICROBIOL, V270, P81; BIRKHEAD NC, 1957, JAMA-J AM MED ASSOC, V163, P821, DOI 10.1001/jama.1957.02970450023007; BJORNSSON J, 2002, INFLAMMATORY DIS BLO, P255; Bonnet F, 2000, JOINT BONE SPINE, V67, P550, DOI 10.1016/S1297-319X(00)00205-0; Brack A, 1999, ARTHRITIS RHEUM, V42, P311, DOI 10.1002/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F; Brack A, 1997, J CLIN INVEST, V99, P2842, DOI 10.1172/JCI119477; Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496; CALAMIA KT, 1981, ARTHRITIS RHEUM, V24, P1414, DOI 10.1002/art.1780241113; Cantini F, 2001, J RHEUMATOL, V28, P1049; Dababneh A, 1998, J RHEUMATOL, V25, P2140; DELECOEUILLERIE G, 1988, ANN RHEUM DIS, V47, P733, DOI 10.1136/ard.47.9.733; Delves PJ, 2000, NEW ENGL J MED, V343, P37, DOI 10.1056/NEJM200007063430107; Delves PJ, 2000, NEW ENGL J MED, V343, P108, DOI 10.1056/NEJM200007133430207; Duhaut P, 2000, CLIN EXP RHEUMATOL, V18, pS22; Elling P, 1996, J RHEUMATOL, V23, P112; EVANS JM, 1994, ARTHRITIS RHEUM-US, V37, P1539, DOI 10.1002/art.1780371020; EVANS JM, 1995, ANN INTERN MED, V122, P502, DOI 10.7326/0003-4819-122-7-199504010-00004; Evans JM, 2000, RHEUM DIS CLIN N AM, V26, P493, DOI 10.1016/S0889-857X(05)70153-8; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gabriel SE, 1999, ARTHRITIS RHEUM, V42, P1255, DOI 10.1002/1529-0131(199906)42:6<1255::AID-ANR23>3.0.CO;2-P; Genereau T, 1999, ARTHRITIS RHEUM, V42, P2674, DOI 10.1002/1529-0131(199912)42:12<2674::AID-ANR25>3.0.CO;2-A; Ghanchi FD, 1997, SURV OPHTHALMOL, V42, P99, DOI 10.1016/S0039-6257(97)00052-0; Gran JT, 2001, RHEUMATOLOGY, V40, P1238, DOI 10.1093/rheumatology/40.11.1238; Gravanis MB, 2000, INT J CARDIOL, V75, pS21, DOI 10.1016/S0167-5273(00)00184-4; Haugeberg G, 1997, SCAND J RHEUMATOL, V26, P383, DOI 10.3109/03009749709065704; Healey JH, 1996, CALCIFIED TISSUE INT, V58, P73, DOI 10.1007/s002239900014; Helweg-Larsen J, 2002, RHEUMATOLOGY, V41, P445, DOI 10.1093/rheumatology/41.4.445; Hoffman GS, 2002, ARTHRITIS RHEUM, V46, P1309, DOI 10.1002/art.10262; Hunder GG, 2002, CLEV CLIN J MED, V69, P79, DOI 10.3949/ccjm.69.Suppl_2.SII79; HUNDER GG, 2002, INFLAMMATORY DIS BLO, P425; Johnston SL, 2002, J CLIN PATHOL, V55, P481, DOI 10.1136/jcp.55.7.481; Jover JA, 2001, ANN INTERN MED, V134, P106, DOI 10.7326/0003-4819-134-2-200101160-00010; Kaiser M, 1999, AM J PATHOL, V155, P765, DOI 10.1016/S0002-9440(10)65175-9; Kaiser M, 1998, ARTHRITIS RHEUM, V41, P623, DOI 10.1002/1529-0131(199804)41:4<623::AID-ART9>3.0.CO;2-6; Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140-6736(02)08761-5; Kelsall BL, 2002, NAT IMMUNOL, V3, P699, DOI 10.1038/ni0802-699; KLEIN RG, 1975, ANN INTERN MED, V83, P806, DOI 10.7326/0003-4819-83-6-806; Krupa WM, 2002, AM J PATHOL, V161, P1815, DOI 10.1016/S0002-9440(10)64458-6; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Levine SM, 2002, CURR OPIN RHEUMATOL, V14, P3, DOI 10.1097/00002281-200201000-00002; Lie J T, 1996, Anat Pathol, V1, P69; LIE JT, 1990, RHEUM DIS CLIN N AM, V16, P269; LIE JT, 1994, J RHEUMATOL, V21, P186; LIU GT, 1994, OPHTHALMOLOGY, V101, P1779; MACHADO EBV, 1988, ARTHRITIS RHEUM, V31, P745, DOI 10.1002/art.1780310607; MANGAT HS, 1995, SURV OPHTHALMOL, V40, P145, DOI 10.1016/S0039-6257(95)80004-2; MartinezTaboada V, 1996, J MOL MED-JMM, V74, P695, DOI 10.1007/s001090050074; Matteson EL, 1996, AM J MED, V100, P193, DOI 10.1016/S0002-9343(97)89458-2; MCDONNELL PJ, 1986, OPHTHALMOLOGY, V93, P518; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Mitchell BM, 2001, INVEST OPHTH VIS SCI, V42, P2572; Mohan Niveditha, 2002, Curr Treat Options Cardiovasc Med, V4, P247, DOI 10.1007/s11936-002-0005-5; Nesher G, 1997, CLIN EXP RHEUMATOL, V15, P303; Nordborg C, 1998, ANN NEUROL, V44, P413, DOI 10.1002/ana.410440323; Pavlica P, 2000, CLIN EXP RHEUMATOL, V18, pS38; Regan MJ, 2002, ARTHRITIS RHEUM-US, V46, P1056, DOI 10.1002/art.517; Reviron D, 2001, EUR J IMMUNOGENET, V28, P83, DOI 10.1046/j.1365-2370.2001.00228.x; Rimenti G, 2000, J RHEUMATOL, V27, P2718; Rittner HL, 1999, J CLIN INVEST, V103, P1007, DOI 10.1172/JCI4711; Rittner HL, 1999, CIRC RES, V84, P1050, DOI 10.1161/01.RES.84.9.1050; ROCHE NE, 1993, ARTHRITIS RHEUM, V36, P1286, DOI 10.1002/art.1780360913; Salvarani C, 2002, ARTHRITIS RHEUM, V46, P3099, DOI 10.1002/art.10580; Salvarani C, 2001, ARTHRIT RHEUM-ARTHR, V45, P140, DOI 10.1002/1529-0131(200104)45:2<140::AID-ANR166>3.0.CO;2-2; Savage COS, 2002, CURR OPIN RHEUMATOL, V14, P15, DOI 10.1097/00002281-200201000-00004; Smetana GW, 2002, JAMA-J AM MED ASSOC, V287, P92, DOI 10.1001/jama.287.1.92; Spiera RF, 2001, CLIN EXP RHEUMATOL, V19, P495; Stanson AW, 2000, CLIN EXP RHEUMATOL, V18, pS43; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Streetz KL, 2001, CELL MOL BIOL, V47, P661; Tovilla-Canales J L, 1998, Curr Opin Ophthalmol, V9, P73; Tso E, 2002, ARTHRITIS RHEUM-US, V46, P1634, DOI 10.1002/art.10251; Uddhammar A, 2002, J RHEUMATOL, V29, P737; WAGNER AD, 1994, J CLIN INVEST, V94, P1134, DOI 10.1172/JCI117428; Wagner AD, 1996, AM J PATHOL, V148, P1925; Wagner AD, 2000, ARTHRITIS RHEUM-US, V43, P1543, DOI 10.1002/1529-0131(200007)43:7<1543::AID-ANR19>3.0.CO;2-8; Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155; Weyand CM, 1997, ARTHRITIS RHEUM, V40, P19, DOI 10.1002/art.1780400105; WEYAND CM, 1992, J CLIN INVEST, V90, P2355, DOI 10.1172/JCI116125; Weyand CM, 1999, ARCH INTERN MED, V159, P577, DOI 10.1001/archinte.159.6.577; Weyand CM, 2003, NEW ENGL J MED, V349, P160, DOI 10.1056/NEJMra022694; Weyand CM, 1996, J CLIN INVEST, V98, P1642, DOI 10.1172/JCI118959; WEYAND CM, 1994, ANN INTERN MED, V121, P484, DOI 10.7326/0003-4819-121-7-199410010-00003; Weyand CM, 2002, ARTHRITIS RHEUM, V46, P457, DOI 10.1002/art.10071; Weyand CM, 1999, ARTHRITIS RHEUM-US, V42, P844, DOI 10.1002/1529-0131(199905)42:5<844::AID-ANR2>3.0.CO;2-M; WEYAND CM, 1994, ARTHRITIS RHEUM, V37, P514, DOI 10.1002/art.1780370411; WEYAND CM, 1994, J EXP MED, V179, P951, DOI 10.1084/jem.179.3.951; Weyand CM, 2000, ARTHRITIS RHEUM, V43, P1041, DOI 10.1002/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7; WYAND CM, 2002, INFLAMMATORY DIS BLO, P1; ZWEEGMAN S, 1993, NETH J MED, V42, P128	99	277	289	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					505	515		10.7326/0003-4819-139-6-200309160-00015	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00015			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679329				2022-12-28	WOS:000185324100008
J	Schroeder, CM; Babcock, HP; Shaqfeh, ESG; Chu, S				Schroeder, CM; Babcock, HP; Shaqfeh, ESG; Chu, S			Observation of polymer conformation hysteresis in extensional flow	SCIENCE			English	Article							COIL-STRETCH TRANSITION; ELONGATIONAL FLOW; HYDRODYNAMIC INTERACTION; FLEXIBLE POLYMERS; LIGHT-SCATTERING; DYNAMICS; BIREFRINGENCE; COEFFICIENTS; POINT; DNA	Highly extensible Escherichia coli DNA molecules in planar extensional flow were visualized in dilute solution by fluorescence microscopy. For a narrow range of flow strengths, the molecules were found in either a coiled or highly extended conformation, depending on the deformation history of the polymer. This conformation hysteresis persists for many polymer relaxation times and is due to conformation-dependent hydrodynamic forces. Polymer conformational free-energy landscapes were calculated from computer simulations and show two free-energy minima for flow strengths near the coil-stretch transition. Hysteresis cycles may directly influence bulk-solution stresses and the development of stress-strain relations for dilute polymer flows.	Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University	Chu, S (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.			Schroeder, Charles/0000-0001-6023-2274; Babcock, Hazen/0000-0003-4835-3692				[Anonymous], 1987, DYNAMICS POLYM LIQUI; Babcock HP, 2003, MACROMOLECULES, V36, P4544, DOI 10.1021/ma034073p; BATCHELOR GK, 1970, J FLUID MECH, V44, P419, DOI 10.1017/S002211207000191X; BENTLEY BJ, 1986, J FLUID MECH, V167, P219, DOI 10.1017/S002211208600280X; BRESTKIN YV, 1987, ACTA POLYM, V38, P470, DOI 10.1002/actp.1987.010380803; De Gennes P.-G., 1979, SCALING CONCEPTS POL; FAN XJ, 1985, J NON-NEWTON FLUID, V18, P255, DOI 10.1016/0377-0257(85)87002-6; FULLER GG, 1980, RHEOL ACTA, V19, P580, DOI 10.1007/BF01517512; Gennes P. G. D., 1990, INTRO POLYM DYNAMICS; HINCH EJ, 1974, C INT CNRS, V233, P241; HSIEH CC, IN PRESS J RHEOL; Hunkeler D, 1996, POLYMER, V37, P4257, DOI 10.1016/0032-3861(96)00290-X; Larson R. G., 1999, STRUCTURE RHEOLOGY C, P443; Lee EC, 1999, MACROMOLECULES, V32, P3295, DOI 10.1021/ma981277a; Lumley J. L., 1973, Journal of Polymer Science, Macromolecular Reviews, V7, P263, DOI 10.1002/pol.1973.230070104; MENASVETA MJ, 1991, MACROMOLECULES, V24, P3427, DOI 10.1021/ma00011a060; Perkins TT, 1997, SCIENCE, V276, P2016, DOI 10.1126/science.276.5321.2016; PERKINS TT, 1995, SCIENCE, V268, P83, DOI 10.1126/science.7701345; Reif F., 1965, FUNDAMENTALS STAT TH; ROTNE J, 1969, J CHEM PHYS, V50, P4831, DOI 10.1063/1.1670977; Smith DE, 1996, MACROMOLECULES, V29, P1372, DOI 10.1021/ma951455p; Smith DE, 1998, SCIENCE, V281, P1335, DOI 10.1126/science.281.5381.1335; TANNER RI, 1975, T SOC RHEOL, V19, P557, DOI 10.1122/1.549385; TOMS BA, 1948, 1 P INT C RHEOL, V2, P135; VIRK PS, 1975, AICHE J, V21, P625, DOI 10.1002/aic.690210402; WIEST JM, 1989, J CHEM PHYS, V90, P587, DOI 10.1063/1.456457; [No title captured]	31	298	302	3	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1515	1519		10.1126/science.1086070	http://dx.doi.org/10.1126/science.1086070			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970560				2022-12-28	WOS:000185255300044
J	Raviv, U; Giasson, S; Kampf, N; Gohy, JF; Jerome, R; Klein, J				Raviv, U; Giasson, S; Kampf, N; Gohy, JF; Jerome, R; Klein, J			Lubrication by charged polymers	NATURE			English	Article							POLYELECTROLYTE BRUSHES; FORCES; SURFACES; LAYERS; SHEAR; INTERFACE; FLUIDITY	Long-ranged forces between surfaces in a liquid control effects from colloid stability(1) to biolubrication(2), and can be modified either by steric factors due to flexible polymers(3), or by surface charge effects(4). In particular, neutral polymer 'brushes' may lead to a massive reduction in sliding friction between the surfaces to which they are attached(5-7), whereas hydrated ions can act as extremely efficient lubricants between sliding charged surfaces(8). Here we show that brushes of charged polymers (polyelectrolytes) attached to surfaces rubbing across an aqueous medium result in superior lubrication compared to other polymeric surfactants. Effective friction coefficients with polyelectrolyte brushes in water are lower than about 0.0006-0.001 even at low sliding velocities and at pressures of up to several atmospheres (typical of those in living systems). We attribute this to the exceptional resistance to mutual interpenetration displayed by the compressed, counterion-swollen brushes, together with the fluidity of the hydration layers surrounding the charged, rubbing polymer segments. Our findings may have implications for biolubrication effects, which are important in the design of lubricated surfaces in artificial implants, and in understanding frictional processes in biological systems.	Weizmann Inst Sci, IL-76100 Rehovot, Israel; Univ Montreal, Dept Chem, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Sch Pharm, Montreal, PQ H3C 3J7, Canada; Univ Laval, CERSIM, Quebec City, PQ G1K 7P4, Canada; Univ Liege, Ctr Educ & Res Macromol, B-4000 Liege, Belgium; Univ Oxford, Phys & Theoret Chem Lab, Oxford OX1 3QZ, England	Weizmann Institute of Science; Universite de Montreal; Universite de Montreal; Laval University; University of Liege; University of Oxford	Klein, J (corresponding author), Weizmann Inst Sci, IL-76100 Rehovot, Israel.	suzanne.giasson@umontreal.ca; jacob.klein@weizmann.ac.il	Raviv, Uri/C-3600-2019	Gohy, Jean-Francois/0000-0003-4169-1883; Kampf, Nir/0000-0002-6713-6979				Abraham T, 2000, MACROMOLECULES, V33, P6051, DOI 10.1021/ma991207j; BORISOV OV, 1994, MACROMOLECULES, V27, P4795, DOI 10.1021/ma00095a021; CLAESSON PM, 1992, LANGMUIR, V8, P1406, DOI 10.1021/la00041a027; Csajka FS, 2001, EUR PHYS J E, V4, P505, DOI 10.1007/s101890170105; De Gennes P.-G., 1979, SCALING CONCEPTS POL; DEGENNES PG, 1987, ADV COLLOID INTERFAC, V27, P189, DOI 10.1016/0001-8686(87)85003-0; Derjaguin BV, 1987, SURFACE FORCES; DOWSON D, 1987, P I MECH ENG H, V201, P189; Ferry J. D., 1985, VISCOELASTIC PROPERT; Gohy JF, 2001, POLYMER, V42, P8637, DOI 10.1016/S0032-3861(01)00375-5; Grest GS, 1999, ADV POLYM SCI, V138, P149; ISRALACHVILI JN, 1992, INTERMOLECULAR SURFA; KAMPF N, UNPUB MACROMOLECULES; Kilbey SM, 1999, MATER RES SOC SYMP P, V543, P181; Klein J, 1998, J CHEM PHYS, V108, P6996, DOI 10.1063/1.476114; KLEIN J, 1994, NATURE, V370, P634, DOI 10.1038/370634a0; Klein J, 1996, ANNU REV MATER SCI, V26, P581, DOI 10.1146/annurev.ms.26.080196.003053; MIKLAVIC SJ, 1988, J PHYS CHEM-US, V92, P6718, DOI 10.1021/j100334a046; Misra S, 1996, MACROMOLECULES, V29, P6056, DOI 10.1021/ma960377i; NAPPER DH, 1983, POLYM STABILIZATION; PASHLEY RM, 1981, J COLLOID INTERF SCI, V80, P153, DOI 10.1016/0021-9797(81)90171-5; PINCUS P, 1991, MACROMOLECULES, V24, P2912, DOI 10.1021/ma00010a043; Raviv U, 2002, LANGMUIR, V18, P7482, DOI 10.1021/la020002s; Raviv U, 2002, J PHYS-CONDENS MAT, V14, P9275, DOI 10.1088/0953-8984/14/40/317; Raviv U, 2002, SCIENCE, V297, P1540, DOI 10.1126/science.1074481; Raviv U, 2001, J PHYS CHEM B, V105, P8125, DOI 10.1021/jp0041860; Raviv U, 2001, NATURE, V413, P51, DOI 10.1038/35092523; Ruths M, 2001, J PHYS CHEM B, V105, P6202, DOI 10.1021/jp010182z; Tadmor R, 2000, LANGMUIR, V16, P9117, DOI 10.1021/la0009137; WIJMANS CM, 1994, MACROMOLECULES, V27, P3238, DOI 10.1021/ma00090a017; WITTEN TA, 1990, MACROMOLECULES, V23, P824, DOI 10.1021/ma00205a022	31	685	700	19	502	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					163	165		10.1038/nature01970	http://dx.doi.org/10.1038/nature01970			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968175	Green Submitted			2022-12-28	WOS:000185236000037
J	Beacham, TD				Beacham, TD			Comment on "Rapid evolution of egg size in captive salmon" (II)	SCIENCE			English	Editorial Material							BRITISH-COLUMBIA; ONCORHYNCHUS; SHIFTS		Fisheries & Oceans Canada, Pacific Biol Stn, Nanaimo, BC V9T 6N7, Canada	Fisheries & Oceans Canada	Beacham, TD (corresponding author), Fisheries & Oceans Canada, Pacific Biol Stn, Nanaimo, BC V9T 6N7, Canada.	Beachamt@pac.dfo-mpo.gc.ca						BEACHAM TD, 1993, J FISH BIOL, V42, P485; BEACHAM TD, 1985, CAN J FISH AQUAT SCI, V42, P1755, DOI 10.1139/f85-220; Hare SR, 2000, PROG OCEANOGR, V47, P103, DOI 10.1016/S0079-6611(00)00033-1; Healey M.C., 1991, PACIFIC SALMON LIFE, P312; Heath DD, 2003, SCIENCE, V299, P1738, DOI 10.1126/science.1079707; King JR, 2000, FISH OCEANOGR, V9, P62; Schwing F, 2000, EOS T AM GEOPHYS UN, V81, P301; Welch DW, 2000, FISH OCEANOGR, V9, P17	8	8	8	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642												2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526063				2022-12-28	WOS:000185678500026
J	Kaplan, LD; Afridi, NA; Holmvang, G; Zukerberg, LR; Harris, NL; Scadden, DT; Ferrell, MA				Kaplan, LD; Afridi, NA; Holmvang, G; Zukerberg, LR; Harris, NL; Scadden, DT; Ferrell, MA			Case 31-2003: A 44-year-old man with HIV infection and a right atrial mass - Diffuse large-B-cell lymphoma of the heart, EBV-positive	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PRIMARY CARDIAC LYMPHOMA; NON-HODGKINS-LYMPHOMA; MALIGNANT-LYMPHOMA; KAPOSIS-SARCOMA; CHEMOTHERAPY; INVOLVEMENT; PATIENT; AIDS		Univ Calif San Francisco, Sch Med, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA; Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Cardiol, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kaplan, LD (corresponding author), Univ Calif San Francisco, Sch Med, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA.							Alam M, 1998, J AM SOC ECHOCARDIOG, V11, P83, DOI 10.1016/S0894-7317(98)70127-0; Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823; Araoz PA, 1999, RADIOGRAPHICS, V19, P1421, DOI 10.1148/radiographics.19.6.g99no031421; BALASUBRAMANYAM A, 1986, CHEST, V90, P243, DOI 10.1378/chest.90.2.243; BAROLDI G, 1988, J AM COLL CARDIOL, V12, P463, DOI 10.1016/0735-1097(88)90420-2; Berarducci L, 1993, J Am Soc Echocardiogr, V6, P539; Burgert SJ, 2000, CATHETER CARDIO INTE, V49, P208, DOI 10.1002/(SICI)1522-726X(200002)49:2<208::AID-CCD21>3.0.CO;2-6; CAIRNS P, 1987, ARCH PATHOL LAB MED, V111, P80; CAMMAROSANO C, 1985, J AM COLL CARDIOL, V5, P703, DOI 10.1016/S0735-1097(85)80397-1; Ceresoli GL, 1997, CANCER-AM CANCER SOC, V80, P1497, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1497::AID-CNCR18>3.0.CO;2-0; Colucci WS, 2001, HEART DIS TXB CARDIO, P1807; CONSTANTINO A, 1987, CANCER, V60, P2801, DOI 10.1002/1097-0142(19871201)60:11<2801::AID-CNCR2820601134>3.0.CO;2-W; D'Amati G, 2001, ANN NY ACAD SCI, V946, P23, DOI 10.1111/j.1749-6632.2001.tb03901.x; Duong M, 1997, CLIN CARDIOL, V20, P497, DOI 10.1002/clc.4960200519; ERRICHETTI A, 1994, PRINCIPLES PRACTICE, P1135; Gates AE, 2002, ONCOLOGY-NY, V16, P441; HOLLADAY AO, 1992, CANCER, V70, P2203, DOI 10.1002/1097-0142(19921015)70:8&lt;2203::AID-CNCR2820700831&gt;3.0.CO;2-6; JANIGAN DT, 1986, CANCER-AM CANCER SOC, V57, P852, DOI 10.1002/1097-0142(19860215)57:4<852::AID-CNCR2820570428>3.0.CO;2-S; Kaplan LD, 1997, NEW ENGL J MED, V336, P1641, DOI 10.1056/NEJM199706053362304; Krishnan A, 2001, BLOOD, V98, P3857, DOI 10.1182/blood.V98.13.3857; LEVISON DA, 1976, THORAX, V31, P595, DOI 10.1136/thx.31.5.595; Little RF, 2003, BLOOD, V101, P4653, DOI 10.1182/blood-2002-11-3589; McAllister H A Jr, 1999, Curr Probl Cardiol, V24, P57; Meng QY, 2002, ONCOL REP, V9, P85; Miyashita T, 2000, JPN CIRC J, V64, P135, DOI 10.1253/jcj.64.135; Nakayama Y, 1997, CARDIOLOGY, V88, P613, DOI 10.1159/000177436; NISHIKAWA Y, 1991, CARDIOLOGY, V78, P357, DOI 10.1159/000174817; Piketty C, 1995, ANN MED INTERNE, V146, P526; Ratner L, 2001, J CLIN ONCOL, V19, P2171, DOI 10.1200/JCO.2001.19.8.2171; REYNEN K, 1995, NEW ENGL J MED, V333, P1610, DOI 10.1056/NEJM199512143332407; Rolla G, 2002, LEUKEMIA RES, V26, P117, DOI 10.1016/S0145-2126(01)00092-3; Sanna P, 1998, ANN HEMATOL, V77, P75, DOI 10.1007/s002770050416; SILVER MA, 1984, AM J CARDIOL, V53, P983, DOI 10.1016/0002-9149(84)90554-X; Takeuchi E, 1998, ANTICANCER RES, V18, P2815; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; VANVOOREN JP, 1995, EUR J HAEMATOL, V55, P274	36	15	16	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1369	1377		10.1056/NEJMcpc030013	http://dx.doi.org/10.1056/NEJMcpc030013			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523146				2022-12-28	WOS:000185644000013
J	McAdams, HH; Shapiro, L				McAdams, HH; Shapiro, L			A bacterial cell-cycle regulatory network operating in time and space	SCIENCE			English	Review							PROTEIN LOCALIZATION; MASTER REGULATOR; HISTIDINE KINASE; TRANSCRIPTION; DIVISION; POLARITY; CTRA	Transcriptional regulatory circuits provide only a fraction of the signaling pathways and regulatory mechanisms that control the bacterial cell cycle. The CtrA regulatory network, important in control of the Caulobacter cell cycle, illustrates the critical role of nontranscriptional pathways and temporally and spatially localized regulatory proteins. The system architecture of Caulobacter cell-cycle control involves top-down control of modular functions by a small number of master regulatory proteins with cross-module signaling coordinating the overall process. Modeling the cell cycle probably requires a top-down modeling approach and a hybrid control system modeling paradigm to treat its combined discrete and continuous characteristics.	Stanford Univ, Sch Med, Dept Dev Biol, Beckman Ctr B300, Stanford, CA 94305 USA	Stanford University	McAdams, HH (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Beckman Ctr B300, Stanford, CA 94305 USA.	hmcadams@stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032506, R37GM032506] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32506/5120 M2, GM51426] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; Aldridge P, 2002, CURR OPIN MICROBIOL, V5, P160, DOI 10.1016/S1369-5274(02)00302-8; Alur R, 2002, COMPUT SCI ENG, V4, P20, DOI 10.1109/5992.976434; Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; Fujita M, 2003, GENE DEV, V17, P1166, DOI 10.1101/gad.1078303; GHOSH R, 2001, LNCS, V2034, P232; GHOSH R, 2002, 41 IEEE C DEC CONTR; Hansen TF, 2003, BIOSYSTEMS, V69, P83, DOI 10.1016/S0303-2647(02)00132-6; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; HECHT GB, 1995, EMBO J, V14, P3915, DOI 10.1002/j.1460-2075.1995.tb00063.x; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; Hinz AJ, 2003, MOL MICROBIOL, V47, P929, DOI 10.1046/j.1365-2958.2003.03349.x; Jacobs C, 2003, MOL MICROBIOL, V47, P1279, DOI 10.1046/j.1365-2958.2003.03379.x; Jenal U, 2000, FEMS MICROBIOL REV, V24, P177, DOI 10.1111/j.1574-6976.2000.tb00538.x; Jenal U, 2002, CURR OPIN MICROBIOL, V5, P558, DOI 10.1016/S1369-5274(02)00378-8; Jensen RB, 2000, TRENDS CELL BIOL, V10, P483, DOI 10.1016/S0962-8924(00)01840-7; Judd EM, 2003, P NATL ACAD SCI USA, V100, P8235, DOI 10.1073/pnas.1433105100; Keiler KC, 2001, J BACTERIOL, V183, P4860, DOI 10.1128/JB.183.16.4860-4865.2001; Laub MT, 2000, SCIENCE, V290, P2144, DOI 10.1126/science.290.5499.2144; Laub MT, 2002, P NATL ACAD SCI USA, V99, P4632, DOI 10.1073/pnas.062065699; Levin PA, 2000, PROKARYOTIC DEVELOPMENT, P167; Lybarger SR, 2001, J BACTERIOL, V183, P3261, DOI 10.1128/JB.183.11.3261-3267.2001; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; Meyer-Ilse W, 2001, J MICROSC-OXFORD, V201, P395, DOI 10.1046/j.1365-2818.2001.00845.x; Quon KC, 1998, P NATL ACAD SCI USA, V95, P120, DOI 10.1073/pnas.95.1.120; Reisenauer A, 2002, EMBO J, V21, P4969, DOI 10.1093/emboj/cdf490; RYAN KR, 2003, ANN REV BIOCH; Shapiro L, 2002, SCIENCE, V298, P1942, DOI 10.1126/science.1072163; Shapiro L, 2000, CELL, V100, P89, DOI 10.1016/S0092-8674(00)81686-4; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Tyson JJ, 2001, NAT REV MOL CELL BIO, V2, P908, DOI 10.1038/35103078; Viollier PH, 2002, EMBO J, V21, P4420, DOI 10.1093/emboj/cdf454; Viollier PH, 2002, P NATL ACAD SCI USA, V99, P13831, DOI 10.1073/pnas.182411999; Wu JG, 1999, P NATL ACAD SCI USA, V96, P13068, DOI 10.1073/pnas.96.23.13068	35	137	144	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1874	1877		10.1126/science.1087694	http://dx.doi.org/10.1126/science.1087694			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512618				2022-12-28	WOS:000185536700040
J	Bertotti, B; Iess, L; Tortora, P				Bertotti, B; Iess, L; Tortora, P			A test of general relativity using radio links with the Cassini spacecraft	NATURE			English	Article							FINE-STRUCTURE CONSTANT; QSO ABSORPTION-LINES; CONSTRAINTS	According to general relativity, photons are deflected and delayed by the curvature of space-time produced by any mass(1-3). The bending and delay are proportional to gamma+1, where the parameter gamma is unity in general relativity but zero in the newtonian model of gravity. The quantity gamma-1 measures the degree to which gravity is not a purely geometric effect and is affected by other fields; such fields may have strongly influenced the early Universe, but would have now weakened so as to produce tiny-but still detectable-effects. Several experiments have confirmed to an accuracy of similar to0.1% the predictions for the deflection(4,5) and delay(6) of photons produced by the Sun. Here we report a measurement of the frequency shift of radio photons to and from the Cassini spacecraft as they passed near the Sun. Our result, gamma=1+(2.1+/-2.3)x10(-5), agrees with the predictions of standard general relativity with a sensitivity that approaches the level at which, theoretically, deviations are expected in some cosmological models(7,8).	Univ Roma La Sapienza, Dipartimento Ingn Aerosp & Astronaut, I-00184 Rome, Italy; Univ Pavia, Dipartimento Fis Nucl & Teor, I-27100 Pavia, Italy; Univ Bologna, Fac Ingn 2, I-47100 Forli, Italy	Sapienza University Rome; University of Pavia; University of Bologna	Iess, L (corresponding author), Univ Roma La Sapienza, Dipartimento Ingn Aerosp & Astronaut, Via Eudossiana 16, I-00184 Rome, Italy.	iess@hermes.ing.uniroma1.it	IESS, Luciano/F-4902-2011; Tortora, Paolo/J-6191-2012	IESS, Luciano/0000-0002-6230-5825; Tortora, Paolo/0000-0001-9259-7673				BERTOTTI B, 1993, ASTRON ASTROPHYS, V269, P608; BERTOTTI B, 1992, CLASSICAL QUANT GRAV, V9, P777, DOI 10.1088/0264-9381/9/3/016; BERTOTTI B, 1998, SOL PHYS, V178, P523; Ciufolini I., 1995, GRAVITATION INERTIA; Damour T, 2002, PHYS REV D, V66, DOI 10.1103/PhysRevD.66.046007; DAMOUR T, 1994, NUCL PHYS B, V423, P532, DOI 10.1016/0550-3213(94)90143-0; Damour T, 2003, ASTROPHYS SPACE SCI, V283, P445, DOI 10.1023/A:1022596316014; Davidson C., 1920, PHILOS T R SOC A, V220, P291, DOI DOI 10.1098/RSTA.1920.0009; Iess L, 1999, CLASSICAL QUANT GRAV, V16, P1487, DOI 10.1088/0264-9381/16/5/303; IESS L, 2003, AEROSPACE C P, V1, P205; LEBACH DE, 1995, PHYS REV LETT, V75, P1439, DOI 10.1103/PhysRevLett.75.1439; Murphy MT, 2001, MON NOT R ASTRON SOC, V327, P1223, DOI 10.1046/j.1365-8711.2001.04841.x; Murphy MT, 2001, MON NOT R ASTRON SOC, V327, P1244, DOI 10.1046/j.1365-8711.2001.04843.x; Murphy MT, 2001, MON NOT R ASTRON SOC, V327, P1237, DOI 10.1046/j.1365-8711.2001.04842.x; Murphy MT, 2001, MON NOT R ASTRON SOC, V327, P1208, DOI 10.1046/j.1365-8711.2001.04840.x; REASENBERG RD, 1979, ASTROPHYS J, V234, pL219, DOI 10.1086/183144; TORTORA P, 2003, AER C P MONT MARCH 2, V3, P1465; TORTORA P, 2002, P WORLD SPAC C HOUST; WILL CM, 1993, THEORY EXPT GRAVITAT; WILL CM, LIVING REV RELATIVIT, V4, P4	20	1318	1327	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					374	376		10.1038/nature01997	http://dx.doi.org/10.1038/nature01997			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508481				2022-12-28	WOS:000185502300033
J	Bird, SM; Hutchinson, SJ; Goldberg, DJ				Bird, SM; Hutchinson, SJ; Goldberg, DJ			Drug-related deaths by region, sex, and age group per 100 injecting drug users in Scotland, 2000-01	LANCET			English	Article							RISK-FACTORS; HEPATITIS-C; AUSTRALIA; PREVALENCE; ANTIBODIES; OVERDOSE; PRISON; HIV	Background In 2000 and 2001, there were 292 and 332 drug-related deaths in Scotland, respectively. Of the 332 people who died in 2001, 65 were of female sex, 80 were younger than 25 years, and 112 were older than 34 years. We assessed the effect of region, sex, and age group on drug-related deaths in Scotland per 100 injecting drug users. Methods We used published regional estimates of current injecting drug users (n=22 805), their sex (30% female) and age distribution (8% older than 34 years in mid-1990s), or corresponding data for problem drug users (21% older than 34 years in 2000) to compare observed with expected drug-related deaths by region, sex, and age group per 1000 population or per 100 injecting drug users. Findings Regional population-based expectations fitted poorly to observed drug-related deaths, but those based on injecting drug users fitted tolerably. Drug-related deaths in 2001 per 100 injecting drug users were significantly lower in female (0.9 [95% Cl 0.6-1.1]) than in male drug users (1.5; 1.3-1.7). They were between two and six times more frequent per 100 injecting drug users older than 34 years than younger than 25 years, depending on whether current injecting drug users' age distribution was assumed to be the same as problem drug users' or as injecting drug users' in the mid-1990s (2.1 [1.7-2.5] or 5.3 [4.3-6.3], respectively). Interpretation Older and male injecting drug users were at highest risk of drug-related death. Injecting drug users' age distribution should be assessed and compared across countries.	MRC, Biostat Unit, Cambridge CB2 2SR, England; Univ Strathclyde, Dept Stat & Modelling Sci, Glasgow, Lanark, Scotland; Scottish Ctr Infect & Environm Hlth, Glasgow, Lanark, Scotland; Univ Glasgow, Publ Hlth & Hlth Policy Sect, Glasgow, Lanark, Scotland	MRC Biostatistics Unit; University of Strathclyde; University of Glasgow	Bird, SM (corresponding author), MRC, Biostat Unit, Cambridge CB2 2SR, England.	sheila.bird@mrc-bsu.cam.ac.uk						Advisory Council on the Misuse of Drugs, 2000, RED DRUG REL DEATHS; AHMED S, 2000, MMWR-MORBID MORTAL W, V49, P489; Allwright S, 2000, BRIT MED J, V321, P78, DOI 10.1136/bmj.321.7253.78; Bellis MA, 2001, J EPIDEMIOL COMMUN H, V55, P843, DOI 10.1136/jech.55.11.843; BEST D, 2000, DRUG ALCOHOL FINDING, V4, P4; Bird AG, 1997, BRIT MED J, V315, P21, DOI 10.1136/bmj.315.7099.21; Bird S M, 2001, J Epidemiol Biostat, V6, P243, DOI 10.1080/135952201317080661; Bird SM, 2003, ADDICTION, V98, P185, DOI 10.1046/j.1360-0443.2003.00264.x; Darke S, 2000, DRUG ALCOHOL DEPEN, V60, P141, DOI 10.1016/S0376-8716(99)00147-7; Darke S, 2000, ADDICTION, V95, P569, DOI 10.1046/j.1360-0443.2000.9545698.x; Hall W, 1998, DRUG ALCOHOL DEPEN, V52, P71, DOI 10.1016/S0376-8716(98)00044-1; HAY G, 2001, EXECUTIVE REPORT EST; Hutchinson SJ, 2000, BRIT J PSYCHIAT, V176, P166, DOI 10.1192/bjp.176.2.166; *INF STAT DIV, 1999, DRUG STAT SCOTL 1998; JACKSON GWL, 2002, 8 GEN REG OFF SCOTL; Long J, 2001, BRIT MED J, V323, P1209, DOI 10.1136/bmj.323.7323.1209; LONG J, 2001, THESIS TRINITY COLL, P62; Seaman SR, 1998, BRIT MED J, V316, P426, DOI 10.1136/bmj.316.7129.426	18	42	42	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 20	2003	362	9388					941	944		10.1016/S0140-6736(03)14362-0	http://dx.doi.org/10.1016/S0140-6736(03)14362-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	724LT	14511926				2022-12-28	WOS:000185489600007
J	Dalakas, MC; Hohlfeld, R				Dalakas, MC; Hohlfeld, R			Polymyositis and dermatomyositis	LANCET			English	Review							INCLUSION-BODY MYOSITIS; NECROSIS-FACTOR-ALPHA; IDIOPATHIC INFLAMMATORY MYOPATHIES; INTERSTITIAL LUNG-DISEASE; MHC CLASS-I; MONOCLONAL-ANTIBODY ANALYSIS; CELL-RECEPTOR REPERTOIRE; HUMAN MUSCLE-CELLS; SKELETAL-MUSCLE; T-LYMPHOCYTES	The inflammatory myopathies, commonly described as idiopathic, are the largest group of acquired and potentially treatable myopathies. On the basis of unique clinical, histopathological, immunological, and demographic features, they can be differentiated into three major and distinct subsets: dermatomyositis, polymyositis, and inclusion-body myositis. Use of new diagnostic criteria is essential to discriminate between them and to exclude other disorders. Dermatomyositis is a microangiopathy affecting skin and muscle; activation and deposition of complement causes lysis of endomysial capillaries and muscle ischaemia. In polymyositis and inclusion-body myositis, clonally expanded CD8-positive cytotoxic T cells invade muscle fibres that express MHC class I antigens, which leads to fibre necrosis via the perforin pathway. In inclusion-body myositis, vacuolar formation with amyloid deposits coexists with the immunological features. The causative autoantigen has not yet been identified. Upregulated vascular-cell adhesion molecule, intercellular adhesion molecule, chemokines, and their receptors promote T-cell transgression, and various cytokines increase the immunopathological process. Early initiation of therapy is essential, since both polymyositis and dermatomyositis respond to immunotherapeutic agents. New immunomodulatory agents currently being tested in controlled trials may prove promising for difficult cases.	NINDS, Neuromuscular Dis Sect, NIH, Bethesda, MD 20892 USA; Univ Munich, Klinikum Grosshadern, Inst Clin Neuroimmunol, D-8000 Munich, Germany; Univ Munich, Klinikum Grosshadern, Max Planck Inst Neurobiol, D-8000 Munich, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Munich; Max Planck Society; University of Munich	Dalakas, MC (corresponding author), NINDS, Neuromuscular Dis Sect, NIH, Bldg 10,Room 4N248,10 Ctr Dr MSC 1382, Bethesda, MD 20892 USA.	dalakasm@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002038] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amato AA, 1996, ANN NEUROL, V40, P581, DOI 10.1002/ana.410400407; Amemiya K, 2000, CLIN IMMUNOL, V94, P99, DOI 10.1006/clim.1999.4823; ARAHATA K, 1988, ANN NEUROL, V23, P493, DOI 10.1002/ana.410230511; ARAHATA K, 1986, ANN NEUROL, V19, P112, DOI 10.1002/ana.410190203; BANKER BQ, 1975, J NEUROPATH EXP NEUR, V34, P46, DOI 10.1097/00005072-197501000-00005; BARKHAUS PE, 1990, MUSCLE NERVE, V13, P247, DOI 10.1002/mus.880130312; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; Behrens L, 1998, J IMMUNOL, V161, P5943; Behrens L, 1997, BRAIN, V120, P929, DOI 10.1093/brain/120.6.929; BENDER A, 1995, J EXP MED, V181, P1863, DOI 10.1084/jem.181.5.1863; Benveniste O, 2001, J IMMUNOL, V167, P3521, DOI 10.4049/jimmunol.167.6.3521; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BOMBARDIERI S, 1989, LANCET, V1, P1138; Buchbinder R, 2001, ANN INTERN MED, V134, P1087, DOI 10.7326/0003-4819-134-12-200106190-00008; BUNCH TW, 1980, ANN INTERN MED, V92, P365, DOI 10.7326/0003-4819-92-3-365; Callen JP, 2000, LANCET, V355, P53, DOI 10.1016/S0140-6736(99)05157-0; Callen JP, 2002, ARCH DERMATOL, V138, P969, DOI 10.1001/archderm.138.7.969; Callen JP, 2001, LANCET, V357, P85, DOI 10.1016/S0140-6736(00)03535-2; CARPENTER S, 1976, NEUROLOGY, V26, P952, DOI 10.1212/WNL.26.10.952; Chaudhry V, 2001, NEUROLOGY, V56, P94, DOI 10.1212/WNL.56.1.94; CHERIN P, 1991, AM J MED, V91, P162, DOI 10.1016/0002-9343(91)90009-M; Choi YC, 2000, NEUROLOGY, V54, P65, DOI 10.1212/WNL.54.1.65; Choy EHS, 2002, RHEUMATOLOGY, V41, P7, DOI 10.1093/rheumatology/41.1.7; Confalonieri P, 2000, J NEUROPATH EXP NEUR, V59, P164, DOI 10.1093/jnen/59.2.164; CRONIN ME, 1989, J RHEUMATOL, V16, P1225; Cupler EJ, 1996, BRAIN, V119, P1887, DOI 10.1093/brain/119.6.1887; Dalakas M., 1988, POLYMYOSITIS DERMATO, P281; Dalakas Marinos C., 2001, Current Opinion in Pharmacology, V1, P300, DOI 10.1016/S1471-4892(01)00053-4; DALAKAS MC, 1986, JAMA-J AM MED ASSOC, V256, P2381, DOI 10.1001/jama.256.17.2381; Dalakas MC, 1998, ARCH NEUROL-CHICAGO, V55, P1509, DOI 10.1001/archneur.55.12.1509; DALAKAS MC, 1995, NEW ENGL J MED, V333, P978, DOI 10.1056/NEJM199510123331506; Dalakas MC, 2002, RHEUM DIS CLIN N AM, V28, P779, DOI 10.1016/S0889-857X(02)00030-3; DALAKAS MC, 1986, NEUROLOGY, V36, P569, DOI 10.1212/WNL.36.4.569; Dalakas MC, 2002, REV NEUROL-FRANCE, V158, P948; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; DALAKAS MC, 1988, ANN NEUROL, V23, pS38, DOI 10.1002/ana.410230713; Dalakas MC, 2001, J NEUROL NEUROSUR PS, V70, P569, DOI 10.1136/jnnp.70.5.569; Dalakas MC, 1998, NEUROLOGY, V51, pS37, DOI 10.1212/WNL.51.6_Suppl_5.S37; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; Dalakas MC, 1997, ANN INTERN MED, V126, P721, DOI 10.7326/0003-4819-126-9-199705010-00008; DALAKAS MC, 2002, NEUROMUSCULAR DISORD, P364; DALAKAS MC, 1994, SEMIN NEUROL, V92, P365; DALAKAS MC, 1995, ANN NEUROL, V37, P74; DALAKAS MC, 1997, SCI AM, V11, P1; DALAKAS MC, 2001, HARRISONS PRINCIPLES, P2524; DALAKAS MC, IN PRESS MYOLOGY; Dayal NA, 2002, LUPUS, V11, P293, DOI 10.1191/0961203302lu186oa; De Bleecker JL, 1999, NEUROMUSCULAR DISORD, V9, P239, DOI 10.1016/S0960-8966(98)00126-6; De Bleecker JL, 2002, NEUROLOGY, V58, P1779, DOI 10.1212/WNL.58.12.1779; De Rossi M, 2000, INT IMMUNOL, V12, P1329, DOI 10.1093/intimm/12.9.1329; DEBLEECKER JL, 1995, AM J PATHOL, V146, P1178; DEMERIEUX P, 1983, ARTHRITIS RHEUM, V26, P961; DIETZ F, 1980, ARTHRITIS RHEUM, V23, P491, DOI 10.1002/art.1780230412; Douglas WW, 2001, AM J RESP CRIT CARE, V164, P1182, DOI 10.1164/ajrccm.164.7.2103110; DOYLE DR, 1983, ANN INTERN MED, V98, P327, DOI 10.7326/0003-4819-98-3-327; EMSLIESMITH AM, 1989, HUM PATHOL, V20, P224, DOI 10.1016/0046-8177(89)90128-7; EMSLIESMITH AM, 1990, ANN NEUROL, V27, P343, DOI 10.1002/ana.410270402; ENGEL AG, 1984, ANN NEUROL, V16, P209, DOI 10.1002/ana.410160207; Engel AG, 1994, MYOLOGY, P1335; Englund P, 2001, AM J PATHOL, V159, P1263, DOI 10.1016/S0002-9440(10)62513-8; Friedman AW, 1996, SEMIN ARTHRITIS RHEU, V26, P459, DOI 10.1016/S0049-0172(96)80026-6; Gherardi RK, 1998, LANCET, V352, P347, DOI 10.1016/S0140-6736(98)02326-5; Goebels N, 1996, J CLIN INVEST, V97, P2905, DOI 10.1172/JCI118749; Gold R, 2003, LANCET NEUROL, V2, P22, DOI 10.1016/S1474-4422(03)00264-3; GRAU JM, 1994, J RHEUMATOL, V21, P381; GRIGGS RC, 1995, ANN NEUROL, V38, P705, DOI 10.1002/ana.410380504; HAUPT HM, 1982, AM J CARDIOL, V50, P998, DOI 10.1016/0002-9149(82)90408-8; HECKMATT J, 1989, LANCET, V1, P1063, DOI 10.1016/S0140-6736(89)92456-2; Hengstman GJD, 2002, J NEUROL, V249, P69, DOI 10.1007/PL00007850; Hengstman GJD, 2001, CURR OPIN RHEUMATOL, V13, P476, DOI 10.1097/00002281-200111000-00004; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; Hill CL, 2001, LANCET, V357, P96, DOI 10.1016/S0140-6736(00)03540-6; Hilton-Jones D, 2001, CURR OPIN NEUROL, V14, P591, DOI 10.1097/00019052-200110000-00007; Hirakata M, 2000, CURR OPIN RHEUMATOL, V12, P501, DOI 10.1097/00002281-200011000-00005; Hofbauer M, 2003, P NATL ACAD SCI USA, V100, P4090, DOI 10.1073/pnas.0236183100; HOHLFELD R, 1991, ANN NEUROL, V29, P498, DOI 10.1002/ana.410290509; HOHLFELD R, 1990, AM J PATHOL, V136, P503; HOHLFELD R, 1991, NEW ENGL J MED, V324, P877, DOI 10.1056/NEJM199103283241303; HOHLFELD R, 1994, IMMUNOL TODAY, V15, P269, DOI 10.1016/0167-5699(94)90006-X; HOHLFELD R, 2002, DIS NERVOUS SYSTEM C, P1527; ILLA I, 1991, ANN NEUROL, V29, P474, DOI 10.1002/ana.410290505; Illa I, 1997, AM J PATHOL, V151, P81; KALOVIDOURIS AE, 1995, J RHEUMATOL, V22, P1698; KARPATI G, 1988, ANN NEUROL, V23, P64, DOI 10.1002/ana.410230111; Karpati G, 2001, DISORDERS VOLUNTARY, P636; Kieseier BC, 2001, BRAIN, V124, P341, DOI 10.1093/brain/124.2.341; KISSEL JT, 1986, NEW ENGL J MED, V314, P329, DOI 10.1056/NEJM198602063140601; KISSEL JT, 1991, ARCH NEUROL-CHICAGO, V48, P26, DOI 10.1001/archneur.1991.00530130034016; Koffman BM, 1998, J NEUROIMMUNOL, V84, P139, DOI 10.1016/S0165-5728(97)00245-2; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Kunkel EJ, 2002, IMMUNITY, V16, P1, DOI 10.1016/S1074-7613(01)00261-8; Kuru S, 2000, ACTA NEUROPATHOL, V99, P585, DOI 10.1007/s004010051165; LAKHANPAL S, 1987, ANN RHEUM DIS, V46, P23, DOI 10.1136/ard.46.1.23; LEFF RL, 1992, LANCET, V339, P1192, DOI 10.1016/0140-6736(92)91134-T; LEONMONZON M, 1994, ANN NEUROL, V36, P643, DOI 10.1002/ana.410360414; LEONMONZON M, 1992, ANN NEUROL, V32, P219, DOI 10.1002/ana.410320215; LEONMONZON M, 1994, NEUROLOGY S, V44, P132; Li M, 2000, J NEUROIMMUNOL, V106, P1, DOI 10.1016/S0165-5728(99)00162-9; Liang L, 2002, CURR OPIN IMMUNOL, V14, P384, DOI 10.1016/S0952-7915(02)00342-4; LOVE LA, 1991, MEDICINE, V70, P360, DOI 10.1097/00005792-199111000-00002; Lundberg I, 1995, J NEUROIMMUNOL, V63, P9, DOI 10.1016/0165-5728(95)00122-0; MANTEGAZZA R, 1993, J CLIN INVEST, V91, P2880, DOI 10.1172/JCI116533; MANTEGAZZA R, 1991, NEUROLOGY, V41, P1128, DOI 10.1212/WNL.41.7.1128; Marie I, 2001, J RHEUMATOL, V28, P2230; Mastaglia FL, 2002, RHEUM DIS CLIN N AM, V28, P723, DOI 10.1016/S0889-857X(02)00021-2; MASTAGLIA FL, 1982, DRUGS, V24, P304, DOI 10.2165/00003495-198224040-00003; Maugars YM, 1996, CLIN EXP RHEUMATOL, V14, P263; MEDSGER TA, 1970, AM J MED, V48, P715, DOI 10.1016/S0002-9343(70)80006-7; MICHAELIS D, 1993, AM J PATHOL, V143, P1142; MILLER FW, 1992, NEW ENGL J MED, V326, P1380, DOI 10.1056/NEJM199205213262102; MIMORI T, 1987, INT J DERMATOL, V26, P419, DOI 10.1111/j.1365-4362.1987.tb00580.x; MORGAN OS, 1989, LANCET, V2, P1184; Murakami N, 1999, MUSCLE NERVE, V22, P889, DOI 10.1002/(SICI)1097-4598(199907)22:7<889::AID-MUS12>3.0.CO;2-B; Murata K, 1999, AM J PATHOL, V155, P453, DOI 10.1016/S0002-9440(10)65141-3; Nagaraju K, 2000, J IMMUNOL, V164, P5459, DOI 10.4049/jimmunol.164.10.5459; Nagaraju K, 2000, P NATL ACAD SCI USA, V97, P9209, DOI 10.1073/pnas.97.16.9209; Nishio J, 2001, J IMMUNOL, V167, P4051, DOI 10.4049/jimmunol.167.7.4051; Nyberg P, 2000, J RHEUMATOL, V27, P940; Oddis CV, 2002, RHEUM DIS CLIN N AM, V28, P979, DOI 10.1016/S0889-857X(02)00028-5; OHANLON TP, 1994, J IMMUNOL, V152, P2569; OTERO C, 1992, Neurology, V42, P388; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; PLUSCHKE G, 1992, J EXP MED, V176, P1785, DOI 10.1084/jem.176.6.1785; Quartier P, 2002, J RHEUMATOL, V29, P1767; Raju R, 2002, NEUROLOGY, V58, pA390; Ramanan AV, 2002, RHEUM DIS CLIN N AM, V28, P833, DOI 10.1016/S0889-857X(02)00024-8; Reed AM, 2002, RHEUM DIS CLIN N AM, V28, P891, DOI 10.1016/S0889-857X(02)00029-7; Reed AM, 2001, CURR OPIN RHEUMATOL, V13, P428, DOI 10.1097/00002281-200109000-00015; Reed AM, 2000, LANCET, V356, P2156, DOI 10.1016/S0140-6736(00)03500-5; ROSENBERG NL, 1988, POLYMYOSITIS DERMATO, P37; Schnabel A, 1998, ARTHRITIS RHEUM-US, V41, P1215, DOI 10.1002/1529-0131(199807)41:7<1215::AID-ART11>3.0.CO;2-Y; Schneider C, 1999, ARCH NEUROL-CHICAGO, V56, P79, DOI 10.1001/archneur.56.1.79; Schneider C, 1996, J NEUROPATH EXP NEUR, V55, P1205, DOI 10.1097/00005072-199612000-00003; SEKUL EA, 1993, SEMIN NEUROL, V13, P256, DOI 10.1055/s-2008-1041132; Shamim EA, 2000, CURR OPIN RHEUMATOL, V12, P482, DOI 10.1097/00002281-200011000-00002; Shamim EA, 2002, ARTHRITIS RHEUM, V46, P1885, DOI 10.1002/art.10358; Shelton GD, 1999, MUSCLE NERVE, V22, P156, DOI 10.1002/(SICI)1097-4598(199902)22:2<156::AID-MUS3>3.0.CO;2-U; SIGURGEIRSSON B, 1992, NEW ENGL J MED, V326, P363, DOI 10.1056/NEJM199202063260602; Smith AG, 2000, MUSCLE NERVE, V23, P1569, DOI 10.1002/1097-4598(200010)23:10<1569::AID-MUS14>3.0.CO;2-M; Sontheimer RD, 2002, DERMATOL CLIN, V20, P387, DOI 10.1016/S0733-8635(02)00021-9; Sparsa A, 2002, ARCH DERMATOL, V138, P885, DOI 10.1001/archderm.138.7.885; STEIN DP, 1993, ANN NEUROL, V34, P268; Sugiura T, 2000, J IMMUNOL, V164, P6593, DOI 10.4049/jimmunol.164.12.6593; Sultan SM, 2002, RHEUMATOLOGY, V41, P22, DOI 10.1093/rheumatology/41.1.22; Targoff IN, 2002, RHEUM DIS CLIN N AM, V28, P859, DOI 10.1016/S0889-857X(02)00032-7; Tews DS, 1996, J NEUROPATH EXP NEUR, V55, P342, DOI 10.1097/00005072-199603000-00009; Tezak Z, 2002, J IMMUNOL, V168, P4154, DOI 10.4049/jimmunol.168.8.4154; UNCINI A, 1990, MUSCLE NERVE, V13, P263, DOI 10.1002/mus.880130315; Werth VP, 2002, J INVEST DERMATOL, V119, P617, DOI 10.1046/j.1523-1747.2002.01869.x; Wiendl H, 2000, ANN NEUROL, V48, P679, DOI 10.1002/1531-8249(200010)48:4<679::AID-ANA19>3.3.CO;2-M; Wiendl H, 2003, BRAIN, V126, P1026, DOI 10.1093/brain/awg114; Wiendl H, 2003, BRAIN, V126, P176, DOI 10.1093/brain/awg017; Wiendl H, 2002, J IMMUNOL, V169, P515, DOI 10.4049/jimmunol.169.1.515; Wucherpfennig KW, 2001, J CLIN INVEST, V108, P1097, DOI 10.1172/JCI200114235	156	953	1049	0	59	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 20	2003	362	9388					971	982		10.1016/S0140-6736(03)14368-1	http://dx.doi.org/10.1016/S0140-6736(03)14368-1			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511932				2022-12-28	WOS:000185489600021
J	Wong, JMY; Collins, K				Wong, JMY; Collins, K			Telomere maintenance and disease	LANCET			English	Review							LINKED DYSKERATOSIS-CONGENITA; HOYERAAL-HREIDARSSON-SYNDROME; STEM-CELL TRANSPLANTATION; SMALL NUCLEOLAR RNPS; APLASTIC-ANEMIA; REVERSE-TRANSCRIPTASE; ATAXIA-TELANGIECTASIA; FANCONI-ANEMIA; BONE-MARROW; LENGTH CHANGES	The proliferative capacity of human cells is regulated by telomerase, an enzyme uniquely specialised for telomeric DNA synthesis. The critical role of telomerase activation in tumour progression and tumour maintenance has been well established in studies of cancer and of oncogenic transformation in cell culture. New evidence suggests that telomerase activation has an important role in normal somatic cells, and that failure to activate sufficient telomerase also promotes disease. We review the evidence for premature telomere attrition in proliferative deficiencies of the human haemopoietic system, and discuss the potential use of telomerase activation in telomere-restorative gene therapy.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Collins, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.	kcollins@socrates.berkeley.edu	Wong, Judy/AAG-1868-2021	Wong, Judy/0000-0001-5572-4143				Aikata H, 2000, EXP CELL RES, V256, P578, DOI 10.1006/excr.2000.4862; Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Akiyama M, 1998, BONE MARROW TRANSPL, V21, P167, DOI 10.1038/sj.bmt.1701060; Akiyama M, 2000, BONE MARROW TRANSPL, V25, P441, DOI 10.1038/sj.bmt.1702144; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Ball SE, 1998, BLOOD, V91, P3582; Blackburn EH, 2000, NAT STRUCT BIOL, V7, P847, DOI 10.1038/79594; Blasco MA, 2002, NAT REV CANCER, V2, P627, DOI 10.1038/nrc862; Blasco MA, 2002, SPRINGER SEMIN IMMUN, V24, P75, DOI 10.1007/s00281-001-0096-1; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Bogliolo M, 2002, MUTAGENESIS, V17, P529, DOI 10.1093/mutage/17.6.529; Brummendorf TH, 2001, BLOOD, V97, P895, DOI 10.1182/blood.V97.4.895; Callen E, 2002, HUM MOL GENET, V11, P439, DOI 10.1093/hmg/11.4.439; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Cossu F, 2002, BRIT J HAEMATOL, V119, P765, DOI 10.1046/j.1365-2141.2002.03822.x; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dokal I, 2000, BRIT J HAEMATOL, V110, P768, DOI 10.1046/j.1365-2141.2000.02109.x; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; Effros RB, 2000, MICROBES INFECT, V2, P69, DOI 10.1016/S1286-4579(00)00283-5; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Goytisolo FA, 2002, ONCOGENE, V21, P584, DOI 10.1038/sj.onc.1205085; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hande MP, 2001, HUM MOL GENET, V10, P519, DOI 10.1093/hmg/10.5.519; Harley CB, 2002, ONCOGENE, V21, P494, DOI 10.1038/sj.onc.1205076; Harrington L, 2002, ONCOGENE, V21, P592, DOI 10.1038/sj.onc.1205084; He J, 2002, ONCOGENE, V21, P7740, DOI 10.1038/sj.onc.1205969; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; KITADA T, 1995, BIOCHEM BIOPH RES CO, V211, P33, DOI 10.1006/bbrc.1995.1774; Knight SW, 1999, BRIT J HAEMATOL, V107, P335, DOI 10.1046/j.1365-2141.1999.01690.x; Knight SW, 1999, AM J HUM GENET, V65, P50, DOI 10.1086/302446; Lee JJ, 1999, BONE MARROW TRANSPL, V24, P411, DOI 10.1038/sj.bmt.1701923; Lee JJ, 2001, BRIT J HAEMATOL, V112, P1025, DOI 10.1046/j.1365-2141.2001.02669.x; Leteurtre F, 1999, BRIT J HAEMATOL, V105, P883, DOI 10.1046/j.1365-2141.1999.01445.x; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Mitchell JR, 2000, MOL CELL, V6, P361, DOI 10.1016/S1097-2765(00)00036-8; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Montanaro L, 2002, J INVEST DERMATOL, V118, P193, DOI 10.1046/j.0022-202x.2001.01634.x; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Price CM, 1999, CURR OPIN GENET DEV, V9, P218, DOI 10.1016/S0959-437X(99)80032-X; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Rufer N, 2001, BLOOD, V98, P597, DOI 10.1182/blood.V98.3.597; Rufer N, 1999, J EXP MED, V190, P157, DOI 10.1084/jem.190.2.157; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Son NH, 2000, J IMMUNOL, V165, P1191, DOI 10.4049/jimmunol.165.3.1191; Sprung CN, 1997, MUTAT RES-FUND MOL M, V379, P177, DOI 10.1016/S0027-5107(97)00119-X; Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168; Ulaner GA, 1998, CANCER RES, V58, P4168; Vessey CJ, 2000, PROG NUCLEIC ACID RE, V63, P189, DOI 10.1016/S0079-6603(08)60723-0; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy T, 2002, LANCET, V359, P2168, DOI 10.1016/S0140-6736(02)09087-6; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Weng NP, 2002, SPRINGER SEMIN IMMUN, V24, P23, DOI 10.1007/s00281-001-0093-4; Weng NP, 1997, P NATL ACAD SCI USA, V94, P10827, DOI 10.1073/pnas.94.20.10827; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Wright WE, 1996, DEV GENET, V18, P173; Wynn RF, 1998, LANCET, V351, P178, DOI 10.1016/S0140-6736(97)08256-1; Yaghmai R, 2000, J PEDIATR-US, V136, P390, DOI 10.1067/mpd.2000.104295	74	230	238	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 20	2003	362	9388					983	988		10.1016/S0140-6736(03)14369-3	http://dx.doi.org/10.1016/S0140-6736(03)14369-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511933				2022-12-28	WOS:000185489600022
J	Crowther, MA; Ginsberg, JS; Julian, J; Denburg, J; Hirsh, J; Douketis, J; Laskin, C; Fortin, P; Anderson, D; Kearon, C; Clarke, A; Geerts, W; Forgie, M; Green, D; Costantini, L; Yacura, W; Wilson, S; Gent, M; Kovacs, MJ				Crowther, MA; Ginsberg, JS; Julian, J; Denburg, J; Hirsh, J; Douketis, J; Laskin, C; Fortin, P; Anderson, D; Kearon, C; Clarke, A; Geerts, W; Forgie, M; Green, D; Costantini, L; Yacura, W; Wilson, S; Gent, M; Kovacs, MJ			A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL WORKSHOP; ORAL ANTICOAGULATION	BACKGROUND: Many patients with the antiphospholipid antibody syndrome and recurrent thrombosis receive doses of warfarin adjusted to achieve an international normalized ratio (INR) of more than 3.0. However, there are no prospective data to support this approach to thromboprophylaxis. METHODS: We performed a randomized, double-blind trial in which patients with antiphospholipid antibodies and previous thrombosis were assigned to receive enough warfarin to achieve an INR of 2.0 to 3.0 (moderate intensity) or 3.1 to 4.0 (high intensity). Our objective was to show that high-intensity warfarin was more effective in preventing thrombosis than moderate-intensity warfarin. RESULTS: A total of 114 patients were enrolled in the study and followed for a mean of 2.7 years. Recurrent thrombosis occurred in 6 of 56 patients (10.7 percent) assigned to receive high-intensity warfarin and in 2 of 58 patients (3.4 percent) assigned to receive moderate-intensity warfarin (hazard ratio for the high-intensity group, 3.1; 95 percent confidence interval, 0.6 to 15.0). Major bleeding occurred in three patients assigned to receive high-intensity warfarin and four patients assigned to receive moderate-intensity warfarin (hazard ratio, 1.0; 95 percent confidence interval, 0.2 to 4.8). CONCLUSIONS: High-intensity warfarin was not superior to moderate-intensity warfarin for thromboprophylaxis in patients with antiphospholipid antibodies and previous thrombosis. The low rate of recurrent thrombosis among patients in whom the target INR was 2.0 to 3.0 suggests that moderate-intensity warfarin is appropriate for patients with the antiphospholipid antibody syndrome.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Undergrad Med Program, Toronto, ON, Canada; Dalhousie Univ, Dept Med, Halifax, NS, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Northwestern Univ, Dept Med, Chicago, IL 60611 USA	McMaster University; McMaster University; University of Toronto; University of Toronto; Dalhousie University; McGill University; University of Ottawa; Western University (University of Western Ontario); Northwestern University	Crowther, MA (corresponding author), St Josephs Hosp, Rm L208,50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.		ginsberg, jeffrey s/ABC-1065-2020; Douketis, James/AAO-5659-2021; Kovacs, Michael/G-3315-2011	Fortin, Paul R./0000-0002-7278-2596; Anderson, David/0000-0003-0845-1722				Brandt JT, 1995, THROMB HAEMOSTASIS, V74, P1597; Crowther MA, 2002, J AM SOC NEPHROL, V13, P2331, DOI 10.1097/01.ASN.0000027356.16598.99; CROWTHER MA, 2002, FUNDAMENTAL CLIN CAR, V44, P49; Kearon C, 1999, NEW ENGL J MED, V341, P298; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; Oden A, 2002, BMJ-BRIT MED J, V325, P1073, DOI 10.1136/bmj.325.7372.1073; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; ROSOVE MH, 1992, ANN INTERN MED, V117, P303, DOI 10.7326/0003-4819-117-4-303; Ruiz-Irastorza G, 2002, ARCH INTERN MED, V162, P1164, DOI 10.1001/archinte.162.10.1164; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F	10	588	614	0	13	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1133	1138		10.1056/NEJMoa035241	http://dx.doi.org/10.1056/NEJMoa035241			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679527	Bronze			2022-12-28	WOS:000185369700006
J	Stevens, JA; Ivison, RJ; Dunlop, JS; Smail, IR; Percival, WJ; Hughes, DH; Rottgering, HJA; van Breugel, WJM; Reuland, M				Stevens, JA; Ivison, RJ; Dunlop, JS; Smail, IR; Percival, WJ; Hughes, DH; Rottgering, HJA; van Breugel, WJM; Reuland, M			The formation of cluster elliptical galaxies as revealed by extensive star formation	NATURE			English	Article							REDSHIFT RADIO GALAXIES; BLACK-HOLES; DUST; EMISSION; MERGERS; QUASARS; PROTOCLUSTER; ABSORPTION; ALIGNMENT; BULGES	The most massive galaxies in the present-day Universe are found to lie in the centres of rich clusters. They have old, coeval stellar populations suggesting that the bulk of their stars must have formed at early epochs in spectacular starbursts(1), which should be luminous phenomena when observed at submillimetre wavelengths(2). The most popular model of galaxy formation predicts that these galaxies formin proto-clusters at high-density peaks in the early Universe(3). Such peaks are indicated by massive high-redshift radio galaxies(4). Here we report deep submillimetre mapping of seven high-redshift radio galaxies and their environments. These data confirm not only the presence of spatially extended regions of massive star-formation activity in the radio galaxies themselves, but also in companion objects previously undetected at any wavelength. The prevalence, orientation, and inferred masses of these submillimetre companion galaxies suggest that we are witnessing the synchronous formation of the most luminous elliptical galaxies found today at the centres of rich clusters of galaxies.	Royal Observ, Astron Technol Ctr, Edinburgh EH9 3HJ, Midlothian, Scotland; Univ Edinburgh, Inst Astron, Edinburgh EH9 3HJ, Midlothian, Scotland; Univ Durham, Inst Computat Cosmol, Durham DH1 3LE, England; Inst Nacl Astrofis Opt & Elect, Puebla 72000, Mexico; Leiden Observ, NL-2300 Leiden, Netherlands; Lawrence Livermore Natl Lab, Inst Geophys & Planetary Phys, Livermore, CA 94459 USA	University of Edinburgh; University of Edinburgh; Durham University; Instituto Nacional de Astrofisica, Optica y Electronica; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Stevens, JA (corresponding author), Royal Observ, Astron Technol Ctr, Blackford Hill, Edinburgh EH9 3HJ, Midlothian, Scotland.		Smail, Ian/M-5161-2013; Ivison, R. J./G-4450-2011; Smail, Ian/AAL-9018-2020	Smail, Ian/0000-0003-3037-257X; Ivison, R. J./0000-0001-5118-1313; Smail, Ian/0000-0003-3037-257X; Stevens, Jason/0000-0002-4010-8310				Archibald EN, 2001, MON NOT R ASTRON SOC, V323, P417, DOI 10.1046/j.1365-8711.2001.04188.x; CHAMBERS KC, 1987, NATURE, V329, P604, DOI 10.1038/329604a0; De Breuck C, 2003, ASTRON ASTROPHYS, V401, P911, DOI 10.1051/0004-6361:20030171; DUNLOP JS, 1994, NATURE, V370, P347, DOI 10.1038/370347a0; Dunlop JS, 2003, MON NOT R ASTRON SOC, V340, P1095, DOI 10.1046/j.1365-8711.2003.06333.x; EALES SA, 1992, ASTROPHYS J, V397, P49, DOI 10.1086/171765; Ellis RS, 1997, ASTROPHYS J, V483, P582, DOI 10.1086/304261; GORENSTEIN P, 1975, ASTROPHYS J, V198, P95, DOI 10.1086/153579; HILDEBRAND RH, 1983, Q J ROY ASTRON SOC, V24, P267; Holland WS, 1999, MON NOT R ASTRON SOC, V303, P659, DOI 10.1046/j.1365-8711.1999.02111.x; Hughes DH, 1997, MON NOT R ASTRON SOC, V289, P766, DOI 10.1093/mnras/289.4.766; Ivison RJ, 2000, ASTROPHYS J, V542, P27, DOI 10.1086/309536; Kauffmann G, 2000, MON NOT R ASTRON SOC, V311, P576, DOI 10.1046/j.1365-8711.2000.03077.x; Kauffmann G, 1996, MON NOT R ASTRON SOC, V281, P487, DOI 10.1093/mnras/281.2.487; Magorrian J, 1998, ASTRON J, V115, P2285, DOI 10.1086/300353; McCarthy P. J., 1987, APJ, V321, P29; Mihos JC, 1996, ASTROPHYS J, V464, P641, DOI 10.1086/177353; Omont A, 1996, NATURE, V382, P428, DOI 10.1038/382428a0; Page MJ, 2001, SCIENCE, V294, P2516, DOI 10.1126/science.1065880; Papadopoulos PP, 2000, ASTROPHYS J, V528, P626, DOI 10.1086/308215; Pentericci L, 2002, ASTRON ASTROPHYS, V396, P109, DOI 10.1051/0004-6361:20021368; Percival WJ, 2003, MON NOT R ASTRON SOC, V338, pL31, DOI 10.1046/j.1365-8711.2003.06317.x; Reuland M, 2003, ASTROPHYS J, V582, pL71, DOI 10.1086/367689; REULAND M, 2003, IN PRESS RADIO GALAX; Scott SE, 2002, MON NOT R ASTRON SOC, V331, P817, DOI 10.1046/j.1365-8711.2002.05193.x; Smail I, 2003, ASTROPHYS J, V583, P551, DOI 10.1086/345474; Smail I, 2002, MON NOT R ASTRON SOC, V331, P495, DOI 10.1046/j.1365-8711.2002.05203.x; SMAIL I, IN PRESS ASTROPHYS J; WEST MJ, 1994, MON NOT R ASTRON SOC, V268, P79, DOI 10.1093/mnras/268.1.79	30	150	151	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					264	267		10.1038/nature01976	http://dx.doi.org/10.1038/nature01976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679908	Green Submitted			2022-12-28	WOS:000185370900036
J	Markowitz, JS; Donovan, JL; DeVane, CL; Taylor, RM; Ruan, Y; Wang, JS; Chavin, KD				Markowitz, JS; Donovan, JL; DeVane, CL; Taylor, RM; Ruan, Y; Wang, JS; Chavin, KD			Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERICUM-PERFORATUM; MAJOR DEPRESSION; PHARMACOKINETICS; ALPRAZOLAM; EXTRACT; DEXTROMETHORPHAN; INHIBITION; PLASMA; IMIPRAMINE; PLACEBO	Context St John's wort is a popular herbal product used to treat depression but it has been implicated in drug interactions. Objective To assess the potential of St John's wort administration to alter the activity of the cytochrome P450 (CYP) enzymes extensively involved in drug metabolism. Design, Setting, and Participants Open-label crossover study with fixed treatment order conducted March 2002 to February 2003 in a US general clinical research center involving 12 healthy volunteers (6 men and 6 women) aged 22 to 38 years before and after 14 days of administration of St John's wort. Intervention Participants were given probe drugs (30 mg of dextromethorphan and 2 mg of alprazolam) to establish baseline CYP 3A4 and CYP 2D6 activity. After a minimum 7-day washout period, participants began taking one 300-mg tablet 3 times per day. After 14 days of St John's wort administration, participants were given the probe drugs along with 1 St John's wort tablet to establish postadministration CYP activity; the St John's wort dosing regimen was continued for 48 hours. Main Outcome Measures Changes in plasma pharmacokinetics of alprazolam as a probe for CYP 3A4 activity and the ratio of dextromethorphan to its metabolite, dextrorphan, in urine as a probe for CYP 2D6 activity. Results A 2-fold decrease in the area under the curve for alprazolam plasma concentration vs time (P<.001) and a 2-fold increase in alprazolam clearance (P<.001) were observed following St John's wort administration. Alprazolam elimination half life was shortened from a mean (SD) of 12.4 (3.9) hours to 6.0 (2.4) hours (P<.001). The mean (SD) urinary ratio of dextromethorphan to its metabolite was 0.006 (0.010) at baseline and 0.014 (0.025) after St John's wort administration (P=.26). Conclusions A 14-day course of St John's wort administration significantly induced the activity of CYP 3A4 as measured by changes in alprazolam pharmacokinetics. This suggests that long-term administration of St John's wort may result in diminished clinical effectiveness or increased dosage requirements for all CYP 3A4 substrates, which represent at least 50% of all marketed medications.	Med Univ S Carolina, Inst Psychiat, Lab Drug Disposit & Pharmacogenet, Dept Pharmaceut Sci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Surg, Div Transplantat, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Markowitz, JS (corresponding author), Med Univ S Carolina, Inst Psychiat, Lab Drug Disposit & Pharmacogenet, Dept Pharmaceut Sci, RM 246 N,67 President St, Charleston, SC 29425 USA.	markowij@musc.edu	DeVane, Lindsay/B-6645-2012		NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT000511] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001070] Funding Source: NIH RePORTER; NCCIH NIH HHS [R21 AT00511] Funding Source: Medline; NCRR NIH HHS [M01 RR01070-18] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barnes J, 2001, J PHARM PHARMACOL, V53, P583, DOI 10.1211/0022357011775910; BLUMENTHAL M, 2003, HERBALGRAM, V58, P71; Brosen K, 1996, THER DRUG MONIT, V18, P393, DOI 10.1097/00007691-199608000-00014; Constantine GH, 1998, PHARM BIOL, V36, P365, DOI 10.1076/phbi.36.5.365.4651; Cui YY, 2002, J CHROMATOGR B, V780, P129, DOI 10.1016/S1570-0232(02)00439-7; Davidson JRT, 2002, JAMA-J AM MED ASSOC, V287, P1807, DOI 10.1001/jama.287.14.1807; de Maat MMR, 2001, AIDS, V15, P420, DOI 10.1097/00002030-200102160-00019; Donovan JL, 2003, FOOD CHEM TOXICOL, V41, P1199, DOI 10.1016/S0278-6915(03)00112-1; Donovan JL, 2003, DRUG METAB DISPOS, V31, P519, DOI 10.1124/dmd.31.5.519; Durr D, 2000, CLIN PHARMACOL THER, V68, P598, DOI 10.1067/mcp.2000.112240; Furukori H, 1998, NEUROPSYCHOPHARMACOL, V18, P364; Gorski JC, 1999, XENOBIOTICA, V29, P931, DOI 10.1080/004982599238173; Greeson JM, 2001, PSYCHOPHARMACOLOGY, V153, P402, DOI 10.1007/s002130000625; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; HENDERSON L, 2003, BR J CLIN PHARM, V55, P112; Hoskins JM, 1997, J CHROMATOGR B, V696, P81, DOI 10.1016/S0378-4347(97)00225-9; Johne A, 2002, J CLIN PSYCHOPHARM, V22, P46, DOI 10.1097/00004714-200202000-00008; Johne A, 1999, CLIN PHARMACOL THER, V66, P338, DOI 10.1053/cp.1999.v66.a101944; Kerb R, 1996, ANTIMICROB AGENTS CH, V40, P2087, DOI 10.1128/AAC.40.9.2087; Lecrubier Y, 2002, AM J PSYCHIAT, V159, P1361, DOI 10.1176/appi.ajp.159.8.1361; Liston HL, 2002, J CLIN PSYCHOPHARM, V22, P169, DOI 10.1097/00004714-200204000-00010; Mai I, 2003, NEPHROL DIAL TRANSPL, V18, P819, DOI 10.1093/ndt/gfg002; Markowitz J S, 2001, Psychopharmacol Bull, V35, P53; MARKOWITZ JS, IN PRESS J CLIN PSYC; Markusen A, 2001, ANTIPODE, V33, P39, DOI 10.1111/1467-8330.00160; MILLER RL, 1988, J CHROMATOGR-BIOMED, V430, P180, DOI 10.1016/S0378-4347(00)83150-3; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Obach RS, 2000, J PHARMACOL EXP THER, V294, P88; Perloff MD, 2001, BRIT J PHARMACOL, V134, P1601, DOI 10.1038/sj.bjp.0704399; Perloff MD, 1999, BIOCHEM PHARMACOL, V57, P1227, DOI 10.1016/S0006-2952(99)00054-4; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; SCHMID B, 1985, CLIN PHARMACOL THER, V38, P618, DOI 10.1038/clpt.1985.235; Schmider J, 1999, PHARMACOGENETICS, V9, P725, DOI 10.1097/01213011-199912000-00007; Shelton RC, 2001, JAMA-J AM MED ASSOC, V285, P1978, DOI 10.1001/jama.285.15.1978; Simmen U, 2003, EUR J PHARMACOL, V458, P251, DOI 10.1016/S0014-2999(02)02818-2; Smith DA, 1998, XENOBIOTICA, V28, P1095, DOI 10.1080/004982598238859; SMITH RB, 1984, PSYCHOPHARMACOLOGY, V84, P452, DOI 10.1007/BF00431449; Sugimoto K, 2001, CLIN PHARMACOL THER, V70, P518, DOI 10.1067/mcp.2001.120025; Venkatakrishnan K, 1998, J CLIN PSYCHOPHARM, V18, P256, DOI 10.1097/00004714-199806000-00015; Wang ZQ, 2002, CLIN PHARMACOL THER, V71, P414, DOI 10.1067/mcp.2002.124080; Wang ZQ, 2001, CLIN PHARMACOL THER, V70, P317, DOI 10.1067/mcp.2001.118522; Woelk H, 2000, BMJ-BRIT MED J, V321, P536, DOI 10.1136/bmj.321.7260.536; WRIGHTON SA, 1992, CRIT REV TOXICOL, V22, P1, DOI 10.3109/10408449209145319; ZHANG Y, 1992, CLIN PHARMACOL THER, V51, P647, DOI 10.1038/clpt.1992.77	46	265	274	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1500	1504		10.1001/jama.290.11.1500	http://dx.doi.org/10.1001/jama.290.11.1500			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RE	13129991				2022-12-28	WOS:000185329000033
J	Peretti-Watel, P; Bendiane, MK; Pegliasco, H; Lapiana, JM; Favre, R; Galinier, A; Moatti, JP				Peretti-Watel, P; Bendiane, MK; Pegliasco, H; Lapiana, JM; Favre, R; Galinier, A; Moatti, JP			Doctors' opinions on euthanasia, end of life care, and doctor-patient communication: telephone survey in France	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN-ASSISTED SUICIDE; ATTITUDES		Reg Ctr Dis Control SE, F-13006 Marseille, France; Inst J Paoli I Calmettes, Hlth & Med Res Natl Inst, Unit 379, F-13009 Marseille, France; Departmental Ctr Private Profess, Marseille, France; Assistance Publ Hop Marseille, Med Oncol Serv, Marseille, France; Assistance Publ Hop Marseille, Dept Penitentiary Care, Marseille, France; Univ Aix Marseille 2, Dept Econ, F-13284 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite	Peretti-Watel, P (corresponding author), Reg Ctr Dis Control SE, F-13006 Marseille, France.		Bendiane, Marc-Karim/M-7060-2019; Peretti-Watel, Patrick/P-4535-2017; Bendiane, Marc-Karim K/F-5414-2010	Bendiane, Marc-Karim K/0000-0003-4329-8807				Ben Diane MK, 2003, PRESSE MED, V32, P488; Emanuel EJ, 2000, ANN INTERN MED, V133, P527, DOI 10.7326/0003-4819-133-7-200010030-00011; Grassi L, 1999, J PAIN SYMPTOM MANAG, V17, P188, DOI 10.1016/S0885-3924(98)00155-9; Hermsen MA, 2002, J PAIN SYMPTOM MANAG, V23, P517, DOI 10.1016/S0885-3924(02)00401-3; Seale C, 2000, SOC SCI MED, V51, P917, DOI 10.1016/S0277-9536(00)00071-X	5	39	40	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					595	596		10.1136/bmj.327.7415.595	http://dx.doi.org/10.1136/bmj.327.7415.595			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969926	Bronze, Green Published			2022-12-28	WOS:000185358700022
J	Wallentin, L; Wilcox, RG; Weaver, WD; Emanuelsson, H; Goodvin, A; Nystrom, P; Bylock, A				Wallentin, L; Wilcox, RG; Weaver, WD; Emanuelsson, H; Goodvin, A; Nystrom, P; Bylock, A		ESTEEM Investigators	Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial	LANCET			English	Article							DIRECT THROMBIN INHIBITOR; ACUTE CORONARY SYNDROMES; UNSTABLE ANGINA; NO INFLUENCE; ACTIVE FORM; PHARMACODYNAMICS; PHARMACOKINETICS; MELAGATRAN; PREVENTION; MANAGEMENT	Background Despite important advances in treatment, the risk of recurrent ischaemic events is high both early and late after an acute coronary syndrome. We aimed to assess the effectiveness of ximelagatran and acetylsalicylic acid for prevention of death, non-fatal myocardial infarction, and severe recurrent ischaemia after a recent myocardial infarction. Methods In this placebo-controlled, double-blind, multicentre, multinational dose-guiding study we assessed 1883 patients who had had recent ST-elevation or non-ST-elevation myocardial infarction. Within 14 days after the index event we randomised the participants in the proportions 1/1/1/1/2 to oral ximelagatran at doses of 24 mg, 36 mg, 48 mg, or 60 mg twice daily, or placebo, respectively for 6 months. All patients received acetylsalicylic acid 160 mg once daily. The primary efficacy outcome was the dose response of ximelagatran by comparison with placebo for the occurrence of all-cause death, non-fatal myocardial infarction, and severe recurrent ischaemia. Analysis was by intention to treat. Findings Oral ximelagatran significantly reduced the risk for the primary endpoint compared with placebo from 16.3% (102 of 638) to 12.7% (154 of 1245) (hazard ratio 0.76, 95% CI 0.59-0.98, p=0.036) for the combined ximelagatran groups versus placebo. There was no indication of a dose response between the ximelagatran groups. Major bleeding events were rare, 1.8 % (23 of 1245) and 0.9 % (six of 638) (hazard ratio 1.97, 95% CI 0.80-4.84) in the combined ximelagatran and placebo groups, respectively. We recorded no serious clinically adverse outcomes judged related to the investigational drug. Interpretation Oral direct thrombin inhibition with ximelagatran and acetylsalicylic acid is more effective than acetylsalicylic acid alone in preventing major cardiovascular events during 6 months of treatment in patients who have had a recent myocardial infarction.	Univ Uppsala Hosp, Uppsala Clin Res Ctr, S-75185 Uppsala, Sweden; Univ Nottingham Hosp, Dept Cardiovasc Med, Nottingham NG7 2UH, England; Henry Ford Hosp, Detroit, MI 48202 USA; AstraZeneca, Charnwood, England; AstraZeneca, Molndal, Sweden	Uppsala University; Uppsala University Hospital; University of Nottingham; Henry Ford Health System; Henry Ford Hospital; AstraZeneca	Wallentin, L (corresponding author), Univ Uppsala Hosp, Uppsala Clin Res Ctr, S-75185 Uppsala, Sweden.	lars.wallentin@ucr.uu.se						Alpert JS, 2000, EUR HEART J, V21, P1502, DOI 10.1053/euhj.2000.2305; Antman EM, 1999, CIRCULATION, V100, P1593, DOI 10.1161/01.CIR.100.15.1593; *ASS SAF EFF NEW T, 2002, LANCET, V358, P605; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bertrand ME, 2002, EUR HEART J, V23, P1809, DOI 10.1053/euhj.2002.3385; Braunwald E, 2002, CIRCULATION, V106, P1893, DOI 10.1161/01.CIR.0000037106.76139.53; Cairns JA, 2001, CHEST, V119, p228S, DOI 10.1378/chest.119.1_suppl.228S; Eriksson B, 2002, LANCET, V360, P1441, DOI 10.1016/S0140-6736(02)11469-3; Eriksson H, 2002, BLOOD, V100, p81A; Eriksson H, 2003, J THROMB HAEMOST, V1, P41, DOI 10.1046/j.1538-7836.2003.00034.x; Eriksson UG, 2003, DRUG METAB DISPOS, V31, P294, DOI 10.1124/dmd.31.3.294; Eriksson UG, 2003, EUR J CLIN PHARMACOL, V59, P35, DOI 10.1007/s00228-003-0565-7; ERIKSSONLEPKOWS.M, 2002, PATHOPHYSIOL HAEMO T, V32, P130; Fager G, 2000, EUR HEART J, V21, P441; Grip L, 1997, EUR HEART J, V18, P1416; Hurlen M, 2002, NEW ENGL J MED, V347, P969, DOI 10.1056/NEJMoa020496; Johansson LC, 2003, CLIN PHARMACOKINET, V42, P475, DOI 10.2165/00003088-200342050-00005; Johansson LC, 2003, CLIN PHARMACOKINET, V42, P381, DOI 10.2165/00003088-200342040-00006; OHLSSON BS, IN PRESS LANCET; Petersen P, 2003, J AM COLL CARDIOL, V41, P1445, DOI 10.1016/S0735-1097(03)00255-9; Sarich TC, 2003, CLIN PHARMACOKINET, V42, P485, DOI 10.2165/00003088-200342050-00006; Sarich TC, 2002, THROMB HAEMOSTASIS, V87, P300; THEROUX P, 1992, NEW ENGL J MED, V327, P141, DOI 10.1056/NEJM199207163270301; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; van Es RF, 2002, LANCET, V360, P109, DOI 10.1016/S0140-6736(02)09409-6; Wallentin L, 1996, LANCET, V347, P561; Wallentin L, 1999, LANCET, V354, P701; Wallentin L, 2003, EUR HEART J, V24, P897, DOI 10.1016/S0195-668X(03)00006-X; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Yusuf S, 2002, LANCET, V359, P294	30	297	308	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2003	362	9386					789	797		10.1016/S0140-6736(03)14287-0	http://dx.doi.org/10.1016/S0140-6736(03)14287-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678873				2022-12-28	WOS:000185188500012
J	Marambaud, P; Wen, PH; Dutt, A; Shioi, J; Takashima, A; Siman, R; Robakis, NK				Marambaud, P; Wen, PH; Dutt, A; Shioi, J; Takashima, A; Siman, R; Robakis, NK			A CBP binding transcriptional repressor produced by the PS1/is an element of-cleavage of N-cadherin is inhibited by PS1FAD mutations	CELL			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; C-FOS; DROSOPHILA-MELANOGASTER; ADHERENS JUNCTIONS; ADHESION SYSTEM; FACTOR CREB; PRESENILIN-1; CLEAVAGE	Presenilin1 (PS1), a protein implicated in Alzheimer's disease (AD), forms complexes with N-cadherin, a transmembrane protein with important neuronal and synaptic functions. Here, we show that a PS1-dependent T-secretase protease activity promotes an epsilon-like cleavage of N-cadherin to produce its intracellular domain peptide, N-Cad/CTF2. NMDA receptor agonists stimulate N-Cad/CTF2 production suggesting that this receptor regulates the epsilon-cleavage of N-cadherin. N-Cad/ CTF2 binds the transcription factor CBP and promotes its proteasomal degradation, inhibiting CRE-dependent transactivation. Thus, the PS1-dependent epsilon-cleavage product N-Cad/CTF2 functions as a potent repressor of CBP/CREB-mediated transcription. Importantly, PS1 mutations associated with familial AD (FAD) and a gamma-secretase dominant-negative mutation inhibit N-Cad/CTF2 production and upregulate CREB-mediated transcription indicating that FAD mutations cause a gain of transcriptional function by inhibiting production of transcriptional repressor N-Cad/CTF2. These data raise the possibility that FAD mutation-induced transcriptional abnormalities maybe causally related to the dementia associated with FAD.	Mt Sinai Med Ctr, Sch Med, Dept Psychiat, New York, NY 10029 USA; Inst Phys & Chem Res, Lab Alzheimers Dis, Wako, Saitama 3510198, Japan; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Mt Sinai Med Ctr, Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; RIKEN; University of Pennsylvania; Icahn School of Medicine at Mount Sinai	Robakis, NK (corresponding author), Mt Sinai Med Ctr, Sch Med, Dept Psychiat, New York, NY 10029 USA.		Robakis, Nikolaos/AAA-1838-2021	Marambaud, Philippe/0000-0002-8983-1497	NIA NIH HHS [P50 AG005138-190025, AG-17926, R01 AG008200-18, AG-08200, AG-05138, R01 AG017926-05] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG017926, R01AG008200, R01AG017926] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Amtul Z, 2002, NEUROBIOL DIS, V9, P269, DOI 10.1006/nbdi.2001.0473; ANDERSON AJ, 1994, EXP NEUROL, V125, P286, DOI 10.1006/exnr.1994.1031; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Banker G., 1991, CULTURING NERVE CELL; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; Dawson TM, 2002, NAT MED, V8, P450, DOI 10.1038/nm0502-450; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Freiman RN, 2002, SCIENCE, V296, P2149, DOI 10.1126/science.1073845; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gillardon F, 1996, BRAIN RES, V706, P169, DOI 10.1016/0006-8993(95)01332-6; Goda Y, 2002, NEURON, V35, P1, DOI 10.1016/S0896-6273(02)00765-1; Goodman RH, 2000, GENE DEV, V14, P1553; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Huntley GW, 2002, CELL, V108, P1, DOI 10.1016/S0092-8674(01)00631-6; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Ludlam WH, 2002, MOL CELL BIOL, V22, P3832, DOI 10.1128/MCB.22.11.3832-3841.2002; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marcus DL, 1998, NEUROBIOL AGING, V19, P393, DOI 10.1016/S0197-4580(98)00077-3; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McLendon C, 2000, FASEB J, V14, P2383; Murayama O, 1999, NEUROSCI LETT, V265, P61, DOI 10.1016/S0304-3940(99)00187-1; Nowotny P, 2000, MOL CELL NEUROSCI, V15, P88, DOI 10.1006/mcne.1999.0805; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Siman R, 2000, J NEUROSCI, V20, P8717; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; ZHANG P, 1992, NEUROSCIENCE, V46, P9, DOI 10.1016/0306-4522(92)90004-L	45	407	420	0	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					635	645		10.1016/j.cell.2003.08.008	http://dx.doi.org/10.1016/j.cell.2003.08.008			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678586	Bronze			2022-12-28	WOS:000185193100012
J	Beveridge, M; Howard, A; Burton, K; Holder, W				Beveridge, M; Howard, A; Burton, K; Holder, W			The Ptolemy project: a scalable model for delivering health information in Africa	BRITISH MEDICAL JOURNAL			English	Article							DEVELOPING-COUNTRIES; INTERNET; SCIENCE		Univ Toronto, Sunnybrook & Womens Coll Hlth Sci, Off Int Surg, Ross Tilley Burn Ctr, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Beveridge, M (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci, Off Int Surg, Ross Tilley Burn Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Howard, Andrew/C-7163-2009	Howard, Andrew/0000-0001-7226-6471				*COL GLOB HLTH RES, 2002, ROL HLTH RES CONTR A; Dickinson G, 1999, CAN MED ASSOC J, V160, P382; Dickson D, 2001, NATURE, V414, P587, DOI 10.1038/414587a; Edejer TTT, 2000, BRIT MED J, V321, P797, DOI 10.1136/bmj.321.7264.797; *GLOB FOR HLTH RES, 2002, 1090 GLOB FOR HLTH R; Godlee F, 2000, LANCET, V356, P1129, DOI 10.1016/S0140-6736(00)02752-5; Horton R, 2000, LANCET, V355, P2231, DOI 10.1016/S0140-6736(00)02414-4; Isaakidis P, 2002, BRIT MED J, V324, P702, DOI 10.1136/bmj.324.7339.702; Kennedy D, 2001, SCIENCE, V294, P2053, DOI 10.1126/science.294.5549.2053; Page J, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-6; PakenhamWalsh N, 1997, BRIT MED J, V314, P90, DOI 10.1136/bmj.314.7074.90; Roberts I, 2001, BRIT MED J, V323, P1485, DOI 10.1136/bmj.323.7327.1485; Smith R, 2003, BRIT MED J, V326, P238, DOI 10.1136/bmj.326.7383.238; Smith R, 1996, BRIT MED J, V313, P1062; *UN DEV PROGR, 2001, HUM DEV REP 2001; *WHO, 2002, WORLD HLTH REP 2002, P186	16	22	23	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					790	793		10.1136/bmj.327.7418.790	http://dx.doi.org/10.1136/bmj.327.7418.790			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525880	Bronze, Green Published			2022-12-28	WOS:000185805100024
J	Nestler, EJ				Nestler, EJ			Patricia S. Goldman-Rakic (1937-2003) - Obituary	NATURE			English	Biographical-Item									Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nestler, EJ (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA.							GOLDMANRAKIC PS, PUBLICATION LIST	1	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					471	471		10.1038/425471a	http://dx.doi.org/10.1038/425471a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523433	Bronze			2022-12-28	WOS:000185648100032
J	Ney, A; Pampuch, C; Koch, R; Ploog, KH				Ney, A; Pampuch, C; Koch, R; Ploog, KH			Programmable computing with a single magnetoresistive element	NATURE			English	Article							LAYERED MAGNETIC-STRUCTURES; GIANT-MAGNETORESISTANCE	The development of transistor-based integrated circuits for modern computing is a story of great success. However, the proved concept for enhancing computational power by continuous miniaturization is approaching its fundamental limits. Alternative approaches consider logic elements that are reconfigurable at run-time to overcome the rigid architecture of the present hardware systems(1). Implementation of parallel algorithms on such 'chameleon' processors has the potential to yield a dramatic increase of computational speed, competitive with that of supercomputers(2). Owing to their functional flexibility, 'chameleon' processors can be readily optimized with respect to any computer application. In conventional microprocessors, information must be transferred to a memory to prevent it from getting lost, because electrically processed information is volatile. Therefore the computational performance can be improved if the logic gate is additionally capable of storing the output. Here we describe a simple hardware concept for a programmable logic element that is based on a single magnetic random access memory (MRAM(3,4)) cell. It combines the inherent advantage of a non-volatile output with flexible functionality which can be selected at run-time to operate as an AND, OR, NAND or NOR gate.	Paul Drude Inst Festkorperelekt, D-10117 Berlin, Germany	Paul Drude Institute for Solid State Electronics	Koch, R (corresponding author), Paul Drude Inst Festkorperelekt, Hausvogteipl 5-7, D-10117 Berlin, Germany.	koch@pdi-berlin.de	Ney, Andreas/D-2771-2013; Koch, Reinhold/C-9667-2012	Ney, Andreas/0000-0002-2388-6006; Koch, Reinhold/0000-0001-8194-8191				BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; BINASCH G, 1989, PHYS REV B, V39, P4828, DOI 10.1103/PhysRevB.39.4828; Black WC, 2000, J APPL PHYS, V87, P6674, DOI 10.1063/1.372806; COMPANO R, 2000, TECHNOLOGICAL ROADMA; Gerrits T, 2002, NATURE, V418, P509, DOI 10.1038/nature00905; Goronkin H., 1999, NANOSTRUCTURE SCI TE, P67; Grunberg P, 2001, PHYS TODAY, V54, P31, DOI 10.1063/1.1381100; MARTIN AJ, 2000, P SSGRR 2000 INT C A; MOODERA JS, 1995, PHYS REV LETT, V74, P3273, DOI 10.1103/PhysRevLett.74.3273; Parkin SSP, 1999, J APPL PHYS, V85, P5828, DOI 10.1063/1.369932; Prinz GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/science.282.5394.1660; Richter R, 2002, J MAGN MAGN MATER, V240, P127, DOI 10.1016/S0304-8853(01)00733-8; Sidhu R. P. S., 1999, Field Programmable Logic and Applications. 9th International Workshop, FPL'99. Proceedings (Lecture Notes in Computer Science Vol.1673), P301	13	316	348	3	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2003	425	6957					485	487		10.1038/nature02014	http://dx.doi.org/10.1038/nature02014			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523439				2022-12-28	WOS:000185648100037
J	Cauley, JA; Robbins, J; Chen, Z; Cummings, SR; Jackson, RD; LaCroix, AZ; LeBoff, M; Lewis, CE; McGowan, J; Neuner, J; Pettinger, M; Stefanick, ML; Wactawski-Wende, J; Watts, NB				Cauley, JA; Robbins, J; Chen, Z; Cummings, SR; Jackson, RD; LaCroix, AZ; LeBoff, M; Lewis, CE; McGowan, J; Neuner, J; Pettinger, M; Stefanick, ML; Wactawski-Wende, J; Watts, NB		Women's Hlth Initiative Investigat	Effects of estrogen plus progestin on risk of fracture and bone mineral density - The Women's Health Initiative randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; VERTEBRAL FRACTURES; POSTMENOPAUSAL WOMEN; OLDER WOMEN; ESTROGEN/PROGESTIN REPLACEMENT; OSTEOPOROTIC FRACTURES; NONVERTEBRAL FRACTURES; ELDERLY WOMEN; HIP FRACTURE; PREVENTION	Context In the Women's Health Initiative trial of estrogen-plus-progestin therapy, women assigned to active treatment had fewer fractures. Objective To test the hypothesis that the relative risk reduction of estrogen plus progestin on fractures differs according to risk factors for fractures. Design, Setting, and Participants Randomized controlled trial (September 1993-July 2002) in which 16608 postmenopausal women aged 50 to 79 years with an intact uterus at baseline were recruited at 40 US clinical centers and followed up for an average of 5.6 years. Intervention Women were randomly assigned to receive conjugated equine estrogen, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n=8506) or placebo (n = 8102). Main Outcome Measures All confirmed osteoporotic fracture events that occurred from enrollment to discontinuation of the trial (July 7, 2002); bone mineral density (BMD), measured in a subset of women (n = 1024) at baseline and years 1 and 3; and a global index, developed to summarize the balance of risks and benefits to test whether the risk-benefit profile differed across tertiles of fracture risk. Results Seven hundred thirty-three women (8.6%) in the estrogen-plus-progestin group and 896 women (11.1%) in the placebo group experienced a fracture (hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.69-0.83). The effect did not differ in women stratified by age, body mass index, smoking status, history of falls, personal and family history of fracture, total calcium intake, past use of hormone therapy, BMD, or summary fracture risk score. Total hip BMD increased 3.7% after 3 years of treatment with estrogen plus progestin compared with 0.14% in the placebo group (P<.001). The HR for the global index was similar across tertiles of the fracture risk scale (lowest fracture risk tertile, HR, 1.20; 95% CI, 0.93-1.58; middle tertile, HR, 1,23; 95% Cl, 1.04-1.46; highest tertile, HR, 1.03; 95% Cl, 0.88-1.24) (P for interaction =.54). Conclusions This study demonstrates that estrogen plus progestin increases BMD and reduces the risk of fracture in healthy postmenopausal women. The decreased risk of fracture attributed to estrogen plus progestin appeared to be present in all subgroups of women examined. When considering the effects of hormone therapy on other important disease outcomes in a global model, there was no net benefit, even in women considered to be at high risk of fracture.	Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Univ Calif Davis, Sch Med, Dept Internal Med, Sacramento, CA 95817 USA; Univ Arizona, Mel & Enid Zuckerman Arizona Coll Publ Hlth, Div Epidemiol & Biostat, Tucson, AZ USA; Univ Calif San Francisco, Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA; Ohio State Univ, Dept Internal Med, Div Endocrinol Diabet & Metab, Columbus, OH 43210 USA; Fred Hutchinson Canc Res Ctr, Womens Hlth Initiat Clin Coordinating Ctr, Seattle, WA 98104 USA; Brigham & Womens Hosp, Div Endocrine Hypertens, Boston, MA 02115 USA; Univ Alabama, Div Prevent Med, Birmingham, AL USA; NIAMSD, Bethesda, MD 20892 USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Ctr Patient Care & Outcomes Res, Milwaukee, WI 53226 USA; Stanford Univ, Dept Med, Stanford Ctr Res Dis Prevent, Palo Alto, CA 94304 USA; SUNY Buffalo, Buffalo, NY 14260 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Davis; University of Arizona; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Ohio; Ohio State University; Fred Hutchinson Cancer Center; Harvard University; Brigham & Women's Hospital; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Medical College of Wisconsin; Medical College of Wisconsin; Stanford University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University System of Ohio; University of Cincinnati	Cauley, JA (corresponding author), Univ Pittsburgh, Dept Epidemiol, Crabtree Hall A524,130 DeSoto St, Pittsburgh, PA 15261 USA.		Wactawski-Wende, Jean/AGH-5457-2022; Cauley, Jane A/N-4836-2015	Wactawski-Wende, Jean/0000-0003-3096-9595; Cauley, Jane A/0000-0003-0752-4408				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Black DM, 2001, OSTEOPOROSIS INT, V12, P519, DOI 10.1007/s001980170072; Black DM, 1999, J BONE MINER RES, V14, P821, DOI 10.1359/jbmr.1999.14.5.821; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BROWN BW, 1997, J GERONTOL A-BIOL, V52, pB166; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; Cauley JA, 2001, AM J MED, V110, P442, DOI 10.1016/S0002-9343(01)00647-7; COOPER C, 1993, BONE, V14, pS89; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; ENSRUD KE, 1995, J BONE MINER RES, V10, P1778; Grady D, 2001, JAMA-J AM MED ASSOC, V285, P2909, DOI 10.1001/jama.285.22.2909; Handa VL, 1996, J AM GERIATR SOC, V44, P1; Hannan EL, 2001, JAMA-J AM MED ASSOC, V285, P2736, DOI 10.1001/jama.285.21.2736; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JACOBSEN SJ, 1992, AM J PUBLIC HEALTH, V82, P1147, DOI 10.2105/AJPH.82.8.1147; Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755; Kado DM, 1999, ARCH INTERN MED, V159, P1215, DOI 10.1001/archinte.159.11.1215; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KRISTAL AR, 1994, P 17 NAT NUTR DAT C, P110; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; Meier CR, 2000, JAMA-J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205; Melton LJ, 1999, OSTEOPOROSIS INT, V9, P29, DOI 10.1007/s001980050113; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Nelson HD, 2002, ANN INTERN MED, V137, P529, DOI 10.7326/0003-4819-137-6-200209170-00015; Nevitt MC, 1998, ANN INTERN MED, V128, P793, DOI 10.7326/0003-4819-128-10-199805150-00001; Pi-Sunyer FX, 1998, AM J CLIN NUTR, V68, P899; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SEELEY DG, 1995, ARCH INTERN MED, V155, P293, DOI 10.1001/archinte.155.3.293; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001-5002	36	771	805	1	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1729	1738		10.1001/jama.290.13.1729	http://dx.doi.org/10.1001/jama.290.13.1729			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519707	Bronze			2022-12-28	WOS:000185606100022
J	Foster, AM; van Dis, J; Steinauer, J				Foster, AM; van Dis, J; Steinauer, J			Educational and legislative initiatives affecting residency training in abortion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; SERVICES; PROGRAMS		Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Hawaii, Honolulu, HI 96822 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Harvard University; Harvard Medical School; University of Hawaii System; University of California System; University of California San Francisco	Foster, AM (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.		Angel M. Foster, DPhil/H-6150-2019	Angel M. Foster, DPhil/0000-0001-8848-203X				*AM AC FAM PHYS JO, 1992, REC COR ED GUID FAM; AMELING R, 2000, FAM PLANN PERSPECT, V32, P320; AMELING R, 2000, FAM PLANN PERSPECT, V32, P268; DARNEY PD, 1987, FAM PLANN PERSPECT, V19, P158, DOI 10.2307/2135161; Finer LB, 2003, PERSPECT SEX REPRO H, V35, P6, DOI 10.1111/j.1931-2393.2003.tb00079.x; Henshaw K, 2003, PERSPECT SEX REPRO H, V35, P16; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; HENSHAW SK, 1995, FAM PLANN PERSPECT, V27, P54, DOI 10.2307/2135905; *KAIS FAM FDN, 1999, AB ISS UPD; Landy U, 2001, FAM PLANN PERSPECT, V33, P88, DOI 10.2307/2673755; MACKAY HT, 1995, FAM PLANN PERSPECT, V27, P112, DOI 10.2307/2136108; *NAT AB FED, 1991, WHO WILL PROV AB ENS; Shanahan MA, 1999, J REPROD MED, V44, P428; Steinauer JE, 2003, AM J OBSTET GYNECOL, V188, P1161, DOI 10.1067/mob.2003.309; Talley P P, 1996, Fam Med, V28, P245; Wear D, 2003, TEACH LEARN MED, V15, P52, DOI 10.1207/S15328015TLM1501_10; Westhoff C, 1994, J Am Med Womens Assoc (1972), V49, P150	17	12	12	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1777	1778		10.1001/jama.290.13.1777	http://dx.doi.org/10.1001/jama.290.13.1777			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519717	Bronze			2022-12-28	WOS:000185606100032
J	Hart, R				Hart, R			ABC of subfertility - Unexplained infertility, endometriosis, and fibroids	BRITISH MEDICAL JOURNAL			English	Review									Univ Western Australia, Sch Womens & Infants Hlth, King Edward Mem Hosp, Subiaco, WA, Australia	King Edward Memorial Hospital; University of Western Australia	Hart, R (corresponding author), Univ Western Australia, Sch Womens & Infants Hlth, King Edward Mem Hosp, Subiaco, WA, Australia.							BUTTRAM VC, 1981, FERTIL STE4RIL, V30, P644; Philips Z, 2000, HUM REPROD, V15, P95, DOI 10.1093/humrep/15.1.95; TEMPLETON A, 1998, EVIDENCE BASED FERTI	3	40	44	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	2003	327	7417					721	724		10.1136/bmj.327.7417.721	http://dx.doi.org/10.1136/bmj.327.7417.721			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728FZ	14512481	Green Published			2022-12-28	WOS:000185708300020
J	Galea, G; Pegg, D				Galea, G; Pegg, D			The ethics of donation: changes are necessary and soon	LANCET			English	Editorial Material									Scottish Natl Blood Transfus Serv, Tissue Serv, Edinburgh EH17 7QT, Midlothian, Scotland; Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England	University of York - UK	Galea, G (corresponding author), Scottish Natl Blood Transfus Serv, Tissue Serv, Edinburgh EH17 7QT, Midlothian, Scotland.							[Anonymous], 2001, ROYAL LIVERPOOL CHIL; *DEP HLTH, 2003, HUM BOD HUM CHOIC SU; *DEP HLTH, 2003, SAV LIV VAL DON TRAN; *DEP HLTH, 2002, HUM BOD HUM CHOIC RE; Kennedy I, 2001, INQUIRY MANAGEMENT C	5	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					932	932		10.1016/S0140-6736(03)14397-8	http://dx.doi.org/10.1016/S0140-6736(03)14397-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511924				2022-12-28	WOS:000185489600005
J	Taket, A; Nurse, J; Smith, K; Watson, J; Shakespeare, J; Lavis, V; Cosgrove, K; Mulley, K; Feder, G				Taket, A; Nurse, J; Smith, K; Watson, J; Shakespeare, J; Lavis, V; Cosgrove, K; Mulley, K; Feder, G			Routinely asking women about domestic violence in health settings	BRITISH MEDICAL JOURNAL			English	Article									London S Bank Univ, Fac Hlth & Social Care, London SE1 0AA, England; Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England; Greenwich Primary Care Trust, Publ Hlth Directorate, London SE10 8QG, England; MWB Business Exchange, Crown Prosecut Serv Headquarters, London EC4A 2AB, England; Summertown Grp Practice, Oxford OX2 7BS, England; Univ Huddersfield, Huddersfield HD1 3DH, W Yorkshire, England; Greater Glasgow NHS Board, Dept Publ Hlth, Glasgow G3 8YU, Lanark, Scotland; Cranmer House, London SW9 6DZ, England; Univ London, Queen Mary, Dept Gen Practice, London E1 4NS, England	London South Bank University; University of London; London School of Hygiene & Tropical Medicine; University of Huddersfield; University of London; Queen Mary University London	Taket, A (corresponding author), London S Bank Univ, Fac Hlth & Social Care, London SE1 0AA, England.		Taket, Ann R/G-1381-2010	Taket, Ann R/0000-0002-0971-5884; Feder, Gene/0000-0002-7890-3926				ANDERSON P, 2002, PERCEPTIONS WOMEN US; *DEP HLTH, 2000, DOM VIOL RES MAN HLT; Gerbert B, 1996, WOMEN HEALTH, V24, P1; Hague G., 1998, DOMESTIC VIOLENCE AC; HARRIS V, 2002, DOMESTIC ABUSE SCREE; *HOM OFF, 2000, RED DOM VIOL WHAT WO; HUMPHREYS C, 2002, ROUTES SAFETY PROTEC; HUMPHREYS C, 2000, GOOD INTENTIONS GOOD; Krug G. E., 2002, WORLD REPORT VIOLENC; Lewis G, 2001, WHY MOTHERS DIE 1997; MEZEY G, IN PRESS BR J OBSTET; MIRLEESBLACK C, 1999, 191 HOM OFF; Ramsay J, 2002, BRIT MED J, V325, P314, DOI 10.1136/bmj.325.7359.314; RATNER PA, 1993, CAN J PUBLIC HEALTH, V84, P246; Sullivan C. M., 2000, DOMESTIC VIOLENCE GU, P126; TAKET AR, IN PRESS EVALUATION; Waalen J, 2000, AM J PREV MED, V19, P230, DOI 10.1016/S0749-3797(00)00229-4; WATTS S, 2000, 2 LOND BOR CAMD, V2; WATTS S, 2000, 1 LOND BOR CAMD; *WHO, 1997, VIOL WOM HLTH PRIOR; Williamson Emma, 2000, DOMESTIC VIOLENCE HL	21	90	91	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 20	2003	327	7416					673	676		10.1136/bmj.327.7416.673	http://dx.doi.org/10.1136/bmj.327.7416.673			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724AC	14500444	Green Published, Green Accepted			2022-12-28	WOS:000185463100028
J	Winemiller, MH; Billow, RG; Laskowski, ER; Harmsen, WS				Winemiller, MH; Billow, RG; Laskowski, ER; Harmsen, WS			Effect of magnetic vs sham-magnetic insoles on plantar heel pain - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIELDS; FASCIITIS; SYSTEMS	Context Despite anecdotal reports, rigorous scientific evidence of the effectiveness of magnetic insoles for the pain of plantar fasciitis is lacking. Objective To determine whether magnetic insoles provide greater subjective improvement for treatment of plantar heel pain compared with identical nonmagnetized insoles. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial conducted from February 12, 2001, to November 9, 2001, of a volunteer sample of 101 adults with diagnoses of plantar heel pain for at least 30 days from a multispecialty group practice clinic in Rochester, Minn. Daily pain diaries were kept for 8 weeks. Interventions Cushioned insoles, with either active bipolar magnets or sham magnets, which were worn daily by the participants for 8 weeks. Main Outcome Measures Reported average daily foot pain (by metered visual analog scale [VAS] and by categorical response of change from baseline) at 4 and 8 weeks, and impact of insoles on employment performance and enjoyment. Results No significant between-group differences were found on any outcome variables studied when comparing active vs sham magnets. Both the nonmagnetic and magnetic groups reported significant improvements in morning foot pain intensity, with mean (SD) VAS scores. improving from 6.9 (2.3) and 6.7 (2.0), respectively, at baseline to 3.9 (2.6) for each group at 8 weeks (P=34). At 8 weeks, 33% of the nonmagnetic group and 35% of the magnetic group reported being all or mostly better (P=.78). At baseline, foot pain interfered moderately with participants' employment enjoyment (mean VAS, 4.2) and improved in both groups by 8 weeks (1.3 and 1.5, respectively; P=.68). Conclusion Static bipolar magnets embedded in cushioned shoe insoles do not provide additional benefit for subjective plantar heel pain reduction when compared with nonmagnetic insoles.	Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA; NW Orthopaed Surg, Mt Vernon, WA USA	Mayo Clinic; Mayo Clinic	Winemiller, MH (corresponding author), Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, 200 1st St SW, Rochester, MN 55905 USA.							BASFORD JR, 1988, ORTHOPEDICS, V11, P285; Basford JR, 1998, ARCH PHYS MED REHAB, V79, P249, DOI 10.1016/S0003-9993(98)90002-8; Borsa PA, 1998, J ATHL TRAINING, V33, P150; BROWN C, 2000, MONDAY POSTERS S4, V95, pS29; CAMPBELL JW, 1974, CLIN ORTHOP RELAT R, P57; Caselli MA, 1997, J AM PODIAT MED ASSN, V87, P11, DOI 10.7547/87507315-87-1-11; Colbert AP, 1999, J BACK MUSCULOSKELET, V13, P19, DOI 10.3233/BMR-1999-13104; Collacott EA, 2000, JAMA-J AM MED ASSOC, V283, P1322, DOI 10.1001/jama.283.10.1322; Crawford F, 2003, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD000416; DAMBROSIA RD, 1985, CLIN SPORT MED, V4, P611; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FINEGOLD L, 1999, SCI REV ALTERNATIVE, V3, P26; HONG CZ, 1987, ARCH PHYS MED REHAB, V68, P162; JOHNSON GR, 1988, PROSTHET ORTHOT INT, V12, P91; LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202; LIN JC, 1985, PSYCHOL REP, V56, P639, DOI 10.2466/pr0.1985.56.2.639; McBryde A M Jr, 1984, Instr Course Lect, V33, P278; OLNEY RK, 1990, MUSCLE NERVE, V13, P957, DOI 10.1002/mus.880131012; Pfeffer G, 1999, FOOT ANKLE INT, V20, P214, DOI 10.1177/107110079902000402; Repacholi MH, 1999, BIOELECTROMAGNETICS, V20, P133, DOI 10.1002/(SICI)1521-186X(1999)20:3<133::AID-BEM1>3.0.CO;2-O; Rosch PJ, 1998, STRESS MEDICINE, V14, P69, DOI 10.1002/(SICI)1099-1700(199804)14:2<69::AID-SMI785>3.0.CO;2-5; SANFILIPPO PB, 1992, J AM PODIAT MED ASSN, V82, P507, DOI 10.7547/87507315-82-10-507; Segal NA, 2001, ARCH PHYS MED REHAB, V82, P1453, DOI 10.1053/apmr.2001.24309; SINGER K, 1995, LOWER EXTREMITY SPIN, P441; TENFORDE TS, 1986, BIOELECTROMAGNETICS, V7, P341, DOI 10.1002/bem.2250070310; TOOMS RE, 1987, ORTHOPEDICS, V10, P1143; TOYSA T, 1997, ACUPUNCT MED, V15, P112; Vallbona C, 1997, ARCH PHYS MED REHAB, V78, P1200, DOI 10.1016/S0003-9993(97)90332-4; Vallbona C, 1999, Phys Med Rehabil Clin N Am, V10, P729; Weintraub MI, 1998, ARCH PHYS MED REHAB, V79, P469, DOI 10.1016/S0003-9993(98)90155-1; WEINTRAUB MI, 1998, AM J PAIN MANAGE, V8, P12	31	42	43	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1474	1478		10.1001/jama.290.11.1474	http://dx.doi.org/10.1001/jama.290.11.1474			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RE	13129987	Bronze			2022-12-28	WOS:000185329000029
J	Hayes, F				Hayes, F			Toxins-antitoxins: Plasmid maintenance, programmed cell death, and cell cycle arrest	SCIENCE			English	Review							ESCHERICHIA-COLI; BACTERIAL-POPULATIONS; NUTRITIONAL STRESS; ADDICTION SYSTEMS; CRYSTAL-STRUCTURE; ANTISENSE RNA; KID TOXIN; INHIBITOR; EVOLUTION; COMPLEX	Antibiotic resistance, virulence, and other plasmids in bacteria use toxin-antitoxin gene pairs to ensure their persistence during host replication. The toxin-antitoxin system eliminates plasmid-free cells that emerge as a result of segregation or replication defects and contributes to intra- and interspecies plasmid dissemination. Chromosomal homologs of toxin-antitoxin genes are widely distributed in pathogenic and other bacteria and induce reversible cell cycle arrest or programmed cell death in response to starvation or other adverse conditions. The dissection of the interaction of the toxins with intracellular targets and the elucidation of the tertiary structures of toxin-antitoxin complexes have provided exciting insights into toxin-antitoxin behavior.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	University of Manchester	Hayes, F (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England.							Allali N, 2002, J BACTERIOL, V184, P3224, DOI 10.1128/JB.184.12.3224-3231.2002; Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; Bishop RE, 1998, J MOL BIOL, V280, P583, DOI 10.1006/jmbi.1998.1894; Camacho AG, 2002, BIOL CHEM, V383, P1701, DOI 10.1515/BC.2002.191; Christensen SK, 2003, MOL MICROBIOL, V48, P1389, DOI 10.1046/j.1365-2958.2003.03512.x; Christensen SK, 2001, P NATL ACAD SCI USA, V98, P14328, DOI 10.1073/pnas.251327898; de la Cueva-Mendez G, 2003, EMBO J, V22, P246, DOI 10.1093/emboj/cdg026; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; GERDES K, 1986, P NATL ACAD SCI USA, V83, P3116, DOI 10.1073/pnas.83.10.3116; Gerdes K, 1997, ANNU REV GENET, V31, P1, DOI 10.1146/annurev.genet.31.1.1; Gerdes K, 2000, J BACTERIOL, V182, P561, DOI 10.1128/JB.182.3.561-572.2000; Grady R, 2003, MOL MICROBIOL, V47, P1419, DOI 10.1046/j.1365-2958.2003.03387.x; Hargreaves D, 2002, STRUCTURE, V10, P1425, DOI 10.1016/S0969-2126(02)00856-0; HAYES F, 2003, PLASMID VECTORS METH, P1; JAFFE A, 1985, J BACTERIOL, V163, P841; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; Jiang Y, 2002, MOL MICROBIOL, V44, P971, DOI 10.1046/j.1365-2958.2002.02921.x; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; Kawano M, 2002, MOL MICROBIOL, V45, P333, DOI 10.1046/j.1365-2958.2002.03042.x; Kobayashi I, 2001, NUCLEIC ACIDS RES, V29, P3742, DOI 10.1093/nar/29.18.3742; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Kristoffersen P, 2000, APPL ENVIRON MICROB, V66, P5524, DOI 10.1128/AEM.66.12.5524-5526.2000; Meinhart A, 2003, P NATL ACAD SCI USA, V100, P1661, DOI 10.1073/pnas.0434325100; Nanbu-Wakao R, 2000, GENES CELLS, V5, P155, DOI 10.1046/j.1365-2443.2000.00316.x; Pedersen K, 2002, MOL MICROBIOL, V45, P501, DOI 10.1046/j.1365-2958.2002.03027.x; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Pedersen K, 1999, MOL MICROBIOL, V32, P1090, DOI 10.1046/j.1365-2958.1999.01431.x; Pomerantsev AP, 2001, PLASMID, V46, P210, DOI 10.1006/plas.2001.1548; Potrykus K, 2002, MICROBIOL-SGM, V148, P2489, DOI 10.1099/00221287-148-8-2489; Rawlings DE, 1999, FEMS MICROBIOL LETT, V176, P269, DOI 10.1111/j.1574-6968.1999.tb13672.x; Read TD, 2003, NATURE, V423, P81, DOI 10.1038/nature01586; RUIZECHEVARRIA MJ, 1995, J MOL BIOL, V247, P568, DOI 10.1006/jmbi.1995.0163; Sat B, 2003, J BACTERIOL, V185, P1803, DOI 10.1128/JB.185.6.1803-1807.2003; Sayeed S, 2000, J BACTERIOL, V182, P2416, DOI 10.1128/JB.182.9.2416-2421.2000; Shapiro JA, 1998, ANNU REV MICROBIOL, V52, P81, DOI 10.1146/annurev.micro.52.1.81; Thomas CM, 2000, HORIZONTAL GENE POOL; Van Melderen L, 2002, INT J MED MICROBIOL, V291, P537; Weaver KE, 2003, J BACTERIOL, V185, P2169, DOI 10.1128/JB.185.7.2169-2177.2003; Yamamoto TAM, 2002, FEBS LETT, V519, P191, DOI 10.1016/S0014-5793(02)02764-3; Yang YL, 1999, CELL DEATH DIFFER, V6, P805, DOI 10.1038/sj.cdd.4400555; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528; Zielenkiewicz U, 2001, ACTA BIOCHIM POL, V48, P1003	42	425	454	5	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1496	1499		10.1126/science.1088157	http://dx.doi.org/10.1126/science.1088157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970556				2022-12-28	WOS:000185255300038
J	Wallenfang, MR; Matunis, E				Wallenfang, MR; Matunis, E			Orienting stem cells	SCIENCE			English	Editorial Material							SELF-RENEWAL; DROSOPHILA; DIVISION		Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Johns Hopkins Med Inst, Dept Cell Biol, Baltimore, MD 21210 USA	University of Pennsylvania; Johns Hopkins University; Johns Hopkins Medicine	Wallenfang, MR (corresponding author), Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.				NICHD NIH HHS [R01 HD040307] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD040307] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; Lambert JD, 2002, NATURE, V420, P682, DOI 10.1038/nature01241; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; McCartney BM, 2001, NAT CELL BIOL, V3, P933, DOI 10.1038/ncb1001-933; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Song XQ, 2003, DEVELOPMENT, V130, P3259, DOI 10.1242/dev.00524; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Zhu CH, 2003, DEVELOPMENT, V130, P2579, DOI 10.1242/dev.00499	12	15	15	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1490	1491		10.1126/science.1090070	http://dx.doi.org/10.1126/science.1090070			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970553				2022-12-28	WOS:000185255300035
J	Giugliano, RP; Braunwald, E				Giugliano, RP; Braunwald, E			Improving antithrombotic treatment in patients after myocardial infarction	LANCET			English	Editorial Material							ACUTE CORONARY SYNDROMES; ASPIRIN; THERAPY; CLOPIDOGREL; WARFARIN; TRIAL; RISK		Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Braunwald, E (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.	ebraunwald@partners.org	Giugliano, Robert/N-7233-2017	Giugliano, Robert/0000-0003-4110-7675				Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Furuya H, 1995, PHARMACOGENETICS, V5, P389, DOI 10.1097/00008571-199512000-00008; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Hurlen M, 2002, NEW ENGL J MED, V347, P969, DOI 10.1056/NEJMoa020496; Kaplan KL, 2002, SEMIN HEMATOL, V39, P187, DOI 10.1053/shem.2002.34092; Oldenburg J, 1997, BRIT J HAEMATOL, V98, P240, DOI 10.1046/j.1365-2141.1997.2213036.x; van Es RF, 2002, LANCET, V360, P109, DOI 10.1016/S0140-6736(02)09409-6; Weitz JI, 2001, CHEST, V119, p95S, DOI 10.1378/chest.119.1_suppl.95S; Yusuf S, 2001, NEW ENGL J MED, V345, P494	9	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2003	362	9386					757	757		10.1016/S0140-6736(03)14296-1	http://dx.doi.org/10.1016/S0140-6736(03)14296-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678866				2022-12-28	WOS:000185188500005
J	Yusuf, S; Pfeffer, MA; Swedberg, K; Granger, CB; Held, P; McMurray, JJV; Michelson, EL; Olofsson, B; Ostergren, J				Yusuf, S; Pfeffer, MA; Swedberg, K; Granger, CB; Held, P; McMurray, JJV; Michelson, EL; Olofsson, B; Ostergren, J		CHARM Investigators Comm	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial	LANCET			English	Article							RANDOMIZED TRIAL; MORTALITY; MORBIDITY; INTERVENTION; DYSFUNCTION; REDUCTION; SURVIVAL; RAMIPRIL; LIFE	Background Half of patients with chronic heart failure (CHF) have preserved left-ventricular ejection fraction (LVEF), but few treatments have specifically been assessed in such patients. In previous studies of patients with CHIF and low LVEF or vascular disease and preserved LVEF, inhibition of the renin-angiotensin system is beneficial. We investigated the effect of addition of an angiotensin-receptor blocker to current treatments. Methods Between March, 1999, and July, 2000, we randomly assigned 3023 patients candesartan (n=1514, target dose 32 mg once daily) or matching placebo (n=1509). Patients had New York Heart Association functional class II-IV CHF and LVEF higher than 40%. The primary outcome was cardiovascular death or admission to hospital for CHF. Analysis was done by intention to treat. Findings Median follow-up was 36.6 months. 333 (22%) patients in the candesartan and 366 (24%) in the placebo group experienced the primary outcome (unadjusted hazard ratio 0.89 [95% CI 0.77-1.03], p=0.118; covariate adjusted 0.86 [0.74-1.01, p=0.051). Cardiovascular death did not differ between groups (170 vs 170), but fewer patients in the candesartan group than in the placebo group were admitted to hospital for CHF once (230 vs 279, p=0.017) or multiple times. Composite outcomes that included non-fatal myocardial infarction and non-fatal stroke showed similar results to the primary composite (388 vs 429; unadjusted 0.88 [0.77-1.01], p=0.078; covariate adjusted 0.86 [0.75-0.99], p=0.037). Interpretation Candesartan has a moderate impact in preventing admissions for CHIF among patients who have heart failure and LVEF higher than 40%.	Hamilton Gen Hosp, McMaster Clin, Hamilton, ON L8L 2X2, Canada; Brigham & Womens Hosp, Boston, MA 02115 USA; Sahlgrenska Univ Hosp Ostra, Gothenburg, Sweden; Duke Univ, Med Ctr, Durham, NC USA; AstraZeneca R&D, Molndal, Sweden; Univ Glasgow, Glasgow, Lanark, Scotland; AstraZeneca LP, Wilmington, DE USA; Karolinska Hosp, S-10401 Stockholm, Sweden	McMaster University; Harvard University; Brigham & Women's Hospital; Sahlgrenska University Hospital; Duke University; AstraZeneca; University of Glasgow; AstraZeneca; Karolinska Institutet; Karolinska University Hospital	Yusuf, S (corresponding author), Hamilton Gen Hosp, McMaster Clin, Room 252,237 Barton St E, Hamilton, ON L8L 2X2, Canada.		Swedberg, Karl/B-2475-2008; omidvari, elham/Q-6686-2016; Granger, Christopher B/D-3458-2014; mcmurray, John/B-2467-2013	Granger, Christopher B/0000-0002-0045-3291; mcmurray, John/0000-0002-6317-3975; Yusuf, Salim/0000-0003-4776-5601				Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Granger CB, 2003, LANCET, V362, P772, DOI 10.1016/S0140-6736(03)14284-5; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; Jong P, 2003, LANCET, V361, P1843, DOI 10.1016/S0140-6736(03)13501-5; McMurray J, 2003, EUR J HEART FAIL, V5, P261, DOI 10.1016/S1388-9842(03)00052-7; McMurray JJV, 2003, LANCET, V362, P767, DOI 10.1016/S0140-6736(03)14283-3; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Perry G, 1997, NEW ENGL J MED, V336, P525; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; Redfield MM, 2003, JAMA-J AM MED ASSOC, V289, P194, DOI 10.1001/jama.289.2.194; Swedberg K, 1999, J Card Fail, V5, P276, DOI 10.1016/S1071-9164(99)90013-1; Yusuf S, 2001, JAMA-J AM MED ASSOC, V286, P1882, DOI 10.1001/jama.286.15.1882; Yusuf S, 2000, NEW ENGL J MED, V342, P145	15	1928	2021	0	51	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					777	781		10.1016/S0140-6736(03)14285-7	http://dx.doi.org/10.1016/S0140-6736(03)14285-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678871				2022-12-28	WOS:000185188500010
J	Sakurai, H; Daiko, T; Hirao, T				Sakurai, H; Daiko, T; Hirao, T			A synthesis of sumanene, a fullerene fragment	SCIENCE			English	Article							TO-BOWL INVERSION		Osaka Univ, Grad Sch Engn, Dept Chem Mat, Osaka 5650871, Japan	Osaka University	Sakurai, H (corresponding author), Osaka Univ, Grad Sch Engn, Dept Chem Mat, Osaka 5650871, Japan.	hsakurai@chem.eng.osaka-u.ac.jp; hirao@chem.eng.osaka-u.ac.jp	Sakurai, Hidehiro/D-2079-2018	Sakurai, Hidehiro/0000-0001-5783-4151				BARTH WE, 1966, J AM CHEM SOC, V88, P380, DOI 10.1021/ja00954a049; BORCHARDT A, 1992, J AM CHEM SOC, V114, P1921, DOI 10.1021/ja00031a080; Borsato G, 2002, J ORG CHEM, V67, P7894, DOI 10.1021/jo020396s; DURR R, 1996, J CHEM SOC CHEM COMM, P2447; Gupta HK, 1997, ORGANOMETALLICS, V16, P3628, DOI 10.1021/om961077s; Imamura K, 1999, CHEM COMMUN, P1859, DOI 10.1039/a905860e; MEHTA G, 1997, ADV STR ORG, V6, P139; Mehta G., 1993, CHEM COMMUN, P1006; Priyakumar UD, 2001, J PHYS CHEM A, V105, P4488, DOI 10.1021/jp0037549; Priyakumar UD, 2001, TETRAHEDRON LETT, V42, P1379, DOI 10.1016/S0040-4039(00)02249-8; SASTRY GN, 1993, J CHEM SOC PERK T 2, P1867, DOI 10.1039/p29930001867; SCOTT LT, 1992, J AM CHEM SOC, V114, P1920, DOI 10.1021/ja00031a079; Sygula A, 2000, J AM CHEM SOC, V122, P6323, DOI 10.1021/ja0011461	13	405	409	3	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1878	1878		10.1126/science.1088290	http://dx.doi.org/10.1126/science.1088290			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	725GW	14512619				2022-12-28	WOS:000185536700041
J	Hudson, MM; Mertens, AC; Yasui, Y; Hobbie, W; Chen, HG; Gurney, JG; Yeazel, M; Recklitis, CJ; Marina, N; Robison, LR; Oeffinger, KC				Hudson, MM; Mertens, AC; Yasui, Y; Hobbie, W; Chen, HG; Gurney, JG; Yeazel, M; Recklitis, CJ; Marina, N; Robison, LR; Oeffinger, KC		Childhood Canc Survivor Study Inve	Health status of adult long-term survivors of childhood cancer - A report from the childhood cancer survivor study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SIBLING ADAPTATION; ADOLESCENT CANCER; HODGKINS-DISEASE; LATE MORTALITY; LATE DEATHS; DIAGNOSIS; LEUKEMIA; SYSTEM; CURE	Context Adult survivors of childhood cancer are at risk for medical and psychosocial sequelae that may adversely affect their health status. Objectives To compare the health status of adult survivors of childhood cancer and siblings and to identify factors associated with adverse outcomes. Design, Setting, and Participants Health status was assessed in 9535 adult participants of the Childhood Cancer Survivor Study, a cohort of long-term survivors of childhood cancer who were diagnosed between 1970 and 1986. A randomly selected cohort of the survivors' siblings (n=2916) served as a comparison group. Main Outcome Measures Six health status domains were assessed: general health, mental health, functional status, activity limitations, cancer-related pain, and cancer-related anxiety/fears. The first 4 domains were assessed in the control group. Results Survivors were significantly more likely to report adverse general health (odds ratio [OR], 2.5; 95% confidence interval [Cl], 2.1-3.0; P<.001), mental health (OR, 1.8; 95% Cl, 1.6-2.1; P<.001), activity limitations (OR, 2.7; 95% Cl, 2.3-3.3; P<.001), and functional impairment(OR, 5.2; 95% Cl, 4.1-6.6; P<.001), compared with siblings. Forty-four percent of survivors reported at least 1 adversely affected health status domain. Sociodemographic factors associated with reporting at least 1 adverse health status domain included being female (OR, 1.4; 95% Cl, 1.3-1.6; P<.001), lower level of educational attainment (OR, 2.0; 95% Cl, 1.8-2.2; P<.001), and annual income less than $20000 (OR, 1.8; 95% Cl, 1.6-2.1; P<.001). Relative to those survivors with childhood leukemia, an increased risk was observed for at least 1 adverse health status domain among those with bone tumors (OR, 2.1; 95% CI, 1.8-2.5; P<.001), central nervous system tumors (OR, 1.7; 95% Cl, 1.5-2.0; P<.001), and sarcomas (OR, 1.2; 95% Cl, 1.1-1.5; P=.01). Conclusion Clinicians caring for adult survivors of childhood cancer should be aware of the substantial risk for adverse health status, especially among females, those with low educational attainment, and those with low household incomes.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN 38163 USA; Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Family Practice, Minneapolis, MN USA; Univ Minnesota, Dept Biostat, Minneapolis, MN USA; Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98104 USA; Childrens Hosp Philadelphia, Dept Oncol, Philadelphia, PA 19104 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Stanford Univ, Med Ctr, Dept Pediat, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Dept Family Practice & Community Med, Dallas, TX USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Fred Hutchinson Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Harvard University; Dana-Farber Cancer Institute; Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hudson, MM (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	melissa.hudson@stjude.org	Yasui, Yutaka/E-2564-2015; Hudson, Melissa M/N-4441-2018; Robison, Leslie/N-8122-2018; Marina, Neyssa/B-7449-2009	Yasui, Yutaka/0000-0002-7717-8638; Hudson, Melissa M/0000-0001-6984-2407; Recklitis, Christopher/0000-0003-1336-8261; Marina, Neyssa/0000-0002-7195-8887	NATIONAL CANCER INSTITUTE [P30CA021765, U24CA055727] Funding Source: NIH RePORTER; NCI NIH HHS [U24 CA055727, 5U24-CA-55727, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson DM, 2001, CANCER-AM CANCER SOC, V92, P2709, DOI 10.1002/1097-0142(20011115)92:10<2709::AID-CNCR1625>3.0.CO;2-D; Barbarin OA, 1995, J PSYCHOSOC ONCOL, V13, P1, DOI 10.1300/J077V13N03_01; *CDCP, 1993, NAT HLTH INT SURV; *CDCP, 1993, BEH RISK FACT SURV S; Chen E, 1998, J Health Psychol, V3, P23, DOI 10.1177/135910539800300102; Crom DB, 1999, INT J CANCER, P25; Derogatis L., 1992, BRIEF SYMPTOM INVENT; Diggle P., 2002, ANAL LONGITUDINAL DA, DOI DOI 10.2307/2983303; Dolgin MJ, 1997, J PSYCHOSOC ONCOL, V15, P1, DOI 10.1300/J077v15n01_01; DREYER ZE, 2002, PRINCIPLES PRACTICE, P1431; Elkin TD, 1997, MED PEDIATR ONCOL, V29, P582, DOI 10.1002/(SICI)1096-911X(199712)29:6<582::AID-MPO13>3.3.CO;2-V; Ettner SL, 1996, J HEALTH ECON, V15, P67, DOI 10.1016/0167-6296(95)00032-1; FEENY D, 1992, J CLIN ONCOL, V10, P923, DOI 10.1200/JCO.1992.10.6.923; GARRE ML, 1994, AM J PEDIAT HEMATOL, V16, P143; GREEN DM, 1994, MED PEDIATR ONCOL, V22, P91, DOI 10.1002/mpo.2950220206; Green DM, 1999, J CLIN ONCOL, V17, P3207, DOI 10.1200/JCO.1999.17.10.3207; Gurney JG, 2003, CANCER-AM CANCER SOC, V97, P663, DOI 10.1002/cncr.11095; Hankin BL, 1999, ANN MED, V31, P372, DOI 10.3109/07853899908998794; HAVERMANS T, 1994, CHILD CARE HLTH DEV, V20, P309, DOI 10.1111/j.1365-2214.1994.tb00393.x; HAWKINS MM, 1990, ARCH DIS CHILD, V65, P1356, DOI 10.1136/adc.65.12.1356; Hobbie WL, 2000, J CLIN ONCOL, V18, P4060, DOI 10.1200/JCO.2000.18.24.4060; HORWITZ WA, 1990, J CLIN CHILD PSYCHOL, V4, P462; Hudson MM, 1998, J CLIN ONCOL, V16, P3592, DOI 10.1200/JCO.1998.16.11.3592; Hudson MM, 1997, J CLIN ONCOL, V15, P2205, DOI 10.1200/JCO.1997.15.6.2205; Kadan-Lottick NS, 2002, JAMA-J AM MED ASSOC, V287, P1832, DOI 10.1001/jama.287.14.1832; Marina N, 1997, PEDIATR CLIN N AM, V44, P1021, DOI 10.1016/S0031-3955(05)70543-5; Mertens AC, 2001, J CLIN ONCOL, V19, P3163, DOI 10.1200/JCO.2001.19.13.3163; NICHOLSON HS, 1994, CANCER, V73, P3094; ROBERTSON CM, 1994, BRIT MED J, V309, P162, DOI 10.1136/bmj.309.6948.162; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; ROURKE M, 2002, 7 INT C LONG TERM CO; Rourke M T, 1999, J Pediatr Oncol Nurs, V16, P126, DOI 10.1177/104345429901600303; Sahler OJZ, 1997, J DEV BEHAV PEDIATR, V18, P233; SAHLER OJZ, 1994, J DEV BEHAV PEDIATR, V15, P353; Sloper P, 1996, J CHILD PSYCHOL PSYC, V37, P597, DOI 10.1111/j.1469-7610.1996.tb01446.x; Zabora J, 2001, PSYCHOSOMATICS, V42, P241, DOI 10.1176/appi.psy.42.3.241; Zebrack BJ, 2002, PEDIATRICS, V110, P42, DOI 10.1542/peds.110.1.42; Zeltzer LK, 1997, J CLIN ONCOL, V15, P547, DOI 10.1200/JCO.1997.15.2.547	38	590	595	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	2003	290	12					1583	1592		10.1001/jama.290.12.1583	http://dx.doi.org/10.1001/jama.290.12.1583			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	723ZK	14506117	Bronze			2022-12-28	WOS:000185461300023
J	Mora, S; Redberg, RF; Cui, YD; Whiteman, MK; Flaws, JA; Sharrett, AR; Blumenthal, RS				Mora, S; Redberg, RF; Cui, YD; Whiteman, MK; Flaws, JA; Sharrett, AR; Blumenthal, RS			Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women - A 20-year follow-up of the lipid research clinics prevalence study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-RATE RECOVERY; NORTH-AMERICAN MEN; PHYSICAL-ACTIVITY; CAUSE MORTALITY; CARDIORESPIRATORY FITNESS; PROGNOSTIC VALUE; RISK ASSESSMENT; DISEASE; CARDIOLOGY; STATEMENT	Context The value of exercise testing in women has been questioned. Objective To determine the prognostic value of exercise testing in a population: based cohort of asymptomatic women followed up for 20 years. Design and Setting Near-maximal Bruce-protocol treadmill test data from the Lipid Research Clinics Prevalence Study (1972-1976) with follow-up through 1995. Participants A total of 2994 asymptomatic North American women, aged 30 to 80 years, without known cardiovascular disease. Main Outcome Measures Cardiovascular and all-cause mortality. Results There were 427 (14%) deaths during 20 years of follow-up, of which 147 were due to cardiovascular causes. Low exercise capacity, low heart rate recovery (HRR), and not achieving target heart rate were independently associated with increased all-cause and cardiovascular mortality. There was no increased cardiovascular death risk for exercise-induced ST-segment depression (age-adjusted hazard ratio, 1.02; 95% confidence interval [CI], 0.57-1.80; P=96). The age-adjusted hazard ratio for cardiovascular death for every metabolic equivalent (MET) decrement in exercise capacity was 1.20 (95% Cl, 1.18-1.30; P<.001); for every 10 beats per minute decrement in HRR, the hazard ratio was 1.36 (95% Cl, 1.19-1.55; P<.001). After adjusting for multiple other risk factors, women who were below the median for both exercise capacity and HRR had a 3.5-fold increased risk of cardiovascular death (95% Cl, 1.57-7.86; P=.002) compared with those above the median for both variables. Among women with low risk Framingham scores, those with below median levels of both exercise capacity and HRR had significantly increased risk compared with women who had above median levels of these 2 exercise variables, 44.5 and 3.5 cardiovascular deaths per 10000 person-years, respectively (hazard ratio for cardiovascular death, 12.93; 95% Cl, 5.62-29.73; P<.001). Conclusion The prognostic value of exercise testing in asymptomatic women derives not from electrocardiographic ischemia but from fitness-related variables.	Johns Hopkins Med Inst, Dept Med, Ciccarone Prevent Cardiol Ctr, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore	Blumenthal, RS (corresponding author), Johns Hopkins Univ Hosp, Ciccarone Prevent Cardiol Ctr, Div Cardiol, Carnegie 538,600 N Wolfe St, Baltimore, MD 21287 USA.	rblument@jhmi.edu	Blumenthal, Roger S/H-3223-2018	Blumenthal, Roger S/0000-0003-1910-3168; Flaws, Jodi/0000-0001-5579-9268; Mora, Samia/0000-0001-6283-0980	NHLBI NIH HHS [T32-HL07024] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007024] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramson JL, 2002, ARCH INTERN MED, V162, P1286, DOI 10.1001/archinte.162.11.1286; Albert CM, 2003, CIRCULATION, V107, P2096, DOI 10.1161/01.CIR.0000065223.21530.11; ALLEN WH, 1980, CIRCULATION, V62, P522, DOI 10.1161/01.CIR.62.3.522; *AM HEART ASS, 2002, HEART DIS STROK STAT; BASS KM, 1993, ARCH INTERN MED, V153, P2209, DOI 10.1001/archinte.153.19.2209; BILLMAN GE, 1984, CIRCULATION, V69, P1182, DOI 10.1161/01.CIR.69.6.1182; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bokhari S, 2002, J AM COLL CARDIOL, V40, P1092, DOI 10.1016/S0735-1097(02)02111-3; BRUCE RA, 1973, AM HEART J, V85, P546, DOI 10.1016/0002-8703(73)90502-4; BRUCE RA, 1983, J AM COLL CARDIOL, V2, P565, DOI 10.1016/S0735-1097(83)80286-1; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Cheng YLJ, 2003, DIABETES CARE, V26, P2052, DOI 10.2337/diacare.26.7.2052; Cole CR, 2000, ANN INTERN MED, V132, P552, DOI 10.7326/0003-4819-132-7-200004040-00007; Cole CR, 1999, NEW ENGL J MED, V341, P1351, DOI 10.1056/NEJM199910283411804; Cui YD, 2001, ARCH INTERN MED, V161, P1413, DOI 10.1001/archinte.161.11.1413; De Leo V, 2000, MATURITAS, V36, P43, DOI 10.1016/S0378-5122(00)00123-7; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; Elhendy A, 2002, AM J CARDIOL, V90, P95, DOI 10.1016/S0002-9149(02)02428-1; Gibbons RJ, 2002, CIRCULATION, V106, P1883, DOI 10.1161/01.CIR.0000034670.06526.15; GORDON DJ, 1986, CIRCULATION, V74, P252, DOI 10.1161/01.CIR.74.2.252; Greenland P, 2001, CIRCULATION, V104, P1863, DOI 10.1161/hc4201.097189; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; IMAI K, 1994, J AM COLL CARDIOL, V24, P1529, DOI 10.1016/0735-1097(94)90150-3; Jouven X, 2000, NEW ENGL J MED, V343, P826, DOI 10.1056/NEJM200009213431201; KANNEL WB, 1985, AM HEART J, V109, P876, DOI 10.1016/0002-8703(85)90653-2; Kwok Y, 1999, AM J CARDIOL, V83, P660, DOI 10.1016/S0002-9149(98)00963-1; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; Mosca L, 1999, CIRCULATION, V99, P2480, DOI 10.1161/01.CIR.99.18.2480; Mosca L, 1997, CIRCULATION, V96, P2468; Myers J, 2002, NEW ENGL J MED, V346, P793, DOI 10.1056/NEJMoa011858; Nishime EO, 2000, JAMA-J AM MED ASSOC, V284, P1392, DOI 10.1001/jama.284.11.1392; Palinkas A, 2002, EUR HEART J, V23, P1587, DOI 10.1053/euhj.2002.3170; Partington S, 2003, AM HEART J, V145, P139, DOI 10.1067/mhj.2003.60; Pollock ML, 1998, MED SCI SPORT EXER, V30, P975, DOI 10.1097/00005768-199806000-00032; RAUTAHARJU PM, 1986, J AM COLL CARDIOL, V8, P1, DOI 10.1016/S0735-1097(86)80084-5; Rice T, 2002, CIRCULATION, V105, P1904, DOI 10.1161/01.CIR.0000014969.85364.9F; Rosenwinkel Eric T., 2001, Cardiology Clinics, V19, P369, DOI 10.1016/S0733-8651(05)70223-X; Shetler K, 2001, J AM COLL CARDIOL, V38, P1980, DOI 10.1016/S0735-1097(01)01652-7; *STAT CORP, 2001, STATA REF MAN REL 7; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; 1997, ARCH INTERN MED, V157, P2413	44	375	395	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	2003	290	12					1600	1607		10.1001/jama.290.12.1600	http://dx.doi.org/10.1001/jama.290.12.1600			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	723ZK	14506119	Bronze			2022-12-28	WOS:000185461300025
J	Rothman, R; Owens, T; Simel, DL				Rothman, R; Owens, T; Simel, DL			Does this child have acute otitis media?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MIDDLE-EAR EFFUSION; DIAGNOSTIC-ACCURACY; PNEUMATIC OTOSCOPY; TYMPANOMETRY; TESTS; BIAS; IDENTIFICATION; MANAGEMENT; INFECTION; SYMPTOMS	Context Acute otitis media (AOM) is one of the most common problems in pediatrics. An accurate diagnosis of AOM can guide proper treatment and follow-up. Objective To systematically review the literature regarding precision and accuracy of history taking and physical examination in diagnosing AOM in children. Data Sources We searched MEDLINE for English-language articles published from 1966 through May 2002. Bibliographies of retrieved articles and textbooks were also searched. Study Selection We located studies with original data on the precision or accuracy of history or physical examination for AOM in children. Of 397 references initially identified, 6 met inclusion criteria for analysis. Data Extraction Two authors independently reviewed and abstracted data to calculate likelihood ratios (LRs) for symptoms and signs. Data Synthesis Four studies of symptoms used clinical diagnosis as the criterion standard and were limited by incorporation bias. Ear pain is the most useful symptom (positive LRs, 3.0-7.3); fever, upper respiratory tract symptoms, and irritability are less useful. One study of clinical signs used tympanocentesis as the criterion standard, and we adjusted the results to correct for verification bias. A cloudy (adjusted LR, 34; 95% confidence interval [CI], 28-42), bulging (adjusted LR, 51; 95% Cl, 36-73), or distinctly immobile (adjusted LR, 31; 95% Cl, 26-37) tympanic membrane on pneumatic otoscopy are the most useful signs for detecting AOM. A distinctly red tympanic membrane is also helpful (adjusted LR, 8.4; 95% Cl, 6.7-11) whereas a normal color makes AOM much less likely (adjusted LR, 0.2; 95% Cl, 0.19-0.21). 1 Conclusions Although many of the studies included in this analysis are limited by bias, a cloudy, bulging, or clearly immobile tympanic membrane is most helpful for detecting AOM. The degree of erythema may also be useful since a normal color makes otitis media unlikely whereas a distinctly red tympanic membrane increases the likelihood significantly.	Vanderbilt Univ, Med Ctr, Ctr Hlth Serv Res, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; Duke Univ, Med Ctr, Durham, NC USA; Durham Vet Affaors Med Ctr, Durham, NC USA; Duke Univ, Dept Med, Durham, NC USA; Duke Univ, Dept Pediat, Durham, NC 27706 USA	Vanderbilt University; Vanderbilt University; Duke University; Duke University; Duke University	Rothman, R (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Hlth Serv Res, Dept Med, Suite 6000,Med Ctr E, Nashville, TN 37232 USA.			Rothman, Russsell/0000-0002-1506-3990				AROLA M, 1990, PEDIATRICS, V86, P848; BAKER RB, 1992, PEDIATRICS, V90, P1006; BARRIGA F, 1986, AM J DIS CHILD, V140, P1237, DOI 10.1001/archpedi.1986.02140260039021; BEGG CB, 1983, BIOMETRICS, V39, P207, DOI 10.2307/2530820; BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; Behrman R. E., 2000, NELSON TXB PEDIAT; BLUESTONE CD, 1979, ANN OTO RHINOL LARYN, V88, P13, DOI 10.1177/00034894790880S503; BLUESTONE CD, 2001, OTITIS MEDIA INFANTS; CANTEKIN EI, 1980, ANN OTO RHINOL LARYN, V89, P190, DOI 10.1177/00034894800890S344; CAVANAUGH RM, 1989, PEDIATRICS, V84, P362; CAVANAUGH RM, 1991, PEDIATRICS, V87, P114; Chan LS, 2001, PEDIATRICS, V108, P248, DOI 10.1542/peds.108.2.248; FINITZO T, 1992, INT J PEDIATR OTORHI, V24, P101, DOI 10.1016/0165-5876(92)90136-D; GIMSING S, 1983, J LARYNGOL OTOL, V97, P587, DOI 10.1017/S0022215100094640; Gonzalez-Vallejo C, 1998, MED DECIS MAKING, V18, P149, DOI 10.1177/0272989X9801800203; Goroll A, 2000, PRIMARY CARE MED OFF; HAYDEN GF, 1985, AM J DIS CHILD, V139, P721, DOI 10.1001/archpedi.1985.02140090083037; HAYDEN GF, 1981, CLIN PEDIATR, V20, P99, DOI 10.1177/000992288102000203; HEIKKINEN T, 1995, ARCH PEDIAT ADOL MED, V149, P26, DOI 10.1001/archpedi.1995.02170130028006; INGVARSSON L, 1982, ACTA PAEDIATR SCAND, V71, P705, DOI 10.1111/j.1651-2227.1982.tb09507.x; KALEIDA PH, 1992, AM J DIS CHILD, V146, P433, DOI 10.1001/archpedi.1992.02160160053013; KARMA PH, 1989, INT J PEDIATR OTORHI, V17, P37, DOI 10.1016/0165-5876(89)90292-9; KLEIN JO, EPIDEMIOLOGY PATHOGE; Kontiokari T, 1998, PEDIATR INFECT DIS J, V17, P676, DOI 10.1097/00006454-199808000-00003; MAINS BT, 1989, J LARYNGOL OTOL, V103, P1134, DOI 10.1017/S0022215100111193; MARCY M, 2001, MANAGEMENT ACUTE OTI, P1; Metlay JP, 1997, JAMA-J AM MED ASSOC, V278, P1440, DOI 10.1001/jama.278.17.1440; Mulherin SA, 2002, ANN INTERN MED, V137, P598, DOI 10.7326/0003-4819-137-7-200210010-00011; NIEMELA M, 1994, PEDIATR INFECT DIS J, V13, P765, DOI 10.1097/00006454-199409000-00002; Noble J, 2001, TXB PRIMARY CARE MED; Pelton SI, 1998, PEDIATR INFECT DIS J, V17, P540, DOI 10.1097/00006454-199806000-00032; Pichichero ME, 2000, AM FAM PHYSICIAN, V61, P2410; Pichichero ME, 2000, AM FAM PHYSICIAN, V61, P2051; Pichichero ME, 2001, ARCH PEDIAT ADOL MED, V155, P1137, DOI 10.1001/archpedi.155.10.1137; PUKANDER J, 1983, ACTA OTO-LARYNGOL, V95, P117, DOI 10.3109/00016488309130924; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Rosenfeld R, 1999, EVIDENCE BASED OTITI; Rosenfeld RM, 2002, INT J PEDIATR OTORHI, V64, P89, DOI 10.1016/S0165-5876(02)00073-3; RUUSKANEN O, 1994, PEDIATR INFECT DIS J, V13, pS23, DOI 10.1097/00006454-199401001-00006; SCHWARTZ RH, 1983, AM J DIS CHILD, V137, P1064, DOI 10.1001/archpedi.1983.02140370026009; Silva AB, 1997, INT J PEDIATR OTORHI, V40, P125, DOI 10.1016/S0165-5876(97)00033-5; SIMEL DL, 1988, J GEN INTERN MED, V3, P423, DOI 10.1007/BF02595917; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Singer AJ, 2000, ANN EMERG MED, V36, P228, DOI 10.1067/mem.2000.109166; Steinbach WJ, 2002, PEDIATRICS, V109, P993, DOI 10.1542/peds.109.6.993; Steinbach WJ, 2002, PEDIATRICS, V109, P404, DOI 10.1542/peds.109.3.404; TEELE DW, 1979, JAMA-J AM MED ASSOC, V242, P2664, DOI 10.1001/jama.242.24.2664; TONER JG, 1990, CLIN OTOLARYNGOL, V15, P121, DOI 10.1111/j.1365-2273.1990.tb00443.x; Weiss JC, 1996, AM FAM PHYSICIAN, V53, P1200; Whited JD, 1998, JAMA-J AM MED ASSOC, V279, P696, DOI 10.1001/jama.279.9.696; ZITELLI B, 1997, ATLAS PEDIAT PHYSICA	51	60	61	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	2003	290	12					1633	1640		10.1001/jama.290.12.1633	http://dx.doi.org/10.1001/jama.290.12.1633			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	723ZK	14506123				2022-12-28	WOS:000185461300029
J	Colombani, J; Raisin, S; Pantalacci, S; Radimerski, T; Montagne, J; Leopold, P				Colombani, J; Raisin, S; Pantalacci, S; Radimerski, T; Montagne, J; Leopold, P			A nutrient sensor mechanism controls Drosophila growth	CELL			English	Article							INSULIN-LIKE PEPTIDES; CELL-GROWTH; DIRECT TARGET; S6 KINASE; FAT-BODY; SIZE; RHEB; TOR; PROLIFERATION; TRANSLATION	Organisms modulate their growth according to nutrient availability. Although individual cells in a multicellular animal may respond directly to nutrient levels, growth of the entire organism needs to be coordinated. Here, we provide evidence that in Drosophila, coordination of organismal growl, originates from the fat body, an insect organ that retains endocrine and storage functions of the vertebrate liver. In a genetic screen for growth modifiers, we identified slimfast, a gene that encodes an amino acid transporter. Remarkably, downregulation of slimfast specifically within the fat body causes a global growth defect similar to that seen in Drosophila raised under poor nutritional conditions. This involves TSC/TOR signaling in the fat body, and a remote inhibition of organismal growth via local repression of P13-kinase signaling in peripheral tissues. Our results demonstrate that the fat body functions as a nutrient sensor that restricts global growth through a humoral mechanism.	Inst Signaling Dev Biol & Canc Res, UMR 6543, CNRS, F-06108 Nice 2, France; Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Friedrich Miescher Institute for Biomedical Research	Leopold, P (corresponding author), Inst Signaling Dev Biol & Canc Res, UMR 6543, CNRS, F-06108 Nice 2, France.	leopold@unice.fr		Colombani, Julien/0000-0002-8250-4899				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Boisclair YR, 2001, J ENDOCRINOL, V170, P63, DOI 10.1677/joe.0.1700063; Britton JS, 1998, DEVELOPMENT, V125, P2149; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Butler AA, 2001, ANNU REV PHYSIOL, V63, P141, DOI 10.1146/annurev.physiol.63.1.141; Campbell LE, 1999, BIOCHEM J, V344, P433, DOI 10.1042/0264-6021:3440433; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CRACE CJ, 1991, UPSALA J MED SCI, V96, P17, DOI 10.3109/03009739109179255; DAVIS KT, 1977, SCIENCE, V196, P438, DOI 10.1126/science.403606; Dean R.L., 1985, P155; Duan C, 2002, J ENDOCRINOL, V175, P41, DOI 10.1677/joe.0.1750041; Efstratiadis A, 1998, INT J DEV BIOL, V42, P955; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Garofalo RS, 2002, TRENDS ENDOCRIN MET, V13, P156, DOI 10.1016/S1043-2760(01)00548-3; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hennig KM, 2002, GENESIS, V34, P107, DOI 10.1002/gene.10139; Huang H, 1999, DEVELOPMENT, V126, P5365; Ikeya T, 2002, CURR BIOL, V12, P1293, DOI 10.1016/S0960-9822(02)01043-6; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kawamura K, 1999, DEVELOPMENT, V126, P211; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimball Sr, 2000, COLD SPRING HARBOR M, V39, P561; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Martin JF, 2000, MECH DEVELOP, V92, P155, DOI 10.1016/S0925-4773(99)00338-X; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Raisin S, 2003, GENETICS, V164, P1015; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Stern D, 2001, CURR BIOL, V11, pR917, DOI 10.1016/S0960-9822(01)00554-1; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zinke I, 2002, EMBO J, V21, P6162, DOI 10.1093/emboj/cdf600; Zinke I, 1999, DEVELOPMENT, V126, P5275	51	573	586	1	69	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					739	749		10.1016/S0092-8674(03)00713-X	http://dx.doi.org/10.1016/S0092-8674(03)00713-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505573	Bronze			2022-12-28	WOS:000185464000011
J	Harrison, T; Samuel, BU; Akompong, T; Hamm, H; Mohandas, N; Lomasney, JW; Haldar, K				Harrison, T; Samuel, BU; Akompong, T; Hamm, H; Mohandas, N; Lomasney, JW; Haldar, K			Erythrocyte G protein-coupled receptor signaling in malarial infection	SCIENCE			English	Article							PLASMODIUM-FALCIPARUM; CHOLESTEROL; TRANSDUCTION; RAFTS	Erythrocytic mechanisms involved in malarial infection are poorly understood. We have found that signaling via the erythrocyte beta2-adrenergic receptor and heterotrimeric guanine nucleotide - binding protein (Galphas) regulated the entry of the human malaria parasite Plasmodium falciparum. Agonists that stimulate cyclic adenosine 3', 5'-monophosphate production led to an increase in malarial infection that could be blocked by specific receptor antagonists. Moreover, peptides designed to inhibit Galphas protein function reduced parasitemia in P. falciparum cultures in vitro, and beta-antagonists reduced parasitemia of P. berghei infections in an in vivo mouse model. Thus, signaling via the erythrocyte beta2-adrenergic receptor and Galphas may regulate malarial infection across parasite species.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37240 USA; New York Blood Ctr, New York, NY 10021 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Vanderbilt University; New York Blood Center	Lomasney, JW (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 Chicago Ave, Chicago, IL 60611 USA.	j-lomasney@northwestern.edu; k-haldar@northwestern.edu	Haldar, Kasturi/C-6685-2014; Hamm, Heidi E/G-2374-2014		NEI NIH HHS [EY10291, EY06062] Funding Source: Medline; NHLBI NIH HHS [HL03961, HL69630, HL55591] Funding Source: Medline; NIAID NIH HHS [AI39071] Funding Source: Medline; NIDDK NIH HHS [DK32094] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006062, R01EY010291] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069630, R29HL055591, R01HL055591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Brittain JE, 2001, J CLIN INVEST, V107, P1555, DOI 10.1172/JCI10817; CHASIS JA, 1989, BLOOD, V74, P1112, DOI 10.1182/blood.V74.3.1112.1112; Desai SA, 1997, P NATL ACAD SCI USA, V94, P2045, DOI 10.1073/pnas.94.5.2045; DVORAK JA, 1975, SCIENCE, V187, P748, DOI 10.1126/science.803712; Dyer M, 2000, MOL BIOCHEM PARASIT, V110, P435, DOI 10.1016/S0166-6851(00)00312-1; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; Lauer S, 2000, EMBO J, V19, P3556, DOI 10.1093/emboj/19.14.3556; Maack K, 2001, BRIT J PHARMACOL, V132, P1817, DOI 10.1038/sj.bjp.0703992; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Nagao E, 2002, EXP PARASITOL, V102, P57, DOI 10.1016/S0014-4894(02)00143-1; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; PETERS W, 1984, ANN TROP MED PARASIT, V78, P561, DOI 10.1080/00034983.1984.11811866; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Samuel BU, 2001, J BIOL CHEM, V276, P29319, DOI 10.1074/jbc.M101268200; SCHRIER SL, 1985, CLIN HAEMATOL, V14, P1; Vanhauwe JF, 2002, J BIOL CHEM, V277, P34143, DOI 10.1074/jbc.M204477200	23	120	123	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1734	1736		10.1126/science.1089324	http://dx.doi.org/10.1126/science.1089324			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500986				2022-12-28	WOS:000185387700048
J	Marshall, MN; Mannion, R; Nelson, E; Davies, HTO				Marshall, MN; Mannion, R; Nelson, E; Davies, HTO			Managing change in the culture of general practice: qualitative case studies in primary care trusts	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AUTONOMY; MANAGERS	Objectives To explore the potential tension between the need for managers to produce measurable change and the skills required to produce cultural change, and to investigate how managers of primary care trusts are attempting to deal with this tension. Design Qualitative case studies using data derived from semistructured interviews and a review of published documents. An established cultural framework was to used to help interpret the findings. Setting Six primary care trusts in England purposefully sampled to represent a range of cultural, structural, geographical, and demographic characteristics. Participants 42 interviews with 39 different senior and middle primary care trust managers conducted over an 18 month period. Results We found two distinct and polarised styles of management. One group of managers adopts a directive style and challenges the prevailing norms and values of clinicians, an approach characteristically seen in organisations with hierarchical cultures. This group is made up mostly of senior managers who are driven principally by the imperative to deliver a political agenda. Managers in the second group are more inclined to work with the prevailing cultures found in general practice, attempting to facilitate change from within rather than forcing change from outside. This management style is characteristically seen in organisations with a clan-type culture. The approach was manifest mostly by middle managers, who seem to act as buffers between the demands of senior managers and their own perception of the ability and willingness of health professionals to cope with change. The different management approaches can lead to tension and dysfunction between tiers of management. Conclusions The development of primary care depends on high quality managers who are able to draw on a range of different management skills and styles. Managers ate most likely to be effective if they appreciate the merits and drawbacks of their different styles and arc willing to work in partnership.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; Univ St Andrews, Dept Management, Ctr Publ Policy & Management, St Andrews KY16 9AL, Fife, Scotland	University of Manchester; University of York - UK; University of St Andrews	Marshall, MN (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.	martin.marshall@man.ac.uk		Davies, Huw/0000-0002-2653-3695; Mannion, Russell/0000-0002-0680-8049				[Anonymous], ORG CULTURE HLTH CAR; Cameron K.S., 1991, RES ORGAN CHANGE DEV, V5, P23; Campbell SM, 2002, QUAL SAF HEALTH CARE, V11, P9, DOI 10.1136/qhc.11.1.9; Davies HTO, 2003, BMJ-BRIT MED J, V326, P646, DOI 10.1136/bmj.326.7390.646; Department of Health, 2000, NHS PLAN PLAN INV PL; Edwards N, 2003, BRIT MED J, V326, P609, DOI 10.1136/bmj.326.7390.609; Ferlie EB, 2001, MILBANK Q, V79, P281, DOI 10.1111/1468-0009.00206; Firth-Cozens J, 2001, QUAL HEALTH CARE, V10, P3; Firth-Cozens J, 2001, SOC SCI MED, V52, P215, DOI 10.1016/S0277-9536(00)00221-5; Gerowitz M B, 1996, Health Serv Manage Res, V9, P69; HALES CP, 1986, J MANAGE STUD, V23, P88, DOI 10.1111/j.1467-6486.1986.tb00936.x; Harrison S, 2000, SOCIOLOGY, V34, P129, DOI 10.1017/S0038038500000092; Harrison S, 2002, SOCIOL HEALTH ILL, V24, P208, DOI 10.1111/1467-9566.00291; HARRISON S, 1994, PUBLIC MONEY MANAGE, V14, P39, DOI 10.1080/09540969409387800; Mannion R., 2003, CULTURES PERFORMANCE; Marshall M, 2002, BRIT J GEN PRACT, V52, P641; Quinn RE., 1981, PUBLIC PRODUCTIVITY, V5, P122, DOI DOI 10.2307/3380029; Schein EH., 2010, ORG CULTURE LEADERSH; Scott T, 2003, HEALTH SERV RES, V38, P923, DOI 10.1111/1475-6773.00154; Scott Tim, 2003, J Health Serv Res Policy, V8, P105, DOI 10.1258/135581903321466085; Shortell SM, 2000, MED CARE, V38, P207, DOI 10.1097/00005650-200002000-00010; Skjorshammer M, 2001, J Interprof Care, V15, P7, DOI 10.1080/13561820020022837; Smith P., 1995, INT J PUBLIC ADMIN, V18, P277, DOI DOI 10.1080/01900699508525011	23	37	37	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	2003	327	7415					599	602		10.1136/bmj.327.7415.599	http://dx.doi.org/10.1136/bmj.327.7415.599			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	722CW	12969929	Green Published, Green Submitted, Bronze, Green Accepted			2022-12-28	WOS:000185358700025
J	Stelter, P; Ulrich, HD				Stelter, P; Ulrich, HD			Control of spontaneous and damage-induced mutagenesis by SUMO and ubiquitin conjugation	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; SPONTANEOUS MUTATION; YEAST; GENE; RAD6; POLYMERASE; EUKARYOTES; PROTEIN; ENCODES	Protein modification by ubiquitin is emerging as a signal for various biological processes in eukaryotes, including regulated proteolysis, but also for non-degradative functions such as protein localization, DNA repair and regulation of chromatin structure(1-4). A small ubiquitin-related modifier (SUMO) uses a similar conjugation system that sometimes counteracts the effects of ubiquitination(5). Ubiquitin and SUMO compete for modification of proliferating cell nuclear antigen (PCNA), an essential processivity factor for DNA replication and repair(6). Whereas multi-ubiquitination is mediated by components of the RAD6 pathway and promotes error-free repair, SUMO modification is associated with replication(6-9). Here we show that RAD6-mediated mono-ubiquitination of PCNA activates translesion DNA synthesis by the damage-tolerant polymerases eta and zeta in yeast. Moreover, polymerase zeta is differentially affected by mono-ubiquitin and SUMO modification of PCNA. Whereas ubiquitination is required for damage-induced mutagenesis, both SUMO and mono-ubiquitin contribute to spontaneous mutagenesis in the absence of DNA damage. Our findings assign a function to SUMO during S phase and demonstrate how ubiquitin and SUMO, by regulating the accuracy of replication and repair, contribute to overall genomic stability.	Max Planck Inst Terr Microbiol, D-35043 Marburg, Germany	Max Planck Society	Ulrich, HD (corresponding author), Max Planck Inst Terr Microbiol, Karl von Frisch Str, D-35043 Marburg, Germany.			Ulrich, Helle D./0000-0003-0431-2223				Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; BROODBAKKER JTW, 1983, OPHTHALMIC PAED GEN, V2, P95, DOI 10.3109/13816818309007797; Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; CASSIERCHAUVAT C, 1991, MUTAT RES, V254, P247, DOI 10.1016/0921-8777(91)90063-U; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; HASTINGS PJ, 1976, NATURE, V264, P719, DOI 10.1038/264719a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; Lawrence CW, 2001, PHILOS T R SOC B, V356, P41, DOI 10.1098/rstb.2000.0001; LAWRENCE CW, 1976, GENETICS, V82, P207; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; McDonald JP, 1997, GENETICS, V147, P1557; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; QUAH SK, 1980, GENETICS, V96, P819; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Ulrich HD, 2002, EUKARYOT CELL, V1, P1, DOI 10.1128/EC.1.1.1-10.2002; von Borstel RC, 1998, GENETICS, V148, P1647; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R	30	657	682	7	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2003	425	6954					188	191		10.1038/nature01965	http://dx.doi.org/10.1038/nature01965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968183				2022-12-28	WOS:000185236000045
J	Puffer, S; Torgerson, DJ; Watson, J				Puffer, S; Torgerson, DJ; Watson, J			Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; CONSENT DESIGNS; BREAST-CANCER; PRIMARY-CARE; PRACTITIONERS; FEEDBACK	Objective To examine the prevalence of a risk of bias associated with the design and conduct of cluster randomised controlled trials among a sample of recently published studies. Design Retrospective review of cluster randomised trials published in the BMJ, Lancet, and New England Journal of Medicine from January 1997 to October 2002. Main outcome measures Prevalence of secure randomisation of clusters, identification of participants before randomisation (to avoid foreknowledge of allocation), differential recruitment between treatment arms, differential application of inclusion and exclusion criteria, and differential attrition. Results Of the 36 trials identified, 24 were published in the BMJ, I I in the Lancet, and a single trial in the New England journal of Medicine. At the cluster level, 15 (42%) trials provided evidence for secure allocation and 25 (69%) used stratified allocation. Few trials showed evidence of imbalance at the cluster level. However, some evidence of susceptibility to risk of bias at the individual level existed in 14 (39%) studies. Conclusions Some recently published cluster randomised trials may not have taken adequate precautions to guard against threats to the internal validity of their design.	Univ York, Dept Hlth Sci, York Trials Unit, York YO10 5DD, N Yorkshire, England	University of York - UK	Torgerson, DJ (corresponding author), Univ York, Dept Hlth Sci, York Trials Unit, York YO10 5DD, N Yorkshire, England.	djt6@york.ac.uk	Watson, Judith/H-5821-2019; Torgerson, David/L-4566-2019	Watson, Judith/0000-0003-0694-3854; Torgerson, David/0000-0002-1667-4275				Alexander FE, 1999, LANCET, V353, P1903, DOI 10.1016/S0140-6736(98)07413-3; Altman DG, 1995, EUR J CANCER, V31A, P1934, DOI 10.1016/0959-8049(95)00470-X; Eccles M, 2001, LANCET, V357, P1406, DOI 10.1016/S0140-6736(00)04564-5; Elbourne DR, 2001, STAT MED, V20, P489, DOI 10.1002/1097-0258(20010215)20:3<489::AID-SIM806>3.0.CO;2-S; Glazener CMA, 1999, BRIT MED J, V318, P627, DOI 10.1136/bmj.318.7184.627; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Kinnersley P, 2000, BRIT MED J, V320, P1043, DOI 10.1136/bmj.320.7241.1043; KJACRGAARD LL, 2001, ANN INTERN MED, V135, P982; O'Connell DL, 1999, BMJ-BRIT MED J, V318, P507, DOI 10.1136/bmj.318.7182.507; Sanci LA, 2000, BRIT MED J, V320, P224, DOI 10.1136/bmj.320.7229.224; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125; ZELEN M, 1990, STAT MED, V9, P645, DOI 10.1002/sim.4780090611	14	244	248	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 4	2003	327	7418					785	787		10.1136/bmj.327.7418.785	http://dx.doi.org/10.1136/bmj.327.7418.785			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525877	Green Published, Bronze			2022-12-28	WOS:000185805100021
J	Beheregaray, LB; Ciofi, C; Geist, D; Gibbs, JP; Caccone, A; Powell, JR				Beheregaray, LB; Ciofi, C; Geist, D; Gibbs, JP; Caccone, A; Powell, JR			Genes record a prehistoric volcano eruption in the Galapagos	SCIENCE			English	Article							POPULATIONS; TORTOISES; HISTORY		Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA; Univ Idaho, Dept Geol Sci, Moscow, ID 83844 USA; SUNY Coll Environm Sci & Forestry, Syracuse, NY 13210 USA; Yale Univ, Yale Inst Biospher Studies, New Haven, CT 06520 USA	Yale University; Idaho; University of Idaho; State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry; Yale University	Beheregaray, LB (corresponding author), Macquarie Univ, Dept Biol Sci, Sydney, NSW 2109, Australia.	luciano.beheregaray@bio.mq.edu.au	Caccone, Adalgisa/AAE-4238-2021; Beheregaray, Luciano B/A-8621-2008; Ciofi, Claudio/AAH-9461-2019; Beheregaray, Luciano/AAY-6384-2021	Caccone, Adalgisa/0000-0002-8949-9260; Beheregaray, Luciano B/0000-0003-0944-3003; Beheregaray, Luciano/0000-0003-0944-3003; CIOFI, CLAUDIO/0000-0001-8537-8659				BEHEREGARAY LB, UNPUB; Caccone A, 2002, EVOLUTION, V56, P2052; CARSON HL, 1990, P NATL ACAD SCI USA, V87, P7055, DOI 10.1073/pnas.87.18.7055; Ciofi C, 2002, MOL ECOL, V11, P2265, DOI 10.1046/j.1365-294X.2002.01617.x; GEIST D, 1994, B VOLCANOL, V56, P243, DOI 10.1007/BF00302078; MACFARLAND C G, 1974, Biological Conservation, V6, P118, DOI 10.1016/0006-3207(74)90024-X; Pritchard Peter C.H., 1996, Chelonian Research Monographs, V1, P1	7	60	72	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					75	75		10.1126/science.1087486	http://dx.doi.org/10.1126/science.1087486			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526072				2022-12-28	WOS:000185678500036
J	Luntz, AC				Luntz, AC			Toward vibrational mode control in catalysis	SCIENCE			English	Editorial Material							CH4 DISSOCIATION; QUANTUM DYNAMICS; MOLECULAR-BEAM; METHANE; NI(100); CHEMISORPTION; SURFACES		Univ So Denmark, Dept Phys, DK-5230 Odense M, Denmark	University of Southern Denmark	Luntz, AC (corresponding author), Univ So Denmark, Dept Phys, DK-5230 Odense M, Denmark.	acluntz@pacbell.net						Beck RD, 2003, SCIENCE, V302, P98, DOI 10.1126/science.1088996; Crim FF, 1999, ACCOUNTS CHEM RES, V32, P877, DOI 10.1021/ar950046a; Higgins J, 2001, J CHEM PHYS, V114, P5277, DOI 10.1063/1.1349895; HOLMBLAD PM, 1995, J CHEM PHYS, V102, P8255, DOI 10.1063/1.468955; Juurlink LBF, 1999, PHYS REV LETT, V83, P868, DOI 10.1103/PhysRevLett.83.868; Kratzer P, 1996, J CHEM PHYS, V105, P5595, DOI 10.1063/1.472399; Kroes GJ, 1999, PROG SURF SCI, V60, P1, DOI 10.1016/S0079-6816(99)00006-4; LUNTZ AC, 1991, SURF SCI, V258, P397, DOI 10.1016/0039-6028(91)90934-K; LUNTZ AC, 1995, J CHEM PHYS, V102, P8264, DOI 10.1063/1.468956; Mortensen H, 2002, J CHEM PHYS, V116, P5781, DOI 10.1063/1.1456509; UKRAINTSEV VA, 1994, J CHEM PHYS, V101, P1564, DOI 10.1063/1.468476	11	29	29	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					70	71		10.1126/science.1090172	http://dx.doi.org/10.1126/science.1090172			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526070				2022-12-28	WOS:000185678500034
J	Zerhouni, E				Zerhouni, E			The NIH roadmap	SCIENCE			English	Editorial Material									NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Zerhouni, E (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.								0	693	743	3	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					63	+		10.1126/science.1091867	http://dx.doi.org/10.1126/science.1091867			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526066				2022-12-28	WOS:000185678500030
J	Lawlor, DA; Patel, R; Ebrahim, S				Lawlor, DA; Patel, R; Ebrahim, S			Association between falls in elderly women and chronic diseases and drug use: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							INSULIN-RESISTANCE; RISK-FACTORS; OLDER WOMEN; HEART; HEALTH	Objective To assess the associations between having had a fall and chronic diseases and drug use in elderly women. Design Cross sectional survey, using data from the British women's heart and health study. Setting General practices in 23 towns in Great Britain. Participants 4050 women aged 60-79 years. Main outcome measure Whether women had had falls in the previous 12 months. Results The prevalence of falling increased with increasing numbers of simultaneously occurring chronic diseases. However, no such relation with falling was found in the fully adjusted data for the number of drugs used. Circulatory disease, chronic obstructive pulmonary disease, depression, and arthritis were all associated with an increased odds of falling. The fully adjusted, population attributable risk of falling associated with having at least one chronic disease was 32.2% (95% confidence interval 19.6% to 42.8%). Only two classes of drugs (hypnotics and anxiolytics, and antidepressants) were independently associated with an increased odds of falling. Each class was associated with an increase of about 50% in the odds of falling, and each had a population attributable risk of <5%. Conclusion Chronic diseases and multiple pathology are more important predictors of falling than polypharmacy.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Lawlor, DA (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.			Lawlor, Debbie A/0000-0002-6793-2262				*BRIT MED ASS ROYA, 2003, BRIT NAT FORM; Campbell AJ, 1999, J AM GERIATR SOC, V47, P850, DOI 10.1111/j.1532-5415.1999.tb03843.x; Campbell J, 1996, ELECTRON WORLD, P361; CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P613, DOI 10.1111/j.1532-5415.1988.tb06155.x; *DEP HLTH, 1999, HLTH SURV ENGLAND CA; Department of Health, 1999, HLTH SURV ENGL CARD; Ensrud KE, 2002, J AM GERIATR SOC, V50, P1629, DOI 10.1046/j.1532-5415.2002.50453.x; Evans JG, 2003, LANCET, V361, P448, DOI 10.1016/S0140-6736(03)12502-0; FINK H, 1998, BROCKLEHURSTS TXB GE, P1337; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Kochar M S, 2000, Curr Hypertens Rep, V2, P457, DOI 10.1007/s11906-000-0028-9; Lawlor DA, 2002, DIABETOLOGIA, V45, P1097, DOI 10.1007/s00125-002-0887-5; Lawlor DA, 2002, BRIT MED J, V325, P805, DOI 10.1136/bmj.325.7368.805; Lawlor DA, 2003, J EPIDEMIOL COMMUN H, V57, P134, DOI 10.1136/jech.57.2.134; Leipzig RM, 1999, J AM GERIATR SOC, V47, P30, DOI 10.1111/j.1532-5415.1999.tb01898.x; MALMIVAARA A, 1993, AM J EPIDEMIOL, V138, P384, DOI 10.1093/oxfordjournals.aje.a116871; MCINTOSH S, 1993, AGE AGEING, V22, P53, DOI 10.1093/ageing/22.1.53; McLeod AA, 2001, BRIT MED BULL, V59, P113, DOI 10.1093/bmb/59.1.113; Neutel CI, 1996, AGE AGEING, V25, P273, DOI 10.1093/ageing/25.4.273; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719	20	246	255	1	21	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	2003	327	7417					712	715		10.1136/bmj.327.7417.712	http://dx.doi.org/10.1136/bmj.327.7417.712			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	728FZ	14512478	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000185708300017
J	Sinclair, DA				Sinclair, DA			An age of instability	SCIENCE			English	Editorial Material							CANCER; YEAST		Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.			Sinclair, David/0000-0002-9936-436X				Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; McMurray MA, 2003, SCIENCE, V301, P1908, DOI 10.1126/science.1087706; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6	7	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1859	1860		10.1126/science.1090465	http://dx.doi.org/10.1126/science.1090465			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512612				2022-12-28	WOS:000185536700034
J	Tournaire-Roux, C; Sutka, M; Javot, H; Gout, E; Gerbeau, P; Luu, DT; Bligny, R; Maurel, C				Tournaire-Roux, C; Sutka, M; Javot, H; Gout, E; Gerbeau, P; Luu, DT; Bligny, R; Maurel, C			Cytosolic pH regulates root water transport during anoxic stress through gating of aquaporins	NATURE			English	Article							PLASMA-MEMBRANE AQUAPORINS; PLANT-CELLS; PHOSPHORYLATION; PERMEABILITY; CHANNELS; INHIBITION; EXPRESSION; TIP	Flooding of soils results in acute oxygen deprivation (anoxia) of plant roots during winter in temperate latitudes, or after irrigation(1), and is a major problem for agriculture. One early response of plants to anoxia and other environmental stresses is down-regulation of water uptake due to inhibition of the water permeability (hydraulic conductivity) of roots (Lp(r))(2-5). Root water uptake is mediated largely by water channel proteins (aquaporins) of the plasma membrane intrinsic protein (PIP) subgroup(6-8). These aquaporins may mediate stress-induced inhibition of Lp(r)(2,4,9) but the mechanisms involved are unknown. Here we delineate the whole-root and cell bases for inhibition of water uptake by anoxia and link them to cytosol acidosis. We also uncover a molecular mechanism for aquaporin gating by cytosolic pH. Because it is conserved in all PIPs, this mechanism provides a basis for explaining the inhibition of Lp(r) by anoxia and possibly other stresses. More generally, our work opens new routes to explore pH-dependent cell signalling processes leading to regulation of water transport in plant tissues or in animal epithelia(10).	Univ Montpellier 2, INRA, CNRS, Unite Mixte Rech 5004, F-34060 Montpellier 1, France; Ecole Natl Agron, F-34060 Montpellier, France; CEA, Physiol Cellulaire Vegetale, F-38054 Grenoble 9, France	INRAE; Institut Agro; Montpellier SupAgro; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Maurel, C (corresponding author), Univ Montpellier 2, INRA, CNRS, Unite Mixte Rech 5004, Pl Viala, F-34060 Montpellier 1, France.		Javot, Helene/AAX-8986-2021	Javot, Helene/0000-0002-4577-2747; Tournaire Roux, Colette/0000-0002-2966-5597; Luu, Doan Trung/0000-0001-9765-2125				Baxter-Burrell A, 2002, SCIENCE, V296, P2026, DOI 10.1126/science.1071505; BIRNER TP, 1993, PLANTA, V190, P474, DOI 10.1007/BF00224786; Clarkson DT, 2000, J EXP BOT, V51, P61, DOI 10.1093/jexbot/51.342.61; Felle HH, 2001, PLANT BIOLOGY, V3, P577, DOI 10.1055/s-2001-19372; Gerbeau P, 2002, PLANT J, V30, P71, DOI 10.1046/j.1365-313X.2002.01268.x; Gout E, 2001, PLANT PHYSIOL, V125, P912, DOI 10.1104/pp.125.2.912; Han ZQ, 1998, J BIOL CHEM, V273, P6001, DOI 10.1074/jbc.273.11.6001; Javot H, 2002, ANN BOT-LONDON, V90, P301, DOI 10.1093/aob/mcf199; Javot H, 2003, PLANT CELL, V15, P509, DOI 10.1105/tpc.008888; Johansson I, 1998, PLANT CELL, V10, P451, DOI 10.1105/tpc.10.3.451; Kamaluddin M, 2001, J EXP BOT, V52, P739, DOI 10.1093/jexbot/52.357.739; Lacombe B, 2000, FEBS LETT, V466, P351, DOI 10.1016/S0014-5793(00)01093-0; Martre P, 2002, PLANT PHYSIOL, V130, P2101, DOI 10.1104/pp.009019; MAUREL C, 1995, EMBO J, V14, P3028, DOI 10.1002/j.1460-2075.1995.tb07305.x; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; Nemeth-Cahalan KL, 2000, J BIOL CHEM, V275, P6777, DOI 10.1074/jbc.275.10.6777; PARISI M, 1984, AM J PHYSIOL, V246, pC157, DOI 10.1152/ajpcell.1984.246.1.C157; Siefritz F, 2002, PLANT CELL, V14, P869, DOI 10.1105/tpc.000901; Steudle E, 1998, J EXP BOT, V49, P775, DOI 10.1093/jexbot/49.322.775; SUBBAIAH CC, 1994, PLANT CELL, V6, P1747, DOI 10.1105/tpc.6.12.1747; Tomos AD, 1999, ANNU REV PLANT PHYS, V50, P447, DOI 10.1146/annurev.arplant.50.1.447; VARAPETIAN BB, 1997, ANN BOT SA, V79, P3; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631; ZHANG WH, 1991, AUST J PLANT PHYSIOL, V18, P603, DOI 10.1071/PP9910603; Zhang WH, 1999, PLANT PHYSIOL, V120, P849, DOI 10.1104/pp.120.3.849	26	496	534	6	152	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					393	397		10.1038/nature01853	http://dx.doi.org/10.1038/nature01853			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508488				2022-12-28	WOS:000185502300040
J	Wells, PS; Anderson, DR; Rodger, M; Forgie, M; Kearon, C; Dreyer, J; Kovacs, G; Mitchell, M; Lewandowski, B; Kovacs, MJ				Wells, PS; Anderson, DR; Rodger, M; Forgie, M; Kearon, C; Dreyer, J; Kovacs, G; Mitchell, M; Lewandowski, B; Kovacs, MJ			Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENOUS THROMBOSIS; PULMONARY-EMBOLISM; NONINVASIVE DIAGNOSIS; PRETEST PROBABILITY; CLINICAL-MODEL; MANAGEMENT; OUTPATIENTS; THROMBOEMBOLISM; EMERGENCY	BACKGROUND: Several diagnostic strategies using ultrasound imaging, measurement of D-dimer, and assessment of clinical probability of disease have proved safe in patients with suspected deep-vein thrombosis, but they have not been compared in randomized trials. METHODS: Outpatients presenting with suspected lower-extremity deep-vein thrombosis were potentially eligible. Using a clinical model, physicians evaluated the patients and categorized them as likely or unlikely to have deep-vein thrombosis. The patients were then randomly assigned to undergo ultrasound imaging alone (control group) or to undergo D-dimer testing (D-dimer group) followed by ultrasound imaging unless the D-dimer test was negative and the patient was considered clinically unlikely to have deep-vein thrombosis, in which case ultrasound imaging was not performed. RESULTS: Five hundred thirty patients were randomly assigned to the control group, and 566 to the D-dimer group. The overall prevalence of deep-vein thrombosis or pulmonary embolism was 15.7 percent. Among patients for whom deep-vein thrombosis had been ruled out by the initial diagnostic strategy, there were two confirmed venous thromboembolic events in the D-dimer group (0.4 percent; 95 percent confidence interval, 0.05 to 1.5 percent) and six events in the control group (1.4 percent; 95 percent confidence interval, 0.5 to 2.9 percent; P=0.16) during three months of follow-up. The use of D-dimer testing resulted in a significant reduction in the use of ultrasonography, from a mean of 1.34 tests per patient in the control group to 0.78 in the D-dimer group (P=0.008). Two hundred eighteen patients (39 percent) in the D-dimer group did not require ultrasound imaging. CONCLUSIONS: Deep-vein thrombosis can be ruled out in a patient who is judged clinically unlikely to have deep-vein thrombosis and who has a negative D-dimer test. Ultrasound testing can be safely omitted in such patients.	Univ Ottawa, Ottawa Hosp, Dept Med, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Ottawa Hosp, Dept Radiol, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Ottawa Hosp, Dept Emergency Med, Ottawa, ON K1Y 4E9, Canada; Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada; Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada; McMaster Univ, Henderson Hosp, Hamilton, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Dalhousie University; Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; Western University (University of Western Ontario); McMaster University	Wells, PS (corresponding author), Univ Ottawa, Ottawa Hosp, Dept Med, Civ Campus,Suite F647,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.		Kovacs, Michael/G-3315-2011	Rodger, Marc/0000-0001-8166-3487; Anderson, David/0000-0003-0845-1722				Aguilar C, 2002, BRIT J HAEMATOL, V118, P275, DOI 10.1046/j.1365-2141.2002.03614.x; Anderson DR, 2000, J EMERG MED, V19, P225, DOI 10.1016/S0736-4679(00)00225-0; Bates SM, 2001, ARCH INTERN MED, V161, P447, DOI 10.1001/archinte.161.3.447; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Brill-Edwards P, 1999, THROMB HAEMOSTASIS, V82, P688; Freyburger G, 1998, THROMB HAEMOSTASIS, V79, P32; GOTTSCHALK A, 1993, J NUCL MED, V34, P1109; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; Janes S, 2001, BRIT J HAEMATOL, V114, P738; Kearon C, 1998, ANN INTERN MED, V129, P425, DOI 10.7326/0003-4819-128-8-199804150-00011; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; Kearon C, 2001, ANN INTERN MED, V135, P108, DOI 10.7326/0003-4819-135-2-200107170-00011; KOOPMAN MMW, 1995, HAEMOSTASIS, V25, P49; Kovacs MJ, 2001, BRIT J HAEMATOL, V115, P140, DOI 10.1046/j.1365-2141.2001.03060.x; Kraaijenhagen RA, 2002, ARCH INTERN MED, V162, P907, DOI 10.1001/archinte.162.8.907; Lennox AF, 1999, J VASC SURG, V30, P794, DOI 10.1016/S0741-5214(99)70003-0; Perrier A, 1999, LANCET, V353, P190, DOI 10.1016/S0140-6736(98)05248-9; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wells PS, 1999, THROMB HAEMOSTASIS, V81, P493; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; Wells PS, 1998, LANCET, V351, P1405, DOI 10.1016/S0140-6736(05)79444-7; Wells PS, 2001, ANN INTERN MED, V135, P98, DOI 10.7326/0003-4819-135-2-200107170-00010	24	894	988	1	40	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2003	349	13					1227	1235		10.1056/NEJMoa023153	http://dx.doi.org/10.1056/NEJMoa023153			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LJ	14507948	Bronze			2022-12-28	WOS:000185488800005
J	Neuberger, J; Price, D				Neuberger, J; Price, D			Role of living liver donation in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							TRANSPLANTATION; DONOR; ADULT; EXPERIENCE; SELECTION; HEALTH		Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, W Midlands, England; De Montfort Univ, Leicester LE1 9BH, Leics, England	University of Birmingham; De Montfort University	Neuberger, J (corresponding author), Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, W Midlands, England.							Abecassis M, 2000, JAMA-J AM MED ASSOC, V284, P2919; Baker A, 1999, BRIT J SURG, V86, P200, DOI 10.1046/j.1365-2168.1999.00991.x; Beavers KL, 2001, LIVER TRANSPLANT, V7, P943, DOI 10.1053/jlts.2001.28443; Broering DC, 2003, J HEPATOL, V38, pS119, DOI 10.1016/S0168-8278(03)00009-6; Brown RS, 2003, NEW ENGL J MED, V348, P818, DOI 10.1056/NEJMsa021345; DAVIES MH, 1992, GUT, V33, P1397, DOI 10.1136/gut.33.10.1397; FISHER NC, 2002, BRIT MED J, V325, P512; Johnson E M, 1997, Clin Transpl, P231; Kahn J, 2002, TRANSPLANTATION, V74, P421, DOI 10.1097/00007890-200208150-00026; Karliova M, 2002, TRANSPLANTATION, V73, P1799, DOI 10.1097/00007890-200206150-00017; Malago M, 2001, LIVER TRANSPLANT, V7, P921, DOI 10.1053/jlts.2001.28301; Marcos A, 2000, LIVER TRANSPLANT, V6, pS59, DOI 10.1053/jlts.2000.19011; Marcos A, 2000, TRANSPLANTATION, V69, P2410, DOI 10.1097/00007890-200006150-00034; Neuberger J, 1999, LANCET, V354, P1636, DOI 10.1016/S0140-6736(99)90002-8; NEUBERGER J, IN PRESS TRANSPLANTA; RAIA S, 1989, LANCET, V2, P497; Ross LF, 2002, TRANSPLANTATION, V74, P418; Shiffman ML, 2002, LIVER TRANSPLANT, V8, P174, DOI 10.1053/jlts.2002.30981; Williams RS, 2003, EUR J GASTROEN HEPAT, V15, P7, DOI 10.1097/00042737-200301000-00003	19	15	15	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 20	2003	327	7416					676	679		10.1136/bmj.327.7416.676	http://dx.doi.org/10.1136/bmj.327.7416.676			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724AC	14500445	Green Published			2022-12-28	WOS:000185463100029
J	Shaham, S				Shaham, S			Apoptosis: A process with a (beta)NAC for complexity	CELL			English	Editorial Material							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; C-ELEGANS		Rockefeller Univ, Lab Dev Genet, New York, NY 10021 USA	Rockefeller University	Shaham, S (corresponding author), Rockefeller Univ, Lab Dev Genet, 1230 York Ave, New York, NY 10021 USA.							Bloss TA, 2003, NATURE, V424, P1066, DOI 10.1038/nature01920; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Rospert S, 2002, CELL MOL LIFE SCI, V59, P1632, DOI 10.1007/PL00012490; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Shaham S, 1999, GENETICS, V153, P1655; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Wang XD, 2001, GENE DEV, V15, P2922	10	5	12	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 19	2003	114	6					659	661		10.1016/S0092-8674(03)00717-7	http://dx.doi.org/10.1016/S0092-8674(03)00717-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505566	Bronze			2022-12-28	WOS:000185464000004
J	Brosnan, SF; de Waal, FBM				Brosnan, SF; de Waal, FBM			Monkeys reject unequal pay	NATURE			English	Article							HUMAN COOPERATION; ULTIMATUM GAME; CAPUCHINS; SOCIOLOGY; BEHAVIOR; ALTRUISM; FAIRNESS; PUZZLE	During the evolution of cooperation it may have become critical for individuals to compare their own efforts and pay-offs with those of others. Negative reactions may occur when expectations are violated. One theory proposes that aversion to inequity can explain human cooperation within the bounds of the rational choice model(1), and may in fact be more inclusive than previous explanations(2-8). Although there exists substantial cultural variation in its particulars, this 'sense of fairness' is probably a human universal(9,10) that has been shown to prevail in a wide variety of circumstances(11-13). However, we are not the only cooperative animals(14), hence inequity aversion may not be uniquely human. Many highly cooperative nonhuman species seem guided by a set of expectations about the outcome of cooperation and the division of resources(15,16). Here we demonstrate that a nonhuman primate, the brown capuchin monkey (Cebus apella), responds negatively to unequal reward distribution in exchanges with a human experimenter. Monkeys refused to participate if they witnessed a conspecific obtain a more attractive reward for equal effort, an effect amplified if the partner received such a reward without any effort at all. These reactions support an early evolutionary origin of inequity aversion.	Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA	Emory University	Brosnan, SF (corresponding author), Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.							ANDREONI J, 1995, AM ECON REV, V85, P891; Andreoni J, 2002, GAME ECON BEHAV, V40, P1, DOI 10.1006/game.2001.0904; Brosnan SF, 2002, HUM NATURE-INT BIOS, V13, P129, DOI 10.1007/s12110-002-1017-2; de Waal F.B.M., 2002, NEUROPSYCHOLOGIA, V1492, P1; de Waal FBM, 1997, J COMP PSYCHOL, V111, P370, DOI 10.1037/0735-7036.111.4.370; de Waal FBM, 2000, NATURE, V404, P563, DOI 10.1038/35007138; DeWaal Frans B. M., 1996, GOOD NATURED ORIGINS; DiBitetti MS, 1997, ANIM BEHAV, V54, P199, DOI 10.1006/anbe.1996.0416; Dugatkin L.A., 1997, COOPERATION ANIMALS; Falk A, 2003, ECON INQ, V41, P20, DOI 10.1093/ei/41.1.20; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151; Fehr E, 2003, NATURE, V422, P137, DOI 10.1038/nature01474; Fehr E, 2003, NATURE, V421, P912, DOI 10.1038/421912a; Frank R.H., 2001, EVOLUTION CAPACITY C, P57; Frank R. H., 1988, PASSIONS REASON STRA; Henrich J, 2000, AM ECON REV, V90, P973, DOI 10.1257/aer.90.4.973; Henrich J, 2001, AM ECON REV, V91, P73, DOI 10.1257/aer.91.2.73; Hirshleifer J., 1987, LATEST BEST ESSAYS E, P307; Johnson DDP, 2003, NATURE, V421, P911, DOI 10.1038/421912a; KAHNEMAN D, 1986, AM ECON REV, V76, P728; Mendres KA, 2000, ANIM BEHAV, V60, P523, DOI 10.1006/anbe.2000.1512; Milinski M, 2002, NATURE, V415, P424, DOI 10.1038/415424a; Nesse R., 2001, EVOLUTION CAPACITY C, P120; Nesse R. M., 2001, EVOLUTION CAPACITY C, P1; Roberts G, 1998, NATURE, V394, P175, DOI 10.1038/28160; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Tinklepaugh OL, 1928, J COMP PSYCHOL, V8, P197, DOI 10.1037/h0075798; WENEKIND C, 2000, SCIENCE, V200, P850; Zizzo D. J., 2001, ANN DECONOMIE STATIS, V63, P39, DOI DOI 10.2307/20076295	30	687	705	7	411	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					297	299		10.1038/nature01963	http://dx.doi.org/10.1038/nature01963			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	722JA	13679918				2022-12-28	WOS:000185370900046
J	Nishioka, Y; Miyazaki, M				Nishioka, Y; Miyazaki, M			Ectopic calcinosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Nagasaki Univ, Nagasaki 8528501, Japan	Nagasaki University	Nishioka, Y (corresponding author), Nagasaki Univ, Nagasaki 8528501, Japan.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					E12	E12		10.1056/ENEJMicm020800	http://dx.doi.org/10.1056/ENEJMicm020800			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679542				2022-12-28	WOS:000185369700009
J	Ruggeri, M; Tosetto, A; Frezzato, M; Rodeghiero, F				Ruggeri, M; Tosetto, A; Frezzato, M; Rodeghiero, F			The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis	ANNALS OF INTERNAL MEDICINE			English	Article							APPARENT POLYCYTHEMIA; OLMSTED COUNTY; POPULATION; DIAGNOSIS; RISK; EPIDEMIOLOGY; MANAGEMENT; MINNESOTA; SURVIVAL; RANGES	Background: The clinical relevance of mild erythrocytosis (hematocrit > 0.48 in women or > 0.51 in men) or thrombocytosis (platelet count > 400 x 10(9) cells/L) in asymptomatic persons is uncertain. Objective: To estimate the frequency of polycythemia vera or essential thrombocythemia in persons with erythrocytosis or thrombocytosis in a general population. Design: Cohort study. Setting: Vicenza, Italy. Participants: 10000 community dwellers age 18 to 65 years and enrolled in the Vicenza Thrombophilia and Atherosclerosis project. Measurements: Platelet count and hematocrit at baseline in all participants and at second follow-up if baseline results were abnormal. Measurement of erythrocyte sedimentation rate, peripheral arterial saturation, serum erythropoietin level, and leukocyte alkaline phosphatase level; chest radiography; abdominal ultrasonography; and occult fecal blood testing were done in persons with confirmed high hematocrit or platelet counts. Polycythemia vera and essential thrombocythemia were diagnosed according to the Polycythemia Study Group criteria. Results: At baseline examination, 1 person had polycythemia vera, 1 had essential thrombocythemia, 88 had erythrocytosis, and 99 had thrombocytosis. Second examination confirmed erythrocytosis in 40% (95% Cl, 29% to 51%) and thrombocytosis in 8% (Cl, 4% to 15%) of those with abnormal baseline results. Among persons with confirmed abnormalities, further evaluation revealed 11 with idiopathic erythrocytosis, 2 with polycythemia vera (3/ 10 000 [Cl, 0.6 to 8.7/10 000]), and 3 with essential thrombocythemia (4/10 000 [Cl, 1.09 to 10.2/10 000]). After 5 years of follow-up, 1 additional person with a high platelet count developed essential thrombocythemia, and no persons developed hemorrhagic or thrombotic complications. Conclusions: The prevalences of polycythemia vera and essential thrombocythemia were higher than expected in this general population. However, the risks for developing polycythemia vera, essential thrombocythemia, or associated vascular complications in persons with erythrocytosis or thrombocytosis were low.	San Bortolo Hosp, Dept Hematol, I-36100 Vicenza, Italy	ULSS 8 Berica; Ospedale San Bortolo di Vicenza	Rodeghiero, F (corresponding author), San Bortolo Hosp, Dept Hematol, I-36100 Vicenza, Italy.	rodeghiero@hemato.ven.it	Tosetto, Alberto/AAM-3200-2020; Tosetto, Alberto/AAB-9320-2022	Tosetto, Alberto/0000-0002-0119-5204; 				ANIA BJ, 1994, AM J HEMATOL, V47, P89, DOI 10.1002/ajh.2830470205; BERGLUND S, 1992, EUR J HAEMATOL, V48, P20; Berk PD, 1997, SEMIN HEMATOL, V34, P77; BERLIN NI, 1975, SEMIN HEMATOL, V12, P339; CARLI PM, 1994, NOUV REV FR HEMATOL, V36, P147; CHAITER Y, 1992, LEUKEMIA LYMPHOMA, V7, P251, DOI 10.3109/10428199209053630; CORTELAZZO S, 1995, NEW ENGL J MED, V332, P1132, DOI 10.1056/NEJM199504273321704; DOUGAN LE, 1981, CANCER, V48, P866, DOI 10.1002/1097-0142(19810801)48:3<866::AID-CNCR2820480334>3.0.CO;2-Y; Fairbanks VF, 2000, EUR J HAEMATOL, V65, P285, DOI 10.1034/j.1600-0609.2000.065005285.x; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; Hills, 1993, STAT MODELS EPIDEMIO; Lengfelder E, 1998, BRIT J HAEMATOL, V100, P15, DOI 10.1046/j.1365-2141.1998.00529.x; Mesa RA, 1999, AM J HEMATOL, V61, P10, DOI 10.1002/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.3.CO;2-9; MESSINEZY M, 1993, EUR J HAEMATOL, V51, P125; MODAN B, 1965, BLOOD-J HEMATOL, V26, P657, DOI 10.1182/blood.V26.5.657.657; MODAN B, 1971, BLOOD-J HEMATOL, V37, P172, DOI 10.1182/blood.V37.2.172.172; Murphy S, 1997, SEMIN HEMATOL, V34, P29; MURPHY S, 1986, SEMIN HEMATOL, V23, P177; Najean Y, 1998, HEMATOL CELL THER, V40, P159; PROCHAZKA AV, 1986, BRIT J CANCER, V53, P59, DOI 10.1038/bjc.1986.9; RIUNITI O, 1995, ANN INTERN MED, V123, P656, DOI 10.7326/0003-4819-123-9-199511010-00003; Rodeghiero F, 1996, THROMB HAEMOSTASIS, V76, P226; Ruggeri M, 1998, BRIT J HAEMATOL, V103, P772; SILVERSTEIN MN, 1971, MAYO CLIN PROC, V46, P751; Streiff MB, 2002, BLOOD, V99, P1144, DOI 10.1182/blood.V99.4.1144; Tefferi A, 1999, MAYO CLIN PROC, V74, P159, DOI 10.4065/74.2.159	26	49	51	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					470	475		10.7326/0003-4819-139-6-200309160-00009	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679323				2022-12-28	WOS:000185324100002
J	Fenton, PM; Whitty, CJM; Reynolds, F				Fenton, PM; Whitty, CJM; Reynolds, F			Caesarean section in Malawi: prospective study of early maternal and perinatal mortality	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-TRANSFUSION; AFRICA	Objective To examine potentially modifiable factors that may influence the high maternal and perinatal mortality associated with caesarean section in Malawi. Design A prospective observational study of 8070 caesarean sections performed between January 1998 and June 2000 and associated complications. Setting 23 district and two central hospitals in Malawi. Participants 45 anaesthetists from hospitals that carried out caesarean sections. Main outcome measures Associations between maternal or perinatal deaths in the first 72 hours and various quantifiable risk factors. Results Questionnaires were returned for 5236 caesarean sections in district hospitals and 2834 in central hospitals; 7622 (94%) were emergencies, 5110 (63%) were because of obstructed labour. Preoperative haemorrhagic shock was present in 610 (7.6%) women, anaemia in 503 (6.2%), and ruptured uterus in 333 (4.1%). Eighty five women died (1.05%), 68 of whom died postoperatively on the wards. Higher maternal mortality was associated with ruptured uterus (adjusted odds ratio 2.3, 95% confidence interval 1.3 to 4.0), little anaesthetic training (2.9, 1.6 to 5.1), general as opposed to spinal anaesthesia (6.6, 2.3 to 18.7), and blood loss requiring transfusion of greater than or equal to 2 units (21.0, 11.7 to 37.7). Perinatal mortality up to 72 hours was 11.2% overall and was significantly associated with ruptured uterus and general rather than spinal anaesthesia. Conclusion In sub-Saharan Africa high maternal and perinatal mortality at caesarean section is associated with major preoperative complications that are unusual in developed countries. Improved training in anaesthetics, wider use of spinal anaesthesia, and improved surveillance and resuscitation in postoperative wards might reduce mortality.	Coll Med, Dept Anaesthesia, Blantyre, Malawi; Univ London London Sch Hyg & Trop Med, Clin Res Unit, London WC1E 7HT, England; St Thomas Hosp, London SE1 7EH, England	University of Malawi; University of London; London School of Hygiene & Tropical Medicine; Guy's & St Thomas' NHS Foundation Trust	Fenton, PM (corresponding author), Meyra, F-47800 Agnac, France.		Whitty, Christopher/C-7740-2012	Whitty, Christopher/0000-0002-6076-5027				CHIPHANGWI JD, 1992, E AFR MED J, V69, P675; Cisse C T, 1998, Sante, V8, P369; Fenton P, 1997, E CENT AFR J SURG, V3, P33; Fenton PM, 1999, ANAESTHESIA, V54, P1055, DOI 10.1046/j.1365-2044.1999.01060.x; Hardy JF, 2000, ANAESTHESIA, V55, P613, DOI 10.1046/j.1365-2044.2000.01479-39.x; Hussein J, 2001, INT J GYNECOL OBSTET, V75, P63, DOI 10.1016/S0020-7292(01)00474-X; McKenzie AG, 1998, INT J OBSTET ANESTH, V7, P237, DOI 10.1016/S0959-289X(98)80045-9; Moodley J, 2000, S AFR MED J, V90, P367; Morris S, 2000, REGIONAL ANALGESIA IN OBSTETRICS, P347; *NAT STAT OFF MAL, 1993, MAL DEM HLTH SURV 19; *NAT STAT OFF MAL, 2001, MAL DEM HLTH SURV 20; NORDBERG EM, 1984, BRIT MED J, V289, P92, DOI 10.1136/bmj.289.6437.92; Taha TE, 1998, AIDS, V12, P197, DOI 10.1097/00002030-199802000-00010; *WORLD BANK, 1994, BETT HLTH AFR LESS E; Zishiri C., 1999, Central African Journal of Medicine, V45, P234	15	103	104	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					587	590A		10.1136/bmj.327.7415.587	http://dx.doi.org/10.1136/bmj.327.7415.587			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969922	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000185358700018
J	Yamashita, YM; Jones, DL; Fuller, MT				Yamashita, YM; Jones, DL; Fuller, MT			Orientation of asymmetric stem cell division by the APC tumor suppressor and centrosome	SCIENCE			English	Article							DROSOPHILA APC2; MITOTIC SPINDLES; SELF-RENEWAL; PROTEIN; MICROTUBULES; CAPTURE; ENCODES	Stem cell self-renewal can be specified by local signals from the surrounding microenvironment, or niche. However, the relation between the niche and the mechanisms that ensure the correct balance between stem cell self-renewal and differentiation is poorly understood. Here, we show that dividing Drosophila male germline stem cells use intracellular mechanisms involving centrosome function and cortically localized Adenomatous Polyposis Coli tumor suppressor protein to orient mitotic spindles perpendicular to the niche, ensuring a reliably asymmetric outcome in which one daughter cell remains in the niche and self-renews stem cell identity, whereas the other, displaced away, initiates differentiation.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University	Fuller, MT (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.	fuller@cmgm.stanford.edu		Fuller, Margaret T/0000-0002-3804-4987; Yamashita, Yukiko/0000-0001-5541-0216	NIDDK NIH HHS [1P01 DK53074] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053074] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akong K, 2002, DEV BIOL, V250, P71, DOI 10.1006/dbio.2002.0777; BLENZ M, 2001, NATURE CELL BIOL, V3, pE67; Bloom K, 2001, CURR BIOL, V11, pR326, DOI 10.1016/S0960-9822(01)00176-2; Deng W, 1997, DEV BIOL, V189, P79, DOI 10.1006/dbio.1997.8669; HEUER JG, 1995, DEVELOPMENT, V121, P3861; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; Jones D. B., UNPUB; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Li KJ, 1996, CELL, V85, P585, DOI 10.1016/S0092-8674(00)81258-1; Liakopoulos D, 2003, CELL, V112, P561, DOI 10.1016/S0092-8674(03)00119-3; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; McCartney BM, 1999, J CELL BIOL, V146, P1303, DOI 10.1083/jcb.146.6.1303; McCartney BM, 2001, NAT CELL BIOL, V3, P933, DOI 10.1038/ncb1001-933; Megraw TL, 2001, CURR BIOL, V11, P116, DOI 10.1016/S0960-9822(01)00017-3; Miller RK, 1998, J CELL BIOL, V140, P377, DOI 10.1083/jcb.140.2.377; Schuyler SC, 2001, J CELL SCI, V114, P247; Segal M, 2001, TRENDS CELL BIOL, V11, P160, DOI 10.1016/S0962-8924(01)01954-7; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Yu X, 1999, NAT CELL BIOL, V1, P144, DOI 10.1038/11064	23	553	576	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1547	1550		10.1126/science.1087795	http://dx.doi.org/10.1126/science.1087795			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970569				2022-12-28	WOS:000185255300054
J	Fischer, H; Hammel, PW; Dragovic, LJ				Fischer, H; Hammel, PW; Dragovic, LJ			Human bites versus dog bites	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Childrens Hosp Michigan, Detroit, MI 48201 USA; Oakland Cty Med Examiners Off, Pontiac, MI 48341 USA	Children's Hospital of Michigan	Fischer, H (corresponding author), Childrens Hosp Michigan, Detroit, MI 48201 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					E11	E11		10.1056/ENEJMicm030134	http://dx.doi.org/10.1056/ENEJMicm030134			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719UH	12968103				2022-12-28	WOS:000185223100007
J	Spies, M; Bianco, PR; Dillingham, MS; Handa, N; Baskin, RJ; Kowalczykowski, SC				Spies, M; Bianco, PR; Dillingham, MS; Handa, N; Baskin, RJ; Kowalczykowski, SC			A molecular throttle: The recombination hotspot chi controls DNA translocation by the RecBCD helicase	CELL			English	Article							HOT SPOT ACTIVITY; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; RECA PROTEIN; ENZYME; RECOGNITION; SEQUENCE; DEGRADATION; MUTATION; POLARITY	RecBCD enzyme is a heterotrimeric helicase/nuclease that initiates homologous recombination at double-stranded DNA breaks. Several of its activities are regulated by the DNA sequence chi (5'-GCTGGTGG-3'), which is recognized in cis by the translocating enzyme. When RecBCD enzyme encounters chi, the intensity and polarity of its nuclease activity are changed, and the enzyme gains the ability to load RecA protein onto the chi-containing, unwound single-stranded DNA. Here, we show that interaction with chi also affects translocation by RecBCD enzyme. By observing translocation of individual enzymes along single molecules of DNA, we could see RecBCD enzyme pause precisely at chi. Furthermore, and more unexpectedly, after pausing at chi, the enzyme continues translocating but at approximately one-half the initial rate. We propose that interaction with chi results in an enzyme in which one of the two motor subunits, likely the RecD motor, is uncoupled from the holoenzyme to produce the slower translocase.	Univ Calif Davis, Ctr Genet & Dev, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Ctr Genet & Dev, Microbiol Sect, Davis, CA 95616 USA.		Handa, Naofumi/H-6640-2017	Handa, Naofumi/0000-0003-3695-1871; Dillingham, Mark/0000-0002-4612-7141; Spies, Maria/0000-0002-7375-8037	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347, R01GM064745] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM064745, GM-64745, GM-41347] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Anderson DG, 1999, J BIOL CHEM, V274, P27139, DOI 10.1074/jbc.274.38.27139; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; Arnold DA, 1998, J BIOL CHEM, V273, P16476, DOI 10.1074/jbc.273.26.16476; ARNOLD DA, 1999, ENCY LIFE SCI; Bianco PR, 1997, P NATL ACAD SCI USA, V94, P6706, DOI 10.1073/pnas.94.13.6706; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; Dillingham MS, 2003, NATURE, V423, P893, DOI 10.1038/nature01673; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1995, J BIOL CHEM, V270, P16360, DOI 10.1074/jbc.270.27.16360; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; Dohoney KM, 2001, NATURE, V409, P370, DOI 10.1038/35053124; KORANGY F, 1994, BIOCHEMISTRY-US, V33, P9552, DOI 10.1021/bi00198a022; KUZMINOV A, 1994, EMBO J, V13, P2764, DOI 10.1002/j.1460-2075.1994.tb06570.x; LAM ST, 1974, GENETICS, V77, P425; LARSSON A, 1994, J AM CHEM SOC, V116, P8459, DOI 10.1021/ja00098a004; LEBOWITZ J, 1985, THESIS J HOPKINS U B; MYERS RS, 1995, P NATL ACAD SCI USA, V92, P6244, DOI 10.1073/pnas.92.14.6244; RINKEN R, 1992, J BACTERIOL, V174, P5424, DOI 10.1128/JB.174.16.5424-5429.1992; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; STAHL FW, 1975, MOL GEN GENET, V140, P29, DOI 10.1007/BF00268986; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; Taylor AF, 2003, NATURE, V423, P889, DOI 10.1038/nature01674; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; Taylor AF, 1999, GENE DEV, V13, P890, DOI 10.1101/gad.13.7.890; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226	30	146	151	0	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					647	654		10.1016/S0092-8674(03)00681-0	http://dx.doi.org/10.1016/S0092-8674(03)00681-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678587	Bronze			2022-12-28	WOS:000185193100013
J	Wolf, DA; Geyer, R				Wolf, DA; Geyer, R			Dynamic release of Cdc34 from SCF: The hand that rocks the cradle	CELL			English	Editorial Material							UBIQUITIN LIGASE; BETA-TRCP1; COMPLEX	Polyubiquitylation is a complex but poorly understood biochemical reaction catalyzed by E3 ubiquitin ligases. In this issue of Cell, Deffenbaugh et al. provide experimental support for a model in which the dynamic release of the ubiquitin-charged E2 Cdc34 from its primary binding site within the rigid cradle-like SCF E3 complex allows for unexpected spatial flexibility to assemble a polyubiquitin chain.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Wolf, DA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.		Wolf, Dieter/AAE-5890-2021	Wolf, Dieter/0000-0002-3761-1070	NIGMS NIH HHS [R01 GM059780] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059780] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Wolf DA, 1999, CURR BIOL, V9, P373, DOI 10.1016/S0960-9822(99)80165-1; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	10	0	0	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					532	533		10.1016/S0092-8674(03)00682-2	http://dx.doi.org/10.1016/S0092-8674(03)00682-2			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678576	Bronze			2022-12-28	WOS:000185193100002
J	Underwood, J				Underwood, J			Commentary: Resuscitating the teaching autopsy	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Sheffield, Sch Med & Biomed Sci, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield	Underwood, J (corresponding author), Univ Sheffield, Sch Med & Biomed Sci, Sheffield S10 2RX, S Yorkshire, England.								0	9	9	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					803	804		10.1136/bmj.327.7418.803	http://dx.doi.org/10.1136/bmj.327.7418.803			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525884	Green Published			2022-12-28	WOS:000185805100028
J	Edwards, KM; Griffin, MR				Edwards, KM; Griffin, MR			Great expectations for a new vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PNEUMOCOCCAL POLYSACCHARIDE VACCINE; CONJUGATE VACCINE; ADULTS		Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University	Edwards, KM (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA.							Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1; Jackson LA, 2003, NEW ENGL J MED, V348, P1747, DOI 10.1056/NEJMoa022678; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823	4	11	11	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1312	1314		10.1056/NEJMp038102	http://dx.doi.org/10.1056/NEJMp038102			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523138				2022-12-28	WOS:000185644000004
J	Eddleston, M; Senarathna, L; Mohamed, F; Buckley, N; Juszczak, E; Sheriff, MHR; Ariaratnam, A; Rajapakse, S; Warrell, D; Rajakanthan, K				Eddleston, M; Senarathna, L; Mohamed, F; Buckley, N; Juszczak, E; Sheriff, MHR; Ariaratnam, A; Rajapakse, S; Warrell, D; Rajakanthan, K			Deaths due to absence of an affordable antitoxin for plant poisoning	LANCET			English	Article							YELLOW OLEANDER; THEVETIA-PERUVIANA	There is a severe shortage of affordable antivenoms and antitoxins in the developing world. An anti-digoxin antitoxin for oleander poisoning was introduced in Sri Lanka in July, 2001, but because of its cost, stocks ran out in July, 2002. We looked at the effect of its introduction and withdrawal on case fatality, and determined its cost-effectiveness. The antitoxin strikingly reduced the case fatality; its absence resulted in a three-fold rise in deaths. At the present price of US$2650 per course, every life saved cost $10 209 and every life year cost $248. Reduction of the antitoxin's price to $400 would reduce costs to $1137 per life gained; a further reduction to $103 would save money for every life gained. Treatments for poisoning and envenoming should be included in the present campaign to increase availability of affordable treatments in the developing world.	Univ Colombo, Fac Med, Dept Clin Med, Ox Col Collaborat, Colombo 08, Sri Lanka; Univ Oxford, Ctr Trop Med, Nuffield Dept Clin Med, Oxford, England; Canberra Clin Sch, Dept Clin Pharmacol & Toxicol, Canberra, ACT, Australia; Inst Hlth Sci, Ctr Stat Med, Oxford, England; Kurunegala Teaching Hosp, Dept Cardiol, Kurunegala, N Western Prov, Sri Lanka	University of Colombo; University of Oxford; University of Oxford	Eddleston, M (corresponding author), Univ Colombo, Fac Med, Dept Clin Med, Ox Col Collaborat, POB 271,25 Kynsey Rd, Colombo 08, Sri Lanka.	eddlestonm@eureka.lk	Buckley, Nicholas A/D-4030-2012; Rajapakse, Senaka/A-8404-2011	Buckley, Nicholas A/0000-0002-6326-4711; Rajapakse, Senaka/0000-0003-1965-6678; Mohamed, Fahim/0000-0003-2849-7269; Senarathna, Lalith/0000-0002-7073-5788	Wellcome Trust [063560] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Eddleston M, 1999, TROP MED INT HEALTH, V4, P266, DOI 10.1046/j.1365-3156.1999.00397.x; Eddleston M, 2000, LANCET, V355, P967, DOI 10.1016/S0140-6736(00)90014-X; Eddleston M, 2003, J TOXICOL-CLIN TOXIC, V41, P309, DOI 10.1081/CLT-120021116; Eddleston M, 2000, HEART, V83, P301, DOI 10.1136/heart.83.3.301; Harrison RA, 2003, TOXICON, V41, P441, DOI 10.1016/S0041-0101(02)00360-4; Lopert R, 2002, LANCET, V359, P2105, DOI 10.1016/S0140-6736(02)08911-0; TABOULET P, 1993, J TOXICOL-CLIN TOXIC, V31, P261, DOI 10.3109/15563659309000393; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7	8	38	40	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2003	362	9389					1041	1044		10.1016/S0140-6736(03)14415-7	http://dx.doi.org/10.1016/S0140-6736(03)14415-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522536				2022-12-28	WOS:000185564600013
J	Bradley, GL; Leevers, SJ				Bradley, GL; Leevers, SJ			Amino acids and the humoral regulation of growth: Fat bodies use slimfast	CELL			English	Editorial Material							DROSOPHILA		BioMed Cent, London W1T 4LB, England; London Res Inst, Growth Regulat Lab, London WC2A 3PX, England		Bradley, GL (corresponding author), BioMed Cent, Middlesex House 34-42 Cleveland Str, London W1T 4LB, England.							Boisclair YR, 2001, J ENDOCRINOL, V170, P63, DOI 10.1677/joe.0.1700063; Britton JS, 1998, DEVELOPMENT, V125, P2149; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; DAVIS KT, 1977, SCIENCE, V196, P438, DOI 10.1126/science.403606; Martin JF, 2000, MECH DEVELOP, V92, P155, DOI 10.1016/S0925-4773(99)00338-X; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Zinke I, 1999, DEVELOPMENT, V126, P5275	8	6	6	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					656	658		10.1016/S0092-8674(03)00721-9	http://dx.doi.org/10.1016/S0092-8674(03)00721-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505564	Bronze			2022-12-28	WOS:000185464000002
J	Cope, GA; Deshaies, RJ				Cope, GA; Deshaies, RJ			COP9 signalosome: A multifunctional regulator of SCF and other cullin-based ubiquitin Ligases	CELL			English	Review							INOSITOL 1,3,4-TRISPHOSPHATE 5/6-KINASE; FISSION YEAST; PROTEIN-KINASE; DEGRADATION; COMPLEX; NEDD8; COP9/SIGNALOSOME; ARABIDOPSIS; P27(KIP1); JAB1/CSN5		CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Deshaies, RJ (corresponding author), CALTECH, Div Biol, 1200 E Calif Blvd, Pasadena, CA 91125 USA.	deshaies@its.caltech.edu	Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354				Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Deshaies RJ, 2000, NAT CELL BIOL, V2, pE102, DOI 10.1038/35014095; Doronkin S, 2002, DEVELOPMENT, V129, P5053; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Feng SH, 2003, PLANT CELL, V15, P1083, DOI 10.1105/tpc.010207; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; Gray WM, 1999, GENE DEV, V13, P1678, DOI 10.1101/gad.13.13.1678; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hwang JW, 2003, FEBS LETT, V541, P102, DOI 10.1016/S0014-5793(03)00321-1; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; Liu C, 2002, MULT SCLER J, V8, P10; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Maytal-Kivity V, 2003, INT J BIOCHEM CELL B, V35, P706, DOI 10.1016/S1357-2725(02)00378-3; Min KW, 2003, J BIOL CHEM, V278, P15905, DOI 10.1074/jbc.M213070200; Mundt KE, 1999, CURR BIOL, V9, P1427, DOI 10.1016/S0960-9822(00)80091-3; Mundt KE, 2002, MOL BIOL CELL, V13, P493, DOI 10.1091/mbc.01-10-0521; Nordgard O, 2001, BIOCHIMIE, V83, P969, DOI 10.1016/S0300-9084(01)01329-3; Oron E, 2002, DEVELOPMENT, V129, P4399; Oshikawa K, 2003, BIOCHEM BIOPH RES CO, V303, P1209, DOI 10.1016/S0006-291X(03)00501-1; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Osterlund MT, 1999, TRENDS CELL BIOL, V9, P113, DOI 10.1016/S0962-8924(99)01499-3; Peng ZH, 2003, CURR BIOL, V13, pR504, DOI 10.1016/S0960-9822(03)00439-1; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Smith P, 2002, DEV BIOL, V251, P333, DOI 10.1006/dbio.2002.0832; Suh GSB, 2002, NEURON, V33, P35, DOI 10.1016/S0896-6273(01)00576-1; Sun Y, 2002, J BIOL CHEM, V277, P45759, DOI 10.1074/jbc.M208709200; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; Wang HY, 2001, SCIENCE, V294, P154, DOI 10.1126/science.1063630; Wang XP, 2003, PLANT CELL, V15, P1071, DOI 10.1105/tpc.009936; Wee S, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-15; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Wilson MP, 2001, J BIOL CHEM, V276, P40998, DOI 10.1074/jbc.M106605200; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zhou CS, 2003, MOL CELL, V11, P927, DOI 10.1016/S1097-2765(03)00136-9; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	57	323	332	3	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					663	671		10.1016/S0092-8674(03)00722-0	http://dx.doi.org/10.1016/S0092-8674(03)00722-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505567	Bronze			2022-12-28	WOS:000185464000005
J	Skryabin, DV; Luan, F; Knight, JC; Russell, PS				Skryabin, DV; Luan, F; Knight, JC; Russell, PS			Soliton self-frequency shift cancellation in photonic crystal fibers	SCIENCE			English	Article							ANOMALOUS-DISPERSION; CHERENKOV RADIATION; GENERATION; GUIDANCE; PULSES; LIGHT	We report the cancellation of the soliton self-frequency shift in a silica-core photonic crystal fiber with a negative dispersion slope. Numerical and experimental results show that stabilization of the soliton wavelength is accompanied by exponential amplification of the red-shifted Cherenkov radiation emitted by the soliton. The spectral recoil from the radiation acts on the soliton to compensate for the Raman frequency shift. This phenomenon may find applications in the development of a family of optical parametric amplifiers.	Univ Bath, Dept Phys, Bath BA2 7AY, Avon, England	University of Bath	Skryabin, DV (corresponding author), Univ Bath, Dept Phys, Bath BA2 7AY, Avon, England.	d.v.skryabin@bath.ac.uk	Skryabin, Dmitry V/F-3589-2011; Russell, Philip St.J./G-5132-2012; Knight, Jonathan C/D-3879-2011; Luan, Feng/A-5109-2011; Skryabin, Dmitry/AAB-4224-2021	Skryabin, Dmitry V/0000-0001-5038-2500; Russell, Philip St.J./0000-0002-8972-2477; Knight, Jonathan C/0000-0002-0802-8804; Skryabin, Dmitry/0000-0001-5038-2500				AKHMEDIEV N, 1995, PHYS REV A, V51, P2602, DOI 10.1103/PhysRevA.51.2602; Cerenkov P, 1934, CR ACAD SCI URSS, V3, P451; Cregan RF, 1999, SCIENCE, V285, P1537, DOI 10.1126/science.285.5433.1537; DIANOV EM, 1985, JETP LETT+, V41, P294; Dudley JM, 2002, J OPT SOC AM B, V19, P765, DOI 10.1364/JOSAB.19.000765; FELLER W, 1966, INTRO PROBABILITY TH, V2, P503; Frank I, 1937, CR ACAD SCI URSS, V14, P109; Gaeta AL, 2002, OPT LETT, V27, P924, DOI 10.1364/OL.27.000924; HASEGAWA A, 2003, OPTICAL SOLITONS FRI; Hermann J., 2002, PHYS REV LETT, V88; Knight JC, 2000, IEEE PHOTONIC TECH L, V12, P807, DOI 10.1109/68.853507; Knight JC, 1998, SCIENCE, V282, P1476, DOI 10.1126/science.282.5393.1476; Knight JC, 1996, OPT LETT, V21, P1547, DOI 10.1364/OL.21.001547; Luo C, 2003, SCIENCE, V299, P368, DOI 10.1126/science.1079549; MITSCHKE FM, 1986, OPT LETT, V11, P659, DOI 10.1364/OL.11.000659; MOLLENAUER LF, 1980, PHYS REV LETT, V45, P1095, DOI 10.1103/PhysRevLett.45.1095; Ranka JK, 2000, OPT LETT, V25, P25, DOI 10.1364/OL.25.000025; Reeves WH, 2003, NATURE, V424, P511, DOI 10.1038/nature01798; Scott A.C., 1999, NONLINEAR SCI EMERGE; Stegeman GI, 1999, SCIENCE, V286, P1518, DOI 10.1126/science.286.5444.1518; Stevens TE, 2001, SCIENCE, V291, P627, DOI 10.1126/science.291.5504.627; Vavilov S.I., 1934, CR DOKL AKAD SCI, V2, P457, DOI [10.3367/UFNr.0093.196710m.0383, DOI 10.3367/UFNR.0093.196710M.0383]; Wadsworth WJ, 2000, ELECTRON LETT, V36, P53, DOI 10.1049/el:20000134; Zakharov VE, 1998, J EXP THEOR PHYS+, V86, P1035, DOI 10.1134/1.558551; ZAKHAROV VE, 1972, SOV PHYS JETP-USSR, V34, P62	25	353	373	5	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1705	1708		10.1126/science.1088516	http://dx.doi.org/10.1126/science.1088516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500977				2022-12-28	WOS:000185387700039
J	Nordin, P; Zetterstrom, H; Gunnarsson, U; Nilsson, E				Nordin, P; Zetterstrom, H; Gunnarsson, U; Nilsson, E			Local, regional, or general anaesthesia in groin hernia repair: multicentre randomised trial	LANCET			English	Article							INGUINAL-HERNIA; HERNIORRHAPHY; OUTCOMES	Background In specialised centres, local anaesthesia is almost always used in groin hernia surgery; whereas in routine surgical practice, regional or general anaesthesia are the methods of choice. In this three-arm multicentre randomised trial, we aimed to compare the three methods of anaesthesia and to determine the extent to which general surgeons can reproduce the excellent results obtained with local anaesthesia in specialised hernia centres. Methods Between January, 1999, and December, 2001, 616 patients at ten hospitals, were randomly assigned to have either local, regional, or general anaesthesia. Primary endpoints were early and late postoperative complications. Secondary endpoints were duration of surgery and anaesthesia, length of postoperative hospital stay, and time to normal activity. Analysis was by intention to treat. Findings Intraoperative tolerance for local anaesthesia was high. In the early postoperative period, local anaesthesia was superior to the other two types with respect to almost all endpoints. At 8 days' and 30 days' follow-up, there were no significant differences between the three groups. Although the mean duration of surgery was longer, the total anaesthesia time-ie, time from the start of anaesthesia until the patient left the operating room-was significantly shorter than it was for regional or general anaesthesia. Interpretation Local anaesthesia has substantial advantages compared with regional or general anaesthesia, such as shorter duration of admission, less postoperative pain, and fewer micturition difficulties. The favourable results obtained with local anaesthesia in specialised hernia centres can, to a great extent, be reproduced by general surgeons in routine surgical practice.	Ostersund Hosp, Dept Surg, S-83183 Ostersund, Sweden; Ostersund Hosp, Dept Anaesthet, Ostersund, Sweden; Univ Uppsala, Mora Hosp, Dept Surg, S-75105 Uppsala, Sweden; Motala Hosp, Dept Surg, Motala, Sweden	Uppsala University	Nordin, P (corresponding author), Ostersund Hosp, Dept Surg, S-83183 Ostersund, Sweden.		Nordin, Pär/Y-6278-2019	Nordin, Par/0000-0001-6117-5777				Aasbo V, 2002, ACTA ANAESTH SCAND, V46, P674, DOI 10.1034/j.1399-6576.2002.460607.x; ALSARRAGE SAM, 1990, J KUWAIT MED ASSOC, V24, P31; AMID PK, 1994, ANN SURG, V220, P735, DOI 10.1097/00000658-199412000-00004; Amid PK, 1996, EUR J SURG, V162, P447; Bay-Nielsen M, 2001, LANCET, V358, P1124, DOI 10.1016/S0140-6736(01)06251-1; Bendavid R, 2001, ABDOMINAL WALL HERNI, P370; Callesen T, 2001, ANESTH ANALG, V93, P1373, DOI 10.1097/00000539-200112000-00004; CAMPBELL MJ, 1995, BRIT MED J, V311, P1145, DOI 10.1136/bmj.311.7013.1145; Cheek CM, 1998, ANN ROY COLL SURG, V80, pS1; Cushing H, 1900, ANN SURG, V31, P1, DOI 10.1097/00000658-190001000-00003; FINLEY RK, 1991, AM SURGEON, V57, P486; FLANAGAN L, 1984, SURG CLIN N AM, V64, P257; Friemert B, 2000, CHIRURG, V71, P52, DOI 10.1007/s001040051012; GODFREY PJ, 1981, BRIT J SURG, V68, P587, DOI 10.1002/bjs.1800680820; Gonullu N N, 2002, Hernia, V6, P29; HAAPANIEMI S, 2001, THESIS LINKOPING U S; Hair A, 2000, BRIT J SURG, V87, P1722, DOI 10.1046/j.1365-2168.2000.01598.x; Kark AE, 1998, J AM COLL SURGEONS, V186, P447, DOI 10.1016/S1072-7515(98)00057-X; Kingsnorth AN, 2000, HERNIA, V4, P1; KNAPP RW, 1976, AM SURGEON, V42, P908; MAKURIA T, 1979, ANN ROY COLL SURG, V61, P291; MERHAV H, 1993, INT SURG, V78, P257; NILSSON E, 2002, NYHUS CONDONS HERNIA, P567; O'Riordan DC, 1998, SURG CLIN N AM, V78, P1129, DOI 10.1016/S0039-6109(05)70374-1; PONKA JL, 1980, HERNIAS ABDOMINAL WA; Song DJ, 2000, ANESTH ANALG, V91, P876, DOI 10.1097/00000539-200010000-00020; TEASDALE C, 1982, ANN ROY COLL SURG, V64, P238; VANDERLINDEN W, 1983, CONTROVERSIES SURG, V2, P1; YOUNG DV, 1987, AM J SURG, V153, P560, DOI 10.1016/0002-9610(87)90154-1	29	155	165	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					853	858		10.1016/S0140-6736(03)14339-5	http://dx.doi.org/10.1016/S0140-6736(03)14339-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678971				2022-12-28	WOS:000185329400008
J	Harper, SM; Neil, LC; Gardner, KH				Harper, SM; Neil, LC; Gardner, KH			Structural basis of a phototropin light switch	SCIENCE			English	Article							PHOTOACTIVE YELLOW PROTEIN; SIGNAL-TRANSDUCTION; RHIZOBIUM-MELILOTI; CHEMICAL-SHIFT; LOV2 DOMAIN; PAS DOMAIN; BINDING; RECEPTOR; KINASE; PHOTOCYCLE	Phototropins are light-activated kinases important for plant responses to blue light. Light initiates signaling in these proteins by generating a covalent protein . flavin mononucleotide (FMN) adduct within sensory Per-ARNT-Sim ( PAS) domains. We characterized the light-dependent changes of a phototropin PAS domain by solution nuclear magnetic resonance spectroscopy and found that an alpha helix located outside the canonical domain plays a key role in this activation process. Although this helix associates with the PAS core in the dark, photoinduced changes in the domain structure disrupt this interaction. We propose that this mechanism couples light-dependent bond formation to kinase activation and identifies a signaling pathway conserved among PAS domains.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gardner, KH (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Gardner, Kevin H./K-7802-2012; Gardner, Kevin/K-5493-2019	Gardner, Kevin H./0000-0002-8671-2556; 	NCI NIH HHS [CA90601] Funding Source: Medline; NIGMS NIH HHS [GM08297] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Briggs WR, 2002, TRENDS PLANT SCI, V7, P204, DOI 10.1016/S1360-1385(02)02245-8; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Christie JM, 2002, PLANT J, V32, P205, DOI 10.1046/j.1365-313X.2002.01415.x; Corchnoy SB, 2003, J BIOL CHEM, V278, P724, DOI 10.1074/jbc.M209119200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Creighton T.E., 1984, PROTEINS STRUCTURE M; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; Crosson S, 2003, BIOCHEMISTRY-US, V42, P2, DOI 10.1021/bi026978l; Dux P, 1998, BIOCHEMISTRY-US, V37, P12689, DOI 10.1021/bi9806652; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Fedorov R, 2003, BIOPHYS J, V84, P2474, DOI 10.1016/S0006-3495(03)75052-8; GILLESGONZALEZ MA, 1993, J BIOL CHEM, V268, P16293; Harper S. R., UNPUB; Hellingwerf KJ, 2003, J PHYS CHEM A, V107, P1082, DOI 10.1021/jp027005y; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; MONSON EK, 1995, J BIOL CHEM, V270, P5243, DOI 10.1074/jbc.270.10.5243; Rubinstenn G, 1999, J MAGN RESON, V137, P443, DOI 10.1006/jmre.1999.1705; Rubinstenn G, 1998, NAT STRUCT BIOL, V5, P568, DOI 10.1038/823; Rutter J, 2001, P NATL ACAD SCI USA, V98, P8991, DOI 10.1073/pnas.161284798; Sakamoto K, 2002, PLANT CELL, V14, P1723, DOI 10.1105/tpc.003293; Salomon M, 2000, BIOCHEMISTRY-US, V39, P9401, DOI 10.1021/bi000585+; Salomon M, 2001, P NATL ACAD SCI USA, V98, P12357, DOI 10.1073/pnas.221455298; Swartz TE, 2002, BIOCHEMISTRY-US, V41, P7183, DOI 10.1021/bi025861u; Swartz TE, 2001, J BIOL CHEM, V276, P36493, DOI 10.1074/jbc.M103114200; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; WISHART DS, 1994, J BIOMOL NMR, V4, P171	29	606	622	3	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1541	1544		10.1126/science.1086810	http://dx.doi.org/10.1126/science.1086810			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970567				2022-12-28	WOS:000185255300052
J	Hastings, A				Hastings, A			Metapopulation persistence with age-dependent disturbance or succession	SCIENCE			English	Article							CANADIAN BOREAL FOREST; LANDSCAPE-SCALE TEST; HABITAT DESTRUCTION; DYNAMICS; MANAGEMENT; COEXISTENCE; MODEL; BIRDS; FROG	Simple metapopulation models with random disturbances are used in species conservation or management, relying on the condition for persistence that the per-patch colonization rate be greater than the per-patch extinction rate. For a general model incorporating the role of succession or patch age - dependent extinction, I show that persistence requires the per-patch colonization rate to be greater than the inverse of mean patch age, where age is the time since the patch became available for colonization. Because mean patch age can be arbitrarily large relative to the extinction rate, currently persisting metapopulations may be persisting despite small colonization rates, and management approaches that do not consider the role of mean patch age may unnecessarily doom populations to extinction.	Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA	University of California System; University of California Davis	Hastings, A (corresponding author), Univ Calif Davis, Dept Environm Sci & Policy, 1 Shields Ave, Davis, CA 95616 USA.		Hastings, Alan/O-6864-2019; Hastings, Alan/A-7423-2008	Hastings, Alan/0000-0002-0717-8026; 				Amarasekare P, 2001, J THEOR BIOL, V209, P333, DOI 10.1006/jtbi.2001.2269; Bengtsson J, 2000, FOREST ECOL MANAG, V132, P39, DOI 10.1016/S0378-1127(00)00378-9; Bergeron Y, 2002, SILVA FENN, V36, P81, DOI 10.14214/sf.553; Bergeron Y, 2001, CAN J FOREST RES, V31, P384, DOI 10.1139/cjfr-31-3-384; Bergman KO, 2002, BIOL CONSERV, V108, P361, DOI 10.1016/S0006-3207(02)00104-0; Carlson A, 2000, P ROY SOC B-BIOL SCI, V267, P1311, DOI 10.1098/rspb.2000.1143; Ellner SP, 2003, ECOLOGY, V84, P882, DOI 10.1890/0012-9658(2003)084[0882:EOSDOM]2.0.CO;2; Feller W., 1971, INTRO PROBABILITY TH, V2; GULVE PS, 1994, ECOLOGY, V75, P1357, DOI 10.2307/1937460; Gyllenberg M, 1997, THEOR POPUL BIOL, V52, P198, DOI 10.1006/tpbi.1997.1333; Hanski I., 1999, METAPOPULATION ECOLO; HASTINGS A, 1994, ANNU REV ECOL SYST, V25, P167; HASTINGS A, 1991, BIOL J LINN SOC, V42, P57, DOI 10.1111/j.1095-8312.1991.tb00551.x; Johnson MP, 2000, P ROY SOC B-BIOL SCI, V267, P1967, DOI 10.1098/rspb.2000.1237; Johnson MP, 2000, OIKOS, V88, P67, DOI 10.1034/j.1600-0706.2000.880108.x; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; Lewis OT, 2001, CONSERV BIOL, V15, P389, DOI 10.1046/j.1523-1739.2001.015002389.x; Lindenmayer D, 2002, FOREST ECOL MANAG, V155, P319, DOI 10.1016/S0378-1127(01)00569-2; Lindenmayer DB, 2001, OIKOS, V92, P445, DOI 10.1034/j.1600-0706.2001.920306.x; Lindenmayer DB, 2001, J APPL ECOL, V38, P36, DOI 10.1046/j.1365-2664.2001.00558.x; NEE S, 1992, J ANIM ECOL, V61, P37, DOI 10.2307/5506; PAINE RT, 1981, ECOL MONOGR, V51, P145, DOI 10.2307/2937261; Poulsen BO, 2002, BIODIVERS CONSERV, V11, P1551, DOI 10.1023/A:1016839518172; PULLIAM HR, 1988, AM NAT, V132, P652, DOI 10.1086/284880; Richards SA, 1999, ECOL APPL, V9, P880, DOI 10.1890/1051-0761(1999)009[0880:OFMFMC]2.0.CO;2; Spence JR, 2001, TRENDS ECOL EVOL, V16, P591, DOI 10.1016/S0169-5347(01)02335-7; Stelter C, 1997, J ANIM ECOL, V66, P508, DOI 10.2307/5945; Wahlberg N, 2002, ECOGRAPHY, V25, P224, DOI 10.1034/j.1600-0587.2002.250210.x; Whitman AA, 1998, BIOTROPICA, V30, P449, DOI 10.1111/j.1744-7429.1998.tb00079.x	29	59	60	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1525	1526		10.1126/science.1087570	http://dx.doi.org/10.1126/science.1087570			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970563				2022-12-28	WOS:000185255300047
J	Luo, HBR; Huang, YE; Chen, JMC; Saiardi, A; Iijima, M; Ye, KQ; Huang, YF; Nagata, E; Devreotes, P; Snyder, SH				Luo, HBR; Huang, YE; Chen, JMC; Saiardi, A; Iijima, M; Ye, KQ; Huang, YF; Nagata, E; Devreotes, P; Snyder, SH			Inositol pyrophosphates mediate chemotaxis in Dictyostelium via pleckstrin homology domain-PtdIns (3,4,5)P3 interactions	CELL			English	Article							DIPHOSPHOINOSITOL PENTAKISPHOSPHATE; SACCHAROMYCES-CEREVISIAE; HEXAKISPHOSPHATE KINASE/; SIGNAL-TRANSDUCTION; TUMOR-SUPPRESSOR; EXCHANGE FACTOR; LEADING-EDGE; PROTEIN; BINDING; CELLS	Inositol phosphates are well-known signaling molecules, whereas the inositol pyrophosphates, such as diphosphoinositol pentakisphosphate (InsP7/IP7) and bis-diphosphoinositol tetrakisphosphate (InsP8/IP8), are less well characterized. We demonstrate physiologic regulation of Dictyostelium chemotaxis by InsP7 mediated by its competition with PtdIns(3,4,5)P3 for binding pleckstrin homology (PH) domain-containing proteins. Chemoattractant stimulation triggers rapid and sustained elevations in InsP7/InsP8 levels. Depletion of InsP7 and InsP8 by deleting the gene for InsP6 kinase (InsP6K/IP6K), which converts inositol hexakisphosphate (InsP6/IP6) to InsP7, causes rapid aggregation of mutant cells and increased sensitivity to cAMP. Chemotaxis is mediated by membrane translocation of certain PH domain-containing proteins via specific binding to PtdIns(3,4,5)P3. InsP7 competes for PH domain binding with PtdIns(3,4,5)P3 both in vitro and in vivo. InsP7 depletion enhances PH domain membrane translocation and augments downstream chemotactic signaling activity.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Emory University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.				NIDA NIH HHS [DA-00074] Funding Source: Medline; NIGMS NIH HHS [GM-28007] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028007, R01GM028007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; Caffrey JJ, 2000, J BIOL CHEM, V275, P12730, DOI 10.1074/jbc.275.17.12730; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Couchman JR, 2002, J BIOL CHEM, V277, P49296, DOI 10.1074/jbc.M209679200; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Devreotes P, 2003, J BIOL CHEM, V278, P20445, DOI 10.1074/jbc.R300010200; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; HUANG KN, 1995, GENETICS, V141, P1275; Huang YE, 2003, MOL BIOL CELL, V14, P1913, DOI 10.1091/mbc.E02-10-0703; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; KONIJN TM, 1970, EXPERIENTIA, V26, P367, DOI 10.1007/BF01896891; Laussmann T, 2000, EUR J BIOCHEM, V267, P2447, DOI 10.1046/j.1432-1327.2000.01264.x; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; Luo HR, 2001, NEURON, V31, P439, DOI 10.1016/S0896-6273(01)00384-1; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Mehrotra B, 1997, J BIOL CHEM, V272, P4237, DOI 10.1074/jbc.272.7.4237; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Saiardi A, 2001, J BIOL CHEM, V276, P39179, DOI 10.1074/jbc.M106842200; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; Williams RSB, 1999, EMBO J, V18, P2734, DOI 10.1093/emboj/18.10.2734; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	45	156	162	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					559	572		10.1016/S0092-8674(03)00640-8	http://dx.doi.org/10.1016/S0092-8674(03)00640-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678580	Bronze			2022-12-28	WOS:000185193100006
J	Wallace, A; Chinn, D; Rubin, G				Wallace, A; Chinn, D; Rubin, G			Taking simvastatin in the morning compared with in the evening: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article									Grangewood Surg, Houghton Le Spring DH4 4RB, Tyne & Wear, England; Univ Sunderland, Ctr Primary & Community Care, Sunderland SR2 7BW, Tyne & Wear, England	University of Sunderland	Wallace, A (corresponding author), Grangewood Surg, Houghton Le Spring DH4 4RB, Tyne & Wear, England.							Cilla DD, 1996, J CLIN PHARMACOL, V36, P604, DOI 10.1002/j.1552-4604.1996.tb04224.x; Kiortsis DN, 2000, J CLIN PHARM THER, V25, P445, DOI 10.1046/j.1365-2710.2000.00315.x; MIETTINEN TA, 1980, ANN CLIN RES, V12, P295; SAITO Y, 1991, ARTERIOSCLER THROMB, V11, P816, DOI 10.1161/01.ATV.11.4.816; 2001, BANDOLIER, V88, P7	5	54	54	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					788	788		10.1136/bmj.327.7418.788	http://dx.doi.org/10.1136/bmj.327.7418.788			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525878	Green Published, Bronze			2022-12-28	WOS:000185805100022
J	Womack, C; Jack, AL				Womack, C; Jack, AL			Family attitudes to research using samples taken at coroner's postmortem examinations: review of records	BRITISH MEDICAL JOURNAL			English	Article									Peterborough Dist Gen Hosp, Dept Cellular Pathol, Peterborough PE3 6DA, England		Womack, C (corresponding author), Peterborough Dist Gen Hosp, Dept Cellular Pathol, Peterborough PE3 6DA, England.							FORBES C, PSYCHOL ASPECTS ORGA; Jack AL, 2003, BRIT MED J, V327, P262, DOI 10.1136/bmj.327.7409.262; Padley DJ, 2003, TRANSPLANTATION, V76, P432, DOI 10.1097/01.TP.0000072780.66347.B1; *RET ORG COMM, QUAL RES EXPL PUBL P; Womack C, 2001, Cell Tissue Bank, V2, P51, DOI 10.1023/A:1011536420618	5	16	17	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					781	782		10.1136/bmj.327.7418.781	http://dx.doi.org/10.1136/bmj.327.7418.781			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525874	Green Published, Bronze			2022-12-28	WOS:000185805100018
J	Marenzi, G; Marana, I; Lauri, G; Assanelli, E; Grazi, M; Campodonico, J; Trabattoni, D; Fabbiocchi, F; Montorsi, P; Bartorelli, AL				Marenzi, G; Marana, I; Lauri, G; Assanelli, E; Grazi, M; Campodonico, J; Trabattoni, D; Fabbiocchi, F; Montorsi, P; Bartorelli, AL			The prevention of radiocontrast-agent-induced nephropathy by hemofiltration	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE-RENAL-FAILURE; PERCUTANEOUS CORONARY INTERVENTION; CONTRAST-MEDIA; RISK-FACTORS; INSUFFICIENCY; DOPAMINE; REVASCULARIZATION; ACETYLCYSTEINE; NEPHROTOXICITY; ANGIOPLASTY	BACKGROUND: Nephropathy induced by exposure to radiocontrast agents, a possible complication of percutaneous coronary interventions, is associated with significant in-hospital and long-term morbidity and mortality. Patients with preexisting renal failure are at particularly high risk. We investigated the role of hemofiltration, as compared with isotonic-saline hydration, in preventing contrast-agent-induced nephropathy in patients with renal failure. METHODS: We studied 114 consecutive patients with chronic renal failure (serum creatinine concentration, >2 mg per deciliter [176.8 micromol per liter]) who were undergoing coronary interventions. We randomly assigned them to either hemofiltration in an intensive care unit (ICU) (58 patients, with a mean [+/-SD] serum creatinine concentration of 3.0+/-1.0 mg per deciliter [265.2+/-88.4 micromol per liter]) or isotonic-saline hydration at a rate of 1 ml per kilogram of body weight per hour given in a step-down unit (56 patients, with a mean serum creatinine concentration of 3.1+/-1.0 mg per deciliter [274.0+/-88.4 micromol per liter]). Hemofiltration (fluid replacement rate, 1000 ml per hour without weight loss) and saline hydration were initiated 4 to 8 hours before the coronary intervention and were continued for 18 to 24 hours after the procedure was completed. RESULTS: An increase in the serum creatinine concentration of more than 25 percent from the base-line value after the coronary intervention occurred less frequently among the patients in the hemofiltration group than among the control patients (5 percent vs. 50 percent, P<0.001). Temporary renal-replacement therapy (hemodialysis or hemofiltration) was required in 25 percent of the control patients and in 3 percent of the patients in the hemofiltration group. The rate of in-hospital events was 9 percent in the hemofiltration group and 52 percent in the control group (P<0.001). In-hospital mortality was 2 percent in the hemofiltration group and 14 percent in the control group (P=0.02), and the cumulative one-year mortality was 10 percent and 30 percent, respectively (P=0.01). CONCLUSIONS: In patients with chronic renal failure who are undergoing percutaneous coronary interventions, periprocedural hemofiltration given in an ICU setting appears to be effective in preventing the deterioration of renal function due to contrast-agent-induced nephropathy and is associated with improved in-hospital and long-term outcomes.	Univ Milan, Ctr Cardiol Monzino, Ist Ric & Cura Carattere Sci, Inst Cardiol, I-20138 Milan, Italy	IRCCS Centro Cardiologico Monzino; University of Milan	Marenzi, G (corresponding author), Univ Milan, Ctr Cardiol Monzino, Ist Ric & Cura Carattere Sci, Inst Cardiol, Via Parea 4, I-20138 Milan, Italy.	giancarlo.marenzi@cardiologicomonzino.it	campodonico, jeness/AAC-2284-2022; Assanelli, Emilio/ABH-4902-2020; Bartorelli, Antonio Luca/ABG-9593-2020; Montorsi, Piero/ABG-9579-2020; Bartorelli, Antonio/K-3955-2018; Trabattoni, Daniela/AAE-6440-2021; Grazi, Marco/ABH-5946-2020	Trabattoni, Daniela/0000-0002-6319-4119; Grazi, Marco/0000-0003-1518-3199; Marenzi, Giancarlo/0000-0003-4410-4461				Abizaid AS, 1999, AM J CARDIOL, V83, P260, DOI 10.1016/S0002-9149(98)00833-9; Best PJM, 2002, J AM COLL CARDIOL, V39, P1113, DOI 10.1016/S0735-1097(02)01745-X; Briguori C, 2002, J AM COLL CARDIOL, V40, P298, DOI 10.1016/S0735-1097(02)01958-7; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Diaz-Sandoval LJ, 2002, AM J CARDIOL, V89, P356, DOI 10.1016/S0002-9149(01)02243-3; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Forni LG, 1997, NEW ENGL J MED, V336, P1303, DOI 10.1056/NEJM199705013361807; Gare M, 1999, J AM COLL CARDIOL, V34, P1682, DOI 10.1016/S0735-1097(99)00422-2; Gruberg L, 2000, J AM COLL CARDIOL, V36, P1542, DOI 10.1016/S0735-1097(00)00917-7; Gruberg L, 2001, CATHETER CARDIO INTE, V52, P409, DOI 10.1002/ccd.1093; Jungers P, 1997, NEPHROL DIAL TRANSPL, V12, P2597, DOI 10.1093/ndt/12.12.2597; Kini AS, 2002, CATHETER CARDIO INTE, V55, P169, DOI 10.1002/ccd.10038; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; Madyoon H, 2001, CATHETER CARDIO INTE, V53, P341, DOI 10.1002/ccd.1178; Marenzi G, 2003, CATHETER CARDIO INTE, V58, P59, DOI 10.1002/ccd.10373; Marenzi G, 2001, J AM COLL CARDIOL, V38, P963, DOI 10.1016/S0735-1097(01)01479-6; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; Morcos SK, 1998, BRIT J RADIOL, V71, P357, DOI 10.1259/bjr.71.844.9659127; Mueller C, 2002, ARCH INTERN MED, V162, P329, DOI 10.1001/archinte.162.3.329; Murphy SW, 2000, J AM SOC NEPHROL, V11, P177, DOI 10.1681/ASN.V111177; Murray P, 2000, AM J RESP CRIT CARE, V162, P777, DOI 10.1164/ajrccm.162.3.ncc400; PORTER GA, 1989, AM J CARDIOL, V64, pE22, DOI 10.1016/0002-9149(89)90730-3; RICH MW, 1990, ARCH INTERN MED, V150, P1237, DOI 10.1001/archinte.150.6.1237; Rihal CS, 2002, CIRCULATION, V105, P2259, DOI 10.1161/01.CIR.0000016043.87291.33; Rubenstein MH, 2000, CIRCULATION, V102, P2966; RUDNICK MR, 1995, KIDNEY INT, V47, P254, DOI 10.1038/ki.1995.32; Schindler R, 2001, NEPHROL DIAL TRANSPL, V16, P1471, DOI 10.1093/ndt/16.7.1471; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; Szczech LA, 2002, CIRCULATION, V105, P2253, DOI 10.1161/01.CIR.0000016051.33225.33; Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304; Ting HH, 2001, AM J CARDIOL, V87, P630, DOI 10.1016/S0002-9149(00)01442-9; Vogt B, 2001, AM J MED, V111, P692, DOI 10.1016/S0002-9343(01)00983-4	32	326	432	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1333	1340		10.1056/NEJMoa023204	http://dx.doi.org/10.1056/NEJMoa023204			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523141				2022-12-28	WOS:000185644000007
J	Tsai, AC				Tsai, AC			Policies to regulate gifts to physicians from industry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHARMACEUTICAL-INDUSTRY; PROMOTION		Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University	Tsai, AC (corresponding author), Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA.		Tsai, Alexander C./F-4247-2015	Tsai, Alexander C./0000-0001-6397-7917				CHREN MM, 1989, JAMA-J AM MED ASSOC, V262, P3448, DOI 10.1001/jama.262.24.3448; Dana J, 2003, JAMA-J AM MED ASSOC, V290, P252, DOI 10.1001/jama.290.2.252; GUYATT G, 1994, CAN MED ASSOC J, V150, P951; HANSON K, DIRECT CONSUMER ADVE; Jung P, 2002, HEALTH AFFAIR, V21, P226, DOI 10.1377/hlthaff.21.2.226; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; SEGLIN JL, 2002, NY TIMES        0818, pC4; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; Tenery RM, 2000, JAMA-J AM MED ASSOC, V283, P391, DOI 10.1001/jama.283.3.391; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; Wilkes MS, 2001, ACAD MED, V76, P1271, DOI 10.1097/00001888-200112000-00026	11	8	8	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1776	1776		10.1001/jama.290.13.1776	http://dx.doi.org/10.1001/jama.290.13.1776			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519716	Bronze			2022-12-28	WOS:000185606100031
J	Mazur, DJ				Mazur, DJ			Influence of the law on risk and informed consent	BRITISH MEDICAL JOURNAL			English	Article							MACARTHUR TREATMENT COMPETENCE	Patients are now routinely given information on risks of treatment as part of informed consent. This has occurred partly in response to legal judgments, but further issues continue to be raised by modern medicine and research that need to be approached proactively.	Dept Vet Affairs Med Ctr, Med Serv P3 MED, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; Oregon Health & Science University	Mazur, DJ (corresponding author), Dept Vet Affairs Med Ctr, Med Serv P3 MED, 3710 SW US Vet Hosp Rd, Portland, OR 97201 USA.							APPELBAUM PS, 1995, LAW HUMAN BEHAV, V19, P105, DOI 10.1007/BF01499321; Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313; Dresser R, 2001, IRB, V23, P1, DOI 10.2307/3563979; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P149, DOI 10.1007/BF01499323; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P127, DOI 10.1007/BF01499322; Horng S, 2002, NEW ENGL J MED, V347, P2134, DOI 10.1056/NEJMsa021182; Lidz CW, 2002, MED CARE, V40, P55, DOI 10.1097/01.MLR.0000023956.25813.18; National Commission for the Protection of Human Subjects of Biomedical and Be- havioural Research, 1978, BELM REP ETH GUID PR; Skene L, 2003, BMJ-BRIT MED J, V324, p39e41	9	33	33	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	2003	327	7417					731	734		10.1136/bmj.327.7417.731	http://dx.doi.org/10.1136/bmj.327.7417.731			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728FZ	14512484	Green Published			2022-12-28	WOS:000185708300024
J	Madec, R; Devincre, B; Kubin, L; Hoc, T; Rodney, D				Madec, R; Devincre, B; Kubin, L; Hoc, T; Rodney, D			The role of collinear interaction in dislocation-induced hardening	SCIENCE			English	Article							SINGLE-CRYSTALS; FLOW-STRESS; JUNCTIONS; STRENGTH; FOREST	We connected dislocation-based atomic-scale and continuum models of plasticity in crystalline solids through numerical simulations of dislocation intersections in face-centered cubic crystals. The results contradict the traditional assumption that strain hardening is governed by the formation of sessile junctions between dislocations. The interaction between two dislocations with collinear Burgers vectors gliding in intersecting slip planes was found to be by far the strongest of all reactions. Its properties were investigated and discussed using a multiscale approach.	CNRS, ONERA, UMR 104, Lab Etud Microstruct, F-92322 Chatillon, France; Ecole Cent Paris, Lab Mecan Sols Struct & Mat, CNRS, UMR 8579, F-92295 Chatenay Malabry, France; Ecole Natl Super Phys Grenoble, CNRS, UMR 5010, F-38402 St Martin Dheres, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); National Office for Aerospace Studies & Research (ONERA); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble	Kubin, L (corresponding author), CNRS, ONERA, UMR 104, Lab Etud Microstruct, 20 Ave Div Leclerc,BP 72, F-92322 Chatillon, France.	kubin@onera.fr	Rodney, David/I-1688-2012	Hoc, Thierry/0000-0001-7467-1462				Basinski S. J., 1979, Dislocations in solids, vol.IV. Dislocations in metallurgy, P261; BASSANI JL, 1991, P ROY SOC LOND A MAT, V435, P21, DOI 10.1098/rspa.1991.0128; Bulatov V, 1998, NATURE, V391, P669, DOI 10.1038/35577; FRANCIOSI P, 1980, ACTA METALL MATER, V28, P273, DOI 10.1016/0001-6160(80)90162-5; Friedel J., 1967, DISLOCATIONS; GilSevillano J., 1993, MAT SCI FORUM, V113, P19, DOI [10.4028/www.scientific.net/MSF.113-115.19, DOI 10.4028/WWW.SCIENTIFIC.NET/MSF.113-115.19]; Hansen N, 1998, ACTA MATER, V46, P1827, DOI 10.1016/S1359-6454(97)00365-0; JACKSON PJ, 1985, PROG MATER SCI, V29, P139, DOI 10.1016/0079-6425(85)90009-X; Madec R, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.255508; Mills MJL, 2011, COMPUT THEOR CHEM, V975, P42, DOI 10.1016/j.comptc.2011.04.004; Rodney D, 1999, PHYS REV LETT, V82, P1704, DOI 10.1103/PhysRevLett.82.1704; SAADA G, 1960, ACTA METALL, V8, P441; SCHOECK G, 1972, PHYS STATUS SOLIDI B, V53, P661, DOI 10.1002/pssb.2220530227; Shenoy VB, 2000, PHYS REV LETT, V84, P1491, DOI 10.1103/PhysRevLett.84.1491; Stach EA, 2000, PHILOS MAG A, V80, P2159, DOI 10.1080/01418610008212156; Stach EA, 2000, PHYS REV LETT, V84, P947, DOI 10.1103/PhysRevLett.84.947; Wickham LK, 1999, PHYS REV LETT, V83, P4574, DOI 10.1103/PhysRevLett.83.4574	17	255	258	5	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1879	1882		10.1126/science.1085477	http://dx.doi.org/10.1126/science.1085477			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512620				2022-12-28	WOS:000185536700042
J	Nam, JM; Thaxton, CS; Mirkin, CA				Nam, JM; Thaxton, CS; Mirkin, CA			Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins	SCIENCE			English	Article							PROSTATE-SPECIFIC ANTIGEN; POLYMERASE-CHAIN-REACTION; IMMUNO-PCR; DNA; ASSAY; TIME; AMPLIFICATION; DIAGNOSIS	An ultrasensitive method for detecting protein analytes has been developed. The system relies on magnetic microparticle probes with antibodies that specifically bind a target of interest [prostate-specific antigen (PSA) in this case] and nanoparticle probes that are encoded with DNA that is unique to the protein target of interest and antibodies that can sandwich the target captured by the microparticle probes. Magnetic separation of the complexed probes and target followed by dehybridization of the oligonucleotides on the nanoparticle probe surface allows the determination of the presence of the target protein by identifying the oligonucleotide sequence released from the nanoparticle probe. Because the nanoparticle probe carries with it a large number of oligonucleotides per protein binding event, there is substantial amplification and PSA can be detected at 30 attomolar concentration. Alternatively, a polymerase chain reaction on the oligonucleotide bar codes can boost the sensitivity to 3 attomolar. Comparable clinically accepted conventional assays for detecting the same target have sensitivity limits of similar to3 picomdar, six orders of magnitude less sensitive than what is observed with this method.	Northwestern Univ, Dept Chem, Evanston, IL 60201 USA; Northwestern Univ, Inst Nanotechnol, Evanston, IL 60201 USA	Northwestern University; Northwestern University	Mirkin, CA (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60201 USA.		Abrams, William R/A-5782-2008; Mirkin, Chad A/E-3911-2010; Nam, Jwa-Min/F-2062-2019	Nam, Jwa-Min/0000-0002-7891-8482; Mirkin, Chad/0000-0002-6634-7627				Black MH, 2000, CLIN CANCER RES, V6, P467; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536; Demers LM, 2000, ANAL CHEM, V72, P5535, DOI 10.1021/ac0006627; Ferguson RA, 1996, CLIN CHEM, V42, P675; GIBBS RA, 1991, CURR OPIN BIOTECH, V2, P69, DOI 10.1016/0958-1669(91)90063-B; Haab BB, 2001, GENOME BIOL, V2; HENDRICKSON ER, 1995, NUCLEIC ACIDS RES, V23, P522, DOI 10.1093/nar/23.3.522; MacBeath G, 2000, SCIENCE, V289, P1760; McKie A, 2002, J IMMUNOL METHODS, V270, P135, DOI 10.1016/S0022-1759(02)00325-3; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Nam JM, 2002, J AM CHEM SOC, V124, P3820, DOI 10.1021/ja0178766; Niemeyer CM, 1999, NUCLEIC ACIDS RES, V27, P4553, DOI 10.1093/nar/27.23.4553; Niemeyer CM, 2002, TRENDS BIOTECHNOL, V20, P395, DOI 10.1016/S0167-7799(02)02022-X; Ries LA, 2002, SEER CANC STAT REV 1; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758; Schweitzer B, 2000, P NATL ACAD SCI USA, V97, P10113, DOI 10.1073/pnas.170237197; STANFORD JL, 1999, NIH PUBLICATION; Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757; YU H, 1995, CLIN CHEM, V41, P430; ZHOU H, 1993, NUCLEIC ACIDS RES, V21, P6038, DOI 10.1093/nar/21.25.6038; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	23	2142	2302	23	937	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1884	1886		10.1126/science.1088755	http://dx.doi.org/10.1126/science.1088755			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512622				2022-12-28	WOS:000185536700044
J	Coureux, PD; Wells, AL; Menetry, J; Yengo, CM; Morris, CA; Sweeney, HL; Houdusse, A				Coureux, PD; Wells, AL; Menetry, J; Yengo, CM; Morris, CA; Sweeney, HL; Houdusse, A			A structural state of the myosin V motor without bound nucleotide	NATURE			English	Article							SMOOTH-MUSCLE MYOSIN; X-RAY STRUCTURES; CRYSTAL-STRUCTURE; LIGHT-CHAIN; ACTIN; BINDING; SUBFRAGMENT-1; DOMAIN; DELETION; CLOSURE	The myosin superfamily of molecular motors use ATP hydrolysis and actin-activated product release to produce directed movement and force(1). Although this is generally thought to involve movement of a mechanical lever arm attached to a motor core(1,2), the structural details of the rearrangement in myosin that drive the lever arm motion on actin attachment are unknown. Motivated by kinetic evidence that the processive unconventional myosin, myosin V, populates a unique state in the absence of nucleotide and actin, we obtained a 2.0 Angstrom structure of a myosin V fragment. Here we reveal a conformation of myosin without bound nucleotide. The nucleotide-binding site has adopted new conformations of the nucleotide-binding elements that reduce the affinity for the nucleotide. The major cleft in the molecule has closed, and the lever arm has assumed a position consistent with that in an actomyosin rigor complex. These changes have been accomplished by relative movements of the subdomains of the molecule, and reveal elements of the structural communication between the actin-binding interface and nucleotide-binding site of myosin that underlie the mechanism of chemo-mechanical transduction.	CNRS, UMR 144, Inst Curie, F-75248 Paris 05, France; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; University of Pennsylvania	Houdusse, A (corresponding author), CNRS, UMR 144, Inst Curie, 26 Rue Ulm, F-75248 Paris 05, France.	lsweeney@mail.med.upenn.edu; anne.houdusse@curie.fr	Sweeney, H Lee/F-1862-2010; Ménétrey, Julie/AAM-6408-2021					BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer CB, 2000, J BIOL CHEM, V275, P38494, DOI 10.1074/jbc.M005585200; COATES JH, 1985, BIOCHEM J, V232, P351, DOI 10.1042/bj2320351; De la Cruz EM, 2000, BIOCHEMISTRY-US, V39, P14196, DOI 10.1021/bi001701b; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Houdusse A, 2001, CURR OPIN STRUC BIOL, V11, P182, DOI 10.1016/S0959-440X(00)00188-3; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; Joel PB, 2001, J BIOL CHEM, V276, P2998, DOI 10.1074/jbc.M006930200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kollmar M, 2002, EMBO J, V21, P2517, DOI 10.1093/emboj/21.11.2517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sasaki N, 1999, J BIOL CHEM, V274, P37840, DOI 10.1074/jbc.274.53.37840; Sasaki N, 2000, J BIOL CHEM, V275, P38705, DOI 10.1074/jbc.M001966200; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; Titus MA, 1997, CURR BIOL, V7, pR301, DOI 10.1016/S0960-9822(06)00143-6; Volkmann N, 2000, NAT STRUCT BIOL, V7, P1147; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Yengo CM, 2002, J BIOL CHEM, V277, P24114, DOI 10.1074/jbc.M111253200; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u	30	238	239	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					419	423		10.1038/nature01927	http://dx.doi.org/10.1038/nature01927			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508494				2022-12-28	WOS:000185502300046
J	Maddox, J				Maddox, J			Edward Teller (1908-2003) - Obituary	NATURE			English	Biographical-Item																			0	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					362	363		10.1038/425362a	http://dx.doi.org/10.1038/425362a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508475				2022-12-28	WOS:000185502300028
J	Solomon, TH; Mezic, I				Solomon, TH; Mezic, I			Uniform resonant chaotic mixing in fluid flows	NATURE			English	Article							VOLUME-PRESERVING FLOWS; IMMISCIBLE IMPURITIES; STOKES FLOWS; ADVECTION; TRANSPORT; INVARIANT; STREAMLINES; CONVECTION; PARTICLES; MAPS	Laminar flows can produce particle trajectories that are chaotic(1,2), with nearby tracers separating exponentially in time. For time-periodic, two-dimensional flows and steady three-dimensional (3D) flows, enhancements in mixing due to chaotic advection are typically limited by impenetrable transport barriers that form at the boundaries between ordered and chaotic mixing regions. However, for time-dependent 3D flows, it has been proposed theoretically(3-5) that completely uniform mixing is possible through a resonant mechanism 5 called singularity-induced diffusion; this is thought to be the case even if the time-dependent and 3D perturbations are infinitesimally small. It is important to establish the conditions for which uniform mixing is possible and whether or not those conditions are met in flows that typically occur in nature. Here we report experimental and numerical studies of mixing in a laminar vortex flow that is weakly 3D and weakly time-periodic. The system is an oscillating horizontal vortex chain (produced by a magnetohydrodynamic technique) with a weak vertical secondary flow that is forced spontaneously by Ekman pumping-a mechanism common in vortical flows with rigid boundaries, occurring in many geophysical, industrial and biophysical flows. We observe completely uniform mixing, as predicted(3-5) by singularity-induced diffusion, but only for oscillation periods close to typical circulation times.	Bucknell Univ, Dept Phys, Lewisburg, PA 17837 USA; Univ Calif Santa Barbara, Dept Mech & Environm Engn, Santa Barbara, CA 93106 USA	Bucknell University; University of California System; University of California Santa Barbara	Mezic, I (corresponding author), Bucknell Univ, Dept Phys, Lewisburg, PA 17837 USA.		Mezic, Igor/R-9659-2018	Mezic, Igor/0000-0002-2873-9013; Solomon, Thomas/0000-0001-9008-0769				AREF H, 1984, J FLUID MECH, V143, P1, DOI 10.1017/S0022112084001233; Aref H, 1999, NATURE, V401, P756, DOI 10.1038/44495; ASHWIN P, 1995, J FLUID MECH, V285, P215, DOI 10.1017/S0022112095000528; BAJER K, 1990, J FLUID MECH, V212, P337, DOI 10.1017/S0022112090001999; BEHRINGER RP, 1991, PHYS FLUIDS A-FLUID, V3, P1243, DOI 10.1063/1.858052; Cartwright JHE, 1996, J FLUID MECH, V316, P259, DOI 10.1017/S0022112096000535; CHANDRASEKHA S, 1961, HYDRODYNAMIC HYDROMA, P39; CLEVER RM, 1974, J FLUID MECH, V65, P625, DOI 10.1017/S0022112074001571; Cussler E.L., 2009, DIFFUSION MASS TRANS; FEINGOLD M, 1988, J STAT PHYS, V50, P529, DOI 10.1007/BF01026490; Fountain GO, 1998, SCIENCE, V281, P683, DOI 10.1126/science.281.5377.683; Fountain GO, 2000, J FLUID MECH, V417, P265, DOI 10.1017/S002211200000118X; HENON M, 1966, CR ACAD SCI A MATH, V262, P312; HOLM DD, 1991, PHYS FLUIDS A-FLUID, V3, P1033, DOI 10.1063/1.858083; Karolyi G, 2000, P NATL ACAD SCI USA, V97, P13661, DOI 10.1073/pnas.240242797; MACKAY RS, 1994, J NONLINEAR SCI, V4, P329, DOI 10.1007/BF02430637; Mezic I, 2001, PHYSICA D, V154, P51, DOI 10.1016/S0167-2789(01)00226-3; PIERREHUMBERT RT, 1991, PHYS FLUIDS A-FLUID, V3, P1250, DOI 10.1063/1.858053; ROMKEDAR V, 1990, J FLUID MECH, V214, P347, DOI 10.1017/S0022112090000167; Shinbrot T, 2001, PHYS REV LETT, V86, P1207, DOI 10.1103/PhysRevLett.86.1207; SOLOMON TH, 1988, PHYS REV A, V38, P6280, DOI 10.1103/PhysRevA.38.6280; Solomon TH, 1996, PHYS REV LETT, V77, P2682, DOI 10.1103/PhysRevLett.77.2682; Solomon TH, 1998, PHYS FLUIDS, V10, P342, DOI 10.1063/1.869526; Sotiropoulos F, 2001, J FLUID MECH, V444, P257, DOI 10.1017/S0022112001005286; STONE HA, 1991, J FLUID MECH, V232, P629, DOI 10.1017/S002211209100383X; Stroock AD, 2002, SCIENCE, V295, P647, DOI 10.1126/science.1066238; Swanson PD, 1996, INT J PHARM, V142, P33, DOI 10.1016/0378-5173(96)04643-1; Vainshtein DL, 1996, CHAOS, V6, P67, DOI 10.1063/1.166151; [No title captured]	30	103	106	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					376	380		10.1038/nature01993	http://dx.doi.org/10.1038/nature01993			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508482				2022-12-28	WOS:000185502300034
J	Aiken, LH; Clarke, SP; Cheung, RB; Sloane, DM; Silber, JH				Aiken, LH; Clarke, SP; Cheung, RB; Sloane, DM; Silber, JH			Educational levels of hospital nurses and surgical patient mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTCOMES; QUALITY; RATES; CARE	Context Growing evidence suggests that nurse staffing affects the quality of care in hospitals, but little is known about whether the educational composition of registered nurses (RNs) in hospitals is related to patient outcomes. Objective To examine whether the proportion of hospital RNs educated at the baccalaureate level or higher is associated with risk-adjusted mortality and failure to rescue (deaths in surgical patients with serious complications). Design, Setting, and Population Cross-sectional analyses of outcomes data for 232342 general, orthopedic, and vascular surgery patients discharged from 168 nonfederal adult general Pennsylvania hospitals between April 1, 1998, and November 30, 1999, linked to administrative and survey data providing information on educational composition, staffing, and other characteristics. Main Outcome Measures Risk-adjusted patient mortality and failure to rescue within 30 days of admission associated with nurse educational level. Results The proportion of hospital RNs holding a bachelor's degree or higher ranged from 0% to 77% across the hospitals. After adjusting for patient characteristics and hospital structural characteristics (size, teaching status, level of technology), as well as for nurse staffing, nurse experience, and whether the patient's surgeon was board certified, a 10% increase in the proportion of nurses holding a bachelor's degree was associated with a 5% decrease in both the likelihood of patients dying within 30 days of admission and the odds of failure to rescue (odds ratio, 0.95; 95% confidence interval, 0.91-0.99 in both cases). Conclusion in hospitals with higher proportions of nurses educated at the baccalaureate level or higher, surgical patients experienced lower mortality and failure-to-rescue rates.	Univ Penn, Ctr Hlth Outcomes & Policy Res, Sch Nursing, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Dept Sociol, Ctr Populat Studies, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Anesthesia, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Aiken, LH (corresponding author), Univ Penn, Ctr Hlth Outcomes & Policy Res, Sch Nursing, 420 Guardian Dr, Philadelphia, PA 19104 USA.	laiken@nursing.upenn.edu		Clarke, Sean/0000-0003-3063-762X	NINR NIH HHS [R01NR04513, R01 NR004513-05, R01 NR004513] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR004513] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987; *AM ASS COLL NURS, 2002, ENR RIS US NURS COLL; *AM BOARD MED SPEC, 2000, OFF ABMS DIR BOARD C; *AM HOSP ASS, 1999, HOSP STAT 1999 ED; American Nurses Association, 2000, NURS STAFF PAT OUTC; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Bishop YM., 2007, DISCRETE MULTIVARIAT; Blegen MA, 1998, NURS RES, V47, P43, DOI 10.1097/00006199-199801000-00008; Blegen MA, 2001, J NURS ADMIN, V31, P33, DOI 10.1097/00005110-200101000-00007; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; Buerhaus PI, 2000, JAMA-J AM MED ASSOC, V283, P2948, DOI 10.1001/jama.283.22.2948; Clarke SP, 2003, AM J NURS, V103, P42, DOI 10.1097/00000446-200301000-00020; Goode CJ, 2001, J NURS ADMIN, V31, P55, DOI 10.1097/00005110-200102000-00002; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; Hickam DH, 2003, AHRQ PUBLICATION; Iezzoni LI, 1997, RISK ADJUSTMENT MEAS; JOHNSON JH, 1988, RES NURS HEALTH, V11, P183, DOI 10.1002/nur.4770110307; Kovner C, 1998, Image J Nurs Sch, V30, P315, DOI 10.1111/j.1547-5069.1998.tb01326.x; Minnick AF, 1997, MED CARE, V35, P399, DOI 10.1097/00005650-199704000-00009; *NAT ADV COUNC NUR, 1996, REP SECR DEP HLTH HU; *NAT COUNC STAT BO, ANN REP 2001; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; *PA DEP HLTH DIV S, 1999, HOSP QUEST REP PER J; Pew Health Professions Commission,, 1998, RECR HLTH PROF PRACT; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Silber JH, 1997, MED CARE, V35, pOS77, DOI 10.1097/00005650-199710001-00011; Silber JH, 2000, ANESTHESIOLOGY, V93, P152, DOI 10.1097/00000542-200007000-00026; Silber JH, 2002, ANESTHESIOLOGY, V96, P1044, DOI 10.1097/00000542-200205000-00004; SILBER JH, 1995, JAMA-J AM MED ASSOC, V274, P317, DOI 10.1001/jama.274.4.317; Silber JH, 2001, MED CARE, V39, P1048, DOI 10.1097/00005650-200110000-00003; Unruh L, 2003, MED CARE, V41, P142, DOI 10.1097/00005650-200301000-00016; *US DEP HHS, 1992, 554872 USDHHS; *US DEP HHS, 1981, SOURC BOOK NURS PERS; *US DEP HHS, 2000, REG NURS POP FIND NA; *US DEP HHS, 1990, 7 US DEP HLTH HUM SE; Young W B, 1991, Image J Nurs Sch, V23, P105	36	1036	1061	0	73	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	2003	290	12					1617	1623		10.1001/jama.290.12.1617	http://dx.doi.org/10.1001/jama.290.12.1617			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	723ZK	14506121	Green Accepted			2022-12-28	WOS:000185461300027
J	Winickoff, DE; Winickoff, RN				Winickoff, DE; Winickoff, RN			The charitable trust as a model for genomic biobanks	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INFORMED CONSENT; TISSUE		Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard University; Massachusetts General Hospital	Winickoff, DE (corresponding author), Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA.							Annas GJ, 2000, NEW ENGL J MED, V342, P1830, DOI 10.1056/NEJM200006153422412; Annas GJ, 2001, JAMA-J AM MED ASSOC, V286, P2326, DOI 10.1001/jama.286.18.2326; Ashburn TT, 2000, ARCH INTERN MED, V160, P3377, DOI 10.1001/archinte.160.22.3377; Barnes M, 2002, J LAW MED ETHICS, V30, P390, DOI 10.1111/j.1748-720X.2002.tb00408.x; Beskow LM, 2001, JAMA-J AM MED ASSOC, V286, P2315, DOI 10.1001/jama.286.18.2315; BOGERT GG, 1992, LAW TRUSTS TRUSTEES, P323; CONNOLLY A, 2002, BOSTON BUSINESS 1122; Eiseman E., 1999, HDB HUMAN TISSUE SOU; Faden Ruth R., 1986, HIST THEORY INFORMED, P151; GOTTLIEB K, 1998, STORED TISSUE SAMPLE; Greely H T, 1999, Wake Forest Law Rev, V34, P737; Greely H T, 1997, Houst Law Rev, V33, P1397; Harrison CH, 2002, AM J LAW MED, V28, P77; Jeffers BR, 2001, ADV NURS SCI, V24, P32, DOI 10.1097/00012272-200112000-00005; Kaiser J, 2002, SCIENCE, V298, P1158, DOI 10.1126/science.298.5596.1158; KOLATA G, 2000, NY TIMES        0317, pA1; Malone T, 2002, J NATL CANCER I, V94, P769; *NAT BIOETH ADV CO, 2001, ETH POL ISS RES INV, pR17; *NAT RES COUNC COM, 1997, EV HUM GEN DIV; National Bioethics Advisory Commission, 1999, RES INV HUM BIOL MAT; Nelkin D, 1998, HASTINGS CENT REP, V28, P30, DOI 10.2307/3528230; *OFF INSP GEN, 1998, I REV BOARDS EM IND; *OFF INSP GEN, 1998, I REV BOARDS TIM REF; Olden K, 2000, NAT REV GENET, V1, P149, DOI 10.1038/35038586; Rose Hilary, 2001, COMMODIFICATION BIOI; Rosenberg R., 2001, BOSTON GLOBE    0221, pD4; Rothstein MA, 2002, J LAW MED ETHICS, V30, P105, DOI 10.1111/j.1748-720X.2002.tb00726.x; Shalala D, 2000, NEW ENGL J MED, V343, P808, DOI 10.1056/NEJM200009143431112; Singer Joseph, 2000, ENTITLEMENT PARADOXE, p[29, 38]; Smaglik P, 2000, NATURE, V407, P821, DOI 10.1038/35038209; Steinbrook R, 2002, NEW ENGL J MED, V346, P1842, DOI 10.1056/NEJMp020046; Steinbrook R, 2002, NEW ENGL J MED, V346, P1425, DOI 10.1056/NEJM200205023461828; Winickoff David E, 2003, Jurimetrics, V43, P187	33	141	141	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1180	1184		10.1056/NEJMsb030036	http://dx.doi.org/10.1056/NEJMsb030036			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	722HQ	13679534				2022-12-28	WOS:000185369700014
J	O'Connor, CM; Dunne, MW; Pfeffer, MA; Muhlestein, JB; Yao, L; Gupta, S; Benner, RJ; Fisher, MR; Cook, TD				O'Connor, CM; Dunne, MW; Pfeffer, MA; Muhlestein, JB; Yao, L; Gupta, S; Benner, RJ; Fisher, MR; Cook, TD		Investigators WIZARD Study	Azithromycin for the secondary prevention of coronary heart disease events - The WIZARD study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	51st Annual Scientific Session of the American-College-of-Cardiology	MAR 17-20, 2002	ATLANTA, GA	Amer Coll Cardiol			CHLAMYDIA-PNEUMONIAE INFECTION; ACUTE MYOCARDIAL-INFARCTION; ARTERY-DISEASE; RABBIT MODEL; ATHEROSCLEROSIS; TWAR; ASSOCIATION; ANTIBODIES; ADULTS	Context Several lines of evidence have implied an association between Chlamydia pneumoniae infection and atherogenesis. Objective To determine the effect of 12 weeks of antibiotic therapy on coronary heart disease events in patients with stable coronary artery disease and known C pneumoniae exposure. Design, Setting, and Participants Randomized, placebo-controlled trial of 7747 adults with previous myocardial infarction that had occurred at least 6 weeks previously (median, 2.6 years) and a C pneumoniae IgG titer of 1:16 or more. Patients were recruited from 271 clinical practices in North America, Europe, Argentina, and India, from October 10, 1997, to July 22, 2001. Intervention The patients received either azithromycin (600 mg/d for 3 days during week 1, then 600 mg/wk during weeks 2-12; n = 3879) or placebo (n = 3868). Main Outcome Measures The primary event was the first occurrence of death from any cause, nonfatal reinfarction, coronary revascularization, or hospitalization for angina. Patients were followed up until 1038 events accrued. Results After a median of 14 months of follow-up, there was no significant risk reduction in the likelihood of a primary event with azithromycin vs placebo (7% [95% confidence interval, -5% to 17%], P=.23). Analysis of hazard ratios suggested early benefits of azithromycin on the primary event and on death or reinfarction, but these decreased over time. There were no significant risk reductions for any of the components of the primary end point including death (8%), recurrent myocardial infarction (7%), revascularization procedures (5%), or hospitalizations for angina (-1%). Adverse events related to study drug were reported by 13.2% of those randomized to receive azithromycin, predominantly a result of diarrhea, compared with 4.6% randomized to receive placebo, and resulted in discontinuation of drug in 1.6% of those taking azithromycin and 0.4% taking placebo. Conclusion Among stable patients with previous myocardial infarction and with evidence of C pneumoniae exposure, a 3-month course of azithromycin did not significantly reduce the clinical sequelae of coronary heart disease.	Pfizer Global Res & Dev, New London, CT 06320 USA; Duke Univ, Durham, NC USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Univ Utah, Latter Day St Hosp, Salt Lake City, UT 84143 USA; Whipps Cross & St Bartholomews Hosp, London, England; Univ Wisconsin, Madison, WI USA	Pfizer; Duke University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Utah System of Higher Education; University of Utah; University of Wisconsin System; University of Wisconsin Madison	Dunne, MW (corresponding author), Pfizer Global Res & Dev, 50 Pequot Ave, New London, CT 06320 USA.	michael_w_dunne@groton.pfizer.com	Dunne, Michael W/AAD-7418-2020	Dunne, Michael W/0000-0001-6186-5196				ANDERSON JL, 1998, CLIN CARDIOL, V21, P429; Barron HV, 2000, CIRCULATION, V102, P2329, DOI 10.1161/01.CIR.102.19.2329; Blessing E, 2000, INFECT IMMUN, V68, P4765, DOI 10.1128/IAI.68.8.4765-4768.2000; DAHLEN GH, 1995, ATHEROSCLEROSIS, V114, P165, DOI 10.1016/0021-9150(94)05480-7; Dunne M, 2000, CURR OPIN INFECT DIS, V13, P583, DOI 10.1097/00001432-200012000-00002; Dunne MW, 2000, J INFECT DIS, V181, pS572, DOI 10.1086/315634; Espinola-Klein C, 2002, CIRCULATION, V105, P15, DOI 10.1161/hc0102.101362; Fong IW, 1997, J CLIN MICROBIOL, V35, P48, DOI 10.1128/JCM.35.1.48-52.1997; GRAYSTON JT, 1992, CLIN INFECT DIS, V15, P757, DOI 10.1093/clind/15.5.757; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; Hu H, 1999, J CLIN INVEST, V103, P747, DOI 10.1172/JCI4582; Jackson LA, 2000, J INFECT DIS, V181, pS579, DOI 10.1086/315628; JUDE B, 1994, CIRCULATION, V90, P1662, DOI 10.1161/01.CIR.90.4.1662; Knoebel E, 1997, INFECT IMMUN, V65, P503, DOI 10.1128/IAI.65.2.503-506.1997; KUO CC, 1995, P NATL ACAD SCI USA, V92, P6911, DOI 10.1073/pnas.92.15.6911; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lindmark E, 2001, JAMA-J AM MED ASSOC, V286, P2107, DOI 10.1001/jama.286.17.2107; Liu L, 2000, MOL CELL BIOCHEM, V215, P123, DOI 10.1023/A:1026531506202; Muhlestein JB, 2000, CIRCULATION, V102, P1755; Muhlestein JB, 1998, CIRCULATION, V97, P633, DOI 10.1161/01.CIR.97.7.633; Parchure N, 2002, CIRCULATION, V105, P1298, DOI 10.1161/hc1102.105649; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; Sinisalo J, 2002, CIRCULATION, V105, P1555, DOI 10.1161/01.CIR.0000012544.07696.1F; Siscovick DS, 2000, CIRCULATION, V102, P2335, DOI 10.1161/01.CIR.102.19.2335; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	27	247	260	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1459	1466		10.1001/jama.290.11.1459	http://dx.doi.org/10.1001/jama.290.11.1459			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	721RE	13129985				2022-12-28	WOS:000185329000027
J	Bertomeu, A; Garcia-Vidal, O; Farre, X; Galobart, A; Vazquez, M; Laguna, JC; Ros, E				Bertomeu, A; Garcia-Vidal, O; Farre, X; Galobart, A; Vazquez, M; Laguna, JC; Ros, E			Preclinical coronary atherosclerosis in a population with low incidence of myocardial infarction: cross sectional autopsy study	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE MORTALITY		Inst Med Legal Catalunya, E-08911 Badalona, Spain; Hosp St Jaume, E-08370 Barcelona, Spain; Ctr Nacl Invest Oncol, E-28029 Madrid, Spain; Hosp Municipal Badalona, E-08911 Badalona, Spain; Univ Barcelona, Fac Farm, Dept Farmacol, E-08028 Barcelona, Spain; Inst Invest Biomed August Pi & Sunyer, Serv Nutr & Dietet, Unidad Lipidos, E-08036 Barcelona, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bertomeu, A (corresponding author), Inst Med Legal Catalunya, C Prim 32-40, E-08911 Badalona, Spain.		Vázquez-Carrera, Manuel/H-2612-2015; Laguna, JCLaguna - Juan C./C-5481-2017; Farré, Xavier/M-9768-2014	Vázquez-Carrera, Manuel/0000-0001-7138-8207; Laguna, JCLaguna - Juan C./0000-0002-7082-0704; Farré, Xavier/0000-0001-8702-4643; Ros, Emilio/0000-0002-2573-1294				ALVAREZ FV, 2003, ENFERMEDADES CARDIOV; Law M, 1999, BRIT MED J, V318, P1471, DOI 10.1136/bmj.318.7196.1471; MARRUGAT J, 1998, CARDIOVASCULAR RISK, V8, P196; McGill HC, 2000, AM J CLIN NUTR, V72, p1307S, DOI 10.1093/ajcn/72.5.1307s; Tunstall-Pedoe H, 2000, LANCET, V355, P688, DOI 10.1016/S0140-6736(99)11181-4	5	21	21	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					591	592		10.1136/bmj.327.7415.591	http://dx.doi.org/10.1136/bmj.327.7415.591			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969923	Bronze, Green Published			2022-12-28	WOS:000185358700019
J	Mudelsee, M; Borngen, M; Tetzlaff, G; Grunewald, U				Mudelsee, M; Borngen, M; Tetzlaff, G; Grunewald, U			No upward trends in the occurrence of extreme floods in central Europe	NATURE			English	Article							EVENTS; CLIMATE	Extreme river floods have been a substantial natural hazard in Europe over the past centuries(1), and radiative effects of recent anthropogenic changes in atmospheric composition are expected to cause climate changes, especially enhancement of the hydrological cycle(2), leading to an increased flood risk(3,4). For the past few decades, however, observations from Europe(1,5-7) do not show a clear increase in flood occurrence rate. Here we present longer-term records of winter and summer floods in two of the largest rivers in central Europe, the Elbe and Oder rivers. For the past 80 to 150 yr, we find a decrease in winter flood occurrence in both rivers, while summer floods show no trend, consistent with trends in extreme precipitation occurrence. The reduction in winter flood occurrence can partly be attributed to fewer events of strong freezing-following such events, breaking river ice at the end of the winter may function as a water barrier and enhance floods severely. Additionally, we detect significant long-term changes in flood occurrence rates in the sixteenth to nineteenth centuries, and conclude that reductions in river length, construction of reservoirs and deforestation have had minor effects on flood frequency.	Univ Leipzig, Inst Meteorol, D-04103 Leipzig, Germany; Tech Univ Cottbus, Inst Hydrol, D-03103 Cottbus, Germany	Leipzig University; Brandenburg University of Technology Cottbus	Mudelsee, M (corresponding author), Boston Univ, Dept Earth Sci, 685 Commonwealth Ave, Boston, MA 02215 USA.		Mudelsee, Manfred/C-6063-2018	Mudelsee, Manfred/0000-0002-2364-9561				Brazdil R, 1999, CLIMATIC CHANGE, V43, P239, DOI 10.1023/A:1005550401857; BRONSTERT A, 2000, P EUR C ADV FLOOD RE; *BUND GEW, 2000, UNT ABFL ELB; *BUR AUSSCH UNT WA, 1896, OD SEIN STROMG SEIN; Christensen JH, 2003, NATURE, V421, P805, DOI 10.1038/421805a; Cowling A, 1996, J AM STAT ASSOC, V91, P1516, DOI 10.2307/2291577; Cox DR, 1966, STAT ANAL SERIES EVE; Disse M, 2001, NAT HAZARDS, V23, P271, DOI 10.1023/A:1011142402374; Fischer Helene, 2001, BMC Physiology, V1, P1, DOI 10.1186/1472-6793-1-1; Folland CK, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P99; Giorgi F, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P583; Glaser R, 2001, KLIMAGESCHICHTE MITT; Grunewald U, 1998, URSACHEN VERLAUF FOL; Helms M., 2002, MORPHODYNAMIK ELBE, P91; Hulme M, 1998, GEOPHYS RES LETT, V25, P3379, DOI 10.1029/98GL02562; *KON ELBSTR, 1898, ELBSTR SEIN STROMG S; *KON ELBSTR BAUV, 1893, HYDR JB ELB 1892; Luterbacher J, 2001, CLIMATIC CHANGE, V49, P441, DOI 10.1023/A:1010667524422; MILITZER S, 1998, KLIMA UMWELT MENSCH; MUDELSEE M, 2002, SCI REPORTS, V26, P149; *OD, 1907, MITT OD STROMB WASS; Palmer TN, 2002, NATURE, V415, P512, DOI 10.1038/415512a; Potzsch C.G., 1784, CHRONOLOGISCHE GESCH; Robson AJ, 2002, PHILOS T ROY SOC A, V360, P1327, DOI 10.1098/rsta.2002.1003; SCHAFER W, 1848, CHRONIK DRESDENER EL; Schmidt M., 2000, HOCHWASSER HOCHWASSE; Sturm K., 2001, PETERMANN GEOGR MITT, V6, P14; Thomas M., 1997, STAT ANAL EXTREME VA; Weikinn C, 1958, QUELLENTEXTE WITTE 1	29	288	298	3	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2003	425	6954					166	169		10.1038/nature01928	http://dx.doi.org/10.1038/nature01928			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968176				2022-12-28	WOS:000185236000038
J	Kelly, J; Kinirons, M				Kelly, J; Kinirons, M			Intracranial tuberculomas	LANCET			English	Editorial Material									St Thomas Hosp, Dept Care Elderly, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust	Kelly, J (corresponding author), St Thomas Hosp, Dept Care Elderly, London SE1 7EH, England.								0	3	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					797	797		10.1016/S0140-6736(03)14288-2	http://dx.doi.org/10.1016/S0140-6736(03)14288-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678874				2022-12-28	WOS:000185188500013
J	Pfeffer, MA; Swedberg, K; Granger, CB; Held, P; McMurray, JJV; Michelson, EL; Olofsson, B; Ostergren, J; Yusuf, S				Pfeffer, MA; Swedberg, K; Granger, CB; Held, P; McMurray, JJV; Michelson, EL; Olofsson, B; Ostergren, J; Yusuf, S		CHARM Investigators Comm	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme	LANCET			English	Article							CONVERTING-ENZYME-INHIBITORS; VENTRICULAR SYSTOLIC FUNCTION; RANDOMIZED-TRIAL; CONTEMPORARY MANAGEMENT; EJECTION FRACTION; SURVIVAL; LOSARTAN; INTERVENTION; INTOLERANT; CARVEDILOL	Background Patients with chronic heart failure (CHF) are at high risk of cardiovascular death and recurrent hospital admissions. We aimed to find out whether the use of an angiotensin-receptor blocker could reduce mortality and morbidity. Methods In parallel, randomised, double-blind, controlled, clinical trials we compared candesartan with placebo in three distinct populations. We studied patients with left-ventricular ejection fraction (LVEF) 40% or less who were not receiving angiotensin-converting-enzyme inhibitors because of previous intolerance or who were currently receiving angiotensin-converting-enzyme inhibitors, and patients with LVEF higher than 40%. Overall, 7601 patients (7599 with data) were randomly assigned candesartan (n=3803, titrated to 32 mg once daily) or matching placebo (n=3796), and followed up for at least 2 years. The primary outcome of the overall programme was all-cause mortality, and for all the component trials was cardiovascular death or hospital admission for CHF. Analysis was by intention to treat. Findings Median follow-up was 37.7 months. 886 (23%) patients in the candesartan and 945 (25%) in the placebo group died (unadjusted hazard ratio 0.91 [95% CI 0.83-1.00], p=0.055; covariate adjusted 0.90 [0.82-0.99], p=0.032), with fewer cardiovascular deaths (691 [18%] vs 769 [20%], unadjusted 0.88 [0.79-0.97], p=0.012; covariate adjusted 0.87 [0.78-0.96], p=0.006) and hospital admissions for CHF (757 [20%] vs 918 [24%], p<0.0001) in the candesartan group. There was no significant heterogeneity for candesartan results across the component trials. More patients discontinued candesartan than placebo because of concerns about renal function, hypotension, and hyperkalaemia. Interpretation Candesartan was generally well tolerated and significantly reduced cardiovascular deaths and hospital admissions for heart failure. Ejection fraction or treatment at baseline did not alter these effects.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Sahlgrens Univ Hosp, Gothenburg, Sweden; Duke Univ, Med Ctr, Durham, NC USA; AstraZeneca R&D, Molndal, Sweden; Univ Glasgow, Glasgow, Lanark, Scotland; AstraZeneca LP, Wilmington, DE USA; Karolinska Hosp, S-10401 Stockholm, Sweden; Hamilton Hlth Sci, Hamilton, ON, Canada; McMaster Univ, Hamilton, ON, Canada	Harvard University; Brigham & Women's Hospital; Sahlgrenska University Hospital; Duke University; AstraZeneca; University of Glasgow; AstraZeneca; Karolinska Institutet; Karolinska University Hospital; McMaster University; McMaster University	Pfeffer, MA (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	mpfeffer@rics.bwh.harvard.edu	mcmurray, John/B-2467-2013; Granger, Christopher B/D-3458-2014; Swedberg, Karl/B-2475-2008	mcmurray, John/0000-0002-6317-3975; Granger, Christopher B/0000-0002-0045-3291; Yusuf, Salim/0000-0003-4776-5601				*AM HEART ASS, 2002, HEART DIS STROK STAT; Bart BA, 1999, EUR HEART J, V20, P1182, DOI 10.1053/euhj.1998.1481; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Goodfriend TL, 1996, NEW ENGL J MED, V334, P1649, DOI 10.1056/NEJM199606203342507; Granger CB, 2003, LANCET, V362, P772, DOI 10.1016/S0140-6736(03)14284-5; Hjalmarson A, 1999, LANCET, V353, P2001; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Lechat P, 1999, LANCET, V353, P9; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Lithell H, 2003, J HYPERTENS, V21, P875, DOI 10.1097/00004872-200305000-00011; MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126; Massie BM, 2002, J AM COLL CARDIOL, V39, P79, DOI 10.1016/S0735-1097(01)01715-6; McMurray J, 2003, EUR J HEART FAIL, V5, P261, DOI 10.1016/S1388-9842(03)00052-7; McMurray JJV, 2003, LANCET, V362, P767, DOI 10.1016/S0140-6736(03)14283-3; Nishikawa K, 1997, J HUM HYPERTENS, V11, pS9; Packer M, 2002, CIRCULATION, V106, P2194, DOI 10.1161/01.CIR.0000035653.72855.BF; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Redfield MM, 2002, NEW ENGL J MED, V347, P1442, DOI 10.1056/NEJMe020115; Stewart S, 2003, HEART, V89, P49, DOI 10.1136/heart.89.1.49; Swedberg K, 1999, J Card Fail, V5, P276, DOI 10.1016/S1071-9164(99)90013-1; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Swedberg K, 2003, J AM COLL CARDIOL, V41, p190A; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2003, LANCET, V362, P777, DOI 10.1016/S0140-6736(03)14285-7; Yusuf S, 2001, JAMA-J AM MED ASSOC, V286, P1882, DOI 10.1001/jama.286.15.1882; Yusuf S, 2000, NEW ENGL J MED, V342, P145	33	1374	1435	0	29	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2003	362	9386					759	766		10.1016/S0140-6736(03)14282-1	http://dx.doi.org/10.1016/S0140-6736(03)14282-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678868				2022-12-28	WOS:000185188500007
J	Lee, KH; Dinner, AR; Tu, C; Campi, G; Raychaudhuri, S; Varma, R; Sims, TN; Burack, WR; Wu, H; Kanagawa, O; Markiewicz, M; Allen, PM; Dustin, ML; Chakraborty, AK; Shaw, AS				Lee, KH; Dinner, AR; Tu, C; Campi, G; Raychaudhuri, S; Varma, R; Sims, TN; Burack, WR; Wu, H; Kanagawa, O; Markiewicz, M; Allen, PM; Dustin, ML; Chakraborty, AK; Shaw, AS			The immunological synapse balances T cell receptor signaling and degradation	SCIENCE			English	Article							CD2-ASSOCIATED PROTEIN; ANTIGEN RECEPTOR; DOWN-MODULATION; ACTIVATION; DYNAMICS; TRANSDUCTION; STIMULATION; SPECIFICITY; COMPLEXES	The immunological synapse is a specialized cell-cell junction between T cell and antigen-presenting cell surfaces. It is characterized by a central cluster of antigen receptors, a ring of integrin family adhesion molecules, and temporal stability over hours. The role of this specific organization in signaling for T cell activation has been controversial. We use in vitro and in silico experiments to determine that the immunological synapse acts as a type of adaptive controller that both boosts T cell receptor triggering and attenuates strong signals.	NYU, Skirball Inst Biomol Med, Program Mol Pathogenesis, New York, NY 10016 USA; NYU, Dept Pathol, New York, NY 10016 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci & Mat Sci Div, Berkeley, CA 94720 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA	New York University; New York University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Washington University (WUSTL); Roche Holding; Genentech; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Dustin, ML (corresponding author), NYU, Skirball Inst Biomol Med, Program Mol Pathogenesis, New York, NY 10016 USA.		Varma, Rajat/I-1209-2012; Dustin, Michael/AAM-4611-2020	Varma, Rajat/0000-0001-5131-0402; Raychaudhuri, Subhadip/0000-0002-9873-6475; Lee, Kyeong-Hee/0000-0002-9455-4201; Raychaudhuri, Subhadip/0000-0003-3426-8382; Dustin, Michael/0000-0003-4983-6389				Chan C, 2001, P NATL ACAD SCI USA, V98, P5758, DOI 10.1073/pnas.101113698; Coombs D, 2002, NAT IMMUNOL, V3, P926, DOI 10.1038/ni838; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Freiberg BA, 2002, NAT IMMUNOL, V3, P911, DOI 10.1038/ni836; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Itoh Y, 1999, J IMMUNOL, V162, P2073; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068; Koretzky GA, 2001, NAT REV IMMUNOL, V1, P95, DOI 10.1038/35100523; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Lanzavecchia A, 2000, CURR OPIN IMMUNOL, V12, P92, DOI 10.1016/S0952-7915(99)00056-4; Lee K. T., UNPUB; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Liu HY, 2000, IMMUNITY, V13, P665, DOI 10.1016/S1074-7613(00)00066-2; Martin S, 1998, EUR J IMMUNOL, V28, P2991, DOI 10.1002/(SICI)1521-4141(199810)28:10<2991::AID-IMMU2991>3.3.CO;2-2; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Qi SY, 2001, P NATL ACAD SCI USA, V98, P6548, DOI 10.1073/pnas.111536798; Schrum AG, 2002, J EXP MED, V196, P793, DOI 10.1084/jem.20020158; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Stefanova I, 2003, NAT IMMUNOL, V4, P248, DOI 10.1038/ni895; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266	29	438	455	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1218	1222		10.1126/science.1086507	http://dx.doi.org/10.1126/science.1086507			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14512504				2022-12-28	WOS:000186544300057
J	McDermott, MB				McDermott, MB			Obtaining consent for autopsy	BRITISH MEDICAL JOURNAL			English	Article									Our Ladys Hosp Sick Children, Dublin 12, Ireland	Our Ladys Children Hospital Crumlin	McDermott, MB (corresponding author), Our Ladys Hosp Sick Children, Dublin 12, Ireland.		McDermott, Michael Francis/GZM-5330-2022					*BRIS ROYAL INF IN, 2000, INT REP INQ MAN CAR; Burton JL, 2003, J CLIN PATHOL, V56, P537, DOI 10.1136/jcp.56.7.537; Drayton J, 2000, J CLIN PATHOL, V53, P646, DOI 10.1136/jcp.53.8.646; *FAC PATH ROYAL CO, 2000, GUID CONS RET TISS P; Knowles D, 2001, J Appl Philos, V18, P215, DOI 10.1111/1468-5930.00190; *ROYAL COLL PATH, 2000, GUID RET TISS ORG PO; Royal College of Pathologists, 2002, GUID AUT PRACT	7	27	27	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					804	806		10.1136/bmj.327.7418.804	http://dx.doi.org/10.1136/bmj.327.7418.804			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525885	Green Published			2022-12-28	WOS:000185805100029
J	Multani, DS; Briggs, SP; Chamberlin, MA; Blakeslee, JJ; Murphy, AS; Johal, GS				Multani, DS; Briggs, SP; Chamberlin, MA; Blakeslee, JJ; Murphy, AS; Johal, GS			Loss of an MDR transporter in compact stalks of maize br2 and sorghum dw3 mutants	SCIENCE			English	Article							GENES	Agriculturally advantageous reduction in plant height is usually achieved by blocking the action or production of gibberellins. Here, we describe a different dwarfing mechanism found in maize brachytic2 (br2) mutants characterized by compact lower stalk internodes. The height reduction in these plants results from the loss of a P-glycoprotein that modulates polar auxin transport in the maize stalk. The sorghum ortholog of br2 is dwarf3 (dw3), an unstable mutant of long-standing commercial interest and concern. A direct duplication within the dw3 gene is responsible for its mutant nature and also for its instability, because it facilitates unequal crossing-over at the locus.	Purdue Univ, Dept Bot & Plant Pathol, W Lafayette, IN 47907 USA; Pioneer HiBred Int Inc, Johnston, IA 50131 USA; Diversa Corp, San Diego, CA 92121 USA; Purdue Univ, Dept Hort, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; DuPont; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Johal, GS (corresponding author), Purdue Univ, Dept Bot & Plant Pathol, W Lafayette, IN 47907 USA.	gjohal@purdue.edu	Johal, Guri/F-5056-2017; Blakeslee, Joshua/G-4420-2011	Johal, Guri/0000-0001-8101-8410; Multani, Dilbag/0000-0003-2343-4613				Hedden P, 2003, TRENDS GENET, V19, P5, DOI 10.1016/S0168-9525(02)00009-4; Karper RE, 1932, AM NAT, V66, P511, DOI 10.1086/280457; Khush GS, 2001, NAT REV GENET, V2, P815, DOI 10.1038/35093585; Langham, 1940, MAIZE GENET COOP NEW, V14, P21; Leng ER, 1951, MAIZE GENET NEWSL, V25, P31; Mullet JE, 2002, CURR OPIN PLANT BIOL, V5, P118, DOI 10.1016/S1369-5266(02)00232-7; Murphy AS, 2002, PLANT PHYSIOL, V128, P935, DOI 10.1104/pp.010519; Noh B, 2003, NATURE, V423, P999, DOI 10.1038/nature01716; Noh B, 2001, PLANT CELL, V13, P2441, DOI 10.1105/tpc.13.11.2441; PARKER KE, 1990, PLANT PHYSIOL, V94, P1763, DOI 10.1104/pp.94.4.1763; QUINBY JR, 1954, AGRON J, V46, P211, DOI 10.2134/agronj1954.00021962004600050007x; QUINBY JR, 1963, GRAIN SORGH RES UT C, V3, P18; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; Sidler M, 1998, PLANT CELL, V10, P1623, DOI 10.1105/tpc.10.10.1623; STEIN OL, 1955, AM J BOT, V42, P885, DOI 10.2307/2485286; TARTOF KD, 1988, GENETICS, V120, P1; Vogler H, 2003, CURR OPIN PLANT BIOL, V6, P51, DOI 10.1016/S1369-5266(02)00013-4	17	348	393	11	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					81	84		10.1126/science.1086072	http://dx.doi.org/10.1126/science.1086072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526073				2022-12-28	WOS:000185678500038
J	Ziegler, AG; Schmid, S; Huber, D; Hummel, M; Bonifacio, E				Ziegler, AG; Schmid, S; Huber, D; Hummel, M; Bonifacio, E			Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BETA-CELL AUTOIMMUNITY; CELIAC-DISEASE PATIENTS; COWS MILK; GERMAN BABYDIAB; ISLET AUTOIMMUNITY; IMMUNE-RESPONSE; GENETIC RISK; YOUNG DAISY; T-CELLS; INSULIN	Context Dietary factors modifying type 1 diabetes mellitus (DM) risk have been proposed, but little is known if they trigger the islet autoimmunity that precedes clinical disease. Objective To determine whether breastfeeding duration, food supplementation, or age at introduction of gluten-containing foods influences the risk of developing islet autoantibodies. Design and Setting Prospective natural history cohort study conducted from 1989 to 2003 in inpatient/outpatient clinics in Germany. Participants The BABYDIAB study follows newborn children of parents with type 1 DM. Eligibility requirements were met in 1610 children. Blood samples were obtained at birth, age 9 months, 2, 5, and 8 years. Dropout rate was 14.4% by age 5 years. Breastfeeding data were obtained by prospective questionnaires (91% complete), and food supplementation data were obtained by family interview (72% for food supplementation and 80% for age of gluten introduction). Main Outcome Measure Development of islet autoantibodies (insulin, glutamic acid decarboxylase, or IA-2 antibodies) in 2 consecutive blood samples. Results Life-table islet autoantibody frequency was 5.8% (SE, 0.6%) by age 5 years. Reduced total or exclusive breastfeeding duration did not significantly increase the risk of developing islet autoantibodies. Food supplementation with gluten-containing foods before age 3 months, however, was associated with significantly increased islet autoantibody risk (adjusted hazard ratio, 4.0; 95% confidence interval, 1.4-11.5; P=.01 vs children who received only breast milk until age 3 months). Four of 17 children who received gluten foods before age 3 months developed islet autoantibodies (life-table 5-year risk, 24%; SE, 10%). All 4 children had the high-risk DRB1*03/04,DQB1*0302 genotype. Early exposure to gluten did not significantly increase the risk of developing celiac disease-associated autoantibodies. Children who first received gluten foods after age 6 months did not have increased risks for islet or celiac disease autoantibodies. Conclusion Ensuring compliance to infant feeding guidelines is a possible way to reduce the risk of development of type 1 DM autoantibodies.	Diabet Res Inst & Hosp Munchen Schwabing, Munich, Germany; Ist Sci San Raffaele, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Ziegler, AG (corresponding author), Diabet Res Inst, Koelner Pl 1, D-80804 Munich, Germany.		Bonifacio, Ezio/E-7700-2010; Ziegler, Anette-Gabriele/M-4614-2014; Hummel, Sandra/Q-3538-2016	Bonifacio, Ezio/0000-0002-8704-4713; Ziegler, Anette-Gabriele/0000-0002-6290-5548; 				Atkinson MA, 1997, J AM COLL NUTR, V16, P334, DOI 10.1080/07315724.1997.10718694; Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0; Bingley PJ, 2003, DIABETES, V52, P1128, DOI 10.2337/diabetes.52.5.1128; BORCHJOHNSEN K, 1984, LANCET, V2, P1083; Cavallo MG, 1996, LANCET, V348, P926, DOI 10.1016/S0140-6736(95)12065-3; Challacombe DN, 1997, ARCH DIS CHILD, V77, P206, DOI 10.1136/adc.77.3.206; Couper JJ, 1999, DIABETES, V48, P2145, DOI 10.2337/diabetes.48.11.2145; Cronin CC, 1997, LANCET, V349, P1096, DOI 10.1016/S0140-6736(96)09153-2; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; Funda DP, 1999, DIABETES-METAB RES, V15, P323; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; GRECO L, 1985, J PEDIATR GASTR NUTR, V4, P52, DOI 10.1097/00005176-198502000-00010; Hummel M, 2000, DIABETOLOGIA, V43, P1005, DOI 10.1007/s001250051483; Hummel M, 2000, DIABETES CARE, V23, P969, DOI 10.2337/diacare.23.7.969; Ivarsson A, 2000, ACTA PAEDIATR, V89, P165, DOI 10.1080/080352500750028771; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; Kimpimaki T, 2001, DIABETOLOGIA, V44, P63, DOI 10.1007/s001250051581; LESLIE RDG, 1994, DIABETES, V43, P843, DOI 10.2337/diabetes.43.7.843; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; MacFarlane AJ, 2003, J BIOL CHEM, V278, P54, DOI 10.1074/jbc.M210636200; Naserke HE, 1999, J CLIN ENDOCR METAB, V84, P1239, DOI 10.1210/jc.84.4.1239; Norris JM, 2002, DIABETES, V51, pA234; Norris JM, 1996, JAMA-J AM MED ASSOC, V276, P609, DOI 10.1001/jama.276.8.609; Schenker M, 1999, DIABETOLOGIA, V42, P671, DOI 10.1007/s001250051214; Strobel S, 1998, IMMUNOL TODAY, V19, P173, DOI 10.1016/S0167-5699(97)01239-5; Vaarala O, 1999, DIABETES, V48, P1389, DOI 10.2337/diabetes.48.7.1389; Vaarala O, 1996, DIABETES, V45, P178, DOI 10.2337/diabetes.45.2.178; van de Wal Y, 1998, P NATL ACAD SCI USA, V95, P10050, DOI 10.1073/pnas.95.17.10050; Ventura A, 2000, J PEDIATR-US, V137, P263, DOI 10.1067/mpd.2000.107160; WEILE B, 1995, J PEDIATR GASTR NUTR, V21, P64, DOI 10.1097/00005176-199507000-00011; Ziegler AG, 1999, DIABETES, V48, P460, DOI 10.2337/diabetes.48.3.460	32	362	373	0	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1721	1728		10.1001/jama.290.13.1721	http://dx.doi.org/10.1001/jama.290.13.1721			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519706	Bronze			2022-12-28	WOS:000185606100021
J	O'Connor, AM; Legare, F; Stacey, D				O'Connor, AM; Legare, F; Stacey, D			Risk communication in practice: the contribution of decision aids	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPROVING PRIMARY-CARE; SELF-MANAGEMENT; CHRONIC ILLNESS; PATIENT; INTERVENTIONS; CONFLICT; DISEASE	As patients want to participate more in decision making, and as the range of medical options expands, clinicians are challenged to improve their communication of risk and supportive skills. Are practitioners' counselling skills up to the job?	Ottawa Civic Hosp, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Laval, Dept Family Med, Quebec City, PQ G1K 7P4, Canada	University of Ottawa; Ottawa Hospital Research Institute; Laval University	O'Connor, AM (corresponding author), Ottawa Civic Hosp, Ottawa Hlth Res Inst, Civ Campus,C4-1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	aoconnor@ohri.ca	Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Legare, France/0000-0002-2296-6696				Barlow J, 2002, PATIENT EDUC COUNS, V48, P177, DOI 10.1016/S0738-3991(02)00032-0; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; BROWN JB, 1989, CAN FAM PHYSICIAN, V35, P153; COULTER A, 2001, EVIDENCE BASED PATIE, P308; Emmons KM, 2001, AM J PREV MED, V20, P68, DOI 10.1016/S0749-3797(00)00254-3; Gray J. A. M., 2001, EVIDENCE BASED PATIE, P19; GUIMOND P, IN PRESS PATIENT ED; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; KEMPER D, 2002, INFORMATION THERAPY; Legare F, 2003, PATIENT EDUC COUNS, V50, P211, DOI 10.1016/S0738-3991(02)00129-5; LESTER GW, 1993, WESTERN J MED, V158, P268; Mead N, 2000, SOC SCI MED, V51, P1087, DOI 10.1016/S0277-9536(00)00098-8; O'Connor A, 2000, MED DECIS MAKING, V20, pA496; OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105; OConnor AM, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431, DOI 10.1002/14651858.CD001431]; Quine, 2002, CHANGING HLTH BEHAV, P123; Riemsma RP, 2003, BMJ-BRIT MED J, V326, P1175, DOI 10.1136/bmj.326.7400.1175; Rutter D., 2002, CHANGING HLTH BEHAV, P1; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089; Schofield T, 2001, EVIDENCE BASED PATIE, P181; Stewart M, 2001, BRIT MED J, V322, P444, DOI 10.1136/bmj.322.7284.444; Towle A, 2001, EVIDENCE BASED PATIE, P245; TUGWELL P, IN PRESS EVIDENCE BA; Vermeire E, 2001, J CLIN PHARM THER, V26, P331, DOI 10.1046/j.1365-2710.2001.00363.x; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; Wennberg JE, 2002, BRIT MED J, V325, P961, DOI 10.1136/bmj.325.7370.961; WENNBERG JE, GEOGRAPHY DEBATE MED; WESTON WW, 1989, CAN FAM PHYSICIAN, V35, P147; Whitlock EP, 2002, AM J PREV MED, V22, P267, DOI 10.1016/S0749-3797(02)00415-4; 1999, CLIN EVIDENCE	32	239	242	0	40	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 27	2003	327	7417					736	740A		10.1136/bmj.327.7417.736	http://dx.doi.org/10.1136/bmj.327.7417.736			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728FZ	14512487	Green Published			2022-12-28	WOS:000185708300027
J	Schaller, B; Graf, R; Jacobs, AH				Schaller, B; Graf, R; Jacobs, AH			Ischaemic tolerance: a window to endogenous neuroprotection?	LANCET			English	Editorial Material							STROKE		Max Planck Inst Neurol Res, Cologne, Germany; Dept Neurol, Cologne, Germany	Max Planck Society	Schaller, B (corresponding author), Max Planck Inst Neurol Res, Cologne, Germany.	bernhard.schaller@pet.mpin-koeln.mpg.de	Jacobs, Andreas H./AAA-6794-2020; Schaller, Bernhard/AAA-4398-2019	Schaller, Bernhard/0000-0002-7710-8090				Bickler PE, 2002, NEUROSCIENTIST, V8, P234; DEGRACIA DJ, 2002, J CEREB BLOOD FLOW M, V22, P393; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Fisher M, 2003, ANN NEUROL, V53, P10, DOI 10.1002/ana.10407; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Heiss WD, 1997, LANCET, V349, P1599, DOI 10.1016/S0140-6736(97)24022-5; Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Moncayo J, 2000, NEUROLOGY, V54, P2089, DOI 10.1212/WNL.54.11.2089; Prass K, 2002, J CEREBR BLOOD F MET, V22, P520, DOI 10.1097/00004647-200205000-00003; Schaller B, 2002, J NEUROL, V249, P1503, DOI 10.1007/s00415-002-0933-8; Shimizu K, 2002, AM J PHYSIOL-HEART C, V283, pH1005, DOI 10.1152/ajpheart.00054.2002; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403	13	52	53	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2003	362	9389					1007	1008		10.1016/S0140-6736(03)14446-7	http://dx.doi.org/10.1016/S0140-6736(03)14446-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522526				2022-12-28	WOS:000185564600003
J	Staessen, JA; Bianchi, G				Staessen, JA; Bianchi, G			Registration of trials and protocols	LANCET			English	Editorial Material							PUBLICATION BIAS; HYPERTENSION; PREVENTION; QUALITY		Katholieke Univ Leuven, Dept Mol & Cardiovasc Onderzoek, Studiecoordinatiecentrum, Hypertensie & Cardiovasc Revalidatie Eenheid, Leuven, Belgium; Univ Vita & Salute San Raffaele, Cattedra & Scuola Nefrol, Milan, Italy	KU Leuven; Vita-Salute San Raffaele University	Staessen, JA (corresponding author), Katholieke Univ Leuven, Dept Mol & Cardiovasc Onderzoek, Studiecoordinatiecentrum, Hypertensie & Cardiovasc Revalidatie Eenheid, Leuven, Belgium.	jan.staessen@med.kuleuven.ac.be	Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				Bandyopadhyay S, 2001, QJM-INT J MED, V94, P127, DOI 10.1093/qjmed/94.3.127; Bianchi G, 2003, PHARMACOGENOMICS, V4, P279, DOI 10.1517/phgs.4.3.279.22694; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Dickersin K, 2003, JAMA-J AM MED ASSOC, V290, P516, DOI 10.1001/jama.290.4.516; Forette F, 2002, ARCH INTERN MED, V162, P2046, DOI 10.1001/archinte.162.18.2046; Freemantle N, 2003, JAMA-J AM MED ASSOC, V289, P2554, DOI 10.1001/jama.289.19.2554; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Olson CM, 2002, JAMA-J AM MED ASSOC, V287, P2825, DOI 10.1001/jama.287.21.2825; Psaty BM, 2003, JAMA-J AM MED ASSOC, V289, P2128, DOI 10.1001/jama.289.16.2128; Schrier RW, 2002, KIDNEY INT, V61, P1086, DOI 10.1046/j.1523-1755.2002.00213.x; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Weber Michael A, 2003, J Clin Hypertens (Greenwich), V5, P9, DOI 10.1111/j.1524-6175.2003.02287.x; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; Yeo KR, 2002, J HYPERTENS, V20, P2057, DOI 10.1097/00004872-200210000-00026	16	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2003	362	9389					1009	1010		10.1016/S0140-6736(03)14448-0	http://dx.doi.org/10.1016/S0140-6736(03)14448-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522528				2022-12-28	WOS:000185564600005
J	Bray, D				Bray, D			Molecular networks: The top-down view	SCIENCE			English	Editorial Material							SMALL-WORLD	Network theory can give a useful overview of how a biological system works. But to make testable predictions, we need the details.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge	Bray, D (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.							Alon U, 2003, SCIENCE, V301, P1866, DOI 10.1126/science.1089072; Barabasi A. L., 2002, FORMULA UNIVERSAL LA; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Fell D., 1997, UNDERSTANDING CONTRO; HINTON GE, 1992, SCI AM, V267, P145, DOI 10.1038/scientificamerican0992-144; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; KACSER H, 1973, S SOC EXP BIOL, V32, P65; KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022-5193(69)90015-0; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Wagner A, 2001, P ROY SOC B-BIOL SCI, V268, P1803, DOI 10.1098/rspb.2001.1711; Wagner A, 2001, MOL BIOL EVOL, V18, P1283, DOI 10.1093/oxfordjournals.molbev.a003913; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	15	143	153	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1864	1865		10.1126/science.1089118	http://dx.doi.org/10.1126/science.1089118			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512614				2022-12-28	WOS:000185536700036
J	Lee, SH; Reeves, JM; Wilson, JC; Hunton, DE; Viggiano, AA; Miller, TM; Ballenthin, JO; Lait, LR				Lee, SH; Reeves, JM; Wilson, JC; Hunton, DE; Viggiano, AA; Miller, TM; Ballenthin, JO; Lait, LR			Particle formation by ion nucleation in the upper troposphere and lower stratosphere	SCIENCE			English	Article							AEROSOL FORMATION; BOUNDARY-LAYER; CLUSTERS; CLIMATE; CLOUDS	Unexpectedly high concentrations of ultra. ne particles were observed over a wide range of latitudes in the upper troposphere and lower stratosphere. Particle number concentrations and size distributions simulated by a numerical model of ion-induced nucleation, constrained by measured thermodynamic data and observed atmospheric key species, were consistent with the observations. These findings indicate that, at typical upper troposphere and lower stratosphere conditions, particles are formed by this nucleation process and grow to measurable sizes with sufficient sun exposure and low preexisting aerosol surface area. Ion-induced nucleation is thus a globally important source of aerosol particles, potentially affecting cloud formation and radiative transfer.	Univ Denver, Dept Engn, Denver, CO 80208 USA; USAF, Res Lab, Space Vehicle Directorate, Hanscom AFB, MA 01731 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	University of Denver; United States Department of Defense; United States Air Force; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Lee, SH (corresponding author), Univ Denver, Dept Engn, Denver, CO 80208 USA.		Lee, Shan-Hu/F-9913-2014	Wilson, James/0000-0003-4699-5827				ARNOLD F, 1982, NATURE, V299, P134, DOI 10.1038/299134a0; ARNOLD F, 1982, NATURE, V297, P371, DOI 10.1038/297371a0; BROCK CA, 1995, SCIENCE, V270, P1650, DOI 10.1126/science.270.5242.1650; Carslaw KS, 2002, SCIENCE, V298, P1732, DOI 10.1126/science.1076964; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; Clarke AD, 1998, SCIENCE, V282, P89, DOI 10.1126/science.282.5386.89; COVERT DS, 1992, J GEOPHYS RES-ATMOS, V97, P20581, DOI 10.1029/92JD02074; EICHKORN S, 2002, GEOPHYS RES LETT, V29; FROYD KD, IN PRESS J PHYS CHEM; HEITMANN H, 1983, NATURE, V306, P747, DOI 10.1038/306747a0; HERMANN M, 2003, J GEOPHYS RES, V108; Korhonen P, 1999, J GEOPHYS RES-ATMOS, V104, P26349, DOI 10.1029/1999JD900784; Kulmala M, 2000, NATURE, V404, P66, DOI 10.1038/35003550; LAAKSO L, 2002, J GEOPHYS RES, V107; Lovejoy Elijah P., COMMUNICATION; Murphy DM, 1998, SCIENCE, V282, P1664, DOI 10.1126/science.282.5394.1664; Nilsson ED, 1998, J GEOPHYS RES-ATMOS, V103, P1381, DOI 10.1029/97JD02629; O'Sullivan DW, 1999, J GEOPHYS RES-ATMOS, V104, P5635, DOI 10.1029/98JD01250; RAES F, 1992, J AEROSOL SCI, V23, P759, DOI 10.1016/0021-8502(92)90042-T; REITER R, 1992, PHENOMENA ATMOSPHERI; Schroder F, 1997, ATMOS RES, V44, P333, DOI 10.1016/S0169-8095(96)00034-8; Seinfeld J. H., 1998, ATMOSPHERIC CHEM PHY; TWOMEY S, 1977, J ATMOS SCI, V34, P1149, DOI 10.1175/1520-0469(1977)034<1149:TIOPOT>2.0.CO;2; Vehkamaki H., 2002, J GEOPHYS RES, V107; Weber RJ, 1999, GEOPHYS RES LETT, V26, P307, DOI 10.1029/1998GL900308; YU F, 2002, J GEOPHYS RES, V107; Yu FQ, 2000, GEOPHYS RES LETT, V27, P883, DOI 10.1029/1999GL011151; Yu FQ, 2001, J GEOPHYS RES-ATMOS, V106, P4797, DOI 10.1029/2000JD900539; ZIEREIS H, 1986, NATURE, V321, P503, DOI 10.1038/321503a0	29	209	211	2	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1886	1889		10.1126/science.1087236	http://dx.doi.org/10.1126/science.1087236			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512623				2022-12-28	WOS:000185536700045
J	Chang, BS; Lowenstein, DH				Chang, BS; Lowenstein, DH			Mechanisms of disease - Epilepsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TEMPORAL-LOBE EPILEPSY; FIBER SYNAPTIC REORGANIZATION; GRANULE CELL NEUROGENESIS; POTASSIUM CHANNEL GENE; GENERALIZED EPILEPSY; ABSENCE SEIZURES; CORTICAL MALFORMATIONS; HIPPOCAMPAL SCLEROSIS; STATUS EPILEPTICUS; MISSENSE MUTATION		Beth Israel Deaconess Med Ctr, Dept Neurol, Comprehens Epilepsy Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Calif San Francisco, Dept Neurol, Epilepsy Ctr, San Francisco, CA 94143 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California San Francisco	Chang, BS (corresponding author), Beth Israel Deaconess Med Ctr, Dept Neurol, Comprehens Epilepsy Ctr, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039950] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39950] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andermann F, 2000, ADV NEUROL, V84, P479; Annegers J. F., 2001, TREATMENT EPILEPSY P, V3, P131; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; Barkovich AJ, 2001, NEUROLOGY, V57, P2168, DOI 10.1212/WNL.57.12.2168; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Bazhenov M, 1999, NAT NEUROSCI, V2, P168, DOI 10.1038/5729; Benbadis SR, 2001, NEUROL CLIN, V19, P251, DOI 10.1016/S0733-8619(05)70018-9; Berkovic SF, 2000, ANN NEUROL, V47, P557; Berkovic SF, 2001, EPILEPSIA, V42, P16, DOI 10.1046/j.1528-1157.2001.0420s5016.x; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Blumcke I, 1999, EPILEPSY RES, V36, P205, DOI 10.1016/S0920-1211(99)00052-2; Bordey A, 2001, J NEUROPHYSIOL, V85, P1719, DOI 10.1152/jn.2001.85.4.1719; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Burgess DL, 1999, EPILEPSY RES, V36, P111, DOI 10.1016/S0920-1211(99)00045-5; Caddick SJ, 1996, MOL NEUROBIOL, V13, P23, DOI 10.1007/BF02740750; Castro PA, 2001, J NEUROSCI, V21, P6626, DOI 10.1523/JNEUROSCI.21-17-06626.2001; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; COENEN AML, 1992, EPILEPSY RES, V12, P75, DOI 10.1016/0920-1211(92)90029-S; CRUNELLI V, 1991, TRENDS NEUROSCI, V14, P16, DOI 10.1016/0166-2236(91)90178-W; Dalby NO, 2001, CURR OPIN NEUROL, V14, P187, DOI 10.1097/00019052-200104000-00009; Danober L, 1998, PROG NEUROBIOL, V55, P27, DOI 10.1016/S0301-0082(97)00091-9; De Fusco M, 2000, NAT GENET, V26, P275; Delgado-Escueta A V, 1999, Adv Neurol, V79, P561; Engel J, 2001, NEUROSCIENTIST, V7, P340, DOI 10.1177/107385840100700410; Engelborghs S, 2000, ACTA NEUROL BELG, V100, P201; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Escayg A, 2000, NAT GENET, V24, P343, DOI 10.1038/74159; Escayg A, 2000, AM J HUM GENET, V66, P1531, DOI 10.1086/302909; FALCONER MA, 1968, ARCH NEUROL-CHICAGO, V19, P353, DOI 10.1001/archneur.1968.00480040019001; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; Futatsugi Y, 1998, BRAIN DEV-JPN, V20, P75, DOI 10.1016/S0387-7604(97)00107-1; GLAUSER TA, 2001, TREATMENT EPILEPSY P, P881; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; Jacobs KM, 1999, EPILEPSY RES, V36, P165, DOI 10.1016/S0920-1211(99)00050-9; JASPER HH, 1947, RES PUBL ASS NERV ME, V26, P272; Jeffreys JGR, 1999, BRAIN, V122, P1007, DOI 10.1093/brain/122.6.1007; Jouvenceau A, 2001, LANCET, V358, P801, DOI 10.1016/S0140-6736(01)05971-2; Kalachikov S, 2002, NAT GENET, V30, P335, DOI 10.1038/ng832; Kim D, 2001, NEURON, V31, P35, DOI 10.1016/S0896-6273(01)00343-9; Kim R, 2001, EPILEPSY SURG, P643; KNEISLER TB, 1995, HIPPOCAMPUS, V5, P151, DOI 10.1002/hipo.450050302; Kostopoulos GK, 2001, EPILEPSIA, V42, P13, DOI 10.1046/j.1528-1157.2001.042suppl.3013.x; Kullmann DM, 2002, BRAIN, V125, P1177, DOI 10.1093/brain/awf130; Kwan P, 2001, PHARMACOL THERAPEUT, V90, P21, DOI 10.1016/S0163-7258(01)00122-X; LIU Z, 1995, PEDIATR NEUROL, V12, P5, DOI 10.1016/0887-8994(94)00122-I; LIU Z, 1994, EPILEPSY RES, V17, P237; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARCUS EM, 1966, ARCH NEUROL-CHICAGO, V14, P601, DOI 10.1001/archneur.1966.00470120033006; Mathern G.W., 1997, EPILEPSY COMPREHENSI, P133; MATHERN GW, 1995, BRAIN, V118, P105, DOI 10.1093/brain/118.1.105; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; Mizrahi EM, 2001, NEUROL CLIN, V19, P427, DOI 10.1016/S0733-8619(05)70025-6; Najm I, 2001, NEUROL CLIN, V19, P237, DOI 10.1016/S0733-8619(05)70017-7; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; Ottman R, 2001, EPILEPSIA, V42, P24, DOI 10.1046/j.1528-1157.2001.0420s5024.x; Panayiotopoulos CP, 1999, ARCH DIS CHILD, V81, P351, DOI 10.1136/adc.81.4.351; Panyiotopoulos CP, 1997, EPILEPSY COMPREHENSI, P2327; Parent JM, 1999, J NEUROSCI, V19, P4508; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 1997, CURR OPIN NEUROL, V10, P103, DOI 10.1097/00019052-199704000-00006; Prasad AN, 1999, EPILEPSIA, V40, P1329, DOI 10.1111/j.1528-1157.1999.tb02004.x; Ribak C E, 1991, Hippocampus, V1, P355, DOI 10.1002/hipo.450010403; Sanchez RM, 2001, EPILEPSIA, V42, P577, DOI 10.1046/j.1528-1157.2001.12000.x; Schachter SC, 2001, NEUROL CLIN, V19, P57, DOI 10.1016/S0733-8619(05)70005-0; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; Scheffer IE, 1997, BRAIN, V120, P479, DOI 10.1093/brain/120.3.479; Schwartzkroin PA, 2000, MENT RETARD DEV D R, V6, P268, DOI 10.1002/1098-2779(2000)6:4<268::AID-MRDD6>3.0.CO;2-B; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SNEAD OC, 1995, ANN NEUROL, V37, P146, DOI 10.1002/ana.410370204; SNEAD OC, 1992, J NEURAL TRANSM-GEN, P7; Stafstrom CE, 2000, MENT RETARD DEV D R, V6, P281, DOI 10.1002/1098-2779(2000)6:4<281::AID-MRDD7>3.0.CO;2-9; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Sugawara T, 2001, P NATL ACAD SCI USA, V98, P6384, DOI 10.1073/pnas.111065098; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Walsh CA, 1999, NEURON, V23, P19, DOI 10.1016/S0896-6273(00)80749-7; WILLIAMS D, 1953, BRAIN, V76, P50, DOI 10.1093/brain/76.1.50; Wuarin JP, 1996, J NEUROSCI, V16, P4438; Zhu WJ, 2000, J NEUROSCI, V20, P8925	89	514	538	5	107	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2003	349	13					1257	1266		10.1056/NEJMra022308	http://dx.doi.org/10.1056/NEJMra022308			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LJ	14507951				2022-12-28	WOS:000185488800009
J	Horton, R				Horton, R			Doctors in conflict: understanding Israel's despair	LANCET			English	Editorial Material							PUBLIC-HEALTH EDUCATION; MEDICAL-ASSOCIATION		Lancet, London NW1 7BY, England		Horton, R (corresponding author), Lancet, London NW1 7BY, England.							[Anonymous], 2002, LANCET, V359, P1261; Blachar Y, 2003, LANCET, V361, P425, DOI 10.1016/S0140-6736(03)12382-3; Giacaman R, 2003, LANCET, V361, P1220, DOI 10.1016/S0140-6736(03)12958-3; Leventhal A, 2003, LANCET, V361, P1222, DOI 10.1016/S0140-6736(03)12959-5; Shauer A, 2003, LANCET, V361, P1221, DOI 10.1016/S0140-6736(03)12957-1; Summerfield D, 2003, BRIT MED J, V327, P561, DOI 10.1136/bmj.327.7414.561; Viskin S, 2003, LANCET, V362, P82, DOI 10.1016/S0140-6736(03)13829-9; Viskin S, 2003, LANCET, V361, P1470, DOI 10.1016/S0140-6736(03)13142-X; Ziv H, 2003, LANCET, V361, P1827, DOI 10.1016/S0140-6736(03)13430-7	9	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					928	929		10.1016/S0140-6736(03)14394-2	http://dx.doi.org/10.1016/S0140-6736(03)14394-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511921				2022-12-28	WOS:000185489600002
J	Fortey, R; Chatterton, B				Fortey, R; Chatterton, B			A Devonian trilobite with an eyeshade	SCIENCE			English	Article							LENSES		Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Univ Alberta, Dept Earth & Atmospher Sci, Edmonton, AB T6G 2E3, Canada	Natural History Museum London; University of Oxford; University of Alberta	Fortey, R (corresponding author), Nat Hist Museum, Dept Palaeontol, Cromwell Rd, London SW7 5BD, England.	raf@nhm.ac.uk						Clarkson E.N.K., 1979, Palaeontology (Oxford), V22, P1; CLARKSON ENK, 1975, NATURE, V254, P613; Gal J, 2000, VISION RES, V40, P843, DOI 10.1016/S0042-6989(99)00216-3; McCormick T, 1998, PALEOBIOLOGY, V24, P235; MILLER WH, 1979, HDB SENSORY PHYSL, V7, P70; MORZADEC P, 1995, NEUES JB GEOL PAL, P577; STOCKTON W L, 1976, Paleobiology, V2, P304; TOWE KM, 1973, SCIENCE, V179, P1007, DOI 10.1126/science.179.4077.1007	8	12	13	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1689	1689		10.1126/science.1088713	http://dx.doi.org/10.1126/science.1088713			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500973				2022-12-28	WOS:000185387700034
J	Wardle, DA; Yeates, GW; Barker, GM; Bellingham, PJ; Bonner, KI; Williamson, WM				Wardle, DA; Yeates, GW; Barker, GM; Bellingham, PJ; Bonner, KI; Williamson, WM			Island biology and ecosystem functioning in epiphytic soil communities	SCIENCE			English	Article							SPECIES-DIVERSITY; MODEL SYSTEMS; POPULATIONS; ABUNDANCE; DYNAMICS; FOREST	Although island attributes such as size and accessibility to colonizing organisms can influence community structure, the consequences of these for ecosystem functioning are little understood. A study of the suspended soils of spatially discrete epiphytes or treetop "islands" in the canopies of New Zealand rainforest trees revealed that different components of the decomposer community responded either positively or negatively to island size, as well as to the tree species that the islands occurred in. This in turn led to important differences between islands in the rates of ecosystem processes driven by the decomposer biota. This system serves as a model for better understanding how attributes of both real and habitat islands may affect key ecosystem functions through determining the community structure of organisms that drive these functions.	Swedish Univ Agr Sci, Fac Forestry, Dept Forest Vegetat Ecol, S-90183 Umea, Sweden; Landcare Res, Lincoln, New Zealand; Landcare Res, Palmerston North, New Zealand; Landcare Res, Hamilton, New Zealand	Swedish University of Agricultural Sciences; Landcare Research - New Zealand; Landcare Research - New Zealand; Landcare Research - New Zealand	Wardle, DA (corresponding author), Swedish Univ Agr Sci, Fac Forestry, Dept Forest Vegetat Ecol, S-90183 Umea, Sweden.	david.wardle@svek.slu.se	Bellingham, Peter/AAP-4302-2020; Wardle, David A./F-6031-2011; Barker, Gary M/C-9974-2011	Wardle, David A./0000-0002-0476-7335; Barker, Gary M/0000-0002-0049-9804				Anderson WB, 1999, OECOLOGIA, V118, P324, DOI 10.1007/s004420050733; Armbruster P, 2002, OIKOS, V96, P225, DOI 10.1034/j.1600-0706.2002.960204.x; Collinge SK, 2000, ECOLOGY, V81, P2211, DOI 10.1890/0012-9658(2000)081[2211:EOGFOI]2.0.CO;2; Gonzalez A, 1998, SCIENCE, V281, P2045, DOI 10.1126/science.281.5385.2045; Gonzalez A, 2002, J ANIM ECOL, V71, P594, DOI 10.1046/j.1365-2656.2002.00625.x; Grime J. P., 2001, PLANT STRATEGIES VEG; LAWTON JH, 1994, OIKOS, V71, P367, DOI 10.2307/3545824; Levine JM, 2000, SCIENCE, V288, P852, DOI 10.1126/science.288.5467.852; Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; Loreau M., 2002, BIODIVERSITY ECOSYST, P294; MAC ARTHUR ROBERT H., 1967; MOEED A, 1983, NEW ZEAL J ECOL, V6, P39; NADKARNI NM, 1994, AM ZOOL, V34, P70; Richardson BA, 2000, J TROP ECOL, V16, P167, DOI 10.1017/S0266467400001346; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; SCHOENER TW, 1983, SCIENCE, V219, P1353, DOI 10.1126/science.219.4590.1353; Setala H, 2002, ECOL RES, V17, P207, DOI 10.1046/j.1440-1703.2002.00480.x; SIMBERLOFF D, 1976, ECOLOGY, V57, P629, DOI 10.2307/1936179; Spiller DA, 1997, OIKOS, V78, P15, DOI 10.2307/3545795; Tscharntke T, 2002, ECOL APPL, V12, P354, DOI 10.1890/1051-0761(2002)012[0354:COSHFT]2.0.CO;2; Vitousek PM, 2002, J BIOGEOGR, V29, P573, DOI 10.1046/j.1365-2699.2002.00707.x; Vitousek PM, 1995, ISLANDS BIOL DIVERSI; Wardle D., 2002, COMMUNITIES ECOSYSTE; Wardle DA, 2002, J BIOGEOGR, V29, P583, DOI 10.1046/j.1365-2699.2002.00708.x; Wardle DA, 1997, SCIENCE, V277, P1296, DOI 10.1126/science.277.5330.1296; Whittaker RJ, 1998, ISLAND BIOGEOGRAPHY	26	70	77	2	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1717	1720		10.1126/science.1087809	http://dx.doi.org/10.1126/science.1087809			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500981				2022-12-28	WOS:000185387700043
J	Cesarman, E				Cesarman, E			Kaposi's sarcoma-associated herpesvirus - The high cost of viral survival	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA	Cornell University	Cesarman, E (corresponding author), Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA.								0	7	7	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1107	1109		10.1056/NEJMp038125	http://dx.doi.org/10.1056/NEJMp038125			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679522				2022-12-28	WOS:000185369700001
J	Delsuc, F; Phillips, MJ; Penny, D				Delsuc, F; Phillips, MJ; Penny, D			Comment on "Hexapod origins: Monophyletic or paraphyletic?"	SCIENCE			English	Editorial Material							PHYLOGENETIC INFERENCE; MITOCHONDRIAL GENOMES; EVOLUTIONARY TREES; SUBSTITUTION; MODEL		Massey Univ, Allan Wilson Ctr Mol Ecol & Evolut, Inst Mol Biosci, Palmerston North, New Zealand	Massey University	Delsuc, F (corresponding author), Massey Univ, Allan Wilson Ctr Mol Ecol & Evolut, Inst Mol Biosci, Sci Tower D,POB 11-222, Palmerston North, New Zealand.	D.Penny@massey.ac.nz	Phillips, Matthew J/J-1365-2012; Penny, David/E-9410-2011; Delsuc, Frederic/B-4381-2009	Phillips, Matthew J/0000-0003-1532-449X; Delsuc, Frederic/0000-0002-6501-6287				Foster PG, 1999, J MOL EVOL, V48, P284, DOI 10.1007/PL00006471; Giribet G, 2001, NATURE, V413, P157, DOI 10.1038/35093097; HENDY MD, 1989, SYST ZOOL, V38, P297, DOI 10.2307/2992396; Holland BR, 2003, SYST BIOL, V52, P229, DOI 10.1080/10635150390192771; Lin YH, 2002, MOL BIOL EVOL, V19, P2060, DOI 10.1093/oxfordjournals.molbev.a004031; Nardi F, 2003, SCIENCE, V299, P1887, DOI 10.1126/science.1078607; Philippe H, 1997, J MOL EVOL, V45, P712; Phillips MJ, 2003, MOL PHYLOGENET EVOL, V28, P171, DOI 10.1016/S1055-7903(03)00057-5; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Sullivan J, 2001, SYST BIOL, V50, P723, DOI 10.1080/106351501753328848; SWOFFORD DS, 2002, PAUP STAR VERSION 4; Thomas RH, 2003, SCIENCE, V299, P1854, DOI 10.1126/science.1083465; Zwickl DJ, 2002, SYST BIOL, V51, P588, DOI 10.1080/10635150290102339	14	111	119	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1482	1483						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970547				2022-12-28	WOS:000185255300028
J	Arnold, DH; Johnston, A				Arnold, DH; Johnston, A			Motion-induced spatial conflict	NATURE			English	Article							PERCEIVED POSITION; CONTRAST; PATTERN; JITTER; SPEED	Borders defined by small changes in brightness (luminance contrast) or by differences in colour (chromatic contrast) appear to move more slowly than those defined by strong luminance contrast(1-4). As spatial coding is influenced by motion(5-7), if placed in close proximity, the different types of moving border might appear to drift apart(8). Using this configuration, we show here that observers instead report a clear illusory spatial jitter of the low-luminance-contrast boundary. This visible interaction between motion and spatial-position coding occurred at a characteristic rate (similar to22.3 Hz), although the stimulus motion was continuous and invariant. The jitter rate did not vary with the speed of movement. The jitter was not due to small involuntary movements of the eyes, because it only occurred at a specific point within the stimulus, the low-luminance-contrast boundary. These findings show that the human visual system contains a neural mechanism that periodically resolves the spatial conflict created by adjacent moving borders that have the same physical but different perceptual speeds.	UCL, Dept Psychol, London WC1E 6BT, England; UCL, Inst Cognit Neurosci, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Arnold, DH (corresponding author), UCL, Dept Psychol, Gower St, London WC1E 6BT, England.	derek.arnold@ucl.ac.uk	Johnston, Alan/B-5393-2008	Johnston, Alan/0000-0001-9026-1199; Arnold, Derek/0000-0003-1027-6222				Anstis S, 2001, PERCEPTION, V30, P785, DOI 10.1068/p3211; Anstis S. M., 1983, COLOUR VISION PHYSL, P155; Blakemore MR, 1999, PERCEPTION, V28, P33, DOI 10.1068/p2722; BRIDGEMAN B, 1991, VISION RES, V31, P1903, DOI 10.1016/0042-6989(91)90185-8; CAMPBELL FW, 1959, J PHYSIOL-LONDON, V145, P579, DOI 10.1113/jphysiol.1959.sp006164; CAVANAGH P, 1984, J OPT SOC AM A, V1, P893, DOI 10.1364/JOSAA.1.000893; DEVALOIS RL, 1991, VISION RES, V31, P1619, DOI 10.1016/0042-6989(91)90138-U; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; Engel AK, 2001, TRENDS COGN SCI, V5, P16, DOI 10.1016/S1364-6613(00)01568-0; Helmholtz H., 1962, TREATISE PHYSL OPTIC; Murakami I, 2003, VISION RES, V43, P957, DOI 10.1016/S0042-6989(03)00070-1; Murakami I, 1998, NATURE, V395, P798, DOI 10.1038/27435; Nguyen-Tri D, 2003, PERCEPTION, V32, P627, DOI 10.1068/p3228; Nishida S, 1999, NATURE, V397, P610, DOI 10.1038/17600; Sherrington CS, 1918, BRAIN, V41, P332, DOI 10.1093/brain/41.3-4.332; THOMPSON P, 1982, VISION RES, V22, P377, DOI 10.1016/0042-6989(82)90153-5; Von Grunau M W, 1976, Vision Res, V16, P397, DOI 10.1016/0042-6989(76)90203-0; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; Whitney D, 2000, NAT NEUROSCI, V3, P954, DOI 10.1038/78878; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115	20	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					181	184		10.1038/nature01955	http://dx.doi.org/10.1038/nature01955			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968181				2022-12-28	WOS:000185236000043
J	Vokrouhlicky, D; Nesvorny, D; Bottke, WF				Vokrouhlicky, D; Nesvorny, D; Bottke, WF			The vector alignments of asteroid spins by thermal torques	NATURE			English	Article							COLLISIONAL EVOLUTION; LIGHTCURVE INVERSION; OPTIMIZATION METHODS; KORONIS FAMILY; SHAPE; EARTH; OBLIQUITY; ORIGIN; STATE; YORP	Collisions have been thought to be the dominant process altering asteroid rotations, but recent observations of the Koronis family of asteroids suggest that this may be incorrect. This group of asteroids was formed in a catastrophic collision several billion years ago; in the intervening period their rotational axes should have become nearly random because of subsequent collisions, with spin rates that follow a maxwellian distribution. What is seen, however, is that the observed family members with prograde spins have nearly identical periods (7.5-9.5 h) and obliquities between 42 and 50 degrees, while those with retrograde spins have obliquities between 154 and 169 degrees with periods either <5 h or> 13 h. Here we show that these non-random orientations and spin rates can be explained by 'thermal torques' (arising from differential solar heating), which modify the spin states over time. In some cases, the asteroids become trapped in spin-orbit resonances. Our results suggest that thermal torques may be more important than collisions in changing the spin states (and possibly shapes) of asteroids with diameters <40 km.	Charles Univ Prague, Inst Astron, CR-18000 Prague 8, Czech Republic; SW Res Inst, Boulder, CO 80302 USA	Charles University Prague	Vokrouhlicky, D (corresponding author), Charles Univ Prague, Inst Astron, Holesovickach 2, CR-18000 Prague 8, Czech Republic.	vokrouhl@mbox.cesnet.cz	Vokrouhlický, David/Q-4359-2017	Vokrouhlický, David/0000-0002-6034-5452				Asphaug E, 1999, ICARUS, V139, P383, DOI 10.1006/icar.1999.6108; Asphaug E, 1996, ICARUS, V121, P225, DOI 10.1006/icar.1996.0083; Belton MJS, 1996, ICARUS, V120, P185, DOI 10.1006/icar.1996.0044; BELTON MJS, 1994, SCIENCE, V265, P1543, DOI 10.1126/science.265.5178.1543; BENDJOYA P, 2003, ASTEROIDS, V3, P613; BINZEL RP, 1988, ICARUS, V73, P303, DOI 10.1016/0019-1035(88)90100-5; BINZEL RP, 1990, ASTEROIDS COMETS MET, V3, P15; Bottke W. F., 2002, ASTEROIDS, P395; Bottke WF, 2001, ASTROPHYS SPACE SC L, V261, P51; Bottke WF, 2001, SCIENCE, V294, P1693, DOI 10.1126/science.1066760; CAPEK D, 2002, ASTEROIDS COMETS MET, P117; CELLINO A, 2003, ASTEROIDS, V3, P632; CHAPMAN CR, 2003, ASTEROIDS, V3, P315; COLOMBO G, 1966, ASTRON J, V71, P891, DOI 10.1086/109983; Davies ME, 1996, ICARUS, V120, P33, DOI 10.1006/icar.1996.0034; Greenberg R, 1996, ICARUS, V120, P106, DOI 10.1006/icar.1996.0040; HENRARD J, 1987, CELESTIAL MECH, V40, P345, DOI 10.1007/BF01235852; HOLSAPPLE K, 2003, ASTEROIDS, V3, P443; Kaasalainen M, 2001, ICARUS, V153, P24, DOI 10.1006/icar.2001.6673; Kaasalainen M, 2001, ICARUS, V153, P37, DOI 10.1006/icar.2001.6674; KNEZEVIC Z, 2003, ASTEROIDS, V3, P603; LASKAR J, 1993, NATURE, V361, P608, DOI 10.1038/361608a0; Love SG, 1997, NATURE, V386, P154, DOI 10.1038/386154a0; MARZARI F, 1995, ICARUS, V113, P168, DOI 10.1006/icar.1995.1014; Michel P, 2001, SCIENCE, V294, P1696, DOI 10.1126/science.1065189; Morbidelli A, 2003, ICARUS, V163, P120, DOI 10.1016/S0019-1035(03)00047-2; Muinonen K, 1998, ASTRON ASTROPHYS, V333, P753; Muinonen K, 1998, ASTRON ASTROPHYS, V332, P1087; Pravec P., 2002, ASTEROIDS 3, P113; Richardson DC, 1998, ICARUS, V134, P47, DOI 10.1006/icar.1998.5954; RICHARDSON DC, 2003, ASTEROIDS, V3, P501; Rubincam DP, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001813; Rubincam DP, 2000, ICARUS, V148, P2, DOI 10.1006/icar.2000.6485; Sidlichovsky M, 1996, CELEST MECH DYN ASTR, V65, P137, DOI 10.1007/BF00048443; Skoglov E, 1996, PLANET SPACE SCI, V44, P1177, DOI 10.1016/S0032-0633(96)00039-6; Slivan SM, 2003, ICARUS, V162, P285, DOI 10.1016/S0019-1035(03)00029-0; Slivan SM, 2002, NATURE, V419, P49, DOI 10.1038/nature00993; Thomas PC, 1996, ICARUS, V120, P20, DOI 10.1006/icar.1996.0033; Vokrouhlicky D, 2000, NATURE, V407, P606, DOI 10.1038/35036528; Vokrouhlicky D, 2002, ICARUS, V159, P449, DOI 10.1006/icar.2002.6918; WARD WR, 1974, J GEOPHYS RES, V79, P3375, DOI 10.1029/JC079i024p03375; ZAPPALA V, 2003, ASTEROIDS, V3, P619	42	156	157	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					147	151		10.1038/nature01948	http://dx.doi.org/10.1038/nature01948			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968171				2022-12-28	WOS:000185236000033
J	Davis, KL; Haroutunian, V				Davis, KL; Haroutunian, V			Global expression-profiling studies and oligodendrocyte dysfunction in schizophrenia and bipolar disorder	LANCET			English	Editorial Material							PROTEOLIPID PROTEIN GENE		CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Haroutunian, V (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.							Bongarzone ER, 1999, J NEUROSCI, V19, P8349; COPLAND C, 2003, POST MORTEM ASSESSME; Davis KL, 2003, ARCH GEN PSYCHIAT, V60, P443, DOI 10.1001/archpsyc.60.5.443; Hof PR, 2003, BIOL PSYCHIAT, V53, P1075, DOI 10.1016/S0006-3223(03)00237-3; Hof PR, 2002, NEUROCHEM RES, V27, P1193, DOI 10.1023/A:1020981510759; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SCHERER SS, 1994, NEURON, V12, P1363, DOI 10.1016/0896-6273(94)90451-0; Sporkel O, 2002, GLIA, V37, P19, DOI 10.1002/glia.10014; Woodruff RH, 2001, INT J DEV NEUROSCI, V19, P379, DOI 10.1016/S0736-5748(00)00083-6	9	44	45	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					758	758		10.1016/S0140-6736(03)14297-3	http://dx.doi.org/10.1016/S0140-6736(03)14297-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678867				2022-12-28	WOS:000185188500006
J	Fox, KM; Bertrand, M; Ferrari, R; Remme, WJ; Simoons, ML; Remme, WJ; Simoons, M; Bassand, JP; Aldershvile, J; Hildebrandt, P; Bertrand, M; Cokkinos, D; Toutouzas, P; Eha, J; Erhardt, L; Erikssen, J; Grybauskas, P; Kalnins, U; Karsch, K; Sechtem, U; Keltai, M; Klein, W; Luscher, T; Mulcahy, D; Nieminen, M; Oto, A; Ozsaruhan, O; Paulus, W; Providencia, L; Riecansky, I; Ruzyllo, W; Ferrari, R; Santini, U; Tavazzi, L; Soler-Soler, J; Widimsky, P; Fox, KM; Julian, D; Dargie, H; Murray, G; Kubler, W; Thygesen, K; Duprez, D; Steg, G; Drexel, H; Gombotz, G; Klein, W; Duprez, D; Heyndrickx, GH; Legrand, V; Materne, P; Van Mieghem, W; Bocek, P; Branny, M; Cech, M; Charouzek, J; Drazka, J; Fabik, L; Florian, J; Francek, L; Groch, L; Havranek, P; Hradec, J; Jansky, P; Jirmar, R; Jokl, I; Krejcova, H; Kvasnak, M; Maratka, T; Marcinek, G; Moravcova, J; Nedbal, P; Peterka, K; Povolny, J; Rosolova, H; Semrad, B; Sochor, K; Spacek, R; Spinar, J; Stipal, R; Stuchlik, K; Sulda, M; Ulman, J; Vaclavicek, A; Vojtisek, P; Bjerregaard-Andersen, H; Hildebrandt, P; Kristensen, K; Madsen, JK; Markenvard, J; Meibom, J; Norgaard, A; Scheibel, M; Eha, J; Leht, A; Teesalu, R; Vahula, V; Itkonen, A; Juvonen, J; Karmakoski, J; Kilkki, E; Koskela, E; Melin, J; Nieminen, MS; Savola, R; Terho, T; Voipio-Pulkki, LM; Apffel, F; Attali, P; Barjhoux, C; Baron, B; Bassand, JP; Berthier, Y; Dambrine, P; Decoulx, E; Deshayes, P; Fouche, R; Genest, M; Godard, S; Guillot, JP; Hanania, G; Khattar, P; Leroy, F; Mansourati, J; Piquemal, R; Quiret, JC; Raynaud, P; Rondepierre, D; Roynard, JL; Sudhibhasilp, S; Van Belle, E; Bilbal, A; Lauer, B; Rettig-Sturmer, G; Riessen, R; Rutsch, W; Sechtem, U; Sigel, HA; Simon, R; Von Schacky, C; Winkelmann, BR; Avgeropoulou, C; Christakos, S; Feggos, S; Floros, S; Fotiadis, I; Goudevenos, I; Kardara, D; Karidis, C; Koliopoulos, N; Kremastinos, D; Lekakis, I; Manolis, A; Pyrgakis, V; Papanikolaou, C; Papasteriadis, E; Skoufas, P; Stravrati, A; Stavridis, A; Syribeis, S; Vardas, P; Vassiliadis, I; Voudris, V; Zobolos, S; Berenyi, I; Edes, I; Janosi, A; Kalo, E; Karpati, P; Kornel, S; Pap, I; Polak, G; Reiber, I; Rusznak, M; Tarjan, J; Timar, S; Toth, K; Barton, J; Crean, P; Daly, K; Kearney, P; Meany, TB; Mulcahy, D; Quigley, P; Antolini, R; Azzolini, P; Bellone, E; Branzi, A; Brunelli, C; Capponi, E; Capucci, A; Casaccia, M; Cecchetti, E; Ceci, V; Celegon, L; Colombo, A; Corsini, G; Cucchini, F; Dalla Volta, S; De Caterina, R; De Luca, I; De Servi, S; Di Donato, M; Di Giacomo, U; Di Pasquale, G; Fiorentini, C; Gaddi, O; Giannetto, M; Giannuzzi, P; Giordano, A; Giovannini, E; Guarnierio, M; Iacono, A; Inama, G; Leghissa, R; Lorusso, R; Marinoni, G; Marzilli, M; Mauri, F; Mosele, GM; Papi, S; Pela, G; Pettinati, G; Polimeni, MR; Portaluppi, F; Proto, C; Renaldini, E; Riva, S; Sanguinetti, M; Santini, M; Severi, S; Sinagra, G; Tantalo, L; Tavazzi, L; Vajola, SF; Volterrani, M; Ansmite, B; Gailiss, E; Gersamija, A; Kalnins, U; Ozolina, MA; Baubiniene, A; Berukstis, E; Grigoniene, L; Kibarskis, A; Kirkutis, A; Marcinkus, R; Milvidaite, I; Vasiliauskas, D; Aalders, JCA; Bruggeling, WAJ; De Feyter, PJ; De Leeuw, MJ; De Waard, DEP; De Weerd, GJ; De Zwaan, C; Dijkgraaf, R; Droste, HT; Freericks, MP; Hagoort-Kok, AW; Hillebrand, F; Jap, WTJ; Jochemsen, GM; Kiemeney, F; Kuijer, PJP; Mannaerts, HFJ; Piek, JJ; Saelman, JPM; Slob, FD; Smits, WCG; Suttorp, MJ; Tan, TB; Van Beek, GJ; Van den Merkhof, LFM; Van der Heyden, R; Van Hessen, MWJ; Van Langeveld, RAM; Van Nierop, PR; Van Rey, FJW; Van Straalen, MJ; Vos, J; Werner, HA; Westendorp, JJC; Erikssen, J; Achremczyk, P; Adamus, J; Baska, J; Bolinska-Soltysiak, H; Bubinski, R; Ceremuzynski, L; Cieslinski, A; Dariusz, D; Drozdowski, P; Dubiel, JS; Galewicz, M; Halawa, B; Janion, M; Jaworska, K; Kaszewska, I; Kleinrok, A; Kornacewicz-Jach, Z; Krawczyk, W; Krynicki, R; Krzciuk, M; Krzeminska-Pakula, M; Kuch, J; Kuzniar, J; Liszewska-Pfejfer, D; Loboz-Grudzien, K; Musial, W; Opolski, G; Pasyk, S; Piwowarska, W; Pulkowski, G; Ruzyllo, W; Rynkiewicz, A; Sinkiewicz, W; Skura, M; Slowinski, S; Smielak-Korombel, W; Targonski, R; Templin, W; Tendera, M; Tracz, W; Trusz-Gluza, M; Wodniecki, J; Zalewski, M; Zinka, E; Carrageta, M; Gil, JC; Ferreira, R; Marques, AL; Andrade, CMS; Seabra-Gomes, R; Bada, V; Belicova, M; Dukat, A; Kaliska, G; Kamensky, G; Micko, K; Mikes, Z; Palinsky, M; Pella, D; Renker, B; Riecansky, I; Sefara, P; Sojka, G; Sulej, P; Szakacs, M; Salcedo, JMA; Orcajo, NA; Garcia, PA; Sanpera, JMA; Azcarate, JA; Mayor, JLB; Martinez, VB; Coronado, JLB; Ojeda, FB; Caimari, RB; Cortada, JB; Valderrama, JC; Ligorit, AD; Caliani, JSE; Aviles, FF; Guerrero, JJG; Lopez, DG; Cocina, EG; Urena, CG; Lorente, LJ; Garcia-Aranda, VL; De Miguel, CM; Montero, JM; Romero, PM; Benito, IM; Lopez, FN; Peiro, FN; De Ros, JO; Mas, JO; Bermejo, MAP; Peralta, LJP; Padial, LR; Sanz, AS; Bonnin, JS; Martin, ES; Belsue, FV; Ekdahl, S; Erhardt, L; Forslund, L; Ohlin, H; Pieper, M; Moccetti, T; Acarturk, E; Guzelsoy, D; Oto, A; Ozsaruhan, O; Turkoglu, C; Adgey, AAJ; Ahsan, A; Al-Khafaji, M; Ball, SG; Birkhead, J; Boon, N; Brack, M; Bridges, A; Buchalter, M; Calder, B; Cooke, RA; Corr, L; Cowell, R; Curzen, NP; Davidson, C; Davies, J; De Belder, MA; Dhiya, L; Doig, JC; Findlay, IN; Fox, KM; Francis, CM; Glancy, JM; Greenwood, TW; Groves, P; Hall, AS; Hamilton, G; Haq, I; Hillman, R; Hubbard, W; Hudson, I; Hutton, I; Ilsley, C; Innes, M; James, M; Jennings, K; Johnston, G; Jones, CJH; Joy, M; Keeling, P; Kooner, J; Lawson, C; Levy, RD; Lip, G; Mclachlan, B; Montgomery, HE; Morley, CA; Murdoch, DL; Muthusamy, R; Oakley, GDG; Penny, W; Percival, R; Purvis, J; Pye, MP; Ramsdale, D; Roberts, DH; Rozkovec, A; Salmassi, AM; Saltissi, S; Sardar, S; Shapiro, LM; Schofield, PM; Stephens, J; Shakespeare, C; Srivastava, S; Swan, JW; Tildesley, G; Travill, C; Wilkinson, PR; Fratacci, MD; Lerebours, G; Deckers, J				Fox, KM; Bertrand, M; Ferrari, R; Remme, WJ; Simoons, ML; Remme, WJ; Simoons, M; Bassand, JP; Aldershvile, J; Hildebrandt, P; Bertrand, M; Cokkinos, D; Toutouzas, P; Eha, J; Erhardt, L; Erikssen, J; Grybauskas, P; Kalnins, U; Karsch, K; Sechtem, U; Keltai, M; Klein, W; Luscher, T; Mulcahy, D; Nieminen, M; Oto, A; Ozsaruhan, O; Paulus, W; Providencia, L; Riecansky, I; Ruzyllo, W; Ferrari, R; Santini, U; Tavazzi, L; Soler-Soler, J; Widimsky, P; Fox, KM; Julian, D; Dargie, H; Murray, G; Kubler, W; Thygesen, K; Duprez, D; Steg, G; Drexel, H; Gombotz, G; Klein, W; Duprez, D; Heyndrickx, GH; Legrand, V; Materne, P; Van Mieghem, W; Bocek, P; Branny, M; Cech, M; Charouzek, J; Drazka, J; Fabik, L; Florian, J; Francek, L; Groch, L; Havranek, P; Hradec, J; Jansky, P; Jirmar, R; Jokl, I; Krejcova, H; Kvasnak, M; Maratka, T; Marcinek, G; Moravcova, J; Nedbal, P; Peterka, K; Povolny, J; Rosolova, H; Semrad, B; Sochor, K; Spacek, R; Spinar, J; Stipal, R; Stuchlik, K; Sulda, M; Ulman, J; Vaclavicek, A; Vojtisek, P; Bjerregaard-Andersen, H; Hildebrandt, P; Kristensen, K; Madsen, JK; Markenvard, J; Meibom, J; Norgaard, A; Scheibel, M; Eha, J; Leht, A; Teesalu, R; Vahula, V; Itkonen, A; Juvonen, J; Karmakoski, J; Kilkki, E; Koskela, E; Melin, J; Nieminen, MS; Savola, R; Terho, T; Voipio-Pulkki, LM; Apffel, F; Attali, P; Barjhoux, C; Baron, B; Bassand, JP; Berthier, Y; Dambrine, P; Decoulx, E; Deshayes, P; Fouche, R; Genest, M; Godard, S; Guillot, JP; Hanania, G; Khattar, P; Leroy, F; Mansourati, J; Piquemal, R; Quiret, JC; Raynaud, P; Rondepierre, D; Roynard, JL; Sudhibhasilp, S; Van Belle, E; Bilbal, A; Lauer, B; Rettig-Sturmer, G; Riessen, R; Rutsch, W; Sechtem, U; Sigel, HA; Simon, R; Von Schacky, C; Winkelmann, BR; Avgeropoulou, C; Christakos, S; Feggos, S; Floros, S; Fotiadis, I; Goudevenos, I; Kardara, D; Karidis, C; Koliopoulos, N; Kremastinos, D; Lekakis, I; Manolis, A; Pyrgakis, V; Papanikolaou, C; Papasteriadis, E; Skoufas, P; Stravrati, A; Stavridis, A; Syribeis, S; Vardas, P; Vassiliadis, I; Voudris, V; Zobolos, S; Berenyi, I; Edes, I; Janosi, A; Kalo, E; Karpati, P; Kornel, S; Pap, I; Polak, G; Reiber, I; Rusznak, M; Tarjan, J; Timar, S; Toth, K; Barton, J; Crean, P; Daly, K; Kearney, P; Meany, TB; Mulcahy, D; Quigley, P; Antolini, R; Azzolini, P; Bellone, E; Branzi, A; Brunelli, C; Capponi, E; Capucci, A; Casaccia, M; Cecchetti, E; Ceci, V; Celegon, L; Colombo, A; Corsini, G; Cucchini, F; Dalla Volta, S; De Caterina, R; De Luca, I; De Servi, S; Di Donato, M; Di Giacomo, U; Di Pasquale, G; Fiorentini, C; Gaddi, O; Giannetto, M; Giannuzzi, P; Giordano, A; Giovannini, E; Guarnierio, M; Iacono, A; Inama, G; Leghissa, R; Lorusso, R; Marinoni, G; Marzilli, M; Mauri, F; Mosele, GM; Papi, S; Pela, G; Pettinati, G; Polimeni, MR; Portaluppi, F; Proto, C; Renaldini, E; Riva, S; Sanguinetti, M; Santini, M; Severi, S; Sinagra, G; Tantalo, L; Tavazzi, L; Vajola, SF; Volterrani, M; Ansmite, B; Gailiss, E; Gersamija, A; Kalnins, U; Ozolina, MA; Baubiniene, A; Berukstis, E; Grigoniene, L; Kibarskis, A; Kirkutis, A; Marcinkus, R; Milvidaite, I; Vasiliauskas, D; Aalders, JCA; Bruggeling, WAJ; De Feyter, PJ; De Leeuw, MJ; De Waard, DEP; De Weerd, GJ; De Zwaan, C; Dijkgraaf, R; Droste, HT; Freericks, MP; Hagoort-Kok, AW; Hillebrand, F; Jap, WTJ; Jochemsen, GM; Kiemeney, F; Kuijer, PJP; Mannaerts, HFJ; Piek, JJ; Saelman, JPM; Slob, FD; Smits, WCG; Suttorp, MJ; Tan, TB; Van Beek, GJ; Van den Merkhof, LFM; Van der Heyden, R; Van Hessen, MWJ; Van Langeveld, RAM; Van Nierop, PR; Van Rey, FJW; Van Straalen, MJ; Vos, J; Werner, HA; Westendorp, JJC; Erikssen, J; Achremczyk, P; Adamus, J; Baska, J; Bolinska-Soltysiak, H; Bubinski, R; Ceremuzynski, L; Cieslinski, A; Dariusz, D; Drozdowski, P; Dubiel, JS; Galewicz, M; Halawa, B; Janion, M; Jaworska, K; Kaszewska, I; Kleinrok, A; Kornacewicz-Jach, Z; Krawczyk, W; Krynicki, R; Krzciuk, M; Krzeminska-Pakula, M; Kuch, J; Kuzniar, J; Liszewska-Pfejfer, D; Loboz-Grudzien, K; Musial, W; Opolski, G; Pasyk, S; Piwowarska, W; Pulkowski, G; Ruzyllo, W; Rynkiewicz, A; Sinkiewicz, W; Skura, M; Slowinski, S; Smielak-Korombel, W; Targonski, R; Templin, W; Tendera, M; Tracz, W; Trusz-Gluza, M; Wodniecki, J; Zalewski, M; Zinka, E; Carrageta, M; Gil, JC; Ferreira, R; Marques, AL; Andrade, CMS; Seabra-Gomes, R; Bada, V; Belicova, M; Dukat, A; Kaliska, G; Kamensky, G; Micko, K; Mikes, Z; Palinsky, M; Pella, D; Renker, B; Riecansky, I; Sefara, P; Sojka, G; Sulej, P; Szakacs, M; Salcedo, JMA; Orcajo, NA; Garcia, PA; Sanpera, JMA; Azcarate, JA; Mayor, JLB; Martinez, VB; Coronado, JLB; Ojeda, FB; Caimari, RB; Cortada, JB; Valderrama, JC; Ligorit, AD; Caliani, JSE; Aviles, FF; Guerrero, JJG; Lopez, DG; Cocina, EG; Urena, CG; Lorente, LJ; Garcia-Aranda, VL; De Miguel, CM; Montero, JM; Romero, PM; Benito, IM; Lopez, FN; Peiro, FN; De Ros, JO; Mas, JO; Bermejo, MAP; Peralta, LJP; Padial, LR; Sanz, AS; Bonnin, JS; Martin, ES; Belsue, FV; Ekdahl, S; Erhardt, L; Forslund, L; Ohlin, H; Pieper, M; Moccetti, T; Acarturk, E; Guzelsoy, D; Oto, A; Ozsaruhan, O; Turkoglu, C; Adgey, AAJ; Ahsan, A; Al-Khafaji, M; Ball, SG; Birkhead, J; Boon, N; Brack, M; Bridges, A; Buchalter, M; Calder, B; Cooke, RA; Corr, L; Cowell, R; Curzen, NP; Davidson, C; Davies, J; De Belder, MA; Dhiya, L; Doig, JC; Findlay, IN; Fox, KM; Francis, CM; Glancy, JM; Greenwood, TW; Groves, P; Hall, AS; Hamilton, G; Haq, I; Hillman, R; Hubbard, W; Hudson, I; Hutton, I; Ilsley, C; Innes, M; James, M; Jennings, K; Johnston, G; Jones, CJH; Joy, M; Keeling, P; Kooner, J; Lawson, C; Levy, RD; Lip, G; Mclachlan, B; Montgomery, HE; Morley, CA; Murdoch, DL; Muthusamy, R; Oakley, GDG; Penny, W; Percival, R; Purvis, J; Pye, MP; Ramsdale, D; Roberts, DH; Rozkovec, A; Salmassi, AM; Saltissi, S; Sardar, S; Shapiro, LM; Schofield, PM; Stephens, J; Shakespeare, C; Srivastava, S; Swan, JW; Tildesley, G; Travill, C; Wilkinson, PR; Fratacci, MD; Lerebours, G; Deckers, J		EURopean Trial Reduction Cardiac E	Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)	LANCET			English	Article							LEFT-VENTRICULAR DYSFUNCTION; CONVERTING-ENZYME-INHIBITORS; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; HYPERTENSION; EXPRESSION; CAPTOPRIL; SURVIVAL; ACE	Background Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure. Methods We recruited patients from October, 1997, to June, 2000. 13 655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12 218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4.2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat. Findings Mean age of patients was 60 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% beta blockers, and 58% lipid-lowering therapy. 603 (10%) placebo and 488 (8%) perindopril patients experienced the primary endpoint, which yields a 20% relative risk reduction (95% CI 9-29, p=0.0003) with perindopril. These benefits were consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated. Interpretation Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease.	Royal Brompton Hosp, Dept Cardiol, London SW3 6NP, England	Royal Brompton Hospital	Fox, KM (corresponding author), Royal Brompton Hosp, Dept Cardiol, Sydney St, London SW3 6NP, England.	k.fox@rbh.nthames.nhs.uk	Sinagra, Gianfranco/AAE-3943-2020; De+Servi, Stefano/AAT-2631-2021; Montgomery, Hugh/L-1229-2019; Portaluppi, Francesco/H-2206-2012; Tendera, Michal/AAA-1875-2022; De Caterina, Raffaele/K-3857-2016; Tavazzi, Luigi/ABD-5119-2020; vardas, panos/ABF-7144-2020; Édes, István/B-8795-2011; Lorusso, Roberto/ABB-9275-2020; Widimsky, Petr/P-8088-2016; volterrani, maurizio/K-5919-2016; Hall, Alistair/K-1953-2019; Vardas, Panos/AAD-5219-2022; Giannuzzi, Pantaleo/K-2797-2016; curzen, nick/AAD-8161-2020; Vardas, Panos/AAP-5694-2021; Manolis, Antonis/F-5003-2014; Sinkiewicz, Wladyslaw/G-5169-2014; Sánchez, Arturo/L-3622-2019; Hradec, Jaromir/S-2388-2016; Rynkiewicz, Andrzej/AAW-8733-2021; FERRARI, ROBERTO/ABD-5169-2020; Riessen, Reimer/AFR-0686-2022; Montgomery, Hugh/C-2592-2008	Portaluppi, Francesco/0000-0002-2948-1579; De Caterina, Raffaele/0000-0003-1637-574X; Tavazzi, Luigi/0000-0003-0336-8356; Lorusso, Roberto/0000-0002-1777-2045; Widimsky, Petr/0000-0001-5686-7752; volterrani, maurizio/0000-0002-2624-9213; Giannuzzi, Pantaleo/0000-0002-2313-9115; Manolis, Antonis/0000-0002-0336-4745; Sánchez, Arturo/0000-0002-4946-1559; Hradec, Jaromir/0000-0001-7597-8239; STEG, Philippe Gabriel/0000-0001-6896-2941; Rynkiewicz, Andrzej/0000-0002-5284-9511; Janion, Marianna/0000-0002-8811-4568; BERTOMEU MARTINEZ, VICENTE/0000-0002-3553-0963; Hall, Alistair/0000-0003-0306-7887; Pella, Daniel/0000-0001-9999-6271; Kearney, Patricia/0000-0001-9599-3540; Montgomery, Hugh/0000-0001-8797-5019; Pela, Giovanna/0000-0001-7676-7281; Ferrari, Roberto/0000-0003-2046-9175; SINAGRA, GIANFRANCO/0000-0003-2700-8478				Alpert JS, 2000, EUR HEART J, V21, P1502, DOI 10.1053/euhj.2000.2305; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ASMAR RG, 1988, CIRCULATION, V78, P941, DOI 10.1161/01.CIR.78.4.941; BALL SG, 1993, LANCET, V342, P821; Bartels GL, 1999, AM J CARDIOL, V83, P332, DOI 10.1016/S0002-9149(98)00863-7; Britten MB, 1999, J INTERN MED, V245, P315, DOI 10.1046/j.1365-2796.1999.00449.x; BROWN NJ, 1998, HYPERTENSION, V32, P1225; CANDIDO RA, 2000, CIRCULATION, V106, P246; Dyker AG, 1997, STROKE, V28, P580, DOI 10.1161/01.STR.28.3.580; Dzau VJ, 2002, CARDIOVASC DRUG THER, V16, P149, DOI 10.1023/A:1015709617405; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Gomma AH, 2001, CARDIOVASC DRUG THER, V15, P169, DOI 10.1023/A:1011131130922; Hornig B, 1997, CIRCULATION, V95, P1115; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; Lloyd-Jones DM, 1999, LANCET, V353, P89, DOI 10.1016/S0140-6736(98)10279-9; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Matsumoto K, 2001, HYPERTENSION, V37, P270, DOI 10.1161/01.HYP.37.2.270; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Myers MG, 1996, CAN J CARDIOL, V12, P1191; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PEDERSEN TR, 1994, LANCET, V344, P1383; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RUTHERFORD JD, 1994, CIRCULATION, V90, P1731, DOI 10.1161/01.CIR.90.4.1731; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; THYBO NK, 1994, HYPERTENSION, V23, P659, DOI 10.1161/01.HYP.23.5.659; VAUGHAN DE, 1995, J CLIN INVEST, V95, P995, DOI 10.1172/JCI117809; Wing LMH, 2003, NEW ENGL J MED, V348, P583, DOI 10.1056/NEJMoa021716; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N; Yusuf S, 2000, NEW ENGL J MED, V342, P145	30	1621	1765	2	107	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2003	362	9386					782	788						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678872				2022-12-28	WOS:000185188500011
J	Shaheen, M; Hilgarth, KA; Hawes, D; Badve, S; Antony, AC				Shaheen, M; Hilgarth, KA; Hawes, D; Badve, S; Antony, AC			A Mexican man with "too much blood"	LANCET			English	Editorial Material							HYPERTENSION; SECONDARY		Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Radiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Shaheen, M (corresponding author), Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA.			Badve, Sunil/0000-0001-8861-9980				BURTON IE, 1994, POSTGRAD MED J, V70, P515, DOI 10.1136/pgmj.70.825.515; CHAN JCM, 1980, PEDIATRICS, V65, P821; SCHWARZ A, 1993, J UROLOGY, V150, P953, DOI 10.1016/S0022-5347(17)35660-4	3	9	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					806	806		10.1016/S0140-6736(03)14291-2	http://dx.doi.org/10.1016/S0140-6736(03)14291-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678877				2022-12-28	WOS:000185188500016
J	Hviid, A; Stellfeld, M; Wohlfahrt, J; Melbye, M				Hviid, A; Stellfeld, M; Wohlfahrt, J; Melbye, M			Association between thimerosal-containing vaccine and autism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POPULATION; REGISTER; MERCURY	Context Mercuric compounds are nephrotoxic and neurotoxic at high doses. Thimerosal, a preservative used widely in vaccine formulations, contains ethylmercury. Thus it has been suggested that childhood vaccination with thimerosal-containing vaccine could be causally related to neurodevelopmental disorders such as autism. Objective To determine whether vaccination with a thimerosal-containing vaccine is associated with development of autism. Design, Setting, and Participants Population-based cohort study of all children born in Denmark from January 1, 1990, until December 31, 1996 (N =467450) comparing children vaccinated with a thimerosal-containing vaccine with children vaccinated with a thimerosal-free formulation of the same vaccine. Main Outcome Measures Rate ratio (RR) for autism and other autistic-spectrum disorders, including trend with dose of ethylmercury. Results During 2986654 person-years, we identified 440 autism cases and 787 cases of other autistic-spectrum disorders. The risk of autism and other autistic-spectrum disorders did not differ significantly between children vaccinated with thimerosal-containing vaccine and children vaccinated with thimerosal-free vaccine (RR, 0.85 [95% confidence interval (0), 0.60-1.20] for autism; RR, 1.12 [95% Cl, 0.88-1.43] for other autistic-spectrum disorders). Furthermore, we found no evidence of a dose-response association (increase in RR per 25 mug of ethylmercury, 0.98 [95% Cl, 0.90-1.06] for autism and 1.03 [95% Cl, 0.98-1.09] for other autistic-spectrum disorders). Conclusion The results do not support a causal relationship between childhood vaccination with thimerosal-containing vaccines and development of autistic-spectrum disorders.	Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen S, Denmark; Statens Serum Inst, Dept Med, DK-2300 Copenhagen, Denmark	Aarhus University; Statens Serum Institut; Statens Serum Institut	Hviid, A (corresponding author), Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, Artillerivej 5, DK-2300 Copenhagen S, Denmark.		Hviid, Anders/AAH-4319-2020	Hviid, Anders/0000-0002-7509-9127; melbye, mads/0000-0001-8264-6785				Andersen TF, 1999, DAN MED BULL, V46, P263; Ball LK, 2001, PEDIATRICS, V107, P1147, DOI 10.1542/peds.107.5.1147; Bertrand J, 2001, PEDIATRICS, V108, P1155, DOI 10.1542/peds.108.5.1155; Clarkson TW, 1997, CRIT REV CL LAB SCI, V34, P369, DOI 10.3109/10408369708998098; Hills, 1993, STAT MODELS EPIDEMIO; Knudsen LB, 1998, DAN MED BULL, V45, P320; Madsen KM, 2002, NEW ENGL J MED, V347, P1477, DOI 10.1056/NEJMoa021134; MALIG C, 1996, 6 IIVRS; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Pichichero ME, 2002, LANCET, V360, P1737, DOI 10.1016/S0140-6736(02)11682-5; Plesner A M, 1994, Ugeskr Laeger, V156, P7497; Ronne T, 1997, Ugeskr Laeger, V159, P1584; Stratton K, 2001, IMMUNIZATION SAFETY	13	175	183	0	108	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1763	1766		10.1001/jama.290.13.1763	http://dx.doi.org/10.1001/jama.290.13.1763			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519711				2022-12-28	WOS:000185606100026
J	Fewell, JH				Fewell, JH			Social insect networks	SCIENCE			English	Editorial Material							DIVISION-OF-LABOR; COLLECTIVE DECISION-MAKING; SELF-ORGANIZATION; SELECTION; EVOLUTION; COLONIES; RECRUITMENT; BEE	Social insect colonies have many of the properties of adaptive networks. The simple rules governing how local interactions among individuals translate into group behaviors are found across social groups, giving social insects the potential to have a profound impact on our understanding of the interplay between network dynamics and social evolution.	Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Fewell, JH (corresponding author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.	j.fewell@asu.edu						Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Alon U, 2003, SCIENCE, V301, P1866, DOI 10.1126/science.1089072; Barabasi A. L., 2002, FORMULA UNIVERSAL LA; Beshers SN, 2001, ANNU REV ENTOMOL, V46, P413, DOI 10.1146/annurev.ento.46.1.413; Bonabeau E, 1998, J THEOR BIOL, V195, P157, DOI 10.1006/jtbi.1998.0789; Bray D, 2003, SCIENCE, V301, P1864, DOI 10.1126/science.1089118; CAMAZINE S, 1993, BEHAV ECOL SOCIOBIOL, V32, P265, DOI 10.1007/BF00166516; Camazine S., 2001, SELF ORG BIOL SYSTEM, DOI DOI 10.1515/9780691212920; Fewell JH, 1999, EVOL ECOL RES, V1, P537; FEWELL JH, 1992, BEHAV ECOL SOCIOBIOL, V30, P387, DOI 10.1007/BF00176173; Gordon DM, 2002, AM NAT, V159, P509, DOI 10.1086/339461; GOSS S, 1989, NATURWISSENSCHAFTEN, V76, P579, DOI 10.1007/BF00462870; GRANOVETTER MS, 1973, AM J SOCIOL, V78, P1360, DOI 10.1086/225469; Hemelrijk CK, 2002, BIOL BULL-US, V202, P283, DOI 10.2307/1543480; Hemelrijk CK, 2002, ETHOLOGY, V108, P655, DOI 10.1046/j.1439-0310.2002.00812.x; HOGEWEG P, 1983, BEHAV ECOL SOCIOBIOL, V12, P271, DOI 10.1007/BF00302895; Holldobler B., 1990, pi; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Moore AJ, 1997, EVOLUTION, V51, P1352, DOI 10.1111/j.1558-5646.1997.tb01458.x; NAUMANN K, 1991, BEHAV ECOL SOCIOBIOL, V29, P321, DOI 10.1007/BF00165956; Pacala SW, 1996, EVOL ECOL, V10, P127, DOI 10.1007/BF01241782; Page RE, 2002, NATURWISSENSCHAFTEN, V89, P91, DOI 10.1007/s00114-002-0299-x; Page RE, 1998, APIDOLOGIE, V29, P171, DOI 10.1051/apido:19980110; Robson SK, 1999, INFORMATION PROCESSING IN SOCIAL INSECTS, P239; Saffre F, 1999, J THEOR BIOL, V198, P507, DOI 10.1006/jtbi.1999.0927; Seeley TD, 1997, AM NAT, V150, pS22, DOI 10.1086/286048; SEELEY TD, 1991, BEHAV ECOL SOCIOBIOL, V28, P277, DOI 10.1007/BF00175101; Sole R, 2000, SIGNS LIFE COMPLEXIT; SOLE R, 2000, SANTA FE WORKING PAP; Theraulaz G, 1998, P ROY SOC B-BIOL SCI, V265, P327, DOI 10.1098/rspb.1998.0299; Wilson DS, 1997, AM NAT, V149, P336, DOI 10.1086/285993; Wilson DS, 1997, AM NAT, V150, pS1, DOI 10.1086/286046	32	204	205	3	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1867	1870		10.1126/science.1088945	http://dx.doi.org/10.1126/science.1088945			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512616				2022-12-28	WOS:000185536700038
J	McMurray, MA; Gottschling, DE				McMurray, MA; Gottschling, DE			An age-induced switch to a hyper-recombinational state	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; MITOTIC RECOMBINATION; GENE CONVERSION; LIFE-SPAN; YEAST; MUTATION; CELLS; REPLICATION; TELOMERE; CANCER	There is a strong correlation between age and cancer, but the mechanism by which this phenomenon occurs is unclear. We chose Saccharomyces cerevisiae to examine one of the hallmarks of cancer-genomic instability as a function of cellular age. As diploid yeast mother cells aged, an similar to100-fold increase in loss of heterozygosity (LOH) occurred. Extending life-span altered neither the onset nor the frequency of age-induced LOH; the switch to hyper-LOH appears to be on its own clock. In young cells, LOH occurs by reciprocal recombination, whereas LOH in old cells was nonreciprocal, occurring predominantly in the old mother's progeny. Thus, nuclear genomes may be inherently unstable with age.	Univ Washington, Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Gottschling, DE (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043893] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACUNA G, 1994, ENVIRON MOL MUTAGEN, V24, P307, DOI 10.1002/em.2850240408; Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; Aguilera A, 2000, YEAST, V16, P731, DOI 10.1002/1097-0061(20000615)16:8<731::AID-YEA586>3.0.CO;2-L; Cairns J, 2002, P NATL ACAD SCI USA, V99, P10567, DOI 10.1073/pnas.162369899; Cost GJ, 1996, YEAST, V12, P939, DOI 10.1002/(SICI)1097-0061(199608)12:10<939::AID-YEA988>3.0.CO;2-L; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; DMELLO NP, 1991, J BACTERIOL, V173, P6709, DOI 10.1128/jb.173.21.6709-6713.1991; FOGEL S, 1963, GENETICS, V48, P321; Frank SA, 2003, GENETICS, V163, P1527; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; Jazwinski SM, 2001, MECH AGEING DEV, V122, P865, DOI 10.1016/S0047-6374(01)00244-5; JUDD SR, 1988, GENETICS, V118, P401; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; MCMURRAY MA, UNPUB; Morley A, 1998, ANN NY ACAD SCI, V854, P20, DOI 10.1111/j.1749-6632.1998.tb09888.x; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; ROMAN H, 1956, COLD SPRING HARB SYM, V21, P175, DOI 10.1101/SQB.1956.021.01.015; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; ZIMMERMANN FK, 1975, MUTAT RES, V31, P71, DOI 10.1016/0165-1161(75)90069-2	25	178	181	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1908	1911		10.1126/science.1087706	http://dx.doi.org/10.1126/science.1087706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512629				2022-12-28	WOS:000185536700051
J	Holland, A; Whittington, J; Hinton, E				Holland, A; Whittington, J; Hinton, E			The paradox of Prader-Willi syndrome: a genetic model of starvation	LANCET			English	Article							GROWTH-HORMONE; ACYLATED PEPTIDE; IMPRINTED GENES; GHRELIN; LEPTIN; FETAL; ILLNESS; OBESITY; PEOPLE; WOMEN	The neurodevelopmental disorder, Prader-Willi syndrome, is generally regarded as a genetic model of obesity. Although the values of some hypothalamic neuropeptides are as expected in obesity, and should result in satiety, we propose that abnormal hypothalamic pathways mean that these are ineffective. We postulate that the body incorrectly interprets the absence of satiation as starvation, and therefore, paradoxically, this syndrome should be redefined as one of starvation that manifests as obesity in a food-rich environment. Also, this syndrome is generally believed to be a contiguous gene disorder, which results from the absence of expression of the paternally derived alleles of maternally imprinted genes on chromosome 15 (15q11-13). We argue, however, that the whole phenotype can be explained by one mechanism and, by implication, the failure of expression of the paternal allele of a single maternally imprinted gene that controls energy balance. We suggest clinical and laboratory approaches to test our hypotheses.	Sect Dev Psychiat, Cambridge CB2 2AH, England		Holland, A (corresponding author), Sect Dev Psychiat, Douglas House, Cambridge CB2 2AH, England.	ajh1008@cam.ac.uk		Hinton, Elanor/0000-0003-2793-8552				Bajoria R, 2002, PLACENTA, V23, P103, DOI 10.1053/plac.2001.0769; Boer H, 2002, LANCET, V359, P135, DOI 10.1016/S0140-6736(02)07340-3; Casanueva Felipe F, 2002, Rev Endocr Metab Disord, V3, P325, DOI 10.1023/A:1020901624103; Chanoine JP, 2002, J PEDIATR GASTR NUTR, V35, P282, DOI 10.1097/00005176-200209000-00009; Date Y, 2000, BIOCHEM BIOPH RES CO, V275, P477, DOI 10.1006/bbrc.2000.3342; DelPparigi A, 2002, J CLIN ENDOCR METAB, V87, P5461, DOI 10.1210/jc.2002-020871; Gallagher RC, 2002, AM J HUM GENET, V71, P669, DOI 10.1086/342408; Ge YL, 2002, BRAIN RES, V957, P42, DOI 10.1016/S0006-8993(02)03583-7; Goldstone AP, 2002, J CLIN ENDOCR METAB, V87, P927, DOI 10.1210/jc.87.2.927; Goldstone AP, 2002, AM J CLIN NUTR, V75, P468, DOI 10.1093/ajcn/75.3.468; Holland AJ, 2003, PSYCHOL MED, V33, P141, DOI 10.1017/S0033291702006736; HOLLAND AJ, 1993, INT J OBESITY, V17, P527; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lobie PE, 2000, GROWTH HORM IGF RES, V10, P51; Miozzo M, 2002, BIOL NEONATE, V81, P217, DOI 10.1159/000056752; Muller J, 1997, ACTA PAEDIATR, V86, P58; Reik W, 2001, NOVART FDN SYMP, V237, P19, DOI 10.1002/0470846666.ch3; Schwartz MW, 2002, NATURE, V418, P595, DOI 10.1038/418595a; Tolle V, 2003, J CLIN ENDOCR METAB, V88, P109, DOI 10.1210/jc.2002-020645; WHITMAN BY, 2001, 4 TRIENN IPWSO SCI C	20	58	64	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 20	2003	362	9388					989	991		10.1016/S0140-6736(03)14370-X	http://dx.doi.org/10.1016/S0140-6736(03)14370-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511934				2022-12-28	WOS:000185489600023
J	Vaupel, JW; Carey, JR; Christensen, K				Vaupel, JW; Carey, JR; Christensen, K			It's never too late	SCIENCE			English	Editorial Material							DIETARY RESTRICTION; AGE; SELECTION; OLDER		Max Planck Inst Demog Res, D-18057 Rostock, Germany; Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; Univ Calif Berkeley, Ctr Econ & Demog Aging, Berkeley, CA 94720 USA; Univ So Denmark, Inst Publ Hlth, DK-5000 Odense, Denmark	Max Planck Society; University of California System; University of California Davis; University of California System; University of California Berkeley; University of Southern Denmark	Vaupel, JW (corresponding author), Max Planck Inst Demog Res, Konrad Zuse Str 1, D-18057 Rostock, Germany.	jwv@demogr.mpg.de	Christensen, Kaare/C-2360-2009	Christensen, Kaare/0000-0002-5429-5292; Vaupel, James/0000-0003-0783-3905	NIA NIH HHS [AG-08761, P01 AG008761-130003, P01 AG008761] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG008761] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aristotle, YOUTH OLD AGE LIFE D; Bergman B, 2002, ACTA OPHTHALMOL SCAN, V80, P598, DOI 10.1034/j.1600-0420.2002.800608.x; Carey J. R., 2003, LONGEVITY BIOL DEMOG, DOI [10.1515/9780691224084, DOI 10.1515/9780691224084]; Carey JR, 2002, AGING CELL, V1, P140, DOI 10.1046/j.1474-9728.2002.00019.x; Carey JR, 1998, SCIENCE, V281, P996, DOI 10.1126/science.281.5379.996; DOBLHAMMER G, LATE LIFE LEGACY VER; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; Gjonca Arjan, 2000, DEMOGR RES, V3, P1, DOI [10.4054/DemRes.2000.3.1, DOI 10.4054/DEMRES.2000.3.1]; Good TP, 2001, J INSECT PHYSIOL, V47, P1467, DOI 10.1016/S0022-1910(01)00138-X; HAMILTON WD, 1966, J THEOR BIOL, V12, P12, DOI 10.1016/0022-5193(66)90184-6; Kannisto Vaino., 1994, DEV OLDEST OLD MORTA; LaCroix A Z, 1992, Clin Geriatr Med, V8, P69; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675; Pagnano MW, 2003, MAYO CLIN PROC, V78, P285, DOI 10.4065/78.3.285; Riley J, 2001, RISING LIFE EXPECTAN; Vaupel JW, 1997, PHILOS T ROY SOC B, V352, P1799, DOI 10.1098/rstb.1997.0164; VAUPEL JW, 1985, AM STAT, V39, P176, DOI 10.2307/2683925; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; VAUPEL JW, 1995, EXCEPTIONAL LONGEVIT, P109	20	69	70	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1679	+		10.1126/science.1090529	http://dx.doi.org/10.1126/science.1090529			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500969	Green Accepted			2022-12-28	WOS:000185387700030
J	Salamini, F				Salamini, F			Hormones and the green revolution	SCIENCE			English	Editorial Material							GENES		Max Planck Inst Breeding Res, D-50829 Cologne, Germany	Max Planck Society	Salamini, F (corresponding author), Max Planck Inst Breeding Res, D-50829 Cologne, Germany.	salamini@mpiz-koeln.mpg.de						BORLAUG NE, 1983, SCIENCE, V219, P689, DOI 10.1126/science.219.4585.689; Hedden P, 2003, TRENDS GENET, V19, P5, DOI 10.1016/S0168-9525(02)00009-4; Ishaaya I., 2001, BIOCH SITES INSECTIC; Khush GS, 2001, NAT REV GENET, V2, P815, DOI 10.1038/35093585; Morgante M, 2003, CURR OPIN BIOTECH, V14, P214, DOI 10.1016/S0958-1669(03)00028-4; Multani DS, 2003, SCIENCE, V302, P81, DOI 10.1126/science.1086072; Noh B, 2003, NATURE, V423, P999, DOI 10.1038/nature01716; Palme K, 1999, CURR OPIN PLANT BIOL, V2, P375, DOI 10.1016/S1369-5266(99)00008-4; Vigouroux Y, 2002, P NATL ACAD SCI USA, V99, P9650, DOI 10.1073/pnas.112324299	9	38	44	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					71	72		10.1126/science.1090811	http://dx.doi.org/10.1126/science.1090811			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526071				2022-12-28	WOS:000185678500035
J	Tang, XD; Xu, R; Reynolds, MF; Garcia, ML; Heinemann, SH; Hoshi, T				Tang, XD; Xu, R; Reynolds, MF; Garcia, ML; Heinemann, SH; Hoshi, T			Haem can bind to and inhibit mammalian calcium-dependent Slo1 BK channels	NATURE			English	Article							CA2+-ACTIVATED K+ CHANNELS; CRYSTAL-STRUCTURE; MEMBRANE	Haem is essential for living organisms, functioning as a crucial element in the redox-sensitive reaction centre in haemproteins(1). During the biogenesis of these proteins, the haem cofactor is typically incorporated enzymatically into the haem pockets of the apo-haemprotein as the functionally indispensable prosthetic group(2,3). A class of ion channel, the large-conductance calcium-dependent Slo1 BK channels, possesses a conserved haem-binding sequence motif. Here we present electrophysiological and structural evidence showing that haem directly regulates cloned human Slo1 channels and wild-type BK channels in rat brain. Both oxidized and reduced haem binds to the hSlo1 channel protein and profoundly inhibits transmembrane K+ currents by decreasing the frequency of channel opening. This direct regulation of the BK channel identifies a previously unknown role of haem as an acute signalling molecule.	Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; St Josephs Univ, Dept Chem, Philadelphia, PA 19131 USA; Merck Res Labs, Dept Ion Channels, Rahway, NJ 07065 USA; Univ Jena, Fac Med, Res Unit Mol & Cellular Biophys, D-07747 Jena, Germany	University of Pennsylvania; Saint Joseph's University; Merck & Company; Friedrich Schiller University of Jena	Hoshi, T (corresponding author), Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA.	hoshi@hoshi.org		Heinemann, Stefan H./0000-0002-4144-0251				Blackmon BJ, 2002, ARCH BIOCHEM BIOPHYS, V407, P196, DOI 10.1016/S0003-9861(02)00471-X; BRAUTIGAN DL, 1977, J BIOL CHEM, V252, P574; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; Dore S, 2002, FREE RADICAL BIO MED, V32, P1276, DOI 10.1016/S0891-5849(02)00805-5; Granick S, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P33; Gribkoff VK, 2001, NAT MED, V7, P471, DOI 10.1038/86546; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; More C, 1999, BIOSPECTROSCOPY, V5, pS3, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S3::AID-BSPY2>3.0.CO;2-P; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Ricci AJ, 2000, J PHYSIOL-LONDON, V524, P423, DOI 10.1111/j.1469-7793.2000.00423.x; SHAKLAI N, 1985, BIOCHIM BIOPHYS ACTA, V821, P355, DOI 10.1016/0005-2736(85)90106-3; Siemen D, 1999, BIOCHEM BIOPH RES CO, V257, P549, DOI 10.1006/bbrc.1999.0496; Taketani S, 1998, J BIOL CHEM, V273, P31388, DOI 10.1074/jbc.273.47.31388; Tang XD, 2001, J GEN PHYSIOL, V117, P253, DOI 10.1085/jgp.117.3.253; Worthington MT, 2001, AM J PHYSIOL-GASTR L, V280, pG1172, DOI 10.1152/ajpgi.2001.280.6.G1172; Xu WH, 2002, SCIENCE, V298, P1029, DOI 10.1126/science.1074360; Yermolaieva O, 2001, BIOPHYS J, V80, p237A; ZhuGe R, 2000, J GEN PHYSIOL, V116, P845, DOI 10.1085/jgp.116.6.845	19	224	234	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2003	425	6957					531	535		10.1038/nature02003	http://dx.doi.org/10.1038/nature02003			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523450				2022-12-28	WOS:000185648100049
J	Williams, M				Williams, M			State ballot initiatives for health care reform	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Meharry Med Coll, Nashville, TN 37208 USA	Meharry Medical College	Williams, M (corresponding author), Meharry Med Coll, Nashville, TN 37208 USA.		Williams, Makeba/R-3492-2019	Williams, Makeba/0000-0002-1946-939X				Agretelis J, 1997, JAMA-J AM MED ASSOC, V278, P1733; Broder DS, 2000, DEMOCRACY DERAILED I; GOLDBERG C, 2002, NY TIMES        0611; LEBLANC S, 2000, S COAST TODAY   1109	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1775	1775		10.1001/jama.290.13.1775	http://dx.doi.org/10.1001/jama.290.13.1775			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519715	Bronze			2022-12-28	WOS:000185606100030
J	Murphy, G				Murphy, G			Lost for words	NATURE			English	News Item							DEVELOPMENTAL DYSLEXIA; CHILDREN; REMEDIATION; DISRUPTION; SYSTEMS; BRAIN		Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England	Imperial College London	Murphy, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.							Eden GF, 2002, NAT NEUROSCI, V5, P1080, DOI 10.1038/nn946; LIVINGSTONE MS, 1991, P NATL ACAD SCI USA, V88, P7943, DOI 10.1073/pnas.88.18.7943; Nicolson RI, 1999, LANCET, V353, P1662, DOI 10.1016/S0140-6736(98)09165-X; Ramus F, 2003, BRAIN, V126, P841, DOI 10.1093/brain/awg076; Ramus F, 2003, CURR OPIN NEUROBIOL, V13, P212, DOI 10.1016/S0959-4388(03)00035-7; Shaywitz BA, 2002, BIOL PSYCHIAT, V52, P101, DOI 10.1016/S0006-3223(02)01365-3; Shaywitz SE, 2003, BIOL PSYCHIAT, V54, P25, DOI 10.1016/S0006-3223(02)01836-X; Shaywitz SE, 1998, P NATL ACAD SCI USA, V95, P2636, DOI 10.1073/pnas.95.5.2636; Stein J, 2001, Dyslexia, V7, P12, DOI 10.1002/dys.186; STEIN JF, 1982, BRIT J OPHTHALMOL, V66, P332, DOI 10.1136/bjo.66.5.332; TALLAL P, 1980, BRAIN LANG, V9, P182, DOI 10.1016/0093-934X(80)90139-X; Temple E, 2003, P NATL ACAD SCI USA, V100, P2860, DOI 10.1073/pnas.0030098100	12	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					340	342		10.1038/425340a	http://dx.doi.org/10.1038/425340a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508456				2022-12-28	WOS:000185502300012
J	Richards, MP; Schulting, RJ; Hedges, REM				Richards, MP; Schulting, RJ; Hedges, REM			Sharp shift in diet at onset of Neolithic	NATURE			English	Editorial Material							DENMARK		Univ Bradford, Dept Archaeol Sci, Bradford BD7 1DP, W Yorkshire, England; Queens Univ Belfast, Sch Archaeol & Palaeoecol, Belfast BT7 1NN, Antrim, North Ireland; Univ Oxford, Archaeol & Hist Art Res Lab, Oxford OX1 3QJ, England	University of Bradford; Queens University Belfast; University of Oxford	Richards, MP (corresponding author), Univ Bradford, Dept Archaeol Sci, Bradford BD7 1DP, W Yorkshire, England.		Richards, Michael/O-3717-2016; Schulting, Rick/AAV-2339-2021; Richards, Michael/A-9374-2008	Richards, Michael/0000-0001-5274-8887; Schulting, Rick/0000-0002-4444-766X; Richards, Michael/0000-0001-5274-8887				CHILDE VG, 1936, MAN MAKES HIMSELF; Dennell R., 1983, EUROPEAN EC PREHISTO; Mellars P., 1987, EXCAVATIONS ORONSAY; Richards M.P., 2002, EUR J ARCHAEOL, V5, P147, DOI DOI 10.1177/14619571020050020201; Richards MP, 1999, ANTIQUITY, V73, P891, DOI 10.1017/S0003598X00065649; Richards MP, 2003, CURR ANTHROPOL, V44, P288, DOI 10.1086/367971; SCHOENINGER MJ, 1983, SCIENCE, V220, P1381, DOI 10.1126/science.6344217; Schulting R, 2002, ANTIQUITY, V76, P1011, DOI 10.1017/S0003598X00091821; SCHWARCZ HP, 1991, YEARB PHYS ANTHROPOL, V34, P283; TAUBER H, 1981, NATURE, V292, P332, DOI 10.1038/292332a0	10	207	211	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					366	366		10.1038/425366a	http://dx.doi.org/10.1038/425366a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	724TG	14508478				2022-12-28	WOS:000185502300030
J	Leinwand, LA				Leinwand, LA			Hope for a broken heart?	CELL			English	Editorial Material							TRANSPLANTED HUMAN HEARTS; STEM-CELLS; CARDIOMYOCYTES; REGENERATION; MUSCLE; ORIGIN		Univ Colorado, Dept Mol Cell & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Leinwand, LA (corresponding author), Univ Colorado, Dept Mol Cell & Dev Biol, Boulder, CO 80309 USA.			LEINWAND, LESLIE/0000-0003-1470-4810				Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Glaser R, 2002, CIRCULATION, V106, P17, DOI 10.1161/01.CIR.0000021923.58307.8F; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Leferovich JM, 2001, P NATL ACAD SCI USA, V98, P9830, DOI 10.1073/pnas.181329398; Muller P, 2002, CIRCULATION, V106, P31, DOI 10.1161/01.CIR.0000022405.68464.CA; Mummery C, 2003, CIRCULATION, V107, P2733, DOI 10.1161/01.CIR.0000068356.38592.68; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081	11	10	10	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 19	2003	114	6					658	659		10.1016/S0092-8674(03)00718-9	http://dx.doi.org/10.1016/S0092-8674(03)00718-9			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505565	Bronze			2022-12-28	WOS:000185464000003
J	Cool, CD; Rai, PR; Yeager, ME; Hernandez-Saavedra, D; Serls, AE; Bull, TM; Geraci, MW; Brown, KK; Routes, JM; Tuder, RM; Voelkel, NF				Cool, CD; Rai, PR; Yeager, ME; Hernandez-Saavedra, D; Serls, AE; Bull, TM; Geraci, MW; Brown, KK; Routes, JM; Tuder, RM; Voelkel, NF			Expression of human herpesvirus 8 in primary pulmonary hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; ENDOTHELIAL GROWTH-FACTOR; TGF-BETA RECEPTOR; KAPOSIS-SARCOMA; PLEXIFORM LESIONS; DNA-SEQUENCES; GERMLINE MUTATIONS; PROTEIN; GENE; GENOME	BACKGROUND: Severe pulmonary hypertension constitutes a group of diseases characterized by complex, lumen-occluding vascular lesions that develop in genetically susceptible persons. The only viral infection associated with severe pulmonary hypertension has been that due to human immunodeficiency virus type 1, but neither the viral genome nor viral antigens have been demonstrated in pathologic lesions. METHODS: We examined lung-tissue samples from 16 patients with sporadic primary pulmonary hypertension and 14 patients with secondary pulmonary hypertension for evidence of infection with human herpesvirus 8 (HHV-8). HHV-8 infection was ascertained immunohistochemically with use of an antibody directed against latency-associated nuclear antigen 1 (LANA-1), and a polymerase-chain-reaction (PCR) assay was performed on lung DNA to detect the viral cyclin gene of HHV-8. Sequence analysis was also performed. RESULTS: In lung tissue from 10 of 16 patients with primary pulmonary hypertension (62 percent), cells within the plexiform lesions as well as cells outside the lesions were positive for LANA-1 on immunohistochemical analysis. Tissue from the same 10 patients contained viral cyclin on PCR analysis. No LANA-1 was detected in lung tissue from patients with secondary pulmonary hypertension, although one such patient had PCR evidence of viral cyclin. Plexiform lesions from patients with primary pulmonary hypertension had a histologic and immunohistochemical resemblance to cutaneous Kaposi's sarcoma lesions. CONCLUSIONS: The spectrum of trigger factors and molecular mechanisms leading to severe pulmonary hypertension and the formation of plexiform lesions is apparently wide, including both genetic and epigenetic factors. Our data suggest that infection with the vasculotropic virus HHV-8 may have a pathogenetic role in primary pulmonary hypertension.	Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care, Pulm Hypertens Ctr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Webb Waring Inst, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Johns Hopkins Univ, Dept Pathol, Cardiopulm Div, Baltimore, MD USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; Johns Hopkins University	Voelkel, NF (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care, Pulm Hypertens Ctr, Box C272,4200 E 9th Ave, Denver, CO 80262 USA.	norbert.voelkel@uchsc.edu	Routes, john/AAA-4833-2021; Brown, Kevin/ABF-2544-2020; Hernandez-Saavedra, Daniel/AGO-1286-2022	Routes, john/0000-0001-8378-3773; Hernandez-Saavedra, Daniel/0000-0003-1449-944X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003911] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL66524, K08 HL03911] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; BULL TM, IN PRESS EUR RESP J; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Dittmer D, 1998, J VIROL, V72, P8309, DOI 10.1128/JVI.72.10.8309-8315.1998; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Eddahibi S, 2000, AM J RESP CRIT CARE, V162, P1493, DOI 10.1164/ajrccm.162.4.2003124; Fakhari FD, 2002, J VIROL, V76, P6213, DOI 10.1128/JVI.76.12.6213-6223.2002; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Geraci MW, 2001, CIRC RES, V88, P555, DOI 10.1161/01.RES.88.6.555; HUMBERT M, 1995, AM J RESP CRIT CARE, V151, P1628, DOI 10.1164/ajrccm.151.5.7735624; Judde JG, 2000, JNCI-J NATL CANCER I, V92, P729, DOI 10.1093/jnci/92.9.729; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Lee SD, 1998, J CLIN INVEST, V101, P927, DOI 10.1172/JCI1910; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; LOSCALZO J, 1992, NEW ENGL J MED, V327, P117, DOI 10.1056/NEJM199207093270209; Machado RD, 2001, AM J HUM GENET, V68, P92, DOI 10.1086/316947; Masood R, 2002, AM J PATHOL, V160, P23, DOI 10.1016/S0002-9440(10)64344-1; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Mehta NJ, 2000, CHEST, V118, P1133, DOI 10.1378/chest.118.4.1133; METTE SA, 1992, AM REV RESPIR DIS, V145, P1196, DOI 10.1164/ajrccm/145.5.1196; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Pan LX, 2001, J MOL DIAGN, V3, P32, DOI 10.1016/S1525-1578(10)60647-2; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; SCHULZ TF, 1998, HUMAN TUMOR VIRUSES, P87; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; SPEICH R, 1991, CHEST, V100, P1268, DOI 10.1378/chest.100.5.1268; Thomson JR, 2000, J MED GENET, V37, P741, DOI 10.1136/jmg.37.10.741; Tuder RM, 1998, J LAB CLIN MED, V132, P16, DOI 10.1016/S0022-2143(98)90020-8; Tuder RM, 2001, J PATHOL, V195, P367, DOI 10.1002/path.953; TUDER RM, 1994, AM J PATHOL, V144, P275; Tuder RM, 2001, CLIN CHEST MED, V22, P405, DOI 10.1016/S0272-5231(05)70280-X; Voelkel NF, 2002, CRIT CARE MED, V30, pS251, DOI 10.1097/00003246-200205001-00013; Voelkel NF, 1995, EUR RESPIR J, V8, P2129, DOI 10.1183/09031936.95.08122129; Weiss R A, 1998, J Natl Cancer Inst Monogr, P51; Yeager ME, 1999, CIRCULATION, V100, P587; Zur Hausen H, 2001, ONCOGENE, V20, P7820, DOI 10.1038/sj.onc.1204958; BLAST 2 SEQUENES	44	213	221	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1113	1122		10.1056/NEJMoa035115	http://dx.doi.org/10.1056/NEJMoa035115			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679525				2022-12-28	WOS:000185369700004
J	Shiffman, RN; Shekelle, P; Overhage, JM; Slutsky, J; Grimshaw, J; Deshpande, AM				Shiffman, RN; Shekelle, P; Overhage, JM; Slutsky, J; Grimshaw, J; Deshpande, AM			Standardized reporting of clinical practice guidelines: A proposal from the conference on guideline standardization	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED TRIALS; CONSORT STATEMENT; QUALITY; CARE; APPROPRIATENESS	Despite enormous energies invested in authoring clinical practice guidelines, the quality of individual guidelines varies considerably. The Conference on Guideline Standardization (COGS) was convened in April 2002 to define a standard for guideline reporting that would promote guideline quality and facilitate implementation. Twenty-three people with expertise and experience in guideline development, dissemination, and implementation participated. A list of candidate guideline components was assembled from the Institute of Medicine Provisional Instrument for Assessing Clinical Guidelines, the National Guideline Clearinghouse, the Guideline Elements Model, and other published guideline models. in a 2-stage modified Delphi process, panelists first rated their agreement with the statement that "[Item, name] is a necessary component of practice guidelines" on a 9-point scale. An individualized report was prepared for each panelist; the report summarized the panelist's rating for each item and the median and dispersion of rankings of all the panelists. In a second round, panelists separately rated necessity for validity and necessity for practical application. Items achieving a median rank of 7 or higher on either scale, with low disagreement index, were retained as necessary guideline components. Representatives of 22 organizations active in guideline development reviewed the proposed items and commented favorably. Closely related items were consolidated into 18 topics to create the COGS checklist. This checklist provides a framework to support more comprehensive documentation of practice guidelines. Most organizations that are active in guideline development found the component items to be comprehensive and to fit within their existing development methods.	Yale Univ, Ctr Med Informat, New Haven, CT 06512 USA	Yale University	Shiffman, RN (corresponding author), Yale Univ, Ctr Med Informat, 300 George St,Suite 501, New Haven, CT 06512 USA.	Richard.Shiffman@yale.edu	Shiffman, Richard/A-7190-2009; Grimshaw, Jeremy/D-8726-2013	Grimshaw, Jeremy/0000-0001-8015-8243; Overhage, Joseph/0000-0003-0223-0195	AHRQ HHS [R13 HS10962] Funding Source: Medline; NLM NIH HHS [R01 LM07199, R29-LM05551] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R13HS010962] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM007199, N01LM005551] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; BROOK RH, 1993, SCHWEIZ MED WSCHR, V123, P249; Choudhry NK, 2002, JAMA-J AM MED ASSOC, V287, P612, DOI 10.1001/jama.287.5.612; Cluzeau F A, 1999, Jt Comm J Qual Improv, V25, P514; Cluzeau FA, 1999, INT J QUAL HEALTH C, V11, P21, DOI 10.1093/intqhc/11.1.21; Cranney A, 2002, BMC MUSCULOSKEL DIS, V3, DOI 10.1186/1471-2474-3-20; Egger M, 2001, JAMA-J AM MED ASSOC, V285, P1996, DOI 10.1001/jama.285.15.1996; Fitch K., 2001, RAND UCLA APPROPRIAT; Graham ID, 2001, CAN MED ASSOC J, V165, P157; Graham ID, 2000, INT J TECHNOL ASSESS, V16, P1024, DOI 10.1017/S0266462300103095; Grilli R, 2000, LANCET, V355, P103, DOI 10.1016/S0140-6736(99)02171-6; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; Hayward R S, 1993, Ann Intern Med, V118, P731; Institute of Medicine, 1992, GUID CLIN PRACT DEV; KAHAN JP, 1994, MED CARE, V32, P357, DOI 10.1097/00005650-199404000-00004; Lavis JN, 1996, CAN MED ASSOC J, V154, P321; LEAPE LL, 1991, JRA02; Littlejohns P, 1999, BRIT J GEN PRACT, V49, P205; Merritt TA, 1997, PEDIATRICS, V99, P100, DOI 10.1542/peds.99.1.100; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; Shiffman RN, 2000, J AM MED INFORM ASSN, V7, P488, DOI 10.1136/jamia.2000.0070488; TIERNEY WM, 1995, J AM MED INFORM ASSN, V2, P316, DOI 10.1136/jamia.1995.96073834; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; NATL GUIDELINE CLEAR; GUIDELINE SUMMARY SH	29	299	326	2	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					493	498		10.7326/0003-4819-139-6-200309160-00013	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00013			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	721PE	13679327				2022-12-28	WOS:000185324100006
J	Bernstein, M				Bernstein, M			Surgical planning error: what's in a name?	LANCET			English	Editorial Material									Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Bernstein, M (corresponding author), Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					908	908		10.1016/S0140-6736(03)14336-X	http://dx.doi.org/10.1016/S0140-6736(03)14336-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678980				2022-12-28	WOS:000185329400025
J	Kirwan, CC; Nath, E; Byrne, GJ; McCollum, CN				Kirwan, CC; Nath, E; Byrne, GJ; McCollum, CN			Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER		Wythenshawe Hosp, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Byrne, GJ (corresponding author), Wythenshawe Hosp, Educ & Res Bldg, Manchester M23 9LT, Lancs, England.		Kirwan, Cliona/HHZ-8872-2022	Kirwan, Cliona/0000-0002-1725-4790; Byrne, Ged/0000-0002-8194-7540				FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; GOODNOUGH LT, 1984, CANCER-AM CANCER SOC, V54, P1264, DOI 10.1002/1097-0142(19841001)54:7<1264::AID-CNCR2820540706>3.0.CO;2-R; Jilma B, 2003, BRIT MED J, V326, P93, DOI 10.1136/bmj.326.7380.93; Thodiyil PA, 2001, ACTA HAEMATOL-BASEL, V106, P73, DOI 10.1159/000046592; WEISS RB, 1981, CANCER TREAT REP, V65, P677	5	33	33	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					597	598		10.1136/bmj.327.7415.597	http://dx.doi.org/10.1136/bmj.327.7415.597			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969928	Green Published, Bronze			2022-12-28	WOS:000185358700024
J	Granger, CB; McMurray, JJV; Yusuf, S; Held, P; Michelson, EL; Olofsson, B; Ostergren, J; Pfeffer, MA; Swedberg, K				Granger, CB; McMurray, JJV; Yusuf, S; Held, P; Michelson, EL; Olofsson, B; Ostergren, J; Pfeffer, MA; Swedberg, K		CHARM Investigators Comm	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial	LANCET			English	Article							CONTEMPORARY MANAGEMENT; RECEPTOR BLOCKERS; RANDOMIZED TRIAL; MORBIDITY; MORTALITY; DYSFUNCTION; PROGRAM; IMPROVEMENT; ANGIOEDEMA; ENALAPRIL	Background Angiotensin-converting-enzyme (ACE) inhibitors improve outcome of patients with chronic heart failure (CHF). A substantial proportion of patients, however, experience no benefit from ACE inhibitors because of previous intolerance. We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in such patients not taking an ACE inhibitor. Methods Between March, 1999, and March, 2001, we enrolled 2028 patients with symptomatic heart failure and left-ventricular ejection fraction 40% or less who were not receiving ACE inhibitors because of previous intolerance. Patients were randomly assigned candesartan (target dose 32 mg once daily) or matching placebo. The primary outcome of the study was the composite of cardiovascular death or hospital admission for CHF. Analysis was by intention to treat. Findings The most common manifestation of ACE-inhibitor intolerance was cough (72%), followed by symptomatic hypotension (13%) and renal dysfunction (12%). During a median follow-up of 33.7 months, 334 (33%) of 1013 patients in the candesartan group and 406 (40%) of 1015 in the placebo group had cardiovascular death or hospital admission for CHF (unadjusted hazard ratio 0.77 [95% CI 0.67-0.89], p=0.0004; covariate adjusted 0.70 [0.60-0.81], p<0.0001). Each component of the primary outcome was reduced, as was the total number of hospital admissions for CHF. Study-drug discontinuation rates were similar in the candesartan (30%) and placebo (29%) groups. Interpretation Candesartan was generally well tolerated and reduced cardiovascular mortality and morbidity in patients with symptomatic chronic heart failure and intolerance to ACE inhibitors.	Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA; Univ Glasgow, Glasgow, Lanark, Scotland; Hamilton Hlth Sci, Hamilton, ON, Canada; McMaster Univ, Hamilton, ON, Canada; AstraZeneca R&D, Molndal, Sweden; AstraZeneca LP, Wilmington, DE USA; Karolinska Hosp, S-10401 Stockholm, Sweden; Brigham & Womens Hosp, Boston, MA 02115 USA; Sahlgrenska Univ Hosp Ostra, Gothenburg, Sweden	Duke University; University of Glasgow; McMaster University; McMaster University; AstraZeneca; AstraZeneca; Karolinska Institutet; Karolinska University Hospital; Harvard University; Brigham & Women's Hospital; Sahlgrenska University Hospital	Granger, CB (corresponding author), Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA.		mcmurray, John/B-2467-2013; Swedberg, Karl/B-2475-2008; Granger, Christopher B/D-3458-2014	mcmurray, John/0000-0002-6317-3975; Granger, Christopher B/0000-0002-0045-3291; Yusuf, Salim/0000-0003-4776-5601				Bart BA, 1999, EUR HEART J, V20, P1182, DOI 10.1053/euhj.1998.1481; Cleland JGF, 2002, LANCET, V360, P1631, DOI 10.1016/S0140-6736(02)11601-1; Cleland JGF, 2003, EUR HEART J, V24, P442, DOI 10.1016/S0195-668X(02)00823-0; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Gavras I, 2003, ARCH INTERN MED, V163, P240, DOI 10.1001/archinte.163.2.240; Granger CB, 2000, AM HEART J, V139, P609, DOI 10.1016/S0002-8703(00)90037-1; Kostis JB, 1996, AM HEART J, V131, P350, DOI 10.1016/S0002-8703(96)90365-8; Maggioni AP, 2002, J AM COLL CARDIOL, V40, P1414, DOI 10.1016/S0735-1097(02)02304-5; McMurray J, 2003, EUR J HEART FAIL, V5, P261, DOI 10.1016/S1388-9842(03)00052-7; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; PACKER M, 2000, AM COLL CARD 49 SCI; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; Riegger GAJ, 1999, CIRCULATION, V100, P2224, DOI 10.1161/01.CIR.100.22.2224; Swedberg K, 1999, J Card Fail, V5, P276, DOI 10.1016/S1071-9164(99)90013-1; Warner KK, 2000, ANN PHARMACOTHER, V34, P526, DOI 10.1345/aph.19294; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	19	1190	1260	1	29	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					772	776		10.1016/S0140-6736(03)14284-5	http://dx.doi.org/10.1016/S0140-6736(03)14284-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678870				2022-12-28	WOS:000185188500009
J	Bendjennat, M; Boulaire, J; Jascur, T; Brickner, H; Barbier, V; Sarasin, A; Fotedar, A; Fotedar, R				Bendjennat, M; Boulaire, J; Jascur, T; Brickner, H; Barbier, V; Sarasin, A; Fotedar, A; Fotedar, R			UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair	CELL			English	Article							NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE ARREST; HUMAN FIBROBLASTS; G(1) ARREST; P53 PROTEIN; IN-VITRO; P21; PCNA; RADIATION; INHIBITION	p53-mediated increase in cyclin-dependent kinase inhibitor p21(WAF1) protein is thought to be the major mediator of cell cycle arrest after DNA damage. Previously p21 protein levels have been reported to increase or to decrease after UV irradiation. We show that p21 protein is degraded after irradiation of a variety of cell types with low but not high doses of UV. Cell cycle arrest occurs despite p21 degradation via Tyr(15) inhibitory phosphorylation of cdk2 and differs from the classical p21-dependent checkpoint elicited by ionizing radiation. In contrast to the basal turnover of p21, degradation of p21 switches to ubiquitin/Skp2-dependent proteasome pathway following UV irradiation. ATR activation after UV irradiation is essential for signaling p21 degradation. Finally, UV-induced p21 degradation is essential for optimal DNA repair. These results provide novel insight into regulation of p21 protein and its role in the cellular response to DNA damage.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Inst Gustave Roussy, F-94805 Villejuif, France; Inst Biol Struct JP Ebel, F-38027 Grenoble, France	UNICANCER; Gustave Roussy; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Fotedar, A (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Rd, San Diego, CA 92121 USA.	afotedar@skcc.org; fotedar@ibs.fr	Boulaire, Jerome/A-5954-2009		NATIONAL CANCER INSTITUTE [R01CA074435, R01CA092321] Funding Source: NIH RePORTER; NCI NIH HHS [CA74435, CA92321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, EXP CELL RES, V221, P326, DOI 10.1006/excr.1995.1382; ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Adimoolam S, 2001, J BIOL CHEM, V276, P25813, DOI 10.1074/jbc.M102240200; Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Boulaire J, 2000, PATHOL BIOL, V48, P190; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CLEAVER JE, 1981, DNA REPAIR LABORATOR, P277; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fotedar R, 1996, ONCOGENE, V12, P2155; Freedman DA, 1999, CANCER RES, V59, P1; Geyer RK, 2000, CELL GROWTH DIFFER, V11, P149; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Rieber M, 2000, INT J CANCER, V86, P462, DOI 10.1002/(SICI)1097-0215(20000515)86:4<462::AID-IJC3>3.0.CO;2-B; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schoenfeld AR, 2000, ONCOGENE, V19, P5851, DOI 10.1038/sj.onc.1203985; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	51	220	225	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	2003	114	5					599	610		10.1016/j.cell.2003.08.001	http://dx.doi.org/10.1016/j.cell.2003.08.001			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678583	Bronze			2022-12-28	WOS:000185193100009
J	Thayer, SP; di Magliano, MP; Heiser, PW; Nielsen, CM; Roberts, DJ; Lauwers, GY; Qi, YP; Gysin, S; Fernandez-del Castillo, CF; Yajnik, V; Antoniu, B; McMahon, M; Warshaw, AL; Hebrok, M				Thayer, SP; di Magliano, MP; Heiser, PW; Nielsen, CM; Roberts, DJ; Lauwers, GY; Qi, YP; Gysin, S; Fernandez-del Castillo, CF; Yajnik, V; Antoniu, B; McMahon, M; Warshaw, AL; Hebrok, M			Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis	NATURE			English	Article							SONIC-HEDGEHOG; INTRAEPITHELIAL NEOPLASIA; SIGNALING PATHWAY; DUCT LESIONS; NEURAL-TUBE; EXPRESSION; GENE; ADENOCARCINOMA; INACTIVATION; CYCLOPAMINE	Hedgehog signalling-an essential pathway during embryonic pancreatic development, the misregulation of which has been implicated in several forms of cancer-may also be an important mediator in human pancreatic carcinoma(1-8). Here we report that sonic hedgehog, a secreted hedgehog ligand, is abnormally expressed in pancreatic adenocarcinoma and its precursor lesions: pancreatic intraepithelial neoplasia (PanIN). Pancreata of Pdx-Shh mice (in which Shh is misexpressed in the pancreatic endoderm) develop abnormal tubular structures, a phenocopy of human PanIN-1 and -2. Moreover, these PanIN-like lesions also contain mutations in K-ras and overexpress HER-2/neu, which are genetic mutations found early in the progression of human pancreatic cancer. Furthermore, hedgehog signalling remains active in cell lines established from primary and metastatic pancreatic adenocarcinomas. Notably, inhibition of hedgehog signalling by cyclopamine induced apoptosis and blocked proliferation in a subset of the pancreatic cancer cell lines both in vitro and in vivo. These data suggest that this pathway may have an early and critical role in the genesis of this cancer, and that maintenance of hedgehog signalling is important for aberrant proliferation and tumorigenesis.	Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Calif San Francisco, Dept Med, Ctr Diabet, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hebrok, M (corresponding author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.		Roberts, Drucilla/AAB-6379-2022; Castillo, Carlos Fenandez-del/AAO-2602-2020	Heiser, Patrick/0000-0002-8831-4973; Pasca di Magliano, Marina/0000-0001-9632-9035	NICHD NIH HHS [R29 HD034448-02] Funding Source: Medline; NIDDK NIH HHS [R01 DK060533] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD034448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060533] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; Day JD, 1996, HUM PATHOL, V27, P119, DOI 10.1016/S0046-8177(96)90364-0; Hardcastle Z, 1998, DEVELOPMENT, V125, P2803; HASEGAWA Y, 1995, ONCOGENE, V10, P1441; Hebrok M, 2000, DEVELOPMENT, V127, P4905; Hebrok M, 2003, MECH DEVELOP, V120, P45, DOI 10.1016/S0925-4773(02)00331-3; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Ito Y, 2002, INT J ONCOL, V20, P1263; Jaffee EM, 1998, CANCER J SCI AM, V4, P194; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Lee J, 1997, DEVELOPMENT, V124, P2537; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; ROBERTS DJ, 2000, DEV GASTROINTESTINAL, P1; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sasaki H, 1997, DEVELOPMENT, V124, P1313; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; van den Brink GR, 2001, GASTROENTEROLOGY, V121, P317, DOI 10.1053/gast.2001.26261; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; Wilentz RE, 1998, CANCER RES, V58, P4740; Wilentz RE, 2000, CANCER RES, V60, P2002	30	1192	1320	2	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					851	856		10.1038/nature02009	http://dx.doi.org/10.1038/nature02009			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14520413	Green Accepted			2022-12-28	WOS:000186118500048
J	Chan, SP; Kao, DI; Tsai, WY; Cheng, SC				Chan, SP; Kao, DI; Tsai, WY; Cheng, SC			The Prp19p-associated complex in spliceosome activation	SCIENCE			English	Article							PRE-MESSENGER-RNA; SM-LIKE PROTEINS; SMALL NUCLEAR RNAS; U6 SNRNA; REQUIRES ATP; YEAST; SITE; ASSOCIATION; COMPONENTS; PRP19	During spliceosome activation, a large structural rearrangement occurs that involves the release of two small nuclear RNAs, U1 and U4, and the addition of a protein complex associated with Prp19p. We show here that the Prp19p-associated complex is required for stable association of U5 and U6 with the spliceosome after U4 is dissociated. Ultraviolet crosslinking analysis revealed the existence of two modes of base pairing between U6 and the 5' splice site, as well as a switch of such base pairing from one to the other that required the Prp19p-associated complex during spliceosome activation. Moreover, a Prp19p-dependent structural change in U6 small nuclear ribonucleoprotein particles was detected that involves destabilization of Sm-like (Lsm) proteins to bring about interactions between the Lsm binding site of U6 and the intron sequence near the 5' splice site, indicating dynamic association of Lsm with U6 and a direct role of Lsm proteins in activation of the spliceosome.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Shih Pai, Taiwan; Acad Sinica, Inst Mol Biol, Nankang, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Cheng, SC (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Shih Pai, Taiwan.	mbscc@ccvax.sinica.edu.tw	Cheng, Soo-Chen/AAZ-7956-2021	Cheng, Soo-Chen/0000-0002-7570-9415; Chan, Shih-Peng/0000-0001-6322-2821				Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; Ajuh P, 2000, EMBO J, V19, P6569, DOI 10.1093/emboj/19.23.6569; Brow DA, 2002, ANNU REV GENET, V36, P333, DOI 10.1146/annurev.genet.36.043002.091635; Burge CB, 1999, RNA WORLD, P525; Chen CH, 2002, NUCLEIC ACIDS RES, V30, P1029, DOI 10.1093/nar/30.4.1029; Chen CH, 2001, J BIOL CHEM, V276, P488, DOI 10.1074/jbc.M006958200; Chen HR, 1998, MOL CELL BIOL, V18, P2196, DOI 10.1128/MCB.18.4.2196; Chen JYF, 2001, MOL CELL, V7, P227, DOI 10.1016/S1097-2765(01)00170-8; CHENG SC, 1994, NUCLEIC ACIDS RES, V22, P1548, DOI 10.1093/nar/22.9.1548; Kim CH, 1996, RNA, V2, P995; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; Makarov EM, 2002, SCIENCE, V298, P2205, DOI 10.1126/science.1077783; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; Ohi MD, 2002, MOL CELL BIOL, V22, P2011, DOI 10.1128/MCB.22.7.2011-2024.2002; Raghunathan PL, 1998, CURR BIOL, V8, P847, DOI 10.1016/S0960-9822(07)00345-4; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; Staley JP, 1999, MOL CELL, V3, P55, DOI 10.1016/S1097-2765(00)80174-4; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; TARN WY, 1993, MOL CELL BIOL, V13, P1883, DOI 10.1128/MCB.13.3.1883; TARN WY, 1994, EMBO J, V13, P2421, DOI 10.1002/j.1460-2075.1994.tb06527.x; Tsai WY, 1999, J BIOL CHEM, V274, P9455, DOI 10.1074/jbc.274.14.9455; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; Wang Q, 2003, J BIOL CHEM, V278, P7875, DOI 10.1074/jbc.M210839200; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	28	243	244	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					279	282		10.1126/science.1086602	http://dx.doi.org/10.1126/science.1086602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	12970570				2022-12-28	WOS:000185825900040
J	Lembo, A; Camilleri, M				Lembo, A; Camilleri, M			Current concepts: Chronic constipation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HIRSCHSPRUNGS-DISEASE; UNITED-STATES; BOWEL HABITS; GUT TRANSIT; STOOL FORM; DEFECATION; HEALTH; EPIDEMIOLOGY; BIOFEEDBACK; MANAGEMENT		Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; Mayo Clin & Mayo Fdn, Div Gastroenterol, Rochester, MN 55905 USA	Harvard University; Beth Israel Deaconess Medical Center; Mayo Clinic	Lembo, A (corresponding author), Beth Israel Deaconess Med Ctr, Div Gastroenterol, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.	alembo@bidmc.harvard.edu			NCCIH NIH HHS [R01AT001414] Funding Source: Medline; NIDDK NIH HHS [K24 DK02638, R01 DK54681] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054681, K24DK002638] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1999, GASTROENTEROLOGY, V116, P732, DOI 10.1016/S0016-5085(99)70195-2; Ashraf W, 1996, AM J GASTROENTEROL, V91, P26; BADIALI D, 1985, DIS COLON RECTUM, V28, P241, DOI 10.1007/BF02554044; BARNES PRH, 1986, GUT, V27, P534, DOI 10.1136/gut.27.5.534; BASSOTTI G, 1993, DIGEST DIS SCI, V38, P1040, DOI 10.1007/BF01295719; CAMILLERI M, 1994, ANN INTERN MED, V121, P520, DOI 10.7326/0003-4819-121-7-199410010-00008; Corazziari E, 1996, DIGEST DIS SCI, V41, P1636, DOI 10.1007/BF02087913; CORTESINI C, 1995, DIGEST DIS SCI, V40, P2450, DOI 10.1007/BF02063253; Degen LP, 1996, GUT, V39, P109, DOI 10.1136/gut.39.1.109; DOIG CM, 1992, BRIT MED J, V305, P462, DOI 10.1136/bmj.305.6851.462; EDERY P, 1994, J MED GENET, V31, P602, DOI 10.1136/jmg.31.8.602; ENCK P, 1993, DIGEST DIS SCI, V38, P1953, DOI 10.1007/BF01297069; EVERETT HC, 1975, AM J PSYCHIAT, V132, P1202; EVERHART JE, 1989, DIGEST DIS SCI, V34, P1153, DOI 10.1007/BF01537261; FLESHMAN JW, 1992, DIS COLON RECTUM, V35, P1019, DOI 10.1007/BF02252990; Flig E, 2000, INT J PHARM, V196, P11, DOI 10.1016/S0378-5173(99)00385-3; Grider JR, 1998, GASTROENTEROLOGY, V115, P370, DOI 10.1016/S0016-5085(98)70203-3; Harewood GC, 1999, AM J GASTROENTEROL, V94, P126; He CL, 2000, GASTROENTEROLOGY, V118, P14, DOI 10.1016/S0016-5085(00)70409-4; HEATON KW, 1992, GUT, V33, P818, DOI 10.1136/gut.33.6.818; HINTON JM, 1969, GUT, V10, P842, DOI 10.1136/gut.10.10.842; JOHANSON JF, 1989, J CLIN GASTROENTEROL, V11, P525, DOI 10.1097/00004836-198910000-00008; KLAUSER AG, 1990, DIGEST DIS SCI, V35, P1271, DOI 10.1007/BF01536418; Knowles CH, 1999, ANN SURG, V230, P627, DOI 10.1097/00000658-199911000-00004; Koch A, 1997, DIS COLON RECTUM, V40, P902, DOI 10.1007/BF02051196; KOUTSOMANIS D, 1995, GUT, V37, P95, DOI 10.1136/gut.37.1.95; KREVSKY B, 1989, AM J GASTROENTEROL, V84, P882; Lieberman DA, 2001, NEW ENGL J MED, V345, P555, DOI 10.1056/NEJMoa010328; LoeningBaucke V, 1996, PEDIATR CLIN N AM, V43, P279, DOI 10.1016/S0031-3955(05)70406-5; Mertz H, 1999, AM J GASTROENTEROL, V94, P609, DOI 10.1016/S0002-9270(98)00803-X; Meshkinpour H, 1998, DIGEST DIS SCI, V43, P2379, DOI 10.1023/A:1026609610466; Muller-Lissner SA, 2001, ALIMENT PHARM THER, V15, P1655, DOI 10.1046/j.1365-2036.2001.01094.x; NYAM DC, 1997, DIS COLON RECTUM, V40, P529; Nyam DCNK, 1997, DIS COLON RECTUM, V40, P273, DOI 10.1007/BF02050415; OBrien MD, 1996, AM J GASTROENTEROL, V91, P2532; Pare P, 2001, AM J GASTROENTEROL, V96, P3130, DOI 10.1111/j.1572-0241.2001.05259.x; Pelsang RE, 1999, AM J GASTROENTEROL, V94, P183; PEZIM ME, 1993, DIS COLON RECTUM, V36, P484, DOI 10.1007/BF02050015; Ponec RJ, 1999, NEW ENGL J MED, V341, P137, DOI 10.1056/NEJM199907153410301; PRESTON DM, 1986, GUT, V27, P41, DOI 10.1136/gut.27.1.41; Rao SSC, 1998, AM J GASTROENTEROL, V93, P1042; REDMOND JM, 1995, AM J GASTROENTEROL, V90, P748; RICHARDSON AC, 1993, CLIN OBSTET GYNECOL, V36, P976, DOI 10.1097/00003081-199312000-00022; Roarty TP, 1997, ALIMENT PHARM THER, V11, P1059, DOI 10.1046/j.1365-2036.1997.00237.x; Ron Y, 2001, DIS COLON RECTUM, V44, P1821, DOI 10.1007/BF02234461; SANDLER RS, 1987, DIGEST DIS SCI, V32, P841, DOI 10.1007/BF01296706; SARLES JC, 1989, INT J COLORECTAL DIS, V4, P167, DOI 10.1007/BF01649696; SONNENBERG A, 1989, DIGEST DIS SCI, V34, P606, DOI 10.1007/BF01536339; Stewart WF, 1999, AM J GASTROENTEROL, V94, P3530, DOI 10.1111/j.1572-0241.1999.01642.x; STIVLAND T, 1991, GASTROENTEROLOGY, V101, P107, DOI 10.1016/0016-5085(91)90466-X; Thompson WG, 1999, GUT, V45, P43; Tzavella K, 1996, EUR J GASTROEN HEPAT, V8, P1207, DOI 10.1097/00042737-199612000-00014; Van Gorkom BAP, 1999, ALIMENT PHARM THERAP, V13, P443; Verne GN, 1997, DIGEST DIS SCI, V42, P1959, DOI 10.1023/A:1018883731556; Voderholzer WA, 1997, AM J GASTROENTEROL, V92, P95; WRENN K, 1989, NEW ENGL J MED, V321, P658; Young JB, 1998, DIABETES CARE, V21, pB156; Young-Fadok TM, 2001, SURG ENDOSC-ULTRAS, V15, P911, DOI 10.1007/s00464-001-0057-8	58	503	561	4	73	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1360	1368		10.1056/NEJMra020995	http://dx.doi.org/10.1056/NEJMra020995			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	727EM	14523145				2022-12-28	WOS:000185644000012
J	Shi, Y; Evans, JE; Rock, KL				Shi, Y; Evans, JE; Rock, KL			Molecular identification of a danger signal that alerts the immune system to dying cells	NATURE			English	Article							URATE MONOHYDRATE CRYSTALS; MONOSODIUM URATE; PARTICULATE ANTIGENS; ENDOGENOUS ADJUVANTS; DENDRITIC CELLS; URIC-ACID; SOLUBILITY; MACROPHAGES; GOUT	In infections, microbial components provide signals that alert the immune system to danger and promote the generation of immunity(1,2). In the absence of such signals, there is often no immune response or tolerance may develop. This has led to the concept that the immune system responds only to antigens perceived to be associated with a dangerous situation such as infection(3,4). Danger signals are thought to act by stimulating dendritic cells to mature so that they can present foreign antigens and stimulate T lymphocytes(2,5-7). Dying mammalian cells have also been found to release danger signals of unknown identity(8-11). Here we show that uric acid is a principal endogenous danger signal released from injured cells. Uric acid stimulates dendritic cell maturation and, when co-injected with antigen in vivo, significantly enhances the generation of responses from CD8(+) T cells. Eliminating uric acid in vivo inhibits the immune response to antigens associated with injured cells, but not to antigens presented by activated dendritic cells. Our findings provide a molecular link between cell injury and immunity and have important implications for vaccines, autoimmunity and inflammation.	Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Proteom & Mass Spectrometry Facil, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Rock, KL (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA.	kenneth.rock@umassmed.edu	Shi, Yan/Y-6642-2019					Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; BOSMANSKY K, 1984, Z RHEUMATOL, V43, P59; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Cox JC, 1997, VACCINE, V15, P248, DOI 10.1016/S0264-410X(96)00183-1; FIDDIS RW, 1983, ANN RHEUM DIS, V42, P12, DOI 10.1136/ard.42.Suppl_1.12; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Hunter RL, 2002, VACCINE, V20, pS7, DOI 10.1016/S0264-410X(02)00164-0; IWATA H, 1989, J UROLOGY, V142, P1095, DOI 10.1016/S0022-5347(17)39003-1; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jeha S, 2001, SEMIN HEMATOL, V38, P4, DOI 10.1053/shem.2001.29017; KIPPEN I, 1974, ANN RHEUM DIS, V33, P313, DOI 10.1136/ard.33.4.313; Koka RM, 2000, AM J PHYSIOL-RENAL, V278, pF989, DOI 10.1152/ajprenal.2000.278.6.F989; Landis RC, 2002, ARTHRITIS RHEUM, V46, P3026, DOI 10.1002/art.10614; LOEB JN, 1972, ARTHRITIS RHEUM-US, V15, P189, DOI 10.1002/art.1780150209; Majno G, 1996, CELLS TISSUES DIS PR; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Schijns VEJC, 2000, CURR OPIN IMMUNOL, V12, P456, DOI 10.1016/S0952-7915(00)00120-5; Shi Y, 2002, EUR J IMMUNOL, V32, P155, DOI 10.1002/1521-4141(200201)32:1<155::AID-IMMU155>3.0.CO;2-P; Shi Y, 2000, P NATL ACAD SCI USA, V97, P14590, DOI 10.1073/pnas.260497597; SMYTH CJ, 1998, GOUT HYPERURICEMIA O; TAK HK, 1980, ARTHRITIS RHEUM, V23, P574, DOI 10.1002/art.1780230509; TALBOTT JH, 1976, GOUT URIC ACID METAB; Vidard L, 1996, J IMMUNOL, V156, P2809; Yagnik DR, 2000, ARTHRITIS RHEUM, V43, P1779, DOI 10.1002/1529-0131(200008)43:8<1779::AID-ANR14>3.0.CO;2-2	26	1272	1350	2	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2003	425	6957					516	521		10.1038/nature01991	http://dx.doi.org/10.1038/nature01991			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14520412				2022-12-28	WOS:000185648100046
J	Lee, Y; Ahn, C; Han, JJ; Choi, H; Kim, J; Yim, J; Lee, J; Provost, P; Radmark, O; Kim, S; Kim, VN				Lee, Y; Ahn, C; Han, JJ; Choi, H; Kim, J; Yim, J; Lee, J; Provost, P; Radmark, O; Kim, S; Kim, VN			The nuclear RNase III Drosha initiates microRNA processing	NATURE			English	Article							RIBONUCLEASE-III; INTERFERENCE; EXPRESSION; DICER; IDENTIFICATION; MATURATION; PROTEINS; ENCODES; GENES	Hundreds of small RNAs of similar to22 nucleotides, collectively named microRNAs (miRNAs), have been discovered recently in animals and plants(1-10). Although their functions are being unravelled(1,2,11-13), their mechanism of biogenesis remains poorly understood. miRNAs are transcribed as long primary transcripts (pri-miRNAs) whose maturation occurs through sequential processing events: the nuclear processing of the pri-miRNAs into stem-loop precursors of similar to70 nucleotides (pre-miRNAs), and the cytoplasmic processing of pre-miRNAs into mature miRNAs(14). Dicer, a member of the RNase III superfamily of bidentate nucleases, mediates the latter step(15-19), whereas the processing enzyme for the former step is unknown. Here we identify another RNase III, human Drosha, as the core nuclease that executes the initiation step of miRNA processing in the nucleus. Immunopurified Drosha cleaved pri-miRNA to release pre-miRNA in vitro. Furthermore, RNA interference of Drosha resulted in the strong accumulation of pri-miRNA and the reduction of pre-miRNA and mature miRNA in vivo. Thus, the two RNase III proteins, Drosha and Dicer, may collaborate in the stepwise processing of miRNAs, and have key roles in miRNA-mediated gene regulation in processes such as development and differentiation.	Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Yonsei Univ, Dept Biol, Seoul 120749, South Korea; CHU Laval, Ctr Rech, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Seoul National University (SNU); Seoul National University (SNU); Yonsei University; Laval University; Karolinska Institutet	Lee, Y (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea.		Provost, Patrick/G-2786-2010; Han, Jinju/D-9091-2017	Provost, Patrick/0000-0002-6099-6562; HAN, Jinju/0000-0003-1844-2301; Kim, Jaekwang/0000-0002-7312-4077				Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Filippov V, 2000, GENE, V245, P213, DOI 10.1016/S0378-1119(99)00571-5; Fortin KR, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-26; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Wu HJ, 2000, J BIOL CHEM, V275, P36957, DOI 10.1074/jbc.M005494200; Zamore PD, 2001, MOL CELL, V8, P1158, DOI 10.1016/S1097-2765(01)00418-X; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	30	3660	4061	9	517	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					415	419		10.1038/nature01957	http://dx.doi.org/10.1038/nature01957			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508493				2022-12-28	WOS:000185502300045
J	Mukherjee, JS				Mukherjee, JS			HIV-1 care in resource-poor settings: a view from Haiti	LANCET			English	Editorial Material							HAART		Harvard Univ, Sch Med, Div Social Med & Hlth Inequal, Partners Hlth, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Partners Healthcare System	Mukherjee, JS (corresponding author), Harvard Univ, Sch Med, Div Social Med & Hlth Inequal, Partners Hlth, Boston, MA 02115 USA.							[Anonymous], 1916, PYGMALION; Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145; *FUND FUND, CURR FUND CRIS; Gilks C, 2001, B WORLD HEALTH ORGAN, V79, P1154; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6	5	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					994	995		10.1016/S0140-6736(03)14373-5	http://dx.doi.org/10.1016/S0140-6736(03)14373-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14513853				2022-12-28	WOS:000185489600026
J	O'Connell, H; Chin, AV; Cunningham, C; Lawlor, B				O'Connell, H; Chin, AV; Cunningham, C; Lawlor, B			Alcohol use disorders in elderly people - redefining an age old problem in old age	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HEAVY DRINKING; LATE-ONSET; COMMUNITY; RISK; MEN; CONSUMPTION; DEPRESSION; PREVALENCE; DEMENTIA; DRINKERS		St James Hosp, Mercers Inst Res Ageing, Dublin 8, Ireland	Trinity College Dublin	O'Connell, H (corresponding author), St James Hosp, Mercers Inst Res Ageing, Dublin 8, Ireland.	henryoconnell@hotmail.com	Ai-Vyrn, Chin/E-4237-2013	Ai-Vyrn, Chin/0000-0002-0332-0048				ADAMS SL, 1991, PSYCHOL REP, V68, P432, DOI 10.2466/PR0.68.2.432-434; Adams WL, 1995, INT J ADDICT, V30, P1693, DOI 10.3109/10826089509071053; BERESFORD TP, 1995, ALCOHOL AGING, P4; BERNADT MW, 1982, LANCET, V2, P235; Blow F, 1991, MICHIGAN ALCOHOLISM; BRENNAN PL, 1991, BRIT J ADDICT, V86, P1139; BRISTOW MF, 1992, BRIT J ADDICT, V87, P291; CALLAHAN CM, 1995, J AM GERIATR SOC, V43, P1378, DOI 10.1111/j.1532-5415.1995.tb06617.x; CHAIKELSON JS, 1994, J STUD ALCOHOL, V55, P133, DOI 10.15288/jsa.1994.55.133; *CNN ASS PRESS REU, ALC EUR YOUTH KILL; COLSHER PL, 1990, J STUD ALCOHOL, V51, P528, DOI 10.15288/jsa.1990.51.528; CURTIS JR, 1989, J AM GERIATR SOC, V37, P310, DOI 10.1111/j.1532-5415.1989.tb05496.x; DUNNE FJ, 1994, BRIT MED J, P308; EKERDT DJ, 1989, J STUD ALCOHOL, V50, P347, DOI 10.15288/jsa.1989.50.347; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Ganry O, 2000, ADDICTION, V95, P107, DOI 10.1046/j.1360-0443.2000.95110711.x; Goldstein MZ, 1996, PSYCHIATR SERV, V47, P941; HORTON A M JR, 1986, MMJ (Maryland Medical Journal), V35, P916; HURT RD, 1988, MAYO CLIN PROC, V63, P753, DOI 10.1016/S0025-6196(12)62354-4; Hybels CF, 2001, GERONTOLOGIST, V41, P357, DOI 10.1093/geront/41.3.357; ILIFFE S, 1991, AGE AGEING, V20, P120, DOI 10.1093/ageing/20.2.120; JANIK SW, 1983, J STUD ALCOHOL, V44, P307, DOI 10.15288/jsa.1983.44.307; Johnson I, 2000, INT J GERIATR PSYCH, V15, P575, DOI 10.1002/1099-1166(200007)15:7<575::AID-GPS151>3.0.CO;2-0; Khan N, 2002, NEW ZEAL MED J, V115, P72; KOFOED LL, 1987, J STUD ALCOHOL, V48, P47, DOI 10.15288/jsa.1987.48.47; Lakhani N, 1997, J ADV NURS, V25, P1227, DOI 10.1046/j.1365-2648.1997.19970251227.x; LISKOW BI, 1989, J STUD ALCOHOL, V50, P414, DOI 10.15288/jsa.1989.50.414; Mulinga JD, 1999, INT J GERIATR PSYCH, V14, P564; *NAT I ALC AB ALC, 1998, ALC AL 40; OSLIN DW, 1998, NIAAA RES MONOGRAPH, V33; Reid MC, 1997, MED CLIN N AM, V81, P999, DOI 10.1016/S0025-7125(05)70560-5; Ruitenberg A, 2002, LANCET, V359, P281, DOI 10.1016/S0140-6736(02)07493-7; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAUNDERS PA, 1991, BRIT J PSYCHIAT, V159, P213, DOI 10.1192/bjp.159.2.213; Skog OJ, 1996, ADDICTION, V91, P325, DOI 10.1111/j.1360-0443.1996.tb02283.x; *STRAT TASK FORC A, 2002, STRAT TASK FORC ALC; *UK NAT DIG ARCH D, 1994, GEN HOUS SURV UK	37	120	125	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2003	327	7416					664	667		10.1136/bmj.327.7416.664	http://dx.doi.org/10.1136/bmj.327.7416.664			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	724AC	14500441	Green Published			2022-12-28	WOS:000185463100025
J	Marler, JR; Goldstein, LB				Marler, JR; Goldstein, LB			Medicine - Stroke - tPA and the clinic	SCIENCE			English	Editorial Material							ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN-ACTIVATOR; PRACTICE GUIDELINES; RT-PA; STATEMENT		Natl Inst Neurol Disorders & Stroke, Clin Trials, Bethesda, MD 20817 USA; Duke Univ, Duke Ctr Cerebrovasc Dis, Dept Med Neurol, Durham, NC 27710 USA; Duke Univ, Ctr Clin Hlth Policy Res, Stroke Policy Program, Durham, NC 27710 USA; Vet Adm Med Ctr, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Marler, JR (corresponding author), Natl Inst Neurol Disorders & Stroke, Clin Trials, Bethesda, MD 20817 USA.	marlerj@ninds.nih.gov						Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Alberts MJ, 2000, JAMA-J AM MED ASSOC, V283, P3102, DOI 10.1001/jama.283.23.3102; Barber PA, 2001, NEUROLOGY, V56, P1015, DOI 10.1212/WNL.56.8.1015; Crocco T J, 1999, Prehosp Emerg Care, V3, P201, DOI 10.1080/10903129908958937; Fagan SC, 1998, NEUROLOGY, V50, P883, DOI 10.1212/WNL.50.4.883; Goldstein L B, 1999, J Stroke Cerebrovasc Dis, V8, P349, DOI 10.1016/S1052-3057(99)80010-X; Goldstein LB, 2000, STROKE, V31, P66, DOI 10.1161/01.STR.31.1.66; Katzan IL, 2003, STROKE, V34, P799, DOI 10.1161/01.STR.0000056944.42686.1E; Kidwell CS, 2000, STROKE, V31, P71, DOI 10.1161/01.STR.31.1.71; LaMonte MP, 2003, STROKE, V34, P725, DOI 10.1161/01.STR.0000056945.36583.37; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; Lopez-Yunez AR, 2001, STROKE, V32, P12, DOI 10.1161/01.STR.32.1.12; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; *NIH, IN PRESS NIH PUBL; Villar-Cordova C, 1998, NEUROLOGY, V50, P1491, DOI 10.1212/WNL.50.5.1491; ZIVIN JA, 1985, SCIENCE, V230, P1289, DOI 10.1126/science.3934754	17	50	54	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1677	1677		10.1126/science.1090270	http://dx.doi.org/10.1126/science.1090270			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500967				2022-12-28	WOS:000185387700028
J	Beaglehole, R; Yach, D				Beaglehole, R; Yach, D			Globalisation and the prevention and control of non-communicable disease: the neglected chronic diseases of adults	LANCET			English	Article							MIDDLE-AGED MEN; CARDIOVASCULAR-DISEASE; PUBLIC-HEALTH; MORTALITY; TIME; FRAMEWORK; OBESITY; SCIENCE; TOBACCO; TRENDS	The growing global burden of non-communicable diseases in poor countries and poor populations has been neglected by policy makers, major multilateral and bilateral aid donors, and academics. Despite strong evidence for the magnitude of this burden, the preventability of its causes, and the threat it poses to already strained health care systems, national and global actions have been inadequate. Globalisation is an important determinant of non-communicable disease epidemics since it has direct effects on risks to populations and indirect effects on national economies and health systems. The globalisation of the production and marketing campaigns of the tobacco and alcohol industries exemplify the challenges to policy makers and public health practitioners. A full range of policy responses is required from government and non-governmental agencies; unfortunately the capacity and resources for this response are insufficient, and governments need to respond appropriately. The progress made in controlling the tobacco industry is a modest cause for optimism.	WHO, CH-1211 Geneva 27, Switzerland	World Health Organization	Beaglehole, R (corresponding author), WHO, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	beagleholer@who.int	Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793				[Anonymous], 2001, ASSESSMENT NATL CAPA; [Anonymous], CORONARY HEART DIS E; [Anonymous], C TRAD DEV LEAST DEV; BARBOZA D, 2003, INT HERALD TRIB 0702; Beaglehole R, 2001, LANCET, V358, P661, DOI 10.1016/S0140-6736(01)05784-1; Berwick DM, 2002, BRIT MED J, V325, P55, DOI 10.1136/bmj.325.7355.55; BETTCHER D, 2001, WHONMHTFI014; Bettcher DW, 2000, B WORLD HEALTH ORGAN, V78, P521; BRANDS A, 2002, WOMEN RAPID RISE NON; BROWN SA, 1997, REVOLUTION CHECKOUT; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; *COMM MACR HLTH, 2001, MACR HLTH INV HLTH D; *DG AGRI, 2002, EXP FEOGA EAGGF COMM; DiGuiseppi C, 1998, BMJ-BRIT MED J, V316, P1426, DOI 10.1136/bmj.316.7142.1426; Ebbeling CB, 2002, LANCET, V360, P473, DOI 10.1016/S0140-6736(02)09678-2; *EC SOC COUNC AD H, 2002, REP SECR GEN; GOODMAN D, 1997, GLOBALISING FOOD; Helliwell J.F., 2000, GLOBALIZATION MYTHS; Jernigan D.H., 1997, THIRSTING MARKETS GL; Kahn EB, 2002, AM J PREV MED, V22, P73, DOI 10.1016/S0749-3797(02)00434-8; Kunst AE, 1998, BMJ-BRIT MED J, V316, P1636, DOI 10.1136/bmj.316.7145.1636; Luo J, 2002, INT J OBESITY, V26, P553, DOI 10.1038/sj.ijo.0801944; Mackenbach JP, 2000, EUR HEART J, V21, P1141, DOI 10.1053/euhj.1999.1990; Mackintosh M., 2001, POVERTY INEQUALITY H; Magnus P, 2001, ARCH INTERN MED, V161, P2657, DOI 10.1001/archinte.161.22.2657; MARSDEN R, 2000, CONSUMING INTERESTS; McGinnis JM, 2001, AM J HEALTH PROMOT, V15, P391, DOI 10.4278/0890-1171-15.5.391; McKee M, 2001, ANN EPIDEMIOL, V11, P1, DOI 10.1016/S1047-2797(00)00080-6; McNeal J. U., 2000, CHILDREN CONSUMERS C; Mintz S.W., 1996, TASTING FOOD TASTING; MORROW RH, 2002, BRIT MED J, V352, P53; Nchinda TC, 2002, SOC SCI MED, V54, P1699, DOI 10.1016/S0277-9536(01)00338-0; NESTLE M, 2013, FOOD POLITICS FOOD I; Ong EK, 2001, AM J PUBLIC HEALTH, V91, P1749, DOI 10.2105/AJPH.91.11.1749; PAXTON A, 1994, FOOD MILES REPORT; Popkin BM, 2002, PUBLIC HEALTH NUTR, V5, P93, DOI 10.1079/PHN200180; RAVEN H, 1995, OUR TROLLEYS RETAILI; Royal College of Physicians, 1962, SMOK HLTH; SALEEBY RN, 1971, REV DIRECTORY ONGOIN; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; Taylor AL, 2000, B WORLD HEALTH ORGAN, V78, P920; *UN NONG LIAIS SER, 2002, VOL APPR CORP RESP R; von Schirnding Y, 2002, REV SAUDE PUBL, V36, P379, DOI 10.1590/S0034-89102002000400001; WALSH D, 2002, WHO S MARK YOUNG PEO; WHO, 2001, WORLD HLTH REPORT 20; Woodward D, 2001, B WORLD HEALTH ORGAN, V79, P875; World Health Organization, 2001, INN CAR CHRON COND B; World Health Organization, 2002, NAT CANC CONTR PROGR; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; World Trade Organisation, 2001, DOH WTO MIN 2001 MIN; Yach D, 1998, AM J PUBLIC HEALTH, V88, P735, DOI 10.2105/AJPH.88.5.735; Yach D, 2001, AM J PUBLIC HEALTH, V91, P1745, DOI 10.2105/AJPH.91.11.1745; Yusuf S, 2002, LANCET, V360, P2, DOI 10.1016/S0140-6736(02)09358-3; Zeltner T., 2000, TOBACCO IND STRATEGI; Zhang X, 2000, J HYPERTENS, V18, pS25; Zwi AB, 2002, SOC SCI MED, V54, P1615, DOI 10.1016/S0277-9536(01)00346-X; [No title captured]	57	308	320	0	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 13	2003	362	9387					903	908		10.1016/S0140-6736(03)14335-8	http://dx.doi.org/10.1016/S0140-6736(03)14335-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	721RH	13678979				2022-12-28	WOS:000185329400024
J	Eaves, AA; Palmer, AR				Eaves, AA; Palmer, AR			Reproduction - Widespread cloning in echinoderm larvae	NATURE			English	Editorial Material							EVOLUTION		Univ Alberta, Dept Biol Sci, Physiol & Cell Biol Grp, Edmonton, AB T6G 2E9, Canada; Univ Alberta, Dept Biol Sci, Systemat & Evolut Grp, Edmonton, AB T6G 2E9, Canada; Bamfield Marine Sci Ctr, Bamfield, BC V0R 1B0, Canada	University of Alberta; University of Alberta; Simon Fraser University	Eaves, AA (corresponding author), Univ Alberta, Dept Biol Sci, Physiol & Cell Biol Grp, Edmonton, AB T6G 2E9, Canada.	aeaves@ualberta.ca	Palmer, A. Richard/A-3593-2010	Palmer, A. Richard/0000-0002-7579-3899				Balser EJ, 1998, BIOL BULL-US, V194, P187, DOI 10.2307/1543049; BOSCH I, 1989, NATURE, V337, P169, DOI 10.1038/337169a0; Cameron CB, 2000, P NATL ACAD SCI USA, V97, P4469, DOI 10.1073/pnas.97.9.4469; Davidson EH, 1998, DEVELOPMENT, V125, P3269; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; JAECKLE WB, 1994, BIOL BULL, V186, P62, DOI 10.2307/1542036; Knott KE, 2003, BIOL BULL-US, V204, P246, DOI 10.2307/1543596; Lacalli TC, 2000, INVERTEBR BIOL, V119, P234; MacBride EW, 1921, NATURE, V106, P501; Mortensen T., 1921, STUDIES DEV LARVAL F; Vickery MS, 2000, BIOL BULL, V199, P298, DOI 10.2307/1543186	11	61	62	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					146	146		10.1038/425146a	http://dx.doi.org/10.1038/425146a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968170	Bronze			2022-12-28	WOS:000185236000032
J	Shiner, A				Shiner, A			Shaping health care in Tanzania - who's pulling the strings?	LANCET			English	Article									UCL, Int Hlth & Med Educ Ctr, London WC1E 6BT, England; Royal Preston Hosp, Preston PR2 9HT, Lancs, England	University of London; University College London; Royal Preston Hospital	Shiner, A (corresponding author), UCL, Int Hlth & Med Educ Ctr, London WC1E 6BT, England.	mmmr7ams@doctors.org.uk		Shiner, Alice/0000-0002-0016-5759				Brown A., 2000, CURRENT ISSUES SECTO; CASSELS A, 1995, 1 WHO NAT HLTH SYST; MWABU G, 1995, HEALTH POLICY PLANN, V10, P164, DOI 10.1093/heapol/10.2.164; TIBAIJUKA AK, 1998, SOCIAL SERVICES CRIS; *UN DEV PROGR, 2001, HUM DEV REP 2001 MAK	5	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2003	362	9386					829	830		10.1016/S0140-6736(03)14280-8	http://dx.doi.org/10.1016/S0140-6736(03)14280-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	719DN	13678883				2022-12-28	WOS:000185188500028
J	Prigent, C; Giet, R				Prigent, C; Giet, R			Aurora A and mitotic commitment	CELL			English	Editorial Material							SIGNALING PATHWAY; KINASE; MATURATION; SPINDLE	A remarkable study published in this issue of Cell (Hirota et al., 2003) reveals a key role of Aurora A protein kinase in G2/M progression. To achieve this role, Aurora A acts in conjunction with the LIM protein Ajuba, which functions as an activating factor.	Univ Rennes 1, Equipe Labellisee Ligue Natl Contre Canc, CNRS, UMR 6061, F-35043 Rennes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Prigent, C (corresponding author), Univ Rennes 1, Equipe Labellisee Ligue Natl Contre Canc, CNRS, UMR 6061, 2 Ave Pr Leon Bernard, F-35043 Rennes, France.							Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936	10	14	16	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					531	532		10.1016/S0092-8674(03)00685-8	http://dx.doi.org/10.1016/S0092-8674(03)00685-8			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678575	Bronze			2022-12-28	WOS:000185193100001
J	Uehlein, N; Lovisolo, C; Siefritz, F; Kaldenhoff, R				Uehlein, N; Lovisolo, C; Siefritz, F; Kaldenhoff, R			The tobacco aquaporin NtAQP1 is a membrane CO2 pore with physiological functions	NATURE			English	Article							NICOTIANA-TABACUM; EXPRESSION; PERMEABILITY; LEAVES; MALATE; PLANTS	Aquaporins, found in virtually all living organisms, are membrane-intrinsic proteins that form water-permeable complexes. The mammalian aquaporin AQP1 has also shown CO2 permeability when expressed heterologously in Xenopus oocytes(1), although whether this is a biochemical curiosity or of physiological significance is a matter of debate(2,3). Here we report that, in the same expression system, a CO2 permeability comparable to that of the human AQP1 is observed for the tobacco plasma membrane aquaporin NtAQP1. NtAQP1 facilitates CO2 membrane transport in the homologous plant system at the cellular level, and has a significant function in photosynthesis and in stomatal opening. NtAQP1 overexpression heightens membrane permeability for CO2 and water, and increases leaf growth. The results indicate that NtAQP1-related CO2 permeability is of physiological importance under conditions where the CO2 gradient across a membrane is small, as is the case between the atmosphere and the inside of a plant cell.	Inst Bot, D-64287 Darmstadt, Germany; Univ Turin, Dept Agr & Pomol, I-10095 Grugliaso, Italy	University of Turin	Kaldenhoff, R (corresponding author), Inst Bot, Schnittspahnstr 3, D-64287 Darmstadt, Germany.		Lovisolo, Claudio/A-6610-2010	Lovisolo, Claudio/0000-0001-8825-2904				Biela A, 1999, PLANT J, V18, P565, DOI 10.1046/j.1365-313X.1999.00474.x; Cooper GJ, 2002, J PHYSIOL-LONDON, V542, P17, DOI 10.1113/jphysiol.2002.023218; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; Evans JR, 1996, PLANT PHYSIOL, V110, P339, DOI 10.1104/pp.110.2.339; Gallois P, 1995, Methods Mol Biol, V49, P39; Gatz C, 1997, ANNU REV PLANT PHYS, V48, P89, DOI 10.1146/annurev.arplant.48.1.89; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; HEDRICH R, 1994, PLANT J, V6, P741, DOI 10.1046/j.1365-313X.1994.6050741.x; Hedrich R, 2001, PLANTA, V213, P594, DOI 10.1007/s004250100524; KAISER WM, 1982, PLANTA, V154, P538, DOI 10.1007/BF00402997; MANSFIELD TA, 1990, ANNU REV PLANT PHYS, V41, P55, DOI 10.1146/annurev.pp.41.060190.000415; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Otto B, 2000, PLANTA, V211, P167, DOI 10.1007/s004250000275; RASCHKE K, 1975, ANNU REV PLANT PHYS, V26, P309, DOI 10.1146/annurev.pp.26.060175.001521; RASCHKE K, 1972, PLANT PHYSIOL, V49, P229, DOI 10.1104/pp.49.2.229; Siefritz F, 2002, PLANT CELL, V14, P869, DOI 10.1105/tpc.000901; Verkman AS, 2002, J PHYSIOL-LONDON, V542, P31, DOI 10.1113/jphysiol.2002.024398; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686	18	471	527	8	120	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					734	737		10.1038/nature02027	http://dx.doi.org/10.1038/nature02027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14520414				2022-12-28	WOS:000185924500045
J	Kummel, AC				Kummel, AC			How to assemble a molecular junction	SCIENCE			English	Editorial Material									Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kummel, AC (corresponding author), Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA.	akummel@ucsd.edu						Hirose Y, 1997, APPL SURF SCI, V113, P291, DOI 10.1016/S0169-4332(96)00886-0; Nazin GV, 2003, SCIENCE, V302, P77, DOI 10.1126/science.1088971; Reichert J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.176804	3	3	4	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					69	70		10.1126/science.1091067	http://dx.doi.org/10.1126/science.1091067			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526069				2022-12-28	WOS:000185678500033
J	Stenzel-Poore, MP; Stevens, SL; Xiong, ZG; Lessov, NS; Harrington, CA; Mori, M; Meller, R; Rosenzweig, HL; Tobar, E; Shaw, TE; Chu, XP; Simon, RP				Stenzel-Poore, MP; Stevens, SL; Xiong, ZG; Lessov, NS; Harrington, CA; Mori, M; Meller, R; Rosenzweig, HL; Tobar, E; Shaw, TE; Chu, XP; Simon, RP			Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states	LANCET			English	Article							PROTEIN-SYNTHESIS; BRAIN INJURY; INHIBITION; CHANNEL; STROKE; MICE; SUPPRESSION; MACROPHAGES; ELONGATION; EXPRESSION	Background Molecular mechanisms of neuroprotection that lead to ischaemic tolerance are incompletely understood. Identification of genes involved in the process would provide insight into cell survival and therapeutic approaches for stroke. We developed a mouse model of neuroprotection in stroke and did gene expression profiling to identify potential neuroprotective genes and their associated pathways. Methods Eight mice per condition were subjected to occlusion of the middle cerebral artery for 15 min (preconditioning), 60 min (injurious ischaemia), or preconditioning followed 72 h later by injurious ischaemia. RNA was extracted from the cortical regions of the ischaemic and non-ischaemic hemispheres. Three pools per condition were generated, and RNA was hybridised to oligonucleotide microarrays for comparison of ischaemic and non-ischaemic hemispheres. Real-time PCR and western blots were used to validate results. Follow-up experiments were done to address the biological relevance of findings. Findings Microarray analysis revealed changes in gene expression with little overlap among the conditions of injurious ischaemia, ischaemic preconditioning, or both. Injurious ischaemia induced upregulation of gene expression; 49 (86%) of 57 genes regulated showed increased expression in the ischaemic hemisphere. By contrast, preconditioning followed by injurious ischaemia resulted in pronounced downregulation; 47 (77%) of 61 regulated genes showed lower expression. Preconditioning resulted in transcriptional changes involved in suppression of metabolic pathways and immune responses, reduction of ion-channel activity, and decreased blood coagulation. Interpretation Preconditioning reprogrammes the response to ischaemic injury. Similar changes reported by others support an evolutionarily conserved endogenous response to decreased blood flow and oxygen limitation such as seen during hibernation.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Oregon Stroke Ctr, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Biostat & Bioinformat Shared Resource Canc Inst, Portland, OR 97201 USA; Robert S Dow Neurobiol Labs, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Stenzel-Poore, MP (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, L220,3181 Sam Jackson Pk Rd, Portland, OR 97239 USA.			Chu, Xiang-Ping/0000-0002-6781-0468	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024728, P01NS035965, R01NS039492] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39492, NS24728, NS35965] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; BUCK LT, 1993, AM J PHYSIOL, V265, pR1020, DOI 10.1152/ajpregu.1993.265.5.R1020; Chen Y, 2001, BIOCHEMISTRY-US, V40, P11565, DOI 10.1021/bi010649w; DIRNAGL U, IN PRESS TRENDS NEUR; Drew KL, 2001, FREE RADICAL BIO MED, V31, P563, DOI 10.1016/S0891-5849(01)00628-1; Esfandiari A, 1997, DEV NEUROSCI-BASEL, V19, P312, DOI 10.1159/000111227; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; FRERICHS KU, 1994, J CEREBR BLOOD F MET, V14, P193, DOI 10.1038/jcbfm.1994.26; Frerichs KU, 1999, ACT NEUR S, V73, P57; Frerichs KU, 1998, P NATL ACAD SCI USA, V95, P14511, DOI 10.1073/pnas.95.24.14511; Frerichs KU, 1998, J CEREBR BLOOD F MET, V18, P168, DOI 10.1097/00004647-199802000-00007; Ghai HS, 1999, AM J PHYSIOL-REG I, V277, pR887, DOI 10.1152/ajpregu.1999.277.3.R887; HASLBERGER A, 1988, CIRC SHOCK, V26, P185; Heusch G, 2000, TRENDS CARDIOVAS MED, V10, P108, DOI 10.1016/S1050-1738(00)00058-X; Hill JK, 1999, BRAIN RES, V820, P45, DOI 10.1016/S0006-8993(98)01140-8; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Iadecola C, 2001, J CEREBR BLOOD F MET, V21, P1436, DOI 10.1097/00004647-200112000-00008; Kasischke K, 1999, STROKE, V30, P1256, DOI 10.1161/01.STR.30.6.1256; Kersten JR, 1997, ANESTHESIOLOGY, V87, P361, DOI 10.1097/00000542-199708000-00024; Lin H, 2002, CIRCULATION, V105, P1962, DOI 10.1161/01.CIR.0000015365.49180.05; LOPASCHUK GD, 1989, CIRC RES, V65, P378, DOI 10.1161/01.RES.65.2.378; MONCADA S, 1983, STROKE, V14, P157, DOI 10.1161/01.STR.14.2.157; Rudolf J, 1999, J CHILD NEUROL, V14, P543, DOI 10.1177/088307389901400813; Shnyra A, 1998, J IMMUNOL, V160, P3729; SIMON RP, 1993, NEUROSCI LETT, V163, P135, DOI 10.1016/0304-3940(93)90364-Q; SRERE HK, 1995, AM J PHYSIOL-REG I, V268, pR1507, DOI 10.1152/ajpregu.1995.268.6.R1507; STOREY KB, 1990, Q REV BIOL, V65, P145, DOI 10.1086/416717; Tasaki K, 1997, BRAIN RES, V748, P267, DOI 10.1016/S0006-8993(96)01383-2; Weih M, 1999, STROKE, V30, P1851, DOI 10.1161/01.STR.30.9.1851; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012	30	313	334	2	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 27	2003	362	9389					1028	1037		10.1016/S0140-6736(03)14412-1	http://dx.doi.org/10.1016/S0140-6736(03)14412-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522533				2022-12-28	WOS:000185564600010
J	Fedullo, PF; Tapson, VF				Fedullo, PF; Tapson, VF			The evaluation of suspected pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HELICAL COMPUTED-TOMOGRAPHY; DEEP VENOUS THROMBOSIS; CLINICAL-MODEL; LUNG SCANS; VENTILATION-PERFUSION; DIAGNOSTIC STRATEGY; D-DIMER; ANGIOGRAPHY; MANAGEMENT; PROBABILITY		Univ Calif San Diego, Med Ctr, Div Pulm & Crit Care Med, San Diego, CA 92103 USA; Duke Univ, Med Ctr, Div Pulm & Crit Care Med, Durham, NC USA	University of California System; University of California San Diego; Duke University	Fedullo, PF (corresponding author), Univ Calif San Diego, Med Ctr, Div Pulm & Crit Care Med, 9300 Campus Point Dr,MC 7381, La Jolla, CA 92037 USA.							ALPERT JS, 1975, AM HEART J, V89, P413, DOI 10.1016/0002-8703(75)90145-3; Asif Arif, 2003, Am J Ther, V10, P137, DOI 10.1097/00045391-200303000-00011; AUGER WR, 1992, RADIOLOGY, V182, P393, DOI 10.1148/radiology.182.2.1732955; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P259, DOI 10.1016/S0033-0620(75)80017-X; DALEN JE, 1971, AM HEART J, V81, P175, DOI 10.1016/0002-8703(71)90128-1; Fedullo PF, 2001, NEW ENGL J MED, V345, P1465, DOI 10.1056/NEJMra010902; Fraser JD, 1999, RADIOLOGY, V211, P9, DOI 10.1148/radiology.211.1.r99ap459; Goldhaber SZ, 2002, ANN INTERN MED, V136, P691, DOI 10.7326/0003-4819-136-9-200205070-00012; Goodman LR, 2000, RADIOLOGY, V215, P535, DOI 10.1148/radiology.215.2.r00ma23535; Gottschalk A, 2000, J NUCL MED, V41, P1049; Greer IA, 2003, CLIN CHEST MED, V24, P123, DOI 10.1016/S0272-5231(02)00055-2; Hamel E, 2001, CHEST, V120, P120, DOI 10.1378/chest.120.1.120; Henry JW, 1996, CHEST, V109, P462, DOI 10.1378/chest.109.2.462; Hiorns MP, 2002, CAN ASSOC RADIOL J, V53, P258; HULL RD, 1988, ARCH INTERN MED, V148, P838, DOI 10.1001/archinte.148.4.838; Kearon C, 1998, ANN INTERN MED, V129, P1044, DOI 10.7326/0003-4819-129-12-199812150-00009; Kelly J, 2002, ARCH INTERN MED, V162, P747, DOI 10.1001/archinte.162.7.747; Khorasani R, 1997, AM J ROENTGENOL, V169, P1355, DOI 10.2214/ajr.169.5.9353458; Konstantinides S, 2002, CIRCULATION, V106, P1263, DOI 10.1161/01.CIR.0000028422.51668.A2; Kruip MJHA, 2002, ARCH INTERN MED, V162, P1631, DOI 10.1001/archinte.162.14.1631; LIPPMANN ML, 1993, CHEST, V104, P983, DOI 10.1378/chest.104.3.983c; MCNEIL BJ, 1976, J NUCL MED, V17, P613; Miniati M, 2003, AM J MED, V114, P173, DOI 10.1016/S0002-9343(02)01478-X; Miniati M, 1999, AM J RESP CRIT CARE, V159, P864, DOI 10.1164/ajrccm.159.3.9806130; Miniati M, 1996, AM J RESP CRIT CARE, V154, P1387, DOI 10.1164/ajrccm.154.5.8912753; Murchison JT, 1997, CLIN RADIOL, V52, P295, DOI 10.1016/S0009-9260(97)80057-8; Musset D, 2002, LANCET, V360, P1914, DOI 10.1016/S0140-6736(02)11914-3; Nilsson T, 1998, EUR RADIOL, V8, P86, DOI 10.1007/s003300050344; Oser RF, 1996, RADIOLOGY, V199, P31, DOI 10.1148/radiology.199.1.8633168; Perrier A, 2000, ARCH INTERN MED, V160, P512, DOI 10.1001/archinte.160.4.512; Perrier A, 2003, AM J RESP CRIT CARE, V167, P39, DOI 10.1164/rccm.2106128; Perrier A, 1999, LANCET, V353, P190, DOI 10.1016/S0140-6736(98)05248-9; Perrier A, 2001, ANN INTERN MED, V135, P88, DOI 10.7326/0003-4819-135-2-200107170-00008; Perrier A, 2000, SCHWEIZ MED WSCHR, V130, P264; Rathbun SW, 2000, ANN INTERN MED, V132, P227, DOI 10.7326/0003-4819-132-3-200002010-00009; Ruiz Y, 2003, EUR RADIOL, V13, P823, DOI 10.1007/s00330-002-1588-7; SMITH RW, 2003, ACAD EMERG MED, V10, P471; STEIN PD, 1991, CHEST, V100, P598, DOI 10.1378/chest.100.3.598; STEIN PD, 1992, CIRCULATION, V85, P462, DOI 10.1161/01.CIR.85.2.462; Stein PD, 2000, CHEST, V117, P39, DOI 10.1378/chest.117.1.39; Stein PD, 1997, CHEST, V111, P1246, DOI 10.1378/chest.111.5.1246; Tapson VF, 1999, AM J RESP CRIT CARE, V160, P1043; ten Wolde M, 2003, CIRCULATION, V107, P2082, DOI 10.1161/01.CIR.0000070020.79932.DB; Torbicki A, 2000, EUR HEART J, V21, P1301; Turkstra F, 1997, ANN INTERN MED, V126, P775, DOI 10.7326/0003-4819-126-10-199705150-00005; van Strijen MJL, 2003, ANN INTERN MED, V138, P307, DOI 10.7326/0003-4819-138-4-200302180-00009; Velmahos GC, 2001, ARCH SURG-CHICAGO, V136, P505, DOI 10.1001/archsurg.136.5.505; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wartski M, 2000, J NUCL MED, V41, P1043; Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153; Wells PS, 1998, ANN INTERN MED, V129, P997, DOI 10.7326/0003-4819-129-12-199812150-00002; Wells PS, 2000, THROMB HAEMOSTASIS, V83, P416; Wicki J, 2001, ARCH INTERN MED, V161, P92, DOI 10.1001/archinte.161.1.92	54	250	265	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2003	349	13					1247	1256		10.1056/NEJMcp035442	http://dx.doi.org/10.1056/NEJMcp035442			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LJ	14507950				2022-12-28	WOS:000185488800008
J	Coulthard, MG; Vernon, SJ; Lambert, HJ; Matthews, JNS				Coulthard, MG; Vernon, SJ; Lambert, HJ; Matthews, JNS			A nurse led education and direct access service for the management of urinary tract infections in children: prospective controlled	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REFLUX NEPHROPATHY; COLLECTION; INFANTS	Objectives To determine whether a nurse led education and direct access service improves the care of children with urinary tract infections. Design Prospective cluster randomised trial. Setting General practitioners in the catchment area of a UK paediatric nephrology department. Participants 88 general practices (346 general practitioners, 107 000 children). Main outcome measures Rate and quality of diagnosis of urinary tract infection, use of prophylactic antibiotics, convenience for families, and the number of infants with vesicoureteric reflux in whom renal scarring may have been prevented. Results The study practices diagnosed twice as many urinary tract infections as the control practices (6.42 v 3.45/1000 children/year; ratio 1.86, 95% confidence interval 1.42 to 2.44); nearly four times more in infants (age <1 year) and six times more in children without specific symptoms. Diagnoses were made more robustly by study practices than by control practices; 99% v 89% of referred patients had their urine cultured and 79% v 60% had bacteriologically proved urinary tract infections (P < 0.001 for both). Overall, 294 of 312 (94%) children aged under 4 years were prescribed antibiotic prophylaxis by study doctors compared with 61 of 147 (41%) by control doctors (P < 0.001). Study families visited hospital half as much as the control families. Twice as many renal scars were identified in patients attending the study practices. Twelve study infants but no control infants had reflux. without scarring. Conclusion A nurse led intervention improved the management of urinary tract infections in children, was valued by doctors and parents, and may have prevented some renal scarring.	Royal Victoria Infirm, Dept Paediat, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Newcastle Univ, Dept Med Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Coulthard, MG (corresponding author), Royal Victoria Infirm, Dept Paediat, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	malcolm.coulthard@nuth.northy.nhs.uk	Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X; Lambert, Heather/0000-0003-4389-4078				[Anonymous], 1991, J R Coll Physicians Lond, V25, P36; Bergman DA, 1999, PEDIATRICS, V103, P843; Coulthard MG, 1997, BMJ-BRIT MED J, V315, P918; Coulthard MG, 2002, PEDIATR NEPHROL, V17, P477, DOI 10.1007/s00467-002-0877-3; Craig JC, 2000, PEDIATRICS, V105, P1236, DOI 10.1542/peds.105.6.1236; Esbjorner E, 1997, PEDIATR NEPHROL, V11, P438, DOI 10.1007/s004670050312; Goonasekera CDA, 1998, J HUM HYPERTENS, V12, P497, DOI 10.1038/sj.jhh.1000653; JADRESIC L, 1993, BRIT MED J, V307, P761, DOI 10.1136/bmj.307.6907.761; Liaw LCT, 2000, BRIT MED J, V320, P1312, DOI 10.1136/bmj.320.7245.1312; RANSLEY PG, 1981, KIDNEY INT, V20, P733, DOI 10.1038/ki.1981.204; RANSLEY PG, 1975, UROL RES, V3, P111; RANSLEY PG, 1978, BRIT J RADIOL      S, V14, P1; Rees JC, 1996, LANCET, V348, P197, DOI 10.1016/S0140-6736(05)66144-2; Vernon S, 1997, BRIT J GEN PRACT, V47, P297; VERNON S, 1994, LANCET, V344, P612, DOI 10.1016/S0140-6736(94)91996-8; Vernon SJ, 1997, BMJ-BRIT MED J, V315, P905; VICKERS D, 1991, LANCET, V338, P767, DOI 10.1016/0140-6736(91)90662-9; WINBERG J, 1974, Acta Paediatrica Scandinavica Supplement, P1	18	25	26	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2003	327	7416					656	659		10.1136/bmj.327.7416.656	http://dx.doi.org/10.1136/bmj.327.7416.656			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724AC	14500439	Bronze, Green Published			2022-12-28	WOS:000185463100023
J	Hirsh, A				Hirsh, A			ABC of subfertility - Male subfertility	BMJ-BRITISH MEDICAL JOURNAL			English	Review							VIOLENCE; WOMEN		Whipps Cross Hosp & Chest Clin, Androl Clin, London, England; Kings Guys & St Thomass Sch Med, London, England	University of London; Queen Mary University London; University of London; King's College London	Hirsh, A (corresponding author), Whipps Cross Hosp & Chest Clin, Androl Clin, London, England.							Campbell JC, 2002, LANCET, V359, P1331, DOI 10.1016/S0140-6736(02)08336-8; CANT B, 2001, REPORT GROUP INTERVI; Edleson JL, 1999, J INTERPERS VIOLENCE, V14, P839, DOI 10.1177/088626099014008004; Garcia-Moreno C, 2000, AIDS, V14, pS253; Gazmararian J A, 2000, Matern Child Health J, V4, P79, DOI 10.1023/A:1009514119423; Hague G, 1998, BRIT J SOC WORK, V28, P369; HAGUE G, 1997, WOMEN STUD INT FORUM, V21, P441; Hargreave TB, 1998, BRIT MED J, V316, P1438, DOI 10.1136/bmj.316.7142.1438; HEISE L, JOHNS HOPKINS U SC L, V11; Hester M., 2000, MAKING IMPACT CHILDR; HIRSH AV, 1999, IN VITRO FERTILISATI; HULL MGR, 1985, BRIT MED J, V291, P1693, DOI 10.1136/bmj.291.6510.1693; Knapp JF, 1998, PEDIATR CLIN N AM, V45, P355, DOI 10.1016/S0031-3955(05)70011-0; MCWILLIAMS M, 1993, BRINGING IT OUT OPEN, P37; Murphy CC, 2001, CAN MED ASSOC J, V164, P1567; ROSENBERG MS, 1990, TREATMENT FAMILY VIO, P186; ROWE PJ, 2000, WHO MANUAL STANDARD; *ROYAL COLL OBST G, 1998, EV BAS GUID MAN INF; *ROYAL COLL OBST G, 2000, EV BAS GUID MAN INF; *ROYAL COLL OBST G, 1998, EV BAS GUID IN INV M; SHANKLEMAN J, 2001, CHILDREN RESIDENT DO, P23; Silva C, 1997, J WOMENS HEALTH, V6, P543, DOI 10.1089/jwh.1997.6.543; SKAKKEBAEK NE, 1994, LANCET, V343, P1473, DOI 10.1016/S0140-6736(94)92586-0; STARK E, 1988, INT J HLTH SERVICES, V9, P453; Sullivan CM, 1999, J CONSULT CLIN PSYCH, V67, P43, DOI 10.1037/0022-006X.67.1.43; VALE J, 2001, MALE SEXUAL DYSFUNCT	26	129	135	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2003	327	7416					669	673A		10.1136/bmj.327.7416.669	http://dx.doi.org/10.1136/bmj.327.7416.669			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	724AC	14500443	Green Published			2022-12-28	WOS:000185463100027
J	Mezard, M				Mezard, M			Passing messages between disciplines	SCIENCE			English	Editorial Material							CODES; SATISFIABILITY		CNRS, Lab Phys Theor & Modeles Stat, F-91405 Orsay, France; Univ Paris 11, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Mezard, M (corresponding author), CNRS, Lab Phys Theor & Modeles Stat, F-91405 Orsay, France.	mezard@lptms.u-psud.fr						Cook SA, 1971, P 3 ANN ACM S THEOR, P151, DOI DOI 10.1145/800157.805047; DUBOIS O, 2001, THEORET COMPUT SCI, V265; Franz S, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.046120; FREY BJ, 2001, IEEE T INF THEORY, V47; Friedgut E, 1999, J AM MATH SOC, V12, P1017, DOI 10.1090/S0894-0347-99-00305-7; Gallager R. G., 1963, LOW DENSITY PARITY C; MacKay DJC, 1996, ELECTRON LETT, V32, P1645, DOI 10.1049/el:19961141; Mezard M, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.056126; Mezard M, 2002, SCIENCE, V297, P812, DOI 10.1126/science.1073287; Mezard M., 1987, WORLD SCI LECT NOT P, V9; Pearl J., 1988, PROBABILISTIC REASON, DOI 10.1016/B978-0-08-051489-5.50008-4; TANNER RM, 1981, IEEE T INFORM THEORY, V27, P533, DOI 10.1109/TIT.1981.1056404; Vicente R, 1999, PHYS REV E, V60, P5352, DOI 10.1103/PhysRevE.60.5352; Yedidia J, 2003, EXPLORING ARTIFICIAL, V8, P236	15	35	36	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1685	1686		10.1126/science.1086309	http://dx.doi.org/10.1126/science.1086309			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500972				2022-12-28	WOS:000185387700033
J	Sanchez-Villagra, MR; Aguilera, O; Horovitz, I				Sanchez-Villagra, MR; Aguilera, O; Horovitz, I			The anatomy of the world's largest extinct rodent	SCIENCE			English	Article							LONG BONES	Phoberomys is reported to be the largest rodent that ever existed, although it has been known only from isolated teeth and fragmentary postcranial bones. An exceptionally complete skeleton of Phoberomys pattersoni was discovered in a rich locality of fossil vertebrates in the Upper Miocene of Venezuela. Reliable body mass estimates yield similar to 700 kilograms, more than 10 times the mass of the largest living rodent, the capybara. With Phoberomys, Rodentia becomes one of the mammalian orders with the largest size range, second only to diprotodontian marsupials. Several postcranial features support an evolutionary relationship of Phoberomys with pakaranas from the South American rodent radiation. The associated fossil fauna is diverse and suggests that Phoberomys lived in marginal lagoons and wetlands.	Univ Tubingen, D-72076 Tubingen, Germany; Univ Nacl Expt Francisco Miranda, CICBA, Coro 4101, Estado Falcon, Venezuela; Univ Calif Los Angeles, Dept Organism Biol Ecol & Evolut, Los Angeles, CA 90095 USA	Eberhard Karls University of Tubingen; University of California System; University of California Los Angeles	Sanchez-Villagra, MR (corresponding author), Univ Tubingen, Morgenstelle 28, D-72076 Tubingen, Germany.	marcelo.sanchez@uni-tuebingen.de	Aguilera, Orangel/D-5055-2013					[Anonymous], 1999, WALKERS MAMMALS WORL; BERTRAM JEA, 1990, J MORPHOL, V204, P157, DOI 10.1002/jmor.1052040205; Biknevicius A.R., 1993, American Museum Novitates, V3079, P1; BIKNEVICIUS AR, 1993, J MAMMAL, V74, P95, DOI 10.2307/1381908; DEMES B, 1989, FOLIA PRIMATOL, V52, P58, DOI 10.1159/000156381; Flynn JJ, 1998, TRENDS ECOL EVOL, V13, P449, DOI 10.1016/S0169-5347(98)01457-8; FRANCIS J C, 1966, Kraglieviana, V1, P89; Huchon D, 2001, MOL PHYLOGENET EVOL, V20, P238, DOI 10.1006/mpev.2001.0961; Kay R., 1997, VERTEBRATE PALEONTOL; KRAGLIEVICH LUCAS, 1932, ANALES SOC CIENT ARGENTINA, V114, P155; LANDRY STUART O., 1957, UNIV CALIFORNIA PUBL ZOOL, V56, P1; McKenna MC, 1997, CLASSIFICATION MAMMA; *MIN EN MIN, 1997, MIN EN MIN B GEOL; MONES A, 1980, Ameghiniana, V17, P277; Mones Alvaro, 1997, Comunicaciones Paleontologicas del Museo de Historia Natural de Montevideo, V2, P1; NEGRI FR, 1999, B MUSEU PARAENSE EMI, V11, P1; Paula Couto C., 1979, TRATADO PALEOMASTOZO; SANCHEZVILLAGRA MR, UNPUB; Springer MS, 2001, P NATL ACAD SCI USA, V98, P6241, DOI 10.1073/pnas.111551998; Starck D., 1995, LEHRBUCH SPEZIELLE 5; Vucetich MG, 1999, CR ACAD SCI II A, V329, P763; Wood R.C., 1976, Breviora, VNo. 436, P1	22	91	97	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1708	1710		10.1126/science.1089332	http://dx.doi.org/10.1126/science.1089332			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500978				2022-12-28	WOS:000185387700040
J	Khosla, S; Melton, LJ; Dekutoski, MB; Oberg, AL; Riggs, BL				Khosla, S; Melton, LJ; Dekutoski, MB; Oberg, AL; Riggs, BL			Incidence of childhood distal forearm fractures over 30 years - A population-based study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEFINED POPULATION; PHYSICAL-ACTIVITY; OSTEOPOROSIS PREVENTION; LIMB FRACTURES; SUBSEQUENT HIP; BONE MASS; CHILDREN; GROWTH; EPIDEMIOLOGY; CALCIUM	Context The incidence of distal forearm fractures in children peaks around the time of the pubertal growth spurt, possibly because physical activity increases at the time of a transient deficit in cortical bone mass due to the increased calcium demand during maximal skeletal growth. Changes in physical activity or diet may therefore influence risk of forearm fracture. Objective To determine whether there has been a change in the incidence of distal forearm fractures in children in recent years. Design, Setting and Patients Population-based study among Rochester, Minn, residents younger than 35 years with distal forearm fractures in 1969-1971, 19791981, 1989-1991, and 1999-2001. Main Outcome Measure Estimated incidence of distal forearm fractures in 4 time periods. Results Comparably age- and sex-adjusted annual incidence rates per 100000 increased from 263.3 (95% confidence interval [Cl], 231.1-295.4) in 1969-1971 to 322.3 (95% Cl, 285.3-359.4) in 1979-1981 and to 399.8 (95% Cl, 361.0-438.6) in 19891991 before leveling off at 372.9 (95% Cl, 339.1-406.7) in 1999-2001. Age-adjusted incidence rates per 100000 were 32% greater Among male residents in 1999-2001 compared with 1969-1971 (409.4 [95% Cl, 359.9-459.0] vs 309.4 [95% Cl, 259.3-359.5]; P=.01) and 56% greater among female residents in the same time periods (334.3 [95% Cl, 288.6-380.1] vs 214.6 [95% Cl, 174.9-254.4]; P<.001). The peak incidence and greatest increase occurred between ages 11 and 14 years in boys and 8 and 11 years in girls. Conclusions There has been a statistically significant increase in the incidence of distal forearm fractures in children and adolescents, but whether this is due to changing patterns of physical activity, decreased bone acquisition due to poor calcium intake, or both is unclear at present. Given the large number of childhood fractures, however, studies are needed to define the cause(s) of this increase.	Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Div Metab Endocrinol & Nutr, Endocrine Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Orthoped Surg, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Melton, LJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, 200 1st St SW, Rochester, MN 55905 USA.		Khosla, Sundeep/AAE-6170-2020	Khosla, Sundeep/0000-0002-2936-4372	NIAMS NIH HHS [AR30582] Funding Source: Medline; NIA NIH HHS [AG04875] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004875] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bailey DA, 2000, J BONE MINER RES, V15, P2245, DOI 10.1359/jbmr.2000.15.11.2245; Bailey DA, 1999, J BONE MINER RES, V14, P1672, DOI 10.1359/jbmr.1999.14.10.1672; BAILEY DA, 1989, J BONE JOINT SURG AM, V71A, P1225, DOI 10.2106/00004623-198971080-00016; Baker SS, 1999, PEDIATRICS, V104, P1152, DOI 10.1542/peds.104.5.1152; BENGNER U, 1985, ACTA ORTHOP SCAND, V56, P158, DOI 10.3109/17453678508994345; BERGSTRALH EJ, 1992, TECHNICAL REPORT SER; BORRUD L, 1997, NUTR WEEK       0418, P4; Bryant RJ, 1999, J AM COLL NUTR, V18, p406S, DOI 10.1080/07315724.1999.10718905; BUHR AJ, 1959, LANCET, V1, P531; CALVO MS, 1993, J NUTR, V123, P1627, DOI 10.1093/jn/123.9.1627; *COMM PROF HOSP AC, 1998, INT CLASS DIS 9 REV, V1; COOPER C, 1995, J BONE MINER RES, V10, P940; Cooper C, 2001, OSTEOPOROSIS INT, V12, P623, DOI 10.1007/s001980170061; Cuddihy MT, 1999, OSTEOPOROSIS INT, V9, P469, DOI 10.1007/s001980050172; DONALDSON LJ, 1990, J EPIDEMIOL COMMUN H, V44, P241, DOI 10.1136/jech.44.3.241; GARRAWAY WM, 1979, MAYO CLIN PROC, V54, P701; GARRAWAY WM, 1979, MAYO CLIN PROC, V54, P708; Golden NH, 2000, ARCH PEDIAT ADOL MED, V154, P542, DOI 10.1001/archpedi.154.6.542; Goulding A, 1998, J BONE MINER RES, V13, P143, DOI 10.1359/jbmr.1998.13.1.143; Goulding A, 2000, J BONE MINER RES, V15, P2011, DOI 10.1359/jbmr.2000.15.10.2011; HAGINO H, 1989, ARCH ORTHOP TRAUM SU, V109, P43, DOI 10.1007/BF00441909; Jonsson B, 1999, ACTA ORTHOP SCAND, V70, P129, DOI 10.3109/17453679909011249; Kemper HCG, 2000, BONE, V27, P847, DOI 10.1016/S8756-3282(00)00397-5; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; KRAMHOFT M, 1988, ACTA ORTHOP SCAND, V59, P557, DOI 10.3109/17453678809148784; LANDIN LA, 1983, ACTA ORTHOP SCAND, V54, P1; LAURITZEN JB, 1993, OSTEOPOROSIS INT, V3, P133, DOI 10.1007/BF01623274; MALLMIN H, 1993, CALCIFIED TISSUE INT, V52, P269, DOI 10.1007/BF00296650; Melton LJ, 1997, NEW ENGL J MED, V337, P1466, DOI 10.1056/NEJM199711133372012; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Melton LJ, 1999, OSTEOPOROSIS INT, V9, P29, DOI 10.1007/s001980050113; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P111; MMCCULLAGH P, 1983, GEN LINEAR MODELS, P127; *NAT RES COUNC, 1989, REC DIET ALL, P174; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Oskam J, 1998, INJURY, V29, P353, DOI 10.1016/S0020-1383(97)00212-X; PARFITT AM, 1994, OSTEOPOROSIS INT, V4, P382, DOI 10.1007/BF01622201; Powell EC, 1996, PEDIATR EMERG CARE, V12, P259, DOI 10.1097/00006565-199608000-00006; Rauch F, 2001, J BONE MINER RES, V16, P1547, DOI 10.1359/jbmr.2001.16.8.1547; Riggs BL, 2002, J BONE MINER RES, V17, P11, DOI 10.1359/jbmr.2002.17.1.11; Tiderius CJ, 1999, ACTA ORTHOP SCAND, V70, P622, DOI 10.3109/17453679908997853; US Department of Agriculture, 1998, 962 USDA NAT FOOD SU; *USDA, 1993, 8711 USDA NAT FOOD C, P1; WONG PCN, 1965, ACTA ORTHOP SCAND, V36, P153, DOI 10.3109/17453676508989381	44	301	308	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1479	1485		10.1001/jama.290.11.1479	http://dx.doi.org/10.1001/jama.290.11.1479			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RE	13129988	Bronze			2022-12-28	WOS:000185329000030
J	Frieden, TR; Sterling, TR; Munsiff, SS; Watt, CJ; Dye, C				Frieden, TR; Sterling, TR; Munsiff, SS; Watt, CJ; Dye, C			Tuberculosis	LANCET			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; SHORT-COURSE CHEMOTHERAPY; DIRECTLY OBSERVED THERAPY; HIV-RELATED TUBERCULOSIS; INTERFERON-GAMMA ASSAY; OBSERVED TREATMENT DOT; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; DOUBLE-BLIND; CONTROLLED-TRIAL	Among communicable diseases, tuberculosis is the second leading cause of death worldwide, killing nearly 2 million people each year. Most cases are in less-developed countries; over the past decade, tuberculosis incidence has increased in Africa, mainly as a result of the burden of HIV infection, and in the former Soviet Union, owing to socioeconomic change and decline of the health-care system. Definitive diagnosis of tuberculosis remains based on culture for Mycobacterium tuberculosis, but rapid diagnosis of infectious tuberculosis by simple sputum smear for acid-fast bacilli remains an important tool, and more rapid molecular techniques hold promise. Treatment with several drugs for 6 months or more can cure more than 95% of patients; direct observation of treatment, a component of the recommended five-element DOTS strategy, is judged to be the standard of care by most authorities, but currently only a third of cases worldwide are treated under this approach. Systematic monitoring of case detection and treatment outcomes is essential to effective service delivery. The proportion of patients diagnosed and treated effectively has increased greatly over the past decade but is still far short of global targets. Efforts to develop more effective tuberculosis vaccines are under way, but even if one is identified, more effective treatment systems are likely to be required for decades. Other modes of tuberculosis control, such as treatment of latent infection, have a potentially important role in some contexts. Until tuberculosis is controlled worldwide, it will continue to be a major killer in less-developed countries and a constant threat in most of the more-developed countries.	New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA; Johns Hopkins Univ, Sch Med, Ctr TB Res, Baltimore, MD USA; Baltimore City Dept Hlth, Eastern Chest Clin, Baltimore, MD USA; Ctr Dis Control & Prevent, Atlanta, GA USA; WHO, CH-1211 Geneva, Switzerland	New York City Department of Health & Mental Hygiene; Johns Hopkins University; Centers for Disease Control & Prevention - USA; World Health Organization	Frieden, TR (corresponding author), New York City Dept Hlth & Mental Hyg, 125 Worth St,CN28,Room 331, New York, NY 10013 USA.	tfrieden@health.nyc.gov	Dye, Christopher/AIC-4659-2022	Frieden, Thomas/0000-0002-4759-2256	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001654] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alpert PL, 1997, CLIN INFECT DIS, V24, P661, DOI 10.1093/clind/24.4.661; Altare F, 2001, J INFECT DIS, V184, P231, DOI 10.1086/321999; ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; *AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221, DOI DOI 10.1164/AJRCCM.161.SUPPLEMENT_; American Academy of Pediatrics Committee on Drugs, 2001, Pediatrics, V108, P776; [Anonymous], 2003, AM J RESP CRIT CARE, V167, P603; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Awomoyi AA, 2002, J INFECT DIS, V186, P1808, DOI 10.1086/345920; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; Balasubramanian Rani, 2000, Indian Journal of Pediatrics, V67, pS34; Bean AGD, 1999, J IMMUNOL, V162, P3504; Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0; Behr MA, 1997, CLIN INFECT DIS, V25, P806, DOI 10.1086/515550; Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002; Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614; Bellete B, 2002, CLIN INFECT DIS, V34, P1449, DOI 10.1086/340397; BERENGUER J, 1992, NEW ENGL J MED, V326, P668, DOI 10.1056/NEJM199203053261004; Brost BC, 1997, OBSTET GYN CLIN N AM, V24, P659, DOI 10.1016/S0889-8545(05)70329-6; *BUR TUB CONTR, 1999, CLIN POL PROT; Burman WJ, 2000, CLIN INFECT DIS, V31, P1390, DOI 10.1086/317504; Burman WJ, 1999, CLIN INFECT DIS, V28, P419, DOI 10.1086/515174; Burman WJ, 2001, AM J RESP CRIT CARE, V164, P7, DOI 10.1164/ajrccm.164.1.2101133; Catanzaro A, 1997, AM J RESP CRIT CARE, V155, P1804, DOI 10.1164/ajrccm.155.5.9154896; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P733; CHAMBERS ST, 1984, LANCET, V2, P181; Chaulk CP, 1998, JAMA-J AM MED ASSOC, V279, P943, DOI 10.1001/jama.279.12.943; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; Comstock GW, 1999, INT J TUBERC LUNG D, V3, P847; COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621; Connolly C, 1999, AIDS, V13, P1543, DOI 10.1097/00002030-199908200-00015; Converse PJ, 1997, J INFECT DIS, V176, P144, DOI 10.1086/514016; Cooksey RC, 1997, J CLIN MICROBIOL, V35, P1281, DOI 10.1128/JCM.35.5.1281-1283.1997; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Corbett EL, 2002, LANCET, V359, P2177, DOI 10.1016/S0140-6736(02)09095-5; Crampin AC, 2001, INT J TUBERC LUNG D, V5, P994; DAVID HL, 1970, APPL MICROBIOL, V20, P810, DOI 10.1128/AEM.20.5.810-814.1970; Delgado JC, 2002, J INFECT DIS, V186, P1463, DOI 10.1086/344891; Donald PR, 1998, INT J TUBERC LUNG D, V2, P704; Dooley DP, 1997, CLIN INFECT DIS, V25, P872, DOI 10.1086/515543; Driver CR, 2001, CLIN INFECT DIS, V33, P1762, DOI 10.1086/323784; Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376, DOI 10.1164/ajrccm.161.4.16141; Dye C, 2003, TUBERCULOSIS, V83, P35, DOI 10.1016/S1472-9792(02)00056-2; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; Dye C, 2000, INT J TUBERC LUNG D, V4, pS146; Dye C, 2000, INT J EPIDEMIOL, V29, P558, DOI 10.1093/ije/29.3.558; ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1; ELLIOTT AM, 1995, J TROP MED HYG, V98, P9; Ellner JJ, 1997, J INFECT DIS, V176, P1351, DOI 10.1086/514132; ENARSON DA, 2000, MANAGEMENT TUBERCULO, P1; Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9; FINE PEM, 2000, LUNG BIOL HEALTH DIS, V144, P503; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Flynn JL, 2000, CURR OPIN IMMUNOL, V12, P432, DOI 10.1016/S0952-7915(00)00116-3; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; FOX W, 1983, BRIT MED J, V287, P33, DOI 10.1136/bmj.287.6384.33; FOX W, 1999, INT J TUBERC LUNG S2, V3, pS231; Frieden T, 2002, INT J TUBERC LUNG D, V6, P371; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; Frieden TR, 1999, LANCET, V353, P146, DOI 10.1016/S0140-6736(05)76181-X; GIRGIS NI, 1991, PEDIATR INFECT DIS J, V10, P179, DOI 10.1097/00006454-199103000-00002; Girling D. J., 1991, American Review of Respiratory Disease, V143, P700; GIRLING DJ, 1982, DRUGS, V23, P56, DOI 10.2165/00003495-198223010-00003; GIRLING DJ, 1989, BIOL MYCOBACTERIA, V3, P285; Goldfarb DS., 1996, TUBERCULOSIS, P609; Goldfeld AE, 1998, JAMA-J AM MED ASSOC, V279, P226, DOI 10.1001/jama.279.3.226; GONZALEZMONTANER LJ, 1994, TUBERCLE LUNG DIS, V75, P341, DOI 10.1016/0962-8479(94)90079-5; Greenwood CMT, 2000, AM J HUM GENET, V67, P405, DOI 10.1086/303012; Griffiths DL, 1999, INT ORTHOP, V23, P73; GROSSET J, 2000, LUNG BIOL HEALTH DIS, V144, P157; GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90; Hakim JG, 2000, HEART, V84, P183, DOI 10.1136/heart.84.2.183; Harries AD, 1997, PHARMACOL THERAPEUT, V73, P1, DOI 10.1016/S0163-7258(96)00115-5; HARRIES AD, 1996, WHOTB9620038; Heifets LB, 1999, INT J TUBERC LUNG D, V3, P564; Hesseling AC, 2002, INT J TUBERC LUNG D, V6, P1038; Hirsch CS, 1999, J INFECT DIS, V180, P2069, DOI 10.1086/315114; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; Iseman Michael D., 2000, CLIN GUIDE TUBERCULO; JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123; Jasmer RM, 2002, ANN INTERN MED, V137, P640, DOI 10.7326/0003-4819-137-8-200210150-00007; Johnson JL, 2001, AIDS, V15, P2137, DOI 10.1097/00002030-200111090-00009; Jones JL, 2000, INT J TUBERC LUNG D, V4, P1026; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; Kamolratanakul P, 1999, T ROY SOC TROP MED H, V93, P552, DOI 10.1016/S0035-9203(99)90379-6; Karyadi E, 2002, AM J CLIN NUTR, V75, P720, DOI 10.1093/ajcn/75.4.720; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Khatri GR, 2002, NEW ENGL J MED, V347, P1420, DOI 10.1056/NEJMsa020098; Kimura M, 1999, J INFECT DIS, V179, P1297, DOI 10.1086/314707; KUBICA G, 1985, PUBLIC HLTH MYCOBACT, P60; LEE CH, 1988, CHEST, V94, P1256, DOI 10.1378/chest.94.6.1256; Lee E, 2002, CLIN INFECT DIS, V34, P365, DOI 10.1086/338149; Lotte A, 1988, Bull Int Union Tuberc Lung Dis, V63, P47; LOUDON RG, 1967, AM REV RESPIR DIS, V95, P435; Mallory KF, 2000, INT J TUBERC LUNG D, V4, P455; Malone RS, 1999, CHEST, V116, P984, DOI 10.1378/chest.116.4.984; Malone RS, 1999, AM J RESP CRIT CARE, V159, P1580, DOI 10.1164/ajrccm.159.5.9810034; Mazurek Gerald H, 2003, MMWR Recomm Rep, V52, P15; Mazurek GH, 2001, JAMA-J AM MED ASSOC, V286, P1740, DOI 10.1001/jama.286.14.1740; MCGAVIN CR, 1985, BRIT MED J, V290, P1106; McGregor MM, 1996, AM J RESP CRIT CARE, V154, P1462, DOI 10.1164/ajrccm.154.5.8912765; MITCHISON DA, 1979, CHEST, V76, P771, DOI 10.1378/chest.76.6_Supplement.771; MORGAN MA, 1983, J CLIN MICROBIOL, V18, P384, DOI 10.1128/JCM.18.2.384-388.1983; MUNSIFF SS, 2000, AIDS READ, V10, P206; MUNSIFF SS, 2000, AIDS READ, V10, P102; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; Murray J, 1999, AM J RESP CRIT CARE, V159, P733, DOI 10.1164/ajrccm.159.3.9804147; Narita M, 1998, AM J RESP CRIT CARE, V158, P157, DOI 10.1164/ajrccm.158.1.9712001; Navas E, 2002, ARCH INTERN MED, V162, P97, DOI 10.1001/archinte.162.1.97; Nivin B, 1998, INFECT CONT HOSP EP, V19, P500; NUNN P, 1991, LANCET, V337, P627; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; Ormerod LP, 1996, TUBERCLE LUNG DIS, V77, P37, DOI 10.1016/S0962-8479(96)90073-8; Ormerod P, 1998, THORAX, V53, P536; Peloquin CA, 1991, DRUG SUSCEPTIBILITY, P59; Perlman DC, 1997, CLIN INFECT DIS, V25, P242, DOI 10.1086/514546; Piatek AS, 2000, ANTIMICROB AGENTS CH, V44, P103, DOI 10.1128/AAC.44.1.103-110.2000; Piatek AS, 1998, NAT BIOTECHNOL, V16, P359, DOI 10.1038/nbt0498-359; Pungrassami P, 2002, INT J TUBERC LUNG D, V6, P389; Quigley MA, 2001, AIDS, V15, P215, DOI 10.1097/00002030-200101260-00011; Rieder H. L., 1999, Epidemiologic basis of tuberculosis control., P1; RIEDER HL, 1990, AM REV RESPIR DIS, V141, P347, DOI 10.1164/ajrccm/141.2.347; RIEDER HL, 2002, INTERVENTIONS TUBERC; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; ROPER WH, 1955, AM REV TUBERC PULM, V71, P616; Schluger NW, 1998, AM J RESP CRIT CARE, V157, P679, DOI 10.1164/ajrccm.157.3.9708002; Schoeman JF, 1997, PEDIATRICS, V99, P226, DOI 10.1542/peds.99.2.226; SCHWANDER S, 1995, TUBERCLE LUNG DIS, V76, P210, DOI 10.1016/S0962-8479(05)80007-3; Seibert Florence B., 1941, AMER REV TUBERC, V44, P9; Shafer RW, 1996, CLIN INFECT DIS, V22, P683, DOI 10.1093/clinids/22.4.683; SHAW JB, 1954, AM REV TUBERC PULM, V69, P724; Shilova MV, 2001, PHILOS T R SOC B, V356, P1069, DOI 10.1098/rstb.2001.0895; SINGH SPN, 1983, J INFECT DIS, V148, P676, DOI 10.1093/infdis/148.4.676; Sodhi A, 1997, CLIN INFECT DIS, V25, P617, DOI 10.1086/513769; Sonnenberg P, 2001, LANCET, V358, P1687, DOI 10.1016/S0140-6736(01)06712-5; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; Sterling TR, 1999, AIDS, V13, P1899, DOI 10.1097/00002030-199910010-00012; Sterling TR, 2001, CLIN INFECT DIS, V33, P976, DOI 10.1086/322670; STRANG JI, 1998, LANCET, V352, P759; STRANG JIG, 1987, LANCET, V2, P1418; Styblo K, 1991, EPIDEMIOLOGY TUBERCU; Suarez PG, 2001, J INFECT DIS, V184, P473, DOI 10.1086/322777; Sutherland I, 1976, Adv Tuberc Res, V19, P1; Thwaites G, 2000, J NEUROL NEUROSUR PS, V68, P289, DOI 10.1136/jnnp.68.3.289; Ting LM, 1999, J IMMUNOL, V163, P3898; Valerio G, 2003, J CHEMOTHERAPY, V15, P66, DOI 10.1179/joc.2003.15.1.66; Vernon A, 1999, LANCET, V353, P1843, DOI 10.1016/S0140-6736(98)11467-8; Von Pirquet C., 1909, J AMER MED ASSOC, V52, P675; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097; Wendel KA, 2001, CHEST, V120, P193, DOI 10.1378/chest.120.1.193; Wendland T, 1999, AIDS, V13, P1857, DOI 10.1097/00002030-199910010-00007; WHO, 2002, COR INF DEV IMM POL; *WHO, 2000, WHOCDSTB2000278; *WHO, 2000, WHA441991REC1; *WHO, 2003, WHOCDSTB2003316; *WHO GLOB TUB PROG, 2003, WHOCDSTB200313 GLOB; *WHO GLOB TUB PROG, 2002, WHOCDSTB2002297 GLOB; *WHO GLOB TUB PROG, 1998, WHOTB98258 GLOB TU 2; Wilkinson D, 1998, BRIT MED J, V317, P625, DOI 10.1136/bmj.317.7159.625; Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6; Wilkinson RJ, 1999, J EXP MED, V189, P1863, DOI 10.1084/jem.189.12.1863; Woods GL, 2000, CLIN INFECT DIS, V31, P1209; Wyser C, 1996, CHEST, V110, P333, DOI 10.1378/chest.110.2.333; Yuen APW, 1997, OTOLARYNG HEAD NECK, V116, P189, DOI 10.1016/S0194-5998(97)70323-1; 2002, MMWR MORB MORTAL WKL, V51, P998; 2002, MMWR MORB MORTAL WKL, V51, P214	167	715	772	4	206	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 13	2003	362	9387					887	899		10.1016/S0140-6736(03)14333-4	http://dx.doi.org/10.1016/S0140-6736(03)14333-4			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678977				2022-12-28	WOS:000185329400022
J	Biggins, JB; Onwueme, KC; Thorson, JS				Biggins, JB; Onwueme, KC; Thorson, JS			Resistance to enediyne antitumor antibiotics by calC self-sacrifice	SCIENCE			English	Article							DNA CLEAVAGE; CALICHEAMICIN; ACTIVATION; BINDING; AGENTS	Antibiotic self-resistance mechanisms, which include drug elimination, drug modi. cation, target modi. cation, and drug sequestration, contribute substantially to the growing problem of antibiotic resistance among pathogenic bacteria. Enediynes are among the most potent naturally occurring antibiotics, yet the mechanism of resistance to these toxins has remained a mystery. We characterize an enediyne self-resistance protein that reveals a self-sacrificing paradigm for resistance to highly reactive antibiotics, and thus another opportunity for nonpathogenic or pathogenic bacteria to evade extremely potent small molecules.	Univ Wisconsin, Sch Pharm, Pharmaceut Sci Div, Lab Biosynthet Chem, Madison, WI 53705 USA; Cornell Univ, Joan & Sanford I Weill Grad Sch Med, Sloan Kettering Div, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA	University of Wisconsin System; University of Wisconsin Madison; Cornell University; Memorial Sloan Kettering Cancer Center	Thorson, JS (corresponding author), Univ Wisconsin, Sch Pharm, Pharmaceut Sci Div, Lab Biosynthet Chem, 777 Highland Ave, Madison, WI 53705 USA.	jsthorson@pharmacy.wisc.edu	Thorson, Jon S/L-3696-2013	Thorson, Jon S/0000-0002-7148-0721; Biggins, John B./0000-0002-0825-3593	NCI NIH HHS [CA84374] Funding Source: Medline; NIAID NIH HHS [AI52218] Funding Source: Medline; NIGMS NIH HHS [GM58196] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052218, R37AI052218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058196] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlert J, 2002, SCIENCE, V297, P1173, DOI 10.1126/science.1072105; BERGMAN RG, 1973, ACCOUNTS CHEM RES, V6, P25, DOI 10.1021/ar50061a004; Biggins JB, 2000, P NATL ACAD SCI USA, V97, P13537, DOI 10.1073/pnas.240460997; Chatterjee M, 1996, J AM CHEM SOC, V118, P1938, DOI 10.1021/ja953162h; CHATTERJEE M, 1993, J AM CHEM SOC, V115, P3374, DOI 10.1021/ja00061a064; DAVIES MJ, 1997, RADICAL MEDIATED PRO, pCH2; DEVOSS JJ, 1990, J AM CHEM SOC, V112, P4554, DOI 10.1021/ja00167a069; Durr F. E., 1995, ENEDIYNE ANTIBIOTICS; ERMACORA MR, 1992, P NATL ACAD SCI USA, V89, P6383, DOI 10.1073/pnas.89.14.6383; GOLDBERG IH, 1997, ENEDIYNE ANTIBIOTICS, pCH16; HOYER D, 1990, J AM CHEM SOC, V112, P3249, DOI 10.1021/ja00164a076; Jones GB, 2000, ORG LETT, V2, P1863, DOI 10.1021/ol005926q; Jones GB, 2000, ORG LETT, V2, P811, DOI 10.1021/ol0055566; Kumar CV, 2002, P NATL ACAD SCI USA, V99, P5810, DOI 10.1073/pnas.082119599; McDonald LA, 1996, J AM CHEM SOC, V118, P10898, DOI 10.1021/ja961122n; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; MYERS AG, 1994, J AM CHEM SOC, V116, P1255, DOI 10.1021/ja00083a012; Oku N, 2003, J AM CHEM SOC, V125, P2044, DOI 10.1021/ja0296780; Plourde G, 2002, BIOORG MED CHEM LETT, V12, P2985; RANA TM, 1991, P NATL ACAD SCI USA, V88, P10578, DOI 10.1073/pnas.88.23.10578; Tenover FC, 2001, CLIN INFECT DIS, V33, pS108, DOI 10.1086/321834; Thorson JS, 2000, CURR PHARM DESIGN, V6, P1841, DOI 10.2174/1381612003398564; Walsh C., 2003, ANTIBIOTICS ACTIONS; Waugh DS, 1996, J BIOMOL NMR, V8, P184; Whitwam RE, 2000, J AM CHEM SOC, V122, P1556, DOI 10.1021/ja993612w	25	71	74	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1537	1541		10.1126/science.1086695	http://dx.doi.org/10.1126/science.1086695			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970566				2022-12-28	WOS:000185255300051
J	Maron, BJ				Maron, BJ			Sudden death in young athletes	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEFT-VENTRICULAR HYPERTROPHY; IMPACT COMMOTIO CORDIS; PROFESSIONAL FOOTBALL PLAYERS; AMERICAN-HEART-ASSOCIATION; CORONARY-ARTERY ANOMALIES; HIGH-SCHOOL; CARDIOVASCULAR-DISEASE; CARDIAC DEATH; EXTERNAL DEFIBRILLATORS; CLINICAL-SIGNIFICANCE		Minneapolis Heart Inst Fdn, Hypertroph Cardiomyopathy Ctr, Minneapolis, MN 55407 USA	Minneapolis Heart Institute Foundation	Maron, BJ (corresponding author), Minneapolis Heart Inst Fdn, Hypertroph Cardiomyopathy Ctr, 920 E 28th St,Suite 60, Minneapolis, MN 55407 USA.		Fahimifar, Sepideh/M-5303-2019					Abernethy WB, 2003, J AM COLL CARDIOL, V41, P280, DOI 10.1016/S0735-1097(02)02633-5; [Anonymous], 1994, J Am Coll Cardiol, V24, P845; BALADY GJ, 1984, AM J CARDIOL, V53, P1339, DOI 10.1016/0002-9149(84)90090-0; Basso C, 2000, J AM COLL CARDIOL, V35, P1493, DOI 10.1016/S0735-1097(00)00566-0; BHARATI S, 1986, J AM COLL CARDIOL, V8, P1096, DOI 10.1016/S0735-1097(86)80387-4; Biffi A, 2002, J AM COLL CARDIOL, V40, P446, DOI 10.1016/S0735-1097(02)01977-0; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; Bourassa MG, 2003, J AM COLL CARDIOL, V41, P351, DOI 10.1016/S0735-1097(02)02768-7; Brugada J, 2002, CIRCULATION, V105, P73, DOI 10.1161/hc0102.101354; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; BURKE AP, 1993, J AM COLL CARDIOL, V21, P117, DOI 10.1016/0735-1097(93)90725-G; CHOI JH, 1990, J FORENSIC SCI, V35, P981; COHEN AJ, 1989, ANN THORAC SURG, V47, P630, DOI 10.1016/0003-4975(89)90454-2; COLAN SD, 1987, J AM COLL CARDIOL, V9, P776, DOI 10.1016/S0735-1097(87)80232-2; CORRADO D, 1994, CIRCULATION, V90, P2315, DOI 10.1161/01.CIR.90.5.2315; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; Corrado D, 1998, NEW ENGL J MED, V339, P364, DOI 10.1056/NEJM199808063390602; Corrado D, 2001, CIRCULATION, V104, P346; DALIENTO L, 1995, J AM COLL CARDIOL, V25, P655, DOI 10.1016/0735-1097(94)00433-Q; Davis JA, 2001, J AM COLL CARDIOL, V37, P593, DOI 10.1016/S0735-1097(00)01136-0; DOUGLAS PS, 1986, AM J CARDIOL, V58, P805, DOI 10.1016/0002-9149(86)90358-9; Douglas PS, 1997, AM J CARDIOL, V80, P1384, DOI 10.1016/S0002-9149(97)00693-0; DRORY Y, 1991, AM J CARDIOL, V68, P1388, DOI 10.1016/0002-9149(91)90251-F; EHSANI AA, 1978, AM J CARDIOL, V42, P52, DOI 10.1016/0002-9149(78)90984-0; Estes NAM, 2001, J CARDIOVASC ELECTR, V12, P1208, DOI 10.1046/j.1540-8167.2001.01208.x; FAGARD R, 1983, CIRCULATION, V67, P896, DOI 10.1161/01.CIR.67.4.896; Feldman AM, 2000, NEW ENGL J MED, V343, P1388, DOI 10.1056/NEJM200011093431908; Franklin B. A., 2001, AM J MED SPORTS, V29, P267; Friedman PA, 2002, J AM COLL CARDIOL, V39, P1808, DOI 10.1016/S0735-1097(02)01864-8; Fuller CM, 1997, MED SCI SPORT EXER, V29, P1131, DOI 10.1097/00005768-199709000-00003; FURLANELLO F, 1984, ANN NY ACAD SCI, V427, P253, DOI 10.1111/j.1749-6632.1984.tb20789.x; Glover DW, 1998, JAMA-J AM MED ASSOC, V279, P1817, DOI 10.1001/jama.279.22.1817; Goldschlager N, 2003, ARCH INTERN MED, V163, P151, DOI 10.1001/archinte.163.2.151; Gomez JE, 1999, ARCH PEDIAT ADOL MED, V153, P723, DOI 10.1001/archpedi.153.7.723; KARK JA, 1987, NEW ENGL J MED, V317, P781, DOI 10.1056/NEJM198709243171301; Kerber RE, 1997, CIRCULATION, V95, P1677; Lange RA, 2001, NEW ENGL J MED, V345, P351, DOI 10.1056/NEJM200108023450507; LANGE RA, 2001, NEW ENGL J MED, V345, P1432; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; Liberthson RR, 1996, NEW ENGL J MED, V334, P1039, DOI 10.1056/NEJM199604183341607; Link M S, 1997, J Interv Card Electrophysiol, V1, P41, DOI 10.1023/A:1009714718034; Link MS, 1999, CIRCULATION, V100, P413, DOI 10.1161/01.CIR.100.4.413; Link MS, 2003, J AM COLL CARDIOL, V41, P99, DOI 10.1016/S0735-1097(02)02669-4; Link MS, 1998, NEW ENGL J MED, V338, P1805, DOI 10.1056/NEJM199806183382504; Link MS, 2001, J AM COLL CARDIOL, V37, P649, DOI 10.1016/S0735-1097(00)01142-6; LONGHURST JC, 1980, J APPL PHYSIOL, V48, P154, DOI 10.1152/jappl.1980.48.1.154; LONGHURST JC, 1981, CIRC RES S1, V48, P172; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1142, DOI 10.1001/jama.287.9.1142; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; Maron BJ, 1998, NEW ENGL J MED, V339, P1632, DOI 10.1056/NEJM199811263392211; Maron BJ, 1998, J AM COLL CARDIOL, V32, P1881, DOI 10.1016/S0735-1097(98)00491-4; Maron BJ, 1998, ANN INTERN MED, V129, P379, DOI 10.7326/0003-4819-129-5-199809010-00006; Maron BJ, 2003, JAMA-J AM MED ASSOC, V290, P599, DOI 10.1001/jama.290.5.599; Maron BJ, 2003, J AM COLL CARDIOL, V41, P974, DOI 10.1016/S0735-1097(02)02976-5; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MARON BJ, 1993, BRIT HEART J, V69, P125; Maron BJ, 2000, NEW ENGL J MED, V342, P365, DOI 10.1056/NEJM200002103420601; Maron BJ, 2002, AM J CARDIOL, V89, P210, DOI 10.1016/S0002-9149(01)02202-0; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; MILLIKEN MC, 1988, AM J CARDIOL, V62, P301, DOI 10.1016/0002-9149(88)90228-7; Montgomery HE, 1997, CIRCULATION, V96, P741; Moss AJ, 2000, NEW ENGL J MED, V342, P398, DOI 10.1056/NEJM200002103420605; Movahed MR, 2002, CIRCULATION, V106, P352; MUELLER FO, 1996, HK SPORT SCI MONOGRA, V8; NEUSPIEL DR, 1985, JAMA-J AM MED ASSOC, V254, P1321, DOI 10.1001/jama.254.10.1321; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Pauschinger M, 1999, CIRCULATION, V99, P1348, DOI 10.1161/01.CIR.99.10.1348; Pelliccia A, 2000, CIRCULATION, V102, P278; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; Pelliccia A, 1999, ANN INTERN MED, V130, P23, DOI 10.7326/0003-4819-130-1-199901050-00005; Pelliccia A, 1996, JAMA-J AM MED ASSOC, V276, P211, DOI 10.1001/jama.276.3.211; Pelliccia A, 2002, CIRCULATION, V105, P944, DOI 10.1161/hc0802.104534; PELLICCIA A, 1993, AM J CARDIOL, V72, P1048, DOI 10.1016/0002-9149(93)90861-6; Pfister GC, 2000, JAMA-J AM MED ASSOC, V283, P1597, DOI 10.1001/jama.283.12.1597; Pluim BM, 2000, CIRCULATION, V101, P336, DOI 10.1161/01.CIR.101.3.336; POST JC, 1995, CIRCULATION, V92, P3163, DOI 10.1161/01.CIR.92.11.3163; Priori SG, 2003, NEW ENGL J MED, V348, P1866, DOI 10.1056/NEJMoa022147; Priori SG, 2002, CIRCULATION, V106, P69, DOI 10.1161/01.CIR.0000020013.73106.D8; RILEYHAGAN M, 1992, AM J CARDIOL, V69, P1067, DOI 10.1016/0002-9149(92)90865-V; ROBERTS WC, 1988, AM J CARDIOL, V62, P1263, DOI 10.1016/0002-9149(88)90271-8; Samenuk D, 2002, MAYO CLIN PROC, V77, P12, DOI 10.4065/77.1.12; Scharhag J, 2002, J AM COLL CARDIOL, V40, P1856, DOI 10.1016/S0735-1097(02)02478-6; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Serra-Grima R, 2000, J AM COLL CARDIOL, V36, P1310, DOI 10.1016/S0735-1097(00)00853-6; SHAPIRO LM, 1985, EUR HEART J, V6, P967, DOI 10.1093/oxfordjournals.eurheartj.a061796; Strasburger JF, 2002, NEW ENGL J MED, V347, P1248, DOI 10.1056/NEJMicm020053; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; THIENE G, 1983, HUM PATHOL, V14, P706; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Valli G, 2002, J AM COLL CARDIOL, V39, P1083, DOI 10.1016/S0735-1097(02)01749-7; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; Vinereanu D, 2001, AM J CARDIOL, V88, P53, DOI 10.1016/S0002-9149(01)01585-5; Wellens HJ, 1997, PACE, V20, P2082, DOI 10.1111/j.1540-8159.1997.tb03633.x; WESSLEN L, 2001, ACTA U UPSAL, P3; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; Yetman AT, 2003, J AM COLL CARDIOL, V41, P329, DOI 10.1016/S0735-1097(02)02699-2; Yetman AT, 1998, NEW ENGL J MED, V339, P1201, DOI 10.1056/NEJM199810223391704; 1994, MED SCI SPORTS EXERC, V26, P1425	102	912	959	0	53	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					1064	1075		10.1056/NEJMra022783	http://dx.doi.org/10.1056/NEJMra022783			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719UH	12968091				2022-12-28	WOS:000185223100010
